PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Weng, YM; Siciliano, SJ; Waldburger, KE; Sirotina-Meisher, A; Staruch, MJ; Daugherty, BL; Gould, SL; Springer, MS; DeMartino, JA				Weng, YM; Siciliano, SJ; Waldburger, KE; Sirotina-Meisher, A; Staruch, MJ; Daugherty, BL; Gould, SL; Springer, MS; DeMartino, JA			Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; EOTAXIN RECEPTOR; EXPRESSION; CLONING; LESTR/FUSIN; CYTOKINES; LIGAND; MEMBER; FAMILY; SDF-1	IP10 and MIG are two members of the CXC branch of the chemokine superfamily whose expression is dramatically up-regulated by interferon (lFN)-gamma, The proteins act largely on natural killer (NK)-cells and activated T-cells and have been implicated in mediating some of the effects of IFN-gamma and Lipopolysaccharides (LPSs), as well as T-cell-dependent anti-tumor responses. Recently both chemokines have been shown to be functional agonists of the same G-protein-coupled receptor, CXCR3, We now report the pharmacological characterization of CXCR3 and find that, when heterologously expressed, CXCR3 binds IP10 and MIG with K-i values of 0.14 and 4.9 nm, respectively. The receptor has very modest affinity for SDF-1 alpha and little or no affinity for other CXC-chemokines, The properties of the endogenous receptor expressed on activated T-cells are similar. Surprisingly, several CC-chemokines, particularly eotaxin and MCP-4, also compete with moderate affinity for the binding of IP10 to CXCR3, Eotaxin does not activate CXCR3 but, in CXCR3-transfected cells, can block IP10-mediated receptor activation. Eotaxin, therefore, may be a natural CXCR3 antagonist.	Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA; Merck Res Labs, Dept Inflammat Res, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	DeMartino, JA (corresponding author), Merck Res Labs, Dept Immunol Res, 126 E Lincoln Ave, Rahway, NJ 07065 USA.	julie_demartino@merck.com						Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; FARBER JM, 1993, BIOCHEM BIOPH RES CO, V192, P223, DOI 10.1006/bbrc.1993.1403; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; Ploix C, 1998, DIABETES, V47, P39, DOI 10.2337/diabetes.47.1.39; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; STREITER RM, 1995, J LEUKOCYTE BIOL, V57, P752; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	25	171	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18288	18291		10.1074/jbc.273.29.18288	http://dx.doi.org/10.1074/jbc.273.29.18288			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660793	hybrid			2022-12-27	WOS:000074828500048
J	Ji, TH; Grossmann, M; Ji, IH				Ji, TH; Grossmann, M; Ji, IH			G protein-coupled receptors I. Diversity of receptor-ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							THROMBIN RECEPTOR; THYROTROPIN RECEPTOR; EXTRACELLULAR DOMAIN; AGONIST RECOGNITION; ADENOSINE RECEPTORS; ANTAGONIST BINDING; ACTIVATION; LOOP; IDENTIFICATION; ARRANGEMENT		Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	University of Wyoming; Walter & Eliza Hall Institute	Ji, TH (corresponding author), Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.	Ji@uwyo.edu			NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Couet J, 1996, J BIOL CHEM, V271, P4545; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; Dias JA, 1998, BIOL REPROD, V58, P1331, DOI 10.1095/biolreprod58.6.1331; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; FAY SP, 1993, BIOCHEMISTRY-US, V32, P1627, DOI 10.1021/bi00057a029; FEN GY, 1995, J BIOL CHEM, V270, P12846; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Furman MI, 1998, P NATL ACAD SCI USA, V95, P3082, DOI 10.1073/pnas.95.6.3082; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; Han M, 1997, P NATL ACAD SCI USA, V94, P13442, DOI 10.1073/pnas.94.25.13442; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; KIM JH, 1995, J BIOL CHEM, V270, P13987, DOI 10.1074/jbc.270.23.13987; Kim JY, 1997, J BIOL CHEM, V272, P2060; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mills JS, 1998, J BIOL CHEM, V273, P10428, DOI 10.1074/jbc.273.17.10428; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; OLAH ME, 1994, J BIOL CHEM, V269, P24692; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Rath P, 1998, BIOCHEM J, V329, P713, DOI 10.1042/bj3290713; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; RIVKEES SA, 1995, J BIOL CHEM, V270, P20485, DOI 10.1074/jbc.270.35.20485; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STRYER L, 1995, BIOCHEMISTRY-US, P300; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	49	502	546	5	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17299	17302		10.1074/jbc.273.28.17299	http://dx.doi.org/10.1074/jbc.273.28.17299			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651309	hybrid			2022-12-27	WOS:000074816100002
J	Kardassis, D; Sacharidou, E; Zannis, VI				Kardassis, D; Sacharidou, E; Zannis, VI			Transactivation of the human apolipoprotein CII promoter by orphan and ligand-dependent nuclear receptors - The regulatory element CIIC is a thyroid hormone response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; ACTIVATION FUNCTION AF-2; C-II GENE; TRANSCRIPTIONAL ACTIVATION; COUP-TF; SUPERFAMILY; PROTEIN; HNF-4; ARP-1; IDENTIFICATION	The regulatory elements CIIC (-159/-116) and CIIB (-102-81) of the apolipoprotein CP (apoCII) promoter have distinct specificities for orphan nuclear receptors (Vorgia, P., Zannis, V. I., and Kardassis, D. (1998) J. Biol. Chem. 273, 4188-4199), In this communication we investigated the contribution of Ligand-dependent and orphan nuclear receptors on the transcriptional regulation of the human apoCII gene. It was found that element CIIC in addition to ARP-1 and EAR-2 binds RXR alpha/T3R beta heterodimers strongly, whereas element CITE binds hepatic nuclear factor 4 (HNF-4) exclusively. Binding is abolished by mutations that alter the HRE binding motifs, Transient cotransfection experiments showed that in the presence of T3, RXR alpha/T3R beta heterodimers transactivated the -205/+18 apoCII promoter 1.6- and 11-fold in HepG2 and COS-l respectively. No transactivation was observed in the presence of 9-cis-retinoic acid. Transactivation requires the regulatory element CIIC, suggesting that this element contains a thyroid hormone response element. HNF-4 did not affect the apoCII promoter activity in HepG2 cells. However, mutations in the HNF-4 binding site on element CIIB and inhibition of HNF-4 synthesis in HepG2 cells by antisense HNF-4 constructs decreased the apoCII promoter activity to 25-40% of the control, indicating that HNF-4 is a positive regulator of the apoCII gene. ARP-1 repressed the -205/+18 but not the -104/+18 apoCII promoter activity in HepG2 cells, indicating that the repression depends on the regulatory element CIIC. In contrast, combination of ARP-I and HNF-4 transactivated different apoCII promoter segments as well as a minimal adenovirus major late promoter driven by the regulatory element CIIB, Mutagenesis or deletion of elements CIIB or CIIC established that the observed transactivation requires DNA binding of one of the two factors and may result from HNF-4-ARP-1 interactions that elicit the transactivation functions of HNF-4. The combined data indicate that RXR alpha/T3R beta in the presence of T3 and HNF-4 can upregulate the apoCII promoter activity by binding to the regulatory elements CIIC and CIIB, respectively. In addition, ARP-1 can either hare inhibitory or stimulatory effects on the apoCII promoter activity via different mechanisms.	Univ Crete, Dept Med, Div Basic Sci, Biochem Sect, Heraklion, Crete, Greece; Inst Mol Biol & Biotechnol, Heraklion, Crete, Greece	University of Crete	Kardassis, D (corresponding author), Univ Crete, Dept Med, Div Basic Sci, Biochem Sect, Heraklion, Crete, Greece.				NHLBI NIH HHS [HL-33952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Drewes T, 1996, MOL CELL BIOL, V16, P925; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JACKSON RL, 1977, P NATL ACAD SCI USA, V74, P1942, DOI 10.1073/pnas.74.5.1942; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Leng X, 1996, MOL CELL BIOL, V16, P2332; LUSIS AJ, 1986, P NATL ACAD SCI USA, V83, P3929, DOI 10.1073/pnas.83.11.3929; Malik S, 1996, MOL CELL BIOL, V16, P1824; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER S, 1993, J BIOL CHEM, V268, P16831; MILLER AL, 1973, J BIOL CHEM, V248, P3359; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Rassoul F, 1988, Dtsch Z Verdau Stoffwechselkr, V48, P104; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SAYER F, 1995, SCIENCE, V270, P1825; SAYER F, 1995, SCIENCE, V270, P1783; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P127; TABLER M, 1994, NUCLEIC ACIDS RES, V22, P3958, DOI 10.1093/nar/22.19.3958; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tzameli I, 1996, J BIOL CHEM, V271, P8402, DOI 10.1074/jbc.271.14.8402; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Vorgia P, 1998, J BIOL CHEM, V273, P4188, DOI 10.1074/jbc.273.7.4188; WEI CF, 1985, J BIOL CHEM, V260, P5211; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	57	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17810	17816		10.1074/jbc.273.28.17810	http://dx.doi.org/10.1074/jbc.273.28.17810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651383	hybrid			2022-12-27	WOS:000074816100076
J	Lam, M; Bhat, MB; Nunez, G; Ma, JJ; Distelhorst, CW				Lam, M; Bhat, MB; Nunez, G; Ma, JJ; Distelhorst, CW			Regulation of Bcl-xl channel activity by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; APOPTOSIS; CA2+; ONCOPROTEIN; MEMBRANE; PROTEIN; NUCLEAR	Recent studies have demonstrated that the anti-apoptotic proteins, Bcl-2 and Bcl-xl, with the carboxyl terminal hydrophobic domain removed, form cation-selective channels in the lipid bilayer reconstitution system. However, the regulatory properties of these channels are unknown. In this study, we investigated the ion-conducting properties of full length Bcl-xl in the lipid bilayer reconstitution system. Our findings indicate that Bcl-xl forms a cation-selective channel that conducts sodium but not calcium and that Bcl-xl channel activity is reversibly inhibited by luminal calcium with a half-dissociation constant of similar to 60 mu M This calcium-de pendent regulation of the Bcl-xl channel provides new insights into the roles of calcium and Bcl-2-related proteins in the programmed cell death pathway.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Michigan System; University of Michigan	Ma, JJ (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxm63@po.cwru.edu; cwd@po.cwru.edu	Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [R01 CA42755] Funding Source: Medline; NIA NIH HHS [AG-15556] Funding Source: Medline; NIDDK NIH HHS [5T32DK07319] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BATY D, 1987, P NATL ACAD SCI USA, V84, P1152, DOI 10.1073/pnas.84.5.1152; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DEJONG D, 1994, CANCER RES, V54, P256; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hidalgo C, 1995, BIOSCIENCE REP, V15, P387, DOI 10.1007/BF01788370; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Klaerke DA, 1997, COMP BIOCHEM PHYS A, V118, P215, DOI 10.1016/S0300-9629(97)00070-4; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Marin MC, 1996, ONCOGENE, V12, P2259; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Triggle DJ, 1997, J HYPERTENS, V15, pS9, DOI 10.1097/00004872-199715055-00003; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	35	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17307	17310		10.1074/jbc.273.28.17307	http://dx.doi.org/10.1074/jbc.273.28.17307			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651311	hybrid			2022-12-27	WOS:000074816100004
J	Leung, SM; Chen, D; DasGupta, BR; Whiteheart, SW; Apodaca, G				Leung, SM; Chen, D; DasGupta, BR; Whiteheart, SW; Apodaca, G			SNAP-23 requirement for transferrin recycling in streptolysin-O-permeabilized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR MEMBRANE-FUSION; PROTEIN-PROTEIN INTERACTIONS; NEUROTOXIN TYPE-A; BOTULINUM NEUROTOXIN; MDCK CELLS; VESICULAR TRANSPORT; CA2+-DEPENDENT EXOCYTOSIS; CLOSTRIDIAL NEUROTOXINS; SYNTAXIN-BINDING; PC12 CELLS	Fusion of recycling and transcytotic vesicles with the apical and basolateral plasma membrane domains of Madin-Darby canine kidney (MDCK) cells requires the N-ethylmaleimide-sensitive factor and is sensitive to botulinum neurotoxin serotype E (BoNT/E). BoNT/E is thought to selectively proteolyze the 25,000-dalton synaptosomal associated protein (SNAP-25), a protein found in neurons or cells of neuroendocrine origin. However, SNAP-25 is not found in MDCK cells. One possible target for BoNT/E in MDCK cells is SNAP-23, a newly described SNAP-25 homolog that is found in several organs including kidney. Currently, the function of SNAP-23 is unknown. We have reconstituted transferrin recycling in permeabilized MDCK cells to assess the role of SNAP-23 in the endocytic traffic of this protein. We find that: (i) SNAP-23 is expressed in MDCK cells and is found both at the basolateral plasma membrane and associated with apical and basolateral vesicles, (ii) canine SNAP-23 is cleaved by BoNT/E, (iii) transferrin recycling is N-ethylmaleimide-sensitive factor-dependent and BoNT/E-sensitive, and (iv) addition of either exogenous SNAP-23 or anti-SNAP-23 antibodies inhibits ligand recycling. Our observations suggest that SNAP-23 may be required for fusion of recycling vesicles with the basolateral membrane of polarized MDCK cells.	Univ Pittsburgh, Renal Electroelyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison	Apodaca, G (corresponding author), Univ Pittsburgh, Renal Electroelyte Div, Dept Med, 982 Scaife Hall, Pittsburgh, PA 15261 USA.	gla6@pop.pitt.edu	Apodaca, Gerard/HCJ-0048-2022	Whiteheart, Sidney/0000-0001-5577-0473	NIAID NIH HHS [R01 AI25144, AI36953] Funding Source: Medline; NIDDK NIH HHS [R01DK51970-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144, R01AI036953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051970] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BANERJEE A, 1993, NEUROSCI LETT, V164, P93, DOI 10.1016/0304-3940(93)90865-I; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASGUPTA BR, 1990, J PHYSIOL-PARIS, V84, P220; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JAHN R, 1994, ANN NY ACAD SCI, V733, P245, DOI 10.1111/j.1749-6632.1994.tb17274.x; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Peng XR, 1997, MOL BIOL CELL, V8, P399, DOI 10.1091/mbc.8.3.399; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schmidt JJ, 1995, J PROTEIN CHEM, V14, P703, DOI 10.1007/BF01886909; SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x; SIMPSON LL, 1983, J PHARMACOL EXP THER, V224, P135; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WILSON KL, 1995, CELL, V81, P475, DOI 10.1016/0092-8674(95)90067-5; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884	60	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17732	17741		10.1074/jbc.273.28.17732	http://dx.doi.org/10.1074/jbc.273.28.17732			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651373	hybrid			2022-12-27	WOS:000074816100066
J	Baxter, RM; Secrist, JP; Vaillancourt, RR; Kazlauskas, A				Baxter, RM; Secrist, JP; Vaillancourt, RR; Kazlauskas, A			Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PROTEIN-TYROSINE KINASES; PDGF RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL-3 KINASE; AUTOPHOSPHORYLATION SITES; PHOSPHORYLATION SITE; INSULIN-RECEPTOR; DNA-SYNTHESIS; SRC FAMILY	Activation of receptor tyrosine kinases is thought to involve ligand-induced dimerization, which promotes receptor transphosphorylation and thereby increases the receptor's phosphotransferase activity. We used two platelet-derived growth factor beta-receptor (beta-PDGFR) mutants to identify events that are required for full engagement (autophosphorylation and activation of the kinase activity) of the beta-PDGFR kinase, The F79/81 receptor (Tyr to Phe substitution at 579 and 581 in the juxtamembrane domain of the receptor) was capable of only very modest ligand dependent autophosphorylation and also failed to associate with numerous SH2 domain-containing proteins, Furthermore, stimulation with platelet-derived growth factor (PDGF) did not increase the kinase activity of the F79/81 mutant toward exogenous substrates, However, the F79/81 receptor had basal kinase activity and could be artificially stimulated by incubation with ATP, Because the low kinase activity of the F857 mutant (Tyr to Phe substitution at 857 in the putative activation loop) could not be increased by incubation with ATP, failure to phosphorylate Tyr-857 may be the reason why the F79/81 mutant has low kinase activity. Surprisingly, the F857 mutant underwent efficient PDGF-dependent autophosphorylation, Thus the PDGF-dependent increase in the kinase activity of the receptor is not required for autophosphorylation. We conclude that full activation of the beta-PDGFR kinase requires at least two, apparently distinct events.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.				NATIONAL EYE INSTITUTE [R01EY011693] Funding Source: NIH RePORTER; NEI NIH HHS [EY 11693] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAZENET CE, 1994, ONCOGENE, V9, P517; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; YU KT, 1985, J BIOL CHEM, V260, P5838	41	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17050	17055		10.1074/jbc.273.27.17050	http://dx.doi.org/10.1074/jbc.273.27.17050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642269	hybrid			2022-12-27	WOS:000074545200059
J	Liberati, C; Ronchi, A; Lievens, P; Ottolenghi, S; Mantovani, R				Liberati, C; Ronchi, A; Lievens, P; Ottolenghi, S; Mantovani, R			NF-Y organizes the gamma-globin CCAAT boxes region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; BINDING FACTOR CBF; CLASS-II; DISPLACEMENT PROTEIN; TRANSCRIPTION FACTOR; GENE PROMOTER; DNA COMPLEX; HEREDITARY PERSISTENCE; REGULATORY ELEMENTS; FUNCTIONAL DOMAINS	The CCAAT-binding activator NF-Y is formed by three evolutionary conserved subunits, two of which contain putative histone-like domains. We investigated NF-Y binding to all CCAAT boxes of globin promoters in direct binding, competition, and supershift electrophoretic mobility shift assay; we found that the alpha, zeta, and proximal gamma CCAAT boxes of human and the prosimian Galago bind avidly, and distal gamma CCAAT boxes have intermediate affinity, whereas the epsilon and beta sequences bind NF-Y very poorly. We developed an efficient in vitro transcription system from erythroid K562 cells and established that both the distal and the proximal CCAAT boxes are important for optimal gamma-globin promoter activity. Surprisingly, NF-Y binding to a mutated distal CCAAT box (a C to T at position -114) is remarkably increased upon occupancy of the high affinity proximal element, located 27 base pairs away. Shortening the distance between the two CCAAT boxes progressively prevents simultaneous CCAAT binding, indicating that NF-Y interacts in a mutually exclusive way with CCAAT boxes closer than 24 base pairs apart. A combination of circular permutation and phasing analysis proved that (i) NF-Y-induced angles of the two gamma-globin CCAAT boxes have similar amplitudes; (ii) occupancy of the two CCAAT boxes leads to compensatory distortions; (iii) the two NF-Y bends are spatially oriented with combined twisting angles of about 100 degrees, Interestingly, such distortions are reminiscent of core histone-DNA interactions. We conclude that NF-Y binding imposes a high level of functionally important coordinate organization to the gamma-globin promoter.	Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20133 Milan, Italy	University of Milan	Ottolenghi, S (corresponding author), Univ Milan, Dipartimento Genet & Biol Microorganismi, Via Celoria 26, I-20133 Milan, Italy.				Telethon [E.0596] Funding Source: Medline	Telethon(Fondazione Telethon)		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FUCHAROEN S, 1990, NUCLEIC ACIDS RES, V18, P5245, DOI 10.1093/nar/18.17.5245; GROSVELD F, 1993, COLD SPRING HARB SYM, V58, P7, DOI 10.1101/SQB.1993.058.01.004; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JACKSON SM, 1998, J LIPID RES, V10, P1; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; KERRPOLA T, 1991, CELL, V66, P316; KIM CG, 1990, J BIOL CHEM, V265, P13362; Kim IS, 1996, MOL CELL BIOL, V16, P4003; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI XY, 1992, J BIOL CHEM, V267, P8984; LIWEBER M, 1994, J IMMUNOL, V153, P4122; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Mantovani R, 1994, Methods Mol Biol, V31, P289; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; Mason MM, 1996, J BIOL CHEM, V271, P25459, DOI 10.1074/jbc.271.41.25459; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PINKHAM JL, 1987, MOL CELL BIOL, V7, P578, DOI 10.1128/MCB.7.2.578; Pondel MD, 1996, NUCLEIC ACIDS RES, V24, P4158, DOI 10.1093/nar/24.21.4158; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; RUDDELL A, 1995, VIROLOGY, V206, P1, DOI 10.1016/S0042-6822(95)80013-1; SCHWEIZERGROYER G, 1994, NUCLEIC ACIDS RES, V22, P1583, DOI 10.1093/nar/22.9.1583; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	45	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16880	16889		10.1074/jbc.273.27.16880	http://dx.doi.org/10.1074/jbc.273.27.16880			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642249	hybrid			2022-12-27	WOS:000074545200039
J	Peng, Y; Genin, A; Spinner, NB; Diamond, RH; Taub, R				Peng, Y; Genin, A; Spinner, NB; Diamond, RH; Taub, R			The gene encoding human nuclear protein tyrosine phosphatase, PRL-1 - Cloning, chromosomal localization, and identification of an intron enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGENERATING LIVER; HEPATOCYTES; SEQUENCE; GROWTH; DNA	Expression of the rat PRL I gene, which encodes a unique nuclear protein tyrosine phosphatase, is positively associated with cellular growth during liver development, regeneration, and oncogenesis but with differentiation in intestine and other tissues. Here, we analyzed the structure of the human PRL-I gene and localized it to chromosome 6 within band q12, Human, rat, and mouse PRL-1 are 100% conserved at the amino acid level and 55% identical to a newly identified Caenorhabditis elegans PRL-I, The presence of two promoter activities, P1 and P2, in the human PRL-I gene were identified by primer extension and RNase protection assays. A functional TATA box was identified in promoter P1 upstream of the non-coding first exon, A non-canonical internal promoter, P2, was found in the first intron that results in PRL-I transcripts beginning 8 base pairs downstream of the 5'-end of exon 2 and causes no alteration in the encoded protein. The first 200-base pair region of either promoter P1 or P2 conferred high basal transcriptional activity. An enhancer that bound a developmentally regulated factor, PRL-I intron enhancer complex (PIEC), was localized to the first intron of the human PRL-1 gene. The presence of PIEC correlated with the ability of the intron enhancer to confer transcriptional activation in HepG2 and F9 cells. The intron enhancer contributed significantly to PRL I promoter activity in HepG2 cells which contain PIEC but not to NIH 3T3 cells which do not.	Univ Penn, Sch Med, Dept Genet, Div Gastroenterol, Philadelphia, PA 19104 USA; Childrens Hosp, Dept Genet, Div Genet, Philadelphia, PA 19104 USA; Childrens Hosp, Dept Pediat, Div Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Taub, R (corresponding author), Univ Penn, Sch Med, Dept Genet, Div Gastroenterol, 705A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK44237, DK49629] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044237, R01DK049629] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIAMOND HR, 1996, AM J PHYSIOL, V271, pG121; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; GREENBAUM LE, 1995, J CLIN INVEST, V96, P1351, DOI 10.1172/JCI118170; LICHTER P, 1992, HUMAN CYTOGENETICS P; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MONTAGNA M, 1995, HUM GENET, V96, P532; Moore DD, 1995, GLOB MOB SURV; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Peng Y, 1997, GENOMICS, V43, P278, DOI 10.1006/geno.1997.4821; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; SEAL SN, 1991, MOL CELL BIOL, V11, P2704, DOI 10.1128/MCB.11.5.2704; Suh E, 1996, MOL CELL BIOL, V16, P619; TAUB R, 1996, PROTEIN PHOSPHORYLAT, P59; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	18	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17286	17295		10.1074/jbc.273.27.17286	http://dx.doi.org/10.1074/jbc.273.27.17286			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642300	hybrid			2022-12-27	WOS:000074545200090
J	Saito, K; Nishijima, M; Kuge, O				Saito, K; Nishijima, M; Kuge, O			Genetic evidence that phosphatidylserine synthase II catalyzes the conversion of phosphatidylethanolamine to phosphatidylserine in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; MUTANT; PHOSPHATIDYLCHOLINE; KINASE	Phosphatidylserine (PS) in mammalian cells is synthesized through the exchange of free L-serine with the base moiety of phosphatidylcholine or phosphatidylethanolamine (PE), The serine base exchange in Chinese hamster ovary (CHO) cells is catalyzed by at least two enzymes, PS synthase (PSS) I and II. A PSS I-lacking mutant of CHO-III cells, PSA-S, which exhibits similar to 2-fold lower serine base exchange activity than CHO-K1, is defective in the conversion of phosphatidylcholine to PS but has the ability to convert PE to PS. The PSA-3 mutant requires exogenous PS or PE for cell growth. In the present study, from PSA-3 mutant cells, we isolated a mutant, named PSB-2, with a further decrease in the serine base exchange activity. The activity in the homogenate of PSB-2 mutant cells was similar to 10% that of PSA-3 mutant cells and similar to 5% that of CHO-K1 cells. The PSB-2 mutant exhibited an similar to 80% reduction in the PSS II mRNA level relative to that in PSA-3 mutant and CHO-K1 cells. These results showed that the PSB-2 mutant is defective in PSS II. Like the PSA-S mutant, the PSB-2 mutant grew well in medium supplemented with PS, However, in the medium supplemented with PE, the PSB-2 mutant was incapable of growth, in contrast to the PSA-3 mutant. In the medium with exogenous PE, the PSB-2 mutant was defective in PS biosynthesis, whereas the PSA-3 mutant synthesized a normal amount of PS, A metabolic labeling experiment with exogenous [P-32]PE revealed that the PSB-2 mutant was defective in the conversion of exogenous PE to PS, This defect and the growth and PS biosynthetic defects of the PSB-2 mutant cultivated with exogenous PE were complemented by the PSS II cDNA In addition, the cDNA of the other PS synthase, PSS I, was shown not to complement the defect in the conversion of exogenous PE to PS of the PSB-2 mutant, implying that PSS I negligibly contributes to the conversion of PE to PS in CHO-K1 cells. These results indicated that PSS LI is critical for the growth and PS biosynthesis of PSA-3 mutant cells cultivated with exogenous PE and suggested that most of the PS formation from PE in CHO-gl cells is catalyzed by PSS II.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 162, Japan	National Institute of Infectious Diseases (NIID)	Kuge, O (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Toyama 1-23-1, Tokyo 162, Japan.			Kuge, Osamu/0000-0003-4962-3519				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; ESKO JD, 1978, P NATL ACAD SCI USA, V75, P1190, DOI 10.1073/pnas.75.3.1190; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1989, BIOCHIM BIOPHYS ACTA, V986, P61, DOI 10.1016/0005-2736(89)90272-1; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGGRAF WD, 1974, H-S Z PHYSIOL CHEM, V355, P1299, DOI 10.1515/bchm2.1974.355.2.1299; MILLER MA, 1986, J BIOL CHEM, V261, P9753; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Sambrook J., 2002, MOL CLONING LAB MANU; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669	23	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17199	17205		10.1074/jbc.273.27.17199	http://dx.doi.org/10.1074/jbc.273.27.17199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642289	hybrid			2022-12-27	WOS:000074545200079
J	Hashimoto, Y; Kohri, K; Kaneko, Y; Morisaki, H; Kato, T; Ikeda, K; Nakanishi, M				Hashimoto, Y; Kohri, K; Kaneko, Y; Morisaki, H; Kato, T; Ikeda, K; Nakanishi, M			Critical role for the 3(10) helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS; CELL-CYCLE; P21; IDENTIFICATION; P27(KIP1); CLONING; BINDING; MOTIF; GENE; P18	Although crystal structural analysis of cyclin A/cyclin-dependent kinase 2 (Cdk2)/p27 (Russo, A. A., Jeffrey, P. D., Pattern, A. K., Massague, J., and Pavletich, N. P. (1996) Nature 382, 325-331) has suggested that the 3(10) helix region in Cdk inhibitors of the Cip/Kip family may be involved in the inhibition of cyclin/Cdk activities, there is no biochemical evidence supporting this hypothesis. In the present study, we demonstrated that cyclin and Cdk binding domains of p57 were necessary but were not sufficient in themselves for the inhibition of cyclin A/Cdk2 and cyclin E/Cdk2, and that the 3(10) helix region of this protein is indispensable for the inhibition of these complexes. In contrast, the 3(10) helix regions of p21 and p27 were not required, and cyclin- and Cdk-binding domains alone were sufficient for the inhibition of all cyclin/Cdk complexes examined. Site-directed mutagenesis identified phenylalanine 79 and tyrosine 80 within the 3(10) helix region of p57 as crucial residues for kinase inhibition, supporting the structural evidence that the 3(10) helix binds deep inside the catalytic cleft of Cdk2, mimicking ATP. Mutations within the 3(10) helix region of the p57 molecule completely abolished the ability to arrest the cell cycle at G(1) in vivo. These results indicate that this region is specifically utilized by p57 in selectively inhibiting cyclin A or E/Cdk2 activities. Thus the 3(10) helix motif may confer a specific regulatory mechanism by which p57 differentially regulates Cdk2 and Cdk4 activities.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 474, Japan; Nagoya City Univ, Sch Med, Dept Urol, Mizuho Ku, Nagoya, Aichi 467, Japan; Nagoya City Univ, Sch Med, Dept Bioregulat Res, Mizuho Ku, Nagoya, Aichi 467, Japan	Nagoya City University; Nagoya City University	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 474, Japan.	mnakani@nils.go.jp						Adams PD, 1996, MOL CELL BIOL, V16, P6623; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; ELDEIRY WS, 1993, CELL, V74, P1009; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fotedar R, 1996, ONCOGENE, V12, P2155; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	29	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16544	16550		10.1074/jbc.273.26.16544	http://dx.doi.org/10.1074/jbc.273.26.16544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632724	hybrid			2022-12-27	WOS:000074436600095
J	Kinoshita, T; Sato, H; Akiko; Okada; Ohuchi, E; Imai, K; Okada, Y; Seiki, M				Kinoshita, T; Sato, H; Akiko; Okada; Ohuchi, E; Imai, K; Okada, Y; Seiki, M			TIMP-2 promotes activation of progelatinase a by membrane-type 1 matrix metalloproteinase immobilized on agarose beads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; IV COLLAGENASE; TISSUE INHIBITOR; GELATINASE-A; 72-KDA GELATINASE; HUMAN FIBROBLASTS; CATALYTIC DOMAIN; CANCER CELLS; SURFACE; EXPRESSION	Membrane-type 1 matrix metalloproteinase (MT1-MMP)/MMP-14 is the activator of progelatinase A (proGelA)/proMMP-2 on the cell surface. However, it was a paradox that a tissue inhibitor of metalloproteinase-2 (TIMP-2), which is an inhibitor of MT1-MMP, is required for proGelA activation by the cells expressing MT1-MMP. In this study, a truncated MT1-MMP having a FLAG-tag sequence at the C terminus (MT1-F) was immobilized onto agarose beads (MT1-F/B) and used to analyze the role of TIMP-2, The proteolytic activity of MT1-F/B against a synthetic peptide substrate was inhibited by TIMP-2 in a dose-dependent manner. In contrast, TIMP-2 promoted the processing of proGelA by MT1-F/B at low concentrations and inhibited it at higher concentrations. TIMP-2 promoted the binding of proGelA to the MT1-F on the beads by forming a trimolecular complex, which was followed by processing of proGelA. A stimulatory effect of TIMP-2 was observed under conditions in which unoccupied MT1-F was still available. Thus, the ternary complex is thought to act as a means to concentrate the substrate to the bead surface and to present it to the neighboring free MT1-F.	Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 108, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 920, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Pathol & Immunol, Kanazawa, Ishikawa 920, Japan; Fuji Chem Ind Ltd, Dept Biopharmaceut, Toyama 933, Japan; Keio Univ, Sch Med, Dept Pathol, Shinnjyuku Ku, Tokyo 160, Japan	University of Tokyo; Kanazawa University; Kanazawa University; Keio University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; Okada, Yasunori/B-5550-2014; Imai, Kazushi/E-7206-2012	Okada, Yasunori/0000-0001-9208-4755; 				Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; EMONARD HP, 1992, CANCER RES, V52, P5845; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Gilles C, 1996, INT J CANCER, V65, P209; Imai K, 1996, CANCER RES, V56, P2707; Kinoshita T, 1996, CANCER RES, V56, P2535; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONSKY WL, 1993, CANCER RES, V53, P3159; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, BIOCHEM J, V284, P935; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yamamoto M, 1996, CANCER RES, V56, P384; YU M, 1995, CANCER RES, V55, P3272	44	244	249	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16098	16103		10.1074/jbc.273.26.16098	http://dx.doi.org/10.1074/jbc.273.26.16098			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632662	hybrid			2022-12-27	WOS:000074436600033
J	Kikkawa, Y; Sanzen, N; Sekiguchi, K				Kikkawa, Y; Sanzen, N; Sekiguchi, K			Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells - Laminin-10/11 mediates cell adhesion through integrin alpha 3 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUES; A-CHAIN; PROTEIN; EXPRESSION; BINDING; RECEPTORS; FIBRONECTIN; DOMAINS; LOCALIZATION; STIMULATION	A panel of human tumor cell lines was screened for selective expression of laminin alpha 5 chain, a newly identified laminin subunit comprising laminin-10 (alpha 5 beta 1 gamma 1) and -11 (alpha 5 beta 2 gamma 1). The lung adenocarcinoma cell line A549 was found to express the alpha 5 chain at relatively high levels but no detectable amounts of other alpha chains. The laminin variants containing alpha 5 chain were purified from the conditioned medium of A549 cells by immunoaffinity chromatography using the anti-laminin monoclonal antibody 4C7 which was shown recently to recognize the laminin alpha 5 chain (Tiger, C.-F., Champliaud, M.-F., Pedrosa-Domellof, F., Thornell, L.-E., Ekblom, P., and Gullberg, D. (1997) J. Biol. Chem. 272, 28590-28595). The purified laminin variants consisted of three chains with molecular masses of 350, 220, and 210 kDa. The 350-kDa chain was specifically recognized by another anti-alpha 5 chain monoclonal antibody capable of recognizing denatured alpha 5 chain on immunoblots, whereas the 810-kDa chain was recognized by an anti-gamma 1 chain antibody. The purified alpha 5 chain-containing laminin variants thereafter referred to as laminin-10/11) were highly active in mediating adhesion of A549 cells to the substratum with potency as high as that of laminin-5 and significantly higher than those of laminin-1, laminin-2/4, or fibronectin. Adhesion to substrata coated with laminin-10/11 was specifically inhibited by anti-integrin antibodies directed against the integrin alpha 3 or beta 1 subunit but not by those against alpha 2 or alpha 6 subunit, indicating that laminin-10/11 is specifically recognized by integrin alpha 3 beta 1. Given the wide distribution of laminin-10/11 in the basement membrane of various tissue types and dominant expression of integrin alpha 3 beta 1 in most epithelial cells, specific interaction of laminin-10/11 with integrin alpha 3 beta 1 may play an important role in in vivo regulation of proliferation and differentiation of epithelial cells through the basement membrane.	Osaka Med Ctr Maternal & Child Hlth, Inst Res, Osaka 5941101, Japan		Sekiguchi, K (corresponding author), Osaka Med Ctr Maternal & Child Hlth, Inst Res, 840 Murodo, Osaka 5941101, Japan.	sekiguch@protein.osaka-u.ac.jp	Kikkawa, Yamato/D-1503-2010	Sanzen, Noriko/0000-0001-6518-403X				Baker SE, 1996, J CELL SCI, V109, P2509; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BROWN JC, 1994, J CELL SCI, V107, P329; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Doliana R, 1997, FEBS LETT, V417, P65, DOI 10.1016/S0014-5793(97)01251-9; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Engvall E, 1996, J CELL BIOCHEM, V61, P493; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; Giancotti FG, 1996, J CELL SCI, V109, P1165; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; Kikkawa Y, 1996, IN VITRO CELL DEV-AN, V32, P46; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; Murayama O, 1996, J BIOCHEM-TOKYO, V120, P445; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; Virtanen I, 1996, AM J RESP CELL MOL, V15, P184, DOI 10.1165/ajrcmb.15.2.8703474; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEWER U, 1983, J BIOL CHEM, V258, P2654	43	190	193	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15854	15859		10.1074/jbc.273.25.15854	http://dx.doi.org/10.1074/jbc.273.25.15854			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624186	Green Published, hybrid			2022-12-27	WOS:000074284200080
J	Rahman, A; Friedman, DS; Goldstein, LSB				Rahman, A; Friedman, DS; Goldstein, LSB			Two kinesin light chain genes in mice - Identification and characterization of the encoded proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST AXONAL-TRANSPORT; BOVINE BRAIN KINESIN; HEAVY-CHAIN; MONOCLONAL-ANTIBODIES; CONVENTIONAL KINESIN; SUPERFAMILY PROTEIN; SEQUENCE-ANALYSIS; MONOMERIC MOTOR; LOCALIZATION; ANTEROGRADE	Native kinesin consists of two light chains and two heavy chains in a 1:1 stoichiometric ratio. To date, only one gene for kinesin light chain has been characterized, while a second gene was identified in a genomic sequencing study but not analyzed biochemically, Here we describe new genes encoding kinesin light chains in mouse. One of these light chains is neuronally enriched, while another shows ubiquitous expression. The presence of multiple kinesin light chain genes in mice is especially interesting, since there are two kinesin heavy chain genes in humans (Niclas, J., Navone, F,, HomBooher, N,, and Vale, R, D. (1994) Neuron 12, 1059-1072), To assess the selectivity of kinesin light chain interaction with the heavy chains, we performed immunoprecipitation experiments. The data suggested that the light chains form homodimers with no specificity in their interaction with the two heavy chains. Immunofluorescence and biochemical subfractionation suggested differences in the subcellular localization of the two kinesin light chain gene products. Although both kinesin light chains are distributed throughout the central and peripheral nervous systems, there is enrichment of one in sciatic nerve axons, while the other shows elevated levels in olfactory bulb glomeruli, These results indicate that the mammalian nervous system contains multiple kinesin light chain gene products with potentially distinct functions.	Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, Program Biomed Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Pharmacol & Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, Program Biomed Sci, Room 334,9500 Gilman Dr, La Jolla, CA 92093 USA.	lgoldstein@ucsd.edu						AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; ARAI M, 1994, J NEUROSCI RES, V38, P348, DOI 10.1002/jnr.490380313; BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; BEUSHAUSEN S, 1993, DNA CELL BIOL, V12, P901, DOI 10.1089/dna.1993.12.901; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; FAN J, 1994, J MOL BIOL, V240, P507, DOI 10.1006/jmbi.1994.1465; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Gindhart JG, 1996, TRENDS BIOCHEM SCI, V21, P52, DOI 10.1016/0968-0004(96)80865-6; Goedert M, 1996, GENOMICS, V32, P173, DOI 10.1006/geno.1996.0102; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HALL DH, 1991, J CELL BIOL, V115, P389; Hanlon DW, 1997, NEURON, V18, P439, DOI 10.1016/S0896-6273(00)81244-1; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; *JACKS LAB, ENC MOUS GEN REL 3 0; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lamerdin JE, 1996, GENOMICS, V34, P399, DOI 10.1006/geno.1996.0303; MATUS A, 1988, TRENDS NEUROSCI, V11, P291, DOI 10.1016/0166-2236(88)90086-0; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Sambrook J., 2002, MOL CLONING LAB MANU; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Yang ZH, 1998, MOL BIOL CELL, V9, P249, DOI 10.1091/mbc.9.2.249	56	92	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15395	15403		10.1074/jbc.273.25.15395	http://dx.doi.org/10.1074/jbc.273.25.15395			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624122	hybrid			2022-12-27	WOS:000074284200016
J	Ohbayashi, N; Hoshikawa, M; Kimura, S; Yamasaki, M; Fukui, S; Itoh, N				Ohbayashi, N; Hoshikawa, M; Kimura, S; Yamasaki, M; Fukui, S; Itoh, N			Structure and expression of the mRNA encoding a novel fibroblast growth factor, FGF-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; NERVOUS-SYSTEM; GENE; MEMBER; OUTGROWTH; CLONING; EMBRYO; CELLS; FGF8	We isolated the cDNA encoding a novel member (207 amino acids) of the fibroblast growth factor (FGF) family from rat embryos. Because this protein is the 18th documented member of the FGF family, we tentatively termed it FGF-18, We have also determined mouse and human FGF-18 with high amino acid identity (99.5 and 99.0%) to rat FGF-18, respectively. Among FGF family members, FGF-18 is most similar (52.7% amino acid identity) to FGF-8 and FGF-17, FGF-18 has a typical signal sequence at its amino terminus. Recombinant rat FGF-18, which was efficiently secreted by High Five insect cells infected with recombinant baculovirus containing the cDNA, induced neurite outgrowth in PC12 cells. The expression of FGF-18 mRNA was examined in adult rat tissues and embryos by Northern blotting analysis and in situ hybridization, FGF-18 mRNA of similar to 2.7 kilobases was preferentially detected in the lung among adult rat tissues examined. In rat embryos, FGF-18 mRNA was detected in several discrete regions at embryonic days 14.5 and 19.5 but not at E10.5, The temporal and spatial patterns of FGF-18 mRNA expression in embryos are quite different from those of FGF-8 and FGF-17 mRNAs reported. The present results indicate that FGF-18 is a unique secreted signaling molecule in the adult lung and developing tissues.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Sangyo Univ, Fac Engn, Dept Biotechnol, Kita Ku, Kyoto 6038555, Japan	Kyoto University; Kyoto Sangyo University	Itoh, N (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Kyoto 6068501, Japan.	itohnobu@pharm.kyoto-u.ac.jp		Yamasaki, Masahiro/0000-0002-5296-4974				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COULIER F, 1991, ANN NY ACAD SCI, V638, P53, DOI 10.1111/j.1749-6632.1991.tb49017.x; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; Lin HY, 1996, J NEUROSCI, V16, P4579; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x	22	135	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18161	18164		10.1074/jbc.273.29.18161	http://dx.doi.org/10.1074/jbc.273.29.18161			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660775	hybrid			2022-12-27	WOS:000074828500030
J	Duncan, EA; Dave, UP; Sakai, J; Goldstein, JL; Brown, MS				Duncan, EA; Dave, UP; Sakai, J; Goldstein, JL; Brown, MS			Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SYNTHASE GENE; EXPRESSION; ACTIVATION; PROMOTER; SREBP-2; DIFFERENTIATION; REDUCTASE	In response to sterol deprivation, two sequential proteolytic cleavages release the NH2-terminal fragments of sterol regulatory element-binding proteins (SREBPs) from cell membranes, The fragments translocate to the nucleus where they activate genes involved in cholesterol and fatty acid metabolism. The SREBPs are bound to membranes in a hairpin fashion. The NH2-terminal and COOH-terminal domains face the cytoplasm, separated by two membrane spanning segments and a short lumenal loop. The first cleavage occurs at Site-1 in the lumenal loop. The NH2-terminal fragment is then released by cleavage at Site-2, which is believed to lie within the first transmembrane segment. Here, we use a novel cysteine panning method to identify the second cleavage site (Site-2) in human SREBP-2 as the Leu(484) Cys(485) bond that lies at the junction between the cytoplasmic NH2-terminal fragment and the first transmembrane segment. We transfected cells with cDNAs encoding fusion proteins with single cysteine residues at positions to the NH2-terminal and COOH-terminal sides of cysteine 485. The NH2-terminal fragments were tested for susceptibility to modification with N-alpha-(3-maleimidylpropionyl)biocytin, which attaches a biotin group to cysteine sulfhydryls, Cysteines to the NH2-terminal side of cysteine 485 were retained on the NH2-terminal fragment, but cysteines to the COOH-terminal side of leucine 484 were lost. Leucine 484 is three residues to the COOH-terminal side of the tetrapeptide Asp-Arg-Ser-Arg, which immediately precedes the first transmembrane segment and is required for Site-2 cleavage.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Duncan, EA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Sakai, Juro/0000-0003-4043-1035	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOLLAG DM, 1991, PROTEIN METHODS, P100; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; DEISENHOFER J, 1989, CHEM SCRIPTA, V29, P205; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; MOCCHETTI I, 1986, P NATL ACAD SCI USA, V83, P7221, DOI 10.1073/pnas.83.19.7221; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1994, J BIOL CHEM, V269, P17267; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Theopold U, 1996, P NATL ACAD SCI USA, V93, P1195, DOI 10.1073/pnas.93.3.1195; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910	30	122	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17801	17809		10.1074/jbc.273.28.17801	http://dx.doi.org/10.1074/jbc.273.28.17801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651382	hybrid			2022-12-27	WOS:000074816100075
J	Nassir, F; Bonen, DK; Davidson, NO				Nassir, F; Bonen, DK; Davidson, NO			Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATIONS; APO-B SECRETION; HEP G2 CELLS; INTRACELLULAR DEGRADATION; BABOON HEPATOCYTES; TRANSLOCATION; PROTEIN; GENE; MUTAGENESIS; PHENOTYPES	Apolipoprotein(a) (apo(a)) is synthesized and secreted from liver cells and represents one of the two major protein components of the atherogenic lipoprotein, Lp(a), Little is known, however, of the factors that regulate the secretion of this protein. We have undertaken an analysis of the response to oleate supplementation in stable clones of HepG2 and McA-RH7777 cells express ing either a 6 K-IV or 17 K-IV isoform of apo(a), These cell lines were examined by pulse chase analysis and each demonstrated an increase (range 2-6-fold) in apo(a) secretion following supplementation with 0.8 mM oleate, Microsomal membranes, prepared from HepG2 cells expressing a 6 K-TV apo(a) isoform, demonstrated that oleate supplementation increased the apparent protection of apo(a) from protease digestion, suggesting that alterations in the translocation efficiency of apo(a) may accompany the addition of oleate, Cells incubated with brefeldin A demonstrated increased recovery of the precursor form of apo(a) with oleate supplementation, suggesting that alterations in post-translational degradation may also contribute to the observed in crease in apo(a) secretion following oleate addition. To further characterize the oleate-dependent increase in apo(a) secretion, cells were incubated with an inhibitor of the microsomal triglyceride transfer protein. These experiments demonstrated a dose dependent decrease in apo(a) secretion from both cell lines. Furthermore, addition of either the microsomal triglyceride transfer protein inhibitor or triacsin C, an inhibitor of acyl-CoA synthase, completely abrogated the oleate-dependent increase in apo(a) secretion. Taken together, these data provide evidence that apo(a) secretion from hepatoma cells may be linked to elements of cellular triglyceride assembly and secretion.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Davidson, NO (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 4076, Chicago, IL 60637 USA.	ndavidso@medicine.bsd.uchicago.edu		Nassir, Fatiha/0000-0002-3653-3621	NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK42030] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, P01HL018577, R37HL038180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angelin B, 1997, CURR OPIN LIPIDOL, V8, P337, DOI 10.1097/00041433-199712000-00003; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bonen DK, 1997, J BIOL CHEM, V272, P5659, DOI 10.1074/jbc.272.9.5659; BONEN DK, 1998, IN PRESS J LIPID RES; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BROUSSEAU ME, 1994, ATHEROSCLEROSIS, V106, P109, DOI 10.1016/0021-9150(94)90087-6; Brunner C, 1996, J BIOL CHEM, V271, P32403, DOI 10.1074/jbc.271.50.32403; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; DAVIDSON NO, 1985, J LIPID RES, V26, P368; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EDELSTEIN C, 1994, CHEM PHYS LIPIDS, V67-8, P135, DOI 10.1016/0009-3084(94)90132-5; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Gaw Allan, 1994, Current Opinion in Lipidology, V5, P149, DOI 10.1097/00041433-199404000-00012; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Hoppichler F, 1996, ATHEROSCLEROSIS, V122, P127, DOI 10.1016/0021-9150(96)05803-0; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Ingram MF, 1996, J LIPID RES, V37, P2202; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENZEL HJ, 1990, J BIOL CHEM, V265, P981; Mooser V, 1996, J CLIN INVEST, V98, P2414, DOI 10.1172/JCI119055; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; Rouy D, 1998, J BIOL CHEM, V273, P1247, DOI 10.1074/jbc.273.2.1247; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; Scanu AM, 1997, J LIPID RES, V38, P2193; SCANU AM, 1992, METABOLISM, V41, P1361, DOI 10.1016/0026-0495(92)90108-M; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1993, J LIPID RES, V34, P509; WHITE AL, 1994, J BIOL CHEM, V269, P28716; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Wu XJ, 1996, J LIPID RES, V37, P1198; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Wu XJ, 1997, ARTERIOSCL THROM VAS, V17, P3347, DOI 10.1161/01.ATV.17.11.3347; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zysow BR, 1997, ARTERIOSCL THROM VAS, V17, P1741, DOI 10.1161/01.ATV.17.9.1741	47	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17793	17800		10.1074/jbc.273.28.17793	http://dx.doi.org/10.1074/jbc.273.28.17793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651381	hybrid			2022-12-27	WOS:000074816100074
J	Takahashi, H; Asano, K; Kinouchi, M; Ishida-Yamamoto, A; Wuepper, KD; Iizuka, H				Takahashi, H; Asano, K; Kinouchi, M; Ishida-Yamamoto, A; Wuepper, KD; Iizuka, H			Structure and transcriptional regulation of the human cystatin A gene - The 12-O-tetradecanoylphorbol-13-acetate (TPA) responsive element-2 site (-272 to -278) on cystatin A gene is critical for TPA-dependent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN INVOLUCRIN GENE; CORNIFIED CELL-ENVELOPE; KERATINOCYTE DIFFERENTIATION; TERMINAL DIFFERENTIATION; EXPRESSION; CYSTEINE; INHIBITOR; EPIDERMIS; PROMOTER	Cystatin A, a cysteine proteinase inhibitor, is one of the precursor proteins of cornified cell envelope of keratinocytes and is expressed during the late stage of keratinocyte differentiation. We have isolated and characterized the human cystatin A gene. The cystatin A gene consists of three exons and two introns, The first, the second, and the third exons consist of coding sequences that are 66, 102, and 126 base pairs in length, respectively. The first and the second introns consist of 14 and 3.6 kilobase pairs, respectively. The transcription initiation site was located 55 base pairs upstream from the first translation site. The fragment, +77 to -2595 in the 5'-flanking region of the human cystatin A gene, was subcloned into a chloramphenicol acetyltransferase (CAT) reporter vector. The expression vector, p2672CAT, produced a significant CAT activity in transiently transfected SV40-transformed human keratinocytes (SVHK cells), that were further stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), a potent protein kinase C activator. Sequence analysis of the gene detected three TPA responsive elements (TRE-1, TRE-2, and TRE-3) and one AP-2 site on the 5' upstream promoter region, Deletion analyses of the p2672CAT vector demonstrated that TRE-2, which was located bet ween -272 and -278, was critical for the regulation by TPA Gel shift analyses revealed that c-Jun, JunD, and c-Fos bound to the TRE-2 region and that the p2672CAT activity level was elevated by co-transfection with c-Jun and c-Fos or with JunD and c-Fos expression vectors. Furthermore, co-transfection of SVHK cells with the protein kinase C-alpha expression vector and the p2672CAT expression vector also resulted in an increased CAT activity. These results indicate that the 5'-flanking region of the human cystatin A gene confers promoter activity and contains a TRE (TRE-2) that mediates, at least in part, the enhanced expression of this gene by TPA.	Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 078, Japan; Oregon Hlth Sci Univ, Dept Dermatol, Portland, OR 97201 USA	Asahikawa Medical College; Oregon Health & Science University	Takahashi, H (corresponding author), Asahikawa Med Coll, Dept Dermatol, 3-11 Nishikagura, Asahikawa, Hokkaido 078, Japan.	ht@asakikawa-med.ac.jp						ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BRZIN J, 1982, FEBS LETT, V138, P193, DOI 10.1016/0014-5793(82)80439-0; BRZIN J, 1983, H-S Z PHYSIOL CHEM, V364, P1475, DOI 10.1515/bchm2.1983.364.2.1475; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; GREEN GDJ, 1984, BIOCHEM J, V218, P939, DOI 10.1042/bj2180939; HAWLEYNELSON P, 1982, EXP CELL RES, V137, P155, DOI 10.1016/0014-4827(82)90017-9; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J BIOL CHEM, V266, P6626; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IshidaYamamoto A, 1997, J INVEST DERMATOL, V108, P12, DOI 10.1111/1523-1747.ep12285611; JARVINEN M, 1978, J INVEST DERMATOL, V71, P114, DOI 10.1111/1523-1747.ep12546165; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; MAFSON RA, 1982, CANCER RES, V42, P4600; MANIATIS T, 1989, MOL CLONING LAB MANU, pCH13; NEUMAN JR, 1987, BIOTECHNIQUES, V5, P441; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SAITOH E, 1987, GENE, V61, P329, DOI 10.1016/0378-1119(87)90196-X; SHAW PA, 1988, J BIOL CHEM, V263, P18133; SIMON M, 1994, KERATINOCYTE HDB, P275; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; STEINBERG ML, 1983, J INVEST DERMATOL, V81, pS131, DOI 10.1111/1523-1747.ep12540905; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TAKAHASHI H, 1995, ARCH DERMATOL RES, V287, P740, DOI 10.1007/BF01105799; TAKAHASHI H, 1990, Journal of Dermatology (Tokyo), V17, P457; TEZUKA T, 1994, DERMATOLOGY, V188, P21, DOI 10.1159/000247079; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WEVERS A, 1992, ARCH DERMATOL RES, V284, P5, DOI 10.1007/BF00371918; YAMADA H, 1987, ARCH DERMATOL RES, V279, P194, DOI 10.1007/BF00413257; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	44	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17375	17380		10.1074/jbc.273.28.17375	http://dx.doi.org/10.1074/jbc.273.28.17375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651321	hybrid			2022-12-27	WOS:000074816100014
J	Deng, JB; Kawakami, Y; Hartman, SE; Satoh, T; Kawakami, T				Deng, JB; Kawakami, Y; Hartman, SE; Satoh, T; Kawakami, T			Involvement of Ras in Bruton's tyrosine kinase-mediated JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; FC-EPSILON-RI; SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; RHO-FAMILY GTPASES; PROTEIN-KINASE; CROSS-LINKING; C-JUN; HEMATOPOIETIC-CELLS	Defects in Bruton's tyrosine kinase (Btk) result in B cell immunodeficiencies in humans and mice. Recent studies showed that Btk is required for maximal activation of JNK, a family of stress-activated protein kinases, induced by several extracellular stimuli including interleukin (IL)-3. On the other hand, IL-3-induced JNK activation is dependent on Ras. In the present study we have investigated whether Ras is involved in Btk-mediated JNK activation in BaF3 mouse pro-B cells. Overexpression of wild-type Btk: protein in these cells enhanced JNK activation upon IL-3 stimulation, whereas expression of kinase-dead Btk partially suppressed JNK activation. Induced expression of the dominant negative Ras(N17) in the cells overexpressing wild-type Btk suppressed JNK activation. Importantly, overexpression of Btk enhanced the level of the GTP-bound, active form of Ras in response to IL-3 stimulation. Btk overexpression also increased the Shc-Grb2 association induced by IL-3 stimulation. Expression of either N17Ras or V12Ras did not impose any effects on Btk kinase activity. These data collectively indicate that Ras plays a role of an intermediary signaling protein in Btk-mediated JNK activation induced by the IL-3 signaling pathway.	La Jolla Inst Allergy & Immunol, Div Allergy, San Diego, CA 92121 USA; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	La Jolla Institute for Immunology; Tokyo Institute of Technology	Kawakami, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Allergy, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	toshi_kawakami@liai.org	Satoh, Takaya/K-2628-2014; Kawakami, Toshiaki/O-1616-2015		NIAID NIH HHS [AI33617, AI38348] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038348, R01AI033617] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COSO OA, 1995, CELL, V81, P1187; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; ISFORT R, 1988, J BIOL CHEM, V263, P19203; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1995, METHOD ENZYMOL, V255, P149; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SORENSEN PHB, 1989, BLOOD, V73, P406; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tarakhovsky A, 1997, CURR OPIN IMMUNOL, V9, P319, DOI 10.1016/S0952-7915(97)80076-3; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	59	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16787	16791		10.1074/jbc.273.27.16787	http://dx.doi.org/10.1074/jbc.273.27.16787			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642236	hybrid			2022-12-27	WOS:000074545200026
J	Rezaie, AR				Rezaie, AR			Calcium enhances heparin catalysis of the antithrombin factor Xa reaction by a template mechanism - Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; ANTICOAGULANT ACTION; PROTEINASE REACTIONS; HIGH-AFFINITY; CA2+ BINDING; THROMBIN; ACCELERATION; OLIGOSACCHARIDES; RESOLUTION; ACTIVATION	It is believed that heparin accelerates factor Xa (FXa) inactivation by antithrombin (AT) by conformationally activating the inhibitor rather than by bridging AT and FXa in a ternary complex (template effect). This is derived from kinetic studies done in the absence of Ca(2+) or in the presence of EDTA. To test the possibility that the anionic Gla domain of FXa, when not neutralized by Ca(2+) ions, prevents heparin binding to FXa, the heparin and pentasaccharide dependence of FXa inactivation by AT in both the absence (100 mu M EDTA) and presence of Ca(2+) (2.5 mM) was studied using wild-type FXa and a FXa derivative that lacks the Gla domain (GDFXa). AT inactivated both FXa derivatives similarly in both the absence and presence of Ca(2+) (k(2) = 1.7-2.5 x 10(3) m(-1) s(-1)). The active AT-binding pentasaccharide also accelerated the inactivation rates of both derivatives similarly in both the absence and presence of Ca(2+) (K(2) = 5.7- 8.0 x 10(5) M(-1) s(-1)). However, in the presence of an optimum concentration of heparin (similar to 50 nM) the inactivation rate constant of FXa in the presence of Ca(2+) (k(2) = 4.4 x 10(7) M(-1) s(-1)) was 13-fold higher than the rate constant in the absence of Ca(2+) (k(2) = 3.5 x 10(6) M(-1) s(-1)). Heparin acceleration of GDFXa inactivation by AT was rapid and insensitive to the presence or absence of Ca(2+) (k(2) = 5.1-5.9 x 10(7) M(-1) s(-1)). The additional cofactor effect of heparin with all FXa derivatives was a bell-shaped curve, which disappeared if the ionic strength of the reaction was increased to similar to 0.4. These results suggest that although the major effect of heparin in acceleration of FXa inactivation is through a heparin-induced conformational change in the reactive site loop of AT, the template effect of heparin, nevertheless, contributes significantly to rapid FXa inactivation at physiological Ca(2+).	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Rezaie, AR (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13Th St, Oklahoma City, OK 73104 USA.	alireza-rezaie@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARROWCLIFFE TW, 1992, ADV EXP MED BIOL, V313, P205; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; OCKELFORD PA, 1982, THROMB RES, V28, P401, DOI 10.1016/0049-3848(82)90121-9; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PLETCHER CH, 1983, J BIOL CHEM, V258, P1086; Rezaie AR, 1998, PROTEIN SCI, V7, P349; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rezaie AR, 1998, BLOOD, V91, P4572, DOI 10.1182/blood.V91.12.4572.412k13_4572_4580; STENFLO J, 1991, BLOOD, V78, P1637; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; THOMAS DP, 1982, THROMB HAEMOSTASIS, V47, P244	29	107	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16824	16827		10.1074/jbc.273.27.16824	http://dx.doi.org/10.1074/jbc.273.27.16824			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642241	hybrid			2022-12-27	WOS:000074545200031
J	Surinya, KH; Cox, TC; May, BK				Surinya, KH; Cox, TC; May, BK			Identification and characterization of a conserved erythroid-specific enhancer located in intron 8 of the human 5-aminolevulinate synthase 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; TRANSCRIPTION FACTOR GATA-1; PORPHOBILINOGEN DEAMINASE GENE; LINKED SIDEROBLASTIC ANEMIA; I HYPERSENSITIVE SITES; KRUPPEL-LIKE FACTOR; DELTA-AMINOLEVULINATE SYNTHASE; IRON-RESPONSIVE ELEMENT; MESSENGER-RNA; 3' ENHANCER	Thirty five kilobases of sequence encompassing the human erythroid Fi-aminolevulinate synthase (ALAS2) gene have been determined. Analysis revealed a very low GC content, few repetitive elements, and evidence for the insertion of a reverse-transcribed mRNA sequence and a neighboring gene. We have investigated whether introns 1, 3, and 8, which correspond to DNase I-hypersensitivity sites in the structurally related mouse ALAS2 gene, affect expression of the human ALAS2 promoter in transient expression assays. Whereas intron 3 was marginally inhibitory, introns 1 and 8 of the human gene stimulated promoter activity. Intron 8 harbored a strong erythroid-specific enhancer activity which was orientation-dependent. Deletion analysis of this region localized enhancer activity to a fragment of 239 base pairs. Transcription factor binding sites clustered within this region include GATA motifs and CACCC boxes, critical regulatory sequences of many erythroid cell-expressed genes. These sites were also identified in the corresponding intron of both the murine and canine ALAS2 genes. Mutagenesis of these conserved sites in the human intron 8 sequence and transient expression analysis in erythroid cells established the functional importance of one GATA motif and two CACCC boxes. The GATA motif bound GATA-1 in vitro, The two functional CACCC boxes each bound Spl or a related protein in vitro, but binding of the erythroid Kruppel-like factor and the basic Kruppel-like factor could not be detected. The intron 8 enhancer region was not activated by GATA-1 together with Spl in transactivation experiments in COS-1 cells indicating the involvement of a related Spl protein or of another unidentified erythroid factor. Overall, these results demonstrate that a GATA-1-binding site and CACCC boxes located within the human ALAS2 intron 8 are critical for the erythroid-specific enhancer activity in transfected erythroid cells, and due to the conserved nature of these binding sites across species, it seems likely that these sites play a functional role in the tissue-restricted expression of the gene in vivo.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	May, BK (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	bmay@biochem.adelaide.edu.au						ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; BOYER G, 1995, ANIM GENET, V26, P206, DOI 10.1111/j.1365-2052.1995.tb03172.x; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CONBOY JG, 1992, J BIOL CHEM, V267, P18753; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TC, 1990, AM J HUM GENET, V46, P107; COX TC, 1992, HUM MOL GENET, V1, P639, DOI 10.1093/hmg/1.8.639; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FUJIWARA J, 1994, J BIOL CHEM, V269, P18558; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kappas A, 1995, METABOLIC MOL BASES, P2103; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KAYA AH, 1994, GENOMICS, V19, P242, DOI 10.1006/geno.1994.1054; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LACRONIQUE V, 1995, J BIOL CHEM, V270, P14989, DOI 10.1074/jbc.270.25.14989; LIM KC, 1994, NUCLEIC ACIDS RES, V22, P1226, DOI 10.1093/nar/22.7.1226; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nemoto Y, 1996, J BIOL CHEM, V271, P13542, DOI 10.1074/jbc.271.23.13542; NICOLIS S, 1991, NUCLEIC ACIDS RES, V19, P5285, DOI 10.1093/nar/19.19.5285; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PERKINS AC, 1995, NATURE, V375, P318; PORCHER C, 1995, J BIOL CHEM, V270, P17368, DOI 10.1074/jbc.270.29.17368; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; Surinya KH, 1997, J BIOL CHEM, V272, P26585, DOI 10.1074/jbc.272.42.26585; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; TAKETANI S, 1995, GENOMICS, V29, P698, DOI 10.1006/geno.1995.9949; TREISMAN R, 1985, NATURE, V315, P72, DOI 10.1038/315072a0; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WEBER F, 1985, NATURE, V315, P75, DOI 10.1038/315075a0; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	73	79	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16798	16809		10.1074/jbc.273.27.16798	http://dx.doi.org/10.1074/jbc.273.27.16798			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642238	hybrid			2022-12-27	WOS:000074545200028
J	Zhou, HL; Summers, SK; Birnbaum, MJ; Pittman, RN				Zhou, HL; Summers, SK; Birnbaum, MJ; Pittman, RN			Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DEATH; PHOSPHORYLATION; DISEASE; SPHINGOMYELINASE; REQUIREMENT; PHOSPHATASE; STIMULATION	Ceramide is an important lipid messenger involved in mediating a variety of cell functions including apoptosis. However, mechanisms responsible for ceramide-induced apoptosis remain unclear. We investigated the possibility that ceramide may decrease antiapoptotic signaling in cells by inhibiting Akt kinase activity. Our data show that C-2-ceramide induces apoptosis in HMN1 motor neuron cells and decreases both basal and insulin- or serum-stimulated Akt kinase activity 65-70%. These results are consistent with decreased Akt kinase activity being involved in the apoptotic effects of ceramide, This possibility is further supported by studies showing that constitutively active Akt kinase decreases C-2-ceramide-induced death of HMN1 cells as well as COS-7 cells. Decreased Akt activity is not due to ceramide activating the ceramide-activated protein phosphatase or to a direct inhibition of Akt kinase by ceramide, suggesting that ceramide acts upstream of Akt kinase to decrease its activity. Treating cells with C-2-ceramide does not affect phosphorylation of insulin receptor substrate-1, interactions between insulin receptor substrate-1 and p85, or insulin-stimulated phosphatidylinositol 3-kinase activity, suggesting that the effects of C-2-ceramide on Akt kinase are not mediated through modulating phosphatidylinositol 3-kinase. In sum, our results suggest that inhibition of the key antiapoptotic kinase, Akt, may play an important role in ceramide-induced apoptosis.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Pittman, RN (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032465] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09475] Funding Source: Medline; NINDS NIH HHS [NS32465] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BOSE R, 1995, CELL, V82, P404; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KNUDSON MC, 1997, NAT GENET, V16, P358; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LIU J, 1994, J BIOL CHEM, V269, P3047; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Parrizas M, 1997, J BIOL CHEM, V272, P154; PITTMAN RP, 1994, J NEUROSCI, V13, P3669; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RINK A, 1995, AM J PATHOL, V147, P1575; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	45	307	316	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16568	16575		10.1074/jbc.273.26.16568	http://dx.doi.org/10.1074/jbc.273.26.16568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632728	hybrid			2022-12-27	WOS:000074436600099
J	Dikov, MM; Reich, MB; Dworkin, L; Thomas, JW; Miller, GG				Dikov, MM; Reich, MB; Dworkin, L; Thomas, JW; Miller, GG			A functional fibroblast growth factor-1 immunoglobulin fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARDIAC ALLOGRAFTS; HUMAN HEPATOMA-CELL; FACTOR-I; T-CELLS; RHEUMATOID-ARTHRITIS; TYROSINE KINASE; MESSENGER-RNA; BOVINE BRAIN; FACTOR FGF; BASIC FGF	Proteins of the fibroblast growth factor (FGF) family play diverse roles in embryonic development, angiogenesis, and wound healing. The most well studied targets of FGF activity typically are cells of mesodermal and neuroectodermal origin; in addition, expression of FGF-1 (acidic FGF) is increased at several sites of chronic immunologic injury, and recent studies show that FGF-1 also may interact with cells of the immune system. In some human T cells, FGF-1 can induce signals necessary for production of interleukin-a, a key cytokine required for T cell proliferation. To better characterize the interaction of FGF-1 with FGF receptors on T cells, a fusion protein was constructed containing a portion of the constant region of human IgG1 (Fc) at the amino terminus of FGF-1, The Fc-FGF-1 fusion protein retained FGF function as determined by stimulation of tyrosine phosphorylation and DNA synthesis in NIH 3T3 cells. Binding of the intact fusion protein to FGF receptor 1 (FGFR1) on T cells was demonstrated by immunoprecipitation of the receptor bound to Fc-FGF-1 and by flow cytometry showing binding of fusion protein to T cells expressing FGFR1. This functional Fc-FGF-1 protein should prove useful in identifying FGFR-expressing cells.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University	Miller, GG (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A3310 Med Ctr N, Nashville, TN 37232 USA.	millergg@ctrvax.vanderbilt.edu		Thomas, James/0000-0002-2098-6458	NHLBI NIH HHS [R01 HL53771] Funding Source: Medline; NIAMS NIH HHS [R01 AR43563] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053771] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BOHLEN P, 1985, EMBO J, V4, P1951, DOI 10.1002/j.1460-2075.1985.tb03876.x; BROJI E, 1993, J CLIN INVEST, V92, P2408; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Byrd V, 1996, ARTHRITIS RHEUM, V39, P914, DOI 10.1002/art.1780390607; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CROWE JS, 1992, CLIN EXP IMMUNOL, V87, P105; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; FERTENSTEIN R, 1996, EMBO J, V271, P1123; FLUGELMAN MY, 1993, CIRCULATION, V88, P2493, DOI 10.1161/01.CIR.88.6.2493; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; JOHNSON HM, 1985, J IMMUNOL, V134, P2824; KAN M, 1988, J BIOL CHEM, V263, P11306; Kerby JD, 1996, TRANSPLANTATION, V62, P190, DOI 10.1097/00007890-199607270-00008; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; MCKEEHAN WL, 1987, ANAL BIOCHEM, V164, P563, DOI 10.1016/0003-2697(87)90534-3; Paul LC, 1996, AM J KIDNEY DIS, V28, P441, DOI 10.1016/S0272-6386(96)90504-1; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SANO H, 1993, J CLIN INVEST, V91, P553, DOI 10.1172/JCI116235; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; WAGNER CR, 1993, J CLIN INVEST, V92, P1269, DOI 10.1172/JCI116699; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; XU JM, 1992, J BIOL CHEM, V267, P17792; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; ZHAO XM, 1993, TRANSPLANTATION, V56, P1177; ZHAO XM, 1995, J IMMUNOL, V155, P3904; ZHAO XM, 1994, J CLIN INVEST, V94, P992, DOI 10.1172/JCI117466; ZHAO XM, 1994, CIRCULATION, V90, P677, DOI 10.1161/01.CIR.90.2.677	41	21	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15811	15817		10.1074/jbc.273.25.15811	http://dx.doi.org/10.1074/jbc.273.25.15811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624181	hybrid			2022-12-27	WOS:000074284200075
J	Kingma, PS; Osheroff, N				Kingma, PS; Osheroff, N			Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing - Abasic lesions as a tool to dissect enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; ANTINEOPLASTIC DRUGS; SITE; REQUIREMENTS; COMPLEX; FORM; NMR	The interaction of topoisomerase II with its DNA cleavage site is critical to the physiological functions of the enzyme. Despite this importance, the specific enzyme-DNA interactions that drive topoisomerase II-mediated DNA cleavage and religation are poorly understood. Therefore, to dissect interactions between the enzyme and its cleavage site, abasic DNA lesions were incorporated into a bilaterally symmetrical and identical cleavage site, Results indicate that topoisomerase II has unique interactions with each position of the 4-base overhang generated by enzyme-mediated DNA cleavage. Lesions located 2 bases 3' to the point of scission stimulated cleavage the most, whereas those 3 bases from the point of scission stimulated cleavage the least. Moreover, an additive and in some cases synergistic cleavage enhancement was observed in oligonucleotides that contained multiple DNA lesions, with levels reaching >60-fold higher than the wild-type substrate. Finally, topoisomerase II efficiently cleaved and religated a DNA substrate in which apyrimidinic sites were simultaneously incorporated at every position on one strand of the 4-base overhang. Therefore, unlike classical DNA ligases in which base pairing is the driving force behind closure of the DNA break, it appears that for topoisomerase II, the enzyme is responsible for the spatial orientation of the DNA termini for ligation.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med Oncol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NIGMS NIH HHS [GM33944, GM53960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; FELIX CA, 1995, CANCER RES, V55, P4287; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GU Y, 1994, CANCER RES, V54, P2326; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; LIU LF, 1983, J BIOL CHEM, V258, P5365; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; RAAP J, 1987, J BIOMOL STRUCT DYN, V5, P219, DOI 10.1080/07391102.1987.10506391; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROWE TC, 1986, CANCER RES, V46, P2021; SANDER M, 1983, J BIOL CHEM, V258, P8421; SCHMIDT VK, 1994, J MOL BIOL, V241, P18, DOI 10.1006/jmbi.1994.1469; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271, DOI 10.1021/bi00200a007; VESNAVER G, 1989, P NATL ACAD SCI USA, V86, P3614, DOI 10.1073/pnas.86.10.3614; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	30	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17999	18002		10.1074/jbc.273.29.17999	http://dx.doi.org/10.1074/jbc.273.29.17999			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660751	hybrid			2022-12-27	WOS:000074828500006
J	Al-Hasani, H; Kinck, CS; Cushman, SW				Al-Hasani, H; Kinck, CS; Cushman, SW			Endocytosis of the glucose transporter GLUT4 is mediated by the GTPase dynamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; TEMPERATURE-SENSITIVE MUTANT; COATED VESICLE FORMATION; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; BREFELDIN-A; 1-PHOSPHATIDYLINOSITOL 3-KINASE; SUBCELLULAR TRAFFICKING; 3T3-L1 ADIPOCYTES; INSULIN-RECEPTOR	To study the role of the GTPase dynamin in GLUT4 intracellular recycling, we have overexpressed dynamin-1 wild type and a GTPase-negative mutant (K44A) in primary rat adipose cells. Transfection was accomplished by electroporation using an hemagglutinin (HA)-tagged GLUT4 as a reporter protein. In cells expressing HA GLUT4 alone, insulin results in an approximate to 7-fold increase in cell surface anti-HA antibody binding. Studies with wortmannin indicate that the kinetics of HA-GLUT4-trafficking parallel those of the native GLUT4 and in addition, that newly synthesized HA-GLUT4 goes to the plasma membrane before being sorted into the insulin responsive compartments. Short term (4 h) coexpression of dynamin-K44A and HA-GLUT4 increases the amount of cell surface HA-GLUT4 in both the basal and insulin-stimulated states. Under conditions of maximal expression of dynamin-K44A (24 h), most or all of the intracellular HA-GLUT4 appears to be present on the cell surface in the basal state, and insulin has no further effect. Measurements of the kinetics of HA-GLUT4 endocytosis show that dynamin-K44A blocks internalization of the glucose transporters. In contrast, expression of dynamin wild type decreases the amount of cell surface HA-GLUT4 in both the basal and insulin stimulated states. These data demonstrate that the endocytosis of GLUT4 is largely mediated by processes which require dynamin.	NIDDK, EDMNS, DB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Al-Hasani, H (corresponding author), NIDDK, EDMNS, DB, NIH, Bldg 10,Rm 5N102,10 Ctr Dr,MSC 1420, Bethesda, MD 20892 USA.	hadi@helix.nih.gov						BAO SC, 1995, J BIOL CHEM, V270, P30199; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; FAN JY, 1983, J CELL SCI, V61, P219; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KONO T, 1981, J BIOL CHEM, V256, P6400; KonoSugita E, 1996, EUR J BIOCHEM, V236, P1033, DOI 10.1111/j.1432-1033.1996.01033.x; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; Malide D, 1997, J HISTOCHEM CYTOCHEM, V45, P1083, DOI 10.1177/002215549704500806; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Malide D, 1997, J CELL SCI, V110, P2795; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; NAKATA T, 1993, J CELL SCI, V105, P1; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OKADA T, 1994, J BIOL CHEM, V269, P3568; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P587; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	60	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17504	17510		10.1074/jbc.273.28.17504	http://dx.doi.org/10.1074/jbc.273.28.17504			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651341	hybrid			2022-12-27	WOS:000074816100034
J	Heraud, JM; Racaud-Sultan, C; Gironcel, D; Albiges-Rizo, C; Giacomini, T; Roques, S; Martel, V; Breton-Douillon, M; Perret, B; Chap, H				Heraud, JM; Racaud-Sultan, C; Gironcel, D; Albiges-Rizo, C; Giacomini, T; Roques, S; Martel, V; Breton-Douillon, M; Perret, B; Chap, H			Lipid products of phosphoinositide 3-kinase and phosphatidylinositol 4 ',5 '-bisphosphate are both required for ADP-dependent platelet spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FOCAL ADHESION KINASE; LIGHT CHAIN KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; THROMBIN RECEPTOR; PHOSPHOLIPASE-C; ACTIVATION; INTEGRIN; WORTMANNIN	We have shown previously that ADP released upon platelet adhesion mediated by alpha(IIb)beta(3) integrin triggers accumulation of phosphatidylinositol 3',4'-bisphosphate (PtdIns-3,4-P-2) (Gironcel, D., Racaud-Sultan, C., Payrastre, B., Haricot, RI., Borchert, G., Kieffer, N., Breton, RI., and Chap, H. (1996) FEES Lett. 389, 253-256). ADP has also been involved in platelet spreading. Therefore, in order to study a possible role of phosphoinositide 3-kinase in platelet morphological changes following adhesion, human platelets were pretreated with specific phosphoinositide 3-kinase inhibitors LY294002 and wortmannin. Under conditions where PtdIns-3,4-P-2 synthesis was totally inhibited (25 mu M LY294002 or 100 nM wortmannin), platelets adhered to the fibrinogen matrix, extended pseudopodia, but did not spread. Moreover, addition of ADP to the medium did not reverse the inhibitory effects of phosphoinositide 3-kinase inhibi tors on platelet spreading. Although synthetic dipalmitoyl PtdIns-3,4-P-2 and dipalnitoyl phosphatidylinositol 3',4',5'-trisphosphate restored only partially platelet spreading, phosphatidylinositol 4',5'-bisphosphate (PtdIns-4,5-P-2) was able to trigger full spreading of wortmannin-treated adherent platelets. Following P-32 labeling of intact platelets, the recovery of [P-32]PtdIns 4,5-P-2 in anti-talin immunoprecipitates from adherent plate lets was found to be decreased upon treatment by wortmannin. These results suggest that the lipid products of phosphoinositide S-kinase are required but not sufficient for ADP-induced spreading of adherent platelets and that PtdIns-4,5-P-2 could be a downstream messenger of this signaling pathway.	Hop Purpan, Inst Federat Rech Immunol Cellulaire & Mol, INSERM, U326, F-31059 Toulouse, France; Fac Med, Inst Albert Bonniot, Lab Etud Differenciat & Adherenee Cellulaires, Unite Mixte Rech CNRS Univ Joseph Fourier 5538, F-38706 La Tronche, France; Ecole Natl Super Aeronaut & Espace, F-31055 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Toulouse; Institut Superieur de l'Aeronautique et de l'Espace (ISAE-SUPAERO)	Racaud-Sultan, C (corresponding author), Hop Purpan, Inst Federat Rech Immunol Cellulaire & Mol, INSERM, U326, F-31059 Toulouse, France.		Albiges-Rizo, Corinne/M-2568-2013; Heraud, Jean-Michel/O-1464-2013; Frachet, Véronique/B-8418-2018; Martel-Frachet, Veronique/B-8657-2014	Heraud, Jean-Michel/0000-0003-1107-0859; Frachet, Véronique/0000-0001-6739-7901; Racaud-Sultan, Claire/0000-0002-6549-1088; ALBIGES-RIZO, Corinne/0000-0002-6333-4150				ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Isenberg G, 1998, INT REV CYTOL, V178, P73; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KOCHS G, 1993, BIOCHEM J, V291, P627, DOI 10.1042/bj2910627; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vignoud L, 1997, J CELL SCI, V110, P1421; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENNSTROM S, 1994, ONCOGENE, V9, P651; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1995, BIOCHEM BIOPH RES CO, V211, P484, DOI 10.1006/bbrc.1995.1839	43	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17817	17823		10.1074/jbc.273.28.17817	http://dx.doi.org/10.1074/jbc.273.28.17817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651384	Green Published, hybrid			2022-12-27	WOS:000074816100077
J	Kwiatkowski, BA; Bastian, LS; Bauer, TR; Tsai, S; Zielinska-Kwiatkowska, AG; Hickstein, DD				Kwiatkowski, BA; Bastian, LS; Bauer, TR; Tsai, S; Zielinska-Kwiatkowska, AG; Hickstein, DD			The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GENE; FUSION; LEUKEMIA; ERYTHROLEUKEMIA; TRANSLOCATION; PROTOONCOGENE; ACTIVATION; PROMOTER; RECEPTOR	The tel gene, recently shown to be translocated in a spectrum of acute and chronic human leukemias, be longs to the ets family of sequence specific transcription factors. To determine the role of Tel in normal hematopoietic development, we used the tel gene as the bait in the yeast two hybrid system to screen a hematopoietic stem cell library. Two partners were identified: Tel binds to itself, and Tel binds to the ets family member Fli-1. In vitro and in vivo assays confirmed these inter actions. In transient transfection assays, Fli-1 transactivates megakaryocytic specific promoters, and Tel inhibits this effect of Fli-1, Transactivation studies using deletion mutants of Tel, and the Tel-AML-1 fusion protein, indicate that the helix-loop-helix domain of Tel only partially inhibits transactivation and that complete inhibition requires the full-length Tel molecule, including the DNA binding domain. The Tel and Fli-1 proteins are expressed early in hematopoiesis, and the inability of Tel fusion proteins such as Tel-AML-1 to counteract Fli-1 mediated transactivation may contribute to the malignant phenotype in human leukemias where this fusion protein is present.	Vet Affairs Paget Sound Hlth Care Syst, Med Res Serv, Seattle, WA 98108 USA; Fred Hutchinson Canc Res Ctr, Div Mol Med, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Oncol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hickstein, DD (corresponding author), Vet Affairs Paget Sound Hlth Care Syst, Med Res Serv, 1660 S Columbian Way, Seattle, WA 98108 USA.							Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bauer TR, 1997, HUM GENE THER, V8, P243, DOI 10.1089/hum.1997.8.3-243; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P38113; HROMAS R, 1994, INT J HEMATOL, V59, P257; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAO VN, 1993, ONCOGENE, V8, P2167; RICARDO R, 1996, BRIT J HAEMATOL, V95, P673; Sambrook J., 2002, MOL CLONING LAB MANU; SETH A, 1990, ONCOGENE, V5, P1761; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZHANG LQ, 1993, ONCOGENE, V8, P1621	19	109	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17525	17530		10.1074/jbc.273.28.17525	http://dx.doi.org/10.1074/jbc.273.28.17525			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651344	hybrid			2022-12-27	WOS:000074816100037
J	Tan, PK; Waites, C; Liu, YJ; Krantz, DE; Edwards, RH				Tan, PK; Waites, C; Liu, YJ; Krantz, DE; Edwards, RH			A leucine-based motif mediates the endocytosis of vesicular monoamine and acetylcholine transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE CORE VESICLES; SYNAPTIC VESICLE; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; FUNCTIONAL IDENTIFICATION; INTERNALIZATION MOTIF; CHROMAFFIN GRANULES; CARBOXYL-TERMINUS; TARGETING SIGNAL; MEMBRANE-PROTEIN	Specific transport proteins mediate the packaging of neurotransmitters into secretory vesicles and consequently require targeting to the appropriate intracellular compartment, To identify residues in the neuron-specific vesicular monoamine transporter (VMAT2) responsible for endocytosis, we examined the effect of amino (NH2-) and carboxyl (COOH-)-terminal mutations on steady state distribution and internalization. Deletion of a critical COOH terminal domain sequence (AKEEKMAIL) results in accumulation of VMAT2 at the plasma membrane and a 50% reduction in endocytosis. Site directed mutagenesis shows that replacement of the isoleucine-leucine pair within this sequence by alanine-alanine alone reduces endocytosis by 50% relative to wild type VMAT2. Furthermore, the KEEKMAIL se quence functions as an internalization signal when transferred to the plasma membrane protein Tac, and the mutation of the isoleucine-leucine pair also abolishes internalization of this protein. The closely related vesicular acetylcholine transporter (VAChT) contains a similar di leucine sequence within the cytoplasmic COOH-terminal domain that when mutated results in accumulation of VAChT at the plasma membrane. The VAChT di-leucine sequence also confers internalization when appended to two other proteins and in one of these chimeras, conversion of the di-leucine sequence to dialanine reduces the internalization rate by 50%. Both VMAT2 and VAChT thus use leucine-based signals for efficient endocytosis and as such are the first synaptic vesicle proteins known to use this motif for trafficking.	Univ Calif San Francisco, Sch Med, Dept Neurol, Grad Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, Grad Program Cell Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurol, Grad Program Neurosci, 3rd & Parnassus Ave, San Francisco, CA 94143 USA.	edwards@itsa.ucsf.edu	Liu, Yongjian/J-7852-2018					BREMNES B, 1994, J CELL SCI, V107, P2021; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gilmor ML, 1996, J NEUROSCI, V16, P2179; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Hao JC, 1997, J NEUROSCI, V17, P1596; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; KREJCI E, 1993, FEBS LETT, V335, P27, DOI 10.1016/0014-5793(93)80432-T; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nirenberg MJ, 1996, J NEUROSCI, V16, P4135; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Ooi CE, 1997, EMBO J, V16, P4508; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; PETER D, 1995, J NEUROSCI, V15, P6179; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHELLER RH, 1995, NEURON, V14, P893; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; TOOZE SA, 1993, MECHANISMS INTRACELL, P157; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VORHEES P, 1995, EMBO J, V14, P4961	68	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17351	17360		10.1074/jbc.273.28.17351	http://dx.doi.org/10.1074/jbc.273.28.17351			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651318	hybrid			2022-12-27	WOS:000074816100011
J	Vinogradova, O; Carlin, C; Sonnichsen, FD; Sanders, CR				Vinogradova, O; Carlin, C; Sonnichsen, FD; Sanders, CR			A membrane setting for the sorting motifs present in the adenovirus E3-13.7 protein which down-regulates the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; SELF-DIFFUSION MEASUREMENTS; LYSOSOMAL ACID-PHOSPHATASE; DI-LEUCINE MOTIF; CYTOPLASMIC TAIL; INTERNALIZATION SIGNAL; ENDOCYTIC PATHWAY; II RECEPTOR; TYROSINE; SYSTEMS	The adenovirus E3-13.7 protein interferes with endo somal protein sorting to down-regulate the epidermal growth factor receptor and related tyrosine kinase receptors. The cytoplasmic C terminus of this protein contains three protein sorting motifs which are related to the function of E3-13.7, In this study, the structure of a 23-residue polypeptide corresponding to this domain was examined using solution NMR and CD spectroscopic methods. The peptide was observed to exist in a mostly random structural state in aqueous solution but underwent high affinity association with dodecylphosphocholine micelles, where it adopted an ordered structure. The affinity of this peptide for the micellar surface and the structure of the bound peptide were independent of pH variation, surface charge, or attachment of a myristoyl anchor to the N-terminal. Studies with phospholipid vesicles suggested that the micellar structural results can be extrapolated to a true lipid bilayer. On the micellar surface all three sorting motifs are closely associated with the water/apolar interface: 72-YLRH and 87-LL lie within interfacial amphipathic helices, while 76-HPQY is non-helical and dimples just above the surface. These results contribute to the development of an understanding of the basis for specificity in recognition of sorting motifs by components of the cellular protein trafficking machinery.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sanders, CR (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	crs4@po.cwru.edu	Sönnichsen, Frank D/D-8408-2011; Vinogradova, Olga/ABE-8367-2020	Sönnichsen, Frank D/0000-0002-4539-3755; Vinogradova, Olga/0000-0001-5101-7361	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047485, R29GM047485] Funding Source: NIH RePORTER; NCI NIH HHS [CA49650] Funding Source: Medline; NHLBI NIH HHS [T32 HL07653] Funding Source: Medline; NIGMS NIH HHS [GM47485] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; AMESON LS, 1995, J CELL BIOL, V129, P1217; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANG CP, 1993, J BIOL CHEM, V268, P19312; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; Gao XF, 1998, BIOPHYS J, V74, P1871, DOI 10.1016/S0006-3495(98)77897-X; Gennis R.B., 1989, BIOMEMBRANES; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; HOFFMAN P, 1994, MOL CELL BIOL, V14, P3996; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JONSSON B, 1986, COLLOID POLYM SCI, V264, P77, DOI 10.1007/BF01410310; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; Kroenke CD, 1997, BIOCHEMISTRY-US, V36, P8145, DOI 10.1021/bi9705669; KUIVINEN E, 1993, J CELL BIOL, V120, P1271, DOI 10.1083/jcb.120.5.1271; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SODERMAN O, 1994, PROG NUCL MAG RES SP, V26, P445, DOI 10.1016/0079-6565(94)80013-8; STILBS P, 1982, J COLLOID INTERF SCI, V87, P385, DOI 10.1016/0021-9797(82)90335-6; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VINOGRADOVA O, 1998, IN PRESS J BIOMOL NM; WILDE A, 1994, J BIOL CHEM, V269, P7131; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17343	17350		10.1074/jbc.273.28.17343	http://dx.doi.org/10.1074/jbc.273.28.17343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651317	hybrid			2022-12-27	WOS:000074816100010
J	Bursey, EH; Burgess, BK				Bursey, EH; Burgess, BK			Characterization of a variant iron protein of nitrogenase that is impaired is its ability to adopt the MgATP-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; KLEBSIELLA-PNEUMONIAE; SIGNAL-TRANSDUCTION; MOLYBDENUM COFACTOR; NUCLEOTIDE-BINDING; FE-PROTEIN; CRYSTALLOGRAPHIC STRUCTURE; ADENOSINE 5'-TRIPHOSPHATE; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE	An Azotobacter vinelandii nitrogenase iron protein mutant has been created which contains an alanine to glycine substitution at amino acid 157, The strain expressing this mutant Fe protein is able to grow under nitrogen-fixing conditions. This contrasts with an A. vinelandii strain described previously which is unable to grow under nitrogen-fixing conditions and which expresses an Fe protein variant that has an alanine to serine mutation at position 157, The A157S Fe protein was unable to support substrate reduction by nitrogenase because of an inability to undergo a required MgATP-induced conformational change. Although the A157G strain grows at 55% of the rate of the wild-type strain, purified A157G; Fe protein is only able to support substrate reduction in in vitro assays at a rate that is approximately 20% of the rate supported by the wildtype Fe protein. Electron paramagnetic resonance, circular dichroism spectroscopies, and enzymatic activity data indicate that the A157G Fe protein adopts the correct conformation upon the binding of MgATP, However, kinetic studies using chelation show that this protein undergoes the conformational change more slowly than the wild-type protein. Thus, this mutant has lower activity because of an impaired ability to undergo this conformational change. Comparison of two available xray crystal structures of the native Fe protein alone and complexed with the MoFe protein has provided us with a model to explain the change in activity in alanine 157 mutants. Steric interactions with the side chain of residue 157 influence the protein's ability to undergo the initial MgATP-induced conformational change. In the case of the A157G mutant, however, once the correct conformation is attained, the protein can participate in all subsequent reactions including complex formation, electron transfer, and MgATP hydrolysis, Thus, the role of alanine 157 is to stabilize the proper initial conformation upon MgATP binding.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NIGMS NIH HHS [GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN L, 1994, J BIOL CHEM, V269, P3290; DEITS TL, 1989, J BIOL CHEM, V264, P6619; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; LANZILOTTA WN, 1995, BIOCHEMISTRY-US, V34, P10713, DOI 10.1021/bi00034a003; Lanzilotta WN, 1996, BIOCHEMISTRY-US, V35, P7188, DOI 10.1021/bi9603985; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PALMER G, 1972, ARCH BIOCHEM BIOPHYS, V153, P325, DOI 10.1016/0003-9861(72)90452-3; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Ryle MJ, 1996, J BIOL CHEM, V271, P1551, DOI 10.1074/jbc.271.3.1551; RYLE MJ, 1995, J BIOL CHEM, V270, P13112, DOI 10.1074/jbc.270.22.13112; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SEEFELDT LC, 1994, PROTEIN SCI, V3, P2073, DOI 10.1002/pro.5560031120; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; SEEFELDT LC, 1993, PROTEIN SCI, V2, P93; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WEHR CT, 1980, NUCL ACID CONSTITUEN; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	45	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16927	16934		10.1074/jbc.273.27.16927	http://dx.doi.org/10.1074/jbc.273.27.16927			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642255	hybrid			2022-12-27	WOS:000074545200045
J	Keller, SH; Lindstrom, J; Taylor, P				Keller, SH; Lindstrom, J; Taylor, P			Inhibition of glucose trimming with castanospermine reduces calnexin association and promotes proteasome degradation of the alpha-subunit of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; BINDING-SITE; PROTEIN-DEGRADATION; LIGAND-BINDING; IN-VITRO; KAPPA-B; RESIDUES; PATHWAY; PHOSPHORYLATION	To identify factors involved in the expression of ligand-gated ion channels, we expressed nicotinic acetylcholine receptors in HEK cells to characterize roles for oligosaccharide trimming, calnexin association, and targeting to the proteasome. The homologous subunits of the acetylcholine receptor traverse the membrane four times, contain at least one oligosaccharide, and are retained in the endoplasmic reticulum until completely assembled into the circular arrangement of subunits of delta-alpha-gamma-alpha-beta to enclose the ion channel. We previously demonstrated that calnexin is associated with unassembled subunits of the receptor, but appears to dissociate when subunits are assembled in various combinations. We used the glucosidase inhibitor castanospermine to block oligosaccharide processing, and thereby inhibit calnexin's interaction with the oligosaccharides in the receptor subunits. Castanospermine treatment reduces the association of calnexin with the alpha-subunit of the receptor, and diminishes the intracellular accumulation of unassembled receptor subunit protein. However, treatment with castanospermine does not appear to alter subunit folding or assembly. In contrast, co-treatment with proteasome inhibitors and castanospermine enhances the accumulation of polyubiquitin-conjugated alpha-subunits, and generally reverses the castanospermine induced loss of alpha-subunit protein. Co-transfection of cDNAs encoding the alpha- and delta-subunits, which leads to the expression of assembled alpha- and delta- subunits, also inhibits the loss of cu-subunits expressed in the presence of castanospermine. Taken together, these observations indicate that calnexin association reduces the degradation of unassembled receptor subunits in the ubiquitin-proteasome pathway.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of Pennsylvania; University of Pennsylvania	Keller, SH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM18360] Funding Source: Medline; NINDS NIH HHS [NS11323, NS09715] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009715, R01NS011323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN TJ, 1988, J CELL BIOL, V106, P469, DOI 10.1083/jcb.106.2.469; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; CHANGEUX JP, 1995, BIOCHEM SOC T, V23, P195, DOI 10.1042/bst0230195; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HERBERT DN, 1996, EMBO J, V15, P2961; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MOSS SJ, 1989, J BIOL CHEM, V264, P20199; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VanLeeuwen JEM, 1997, J BIOL CHEM, V272, P4179, DOI 10.1074/jbc.272.7.4179; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	51	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17064	17072		10.1074/jbc.273.27.17064	http://dx.doi.org/10.1074/jbc.273.27.17064			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642271	hybrid			2022-12-27	WOS:000074545200061
J	Sreenivas, A; Patton-Vogt, JL; Bruno, V; Griac, P; Henry, SA				Sreenivas, A; Patton-Vogt, JL; Bruno, V; Griac, P; Henry, SA			A role for phospholipase D (Pld1p) in growth, secretion, and regulation of membrane lipid synthesis in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSFER PROTEIN; IDENTIFICATION; GENE; MEIOSIS	The SEC14 gene encodes a phosphatidylinositol/phosphatidylcholine transfer protein essential for secretion and growth in yeast (1). Mutations (cki1, cct1, and cpt1) in the CDP-choline pathway for phosphatidylcholine synthesis suppress the sec14 growth defect (2), permitting sec14(ts) cki1, sec14(ts) cct1, and sec14(ts) cpt1 strains to grow at the sec14(ts) restrictive temperature. Previously, we reported that these double mutant strains also ex crete the phospholipid metabolites, choline and inositol (3). We now report that these choline and inositol excretion phenotypes are eliminated when the SPO14 (PLD1) gene encoding phospholipase DI is deleted. In contrast to sec14(ts) cki1 strains, sec14(ts) cki1 pld1 strains are not viable at the sec14(ts) restrictive temperature and exhibit a pattern of invertase secretion comparable with sec14(ts) strains, Thus, the PLD1 gene product appears to play an essential role in the suppression of the sec14(ts) defect by CDP-choline pathway mutations, indicating a role for phospholipase D1 in growth and secretion. Furthermore, sec14(ts) strains exhibit elevated Ca2+-independent, phophatidylinositol 4,5-bisphosphate-stimulated phospholipase D activity, We also propose that phospholipase D1-mediated phosphatidylcholine turnover generates a signal that activates transcription of INO1, the structural gene for inositol l-phosphate synthase.	Carnegie Mellon Univ, Dept Sci Biol, Pittsburgh, PA 15213 USA; Slovak Acad Sci, Inst Anim Biochem & Genet, Ivanka Pri Dunaj 90028, Czech Republic	Carnegie Mellon University; Slovak Academy of Sciences	Henry, SA (corresponding author), Carnegie Mellon Univ, Dept Sci Biol, 440 5th Ave, Pittsburgh, PA 15213 USA.		Henry, Susan/K-5464-2014; , Peter/ABA-9227-2020	, Peter/0000-0003-3538-0405	NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P7789; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; DAUM G, 1983, BIOCHIM BIOPHYS ACTA, V753, P430, DOI 10.1016/0005-2760(83)90067-X; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GRAVES JA, 1996, THESIS CARNEGIEMELLO; GREENBERG ML, 1982, GENETICS, V100, P19; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; HONIGBERG SM, 1992, GENETICS, V130, P703; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; Mayr JA, 1996, FEBS LETT, V393, P236, DOI 10.1016/0014-5793(96)00893-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Wakelam MJO, 1997, SEMIN CELL DEV BIOL, V8, P305, DOI 10.1006/scdb.1997.0152; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Waksman M, 1997, J BIOL CHEM, V272, P36	29	124	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16635	16638		10.1074/jbc.273.27.16635	http://dx.doi.org/10.1074/jbc.273.27.16635			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642212	hybrid			2022-12-27	WOS:000074545200002
J	Kekuda, R; Prasad, PD; Wu, XA; Wang, HP; Fei, YJ; Leibach, FH; Ganapathy, V				Kekuda, R; Prasad, PD; Wu, XA; Wang, HP; Fei, YJ; Leibach, FH; Ganapathy, V			Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; COTRANSPORTER; MECHANISMS; ANIONS; KIDNEY; SYSTEM	We have isolated a cDNA from rat placenta which, when expressed heterologously, mediates the transport of a wide spectrum of organic cations, The cDNA codes for a protein of 551 amino acids containing 12 putative transmembrane domains, Northern blot analysis indicates that this transporter is expressed most abundantly in the placenta and moderately in the intestine, heart, and brain. The expression is comparatively low in the kidney and lung and is undetectable in the Liver. This transporter is distinct from the previously cloned organic cation transporters (OCT1, OCT2, NKT, NLT, RST, and OCTN1), When expressed in HeLa cells, the cDNA induces the transport of tetraethylammonium and guanidine, Competition experiments indicate that this transport process recognizes a large number of organic cations, including the neurotoxin 1-methyl-4-phenylpyridinium, as substrates, The cDNA-induced transport is markedly influenced by extracellular pH, However, when expressed in Xenopus laevis oocytes, the cDNA-induced transport is electrogenic, associated with the transfer of positive charge into the oocytes, Under voltage clamp conditions, tetraethylammonium evokes inward currents that are concentration- and potential-dependent. This potential-sensitive organic cation transporter, designated as OCT3, represents a new member of the OCT gene family.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				NICHD NIH HHS [HD 10045] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Busch AE, 1996, FEBS LETT, V395, P153, DOI 10.1016/0014-5793(96)01030-7; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Grundemann D, 1997, J BIOL CHEM, V272, P10408; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Kekuda R, 1997, AM J PHYSIOL-GASTR L, V272, pG1463, DOI 10.1152/ajpgi.1997.272.6.G1463; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PRASAD PD, 1992, J BIOL CHEM, V267, P23632; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Zevin S, 1997, PHARMACEUT RES, V14, P401, DOI 10.1023/A:1012022810550; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	29	349	360	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15971	15979		10.1074/jbc.273.26.15971	http://dx.doi.org/10.1074/jbc.273.26.15971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632645	hybrid			2022-12-27	WOS:000074436600016
J	Kobayashi, K; Tsubaki, M; Tagawa, S				Kobayashi, K; Tsubaki, M; Tagawa, S			Distinct roles of two heme centers for transmembrane electron transfer in cytochrome b(561) from bovine adrenal chromaffin vesicles as revealed by pulse radiolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION PROPERTIES; ASCORBIC-ACID; ACHROMOBACTER-CYCLOCLASTES; GRANULE MEMBRANES; NITRITE REDUCTASE; POLYPEPTIDE; ABSORPTION; TRANSPORT; SPECTRUM; RADICALS	The reaction of monodehydroascorbate (MDA) radical with purified cytochrome b(561) from bovine adrenal chromaffin vesicles was investigated by the technique of pulse radiolysis. Radiolytically generated MDA radical oxidized rapidly the reduced form of cytochrome b(561) to yield the oxidized form. Subsequently the oxidized form of cytochrome b(561) was re-reduced by ascorbate in the medium. The second-order rate constants of the reaction of MDA radical were increased with decreasing pH, whereas a maximum of the second-order rate constant for the reaction with ascorbate was obtained around pH 6.8. At excess MDA radical to cytochrome b(561) concentration, only half of the heme in cytochrome b561 was oxidized, indicating that only one of the two heme centers can react with MDA radical. On the other hand, when the reactions were examined using cytochrome b(561) pretreated in a mild alkaline condition in the oxidized state, the cytochrome b(561) could not be oxidized with MDA radical, suggesting that the heme center specific for the electron donation to MDA radical is selectively modified upon the alkaline treatment. These results suggest that the two heme b centers have distinct roles for the electron donation to MDA radical and the electron acceptance from ascorbate, respectively.	Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Kamigoori, Hyogo 6781297, Japan	Osaka University; University of Hyogo	Kobayashi, K (corresponding author), Osaka Univ, Inst Sci & Ind Res, Mihogaoka 8-1, Osaka 5670047, Japan.		Kobayashi, Kazuo/H-9279-2012	Kobayashi, Kazuo/0000-0002-5586-9112				APPS DK, 1984, BIOCHIM BIOPHYS ACTA, V764, P8, DOI 10.1016/0005-2728(84)90134-8; APPS DK, 1980, NEUROSCIENCE, V5, P2279, DOI 10.1016/0306-4522(80)90143-8; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BERGSTROM J, 1983, FEBS LETT, V164, P71, DOI 10.1016/0014-5793(83)80021-0; BIELSKI BHJ, 1970, J AM CHEM SOC, V92, P3793, DOI 10.1021/ja00715a046; BIELSKI BHJ, 1971, J AM CHEM SOC, V93, P5624, DOI 10.1021/ja00751a006; CABELLI DE, 1983, J PHYS CHEM-US, V87, P1809, DOI 10.1021/j100233a031; DILIBERTO EJ, 1983, J BIOL CHEM, V258, P2886; DUONG LT, 1982, J BIOL CHEM, V257, P8561; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; IYANAGI T, 1985, BIOCHIM BIOPHYS ACTA, V806, P255, DOI 10.1016/0005-2728(85)90103-3; IYANAGI T, 1984, BIOCHEMISTRY-US, V23, P1418, DOI 10.1021/bi00302a013; JALUKAR V, 1991, J BIOL CHEM, V266, P6878; KELLEY PM, 1986, J BIOL CHEM, V261, P6429; KELLEY PM, 1990, J BIOL CHEM, V265, P19409; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; KOBAYASHI K, 1991, BIOCHEMISTRY-US, V30, P8310, DOI 10.1021/bi00098a005; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27551, DOI 10.1074/jbc.270.46.27551; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; Okuyama E, 1998, BBA-PROTEIN STRUCT M, V1383, P269, DOI 10.1016/S0167-4838(97)00216-1; ORMEJOHN.NR, 1971, BIOCHEM BIOPH RES CO, V45, P871, DOI 10.1016/0006-291X(71)90419-0; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SKOTLAND T, 1980, BIOCHIM BIOPHYS ACTA, V630, P30, DOI 10.1016/0304-4165(80)90134-8; SRIVASTAVA M, 1994, BIOCHEM J, V303, P915, DOI 10.1042/bj3030915; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; Suzuki S, 1997, J BIOL INORG CHEM, V2, P265, DOI 10.1007/s007750050132; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; Tsubaki M, 1997, J BIOL CHEM, V272, P23206, DOI 10.1074/jbc.272.37.23206; WAKEFIELD LM, 1984, J BIOCHEM BIOPH METH, V9, P331, DOI 10.1016/0165-022X(84)90017-4; WAKEFIELD LM, 1982, FED PROC, V41, P839	34	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16038	16042		10.1074/jbc.273.26.16038	http://dx.doi.org/10.1074/jbc.273.26.16038			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632654	hybrid			2022-12-27	WOS:000074436600025
J	Kuhlbrodt, K; Herbarth, B; Sock, E; Enderich, J; Hermans-Borgmeyer, I; Wegner, M				Kuhlbrodt, K; Herbarth, B; Sock, E; Enderich, J; Hermans-Borgmeyer, I; Wegner, M			Cooperative function of POU proteins and SOX proteins in glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SCIP; DNA-BINDING; JC VIRUS; NUCLEOPROTEIN STRUCTURES; SCHWANN-CELLS; HMG DOMAIN; EXPRESSION; GENE; DIFFERENTIATION; ELEMENTS	Glial cells of the oligodendrocyte lineage express several highly related POU proteins including Tst-1/Oct6/ SCIP and Brn-1. Tst-1/Oct6/SCIP, but not Brn-1 efficiently cooperated with Sox10, the only SRY box protein so far identified in oligodendrocytes, Here we show that, in addition to Sox10, cells of the oligodendrocyte lineage contain significant amounts of the related SRY box proteins Sox4 and Sox11. During development, Sox11 was strongly expressed in the central nervous system. It was first detected in neural precursors throughout the neuroepithelium, During later stages of neural development, Sox11 was additionally expressed in areas of the brain in which neurons undergo differentiation. In agreement with its expression in neural precursors, Sox11 levels in cells of the oligodendrocyte lineage were high in precursors and down-regulated during terminal differentiation. Outside the nervous system, expression of Sox11 was also detected in the developing limbs, face, and kidneys, Structure function analysis revealed that Sox11 has a strong intrinsic transactivation capacity which is mediated by a transactivation domain in its carboxyl-terminal part. In addition, Sox11 efficiently synergized with Brn-1. Synergy was dependent on binding of both proteins to adjacent DNA elements, and required the presence of the respective transactivation domain in each protein. Our data suggest the existence of a specific code in which POU proteins require specific Sox proteins to exhibit cooperative effects in glial cells.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Wegner, M (corresponding author), ZMNH, Martinistr 52, D-20246 Hamburg, Germany.	wegner@plexus.uke.uni-hamburg.de		Sock, Elisabeth/0000-0001-9925-3136; Wegner, Michael/0000-0002-4586-3294				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097-0177(199710)210:2<79::AID-AJA1>3.0.CO;2-6; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Jay P, 1997, HUM MOL GENET, V6, P1069, DOI 10.1093/hmg/6.7.1069; JAY P, 1995, GENOMICS, V29, P541, DOI 10.1006/geno.1995.9970; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; Miyata S, 1996, BBA-GENE STRUCT EXPR, V1308, P23, DOI 10.1016/0167-4781(96)00091-7; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PORTER S, 1986, J NEUROSCI, V6, P3070; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Schreiber J, 1997, J BIOL CHEM, V272, P32286, DOI 10.1074/jbc.272.51.32286; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; Sock E, 1997, J NEUROCHEM, V68, P1911; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	41	185	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16050	16057		10.1074/jbc.273.26.16050	http://dx.doi.org/10.1074/jbc.273.26.16050			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632656	hybrid			2022-12-27	WOS:000074436600027
J	Mora-Garcia, S; Rodriguez-Suarez, R; Wolosiuk, RA				Mora-Garcia, S; Rodriguez-Suarez, R; Wolosiuk, RA			Role of electrostatic interactions on the affinity of thioredoxin for target proteins - Recognition of chloroplast fructose-1,6-bisphosphatase by mutant Escherichia coli thioredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ACTIVATION; REDUCTASE; RESOLUTION; RESIDUES; MUTATION; IDENTIFICATION; RIBONUCLEASE; STIMULATION	Chloroplast thioredoxin-f functions efficiently in the light-dependent activation of chloroplast fructose-1,6-bisphosphatase by reducing a specific disulfide bond located at the negatively charged domain of the enzyme. Around the nucleophile cysteine of the active site (-W-C-G-P-C-), chloroplast thioredoxin-f shows lower density of negative charges than the inefficient modulator Escherichia coli thioredoxin, To examine the contribution of long range electrostatic interactions to the thiol/disulfide exchange between protein-disulfide oxidoreductases and target proteins, we constructed three variants off. coli thioredoxin in which an acidic (Glu-30) and a neutral residue (Leu-94) were replaced by lysines, After purification to homogeneity, the reduction of the unique disulfide bond by NADPH via NADP-thioredoxin reductase proceeded at similar rates for all variants. However, the conversion of cysteine residues back to cystine depended on the target protein. Insulin and difluoresceinthiocarbamyl-insulin oxidized the sulfhydryl groups of E30K and E30K/L94K mutants more effectively than those of wild type and L94K counterparts, Moreover, the affinity of E30g, L94R, and E30K/L94K E. coli thioredoxin for chloroplast fructose-1,6-bisphosphatase (A(0.5) = 9, 7, and 3 mu M, respectively) increased with the number of positive charges, and was higher than wild type thioredoxin (A(0.5)= 33 mu M), though still lower than that of thioredoxin-f (A(0.5) = 0.9 mu M). We also demonstrated that shielding of electrostatic interactions with high salt concentrations not only brings the A(0.5) for all bacterial variants to a limiting value of similar to 9 mu M but also increases the A,, of chloroplast thioredoxin-f, While negatively charged chloroplast fructose-1,6-bisphosphatase (pI = 4.9) readily interacted with mutant thioredoxins, the reduction rate of rapeseed napin (pI = 11.2) diminished with the number of novel lysine residues. These findings suggest that the electrostatic interactions between thioredoxin and (some of) its target proteins controls the formation of the binary noncovalent complex needed for the subsequent thiol/disulfide exchange.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Fdn Campomar,Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires	Wolosiuk, RA (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Fdn Campomar,Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim, Antonio Machado 151, RA-1405 Buenos Aires, DF, Argentina.	rwolo@iris.iib.uba.ar						BALLICORA MA, 1994, EUR J BIOCHEM, V222, P467, DOI 10.1111/j.1432-1033.1994.tb18887.x; Ballicora MA, 1998, CELL MOL BIOL, V44, P431; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CORLEY E, 1983, BIOCHEM BIOPH RES CO, V115, P707, DOI 10.1016/S0006-291X(83)80202-2; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DROUX M, 1988, CR HEBD ACAD SCI, V305, P335; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICSON ML, 1986, J BIOL CHEM, V261, P4576; Geck RK, 1996, J BIOL CHEM, V271, P24736, DOI 10.1074/jbc.271.40.24736; GENOVESIOTAVERNE JC, 1991, J MOL BIOL, V222, P459, DOI 10.1016/0022-2836(91)90488-R; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; HABERLEIN I, 1995, BBA-PROTEIN STRUCT M, V1253, P169, DOI 10.1016/0167-4838(95)00153-1; HARTMAN H, 1990, MOL BIOL EVOL, V7, P247; HERTIG CM, 1983, J BIOL CHEM, V258, P984; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Heuck AP, 1997, ANAL BIOCHEM, V248, P94, DOI 10.1006/abio.1997.2123; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HUBER HE, 1986, J BIOL CHEM, V261, P5006; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Jaramillo JL, 1997, PLANT PHYSIOL, V114, P1169, DOI 10.1104/pp.114.4.1169; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KALLIS GB, 1980, J BIOL CHEM, V255, P261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Moore DD, 1995, GLOB MOB SURV; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MoraGarcia S, 1996, FEBS LETT, V380, P123, DOI 10.1016/0014-5793(96)00022-1; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; NAVARRO JA, 1991, BIOCHEMISTRY-US, V30, P2192, DOI 10.1021/bi00222a024; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBLONG JE, 1995, BIOCHEMISTRY-US, V34, P3319, DOI 10.1021/bi00010a022; PADROS E, 1982, EUR J BIOCHEM, V127, P117, DOI 10.1111/j.1432-1033.1982.tb06844.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; POWIS G, 1994, ONCOL RES, V6, P539; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REUTIMANN H, 1981, J BIOL CHEM, V256, P6796; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; RodriguezSuarez RJ, 1997, BIOCHEM BIOPH RES CO, V232, P388, DOI 10.1006/bbrc.1997.6242; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; SALAMON Z, 1992, ARCH BIOCHEM BIOPHYS, V299, P193, DOI 10.1016/0003-9861(92)90262-U; SAMBROOK JE, 1989, MOL CLONING LB MANUA; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; SCHURMANN P, 1985, PHYSIOL VEG, V23, P813; SCHURMANN P, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P153; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; STEIN M, 1987, J BIOL CHEM, V262, P16171; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4299, DOI 10.1021/bi00013a019; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	61	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16273	16280		10.1074/jbc.273.26.16273	http://dx.doi.org/10.1074/jbc.273.26.16273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632687	hybrid			2022-12-27	WOS:000074436600058
J	Pappas, A; Yang, WL; Park, TS; Carman, GM				Pappas, A; Yang, WL; Park, TS; Carman, GM			Nucleotide-dependent tetramerization of CTP synthetase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTIDINE 5'-TRIPHOSPHATE; URA7 GENE; PHOSPHORYLATION; MECHANISM; OLIGOMERIZATION; BIOSYNTHESIS; INHIBITION; MUTANTS; TUMORS	The nucleotide-dependent tetramerization of purified native URA7-encoded CTP synthetase (EC 6.3,4.2, UTP: ammonia ligase (ADP-forming)) from the yeast Saccharomyces cerevisiae was characterized. CTP synthetase existed as a dimer in the absence of ATP and UTP. In the presence of saturating concentrations of ATP and UTP, the CTP synthetase protein existed as a tetramer. Increasing concentrations of ATP and UTP caused a dose-dependent conversion of the dimeric species to a tetramer, The kinetics of enzyme tetramerization correlates with the kinetics of enzyme activity. The tetramerization of CTP synthetase was dependent on UTP and Mg2+ ions. ATP facilitated the UTP-dependent tetramerization of CTP synthetase by a mechanism that involved the ATP-dependent phosphorylation of UTP catalyzed by the enzyme. The glutaminase reaction that is catalyzed by the enzyme was not required for enzyme tetramerization. CTP, a potent inhibitor of CTP synthetase activity, did not inhibit the ATP/UTP-dependent tetramerization of the enzyme. Phosphorylation of the purified native CTP synthetase with protein kinase A and protein kinase C facilitated the nucleotide-dependent tetramerization. Dephosphorylation of native CTP synthetase with alkaline phosphatase prevented the nucleotide-dependent tetramerization of the enzyme. This correlated with the inactivation of CTP synthetase activity, Rephosphorylation of the dephosphorylated enzyme with protein kinase A and protein kinase C resulted in a partial restoration of the nucleotide-dependent tetramerization of the enzyme. This tetramerization correlated with the partial restoration of CTP synthetase activity. Taken together, these results indicated that enzyme tetramerization was required for CTP synthetase activity and that enzyme phosphorylation played an important role in the tetramerization and regulation of the enzyme.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.				NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1987, J BIOL CHEM, V262, P5106; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, 1992, PROTEIN SCI, V1, P472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; KIZAKI H, 1980, CANCER RES, V40, P3921; KOSHLAND DE, 1974, ENZYMES, P539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MONTENARH M, 1987, FEBS LETT, V221, P199, DOI 10.1016/0014-5793(87)80925-0; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBERTSON JG, 1993, BIOCHEMISTRY-US, V32, P3769, DOI 10.1021/bi00065a032; Segel IH, 1975, ENZYME KINETICS BEHA; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	39	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15954	15960		10.1074/jbc.273.26.15954	http://dx.doi.org/10.1074/jbc.273.26.15954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632643	hybrid			2022-12-27	WOS:000074436600014
J	Fisher, DA; Smith, JF; Pillar, JS; St Denis, SH; Cheng, JB				Fisher, DA; Smith, JF; Pillar, JS; St Denis, SH; Cheng, JB			Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CAMP-SPECIFIC PHOSPHODIESTERASE; MOLECULAR-CLONING; MESSENGER-RNA; CDNA; EXPRESSION; PROTEIN; BINDING; ROLIPRAM; DOMAIN	We have cloned and characterized the first human isozyme in a new family of cyclic nucleotide phosphodiesterases, PDE9A. By sequence homology in the catalytic domain, PDE9A is almost equidistant from all eight known mammalian PDE families but is most similar to PDE8A (34% amino acid identity) and least like PDE5A (28% amino acid identity). We report the cloning of human cDNA encoding a full-length protein of 593 amino acids, including a 261-amino acid region located near the C terminus that is homologous to the similar to 270-amino acid catalytic domain of other PDEs, PDE9A is expressed in all eight tissues examined as a similar to 2.0-kilobase mRNA, with highest levels in spleen, small intestine, and brain. The full-length PDE9A was expressed in baculovirus fused to an N-terminal g-amino acid FLAG tag. Kinetic analysis of the baculovirus-expressed enzyme shows it to be a very high affinity cGMP-specific PDE with a K-m of 170 nM for cGMP and 230 mu M for cAMP. The K-m for cGMP makes PDESA one of the highest affinity PDEs known. The V-max for cGMP (4.9 nmol/min/mu g recombinant enzyme) is about twice as fast as that of PDE4 for cAMP. The enzyme is about twice as active in vitro in 1-10 mM Mn2+ than in the same concentration of Mg2+ Or Ca2+. PDESA is insensitive (up to 100 mu M) to a variety of PDE inhibitors including rolipram, vinpocetine, SKF-94120, dipyridamole, and 3-isobutyl-1-methyl xanthine but is inhibited (IC50 = 35 mu M) by zaprinast, a PDEB inhibitor. PDE9A lacks a region homologous to the allosteric cGMP-binding regulatory regions found in the cGMP-binding PDEs: PDE2, PDE5, and PDE6.	Pfizer Inc, Pfizer Cent Res, Dept Mol Sci, Groton, CT 06340 USA; Pfizer Inc, Pfizer Cent Res, Dept Canc Immunol & Infect Dis, Groton, CT 06340 USA	Pfizer; Pfizer	Fisher, DA (corresponding author), Pfizer Inc, Pfizer Cent Res, Dept Mol Sci, Groton, CT 06340 USA.	douglas_a_fisher@groton.pfizer.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GRENS A, 1990, J BIOL CHEM, V265, P11810; Kleinman EF, 1998, J MED CHEM, V41, P266, DOI 10.1021/jm970685m; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Loomis WF, 1997, J CELL SCI, V110, P1141; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; Proudfoot N J, 1976, Prog Nucleic Acid Res Mol Biol, V19, P123; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEGEL IH, 1976, BIOCH CALCULATIONS, P233; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Thompson W J, 1974, Methods Enzymol, V38, P205; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018	28	291	324	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15559	15564		10.1074/jbc.273.25.15559	http://dx.doi.org/10.1074/jbc.273.25.15559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624146	hybrid			2022-12-27	WOS:000074284200040
J	Hesselgesser, J; Ng, HP; Liang, M; Zheng, W; May, K; Bauman, JG; Monahan, S; Islam, I; Wei, GP; Ghannam, A; Taub, DD; Rosser, M; Snider, RM; Morrissey, MM; Perez, HD; Horuk, R				Hesselgesser, J; Ng, HP; Liang, M; Zheng, W; May, K; Bauman, JG; Monahan, S; Islam, I; Wei, GP; Ghannam, A; Taub, DD; Rosser, M; Snider, RM; Morrissey, MM; Perez, HD; Horuk, R			Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPEPTIDE ANTAGONIST; GENERATION COMPOUNDS; EXPRESSION; RANTES; POTENT; ENCEPHALOMYELITIS; INTERLEUKIN-8; CHEMOTAXIS; CYTOKINES; PROTEINS	The CC chemokines macrophage inflammatory pro tein-1 alpha (MIP-1 alpha) and RANTES (regulated on activation normal T cell expressed) have been implicated in rheumatoid arthritis and multiple sclerosis, Since their effects are mediated through the CCR1 chemokine receptor, we set up a small molecule CCR1 antagonist program to search for inhibitors. Through high capacity screening we discovered a number of 4-hydroxypiperidine compounds with CCR1 antagonist activity and report their synthesis and in vitro pharmacology here. Scatchard analysis of the competition binding data revealed that the compounds had K-i values ranging from 40 to 4000 nM. The pharmacological profile of the most potent member of this series, compound 1 (2-2-diphenyl-5-(4-chlorophenyl)piperidin-lyl)valeronitrite), was further evaluated. Compound 1 showed concentration-dependent inhibition of MIP-1 alpha-induced extracellular acidification and Ca2+ mobilization demonstrating functional antagonism. When given alone, the compound did not elicit any responses, indicating the absence of intrinsic agonist activity. Compound 1 inhibited MIP-1 alpha- and RANTES-induced migration in peripheral blood mononuclear cells in a dose-responsive manner. Selectivity testing against a panel of seven transmembrane domain receptors indicated that compound 1 is inactive on a number of receptors at concentrations up to 10 mu M. This is the first description of CCR1 receptor antagonists that may be useful in the treatment of chronic inflammatory diseases involving MIP-1 alpha, RANTES, and CCR1.	Berlex BioSci, Dept Immunol, Richmond, CA 94806 USA; Berlex BioSci, Dept Pharmaceut Discovery, Richmond, CA 94806 USA; NIA, Natl Inst Hlth, Immunol Lab, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Horuk, R (corresponding author), Berlex BioSci, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94806 USA.		Zheng, Wei/GOE-5990-2022; Zheng, Wei/J-8889-2014	Zheng, Wei/0000-0003-1034-0757				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, ADV EXP MED BIOL, V351, P1; CHANG RSL, 1985, SCIENCE, V230, P177, DOI 10.1126/science.2994227; CUSACK B, 1994, PSYCHOPHARMACOLOGY, V114, P559, DOI 10.1007/BF02244985; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KATO K, 1997, Patent No. 24325; Mackay CR, 1997, CURR BIOL, V7, pR384, DOI 10.1016/S0960-9822(06)00181-3; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; Richelson E, 1996, J CLIN PSYCHIAT, V57, P4; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SAWUTZ DG, 1994, P NATL ACAD SCI USA, V91, P4693, DOI 10.1073/pnas.91.11.4693; SCHALL TJ, 1994, CYTOKINE HDB, P419; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SNOWDEN N, 1994, LANCET, V343, P547, DOI 10.1016/S0140-6736(94)91503-2; TAUB DD, 1995, J IMMUNOL METHODS, V184, P187, DOI 10.1016/0022-1759(95)00087-Q; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756	29	123	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15687	15692		10.1074/jbc.273.25.15687	http://dx.doi.org/10.1074/jbc.273.25.15687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624164	hybrid			2022-12-27	WOS:000074284200058
J	Kyritsis, P; Hatzfeld, OM; Link, TA; Moulis, JM				Kyritsis, P; Hatzfeld, OM; Link, TA; Moulis, JM			The two [4Fe-4S] clusters in Chromatium vinosum ferredoxin have largely different reduction potentials - Structural origin and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; CLOSTRIDIUM-PASTEURIANUM FERREDOXIN; MAGNETIC CIRCULAR-DICHROISM; DIRECT ELECTRON-TRANSFER; GLASSY-CARBON ELECTRODE; 2<4FE-4S> FERREDOXIN; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; REDOX POTENTIALS; SPECTROSCOPIC CHARACTERIZATION	The 2[4Fe-4S] ferredoxin from Chromatium vinosum arises as one prominent member of a recently defined family of proteins found in very diverse bacteria. The potentiometric circular dichroism titrations of the protein and of several molecular variants generated by site-directed mutagenesis have established that; the reduction potentials of the two clusters differ widely by almost 200 mV. This large difference has been confirmed by electrochemical methods, and each redox transition has been assigned to one of the clusters. The unusually Bow potential center is surprisingly the one that displays a conventional (CXXCXXC)-X-1-C-2-X-3-C-4 (X-n, variable amino acid) binding motif and a structural environment similar to that of clusters having less negative potentials. A comparison with other ferredoxins has highlighted factors contributing to the reduction potential of [4Fe-4S] clusters in proteins. (i) The loop between the coordinating cysteines 40 and 49 and the e terminus alpha-helix of C. vinosum ferredoxin cause a negative, but relatively moderate, shift of similar to 60 mV for the nearby cluster. (ii) Very negative potentials, below -600 mV, correlate with the presence of a bulky side chain in position X-4 of the coordinating triad of cysteines. These findings set the B?framework in which previous observations on ferredoxins can be better understood. They also shed light onto thee possible occurrence and properties of very low potential [4Fe-4S] clusters in less well characterized proteins.	CEA, DBMS, MEP, Lab Metalloprot, F-38054 Grenoble 9, France; Univ Frankfurt Klinikum, Inst Biochem 1, ZBC, D-60590 Frankfurt, Germany	CEA; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Moulis, JM (corresponding author), CEA, DBMS, MEP, Lab Metalloprot, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jean-marc.moulis@cea.fr	Kyritsis, Panayotis/M-8222-2013	Kyritsis, Panayotis/0000-0002-3908-4649; Moulis, Jean-Marc/0000-0001-5615-9852				ALBRACHT PJA, 1997, BIOCHIM BIOPHYS ACTA, V1318, P92; ARMENGAUD J, 1994, THESIS U J FOURIER G; ARMSTRONG FA, 1987, J ELECTROANAL CHEM, V217, P331, DOI 10.1016/0022-0728(87)80228-0; ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; BACHOFEN R, 1966, BIOCHIM BIOPHYS ACTA, V120, P259, DOI 10.1016/0926-6585(66)90345-1; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; DAAS PJH, 1994, FEBS LETT, V356, P342, DOI 10.1016/0014-5793(94)01313-6; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; DAVASSE V, 1992, BIOCHEM BIOPH RES CO, V185, P341, DOI 10.1016/S0006-291X(05)80991-X; DUEE ED, 1994, J MOL BIOL, V243, P683, DOI 10.1016/0022-2836(94)90041-8; EVANS MCW, 1966, P NATL ACAD SCI USA, V55, P928, DOI 10.1073/pnas.55.4.928; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GEORGE SJ, 1991, NEW J CHEM, V15, P455; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; HAGEN WR, 1989, EUR J BIOCHEM, V182, P523, DOI 10.1111/j.1432-1033.1989.tb14859.x; HEERING HA, 1995, BIOCHEMISTRY-US, V34, P14675, DOI 10.1021/bi00045a008; HUBER JG, 1995, BIOCHEMISTRY-US, V34, P194, DOI 10.1021/bi00001a024; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; KE B, 1974, ARCH BIOCHEM BIOPHYS, V162, P301, DOI 10.1016/0003-9861(74)90129-5; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; Macedo AL, 1996, BIOCHEM BIOPH RES CO, V229, P524, DOI 10.1006/bbrc.1996.1837; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Mauk AG, 1997, J BIOL INORG CHEM, V2, P119, DOI 10.1007/s007750050115; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; MOULIS JM, 1984, BIOCHEMISTRY-US, V23, P6605, DOI 10.1021/bi00321a050; MOULIS JM, 1982, BIOCHEMISTRY-US, V21, P4762, DOI 10.1021/bi00262a037; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; Moulis JM, 1996, BBA-GENE STRUCT EXPR, V1308, P12, DOI 10.1016/0167-4781(96)00082-6; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; MOULIS JM, 1994, BIOMETALS, V7, P272, DOI 10.1007/BF00144121; NICHOLSON RS, 1965, ANAL CHEM, V37, P1351, DOI 10.1021/ac60230a016; OTAKA E, 1987, J MOL EVOL, V26, P257, DOI 10.1007/BF02099857; PISZKIEWICZ D, 1981, BIOCHEMISTRY-US, V20, P363, DOI 10.1021/bi00505a021; QUINKAL I, 1994, PROTEIN ENG, V7, P681, DOI 10.1093/protein/7.5.681; Quinkal I, 1996, BBA-PROTEIN STRUCT M, V1295, P201, DOI 10.1016/0167-4838(96)00042-8; Saeki K, 1996, J BIOL CHEM, V271, P31399, DOI 10.1074/jbc.271.49.31399; SALMON RT, 1980, J ELECTROANAL CHEM, V112, P253, DOI 10.1016/S0022-0728(80)80407-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SMITH ET, 1990, J BIOL CHEM, V265, P14371; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; STOMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633, DOI 10.1021/bi00657a024; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; SWEENEY WV, 1980, ANNU REV BIOCHEM, V49, P139, DOI 10.1146/annurev.bi.49.070180.001035; TABOR S, 1990, CURRENT PROTOCOLS MO; VANDIJK C, 1984, FEBS LETT, V166, P76, DOI 10.1016/0014-5793(84)80048-4; VOLLMER SJ, 1983, J BIOL CHEM, V258, P4284; Warshel A, 1997, J BIOL INORG CHEM, V2, P143, DOI 10.1007/s007750050119	57	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15404	15411		10.1074/jbc.273.25.15404	http://dx.doi.org/10.1074/jbc.273.25.15404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624123	hybrid			2022-12-27	WOS:000074284200017
J	Potter, LR; Hunter, T				Potter, LR; Hunter, T			Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION ACTIVITIES; GUANYLYL CYCLASE RECEPTORS; ATP-REGULATORY MODULE; LIGAND-BINDING; ATRIAL; ACTIVATION; FAMILY; EXPRESSION; DEPHOSPHORYLATION; DESENSITIZATION	C-type natriuretic peptide (CNP) is a newly discovered factor that stimulates vasorelaxation and inhibits cell proliferation. Natriuretic peptide receptor-B (NPR-B) is the primary signaling molecule for CNP. Recently, the guanylyl cyclase activity of NPR-B was shown to correlate with its phosphorylation state, and it was suggested that receptor dephosphorylation is a mechanism of desensitization. We now report the identification and characterization of the major NPR-B phosphorylation sites. Mutagenesis and comigration studies using synthetic phosphopeptides were employed to identify five residues (Ser-513, Thr-516, Ser-518, Ser-523, and Ser-526) within the kinase homology domain that are phosphorylated when NPR-B is expressed in human 293 cells. Mutation of any of these residues to alanine reduced the receptor's phosphorylation state and CNP-dependent guanylyl cyclase activity. The reductions were not explained by decreases in receptor protein level as indicated by immunoblot analysis and determinations of cyclase activity in the absence of CNP or in the presence of detergent. Elimination of all of the phosphorylation sites resulted in a completely dephosphorylated receptor whose CNP-dependent cyclase activity was decreased by >90%. However, unlike NPR-A, the dephosphorylated receptor was not completely unresponsive to hormone. Finally, two additional residues (Gly-521 and Ser-522) were identified that when mutated to alanine reduced the overall phosphorylation state and hormone responsiveness of the receptor without abolishing the phosphorylation of a specific site. These data indicate that phosphorylation of the kinase homology domain is a critical event in the regulation of NPR-B.	Salk Inst Biol Studies, Mol Biol & Virol Lab, San Diego, CA 92186 USA	Salk Institute	Potter, LR (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, POB 85800, San Diego, CA 92186 USA.	potter@salk.edu			NCI NIH HHS [CA14195, F32 CA067452, CA39780, CA-67452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA067452, R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Brown J, 1997, AM J PHYSIOL-HEART C, V272, pH2919, DOI 10.1152/ajpheart.1997.272.6.H2919; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DUDA T, 1995, BIOCHEM BIOPH RES CO, V209, P286, DOI 10.1006/bbrc.1995.1501; DUDA T, 1993, FEBS LETT, V315, P143, DOI 10.1016/0014-5793(93)81151-O; Duda T, 1995, MOL CELL BIOCHEM, V152, P179, DOI 10.1007/BF01076081; FENRICK R, 1994, MOL CELL BIOCHEM, V137, P173, DOI 10.1007/BF00944079; FURUYA M, 1995, ANN NY ACAD SCI, V748, P517; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1992, BIOCHEM J, V282, P533, DOI 10.1042/bj2820533; HAGIWARA H, 1994, J BIOL CHEM, V269, P10729; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KATAFUCHI T, 1994, EUR J BIOCHEM, V222, P835, DOI 10.1111/j.1432-1033.1994.tb18930.x; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MCDOWELL G, 1995, EUR J CLIN INVEST, V25, P291, DOI 10.1111/j.1365-2362.1995.tb01704.x; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; Ueno H, 1997, CIRCULATION, V96, P2272; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	40	99	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15533	15539		10.1074/jbc.273.25.15533	http://dx.doi.org/10.1074/jbc.273.25.15533			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624142	hybrid			2022-12-27	WOS:000074284200036
J	Yamauchi, T; Kaburagi, Y; Ueki, K; Tsuji, Y; Stark, GR; Kerr, IM; Tsushima, T; Akanuma, Y; Komuro, I; Tobe, K; Yazaki, Y; Kadowaki, T				Yamauchi, T; Kaburagi, Y; Ueki, K; Tsuji, Y; Stark, GR; Kerr, IM; Tsushima, T; Akanuma, Y; Komuro, I; Tobe, K; Yazaki, Y; Kadowaki, T			Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOCYTES; INHIBITOR WORTMANNIN; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; PROTEIN; IRS-1; CELLS; MICE; SHC; IDENTIFICATION	Growth hormone (GH) and prolactin (PRL) binding to their receptors, which belong to the cytokine receptor superfamily, activate Janus kinase (JAK) 2 tyrosine kinase, thereby leading to their biological actions. We recently showed that GH mainly stimulated tyrosine phosphorylation of epidermal growth factor receptor and its association with Grb2, and concomitantly stimulated mitogen-activated protein kinase activity in liver, a major target tissue. Using specific antibodies, we now show that GH was also able to induce tyrosine phosphorylation of insulin receptor substrate (IRS)-1/IRS-8 in liver. In addition, the major tyrosine-phosphorylated protein in anti-p85 phosphatidylinositol 3-kinase (PI3-kinase) immunoprecipitate from liver of wild-type mice was IRS-l, and IRS-2 in IRS-1 deficient mice, but not epidermal growth factor receptor. These data suggest that tyrosine phosphorylation of IRS-1 may be a major mechanism for GH-induced PIS-kinase activation in physiological target organ of GH, liver. We also show that PRL was able to induce tyrosine phosphorylation of both IRS-1 and IRS-2 in COS cells transiently transfected with PRLR and in CHO-PRLR cells. Moreover, we show that tyrosine phosphorylation of IRS-3 was induced by both GH and PRL in COS cells transiently transfected with IRS-3 and their cognate receptors. By using the JAK2-deficient cell lines or by expressing a dominant negative JAK2 mutant, we show that JAK2 is required for the GH-and PRL-dependent tyrosine phosphorylation of IRS-1, -2, and -3, Finally, a specific PI3-kinase inhibitor, wortmannin, completely blocked the anti-lipolytic effect of GH in 3T3 L1 adipocytes. Taken together, the role of IRS-1, -2, and -3 in GH and PRL signalings appears to be phosphorylated by JAK2, thereby providing docking sites for p85 PI3-kinase and activating PI3-kinase and its downstream biological effects.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1130033, Japan; Cleveland Clin Fdn, Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Imperial Canc Res Fund, London WC2A 3PX, England; Tokyo Womens Med Coll, Dept Internal Med 2, Tokyo 162, Japan; Adahi Life Fdn, Inst Diabet Care & Res, Tokyo 100, Japan	University of Tokyo; Cleveland Clinic Foundation; Cancer Research UK; Tokyo Women's Medical University	Kadowaki, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; BIRNBAUM RS, 1976, ENDOCRINOLOGY, V99, P1336, DOI 10.1210/endo-99-5-1336; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HONEYMAN TW, 1980, AM J PHYSIOL, V238, P389; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KADOWAKI T, 1996, ENDOCR J, V43, P33; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; NICOLL CS, 1985, PROLACTIN BASIC CLIN, P393; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; ROUPAS P, 1994, TRENDS ENDOCRIN MET, V5, P154, DOI 10.1016/1043-2760(94)90012-4; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1994, J BIOL CHEM, V269, P5364; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WHITE MF, 1994, J BIOL CHEM, V268, P1; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	48	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15719	15726		10.1074/jbc.273.25.15719	http://dx.doi.org/10.1074/jbc.273.25.15719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624169	hybrid			2022-12-27	WOS:000074284200063
J	Zhuang, JG; Ren, Y; Snowden, RT; Zhu, HJ; Gogvadze, V; Savill, JS; Cohen, GM				Zhuang, JG; Ren, Y; Snowden, RT; Zhu, HJ; Gogvadze, V; Savill, JS; Cohen, GM			Dissociation of phagocyte recognition of cells undergoing apoptosis from other features of the apoptotic program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE/CED-3 PROTEASE; POLY(ADP-RIBOSE) POLYMERASE; PHOSPHATIDYLSERINE EXPOSURE; VITRONECTIN RECEPTOR; ICE FAMILY; CLEAVAGE; MITOCHONDRIAL; DNA; FRAGMENTATION; LYMPHOCYTES	Apoptosis is a programmed form of cell death characterized by biochemical and morphological changes affecting the nucleus, cytoplasm, and plasma membrane. These changes in various cellular compartments are widely regarded as mechanistically linked events in a single "program" in which activation of caspases and proteolysis of intracellular substrates represent a final common pathway leading to cell death. To date there has been very limited exploration of the linkage of this program to the plasma membrane changes, which bring about swift recognition, uptake, and safe degradation of apoptotic cells by phagocytes. Using the mitochondrial inhibitors antimycin A and oligomycin in human monocytic THP.1 cells triggered into apoptosis, we report the uncoupling of plasma membrane changes from other features of apoptosis. These inhibitors blocked increased plasma membrane permeability, externalization of phosphatidylserine, and recognition by two classes of phagocytes but not activation of caspase-3, cleavage of poly(ADP-ribose) polymerase and DNA fragmentation. Externalization of phosphatidylserine in apoptotic human leukemic U937 cells was also dissociated from caspase activation. Thus changes governing safe clearance of apoptotic cells may be regulated by an independent pathway to those bringing about caspase activation. This finding could have important consequences for attempts to manipulate cell death for therapeutic gain in vivo.	Univ Leicester, Ctr Mechanisms Human Toxic, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Nottingham Hosp, Dept Med, Div Renal & Inflammatory Dis, Nottingham NG7 2UH, England	University of Leicester; University of Nottingham	Cohen, GM (corresponding author), Univ Leicester, Ctr Mechanisms Human Toxic, MRC, Toxicol Unit, POB 138,Lancaster Rd,Hodgkin Bldg, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008; Gogvadze, Vladimir/A-4392-2014	Zhuang, Jianguo/0000-0003-3245-0789				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BICKNELL GR, 1994, J CELL SCI, V107, P2483; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Castedo M, 1996, J IMMUNOL, V157, P512; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIU X, 1996, CELL, V86, P1331; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; NICHOLLS DG, 1992, BIOENERGETICS, V2, P132; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V; Zhu HJ, 1997, CELL DEATH DIFFER, V4, P590, DOI 10.1038/sj.cdd.4400284	36	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15628	15632		10.1074/jbc.273.25.15628	http://dx.doi.org/10.1074/jbc.273.25.15628			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624155	hybrid			2022-12-27	WOS:000074284200049
J	Bouck, J; Fu, XD; Skalka, AM; Katz, RA				Bouck, J; Fu, XD; Skalka, AM; Katz, RA			Role of the constitutive splicing factors U2AF(65) and SAP49 in suboptimal RNA splicing of novel retroviral mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYPYRIMIDINE TRACT; BRANCH POINT; SPLICEOSOME; SEQUENCE; ENHANCER; PROTEINS; SITE; IDENTIFICATION; COMPLEX	Retroviruses display a unique form of alternative splicing in which both spliced and unspliced RNAs accumulate in the cytoplasm, Simple retroviruses, such as avian sarcoma virus, do not encode regulatory proteins that affect splicing; this process is controlled solely through interactions between the viral RNA and the host cell splicing machinery. Previously, we described the selection and characterization of novel avian sarcoma virus mutants. These viruses were separated into two classes based upon analysis of splicing intermediates produced in infected cells and in a cell-free system. One class, which included mutants with altered polypyrimidine tract or branch point sequences, showed significant accumulation of intermediates, suggesting that splicing was regulated in step 2, The other class, which included mutants with deletions of exonic enhancer sequences, did not accumulate splicing intermediates, suggesting that splicing was regulated before step 1 of the splicing reaction. In this report, we show that a mutant blocked at step 1 fails to form a stable spliceosomal complex, whereas one blocked at step 2 shows a defect in its ability to transit through the last spliceosomal complex. Using UV cross-linking methods, we show that regulation at each step is associated with specific changes in the binding of cellular splicing factors. Regulation at step 1 is correlated with decreased crosslinking of the factor U2AF(65), whereas regulation at step 2 is correlated with enhanced cross-linking of the factor SAP49, Because these mutations were isolated by selection for replication-competent viruses, we conclude that retroviral splicing may be regulated in vivo through altered binding of constitutive splicing factors.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA	Fox Chase Cancer Center; University of Pennsylvania; University of California System; University of California San Diego	Katz, RA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	r_katz@retro2.fccc.edu			NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achsel T, 1996, J BIOCHEM, V120, P53; Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; Ashiya M, 1997, RNA, V3, P996; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BOUCK J, 1995, MOL CELL BIOL, V15, P2663; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; FU XD, 1995, RNA, V1, P663; FU XD, 1991, GENE DEV, V5, P211, DOI 10.1101/gad.5.2.211; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Inoue Kunio, 1995, Gene Expression, V4, P177; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LEE CG, 1993, J BIOL CHEM, V268, P13472; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; McKeown M, 1993, CURR OPIN CELL BIOL, V5, P448, DOI 10.1016/0955-0674(93)90010-N; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Moore M.J., 1993, SPLICING PRECURSORS; NEWMAN A, 1994, CURR BIOL, V4, P462, DOI 10.1016/S0960-9822(00)00104-4; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; O'Farrell P H, 1977, Methods Cell Biol, V16, P407; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; WANG J, 1995, RNA, V1, P335; WILL CC, 1994, ANAL RIBONUCLEOPROTE, V1, P141; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	41	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15169	15176		10.1074/jbc.273.24.15169	http://dx.doi.org/10.1074/jbc.273.24.15169			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614130	hybrid			2022-12-27	WOS:000074160400072
J	Fromm, SV; Mey-Tal, SW; Coligan, JE; Schechter, C; Ehrlich, R				Fromm, SV; Mey-Tal, SW; Coligan, JE; Schechter, C; Ehrlich, R			MHC class I heavy chain mRNA must exceed a threshold level for the reconstitution of cell surface expression of class I MHC complexes in cells transformed by the highly oncogenic adenovirus 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; HLA CLASS-I; INTRACELLULAR-TRANSPORT; T-CELLS; MONOCLONAL-ANTIBODIES; PEPTIDE TRANSPORTER; GENE-EXPRESSION; DOWN-REGULATION; MOLECULES; BETA-2-MICROGLOBULIN	In primary embryonal fibroblasts from transgenic mice expressing H-2(b) genes and a miniature swine class I transgene (PD1), transformation with adenovirus 12 results in suppression of assembly and cell surface expression of all class I complexes. Cell surface expression of PD1 can be recovered by transfecting the cells with peptide transporter genes. However, reconstitution of the H-2K(b) gene expression requires, in. addition, a 2-fold increase in the steady state level of the H-2K(b) mRNA that can be attained by treatment of the cells with interferons or by transfecting them with the H-2K(b) gene. A detailed analyses of the biogenesis of class I molecules has revealed the steady state expression of free class I heavy chains that are not converted into conformed complexes even when peptide transporter genes are overexpressed, The fact that class I complex assembly seems to be highly inefficient in certain cell lines might be a major in vivo obstacle for the elimination of trans formed or virus-infected cells by cytotoxic T lymphocytes, especially in view of the fact that the level of class I gene transcription is often down-regulated in cancel cells and/or that assembly of class I major histocompatibility complexes can be subverted by virus-encoded proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; NIAID, Mol Struct Lab, NIH, Bethesda, MD 20892 USA	Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ehrlich, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DAVIS WC, 1987, VET IMMUNOL IMMUNOP, V15, P337, DOI 10.1016/0165-2427(87)90005-5; EHRLICH R, 1989, IMMUNOGENETICS, V30, P18, DOI 10.1007/BF02421465; EHRLICH RE, 1995, IMMUNOL RES, V14, P77, DOI 10.1007/BF02918170; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; Geginat G, 1997, J IMMUNOL, V158, P3303; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; GUSSOW D, 1987, J IMMUNOL, V139, P3132; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JACOBY WB, 1979, METHOD ENZYMOL, V58, P110; Jones TR, 1996, P NATL ACAD SCI USA, V93, P11327, DOI 10.1073/pnas.93.21.11327; KHANNA R, 1994, INT IMMUNOL, V6, P639, DOI 10.1093/intimm/6.4.639; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LEBOUTEILLER P, 1994, CRIT REV IMMUNOL, V14, P89, DOI 10.1615/CritRevImmunol.v14.i2.10; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; MALOY WL, 1988, MOL IMMUNOL, V25, P453; MeyTal SV, 1997, J BIOL CHEM, V272, P353, DOI 10.1074/jbc.272.1.353; Min W, 1996, J IMMUNOL, V156, P3174; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; OTTEN GR, 1992, J IMMUNOL, V148, P3723; OZATO K, 1981, J IMMUNOL, V126, P317; REALINI C, 1994, J BIOL CHEM, V269, P20727; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; Rodriguez AM, 1997, EUR J IMMUNOL, V27, P45, DOI 10.1002/eji.1830270108; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHEMESH J, 1993, J BIOL CHEM, V268, P15704; SHEMESH J, 1991, J VIROL, V65, P5544, DOI 10.1128/JVI.65.10.5544-5548.1991; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; Solheim JC, 1997, J IMMUNOL, V158, P2236; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL R, 1979, ADV IMMUNOL, V22, P51	53	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15209	15216		10.1074/jbc.273.24.15209	http://dx.doi.org/10.1074/jbc.273.24.15209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614135	hybrid			2022-12-27	WOS:000074160400077
J	DiCiommo, DP; Bremner, R				DiCiommo, DP; Bremner, R			Rapid, high level protein production using DNA-based semliki forest virus vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINDBIS-VIRUS; EXPRESSION VECTORS; RNA; PARTICLES; GENE; RECOMBINATION; SYSTEM; CELLS	Semliki Forest virus (SFV) vectors can be produced faster, and have a wider host range, than baculovirus vectors, However, the original SFV system requires in vitro manipulation of RNA. me have generated a system that is wholly DNA-based, Both the replicon vector, encoding SFV polymerase and the protein of interest, and the helper vector, encoding viral structural proteins, were modified so that expression was RNA polymerase II-dependent. Transfection of the modified replicon plasmid alone generated 20-30-fold more protein than obtained from a simple expression vector, Expression required the SFV replicase, which amplifies replicon RNA. The SFV-based vector generated 10-20-fold more protein than a plasmid based on Sindbis virus. Cotransfection of SFV replicon and helper vectors generated viral titers of around 10(6) infectious particles/ml. A single electroporation, plated on one IO-cm plate, generated enough virus (10(7) particles) to produce >500 mu g of protein, mild type, replication proficient virus was not detected in three tests utilizing almost 10(8) viral particles, a distinct advantage over a DNA Sindbis-based system in which over half the virus particles generated are fully infectious. The new SFV vectors significantly enhance the utility of this expression system.	Eye Res Inst Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Toronto; University of Toronto	Bremner, R (corresponding author), Eye Res Inst Canada, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212				BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Couffinhal T, 1997, HUM GENE THER, V8, P929, DOI 10.1089/hum.1997.8.8-929; Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; FROLOV I, 1994, J VIROL, V68, P8111, DOI 10.1128/JVI.68.12.8111-8117.1994; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; Frolova E, 1997, J VIROL, V71, P248, DOI 10.1128/JVI.71.1.248-258.1997; HERWEIJER H, 1995, HUM GENE THER, V6, P1161, DOI 10.1089/hum.1995.6.9-1161; JALANKO A, 1985, VIROLOGY, V141, P257, DOI 10.1016/0042-6822(85)90256-9; Jones I, 1996, CURR OPIN BIOTECH, V7, P512, DOI 10.1016/S0958-1669(96)80054-1; Li KJ, 1996, P NATL ACAD SCI USA, V93, P11658, DOI 10.1073/pnas.93.21.11658; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LILJESTROM P, 1994, CURRENT PROTOCOLS MO, V2; Liljestrom Peter, 1994, Current Opinion in Biotechnology, V5, P495, DOI 10.1016/0958-1669(94)90063-9; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; RAJU R, 1995, J VIROL, V69, P7391, DOI 10.1128/JVI.69.12.7391-7401.1995; ROLLS MM, 1994, CELL, V79, P497, DOI 10.1016/0092-8674(94)90258-5; Sambrook J, 1987, MOL CLONING LAB MANU; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; THOMSON M, 1994, VIROLOGY, V199, P354, DOI 10.1006/viro.1994.1133; Tubulekas I, 1997, GENE, V190, P191, DOI 10.1016/S0378-1119(96)00679-8; WEISS BG, 1991, J VIROL, V65, P4017, DOI 10.1128/JVI.65.8.4017-4025.1991	28	91	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18060	18066		10.1074/jbc.273.29.18060	http://dx.doi.org/10.1074/jbc.273.29.18060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660762	hybrid			2022-12-27	WOS:000074828500017
J	Furukawa, T; Miura, R; Mori, Y; Strobeck, M; Suzuki, K; Ogihara, Y; Asano, T; Morishita, R; Hashii, M; Higashida, H; Yoshii, M; Nukada, T				Furukawa, T; Miura, R; Mori, Y; Strobeck, M; Suzuki, K; Ogihara, Y; Asano, T; Morishita, R; Hashii, M; Higashida, H; Yoshii, M; Nukada, T			Differential interactions of the C terminus and the cytoplasmic I-II loop of neuronal Ca2+ channels with G-protein alpha and beta gamma subunits - II. Evidence for direct binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-OPIOID RECEPTORS; CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; PERTUSSIS TOXIN; NG108-15 CELLS; INHIBITION; MODULATION; BRAIN; CURRENTS; PURIFICATION	The present study was designed to obtain evidence for direct interactions of G-protein alpha (G alpha) and beta gamma subunits (G beta gamma) with N- (alpha(1B)) and P/Q-type (alpha(1A)) Ca2+ channels, using synthetic peptides and fusion proteins derived from loop 1 (cytoplasmic loop between repeat I and II) and the C terminus of these channels. For N-type, prepulse facilitation as mediated by G beta gamma was impaired when a synthetic loop 1 peptide was applied intracellulary. Receptor agonist-induced inhibition of N-type as mediated by G alpha was also impaired by the loop 1 peptide but only when applied in combination with a C-terminal peptide. For P/Q-type channels, by contrast, the G alpha-mediated inhibition was diminished by application of a C-terminal peptide alone. Moreover, in vitro binding analysis for N- and P/Q-type channels revealed direct interaction of G alpha with C-terminal fusion proteins as well as direct interaction of G beta gamma with loop 1 fusion proteins. These findings define loop 1 of N- and P/Q-type Ca2+ channels as an interaction site for G beta gamma and the C termini for G alpha.	Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, Tokyo 156, Japan; Tokyo Inst Psychiat, Dept Neurophysiol, Setagaya Ku, Tokyo 156, Japan; Teikyo Univ, Fac Med, Dept Internal Med, Itabashi Ku, Tokyo 173, Japan; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Daiichi Pharmaceut Co Ltd, Tokyo R&D Ctr, New Prod Res Labs 3, Edogawa Ku, Tokyo 134, Japan; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 48003, Japan; Kanazawa Univ, Sch Med, Neuroinformat Res Inst, Dept Biophys, Kanazawa, Ishikawa 920, Japan	Tokyo Institute of Psychiatry; Tokyo Institute of Psychiatry; Teikyo University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University System of Ohio; University of Cincinnati; Daiichi Sankyo Company Limited; Kanazawa University	Nukada, T (corresponding author), Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 156, Japan.		higashida, haruhiro/L-3773-2015	higashida, haruhiro/0000-0002-1779-0606				ASANO T, 1988, J BIOCHEM-TOKYO, V103, P950, DOI 10.1093/oxfordjournals.jbchem.a122392; ASANO T, 1993, J BIOL CHEM, V268, P20512; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; Furukawa T, 1998, J BIOL CHEM, V273, P17585, DOI 10.1074/jbc.273.28.17585; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HIGASHIDA H, 1990, P ROY SOC B-BIOL SCI, V242, P68, DOI 10.1098/rspb.1990.0105; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSUNOO A, 1986, P NATL ACAD SCI USA, V83, P9832, DOI 10.1073/pnas.83.24.9832; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; YOSHII M, 1994, BRAIN RES, V642, P123, DOI 10.1016/0006-8993(94)90913-X; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	43	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17595	17603		10.1074/jbc.273.28.17595	http://dx.doi.org/10.1074/jbc.273.28.17595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651354	hybrid			2022-12-27	WOS:000074816100047
J	Uhlmann, EJ; Subramanian, T; Vater, CA; Lutz, R; Chinnadurai, G				Uhlmann, EJ; Subramanian, T; Vater, CA; Lutz, R; Chinnadurai, G			A potent cell death activity associated with transient high level expression of BCL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICULAR LYMPHOMA; SOMATIC MUTATION; HOMOLOG BAK; GENE; APOPTOSIS; PROTEIN; INDUCTION; DISTINCT; SURVIVAL; BH1	The BCL-2 proto-oncogene contains unusually long untranslated 5' and 3' sequences. Deletion of the sequences flanking the BCL-2 open reading frame dramatically increases the level of protein expression. Transient high level BCL-2 protein expression mediated by plasmid transfection or by infection with recombinant adenovirus results in potent apoptosis of several cell lines. Detailed mutational (deletion and add-back) analysis reveals that both 5'- and 3'-flanking sequences con tribute to the negative modulation of protein expression from the BCL-2 open reading frame. It appears that these sequences exert the negative regulatory effect in an orientation-dependent manner. Analysis of BCL-2 RNA levels indicate that elevated levels of mRNA may be the primary cause of elevated levels of protein expression. Apoptosis induced by adenovirus vectors expressing elevated levels of BCL-2 can be readily inhibited by the caspase inhibitor z-VAD-fmk, suggesting that high levels of BCL-2 expression induce apoptosis via the caspase cascade. Mutational analysis of BCL-2 indicates that its pro-apoptotic activity is separable from its antiapoptosis activity. Our results raise the possibility that oncogenic conversion of BCL-2 may require somatic mutations in the pro-apoptotic activity, in addition to other activating mutations that result in enhanced expression. Consistent with this hypothesis, a somatic mutation of BCL-2 observed in multiple human tumors results in reduced apoptosis activity.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA; Apoptosis Technol Inc, Cambridge, MA 02139 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, CA-73803, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; FU LN, 1997, EMBO J, V16, P5117; Harigai M, 1996, ONCOGENE, V12, P1369; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HENGARTNER MO, 1994, NATURE, V369, P319; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1992, BLOOD, V80, P879; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; Oh JH, 1997, NEUROREPORT, V8, P1851, DOI 10.1097/00001756-199705260-00012; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rokhlin OW, 1997, CANCER RES, V57, P1758; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TANAKA S, 1992, BLOOD, V79, P229; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; VENKATESH LK, 1990, P NATL ACAD SCI USA, V87, P8746, DOI 10.1073/pnas.87.22.8746; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	47	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17926	17932		10.1074/jbc.273.28.17926	http://dx.doi.org/10.1074/jbc.273.28.17926			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651399	hybrid			2022-12-27	WOS:000074816100092
J	Yang, MZ; Kurkinen, M				Yang, MZ; Kurkinen, M			Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts - CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; EXTRACELLULAR-MATRIX; INTERSTITIAL COLLAGENASE; GELATINASE-B; DEVELOPMENTAL EXPRESSION; MESSENGER-RNAS; IV COLLAGENASE; CDNA LIBRARY; GENE FAMILY; IDENTIFICATION	We cloned a novel matrix metalloproteinase (MMP) called CMMP from cultured primary chicken embryo fibroblasts. The cDNA-derived CMMP sequence contains 472 amino acids including a putative 19-residue signal peptide and a unique cysteine in the catalytic domain, an insertion in a sequence motif that binds the structural (noncatalytic) zinc of MMPs. Strikingly, a homologously inserted cysteine is also found in Xenopus XMMP and human MMP19, two recently cloned novel members of the MMP family. Phylogenetic analysis suggest that XMMP and MMP19 represent founding members of the MMP family, whereas CMMP is related to collagenase MMPs. Bacterially produced recombinant CMMP (without the amino-terminal inhibition domain), which was autoproteolyzed at the carboxyl-terminal domain, digested casein and gelatin. As shown by Northern blotting, CMMP mRNA of 1.8 kilobase pairs was constitutively expressed in cultured primary chicken embryo fibroblasts and up-regulated by tumor necrosis factor-alpha and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, but it was not regulated by interleukin-1, basic fibroblast growth factor, or retinoic acid. CMMP mRNA of 1.8 kb was also detected in the head and body of 8-day-old chicken embryos and dramatically up-regulated in 9-day-old embryos.	Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA	Wayne State University; Wayne State University	Kurkinen, M (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, 5125 Biol Sci Bldg,5047 Gullen Mall, Detroit, MI 48202 USA.	markku@cmb.biosci.wayne.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24442] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSHUL SF, 1997, INPRESS NUCL ACIDS R, V25; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; APTE AN, 1993, BIOTECHNIQUES, V15, P890; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; Bartlett JD, 1996, GENE, V183, P123, DOI 10.1016/S0378-1119(96)00525-2; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CANETESOLER R, 1995, DEV DYNAM, V204, P30, DOI 10.1002/aja.1002040105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; Cossins J, 1996, BIOCHEM BIOPH RES CO, V228, P494, DOI 10.1006/bbrc.1996.1688; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Kokorine I, 1996, J CELL SCI, V109, P2151; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; MATRISIAN LM, 1992, BIOESSAYS, V6, P121; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; MATTOT V, 1995, J CELL SCI, V108, P529; MERTZ LM, 1994, ANAL BIOCHEM, V221, P160, DOI 10.1006/abio.1994.1392; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Otter M, 1995, BIOCHEM MOL BIOL INT, V37, P563; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Puente XS, 1996, CANCER RES, V56, P944; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOCKER W, 1995, PROTEIN SCI, V4, P823; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WERB Z, 1994, TXB RHEUMATOLOGY, P248; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yang MZ, 1997, J BIOL CHEM, V272, P13527, DOI 10.1074/jbc.272.21.13527; YANG MZ, 1994, EUR J BIOCHEM, V222, P651, DOI 10.1111/j.1432-1033.1994.tb18909.x; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015	68	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17893	17900		10.1074/jbc.273.28.17893	http://dx.doi.org/10.1074/jbc.273.28.17893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651395	hybrid			2022-12-27	WOS:000074816100088
J	Barsalou, A; Gao, WL; Anghel, SI; Carriere, J; Mader, S				Barsalou, A; Gao, WL; Anghel, SI; Carriere, J; Mader, S			Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; BINDING-PROPERTIES; RECEPTOR; TAMOXIFEN; GENE; ANTIESTROGENS; GROWTH; PROMOTER; DOMAINS	Anti-estrogens like hydroxytamoxifen (OHT) have mixed agonist/antagonist activities, leading to tissue-specific stimulation of cellular proliferation. Partial agonist activity of OHT can be observed in vitro in endometrial carcinoma cells like Ishikawa. Here, we have compared several anti-estrogens (including extensively characterized OHT and pure anti-estrogens such as ICI164,384 and RU58,668, which are devoid of uterotrophic activity) for their capacity to stimulate promoters containing estrogen response elements (EREs) or AP1-binding sites (12-O-tetradecanoylphorbol-13-acetate response elements, TREs), the two types of DNA motifs known to mediate transcriptional stimulation by estrogen receptors. Assays were performed in Ishikawa cells either by transient transfection or by using cell lines with stably propagated reporter vectors. In transient transfection experiments, none of the anti-estrogens displayed agonist activity on the promoters tested. In contrast, significant transcriptional stimulation was observed with low concentrations of OHT and RU39,411 in Ishikawa cells stably propagating reporter constructs containing a minimal ERE3-TATA promoter. In addition, micromolar concentrations of OHT, but not of RU39,411, stimulated stably propagated AP1-responsive reporter constructs. No transcriptional stimulation of ERE- or TRE-containing promoters was observed with the pure anti-estrogens ICI164,384 and RU58,668. These results indicate that the presence of estrogen response elements in promoters is sufficient to mediate cell-specific agonism of anti-estrogens at the transcriptional level, and that stimulation of AP1 activity may be restricted to a subset of anti-estrogens possessing agonist activity on EREs. In addition, our results suggest that transient transfections do not fully recapitulate in vivo conditions required to observe agonist activity of anti-estrogens.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Mader, S (corresponding author), Univ Montreal, Fac Med, Dept Biochim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maders@bch.umontreal.ca						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ANZAI Y, 1989, CANCER RES, V49, P2362; Aumais JP, 1997, J BIOL CHEM, V272, P12229, DOI 10.1074/jbc.272.18.12229; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOTTARDIS MM, 1988, CANCER RES, V48, P812; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JIN L, 1995, STEROIDS, V60, P512, DOI 10.1016/0039-128X(95)00079-6; JORDAN VC, 1990, BREAST CANCER RES TR, V15, P125, DOI 10.1007/BF01806350; KASTNER P, 1990, EMBO J, V9, P1608; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; RAYNAUD JP, 1978, CANCER RES, V38, P3044; SALMON J, 1983, J STEROID BIOCHEM, V18, P565, DOI 10.1016/0022-4731(83)90132-2; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VANDEVELDE P, 1994, J STEROID BIOCHEM, V48, P187, DOI 10.1016/0960-0760(94)90144-9; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WAKELING AE, 1990, J STEROID BIOCH MOL, V37, P71; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1994, BIO-TECHNOL, V12, P1003, DOI 10.1038/nbt1094-1003; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	51	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17138	17146		10.1074/jbc.273.27.17138	http://dx.doi.org/10.1074/jbc.273.27.17138			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642281	hybrid			2022-12-27	WOS:000074545200071
J	Nohturfft, A; Brown, MS; Goldstein, JL				Nohturfft, A; Brown, MS; Goldstein, JL			Topology of SREBP cleavage-activating protein, a polytopic membrane protein with a sterol-sensing domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; DEGRADATION; GLYCOPROTEIN; RECEPTOR; ENZYME; GENE	The NH2-terminal fragments of sterol regulatory element-binding proteins (SREBPs) are released from endoplasmic reticulum membranes by proteases whose activities depend upon SREBP cleavage-activating protein (SCAP), a polytopic endoplasmic reticulum membrane protein. The activity of SCAP is inhibited by sterols, which appear to interact with the polytopic membrane domain of SCAP. Here, we use protease protection and N-linked glycosylation site-mapping techniques to define the topology of the eight membrane-spanning domains of SCAP, The data indicate that the NH,terminus and COOH terminus of SCAP face the cytosol, The long intralumenal loops after membrane-spanning segments I and 7 are glycosylated, confirming their lumenal location. The region comprising membrane-spanning segments 2-6 shows sequence resemblance to putative sterol-sensing domains in three other proteins: 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase), the Niemann-Pick CI protein, and the morphogen receptor Patched. The orientation of the eight membrane-spanning segments in SCAP is consistent with the model proposed for HMG-CoA reductase (Olender, E, H,, and Simoni, R. D, (1992) J. Biol. Chem. 267, 4223-4235), The membrane-spanning domains of SCAP and HMG-CoA reductase confer sterol sensitivity upon the functional activities of the two molecules. The common membrane topology of the two proteins is consistent with the notion that sterols regulate both proteins by a common mechanism.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nohturfft, A (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.			Nohturfft, Axel/0000-0001-9484-3209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; INOUE S, 1992, J BIOL CHEM, V267, P9080; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KOCH GLE, 1988, J CELL SCI, V90, P485; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	37	157	168	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17243	17250		10.1074/jbc.273.27.17243	http://dx.doi.org/10.1074/jbc.273.27.17243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642295	Green Published, hybrid			2022-12-27	WOS:000074545200085
J	Long, JC; Wang, S; Vik, SB				Long, JC; Wang, S; Vik, SB			Membrane topology of subunit a of the F1F0 ATP synthase as determined by labeling of unique cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; ALPHA-SUBUNIT; A-SUBUNIT; TRANSMEMBRANE TOPOLOGY; EPSILON-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; PROTON TRANSLOCATION; NUCLEOTIDE-SEQUENCE; MUTAGENIC ANALYSIS	The membrane topology of the a subunit of the F1F0 ATP synthase from Escherichia coli has been probed by surface labeling using 3-(N-maleimidylpropionyl) biocytin. Subunit a has no naturally occurring cysteine residues, allowing unique cysteines to be introduced at the following positions: 8, 24, 27, 69, 89, 128, 131, 172, 176, 196, 238, 241, and 277 (following the COOH-terminal 271 and a hexahistidine tag). None of the single mutations affected the function of the enzyme, as judged by growth on succinate minimal medium. Membrane vesicles with an exposed cytoplasmic surface were prepared using a French pressure cell, Before labeling the membranes were incubated with or without a highly charged sulfhydryl reagent, 4-acetamido-4'-maleimidylstilbene-2,2'disulfonic acid. After labeling with the less polar biotin maleimide, the samples were solubilized with octyl glucoside/cholate and the subunit a was purified via the oligohistidine at its COOH terminus using immobilized nickel chromatography. The purified samples were electrophoresed and transferred to nitrocellulose for detection by avidin conjugated to alkaline phosphatase. Results indicated cytoplasmic accessibility for residues 69, 172, 176, and 277 and periplasmic accessibility for residues 8, 24, 27, and 131. On the basis of these and earlier results, a transmembrane topology for the subunit a is proposed.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	svik@mail.smu.edu		Vik, Steven/0000-0002-5285-015X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040508, GM40508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Hagting A, 1997, BIOCHEMISTRY-US, V36, P6777, DOI 10.1021/bi963068t; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Miller J. H., 1972, EXPT MOL GENETICS, P431; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1994, J BIOL CHEM, V269, P30364; VIK SB, 1987, J BIOL CHEM, V262, P8340; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONMEYENBURG K, 1985, EMBO J, V4, P2357, DOI 10.1002/j.1460-2075.1985.tb03939.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WANG S, 1994, J BIOL CHEM, V269, P3095; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	67	109	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16235	16240		10.1074/jbc.273.26.16235	http://dx.doi.org/10.1074/jbc.273.26.16235			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632682	hybrid			2022-12-27	WOS:000074436600053
J	Weiner, JK; Chen, AP; Davis, BH				Weiner, JK; Chen, AP; Davis, BH			E-box-binding repressor is down-regulated in hepatic stellate cells during up-regulation of mannose 6-phosphate insulin-like growth factor-II receptor expression in early hepatic fibrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN PROMOTER; FACTOR-BETA; GENE-TRANSCRIPTION; ACTIVATION; RAT; PROTEIN; LIVER; FIBROSIS; RETINOL; MYC	Hepatic stellate cells become activated during the early stages of hepatic injury associated with fibrogenesis, The mannose 6-phosphate/insulin-like growth factor-II receptor (M6P/IGFIIR) plays an important role in early fibrogenesis by participating in the activation of latent transforming growth factor-beta, a potent inducer of the matrix proteins in activated stellate cells that define the fibrotic phenotype. In this study we examined hepatic stellate cell regulation of M6P/IGFIIR expression and found that M6P/IGFIIR mRNA transcript levels increased in stellate cells from rats exposed to carbon tetrachloride (CCl4), a potent fibrogenic stimulant. Two E-boxes residing in the proximal promoter of M6P/IG-FIIR were found to each bind a novel 75-kDa transcription factor (P75) in quiescent stellate cells of normal livers. This E-box binding was down-regulated as an early response in stellate cells exposed to CCl4, coinciding with increased M6P/IGFIIR transcript levels. Mutagenized E-boxes in M6P/IGFIIR promoter-chloramphenicol acetyltransferase (CAT) reporter constructs produced a substantial increase in reporter expression when compared with the corresponding native promoter-CAT construct when transfected in culture-activated stellate cells, suggesting P75's role as a repressor, The results indicate P75's participation in the regulation of M6P/IGFIIR transcription in hepatic stellate cells during fibrogenesis.	Univ Chicago, Med Ctr, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center	Davis, BH (corresponding author), Univ Chicago, Med Ctr, Dept Med, Gastroenterol Sect, MC 4076,5841 S Maryland Ave, Chicago, IL 60637 USA.	bhdavis@medicine.bsd.uchicago.edu			NIDDK NIH HHS [DK40223, DK 42086, DK02022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, K08DK002022, R29DK040223] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Davis BH, 1996, CLIN LAB MED, V16, P361, DOI 10.1016/S0272-2712(18)30274-9; DAVIS BH, 1987, J BIOL CHEM, V262, P10280; DAVIS BH, 1988, HEPATOLOGY, V8, P788, DOI 10.1002/hep.1840080416; DEBLESER PJ, 1995, HEPATOLOGY, V21, P1429, DOI 10.1016/0270-9139(95)90066-7; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; LIU D, 1995, MOL ENDOCRINOL, V9, P1477; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; Sambrook J., 2002, MOL CLONING LAB MANU; SAPERSTEIN LA, 1994, HEPATOLOGY, V19, P412; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021	34	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15913	15919		10.1074/jbc.273.26.15913	http://dx.doi.org/10.1074/jbc.273.26.15913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632637	hybrid			2022-12-27	WOS:000074436600008
J	Zheleva, D; Sharma, J; Panico, M; Morris, HR; Barber, J				Zheleva, D; Sharma, J; Panico, M; Morris, HR; Barber, J			Isolation and characterization of monomeric and dimeric CP47-reaction center photosystem II complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MASS PROTEINS; CORE COMPLEX; SPINACH; CHLOROPHYLL; POLYPEPTIDE; PLANTS	Using the detergents n-dodecyl beta-D-maltoside and heptyl thioglycopyranoside, a subcore complex of photosystem II (PSII) has been isolated that contains the chlorophyll-binding protein, CP47, and the reaction center components, D1, D2, and cytochrome b(559). We have found, by using sucrose density centrifugation, that the resulting preparation consisted of a mixture of dimeric and monomeric forms of the CP47 reaction center (RC) complex, having molecular masses of 410 +/- 30 and 200 +/- 28 kDa, respectively, as estimated by size exclusion chromatography. The level of the dimer in the preparation is significantly higher than the monomeric form. Both the monomer and dimer contain the proteins CP47, D1, and D2 and the alpha- and beta-subunits of cytochrome b(559). Analyses by mass spectrometry and N-terminal sequencing showed that both forms of the CP47-RC complex contain the products of the psbI, psbT(c) (chloroplast gene), and psbW with molecular masses of 4195,5, 3849.6, and 5927.4 Da, respectively. In contrast to the monomeric form, the CP47-RC dimer contained two extra proteins with low molecular weights, identified as the products of the psbL and psbK genes having molecular masses of 4365.5 and 4292.1, respectively, It was also found that the dimer contained slightly more molecules of chlorophyll a (21 +/- 2.5) than the monomer (18 +/- 1.5), a characteristic also observed in the room temperature absorption spectrum by comparing the ratio of absorption at 416 and 435 nm. Of particular note was the finding that the dimer, but not the monomer, contained plastoquinone-9 (estimated to be 1.5 +/- 0.3 molecules per RC). The results indicate that the CP47-RC monomer is derived from the dimeric form of the complex, and therefore the latter is likely to represent an in vivo conformation. The PsbT(c) as well as the PsbI and PsbW proteins are identified as being intimately associated with the D1 and D2 proteins, and in the case of the dimer, importance is placed on the PsbL and PsbK proteins in sustaining plastoquinone binding and maintenance of the dimeric organization. Assuming only one copy of the alpha- and beta-subunits of cytochrome b(559), the monomeric and dimeric forms of the complex mould be expected to contain 21 and 23 x 2 transmembrane helices, respectively.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England.	j.barber@ic.ac.uk	choudhary, jyoti/S-1232-2017	choudhary, jyoti/0000-0003-0881-5477				BARBATO R, 1991, FEBS LETT, V286, P86, DOI 10.1016/0014-5793(91)80947-2; BARBER J, 1989, OXFORD SURVEYS PLANT, V6, P115; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; DallaChiesa M, 1996, PHOTOSYNTH RES, V50, P79, DOI 10.1007/BF00018223; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; EIJCKELHOFF C, 1995, BBA-BIOENERGETICS, V1231, P21, DOI 10.1016/0005-2728(95)00055-N; GHANOTAKIS DF, 1989, BIOCHIM BIOPHYS ACTA, V974, P44, DOI 10.1016/S0005-2728(89)80164-1; GOUNARIS K, 1990, FEBS LETT, V265, P88, DOI 10.1016/0014-5793(90)80890-U; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; KOBAYASHI M, 1990, FEBS LETT, V260, P138, DOI 10.1016/0014-5793(90)80086-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1983, BIOCHIM BIOPHYS ACTA, V724, P201, DOI 10.1016/0005-2728(83)90139-1; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MIYAZAKI A, 1989, BIOCHIM BIOPHYS ACTA, V933, P423; MONOD C, 1994, EMBO J, V13, P2747, DOI 10.1002/j.1460-2075.1994.tb06568.x; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; MURATA N, 1988, FEBS LETT, V235, P283, DOI 10.1016/0014-5793(88)81280-8; NAGATSUKA T, 1991, BIOCHIM BIOPHYS ACTA, V1057, P223, DOI 10.1016/S0005-2728(05)80105-7; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REDFEARN ER, 1962, PHYTOCHEMISTRY, V1, P147, DOI 10.1016/S0031-9422(00)82816-2; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; WEBBER AN, 1989, FEBS LETT, V242, P251; Zechmeister L, 1943, J AM CHEM SOC, V65, P1522, DOI 10.1021/ja01248a025; Zheleva D, 1996, BIOCHEMISTRY-US, V35, P15074, DOI 10.1021/bi961382h	32	89	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16122	16127		10.1074/jbc.273.26.16122	http://dx.doi.org/10.1074/jbc.273.26.16122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632665	hybrid			2022-12-27	WOS:000074436600036
J	Champigny, G; Voilley, N; Waldmann, R; Lazdunski, M				Champigny, G; Voilley, N; Waldmann, R; Lazdunski, M			Mutations causing neurodegeneration in Caenorhabditis elegans drastically alter the pH sensitivity and inactivation of the mammalian H+-gated Na+ channel MDEG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS SUBUNITS; SODIUM-CHANNEL; CLONING; EXPRESSION; NEURONS	The mammalian degenerin MDEG1 belongs to the nematode degenerin/epithelial Na+ channel superfamily. It is constitutively activated by the same mutations that cause gain-of-function of the Caenorhabditis elegans degenerins and neurodegeneration. ASIC and DRASIC, which were recently cloned, are structural homologues of MDEG1 and behave as H+-gated cation channels, MDEG1 is also a H+-activated Na+ channel, but it differs from ASIC in its lower pH sensitivity and slower kinetics, In addition to the generation of a constitutive current, mutations in MDEG1 also alter the properties of the H+-gated current. Replacement of Gly-430 in MDEG1 by bulkier amino acids, such as Val, Phe, or Thr, drastically increases the H+ sensitivity of the channel (half-maximal pH (pH(m)) similar to 4.4 for MDEG1, pH(m) similar to 6.7 for the different mutants). Furthermore, these replacements completely suppress the inactivation observed with the wild-type channel and increase the sensitivity of the H+-gated channel to blockade by amiloride by a factor of 10 without modification of its conductance and ionic selectivity. These results as well as those obtained with other mutants clearly indicate that the region surrounding Gly-430, situated just before the second transmembrane segment, is essential for pH sensitivity and gating.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Waldmann, Rainer/Q-2108-2016	Waldmann, Rainer/0000-0002-4599-2926				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	28	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15418	15422		10.1074/jbc.273.25.15418	http://dx.doi.org/10.1074/jbc.273.25.15418			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624125	hybrid			2022-12-27	WOS:000074284200019
J	Ohtaki, T; Ogi, K; Masuda, Y; Mitsuoka, K; Fujiyoshi, Y; Kitada, C; Sawada, H; Onda, H; Fujino, M				Ohtaki, T; Ogi, K; Masuda, Y; Mitsuoka, K; Fujiyoshi, Y; Kitada, C; Sawada, H; Onda, H; Fujino, M			Expression, purification, and reconstitution of receptor for pituitary adenylate cyclase-activating polypeptide - Large-scale purification of a functionally active G protein-coupled receptor produced in Sf9 insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; MOLECULAR-CLONING; PACAP RECEPTOR; MUSCARINIC RECEPTORS; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; SPLICE VARIANTS; I RECEPTOR; RAT-BRAIN; PEPTIDE	Human pituitary adenylate cyclase-activating polypeptide (PACAP) receptor was expressed in Sf9 insect cells and Chinese hamster ovary (CHO) cells. The recombinant receptor in Sf9 cell membranes had low affinity for I-125-PACAP27 (K-d = 155.3 pM) and was insensitive to guanosine 5'-O-3-thiotriphosphate (GTP gamma S), whereas the receptor in CHO membranes had a high affinity (K-d = 44.4 pM) and was GTP gamma S sensitive, The receptor in Sf9 membranes was converted to a high affinity state (K-d = 20-40 pM) following solubilization with digitonin, A large quantity (2 mg from 8 liters of insect cells) of the purified PACAP receptors (B-max = 23.9 nmol/mg of protein) were obtained in a digitonin-induced high affinity state (K-d = 17.3 pM) using biotinylated ligand affinity chromatography. The apparent molecular weight of the purified receptor (M-r = 48,000) was smaller than that of the receptor from CHO cells (M-r = 58,000) due to differences in asparagine-linked sugar chains, The purified receptor reverted to a low affinity state (K-d = 182.6 pM) upon reconstitution into lipid vesicles, however, the receptor reconstituted with G(s) protein had a high affinity (K-d = 40.2 pM) and was GTP gamma S sensitive. [S-35]GTP gamma S binding to the reconstituted G(s) protein was enhanced by PACAP27 and PACAP38 (EC50 = 42.8 and 9.4 pM, respectively) but not by antagonist PACAP(6-38), indicating that the purified receptor was functionally active.	Takeda Chem Ind Ltd, Discovery Res Labs 1, Pharmaceut Discovery Res Div, Tsukuba, Ibaraki 3004293, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Biotechnol Labs, Yodogawa Ku, Osaka 5328686, Japan	Takeda Chemical Industries; Kyoto University; Takeda Chemical Industries	Ohtaki, T (corresponding author), Takeda Chem Ind Ltd, Discovery Res Labs 1, Pharmaceut Discovery Res Div, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.		Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493				Altmann F, 1996, TRENDS GLYCOSCI GLYC, V8, P101, DOI 10.4052/tigg.8.101; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CUBERO A, 1984, J BIOL CHEM, V259, P1344; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DELPORTE C, 1995, MOL CELL ENDOCRINOL, V107, P71, DOI 10.1016/0303-7207(94)03424-R; Doi T, 1997, EUR J BIOCHEM, V248, P139, DOI 10.1111/j.1432-1033.1997.00139.x; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; FAUSSNER A, 1991, J BIOL CHEM, V266, P9442; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; GRIGORIADIS DE, 1989, ENDOCRINOLOGY, V125, P3068, DOI 10.1210/endo-125-6-3068; HAGA K, 1986, J BIOL CHEM, V261, P133; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAZUM E, 1986, J BIOL CHEM, V261, P3043; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda Y, 1996, J PHARMACOL EXP THER, V279, P675; MATSUMOTO H, 1993, ENDOCRINOLOGY, V133, P2150, DOI 10.1210/en.133.5.2150; MICHEL H, 1980, P NATL ACAD SCI-BIOL, V77, P338, DOI 10.1073/pnas.77.1.338; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MORROW JA, 1993, FEBS LETT, V329, P99, DOI 10.1016/0014-5793(93)80202-6; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; Nekrasova E, 1996, EUR J BIOCHEM, V238, P28, DOI 10.1111/j.1432-1033.1996.0028q.x; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; Ohtaki T, 1996, ANN NY ACAD SCI, V805, P590; OHTAKI T, 1993, J BIOL CHEM, V268, P26650; OHTAKI T, 1996, BIOMETHODS, V7, P45; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PARKER EM, 1991, J BIOL CHEM, V266, P519; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; POTTER LT, 1991, MOL PHARMACOL, V39, P211; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHEIKH SP, 1991, J BIOL CHEM, V266, P23959; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V195, P881, DOI 10.1006/bbrc.1993.2127; Tanaka T, 1998, J BIOL CHEM, V273, P3247, DOI 10.1074/jbc.273.6.3247; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WATANABE T, 1995, AM J PHYSIOL-ENDOC M, V269, pE903, DOI 10.1152/ajpendo.1995.269.5.E903; Wehmeyer A, 1997, J NEUROCHEM, V68, P1361; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; YADA T, 1994, J BIOL CHEM, V269, P1290	62	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15464	15473		10.1074/jbc.273.25.15464	http://dx.doi.org/10.1074/jbc.273.25.15464			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624132	hybrid			2022-12-27	WOS:000074284200026
J	Cens, T; Restituito, S; Vallentin, A; Charnet, P				Cens, T; Restituito, S; Vallentin, A; Charnet, P			Promotion and inhibition of L-type Ca2+ channel facilitation by distinct domains of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NEURONAL CALCIUM CHANNELS; RAT VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CELLS; POTENTIATION; EXPRESSION; PHOSPHORYLATION; ACTIVATION	Ca2+ current potentiation by conditioning depolarization is a general mechanism by which excitable cells can control the level of Ca2+ entry during repetitive depolarizations. Several types of Ca2+ channels are sensitive to conditioning depolarization, however, using clearly distinguishable mechanisms. In the case of L-type Ca2+ channels, prepulse-induced current facilitation can only be recorded when the pore-forming alpha(1C) subunit is coexpressed with the auxiliary beta(1), beta(3), or beta(4), but not beta(2), subunit, These four beta subunits are composed of two conserved domains surrounded by central, N-terminal, and C-terminal variable regions. Using different deleted and chimeric forms of the beta(1) and beta(2) subunits, we have mapped essential sequences for L-type Ca2+ channel facilitation. A first sequence, located in the second conserved domain of all beta subunits, is responsible for the promotion of current facilitation by the beta subunit. A second sequence of 16 amino acids, located on the N-terminal tail of the beta(2) subunit, induces a transferable block of L-type current facilitation. Site-specific mutations reveal the essential inhibitory role played by three positive charges on this segment. The lack of prepulse-induced current facilitation recorded with some truncated forms of the beta(2) subunit suggests the existence of an additional inhibitory sequence in the beta(2) subunit.	Ctr Rech Biochim Macromol, CNRS, Unite Propre Rech 1086, F-34033 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Charnet, P (corresponding author), Ctr Rech Biochim Macromol, CNRS, Unite Propre Rech 1086, 1919 Route Mende,BP 5051, F-34033 Montpellier, France.	charnet@xerxes.crbm.cnrs-mop.fr	Cens, Thierry/M-3337-2017	Cens, Thierry/0000-0002-4109-2779; Charnet, Pierre/0000-0003-4692-528X				AdachiAkahane S, 1996, J GEN PHYSIOL, V108, P435, DOI 10.1085/jgp.108.5.435; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Fleig A, 1996, J PHYSIOL-LONDON, V496, P339, DOI 10.1113/jphysiol.1996.sp021689; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Parri HR, 1996, J NEUROSCI, V16, P4890; PELZER D, 1990, REV PHYSIOL BIOCH P, V114, P107; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RICHARD S, 1990, AM J PHYSIOL, V258, pH1872, DOI 10.1152/ajpheart.1990.258.6.H1872; RICHARD S, 1993, J PHYSIOL-LONDON, V462, P197, DOI 10.1113/jphysiol.1993.sp019551; SCULPTOREANU A, 1995, AM J PHYSIOL-CELL PH, V269, pC725, DOI 10.1152/ajpcell.1995.269.3.C725; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1994, BIOPHYS J, V66, pA128	33	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18308	18315		10.1074/jbc.273.29.18308	http://dx.doi.org/10.1074/jbc.273.29.18308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660796	hybrid			2022-12-27	WOS:000074828500051
J	Currie, RA				Currie, RA			Biochemical characterization of the NF-Y transcription factor complex during B lymphocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II GENES; CCAAT-BINDING PROTEIN; DNA-BINDING; HETEROLOGOUS SUBUNITS; SEQUENCE IDENTITY; MOLECULAR-CLONING; HUMAN COACTIVATOR; NUCLEAR FACTORS; PLASMA-CELLS; DRA PROMOTER	The transcription factor, NF-Y, plays a critical role in tissue-specific major histocompatibility complex class II gene transcription. In this report the biochemical properties of the heterotrimeric NF-Y complex have been characterized during stage-specific B-cell development, and in several class II- mutant B-cell lines, which represent distinct bare lymphocyte syndrome class II genetic complementation groups. The NF-Y complex derived from class II+ mature B-cells bound with high affinity to anion exchangers, and eluted as an intact trimeric complex, whereas, NF-Y derived from class II plasma B-cells, and from bare lymphocyte syndrome group II cell lines, RJ2.2.5 and RM3, dissociated into discrete NF-YA and NF-YB:C subunit fractions. Recombination of the MPC11 plasma B-cell derived NF-P A:B:C complex with the low molecular mass protein fraction, NF-Y-associated factors (YAFs), derived from mature A20 B cell nuclei, conferred high affinity anion exchange binding to NF-Y as an intact trimeric complex. Recombination of the native NF-YA:B:C complex with the transcriptional cofactor, PC4, likewise conferred high affinity NF-Y binding to anion exchangers, and stabilized NF-Y interaction with CCAAT-box DNA motifs in vitro. Interaction between PC4 and NF-Y was mapped to the C-terminal region of PC4, and the subunit interaction subdomain of the highly conserved DNA binding-subunit interaction domain (DBD) of NF-YA. These results suggest that in class II+ mature B-cells NF-Y is associated with the protein cofactor, PC4, which may play an important role in NF-Y-mediated transcriptional control of class II genes.	Wheeler Inst Biomed Res, Lab Gene Regulat, Huntington, NY 11743 USA		Currie, RA (corresponding author), Wheeler Inst Biomed Res, Lab Gene Regulat, Huntington, NY 11743 USA.				NIAID NIH HHS [AI37686] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI037686] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUARENTE L, 1993, TRANSCRIPTIONAL REGU, V2, P1007; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MIWA K, 1987, P NATL ACAD SCI USA, V84, P4939, DOI 10.1073/pnas.84.14.4939; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1994, P NATL ACAD SCI USA, V91, P20020; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SOMA GI, 1984, BIOCHEM BIOPH RES CO, V124, P164, DOI 10.1016/0006-291X(84)90931-8; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VIVILLE S, 1991, J IMMUNOL, V146, P3211; VUORIO T, 1990, J BIOL CHEM, V265, P22480; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; XING YY, 1994, P NATL ACAD SCI USA, V91, P3009, DOI 10.1073/pnas.91.8.3009	60	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18220	18229		10.1074/jbc.273.29.18220	http://dx.doi.org/10.1074/jbc.273.29.18220			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660784	hybrid			2022-12-27	WOS:000074828500039
J	Tang, H; Kerins, DM; Hao, Q; Inagami, T; Vaughan, DE				Tang, H; Kerins, DM; Hao, Q; Inagami, T; Vaughan, DE			The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELLULAR RECEPTOR; GROWTH-FACTOR; IN-VIVO; BINDING; SURFACE; SRC; EXPRESSION; INDUCTION; MIGRATION	Urokinase-type plasminogen activator (uPA) binds to cells via a specific glycosylphosphatidyilinositol-anchored receptor. Although occupancy of the uPA receptor (uPAR) has been shown to alter cellular function and to induce gene expression, the signaling mechanism has not been characterized. Urokinase induced an increase in the tyrosine phosphorylation of multiple proteins in bovine aortic endothelial cells. In contrast, low molecular weight uPA did not induce this response. Analysis by immunoblotting demonstrated tyrosine phosphorylation of focal adhesion kinase (FAK), the focal adhesion-associated proteins paxillin and p130(cas), and mitogen-activated protein kinase (MAPK) following the occupancy of the uPAR by uPA Treatment of cells with phosphatidylinositol-specific phospholipase C, which cleaves glycosylphosphatidylinositol-linked proteins from the cell surface, blocked the uPA-induced tyrosine phosphorylation of FAK, indicating the requirement of an intact uPAR on the cell surface. The uPA-induced activation of MAPK was completely inhibited by genistein, but not by 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, a specific inhibitor of Src family kinases, Thus, this study demonstrates a novel role for the uPAR in endothelial cell signal transduction that invoices the activation of FAK and MAPK, which are mediated by the receptor-binding domain of uPA. This may have important implications for the mechanism through which uPA influences cell migration and differentiation.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem,Div Cardiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Vaughan, DE (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Biochem,Div Cardiol, Rm 315 MRBII, Nashville, TN 37232 USA.	doug.vaughan@mcmail.vanderbilt.edu	Kerins, David/AAE-5692-2020		NHLBI NIH HHS [HL35323, HL14192, HL51387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035323, R01HL051387, P50HL014192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONESE M, 1995, BIOL CHEM H-S, V376, P143; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; ILLC D, 1995, NATURE, V377, P539; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; KRATZSCHMAR J, 1993, GENE, V125, P177, DOI 10.1016/0378-1119(93)90325-W; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; REUNING U, 1993, THROMB RES, V72, P59, DOI 10.1016/0049-3848(93)90173-L; REUNING U, 1992, ARTERIOSCLER THROMB, V12, P1161, DOI 10.1161/01.ATV.12.10.1161; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLAEPFER DD, 1994, NATURE, V372, P786; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STEFANOVA I, 1991, J IMMUNOL, V147, P1587; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAHASHI K, 1990, THROMB RES, P55; TESFAIGZI J, 1994, BIOTECHNIQUES, V17, P268; TURNER CE, 1993, J CELL SCI, V105, P637; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	46	154	162	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18268	18272		10.1074/jbc.273.29.18268	http://dx.doi.org/10.1074/jbc.273.29.18268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660790	hybrid			2022-12-27	WOS:000074828500045
J	Baker, LP; Nielsen, MD; Impey, S; Metcalf, MA; Poser, SW; Chan, G; Obrietan, K; Hamblin, MW; Storm, DR				Baker, LP; Nielsen, MD; Impey, S; Metcalf, MA; Poser, SW; Chan, G; Obrietan, K; Hamblin, MW; Storm, DR			Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the G(s)-coupled 5-hydroxytryptamine subtype 5-HT7A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CIRCADIAN CLOCK; SEROTONIN RECEPTOR; RAT-BRAIN; MOLECULAR-CLONING; INTRACELLULAR CALCIUM; PERTUSSIS-TOXIN; MESSENGER-RNA; HIGH-AFFINITY; CELLS; EXPRESSION	The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) plays an important regulatory role in developing and adult nervous systems, With the exception of the 5-HT3 receptor, all of the cloned serotonin receptors belong to the G protein-coupled receptor superfamily, Subtypes 5 HT6 and 5-HT7 couple to stimulation of adenylyl cyclases through G(s) and display high affinities for antipsychotic and antidepressant drugs. In the brain, mRNA for 5-HT6 is found at high levels in the hippocampus, striatum, and nucleus accumbens, 5-HT7 mRNA is most abundant in the hippocampus, neocortex, and hypothalamus. To better understand how serotonin might control cAMP levels in the brain, we coexpressed 5-HT6 or 5-HT7A receptors with specific isoforms of adenylyl cyclase in HEK 293 cells. The 5-HT6 receptor functioned as a typical G(s)-coupled receptor in that it stimulated AC5, a G(s)-sensitive adenylyl cyclase, but not AC1 or AC8, calmodulin (CaM)-stimulated adenylyl cyclases that are not activated by G(s) coupled receptors in vivo. Surprisingly, serotonin activation of 5-HT7A stimulated AC1 and AC8 by increasing intracellular Ca2+. 5-HT also increased intracellular Ca2+ in primary neuron cultures. These data define a novel mechanism for the regulation of intracellular cAMP by serotonin.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Storm, DR (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chan, Guy/B-1862-2009		PHS HHS [20498] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADHAM N, 1993, N-S ARCH PHARMACOL, V348, P566, DOI 10.1007/BF00167231; AKIYOSHI J, 1995, J NEUROCHEM, V64, P2473; Bachus SE, 1996, J CLIN PSYCHIAT, V57, P72; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BARD JA, 1993, J BIOL CHEM, V268, P23422; Beeckmans K, 1996, ACTA NEUROL BELG, V96, P35; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Contesse V, 1996, MOL PHARMACOL, V49, P481; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DICKENSON JM, 1995, BRIT J PHARMACOL, V116, P2889, DOI 10.1111/j.1476-5381.1995.tb15941.x; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3; Heidmann DEA, 1997, J NEUROCHEM, V68, P1372; Hirst WD, 1997, BRIT J PHARMACOL, V120, P509, DOI 10.1038/sj.bjp.0700921; HOYER D, 1994, PHARMACOL REV, V46, P157; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; Jasper JR, 1997, BRIT J PHARMACOL, V122, P126, DOI 10.1038/sj.bjp.0701336; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kohen R, 1996, J NEUROCHEM, V66, P47; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Leonard BE, 1996, PSYCHOTHER PSYCHOSOM, V65, P66, DOI 10.1159/000289049; LOVENBERG TW, 1993, NEURON, V11, P449, DOI 10.1016/0896-6273(93)90149-L; MARTIN GR, 1994, PHARMACOL THERAPEUT, V62, P283, DOI 10.1016/0163-7258(94)90048-5; MASTERS SB, 1985, BIOCHEM J, V227, P933, DOI 10.1042/bj2270933; MESTON CM, 1992, J PSYCHOACTIVE DRUGS, V24, P1; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONSMA FJ, 1993, MOL PHARMACOL, V43, P320; MORK A, 1990, EUR J PHARMACOL, V175, P237, DOI 10.1016/0014-2999(90)90560-S; Nibuya M, 1996, J NEUROSCI, V16, P2365; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Obrietan K, 1998, J NEUROPHYSIOL, V79, P1360, DOI 10.1152/jn.1998.79.3.1360; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PROSSER RA, 1994, BRAIN RES, V644, P67, DOI 10.1016/0006-8993(94)90348-4; PROSSER RA, 1989, J NEUROSCI, V9, P1073; ROTH BL, 1994, J PHARMACOL EXP THER, V268, P1403; RUAT M, 1993, P NATL ACAD SCI USA, V90, P8547, DOI 10.1073/pnas.90.18.8547; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoeffter P, 1996, BRIT J PHARMACOL, V117, P993, DOI 10.1111/j.1476-5381.1996.tb16687.x; SHEN Y, 1993, J BIOL CHEM, V268, P18200; Shimizu M, 1996, J PHARMACOL EXP THER, V279, P1551; Simansky KJ, 1996, BEHAV BRAIN RES, V73, P37, DOI 10.1016/0166-4328(96)00066-6; Soares JC, 1997, BIOL PSYCHIAT, V41, P86, DOI 10.1016/S0006-3223(96)00006-6; Stam NJ, 1997, FEBS LETT, V413, P489, DOI 10.1016/S0014-5793(97)00964-2; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Ullmer C, 1996, BRIT J PHARMACOL, V117, P1081, DOI 10.1111/j.1476-5381.1996.tb16700.x; WARD RP, 1995, NEUROSCIENCE, V64, P1105, DOI 10.1016/0306-4522(94)00439-C; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZGOMBICK JM, 1993, MOL PHARMACOL, V44, P575	62	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17469	17476		10.1074/jbc.273.28.17469	http://dx.doi.org/10.1074/jbc.273.28.17469			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651336	hybrid			2022-12-27	WOS:000074816100029
J	Dizhoor, AM; Boikov, SG; Olshevskaya, EV				Dizhoor, AM; Boikov, SG; Olshevskaya, EV			Constitutive activation of photoreceptor guanylate cyclase by Y99C mutant of GCAP-1 - Possible role in causing human autosomal dominant cone degeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; EXPRESSION; PROTEIN; RETINA; PHOSPHODIESTERASE; RETGC	Photoreceptor membrane guanylate cyclases (RetGC) are regulated by calcium-binding proteins, GCAP-1 and GCAP-2. At Ca2+ concentrations below 100 nM, characteristic of light adapted photoreceptors, guanylate cyclase-activating protein (GCAPs) activate RetGC, and at free Ca2+ concentrations above 500 nM, characteristic of dark-adapted photoreceptors, GCAPs inhibit RetGC. A mutation, Y99C, in human GCAP-1 was recently found to be linked to autosomal dominant cone dystrophy in a British family (Payne, A. M., Downes, S. M., Bessant, D. A. R., Taylor, R., Holder, G. E., Warren, M. J., Bird, A. C., and Bhattachraya, S. S. (1998) Hum. Mol. Genet. 7, 273-277). We produced recombinant Y99C GCAP-1 mutant and tested its ability to activate RetGC in vitro at various free Ca2+ concentrations. The Y99C mutation does not decrease the ability of GCAP-1 to activate RetGC. However, RetGC stimulated by the Y99C GCAP-1 remains active even at Ca2+ concentration above 1 mu M. Hence, the cyclase becomes constitutively active within the whole physiologically relevant range of free Ca2+ concentrations. We have also found that the Y99C GCAP-1 can activate RetGc even in the presence of Ca2+ loaded nonmutant GCAPs. This is consistent with the fact that cone degeneration was dominant in human patients who carried such mutation (Payne, A. M., Downes, S. M., Bessant, D. A. R., Taylor, R., Holder, G. E., Warren, M. J., Bird, A. C., and Bhattachraya, S. S. (1998) Hum. Mol. Genet. 7, 273-277). A similar mutation, Y104C, in GCAP-2 results in a different phenotype. This mutation apparently does not affect Ca2+ sensitivity of GCAP-S. Instead, the Y104C GCAP-2 stimulates RetGC less efficiently than the wild-type GCAP-2. Our data indicate that cone degeneration associated with the Y99C mutation in GCAP-1 can be a result of constitutive acti vation of cGMP synthesis.	Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Dizhoor, AM (corresponding author), Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, 4717 St Antoine, Detroit, MI 48201 USA.	adizhoor@med.wayne.edu		Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY11522] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Cuenca N., 1997, Investigative Ophthalmology and Visual Science, V38, pS21; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Kachi S., 1998, IOVS, V39, pS1051; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P322; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; SempleRowland SL, 1996, FEBS LETT, V385, P47, DOI 10.1016/0014-5793(96)00345-6; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1995, MOL CELL BIOCHEM, V148, P139, DOI 10.1007/BF00928151; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	29	136	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17311	17314		10.1074/jbc.273.28.17311	http://dx.doi.org/10.1074/jbc.273.28.17311			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651312	hybrid			2022-12-27	WOS:000074816100005
J	Karuppayil, SM; Moran, E; Das, GM				Karuppayil, SM; Moran, E; Das, GM			Differential regulation of p53-dependent and -independent proliferating cell nuclear antigen gene transcription by 12 S E1A oncoprotein requires CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1A-ASSOCIATED PROTEIN P300; BASAL PROMOTER ELEMENTS; ADENOVIRUS E1A; P53; ACTIVATION; BINDING; COACTIVATOR; REPRESSION; PRODUCTS; FAMILY	The tumor suppressor protein p53 and the adenoviral 12 S E1A oncoprotein are both known to elicit their biological effects mainly by regulating the transcription of important cellular genes. The human proliferating cell nuclear antigen (PCNA) gene is a transcriptional target of both p53 and E1A. We have analyzed the effects of p53 and 12 S E1A, separately as well as together, on PCNA gene transcription. Our results showed that whereas both p53 and 12 S E1A separately activated PCNA transcription, 12 S E1A repressed p53-mediated transcriptional activation. Thus, 12 S E1A uses a dual strategy of transcriptional activation and repression to take control of the cellular PCNA gene regulation. The cyclic AMP-response element in the PCNA core promoter, besides being crucial for basal transcription, synergizes with p53 to activate transcription. The cyclic AMP response element-binding protein (CREB)-binding protein (CBP) is an essential component of both the transcriptional activation and repression by E1A. Our data demonstrate for the first time that E1A can modulate CBP function to activate PCNA transcription, while at the same time repressing p53-mediated activation by disrupting CBP interaction with p53, thereby uncoupling PCNA transcription from the regulatory effects of p53.	Univ Texas, Hlth Sci Ctr, Canc Therapy & Res Ctr, Gene Regulat Lab, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Das, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Canc Therapy & Res Ctr, Gene Regulat Lab, 8122 Datapoint Dr,Suite 700, San Antonio, TX 78229 USA.		Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093	NCI NIH HHS [P30 CA54174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DAS G, 1993, J BIOL CHEM, V268, P25026; ENAMI KH, 1995, MOL CELL BIOL, V15, P5906; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Scolnick DM, 1997, CANCER RES, V57, P3693; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	34	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17303	17306		10.1074/jbc.273.28.17303	http://dx.doi.org/10.1074/jbc.273.28.17303			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651310	hybrid			2022-12-27	WOS:000074816100003
J	Su, J; Chai, XY; Kahn, B; Napoli, JL				Su, J; Chai, XY; Kahn, B; Napoli, JL			cDNA cloning, tissue distribution, and substrate characteristics of a cis-retinol/3 alpha-hydroxysterol short-chain dehydrogenase isozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RAT VENTRAL PROSTATE; BETA-CAROTENE; ALCOHOL-DEHYDROGENASE; METABOLIZING ENZYMES; ISOMERS; SEPARATION; VEGETABLES; EXPRESSION; ANDROGENS	We report here a mouse cDNA that encodes a 316-amino acid short chain dehydrogenase that prefers NAD(+) as its cofactor and recognizes as substrates androgens and retinols, i.e. has steroid 3 alpha- and 17 beta-dehydrogenase and cis/trans-retinol catalytic activities. This (c) under bar is-(r) under bar etinol/(a) under bar ndrogen dehydrogenase type (2) under bar (CRAD2) shares close amino acid similarity with mouse retinol dehydrogenase isozyme types 1 and 2 and CRAD1 (86, 84, and 87%, respectively). CRAD2 exhibits cooperative kinetics with 3 alpha-adiol (3 alpha-hydroxysteroid dehydrogenase activity) and testosterone (17 beta-hydroxysteroid dehydrogenase activity), but Michaelis-Menten kinetics with androsterone (3 alpha-hydroxysteroid dehydrogenase activity), 11-cis-retinol, all-trans-retinol, and 9-cis-retinol, with V/K-0.5 values of 1.6, 0.2, 0.1, 0.04, 0.005, and not saturated, respectively. Carbenoxolone (IC50 = 2 mu M) and 4-methylpyrazole (IC50 = 5 mM) inhibited CRAD2, but neither ethanol nor phosphatidylcholine had marked effects on its activity. Liver expressed CRAD2 mRNA intensely, with expression in lung, eye, kidney, and brain (2.9, 2, 1.6, and 0.6% of liver mRNA respectively). CRAD2 represents the fifth isozyme in a group of short chain dehydrogenase/reductase isozymes (retinol dehydrogenases 1-3 and CRAD1), closely related in primary amino acid sequence (similar to 85%), that are expressed in different quantities in various tissues, have different substrate specificities, and may serve different physiological functions. CRAD2 may alter the amounts of active and inactive androgens and/or convert retinols into retinals. These data expand insight into the multifunctional nature of short-chain dehydrogenases/reductases and into the enzymology of steroid and retinoid metabolism.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Napoli, JL (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1994, STEROIDS, V59, P248, DOI 10.1016/0039-128X(94)90109-0; BAKER ME, 1991, MOL CELL ENDOCRINOL, V78, pC99, DOI 10.1016/0303-7207(91)90178-U; Beaulieu M, 1996, J BIOL CHEM, V271, P22855, DOI 10.1074/jbc.271.37.22855; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOUDOU P, 1994, J CLIN ENDOCR METAB, V78, P1064, DOI 10.1210/jc.78.5.1064; BOUDOU P, 1995, J CLIN ENDOCR METAB, V80, P1158, DOI 10.1210/jc.80.4.1158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PS, 1959, NATURE, V184, P1377, DOI 10.1038/1841377a0; BRUCHOVSKY N, 1971, ENDOCRINOLOGY, V89, P1212, DOI 10.1210/endo-89-5-1212; BUSHWAY RJ, 1985, J LIQ CHROMATOGR, V8, P1527, DOI 10.1080/01483918508067163; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANDLER LA, 1987, J FOOD SCI, V52, P669, DOI 10.1111/j.1365-2621.1987.tb06700.x; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; DANIELPOUR D, 1994, CANCER RES, V54, P3413; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; EDWARDS CRW, 1993, J STEROID BIOCHEM, V45, P1, DOI 10.1016/0960-0760(93)90114-C; GIFFIN JE, 1995, METABOLIC MOL BASIS, P2967; HUANG HFS, 1994, BIOL REPROD, V51, P541, DOI 10.1095/biolreprod51.3.541; Huang HFS, 1997, ENDOCRINOLOGY, V138, P553, DOI 10.1210/en.138.2.553; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KRIEG M, 1995, J STEROID BIOCHEM, V53, P395, DOI 10.1016/0960-0760(95)00085-E; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; Lotan R, 1988, Prog Clin Biol Res, V259, P261; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mahendroo MS, 1996, MOL ENDOCRINOL, V10, P380, DOI 10.1210/me.10.4.380; MARKS AR, 1992, J BIOL CHEM, V267, P15459; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MOORE RJ, 1973, ENDOCRINOLOGY, V93, P581, DOI 10.1210/endo-93-3-581; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; OLSON JA, 1995, NUTR BLINDNESS; ONEIL CA, 1992, J CHROMATOGR, V624, P235, DOI 10.1016/0021-9673(92)85682-J; OPPERMAN UCT, 1996, ENZYMOL MOL BIOL CAR, V6, P403; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SCHULTZ FM, 1974, ENDOCRINOLOGY, V94, P979; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; STAHL W, 1993, CLIN CHEM, V39, P810; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; TAUROG JD, 1975, BIOCHEMISTRY-US, V14, P810, DOI 10.1021/bi00675a026; Wilson J D, 1970, Recent Prog Horm Res, V26, P309; WU L, 1993, J BIOL CHEM, V268, P12964; Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106	52	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17910	17916		10.1074/jbc.273.28.17910	http://dx.doi.org/10.1074/jbc.273.28.17910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651397	hybrid			2022-12-27	WOS:000074816100090
J	Lee, SK; Kim, HJ; Na, SY; Kim, TS; Choi, HS; Im, SY; Lee, JW				Lee, SK; Kim, HJ; Na, SY; Kim, TS; Choi, HS; Im, SY; Lee, JW			Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR-PROTEIN CBP; DNA-BINDING; LEUCINE-ZIPPER; TRANSCRIPTIONAL ACTIVATION; COILED COILS; GENE FAMILY; P300; ONCOGENE; COMPLEX	Steroid receptor coactivator-l (SRC-1) specifically bound to the transcription factor AP-I subunits c-Jun and c-Fos, as demonstrated by the yeast two-hybrid tests and glutathione S-transferase pull down assays. The c-Jun and c-Fos binding sites were localized to the C-terminal subregion of SRC-1 (amino acids 1101-1441) that encompasses the previously described histone acetyltransferase and receptor-binding domains. In mammalian cells, SRC-I, similar to the previous results with CBP-p300 (Arias, J., Alberts, A. S., Brindle, P., Claret, F. X., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994) Nature 370, 226-229; Bannister, A. J., and Kouzarides, T. (1995) EMBO J. 14, 4758-4762), potentiated the AP-l-mediated transactivations in a dose-dependent manner and derepressed the mutual inhibitions between nuclear receptors and AP-1. Furthermore, coexpression of p300 further enhanced this SRC-1-potentiated level of transactivations. Thus, we concluded that at least two distinct coactivator molecules may cooperate to regulate AP-l-dependent transactivations and mediate transrepression between AP-I and nuclear receptors in vivo.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Microbiol, Kwangju 500757, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University	Lee, JW (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr						ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL FM, 1995, CURRENT PROTOC0LS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIM HJ, 1998, IN PRESS MOL ENDOCRI; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	57	176	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16651	16654		10.1074/jbc.273.27.16651	http://dx.doi.org/10.1074/jbc.273.27.16651			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642216	hybrid			2022-12-27	WOS:000074545200006
J	Mannstadt, M; Luck, MD; Gardella, TJ; Juppner, H				Mannstadt, M; Luck, MD; Gardella, TJ; Juppner, H			Evidence for a ligand interaction site at the amino-terminus of the parathyroid hormone (PTH)/PTH-related protein receptor from cross-linking and mutational studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; PEPTIDE RECEPTOR; PLASMA-MEMBRANE; BINDING; AGONIST; DETERMINANTS; MUTAGENESIS; EXPRESSION; PTH-(1-34); CALCITONIN	Low resolution mutational studies have indicated that the amino-terminal extracellular domain of the rat parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor (rP1R) interacts with the carboxyl-terminal portion of PTH-(1-34) or PTHrP-(1-36), To further define ligand-receptor interactions, we prepared a fully functional photoreactive analog of PTHrP, [Ile(5),Bpa(23),Tyr(36)] PTHrP-(1-36)-amide ([Bpa(23)]PTHrP, where Bpa is p-benzoyl-L-phenylalanine), Upon photolysis, radioiodinated [Bpa23]PTHrP covalently and specifically bound to the rP1R, CNBr cleavage of the broad approximate to 80-kDa complex yielded a radiolabeled approximate to 9-kDa nonglycosylated protein band that could potentially be assigned to rP1R residues 23-63, Tyr(23) being the presumed amino-terminus of the receptor. This assignment was confirmed using a mutant rP1R (rP1R-M63I) that yielded, upon photoligand binding and CNBr digestion, a broad protein band of approximate to 46 kDa, which was reduced to a sharp band of approximate to 20 kDa upon deglycosylation, CNBr digestion of complexes formed with two additional rP1R double mutants (rP1R-M63I/L40M and rP1R-M63I/L41M) yielded non-glycosylated protein bands that were approximate to 6 kDa in size, indicating that [Bpa23]PTHrP cross-links to amino acids 23-40 of the rP1R, This segment overlaps a receptor region previously identified by deletion mapping to be important for ligand binding. Alanine scanning of this region revealed two residues, Thr(33) and Gln(37), as being functionally involved in ligand binding. Thus, the convergence of photoaffinity cross-linking and mutational data demonstrates that the extreme amino-terminus of the rP1R participates in ligand binding.	Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Childrens Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Juppner, H (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Wellman 503,50 Blossom St, Boston, MA 02114 USA.		Mannstadt, Michael/AAO-1124-2020	Mannstadt, Michael/0000-0003-0867-9778	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1997, J BONE MINER RES, V12, pS363; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; Segre Gino V., 1996, P377; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; SHIGENO C, 1988, J BIOL CHEM, V263, P3864; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo-122-4-1208; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	33	90	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16890	16896		10.1074/jbc.273.27.16890	http://dx.doi.org/10.1074/jbc.273.27.16890			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642250	hybrid			2022-12-27	WOS:000074545200040
J	Jeyakumar, LH; Copello, JA; O'Malley, AM; Wu, GM; Grassucci, R; Wagenknecht, T; Fleischer, S				Jeyakumar, LH; Copello, JA; O'Malley, AM; Wu, GM; Grassucci, R; Wagenknecht, T; Fleischer, S			Purification and characterization of ryanodine receptor 3 from mammalian tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; CHICKEN SKELETAL-MUSCLE; FK506 BINDING-PROTEIN; CA2+ RELEASE; MICE LACKING; ELECTRON-MICROSCOPY; TERMINAL CISTERNAE; FEET STRUCTURES; SMOOTH-MUSCLE	The ryanodine receptors are intracellular Ca2+ release channels that play a key role in cell signaling via Ca2+. There are three isoforms, Isoform 1 from skeletal muscle and isoform 2 from heart have been characterized. Isoform 3 is widely distributed in many mammalian tissues although in minuscule amounts, Its low abundance has hampered its study. We now describe methodology to isolate mammalian isoform 3 in amounts sufficient for biochemical and biophysical characterization, Bovine diaphragm sarcoplasmic reticulum fractions enriched in terminal cisternae containing both isoforms 1 (>95%) and 3 (<5% of the ryanodine binding) served as starting source, Isoform 3 was selectively immunoprecipitated from the 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid (CHAPS)-solubilized fraction and eluted with peptide epitope. Isoform 3 thus prepared is highly purified as characterized by SDS-polyacryamide gel electrophoresis, Coomassie Blue staining, and by high affinity ryanodine binding. The purified isoform 3 was incorporated into planar lipid bilayers, and its channel properties were studied. Channel characteristics in common with the other two isoforms are slope conductance, higher selectivity to Ca2+ versus K+ (P(Ca/K)similar to 6), and response to drugs and Ligands. In its response to Ca2+ and ATP, it more closely resembles isoform 2. The first two-dimensional structure of isoform 3 was obtained by cryoelectron microscopy and image enhancement techniques.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, New York State Dept Hlth, Albany, NY 12201 USA	Vanderbilt University; Vanderbilt University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Fleischer, S (corresponding author), Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA.	fleiscs@ctrvax.Vanderbilt.edu			NHLBI NIH HHS [HL32711, 5 T32 HLO7411-19] Funding Source: Medline; NIAMS NIH HHS [AR40615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711, T32HL007411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; Barg S, 1997, AM J PHYSIOL-CELL PH, V272, pC1726, DOI 10.1152/ajpcell.1997.272.5.C1726; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; Copello JA, 1997, BIOPHYS J, V73, P141, DOI 10.1016/S0006-3495(97)78055-X; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DiJulio DH, 1997, J BIOL CHEM, V272, P15687, DOI 10.1074/jbc.272.25.15687; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; Ikemoto T, 1997, J PHYSIOL-LONDON, V501, P305, DOI 10.1111/j.1469-7793.1997.305bn.x; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jeyakumar LH, 1998, BIOPHYS J, V74, pA58; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LEPAULT J, 1983, J MICROSC-OXFORD, V129, P89, DOI 10.1111/j.1365-2818.1983.tb04163.x; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNN S, 1995, FEBS LETT, V372, P6, DOI 10.1016/0014-5793(95)00924-X; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; Murayama T, 1997, J BIOL CHEM, V272, P24030, DOI 10.1074/jbc.272.38.24030; Murayama T, 1996, J BIOL CHEM, V271, P5079; OBRIEN J, 1993, BIOPHYS J, V65, P2418, DOI 10.1016/S0006-3495(93)81303-1; OBRIEN J, 1995, BIOPHYS J, V68, P471, DOI 10.1016/S0006-3495(95)80208-0; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; RADERMACHER M, 1992, BIOPHYS J, V61, P936, DOI 10.1016/S0006-3495(92)81900-8; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SHARMA MR, 1997, BIOPHYS J, V71, pA332; SHOMER NH, 1994, BIOPHYS J, V67, P641, DOI 10.1016/S0006-3495(94)80524-7; Sonnleitner A, 1997, CELL CALCIUM, V21, P283, DOI 10.1016/S0143-4160(97)90116-0; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Verma V, 1996, BIOCHEM J, V319, P449, DOI 10.1042/bj3190449	66	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16011	16020		10.1074/jbc.273.26.16011	http://dx.doi.org/10.1074/jbc.273.26.16011			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632651	hybrid			2022-12-27	WOS:000074436600022
J	Kubrich, M; Rassow, J; Voos, W; Pfanner, N; Honlinger, A				Kubrich, M; Rassow, J; Voos, W; Pfanner, N; Honlinger, A			The import route of ADP/ATP carrier into mitochondria separates from the general import pathway of cleavable preproteins at the trans side of the outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; YEAST MITOCHONDRIA; PROTEIN IMPORT; INNER MEMBRANE; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; RECEPTOR COMPLEX; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEINS; INSERTION PORE	The ADP/ATP carrier (AAC) of the mitochondrial inner membrane is synthesized in the cytosol without a cleavable presequence. The preprotein preferentially binds to the mitochondrial surface receptor Tom70 and joins the import pathway of presequence-carrying preproteins at the cis side of the outer membrane. Little is known about the translocation of the AAC across the outer membrane and where its import route separates from that of cleavable preproteins. Here we have characterized a translocation intermediate of AAC during transfer across the outer membrane. The major portion of the preprotein is exposed to the intermembrane space, while a short segment is still accessible to externally added protease, This intermediate can be quantitatively chased to the fully imported form in the inner membrane. Its accumulation depends on Tom7, but not on the intermembrane space domain of Tom22 in contrast to cleavable preproteins. Moreover, opening of the intermembrane space inhibits the import of AAC, but not that of cleavable preproteins into mitoplasts. We conclude that the import route of AAC diverges from the general import pathway of cleavable preproteins already at the trans side of the outer membrane.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	pfanner@ruf.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021					ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; Haucke V, 1997, EMBO J, V16, P4560, DOI 10.1093/emboj/16.15.4560; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SIKORSKI RS, 1989, GENETICS, V122, P19; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1988, FEBS LETT, V229, P25, DOI 10.1016/0014-5793(88)80790-7; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; Zara V, 1996, MOL CELL BIOL, V16, P6524	47	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16374	16381		10.1074/jbc.273.26.16374	http://dx.doi.org/10.1074/jbc.273.26.16374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632701	hybrid			2022-12-27	WOS:000074436600072
J	Pellicena, P; Stowell, KR; Miller, WT				Pellicena, P; Stowell, KR; Miller, WT			Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; C-SRC; PP60C-SRC; PEPTIDES; SPECIFICITY	Src family protein-tyrosine kinases possess several modular domains important for regulation of catalytic activity and interaction with potential substrates, Here, we explore interactions between the SH2 domain of Hck, a Src family kinase, and substrates containing SH2 domain-binding sites, We have synthesized a series of peptide substrates containing a high affinity SH2 domain binding site, (phospho)Tyr-Glu-Glu-Ile. We show that the presence of this sequence in a peptide results in a dramatic increase in the phosphorylation rate of a second tyrosine located at the N terminus. Enhanced phosphorylation is not a consequence of stimulation of enzymatic activity by C-terminal tail displacement but is imparted instead by a 10-fold reduction in the Ii, of the phosphotyrosine-containing peptide when compared with a control, The isolated catalytic domain of the nonreceptor tyrosine kinase Abl does not show a preference for the pYEEI motif-containing peptide; however, the preference is restored when the SH2 domain of Src is introduced into Abl, Furthermore, enhanced phosphorylation is dependent on the distance between SH2 domain-binding site and phosphorylatable tyrosine, with the minimum distance requirement being seven amino acids. Reversing the orientation of the pYEEI motif with respect to the substrate sequence decreases phosphorylation by down-regulated Hck, but both orientations are utilized equally well by activated Hck, We discuss the possible implications of these results for processive phosphorylation of substrates in vivo by Src family kinases.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NCI NIH HHS [CA58530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058530, R01CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Atherton E., 1990, SOLID PHASE PEPTIDE; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GARCIA P, 1993, J BIOL CHEM, V268, P25146; KING LA, 1995, BACULOVIRUS EXPRESSI; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Lewis LA, 1997, J IMMUNOL, V159, P2292; LIU XQ, 1993, ONCOGENE, V8, P1119; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schulz G. E., 1979, PRINCIPLES PROTEIN S, P66; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TILL JH, 1994, J BIOL CHEM, V269, P7423; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15325	15328		10.1074/jbc.273.25.15325	http://dx.doi.org/10.1074/jbc.273.25.15325			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624111	hybrid			2022-12-27	WOS:000074284200005
J	Picard, V; Epsztejn, S; Santambrogio, P; Cabantchik, ZI; Beaumont, C				Picard, V; Epsztejn, S; Santambrogio, P; Cabantchik, ZI; Beaumont, C			Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RESPONSIVE ELEMENT; OXIDATIVE STRESS; ERYTHROID-CELLS; MESSENGER-RNA; NITRIC-OXIDE; SUBUNIT GENE; K562 CELLS; H-SUBUNIT; HYPERFERRITINEMIA	In vitro studies have shown that ferritin iron incorporation is mediated by a ferroxidase activity associated with ferritin H subunits (H-Ft) and a nucleation center-associated with ferritin L subunits (L-Ft). To assess the role played by the ferritin subunits in regulating intracellular iron distribution, we transfected mouse erythroleukemia cells with the H-Ft subunit gene mutated in the iron-responsive element, Stable transfectants displayed high H-Ft levels and reduced endogenous L-Ft levels, resulting in a marked change in the H:L subunit ratio from 1:1 in control cells to as high as 20:1 in some transfected clones. The effects of H-Ft overexpression on the labile iron pool were determined in intact cells by a novel method based on the fluorescent metallosensor calcein, H-Ft overexpression resulted in a significant reduction in the iron pool, from 1.3 mu m in control cells to 0.56 mu m in H-Ft transfectants, and in higher buffering capacity following iron loads. A fraction of the H-Ft-associated iron was labile, available to cell-permeant, but not cell-impermeant, chelators. The results of this study provide the first in vivo direct demonstration of the capacity of H-Ft to sequester cell iron and to regulate the levels of the labile iron pool.	Fac Xavier Bichat, INSERM U409, F-75870 Paris 18, France; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; San Raffaele Sci Inst, Dipartimento Ricerca Biol & Tecnol, I-20132 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hebrew University of Jerusalem; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Beaumont, C (corresponding author), Fac Xavier Bichat, INSERM U409, BP416, F-75870 Paris 18, France.		Santambrogio, Paolo/AAN-3837-2020	Santambrogio, Paolo/0000-0002-5481-2130	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI020342, R01AI020342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaumont C, 1996, J BIOL CHEM, V271, P7923, DOI 10.1074/jbc.271.14.7923; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; Drapier JC, 1996, BIOESSAYS, V18, P549, DOI 10.1002/bies.950180706; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Gerard B, 1996, EXP CELL RES, V228, P8, DOI 10.1006/excr.1996.0292; GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050; GUO B, 1994, J BIOL CHEM, V269, P24252; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOYES KP, 1993, BRIT J HAEMATOL, V85, P393, DOI 10.1111/j.1365-2141.1993.tb03184.x; JACOBS A, 1977, BLOOD, V50, P433; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; NEEDHAM M, 1992, NUCLEIC ACIDS RES, V20, P997, DOI 10.1093/nar/20.5.997; NUNEZ MT, 1980, BLOOD, V55, P1051; Okada S, 1996, PATHOL INT, V46, P311, DOI 10.1111/j.1440-1827.1996.tb03617.x; Picard V, 1996, BLOOD, V87, P2057; POLLACK S, 1980, BLOOD, V56, P564; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Richardson DR, 1996, BLOOD, V87, P3477, DOI 10.1182/blood.V87.8.3477.bloodjournal8783477; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SANTAMBROGIO P, 1997, INT S IR BIOL MED SA, P230; TANG CK, 1992, J BIOL CHEM, V267, P24466; Wu CG, 1997, INT J ONCOL, V11, P187	30	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15382	15386		10.1074/jbc.273.25.15382	http://dx.doi.org/10.1074/jbc.273.25.15382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624120	hybrid			2022-12-27	WOS:000074284200014
J	Leenders, F; Vater, J; Stein, T; Franke, P				Leenders, F; Vater, J; Stein, T; Franke, P			Characterization of the binding site of the tripeptide intermediate D-phenylalanyl-L-prolyl-L-valine in gramicidin S biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE; PEPTIDE	The tripeptide intermediate D-Phe-Pro-Val in the biosynthesis of gramicidin S was labeled by incorporation of either L-[C-14]phenylalanine or L-[C-14]valine in an in vitro biosynthetic assay. The gramicidin S synthetase S-tripeptide complex was first digested with CNBr and subsequently by Staphylococcus aureus V8 protease, The active site peptide carrying the radioactively labeled tripeptide was isolated in pure form by reversed phase high performance liquid chromatography technology and analyzed by liquid phase sequencing, mass spectrometry, and amino acid analysis, It was demonstrated that D-Phe-Pro-Val is attached to the 4'-phosphopantetheine cofactor at the thiolation center for valine of gramicidin S synthetase 2, In this way the attachment site of a peptide intermediate in nonribosomal peptide biosynthesis was identified for the first time. Our results are in full agreement with the multiple carrier model of nonribosomal peptide biosynthesis (Stein, T., Vater, J., Kruft, V., Otto, A., Wittmann-Liebold, B., Franke, P., Panico, M., McDowell, R., and Morris, H. R. (1996) J. Biol. Chem, 271, 15426-15435), which predicts that the growing peptide chain in the elongation process should always be bound to the thiotemplate site specific for its C-terminal amino acid component.	Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, D-10587 Berlin, Germany; Frei Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Technical University of Berlin; Free University of Berlin	Vater, J (corresponding author), Tech Univ Berlin, Max Volmer Inst Biophys Chem & Biochem, Franklinstr 29, D-10587 Berlin, Germany.			Vater, Joachim/0000-0002-4478-4244				BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU CW, 1984, THESIS TU BERLIN; GADOW A, 1983, EUR J BIOCHEM, V132, P229, DOI 10.1111/j.1432-1033.1983.tb07352.x; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; Laland S G, 1973, Essays Biochem, V9, P31; LALAND SG, 1972, NATURE-NEW BIOL, V239, P43, DOI 10.1038/newbio239043a0; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; STEIN T, 1994, FEBS LETT, V340, P39, DOI 10.1016/0014-5793(94)80169-X; STEIN T, 1996, J BIOL CHEM, V271, P15426; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VATER J, 1987, EUR J BIOCHEM, V163, P297, DOI 10.1111/j.1432-1033.1987.tb10800.x; Vater J, 1997, J PROTEIN CHEM, V16, P557, DOI 10.1023/A:1026386100259; VATER J, 1985, BIOCHEMISTRY-US, V24, P2022, DOI 10.1021/bi00329a033; VATER J, 1990, BIOCH PEPTIDE ANTIBI, P33; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262; VONDOHREN H, 1982, PEPTIDE ANTIBIOTCS B, P169	24	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18011	18014		10.1074/jbc.273.29.18011	http://dx.doi.org/10.1074/jbc.273.29.18011			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660754	hybrid			2022-12-27	WOS:000074828500009
J	Siddhanta, A; Shields, D				Siddhanta, A; Shields, D			Secretory vesicle budding from the trans-Golgi network is mediated by phosphatidic acid levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PLECKSTRIN-HOMOLOGY DOMAINS; PHOSPHOLIPASE-D; CELLS; PHOSPHOINOSITIDES; ACTIVATION; MEMBRANES; COMPLEX; KINASE	Phospholipid metabolism plays a central role in regulating vesicular traffic in the secretory pathway. In mammalian cells, activation of a Golgi-associated phospholipase D activity by ADP-ribosylation factor results in hydrolysis of phosphatidylcholine to phosphatidic acid (PA). This reaction has been proposed to stimulate nascent secretory vesicle budding from the trans-Golgi network. It is unclear whether PA itself or diacylglycerol (DAG), a metabolite implicated in yeast secretory vesicle formation, regulates budding. To distinguish between these possibilities we have used a permeabilized cell system supplemented with phospholipid-modifying enzymes that generate either DAG or PA. The data demonstrate that in mammalian cells accumulation of PA rather than DAG is a key step in regulating budding of secretory vesicles from the trans-Golgi network.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Shields, D (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021860, R37DK021860] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK21860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Austin CD, 1996, J CELL BIOL, V135, P1471, DOI 10.1083/jcb.135.6.1471; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169	26	124	125	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17995	17998		10.1074/jbc.273.29.17995	http://dx.doi.org/10.1074/jbc.273.29.17995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660750	hybrid			2022-12-27	WOS:000074828500005
J	Yuan, CS; Wnuk, SF; Robins, MJ; Borchardt, RT				Yuan, CS; Wnuk, SF; Robins, MJ; Borchardt, RT			A novel mechanism-based inhibitor (6 '-bromo-5 ',6 '-didehydro-6 '-deoxy-6 '-fluorohomoadenosine) that covalently modifies human placental S-adenosylhomocysteine hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-HOMOCYSTEINE HYDROLASE; SPECTRUM ANTIVIRAL AGENTS; NEPLANOCIN-A; INACTIVATION; NUCLEOSIDES; DESIGN; TARGET; METHYLTRANSFERASES; CHEMOTHERAPY; ANALOGS	Most inhibitors of S-adenosylhomocysteine (AdoHcy) hydrolase function as substrates for the "3'-oxidative activity" of the enzyme and convert the enzyme from its active form (NAD(+)) to its inactive form (NADH) (Liu, S,, Wolfe, M. S., and Borchardt, R. T. (1992) Antivir. Res. 19, 247-265), In this study, we describe the effects of a mechanism-based inhibitor, 6'-bromo-5',6'-didehydro-6'-deoxy-6'-fluorohomoadenosine (BDDFHA), which functions as a substrate for the "6'-hydrolytic activity" of the enzyme with subsequent formation of a covalent linkage with the enzyme. Incubation of human placental AdoHcy hydrolase with BDDFHA results in a maximum inactivation of 83% with the remaining enzyme activity exhibiting one-third of the k(cat) value of the native enzyme. This partial inactivation is concomitant with the release of both Br- and F- ions and the formation of adenine (Ade). The enzyme can be covalently labeled with [8-H-3]BDDFHA, resulting in a stoichiometry of 2 mol of BDDFHA/mol of the tetrameric enzyme. The H-3-labeled enzyme retains its original NAD(+)/NADH content. Tryptic digestion and subsequent protein sequencing of the [8-H-3]BDDFHA-labeled enzyme revealed that Arg(196) is the residue that is associated with the radiolabeled inhibitor. The partition ratio of the Ade formation (nonlethal event) to covalent acylation (lethal event) is approximately 1:1. From these experimental results, a possible mechanism by which BDDFHA inactivates AdoHcy hdyrolase is proposed: enzyme-mediated water addition at the C-6' position of BDDFHA followed by elimination of Br- ion results in the formation of homoAdo 6'-carboxyl fluoride (HACF). HACF then partitions in two ways: (a) attack by a proximal nucleophile (Arg196) to form an amide bond after expulsion of F- ion (lethal event) or (b) depurination to form Ade and hexose-derived 6-carboxyl fluoride (HDCF), which is further hydrolyzed to hexose-derived B-carboxylic acid (HDCA) and F- ion (nonlethal event).	Univ Kansas, Dept Biochem, Lawrence, KS 66047 USA; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	University of Kansas; Brigham Young University	Borchardt, RT (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Simons Res Labs, 2095 Constant Ave, Lawrence, KS 66047 USA.	borchardt@smissman.hbc.ukans.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BORCHERDING DR, 1988, J MED CHEM, V31, P1729, DOI 10.1021/jm00117a011; BORCHERDING DR, 1987, J ORG CHEM, V52, P5457, DOI 10.1021/jo00233a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DELAHABA G, 1959, J BIOL CHEM, V234, P603; GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4; GUPTA RA, 1995, ARCH BIOCHEM BIOPHYS, V319, P365, DOI 10.1006/abbi.1995.1306; HASOBE M, 1989, ANTIMICROB AGENTS CH, V33, P828, DOI 10.1128/AAC.33.6.828; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; HUGGING JW, 1995, 8 INT C ANT RES APR; JARVI ET, 1991, J MED CHEM, V34, P647, DOI 10.1021/jm00106a028; Keller B. T., 1988, ANTIVIRAL DRUG DEV M, P123; KITZ R, 1962, J BIOL CHEM, V237, P3245; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; LIU SM, 1992, BIOORG MED CHEM LETT, V2, P1741, DOI 10.1016/S0960-894X(00)80467-9; MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021; MCCARTHY JR, 1989, J AM CHEM SOC, V111, P1127, DOI 10.1021/ja00185a052; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PARRY RJ, 1991, BIOCHEMISTRY-US, V30, P9988, DOI 10.1021/bi00105a025; ROBINS MJ, 1992, J MED CHEM, V35, P2283, DOI 10.1021/jm00090a020; SILVERMAN RB, 1988, MECHANISM BASED ENZY, V1, P3; Wnuk SF, 1997, J MED CHEM, V40, P1608, DOI 10.1021/jm960828p; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; WOLOS JA, 1993, CELL IMMUNOL, V149, P402, DOI 10.1006/cimm.1993.1165; WOLOS JA, 1993, J IMMUNOL, V151, P526; Yuan CS, 1996, J BIOL CHEM, V271, P28009, DOI 10.1074/jbc.271.45.28009; YUAN CS, 1995, J BIOL CHEM, V270, P16140, DOI 10.1074/jbc.270.27.16140; YUAN CS, 1993, J BIOL CHEM, V268, P17030; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P3758, DOI 10.1021/bi00178a036; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P12305, DOI 10.1021/bi00206a038	34	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18191	18197		10.1074/jbc.273.29.18191	http://dx.doi.org/10.1074/jbc.273.29.18191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660780	hybrid			2022-12-27	WOS:000074828500035
J	Chaudhary, D; O'Rourke, K; Chinnaiyan, AM; Dixit, VM				Chaudhary, D; O'Rourke, K; Chinnaiyan, AM; Dixit, VM			The death inhibitory molecules CED-9 and CED-4L use a common mechanism to inhibit the CED-3 death protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; APOPTOSIS; ENCODES; BCL-2	The apoptotic machinery of Caenorhabditis elegans includes three core interacting components: CED-3, CED-4, and CED-9, CED-3 is a death protease composed of a prodomain and a protease domain. CED-4 is a P-loop-containing, nucleotide-binding molecule that complexes with the single polypeptide zymogen form of CED-3, promoting its activation by autoprocessing, CED-9 blocks death by complexing with CED-4 and suppressing its ability to promote CED-3 activation. A naturally occurring alternatively spliced form of CED-4 that contains an insertion within the nucleotide-binding region (CED-4L) functions as a dominant negative inhibitor of CED-3 processing and attenuates cell death. Domain mapping studies revealed that distinct regions within CED-4 bind to the CED-3 prodomain and protease domain. Importantly, the CED-4 P-loop was involved in prodomain binding, Disruption of P-loop geometry because of mutation of a critical lysine (K165R) or insertional inactivation (CED-4L) abolished prodomain binding. Regardless, K165R and CED-4L still retained CED-3 binding through the protease domain but were unable to initiate CED-3 processing. Therefore, the P-loop-prodomain interaction is critical for triggering CED-4-mediated CED-3 processing. Underscoring the importance of this interaction was the finding that CED-9 contacted the P-loop and selectively inhibited its interaction with the CED-3 prodomain. These results provide a simple mechanism for how CED-9 functions to block CED-4-mediated CED-3 processing and cell death.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Dixit, VM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	PHS HHS [7863] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bauer MKA, 1997, FEBS LETT, V402, P256, DOI 10.1016/S0014-5793(96)01497-4; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Hawkins C J, 1997, Semin Immunol, V9, P25, DOI 10.1006/smim.1996.0052; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; JACOBSON MD, 1997, CURR BIOL, V7, P277; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MOUNTZ JD, 1996, J CLIN IMMUNOL IMM S, V80, P2; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	36	31	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17708	17712		10.1074/jbc.273.28.17708	http://dx.doi.org/10.1074/jbc.273.28.17708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651369	hybrid			2022-12-27	WOS:000074816100062
J	Hsieh, TY; Matsumoto, M; Chou, HC; Schneider, R; Hwang, SB; Lee, AS; Lai, MMC				Hsieh, TY; Matsumoto, M; Chou, HC; Schneider, R; Hwang, SB; Lee, AS; Lai, MMC			Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; TRANSCRIPTIONAL REGULATION; HEPATOCELLULAR-CARCINOMA; MAMMALIAN-CELLS; GENE-PRODUCTS; BINDING; INFECTION; PROMOTER; DNA; EXPRESSION	Hepatitis C virus (HCV) core protein, a component of viral nucleocapsid, has been shown to modulate cellular and viral promoter activities. To identify potential cellular targets for HCV core protein, a human liver cDNA library was screened for core-interacting proteins using the yeast two-hybrid system. Among the proteins identified was heterogeneous nuclear ribonucleoprotein K (hnRNP K), which has been demonstrated to be a transcriptional regulator. The interaction of HCV core protein with hnRNP K was confirmed by glutathione transferase fusion protein binding assay, protein-protein blotting assay, and coimmunoprecipitation in vitro and in vivo. Additionally, these two proteins were shown to be partially colocalized in the nucleus. The hnRNP K-binding site in HCV core protein was mapped to the region from amino acid residues 25-91, a hydrophilic area near the N terminus. The HCV core protein-binding domain was located within amino acid residues 250 to 392, which contain the three proline-rich domains, of hnRNP K. Furthermore, HCV core protein relieved the suppression effect of hnRNP K on the activity of the human thymidine kinase gene promoter. The specific binding of HCV core protein to hnRNP K suggests that multiple functions of hnRNP K may be disrupted by the core protein during HCV infection and thus explains, in part, the pathogenesis of HCV.	Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Norris Canc Res Inst, Los Angeles, CA 90033 USA; Hallym Univ, Hallym Acad Sci, Inst Environm & Life Sci, Chuncheon 200702, South Korea	University of Southern California; Howard Hughes Medical Institute; University of Southern California; University of Southern California; University of Southern California; Hallym University	Lai, MMC (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-401, Los Angeles, CA 90033 USA.		Lai, Michael M. C./I-7001-2012	Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038] Funding Source: NIH RePORTER; NCI NIH HHS [CA27607] Funding Source: Medline; NIAID NIH HHS [AI40038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALMASIO P, 1992, LANCET, V339, P989, DOI 10.1016/0140-6736(92)91563-N; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Buchenau P, 1997, J CELL BIOL, V137, P291, DOI 10.1083/jcb.137.2.291; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PJ, 1992, VIROLOGY, V188, P102, DOI 10.1016/0042-6822(92)90739-C; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLLETT MS, 1992, COMP IMMUNOL MICROB, V15, P145, DOI 10.1016/0147-9571(92)90087-8; CUTHBERT JA, 1994, CLIN MICROBIOL REV, V7, P505, DOI 10.1128/CMR.7.4.505-532.1994; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DIBISCEGLIE AM, 1994, J CLIN GASTROENTEROL, V19, P222, DOI 10.1097/00004836-199410000-00011; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HARTMANN H, 1995, Z GASTROENTEROL, V33, P643; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Hwang Soon B., 1995, Journal of Biomedical Science, V2, P227, DOI 10.1007/BF02253382; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; Kai N, 1997, J NEUROSCI RES, V48, P407, DOI 10.1002/(SICI)1097-4547(19970601)48:5<407::AID-JNR3>3.3.CO;2-F; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIM YK, 1992, J BIOL CHEM, V267, P2723; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; LO SY, 1994, VIROLOGY, V199, P124, DOI 10.1006/viro.1994.1104; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Matsumoto M, 1996, VIROLOGY, V218, P43, DOI 10.1006/viro.1996.0164; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Okada K, 1996, CLIN NEPHROL, V45, P71; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; RUGGIERI A, 1997, VIROLOGY, V64, P73; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SHIH CM, 1995, J VIROL, V69, P1160, DOI 10.1128/JVI.69.2.1160-1171.1995; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	62	126	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17651	17659		10.1074/jbc.273.28.17651	http://dx.doi.org/10.1074/jbc.273.28.17651			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651361	hybrid			2022-12-27	WOS:000074816100054
J	Lacaille, VG; Androlewicz, MJ				Lacaille, VG; Androlewicz, MJ			Herpes simplex virus inhibitor ICP47 destabilizes the transporter associated with antigen processing (TAP) heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; PEPTIDE-BINDING-SITE; EXPRESSION; PROTEIN; REGION; GENE; SPECIFICITY; PATHWAY; CELLS	Chemical cross-linking of the transporter associated with antigen processing (TAP) heterodimer was used to determine whether the herpes simplex virus inhibitor of TAP, ICP47, induces a conformational change in TAP. Cross-linking of TAP in cellular membranes produced a major species of similar to 220 kDa which was comprised solely of TAP.1 and TAP.2 and most Likely represents the TAP heterodimer. Interestingly, prior treatment of TAP-containing membranes with TAP peptide substrates stimulated the formation of the cross-linked TAP heterodimer, whereas pretreatment of membranes with ICP47 completely blocked the formation of the crosslinked heterodimer. These data suggest that suitable substrates for TAP stabilize the TAP heterodimer, whereas ICP47 destabilizes the heterodimer. The results indicate that subtle conformational changes occur in the TBP heterodimer upon the binding of peptides and the inhibitor ICP47 and that ICP47 has a deleterious effect on TAP heterodimer structure, in addition to its role as a potent blocker of substrate binding to TAP.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Androlewicz, MJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	androlma@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA069115] Funding Source: NIH RePORTER; NCI NIH HHS [CA69115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Galocha B, 1997, J EXP MED, V185, P1565, DOI 10.1084/jem.185.9.1565; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KOENIG S, 1990, J IMMUNOL, V145, P127; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PULVERTAFT RJV, 1964, LANCET, V1, P238; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCOTT JE, 1995, J IMMUNOL, V155, P143; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; Stephens DB, 1997, FEBS LETT, V416, P353, DOI 10.1016/S0014-5793(97)01221-0; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4	33	47	51	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17386	17390		10.1074/jbc.273.28.17386	http://dx.doi.org/10.1074/jbc.273.28.17386			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651323	hybrid			2022-12-27	WOS:000074816100016
J	Shen, ZC; Jacobs-Lorena, M				Shen, ZC; Jacobs-Lorena, M			A type I peritrophic matrix protein from the malaria vector Anopheles gambiae binds to chitin - Cloning, expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE CHITINASE; LUCILIA-CUPRINA; BLOOD MEAL; MEMBRANE; SEQUENCE; CLEAVAGE; CDNA; DNA; GUT	Upon feeding, mosquito midguts secrete the peritrophic matrix (PM), an extracellular chitin-containing envelope that completely surrounds the blood meal. Because the malaria parasite must cross the PM to complete its life cycle in the mosquito, the PM is a potential barrier for malaria transmission. By antibody screening of an expression library we have identified and partially characterized a cDNA encoding a putative PM protein, termed Anopheles gambiae adult peritrophin 1 (Ag-Aper1). Ag-Aper1 is the first cloned PM gene from a disease vector. Northern analysis detected an abundant Ag-Aper1 transcript only in the adult gut, and not in any other tissues or at any other stages of development. The predicted amino acid sequence indicates that it has two tandem chitin-binding domains that share high sequence similarity with each other and also with the chitin-binding domain of an adult gut-specific chitinase from the same organism. The presumed ability of Ag-Aper1 to bind chitin was verified by a functional assay with the baculovirus-expressed recombinant protein. Ag-Aper1 did bind to chitin but not to cellulose, indicating that Ag-Aper1 binds chitin specifically. The double chitin-binding domain organization of Ag-Aper1 suggests that each protein molecule is able to link two chitin polymer chains. Hence, this protein is likely to act as a molecular linker that connects PM chitin fibrils into a three-dimensional network.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University	Jacobs-Lorena, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.							ALTSCHUL T, 1990, J MOL BIOL, V215, P401; BILLINGSLEY PF, 1992, J PARASITOL, V78, P430, DOI 10.2307/3283640; CAMPBELL BC, 1992, INSECT BIOCHEM MOLEC, V22, P415, DOI 10.1016/0965-1748(92)90136-3; Casu R, 1997, P NATL ACAD SCI USA, V94, P8939, DOI 10.1073/pnas.94.17.8939; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMPTON JM, 1994, ANN TROP MED PARASIT, V88, P3, DOI 10.1080/00034983.1994.11812828; EAST IJ, 1993, INT J PARASITOL, V23, P221, DOI 10.1016/0020-7519(93)90144-N; Edwards MJ, 1997, INSECT BIOCHEM MOLEC, V27, P1063, DOI 10.1016/S0965-1748(97)00093-3; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Freyvogel T. A., 1965, Acta Tropica Basle, V22, P148; FREYVOGEL THIERRY A., 1965, ACTA TROP, V22, P118; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; Jacobs-Lorena Marcelo, 1996, P318; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehane MJ, 1997, ANNU REV ENTOMOL, V42, P525, DOI 10.1146/annurev.ento.42.1.525; Lemos FJA, 1996, INSECT BIOCHEM MOLEC, V26, P651, DOI 10.1016/S0965-1748(96)00014-8; Moskalyk LA, 1996, INSECT MOL BIOL, V5, P261, DOI 10.1111/j.1365-2583.1996.tb00100.x; Muller H.M., 1993, Parassitologia (Rome), V35, P73; Muller HM, 1995, EXP PARASITOL, V81, P371, DOI 10.1006/expr.1995.1128; MULLER HM, 1993, EMBO J, V12, P2891, DOI 10.1002/j.1460-2075.1993.tb05951.x; PETERS W, 1992, ZOOPHYSIOLOGY PERITR, V130; RAMOS A, 1994, J EXP ZOOL, V268, P269, DOI 10.1002/jez.1402680403; REGEV A, 1996, APPL ENVIRON MICROB, V62, P381; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Tellam R. L., 1996, P86; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299; WILLADSEN P, 1993, PARASITOL TODAY, V9, P132, DOI 10.1016/0169-4758(93)90177-H	34	139	161	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17665	17670		10.1074/jbc.273.28.17665	http://dx.doi.org/10.1074/jbc.273.28.17665			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651363	hybrid			2022-12-27	WOS:000074816100056
J	Shrikumar, A; Cooperman, BS				Shrikumar, A; Cooperman, BS			Antichymotrypsin interaction with chymotrypsin - Reactions following encounter complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; SERPIN; THROMBIN; ALPHA-1-ANTICHYMOTRYPSIN; ANTITHROMBIN; EXPRESSION; INHIBITION; MECHANISM; FORM	Serpins, serine proteinase inhibitors, form enzymatically inactive, 1:1 complexes (denoted E*I*) with their target proteinases, that only slowly release I*, in which the P1-P1' linkage is cleaved. Recently we presented evidence that the serpin antichymotrypsin (ACT, I) reacts with the serine proteinase chymotrypsin (Chtr, E) to form an E*I* complex via a three-step mechanism, E + I reversible arrow E .I reversible arrow EI' reversible arrow E*I* in which EI', which retains the P1-P1' linkage, is formed in a partly or largely rate-determining step, depending on temperature (O'Malley, K. H, Nair, S, A., Rubin, H., and Cooperman, B, S, (1997) J. Biol. Chem. 272, 5354-5359). Here we extend these studies through the introduction of a new assay for the formation of the postcomplex fragment, corresponding to ACT residues 359 (the P1' residue) to 398 (the C ter minus), coupled with rapid quench flow kinetic analysis. We show that the E I encounter complex of wild type-rACT and Chtr forms both E*I* and postcomplex fragment with the same rate constant, so that both spe cies arise from EI' conversion to E*I*. These results sup port our earlier conclusion that the P1-P1' linkage is preserved in EI' and imply that E*I* corresponds to a covalent adduct of E and I, either acyl enzyme or the tetrahedral intermediate formed by water attack on acyl enzyme. Furthermore, we show that the A347R (P12) variant of rACT, which is a substrate rather than an inhibitor of Chtr, has a rate constant for postcomplex fragment formation from the E I complex very similar to that observed for WT-rACT, implying that EI' is the common intermediate from which partitioning to inhibitor and substrate pathways occurs. These results are used to elaborate a proposed scheme for ACT interaction with Chtr that is considered in the light of relevant results from studies of other serpin-serine proteinase pairs.	Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	University of Pennsylvania	Cooperman, BS (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.	cooprman@pobox.upenn.edu			NATIONAL INSTITUTE ON AGING [R01AG010599] Funding Source: NIH RePORTER; NIA NIH HHS [AG10599] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1982, J BIOL CHEM, V257, P9487; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIEBERMAN J, 1995, NEUROBIOL AGING, V16, P747, DOI 10.1016/0197-4580(95)00056-K; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PEEHL DM, 1995, CANCER-AM CANCER SOC, V75, P2021, DOI 10.1002/1097-0142(19950401)75:7+<2021::AID-CNCR2820751644>3.0.CO;2-R; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SASAGAWA T, 1982, J CHROMATOGR, V240, P329, DOI 10.1016/S0021-9673(00)99612-2; SCALIA R, 1995, SHOCK, V4, P251, DOI 10.1097/00024382-199510000-00004; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; WEI A, 1994, NAT STRUCT BIOL, V1, P250; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; ZHONG JQ, 1996, THESIS U PENNSYLVANI	29	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17459	17462		10.1074/jbc.273.28.17459	http://dx.doi.org/10.1074/jbc.273.28.17459			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651334	hybrid			2022-12-27	WOS:000074816100027
J	Zeng, HW; Jackson, DA; Oshima, H; Simons, SS				Zeng, HW; Jackson, DA; Oshima, H; Simons, SS			Cloning and characterization of a novel binding factor (GMEB-2) of the glucocorticoid modulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; TRANSCRIPTION FACTORS; RESPONSE ELEMENT; RECEPTOR; CELL; EXPRESSION; INDUCTION; ACTIVATION; SUPPRESSIN; UPSTREAM	The 21-base pair glucocorticoid modulatory element (GME) of the rat tyrosine aminotransferase gene is the only cis-acting element known to modulate the transcriptional activity of receptors bound to glucocorticoid response elements. Specifically, the GME increases the activity of complexes bound both by physiological concentrations of glucocorticoids, due to a left shift in the dose-response curve, and by saturating concentrations of anti-glucocorticoids. For this reason, the nuclear protein(s) that has been demonstrated to bind to the GME is of major interest as a possible transcription factor with hitherto undescribed properties. Subsequent studies indicated that not one but two proteins of 88 and 67 kDa (= GMEB-1 and -2, respectively) formed a heteromeric complex with double-stranded GME oligonucleotides in gel shift assays and participated in the expression of GME activity (Oshima, H., Szapary, D., and Simons, S. S., Jr. (1995) J. Biol. Chem. 270, 21895-21910). Here, we report the use of polymerase chain reaction of degenerate oligonucleotides and 5'- and 3'-rapid amplification of cDNA ends to clone two cDNAs of 2.0 and 1.9 kilobase pairs that probably result hom alternative splicing. Both cDNAs encoded open reading frames containing all four previously sequenced peptides. The longer 2.0-kilobase pair cDNA encoded an open reading frame for an acidic, 529-amino acid protein and afforded a major 67-kDa and a minor 58-kDa protein after in vitro transcription/translation. Both proteins were recognized by a mono-epitopic antibody raised against a peptide of GMEB-2. The in vitro translated protein bound to GME DNA in gel shift assays. However, the binding to GME DNA increased markedly after mixing with authentic GMEB-1 to give a gel-shifted complex that was similar to that derived hom HTC cell cytosol. GMEB-2 shares a unique domain (KDWKR) with proteins derived from diverse organisms as follows: Drosophila (DEAF-I), rat (Suppressin), and Caenorhabditis elegans (three unknown open reading frames). Collectively, these data suggest that the 67-kDa GMEB-2 not only is an important factor for the modulation of glucocorticoid receptor bound to glucocorticoid response elements but also may belong to a novel family of transcription factors.	NIDDK, LMCB, Steroid Hormone Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDK, LMCB, Steroid Hormone Sect, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.	steroids@helix.nih.gov	Jackson, David/E-9984-2014					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAN EMH, 1994, IMMUNOL RES, V13, P1, DOI 10.1007/BF02918219; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HUTCHISON KA, 1993, J STEROID BIOCHEM, V46, P681, DOI 10.1016/0960-0760(93)90309-K; JACKSON DA, 1998, IN PRESS J STEROID B; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LeBoeuf R D, 1994, Immunomethods, V5, P79, DOI 10.1006/immu.1994.1040; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; Montano MM, 1997, MOL ENDOCRINOL, V11, P330, DOI 10.1210/me.11.3.330; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SCHWEIZERGROYER G, 1992, J STEROID BIOCHEM, V41, P747, DOI 10.1016/0960-0760(92)90416-G; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1989, CANCER RES, V49, pS2244; SIMONS SS, 1983, J STEROID BIOCHEM, V31, P1; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; THOMPSON EB, 1979, GLUCOCORTICOID HORMO, P203; TOMKINS GM, 1970, COLD SPRING HARB SYM, V35, P635, DOI 10.1101/SQB.1970.035.01.078; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; ZARET KS, 1992, P NATL ACAD SCI USA, V89, P6540, DOI 10.1073/pnas.89.14.6540	47	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17756	17762		10.1074/jbc.273.28.17756	http://dx.doi.org/10.1074/jbc.273.28.17756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651376	hybrid			2022-12-27	WOS:000074816100069
J	Kojima, H; Endo, K; Moriyama, H; Tanaka, Y; Alnemri, ES; Slapak, CA; Teicher, B; Kufe, D; Datta, R				Kojima, H; Endo, K; Moriyama, H; Tanaka, Y; Alnemri, ES; Slapak, CA; Teicher, B; Kufe, D; Datta, R			Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; OVEREXPRESSION; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; CIS-DIAMMINEDICHLOROPLATINUM(II); INDUCTION; BCL-X(L); DRUGS	Acquired multidrug resistance to anti-cancer agents has been associated with overexpression of the P-glycoprotein and other members of the ATP-binding cassette superfamily. The present studies demonstrate that SCC-25 cells selected for resistance to the alkylating agent cisplatin (CDDP) overexpress the anti-apoptotic Bcl-x(L) protein. In contrast to parental cells, the SCC-25/CDDP-resistant variant failed to exhibit activation of caspase-3, cleavage of protein kinase C delta, and other characteristics of apoptosis in response to CDDP. Similar results were obtained when SCC-25/CDDP cells were exposed to the structurally and functionally unrelated antimetabolite l-beta-D-arabinofuranosyl-cytosine (ara-C). Other cells selected for resistance to doxorubicin or vincristine also exhibited overexpression of Bcl-x(L) and failed to respond to CDDP and ara-C with activation of caspase-3. The results further demonstrate that multidrug-resistant cells exhibit a block in the release of mitochondrial cytochrome c into the cytosol and that this effect is dependent on overexpression of Bcl-x(L). The demonstration that lysates from the resistant cells respond to the addition of cytochrome c with activation of caspase-3 confirms that the block in apoptosis is because of inhibition of mitochondrial cytochrome c release, These findings demonstrate that cells respond to diverse classes of anti-cancer drugs with overexpression of Bcl-x(L) and that this response represents another mechanism of acquired multidrug resistance.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Jikei Univ, Sch Med, Dept Otolaryngol, Tokyo 105, Japan; Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Jikei University; Jefferson University; Eli Lilly	Datta, R (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	Rakesh_Datta@dfci.harvard.edu	Alnemri, Emad S/B-4526-2010		NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FRAM RJ, 1982, CANCER RES, V42, P4050; FUTSCHER BW, 1994, BIOCHEM PHARMACOL, V47, P1601, DOI 10.1016/0006-2952(94)90538-X; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GRANT CE, 1994, CANCER RES, V54, P357; HOCKENBERY DM, 1990, NATURE, V38, P334; Huang Y, 1997, LEUKEMIA, V11, P253, DOI 10.1038/sj.leu.2400557; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LING V, 1997, CANC CHEMOTHER PHA S, V40, P3; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; TEICHER BA, 1987, CANCER RES, V47, P388; TEICHER BA, 1991, INT J CANCER, V47, P252, DOI 10.1002/ijc.2910470214; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMAN GJR, 1993, CANCER RES, V53, P1747; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	113	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16647	16650		10.1074/jbc.273.27.16647	http://dx.doi.org/10.1074/jbc.273.27.16647			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642215	hybrid			2022-12-27	WOS:000074545200005
J	Tisdale, EJ; Jackson, MR				Tisdale, EJ; Jackson, MR			Rab2 protein enhances coatomer recruitment to pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; KINASE-C; BETA-COP; DEPENDENT FORMATION; TRANSPORT VESICLES; COATED VESICLES; CELL-SURFACE; MEMBRANES	The Rab2 protein is a resident of pre-Golgi intermediates and required for vesicular transport in the early secretory pathway. We have previously shown that a peptide corresponding to the amino terminus of Rab2 (residues 2-14) arrests protein traffic prior to a rate-limiting event in VSV-G movement through pre-GoIgi structures (Tisdale, E. J., and Balch, W. E. (1996) J. Biol, Chem. 271, 29372-29379). To determine the mechanism by which this peptide inhibits transport, we investigated the effect of the Rab2 peptide on the distribution of the beta-COP subunit of coatomer because COPI partially localizes to pre-Golgi intermediates, We found that the peptide caused a dramatic change in the distribution of pre-Golgi intermediates containing beta-COP. A quantitative binding assay was employed to measure recruitment of beta-COP to membrane when incubated with the Rab2 (13-mer). Peptide-treated microsomes showed a 25-70% increase in the level of membrane-associated beta-COP. The enhanced recruitment of coatomer to membrane was specific to the Rab2 (13-mer) and required guanosine 5'-3-O-(thio)triphosphate, ADP ribosylation factor, and protein kinase C-like activity. The ability to enhance beta-COP membrane binding was not limited to the peptide. Similarly, the addition of recombinant Rab2 protein to the assay promoted beta-COP membrane association. Our results suggest that the Rab2 peptide causes the persistent recruitment of COPI to pre-Golgi intermediates which ultimately arrests protein transport due to the inability of membranes to uncoat.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA	Wayne State University; Johnson & Johnson; Johnson & Johnson USA	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA.	etisdale@med.wayne.edu						ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CAVENAGH M, 1996, J BIOL CHEM, V36, P21767; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GOODNIGHT J, 1995, J BIOL CHEM, V270, P991; HALLER H, 1994, ANN NY ACAD SCI, V733, P313, DOI 10.1111/j.1749-6632.1994.tb17281.x; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITNEY JA, 1995, CELL, V83, P703; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	46	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17269	17277		10.1074/jbc.273.27.17269	http://dx.doi.org/10.1074/jbc.273.27.17269			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642298	hybrid			2022-12-27	WOS:000074545200088
J	Fraser, RA; Heard, DJ; Adam, S; Lavigne, AC; Le Douarin, B; Tora, L; Losson, R; Rochette-Egly, C; Chambon, P				Fraser, RA; Heard, DJ; Adam, S; Lavigne, AC; Le Douarin, B; Tora, L; Losson, R; Rochette-Egly, C; Chambon, P			The putative cofactor TIF1 alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; RETINOIC ACID RECEPTOR; ACTIVATING DOMAINS; TRANSCRIPTION; COACTIVATORS; ANTIBODIES; COMPLEX; DECADE; AF-2	Ligand-induced gene activation by nuclear receptors (NRs) is a complex process requiring dissociation of corepressors and recruitment of coactivators. The putative transcriptional intermediary factor TIF1 alpha has been previously characterized as a nuclear protein that interacts directly with the AF-2 ligand-dependent activating domain present in the ligand-binding domain of numerous steroid and nonsteroid receptors, including the estrogen (ER alpha) and retinoid X (RXR alpha) receptors. We report here that TIF1 alpha is both a phosphoprotein and a protein kinase. TIF1 alpha coexpressed in COS-l cells with RXRa or ERa! is phosphorylated and becomes hyperphosphorylated upon ligand treatment. This hyperphosphorylation requires the binding of TIF1 alpha to transcriptionally active NRs since it is prevented by mutations either in the core (alpha-helix 12 of the ligand-binding domain) of the AF-2 activating domains of RXR alpha and ER alpha or in the NR box of TIF1 alpha that are known to prevent TIF1 alpha-NR interactions. Thus, TIF1 alpha is a phosphoprotein that undergoes ligand-dependent hyperphosphorylation as a consequence of nuclear receptor binding. We further show that purified recombinant TIF1 alpha possesses intrinsic kinase activity and that, in addition to autophosphorylation, TIF1 alpha selectively phosphorylates the transcription factors TFIIE alpha, TAF(II)28, and TAF(II)55 in vitro. These latter results raise the possibility that TIF1 alpha may act, at least in part, by phosphorylating and modifying the activity of components of the transcriptional machinery.	Universite Louis Pasteur, Coll France, CNRS,INSERM, Inst Genet & Biol Mol Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Universite Louis Pasteur, Coll France, CNRS,INSERM, Inst Genet & Biol Mol Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	igbmc@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018; Lavigne, Anne-Claire/O-8805-2015	Tora, Laszlo/0000-0001-7398-2250; 				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Losson R, 1997, BIOL CHEM, V378, P579; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	39	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16199	16204		10.1074/jbc.273.26.16199	http://dx.doi.org/10.1074/jbc.273.26.16199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632676	Green Published, hybrid			2022-12-27	WOS:000074436600047
J	Jin, W; Huang, ESC; Bi, WQ; Cote, GJ				Jin, W; Huang, ESC; Bi, WQ; Cote, GJ			Exon sequence is required for regulated RNA splicing of the human fibroblast growth factor receptor-1 alpha-exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASTROCYTOMAS; SITE SELECTION	Alternative RNA processing of the human fibroblast growth factor receptor-1 transcript results in receptor forms that vary in their affinity for fibroblast growth factor. An alternative RNA processing event involving recognition of the alpha-exon is deregulated during neoplastic transformation of glial cells. We have previously established a splicing reporter/transfection cell culture model system to identify sequences involved in recognition of this exon. In this study, the system was used to identify two sequence elements that differentially function to regulate splicing of this exon. Exclusion of the alpha-exon in glioblastoma cells specifically required the downstream intron sequence comprising the 5'-splice site. Replacement or mutation of this sequence increasing complementarity to U1 RNA resulted in enhanced exon recognition in SNB-19 glioblastoma cells. Sequences within the exon were found to be required for alpha-exon inclusion. Deletion and gain-of-function experiments identified a 69-nucleotide exon sequence that was specifically required for alpha-exon inclusion. These studies indicate that multiple sequences are required for the regulated recognition of the alpha-exon.	Univ Texas, Md Anderson Canc Ctr, Endocrinol Sect, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Cote, GJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Endocrinol Sect, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA067946, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA16672, CA67946] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cote GJ, 1997, J BIOL CHEM, V272, P1054, DOI 10.1074/jbc.272.2.1054; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FU XD, 1995, RNA, V1, P663; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Inoue Kunio, 1995, Gene Expression, V4, P177; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mason I, 1996, CURR BIOL, V6, P672, DOI 10.1016/S0960-9822(09)00446-1; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	25	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16170	16176		10.1074/jbc.273.26.16170	http://dx.doi.org/10.1074/jbc.273.26.16170			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632672	hybrid			2022-12-27	WOS:000074436600043
J	Thorelli, E; Kaufman, RJ; Dahlback, B				Thorelli, E; Kaufman, RJ; Dahlback, B			The c-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; COAGULATION FACTOR-V; THROMBIN-CATALYZED ACTIVATION; BOVINE FACTOR-V; FACTOR-VIII; ELECTRON-MICROSCOPY; FACTOR-XA; SECONDARY STRUCTURE; SULFATION; CLEAVAGE	Factor V (FV) is recently shown to express anticoagulant activity. It functions as a synergistic cofactor with protein S to activated protein C (APC) in the degradation of factor VIIIa (FVIIIa). FV is composed of multiple domains, A1-A2-B-A3-C1-C2. Thrombin cleaves FV at Arg-709, Arg-1018, and Arg-1545 that leads to the generation of a procoagulant FV species which functions as a cofactor to factor Xa (FXa) in the activation of prothrombin to thrombin. During the activation process, the B-domain is released from the heavy (A1-A2) and light chains (A3-C1-C2) which constitute the active FV (FVa). To elucidate which effect the different thrombin cleavages in FV have on the ability of FV to express APC-cofactor activity, seven recombinant FV mutants containing all possible combinations of mutated and native thrombin cleavage sites were tested in a FVIIIa degradation assay. Thrombin cleavage at Arg-709 and/or Arg-1018 yielded FV molecules that were still able to function as APC cofactors, whereas cleavage at Arg-1545 led to a complete loss in APC-cofactor function. This suggests that the APC-cofactor function of FV depends on the B-domain remaining attached to the A3 domain, The importance of the FV B-domain for expression of APC-cofactor activity was further investigated using two B-domain deleted FV molecules, FV des-709-1545 (with the whole B-domain deleted) and FV des-709-1476 (with amino acids 710-1476 of the B-domain being removed). FV des-709-1476 expressed APC cofactor activity, whereas the FV des-709-1545 was completely devoid of such activity. Thus, the C-terminal part of the B-domain (residues 1477-1545) was crucial for the APC-cofactor function. FV and factor VIII (FVIII) are homologous proteins having similar domain organization, A FV/FVIII chimera, harboring the B-domain from FVIII (FVBVIII) instead of the FV B-domain did not work as an APC cofactor, further illustrating the importance of the FV B-domain for the APC-cofactor function.	Univ Lund, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Michigan, Med Ctr, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Lund University; Skane University Hospital; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Dahlback, B (corresponding author), Univ Lund, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.			Dahlback, Bjorn/0000-0003-1546-0328				BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; DAHLBACK B, 1978, BIOCHEMISTRY-US, V17, P4938, DOI 10.1021/bi00616a013; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DAHLBACK B, 1986, J BIOL CHEM, V261, P9495; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON C T, 1973, Thrombosis Research, V2, P509, DOI 10.1016/0049-3848(73)90004-2; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; HORTIN GL, 1990, BLOOD, V76, P946; HTORELLI E, 1997, EUR J BIOCHEM, V247, P12; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LEYTE A, 1991, J BIOL CHEM, V266, P740; Lu DS, 1996, BLOOD, V87, P4708, DOI 10.1182/blood.V87.11.4708.bloodjournal87114708; MARQUETTE KA, 1995, BLOOD, V86, P3026; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; REST B, 1994, PROTEINS, V20, P216; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shen L, 1997, THROMB HAEMOSTASIS, V78, P1030; SHEN L, 1994, J BIOL CHEM, V269, P18735; STOYLOVA S, 1994, FEBS LETT, V351, P330, DOI 10.1016/0014-5793(94)00881-7; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; THORELLI E, 1998, IN PRESS THROMB HAEM; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; Varadi K, 1996, THROMB HAEMOSTASIS, V76, P208; VARADI K, 1995, THROMB HAEMOSTASIS, V73, P730; VILLOUTREIX BO, 1998, IN PRESS PROTEIN SCI; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; YEGNESWARAN D, 1997, J BIOL CHEM, V272, P25013; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	48	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16140	16145		10.1074/jbc.273.26.16140	http://dx.doi.org/10.1074/jbc.273.26.16140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632668	hybrid			2022-12-27	WOS:000074436600039
J	Yang, YD; Pham, CD; Vuyyuru, VB; Liu, H; Arlinghaus, RB; Singh, B				Yang, YD; Pham, CD; Vuyyuru, VB; Liu, H; Arlinghaus, RB; Singh, B			Evidence of a functional interaction between serine 3 and serine 25 Mos phosphorylation sites - A dominant inhibitory role of serine 25 phosphorylation on Mos protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; XENOPUS-OOCYTE MATURATION; MURINE SARCOMA-VIRUS; MEIOTIC MATURATION; NUCLEOTIDE-SEQUENCE; CYTOSTATIC FACTOR; ONCOGENE PRODUCT; MEIOSIS-II; ACTIVATION; EGGS	Recently, we identified the major in vivo phosphorylation site on v-Mos as Ser-56, which is phosphorylated by cyclic AMP dependent protein kinase (PKA). Others have shown that c-Mos phosphorylation at Ser-3 (equivalent to Ser-34 in v-Mos) is important for the interaction of c-Mos with its substrate MEK and for its stability and cytostatic factor activity in eggs. To investigate the role of Ser-56 phosphorylation, we generated site-directed mutants of v-Mos that would mimic phosphorylation in terms of charge at positions 56 and 34. After mutating serine (S) residues with alanine (A) or glutamic acid (E) in different combinations, various v-Mos mutants were expressed in a rabbit reticulocyte lysate in vitro translation system and in COS-1 or MIH/3T3 cells. The effect of mutations on Mos function was evaluated by in vitro protein kinase assays and by the ability of Mos to cause neoplastic transformation of NIH/3T3 cells. The S56E but not the S56A mutation inhibited v-Mos kinase activity suggesting that Ser-56 phosphorylation has an inhibitory role. As predicted from Xenopus c-Mos studies, S34A but not S34E mutation inhibited v-Mos activity. Studies with the double mutants showed that the S56E mutation but not S56A mutation inhibited v-Mos kinase activity of both S34A and S34E mutants. Interestingly, the S56A mutation blocked the inhibitory effect of the S34A mutation on v-Mos kinase suggesting that in c-Mos the corresponding serine (Ser-25) can influence the regulation of c-Mos by Ser-3. Results showing inhibition of v Mos kinase activity of the S34E mutant by the S56E mutation is significant as it suggests that doubly phosphorylated Mos at these residues would be inactive. Because residues corresponding to both v-Mos Ser-34 and Ser-56 are evolutionarily conserved in c-Mos, the kinase activity of c-Mos during meiosis may also be regulated in the same manner as v-Mos kinase activity.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 172, Houston, TX 77030 USA.	balraj_singh@path.mdacc.tmc.edu			NCI NIH HHS [CA45125, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1995, ONCOGENE, V10, P1149; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; Pham CD, 1997, INT J GYNECOL CANCER, V7, P314, DOI 10.1046/j.1525-1438.1997.00461.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; Singh B, 1997, Prog Cell Cycle Res, V3, P251; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; Yang YD, 1996, MOL CELL BIOL, V16, P800; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43	39	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15946	15953		10.1074/jbc.273.26.15946	http://dx.doi.org/10.1074/jbc.273.26.15946			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632642	hybrid			2022-12-27	WOS:000074436600013
J	Layne, MD; Endege, WO; Jain, MK; Yet, SF; Hsieh, CM; Chin, MT; Perrella, MA; Blanar, MA; Haber, E; Lee, ME				Layne, MD; Endege, WO; Jain, MK; Yet, SF; Hsieh, CM; Chin, MT; Perrella, MA; Blanar, MA; Haber, E; Lee, ME			Aortic carboxypeptidase-like protein, a novel protein with discoidin and carboxypeptidase-like domains, is up-regulated during vascular smooth muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIII; NEURAL CREST; MESSENGER-RNA; FACTOR-V; GROWTH; EXPRESSION; SEQUENCES; CLONING; KINASE; FIBRONECTIN	Phenotypic modulation of vascular smooth muscle cells plays an important role in the pathogenesis of arteriosclerosis, In a screen of proteins expressed in human aortic smooth muscle cells, we identified a novel gene product designated aortic carboxypeptidase-like protein (ACLP), The similar to 4-kilobase human cDNA and its mouse homologue encode 1158 and 1128 amino acid proteins, respectively, that are 85% identical. ACLP is a nonnuclear protein that contains a signal peptide, a lysine- and proline-rich Il-amino acid repeating motif, a discoidin-like domain, and a C-terminal domain with 39% identity to carboxypeptidase E, By Western blot analysis and in situ hybridization, we detected abundant ACLP expression in the adult aorta. ACLP was expressed predominantly in the smooth muscle cells of the adult mouse aorta but not in the adventitia or in several other tissues. In cultured mouse aortic smooth muscle cells, ACLP mRNA and protein were up-regulated 2-3-fold after serum starvation. Using a recently developed neural crest cell to smooth muscle cell in vitro differentiation system, we found that ACLP mRNA and protein were not expressed in neural crest cells but were up-regulated dramatically with the differentiation of these cells. These results indicate that ACLP may play a role in differentiated vascular smooth muscle cells.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Bristol-Myers Squibb	Lee, ME (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Bldg 2,677 Huntington Ave, Boston, MA 02115 USA.	lee@cvlab.harvard.edu	Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870	NHLBI NIH HHS [HL03194] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; ELANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870; ELANAR MA, 1992, SCIENCE, V256, P1014; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hsieh CM, 1996, J BIOL CHEM, V271, P17354, DOI 10.1074/jbc.271.29.17354; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCCA D, 1991, CANCER RES, V51, P4994; LEE WS, 1993, ENDOCRINOLOGY, V132, P2136, DOI 10.1210/en.132.5.2136; LEE WS, 1994, J BIOL CHEM, V269, P12032; LI XM, 1994, J BIOL CHEM, V269, P19653; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; OWENS GK, 1995, PHYSIOL REV, V75, P487; PIERSCHBACHER MD, 1985, J CELL BIOCHEM, V28, P115, DOI 10.1002/jcb.240280205; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Song LX, 1997, J BIOL CHEM, V272, P10543; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAN MS, 1994, KIDNEY INT, V46, P690, DOI 10.1038/ki.1994.322; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	43	68	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15654	15660		10.1074/jbc.273.25.15654	http://dx.doi.org/10.1074/jbc.273.25.15654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624159	hybrid			2022-12-27	WOS:000074284200053
J	McGaughey, GB; Gagne, M; Rappe, AK				McGaughey, GB; Gagne, M; Rappe, AK			pi-stacking interactions - Alive and well in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL-ENERGY SURFACE; BENZENE DIMER; AROMATIC INTERACTIONS; 7-METHYLGUANINE BASE; ENERGETICS; PHASE; SET	A representative set of high resolution x-ray crystal structures of nonhomologous proteins have been examined to determine the preferred positions and orientations of noncovalent interactions between the aromatic side chains of the amino acids phenylalanine, tyrosine, histidine, sued tryptophan. To study the primary interactions between aromatic amino acids, care has been taken to examine only isolated pairs (dimers) of amino acids because trimers and higher order clusters of aromatic amino acids behave differently than their dimer counterparts, We find that pairs (dimers) of aromatic side chain amino acids preferentially align their respective aromatic rings in am off-centered parallel orientation, Further, we find that this parallel-displaced structure is 0.5-0.75 kcal/mol more stable than a T-shaped structure for phenylalanine interactions and I kcal/mol more stable than a T-shaped structure for the foil set of aromatic side chain amino acids. This experimentally determined structure and energy difference is consistent with ab initio and molecular mechanics calculations of benzene dinner, however, the results are not in agreement with previously published analyses of aromatic amino acids in proteins. The preferred orientation is referred to as parallel displaced pi-stacking.	Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA; Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Wyeth Ayerst Res, Struct Biol, Princeton, NJ 08540 USA	Colorado State University; University of Colorado System; University of Colorado Boulder; Pfizer	Rappe, AK (corresponding author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.	trappe@snail.chm.colostate.edu						ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; ABRAHAM RJ, 1976, J CHEM SOC CHEM COMM, P699, DOI 10.1039/c39760000699; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL T, 1986, SCIENCE, V234, P1005, DOI 10.1126/science.3775369; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CASTONGUAY LA, 1991, J AM CHEM SOC, V113, P7177, DOI 10.1021/ja00019a013; Chipot C, 1996, J AM CHEM SOC, V118, P11217, DOI 10.1021/ja961379l; COZZI F, 1993, J AM CHEM SOC, V115, P5330, DOI 10.1021/ja00065a069; FAN CF, 1992, MACROMOLECULES, V25, P3667, DOI 10.1021/ma00040a010; Gilman AG, 1993, PHARM BASIS THERAPEU; HOBOHM U, 1994, PROTEIN SCI, V3, P522; HOBOHM U, 1992, PROTEIN SCI, V1, P409; HOBZA P, 1994, J AM CHEM SOC, V116, P3500, DOI 10.1021/ja00087a041; Hobza P, 1996, J PHYS CHEM-US, V100, P18790, DOI 10.1021/jp961239y; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; HUNTER CA, 1993, PHILOS T R SOC A, V345, P77, DOI 10.1098/rsta.1993.0119; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; Jaffe RL, 1996, J CHEM PHYS, V105, P2780, DOI 10.1063/1.472140; KAMIICHI K, 1986, FEBS LETT, V195, P57, DOI 10.1016/0014-5793(86)80129-6; KOLB HC, 1994, J AM CHEM SOC, V116, P1278, DOI 10.1021/ja00083a014; Pietsch MA, 1996, J AM CHEM SOC, V118, P10908, DOI 10.1021/ja960293p; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; Singh J., 1992, ATLAS PROTEIN SIDE C, VI; Sun S, 1996, J PHYS CHEM-US, V100, P13348, DOI 10.1021/jp960739o; TANNER D, 1989, PROG RUBBER PLAST TE, V5, P229; THORNTON JM, 1988, BIOCHEM SOC T, V16, P927, DOI 10.1042/bst0160927; Tsuzuki S, 1996, CHEM PHYS LETT, V252, P206, DOI 10.1016/0009-2614(96)00173-X	30	902	927	1	127	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15458	15463		10.1074/jbc.273.25.15458	http://dx.doi.org/10.1074/jbc.273.25.15458			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624131	hybrid			2022-12-27	WOS:000074284200025
J	Soderling, SH; Bayuga, SJ; Beavo, JA				Soderling, SH; Bayuga, SJ; Beavo, JA			Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP-BINDING-SITES; PARTICULATE GUANYLATE-CYCLASE; EXPRESSED SEQUENCE TAGS; PHOTORECEPTOR PHOSPHODIESTERASE; ENDOGENOUS ATRIOPEPTIN; PHOSPHORYLATION; GMP; CHROMATOGRAPHY; TRANSDUCTION; SEARCH	We report the cloning, expression, and characterization of a new family of cyclic nucleotide phosphodiesterase (PDE) that has unique kinetic and inhibitor specificities, A clone corresponding to the C terminus of this PDE was initially identified by a bioinformatic approach and used to isolate a cDNA that is likely full-length, This novel PDE, designated as MMPDE9A1, shows highest mRNA expression in kidney with lower levels in liver, lung, and brain. The mRNA size by Northern blot analysis is approximately 2.0 kilobases, and the cDNA encoding PDE9A1 is 1929 base pairs in length. The largest open reading frame predicts a protein of 534 amino acids with a molecular mass of 62,000 Da. When expressed in COS-7 cells, PDE9A1 activity was not inhibited well by either the nonselective inhibitor 3-isobutyl-1-methyl-xanthine or the new selective PDE5 inhibitor, sildenafil, but it is inhibited by the PDE1/5 inhibitor (+)-cis-5,6a,7,8,9 hyl] phenylmethyl]-5-methyl-cylopent[4,5]imidao[2,1-b]]purin-49(3H)one (SCH51866) with an IC50 of 1.55 mu M. This new phosphodiesterase is highly specific for cGMP, Its K-m of similar to 0.07 mu M for cGMP is the lowest yet reported for a PDE, being at least 40-170 times lower than that of PDE5 and PDE6, respectively.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.				NIDDK NIH HHS [DK21723] Funding Source: Medline; NIGMS NIH HHS [GM07750] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boolell M, 1996, Int J Impot Res, V8, P47; BURNS F, 1994, BRIT J PHARMACOL, V113, P3, DOI 10.1111/j.1476-5381.1994.tb16164.x; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Loomis WF, 1997, J CELL SCI, V110, P1141; MOTOJIMA K, 1994, J BIOL CHEM, V269, P9030; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; TREMBLAY J, 1985, FEBS LETT, V181, P17, DOI 10.1016/0014-5793(85)81105-4; Vemulapalli S, 1996, J CARDIOVASC PHARM, V28, P862, DOI 10.1097/00005344-199612000-00018; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WILKINS MR, 1990, P NATL ACAD SCI USA, V87, P6465, DOI 10.1073/pnas.87.16.6465; WILKINS MR, 1990, J CLIN INVEST, V85, P1274, DOI 10.1172/JCI114564; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; ZEIDEL ML, 1987, AM J PHYSIOL, V252, pF551, DOI 10.1152/ajprenal.1987.252.3.F551	33	232	252	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15553	15558		10.1074/jbc.273.25.15553	http://dx.doi.org/10.1074/jbc.273.25.15553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624145	hybrid			2022-12-27	WOS:000074284200039
J	Prasad, R; Beard, WA; Strauss, PR; Wilson, SH				Prasad, R; Beard, WA; Strauss, PR; Wilson, SH			Human DNA polymerase beta deoxyribose phosphate lyase - Substrate specificity and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ALDEHYDIC ABASIC SITES; ESCHERICHIA-COLI; PYRIDOXAL 5'-PHOSPHATE; APURINIC ENDONUCLEASE; BOVINE TESTIS; DAMAGED DNA; ACTIVE-SITE; LIGASE-I; BINDING	DNA polymerase beta (beta-pol) cleaves the sugar-phosphate bond 3' to an intact apurinic/apyrimidinic (AP) site (i.e. AP lyase activity). The same bond is cleaved even if the AP site has been previously 5'-incised by AP endonuclease, resulting in a 5' 2-deoxyribose 5-phosphate (i.e. dRP lyase activity). We characterized these lyase reactions by steady-state kinetics with the aminoterminal 8-kDa domain of beta-pol and with the entire 39-kDa polymerase, Steady-state kinetic analyses show that the Michaelis constants for both the dRP and AP lyase activities of beta-pol are similar. However, k(cat) is approximately 200-fold lower for the AP lyase activity on an intact AP site than for an AP endonuclease-preincised site. The 8-kDa domain was also less efficient with an intact AP site than on a preincised site. The full-length enzyme and the 8-kDa domain efficiently remove the 5' dRP from a preincised AP site in the absence of Mg2+, and the pH profiles of beta-pol and 8-kDa domain dRP lyase catalytic efficiency exhibit a broad alkaline pH optimum. An inhibitory effect of pyridoxal 5'-phosphate on the dRP lyase activity is consistent with involvement of a primary amine (Lys(72)) as the Schiff base nucleophile during lyase chemistry.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Medical Branch Galveston	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr,Bldg 101,Rm B246, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BRIEMER LH, 1984, J BIOL CHEM, V259, P5543; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; CHETSANGA CJ, 1981, BIOCHEMISTRY-US, V20, P5201, DOI 10.1021/bi00521a016; CONE R, 1980, J BIOL CHEM, V255, P354; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; GOSSARD F, 1978, EUR J BIOCHEM, V82, P321, DOI 10.1111/j.1432-1033.1978.tb12026.x; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LIU D, 1990, BIOCHEMISTRY-US, V35, P6188; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; Mullen GP, 1997, TETRAHEDRON, V53, P12057, DOI 10.1016/S0040-4020(97)00768-0; MULLEN GP, 1997, BASE EXCISION REPAIR, P121; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Wang ZG, 1997, J BIOL CHEM, V272, P24064, DOI 10.1074/jbc.272.38.24064; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	54	163	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15263	15270		10.1074/jbc.273.24.15263	http://dx.doi.org/10.1074/jbc.273.24.15263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614142	hybrid			2022-12-27	WOS:000074160400084
J	Phi-van, L; Sellke, C; von Bodenhausen, A; Stratling, WH				Phi-van, L; Sellke, C; von Bodenhausen, A; Stratling, WH			An initiation zone of chromosomal DNA replication at the chicken lysozyme gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; XENOPUS EGG EXTRACT; MAMMALIAN-CELLS; RIBOSOMAL DNA; BROAD ZONE; ORIGIN; DOMAIN; SITES; EXPRESSION; REGION	The chicken lysozyme gene domain is distinguished by a broad knowledge of how its expression is regulated. Here, we examined the in vivo replication of the lysozyme gene locus using polymerase chain reaction amplification and competitive polymerase chain reaction of size-fractionated, nascent DNA strands. We found that DNA replication initiates at multiple sites within a broad initiation zone spanning at least 20 kilobases, which includes most of the lysozyme gene domain, The 5' border of this zone is probably located downstream of the lysozyme 5' nuclear matrix attachment region. Preferred initiation occurs in a 3'-located subzone. The initiation zone at the lysozyme gene locus is also active in nonexpressing Liver DU249 cells. Furthermore, examining the timing of DNA replication at the lysozyme gene locus revealed that the gene locus replicates early during S phase in both HD11 and DU249 cells, irrespective of its transcriptional activity.	Bundesforsch Anstalt Landwirtschaft, Inst Tierzucht & Tierverhalten, D-29223 Celle, Germany; Univ Hamburg, Inst Physiol Chem, D-20246 Hamburg, Germany	University of Hamburg	Phi-van, L (corresponding author), Bundesforsch Anstalt Landwirtschaft, Inst Tierzucht & Tierverhalten, Dornbergstr 25-27, D-29223 Celle, Germany.							ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ARIIZUMI K, 1993, P NATL ACAD SCI USA, V90, P3695, DOI 10.1073/pnas.90.8.3695; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BLOW JJ, 1990, J CELL SCI, V95, P383; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dhar SK, 1996, MOL CELL BIOL, V16, P2314; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P29; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; ERISMAN MD, 1988, ONCOGENE HDB, P341; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GOETHE R, 1994, J BIOL CHEM, V269, P31302; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; HAHN M, 1988, MOL CELL BIOL, V8, P2659, DOI 10.1128/MCB.8.6.2659; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HECK MMS, 1990, J CELL BIOL, V110, P903, DOI 10.1083/jcb.110.4.903; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; JACKSON DA, 1986, EMBO J, V5, P1403, DOI 10.1002/j.1460-2075.1986.tb04374.x; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kumar S, 1996, NUCLEIC ACIDS RES, V24, P3289, DOI 10.1093/nar/24.17.3289; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; SHINOMIYA T, 1993, MOL CELL BIOL, V13, P4098, DOI 10.1128/MCB.13.7.4098; SHINOMIYA T, 1994, MOL CELL BIOL, V14, P7394, DOI 10.1128/MCB.14.11.7394; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VASSILEV L, 1989, NUCLEIC ACIDS RES, V17, P7693, DOI 10.1093/nar/17.19.7693; VASSILEV LT, 1992, CRIT REV BIOCHEM MOL, V27, P445, DOI 10.3109/10409239209082569; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; VITRAPERLMAN VJ, 1993, MOL CELL BIOL, V13, P5931; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; YOON Y, 1995, MOL CELL BIOL, V15, P2482; ZHU J, 1992, CHROMOSOMA, V102, P7	59	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18300	18307		10.1074/jbc.273.29.18300	http://dx.doi.org/10.1074/jbc.273.29.18300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660795	hybrid			2022-12-27	WOS:000074828500050
J	Price, ER; Ding, HF; Badalian, T; Bhattacharya, S; Takemoto, C; Yao, TP; Hemesath, TJ; Fisher, DE				Price, ER; Ding, HF; Badalian, T; Bhattacharya, S; Takemoto, C; Yao, TP; Hemesath, TJ; Fisher, DE			Lineage-specific signaling in melanocytes - c-Kit stimulation recruits p300/CBP to microphthalmia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUBINSTEIN-TAYBI-SYNDROME; RECEPTOR TYROSINE KINASE; NUCLEAR-PROTEIN CBP; TRANSCRIPTION FACTOR; GENE-PRODUCT; IN-VIVO; HISTONE ACETYLTRANSFERASE; CONSERVED FAMILY; PHOSPHATASE SHP1; MAST-CELLS	During melanocyte development, the cytokine Steel factor activates its receptor c-Kit, initiating a signal transduction cascade, which is vital for lineage determination via unknown downstream nuclear targets. c-Kit has recently been found to trigger mitogen-activated protein kinase-mediated phosphorylation of Microphthalmia (Mi), a lineage-restricted transcription factor, which, like Steel factor and c-Kit, is essential for melanocyte development. This cascade results in increased Mi-dependent transcriptional reporter activity, Here we examine the mechanism by which Mi is activated by this pathway. Phosphorylation does not significantly alter Mi's nuclear localization, DNA binding, or dimerization, However, the transcriptional coactivator p300/CBP selectively associates with mitogen-activated protein kinase-phosphorylated Mi, even under conditions in which non-MAPK phospho-Mi is more abundant. Moreover, p300/CBP coactivates Mi transcriptional activity in a manner dependent upon this phosphorylation, Mi thus joins CREB as a transcription factor whose signal-responsive phosphorylation regulates coactivator recruitment, in this case modulating lineage development in melanocytes.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Fisher, DE (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Takemoto, Clifford M/Y-7558-2018; Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478; Ding, Han-Fei/0000-0001-5702-3439				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FRYNS JP, 1995, J MED GENET, V32, P668, DOI 10.1136/jmg.32.8.668; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HERRANZ P, 1994, CLIN EXP DERMATOL, V19, P170, DOI 10.1111/j.1365-2230.1994.tb01152.x; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lenormand JL, 1997, MOL CELL BIOL, V17, P584, DOI 10.1128/MCB.17.2.584; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	50	152	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17983	17986		10.1074/jbc.273.29.17983	http://dx.doi.org/10.1074/jbc.273.29.17983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660747	hybrid			2022-12-27	WOS:000074828500002
J	Yue, CP; Dodge, KL; Weber, G; Sanborn, BM				Yue, CP; Dodge, KL; Weber, G; Sanborn, BM			Phosphorylation of serine 1105 by protein kinase A inhibits phospholipase C beta(3) stimulation by G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOMETRIAL CELLS; CYCLIC-AMP; ALPHA-SUBUNITS; SMOOTH-MUSCLE; C ACTIVITY; ACTIVATION; ADENOSINE-3',5'-MONOPHOSPHATE; PURIFICATION; CALCIUM; CONTRACTION	The mechanism by which protein kinase A (PKA) inhibits G alpha(q)-stimulated phospholipase C activity of the beta subclass (PLC beta) is unknown. We present evidence that phosphorylation of PLC beta(3) by PKA results in inhibition of G alpha(q)-stimulated PLC beta(3) activity, and we identify the site of phosphorylation. Two-dimensional phosphoamino acid analysis of in vitro phosphorylated PLC beta(3) revealed a single phosphoserine as the putative PKA site, and peptide mapping yielded one phosphopeptide. The residue was identified as Ser(1105) by direct sequencing of reverse-phase high pressure liquid chromatography-isolated phosphopeptide and by site-directed mutagenesis. Overexpression of G alpha(q) with PLC beta(3) or PLCP, (Serll05 --> Ala) mutant in COSM6 cells resulted in a 5-fold increase in [H-3]phosphatidylinositol 1,4,5trisphosphate formation compared with expression of G alpha(q), PLC beta(3), or PLC beta(3), (Ser(1105) --> Ala) mutant alone. Whereas G alpha(q)-stimulated PLC beta(3) activity was inhibited by 58-71% by overexpression of PKA catalytic subunit, G alpha(q)-stimulated PLC beta(3) (Ser(1105) --> Ala) mutant activity was not affected. Furthermore, phosphatidylinositide turnover stimulated by presumably G alpha(q)-coupled M1 muscarinic and oxytocin receptors was completely inhibited by pretreating cells with 8-[4-chlorophenythio]cAMP in RBL-2H3 cells expressing only PLCP beta(3). These data establish that direct phosphorylation by PKA of Ser(1105) in the putative G-box of PLC beta(3) inhibits G alpha(q)-stimulated PLC beta(3) activity. This can at least partially explain the inhibitory effect of PKA on G alpha(q)-stimulated phosphatidylinositide turnover observed in a variety of cells and tissues.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Karolinska Hosp, Dept Mol Med, Clin Genet Unit, CMM, S-17176 Stockholm, Sweden	University of Texas System; Karolinska Institutet; Karolinska University Hospital	Sanborn, BM (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	bsanborn@bmb.med.uth.tmc.edu	Weber, Günther/F-3410-2016	Weber, Gunther/0000-0002-3861-808X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009618, R01HD009618, T32HD007325] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07325, HD09618] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ARNAUDEAU S, 1994, PFLUG ARCH EUR J PHY, V428, P51, DOI 10.1007/BF00374751; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hoiting BH, 1996, BRIT J PHARMACOL, V117, P419, DOI 10.1111/j.1476-5381.1996.tb15207.x; HSU CJ, 1985, ENDOCRINOLOGY, V116, P2029, DOI 10.1210/endo-116-5-2029; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; LAGERCRANTZ J, 1995, GENOMICS, V26, P467, DOI 10.1016/0888-7543(95)80164-H; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MCATEE P, 1990, J BIOL CHEM, V265, P6788; Meij JTA, 1996, BIOCHEM BIOPH RES CO, V225, P705, DOI 10.1006/bbrc.1996.1239; PITTNER RA, 1989, BIOCHEM J, V257, P455, DOI 10.1042/bj2570455; RAO MR, 1986, ENDOCRINOLOGY, V119, P435; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Richardson RM, 1998, J BIOL CHEM, V273, P10690, DOI 10.1074/jbc.273.17.10690; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; TACHADO SD, 1992, CELL SIGNAL, V4, P61, DOI 10.1016/0898-6568(92)90008-V; TAGUCHI M, 1988, ENDOCRINOLOGY, V123, P2019, DOI 10.1210/endo-123-4-2019; WEN YS, 1992, ENDOCRINOLOGY, V131, P1377, DOI 10.1210/en.131.3.1377; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811; YADA Y, 1989, FEBS LETT, V242, P368, DOI 10.1016/0014-5793(89)80503-4	30	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18023	18027		10.1074/jbc.273.29.18023	http://dx.doi.org/10.1074/jbc.273.29.18023			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660757	hybrid			2022-12-27	WOS:000074828500012
J	Kaur, P; Russell, J				Kaur, P; Russell, J			Biochemical coupling between the DrrA and DrrB proteins of the doxorubicin efflux pump of Streptomyces peucetius	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPORT; CELLS	The drrAB operon of Streptomyces peucetius encodes for resistance to the antibiotics doxorubicin and daunorubicin, Subcloning of the drrAB genes in Escherichia coli has previously been shown to result in expression of DrrA and DrrB proteins and resistance to doxorubicin in a sensitive strain of E, coli, DrrA, a peripheral membrane protein, binds ATP in a UV-catalyzed reaction in a doxorubicin-dependent manner; DrrB, a hydrophobic protein, is localized to the inner membrane of E, coli (Kaur, P, (1997) J, Bacteriol. 179, 569-575), The present study provides evidence that DrrB, the membrane component of the complex, is stably maintained in the cell only if DrrA is present. Furthermore, it was found that the catalytic component DrrA is in an active conformation only when it is in a complex with DrrB, In a subclone containing the drrB gene by itself, no DrrB protein could be detected, although a translational fusion of the first 15 amino acids of DrrB to beta-galactosidase indicated that DrrB is translated in the absence of DrrA, Upon co-transformation with a plasmid containing the drrA gene in trans, DrrB could again be detected in these cells. UV cross-linking studies with [alpha-P-32]ATP showed that only the membrane bound form of DrrA in cells containing both DrrA and DrrB was in a conformation competent to bind ATP, Chemical cross linking studies also provided direct evidence for interaction between the two proteins. Based on these analyses, a model for interaction between DrrA and DrrB proteins is presented.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Kaur, P (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30303 USA.				NIGMS NIH HHS [R29 GM51981-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051981] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; Hwang JW, 1997, J BACTERIOL, V179, P6264, DOI 10.1128/jb.179.20.6264-6270.1997; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; Kaur P, 1997, J BACTERIOL, V179, P569, DOI 10.1128/jb.179.3.569-575.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Miller JH., 1992, EXPT MOL GENETICS; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; Sambrook J., 2002, MOL CLONING LAB MANU; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023	12	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17933	17939		10.1074/jbc.273.28.17933	http://dx.doi.org/10.1074/jbc.273.28.17933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651400	hybrid			2022-12-27	WOS:000074816100093
J	Tzingounis, AV; Lin, CL; Rothstein, JD; Kavanaugh, MP				Tzingounis, AV; Lin, CL; Rothstein, JD; Kavanaugh, MP			Arachidonic acid activates a proton current in the rat glutamate transporter EAAT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR PURKINJE-CELLS; GATED CHLORIDE CHANNEL; SYNAPTIC TRANSMISSION; INTRACELLULAR PH; GLIAL-CELLS; ION FLUXES; SALAMANDER; SYNAPTOSOMES; MODULATION; SYNAPSES	The excitatory amino acid transporter EAAT4 is expressed predominantly in Purkinje neurons in the rat cerebellum (1-3), and it participates in postsynaptic reuptake of glutamate released at the climbing fiber syn apse (4). Transporter-mediated currents in Purkinje neurons are increased more than 3-fold by arachidonic acid, a second messenger that is liberated following de polarization-induced Ca2+ activation of phospholipase A(2) (5). In this study we demonstrate that application of arachidonic acid to oocytes expressing rat EAAT4 increased glutamate-induced currents to a similar extent. However, arachidonic acid did not cause an increase in the rate of glutamate transport or in the chloride current associated with glutamate transport but rather activated a proton-selective conductance. These data reveal a novel action of arachidonate on a glutamate transporter and suggest a mechanism by which synaptic activity may decrease intracellular pH in neurons where this transporter is localized.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Oregon Health & Science University; Johns Hopkins University	Kavanaugh, MP (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	kavanaug@ohsu.edu	rothstein, jeffrey d/C-9470-2013; Lin, Chien-liang G/E-3513-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; Bergles DE, 1997, P NATL ACAD SCI USA, V94, P14821, DOI 10.1073/pnas.94.26.14821; Billups B, 1996, J NEUROSCI, V16, P6722; Cao YW, 1997, J NEUROSCI, V17, P2257; CHAN PH, 1983, J NEUROCHEM, V40, P309, DOI 10.1111/j.1471-4159.1983.tb11284.x; Clark BA, 1997, J PHYSIOL-LONDON, V502, P335, DOI 10.1111/j.1469-7793.1997.335bk.x; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; Eliasof S, 1998, J NEUROSCI, V18, P698; Fairman W. A., 1997, Society for Neuroscience Abstracts, V23, P1790; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; Kataoka Y, 1997, J NEUROSCI, V17, P7017; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Linden DJ, 1995, NEURON, V15, P1393, DOI 10.1016/0896-6273(95)90017-9; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Nagao S, 1997, NEUROSCIENCE, V78, P929; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PICAUD SA, 1995, J NEUROPHYSIOL, V74, P1760, DOI 10.1152/jn.1995.74.4.1760; RHOADS DE, 1982, J NEUROCHEM, V38, P1255, DOI 10.1111/j.1471-4159.1982.tb07898.x; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; Sonders MS, 1997, J NEUROSCI, V17, P960; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; Takahashi M, 1997, J EXP BIOL, V200, P401; Takahashi M, 1996, J PHYSIOL-LONDON, V497, P523, DOI 10.1113/jphysiol.1996.sp021785; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WEBB DJ, 1981, J CELL BIOL, V91, P562, DOI 10.1083/jcb.91.2.562; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	36	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17315	17317		10.1074/jbc.273.28.17315	http://dx.doi.org/10.1074/jbc.273.28.17315			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651313	Green Published, hybrid			2022-12-27	WOS:000074816100006
J	Fujita, M; Yamada, C; Tsurumi, T; Hanaoka, F; Matsuzawa, K; Inagaki, M				Fujita, M; Yamada, C; Tsurumi, T; Hanaoka, F; Matsuzawa, K; Inagaki, M			Cell cycle- and chromatin binding state-dependent phosphorylation of human MCM heterohexameric complexes - A role for cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; DNA-REPLICATION; S-PHASE; FISSION YEAST; NUCLEAR-LOCALIZATION; HUMAN MEMBER; PROTEINS; XENOPUS; MUTANT; FAMILY	The mammalian MCM protein family, presently with six members, exists in the nuclei in two forms, chromatin-bound and unbound. The former dissociates from chromatin with progression through the S phase. Recently, we have established a procedure to isolate chromatin-bound and unbound complexes containing all six human MCM (hMCM) proteins by immunoprecipitation. In the present study, we applied this procedure to HeLa cells synchronized in each of the G(1), S, and G(2)/M phases and could detect hMCM heterohexameric complexes in all three. In addition, depending on the cell cycle and the state of chromatin association, hMCM2 and 4 in the complexes were found to variously change their phosphorylation states. Concentrating attention on G(2)/M phase hyperphosphorylation, we found hMCM2 and 4 in the complexes to be good substrates for cdc2/cyclin B in vitro. Furthermore, when cdc2 kinase was inactivated in temperature-sensitive mutant murine FT210 cells, the G(2)/M hyperphosphorylation of the murine MCM2 and MCM4 and release of the MCMs from chromatin in the G(2) phase were severely impaired. Taken together, the data suggest that the six mammalian MCM proteins function and undergo cell cycle-dependent regulation as heterohexameric complexes and that phosphorylation of the complexes by cdc2 kinase may be one of mechanisms negatively regulating the MCM complex-chromatin association.	Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 565, Japan; Hokkaido Univ, Inst Immunol Sci, Sapporo, Hokkaido 060, Japan	Aichi Cancer Center; Aichi Cancer Center; Osaka University; Hokkaido University	Fujita, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan.		Inagaki, Masaki/B-9920-2016	Fujita, Masatoshi/0000-0001-6617-2452				BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1997, J BIOL CHEM, V272, P10928; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Lei M, 1996, MOL CELL BIOL, V16, P5081; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; Miyake S, 1996, GENE, V175, P71, DOI 10.1016/0378-1119(96)00122-9; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TREISMAN JE, 1995, GENE DEV, V9, P1709, DOI 10.1101/gad.9.14.1709; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105	51	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17095	17101		10.1074/jbc.273.27.17095	http://dx.doi.org/10.1074/jbc.273.27.17095			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642275	hybrid			2022-12-27	WOS:000074545200065
J	Li, LQ; Lee, TK; Meier, PJ; Ballatori, N				Li, LQ; Lee, TK; Meier, PJ; Ballatori, N			Identification of glutathione as a driving force and leukotriene C-4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; FUNCTIONAL-CHARACTERIZATION; CYSTEINYL LEUKOTRIENES; REDUCED GLUTATHIONE; EXPRESSION CLONING; ANION TRANSPORTER; MEMBRANE-VESICLES; BILIARY-EXCRETION; XENOPUS-LAEVIS; HEPATOCYTES	oatp1 is an hepatic sinusoidal organic anion transporter that mediates uptake of various structurally unrelated organic compounds from blood, The driving force for uptake on oatp1 has not been identified, although a role for bicarbonate has recently been proposed. The present study examined whether oatp1-mediated uptake is energized by efflux (countertransport) of intracellular reduced glutathione (GSH), and whether hydrophobic glutathione S-conjugates such as leukotriene C-4 (LTC4) and S-dinitrophenyl glutathione (DNP-SG) form a novel class of substrates for oatp1, Xenopus laevis oocytes injected with the complementary RNA for oapt1 demonstrated higher uptake of 10 nM [H-3]LTC4 and 50 mu M [H-3]DNP-SG, and higher efflux of [H-3]GSH (2.5 mM endogenous intracellular GSH concentration). The oatp1-stimulated LTC4 and DNP-SG uptake was independent of the Na+ gradient, cis-inhibited by known substrates of this transport protein and by 1 mM GSH, and was saturable, with apparent K-m values of 0.27 +/- 0.06 and 408 +/- 95 mu M, respectively. Uptake of [H-3]taurocholate, an endogenous substrate of oatp1, was competitively inhibited by DNP-SG, Of significance, oatp1-mediated taurocholate and LTC4 uptake was cis-inhibited and trans-stimulated by GSH, and [H-3]GSH efflux was enhanced in the presence of extracellular taurocholate or sulfobromophthalein, indicating that GSH efflux down its large electrochemical gradient provides the driving force for uptake via oatp1, The stoichiometry of GSH/taurocholate exchange was 1:1, These findings identify a new class of substrates for oatp1 and provide evidence for GSH-dependent oatp1-mediated substrate transport.	Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; Univ Zurich Hosp, Dept Med, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland	University of Rochester; University of Zurich; University Zurich Hospital	Ballatori, N (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006484, P30ES001247] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48823] Funding Source: Medline; NIEHS NIH HHS [ES06484, ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		APPELGREN LE, 1982, J BIOL CHEM, V257, P531; AW TY, 1984, J BIOL CHEM, V259, P9355; AW TY, 1986, AM J PHYSIOL, V251, P354; BALLATORI N, 1995, J BIOL CHEM, V270, P3594, DOI 10.1074/jbc.270.8.3594; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; Ballatori N, 1996, AM J PHYSIOL-REG I, V270, pR1156, DOI 10.1152/ajpregu.1996.270.5.R1156; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; FARRIS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V18, pG403; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; HINCHMAN CA, 1993, AM J PHYSIOL, V265, pG547, DOI 10.1152/ajpgi.1993.265.3.G547; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; LEE TK, 1998, IN PRESS YALE J BIOL; LEIER I, 1992, EUR J BIOCHEM, V209, P281, DOI 10.1111/j.1432-1033.1992.tb17287.x; LI L, 1998, IN PRESS YALE J BIOL; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LU SC, 1993, J CLIN INVEST, V92, P1188, DOI 10.1172/JCI116689; LU SC, 1994, MOL PHARMACOL, V46, P578; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; Paulusama C. C., 1997, Hepatology, V26, p292A; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Satlin LM, 1997, J BIOL CHEM, V272, P26340, DOI 10.1074/jbc.272.42.26340; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; SIMONSON GD, 1994, J CELL SCI, V107, P1065; SNUTCH TP, 1992, METHOD ENZYMOL, V207, P279; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; WETTSTEIN M, 1989, EUR J BIOCHEM, V181, P115, DOI 10.1111/j.1432-1033.1989.tb14701.x; WETTSTEIN M, 1990, EUR J BIOCHEM, V191, P251, DOI 10.1111/j.1432-1033.1990.tb19117.x; WHELAN G, 1970, J LAB CLIN MED, V75, P542; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	43	215	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16184	16191		10.1074/jbc.273.26.16184	http://dx.doi.org/10.1074/jbc.273.26.16184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632674	hybrid			2022-12-27	WOS:000074436600045
J	Pommier, J; Mejean, V; Giordano, G; Iobbi-Nivol, C				Pommier, J; Mejean, V; Giordano, G; Iobbi-Nivol, C			TorD, a cytoplasmic chaperone that interacts with the unfolded trimethylamine N-oxide reductase enzyme (TorA) in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; DENITRIFICANS; RESPIRATION; INVOLVEMENT; CYTOCHROMES; INDUCTION; SEQUENCE; PROTEINS; CLONING; OPERON	Reduction of trimethylamine N-oxide (TMAO) in Escherichia coli involves the terminal molybdoreductase TorA, located in the periplasm, and the membrane anchored c type cytochrome TorC. In this study, the role of the Toro protein, encoded by the third gene of torCAD operon, is investigated. Construction of a mutant, in which the torD gene is interrupted, showed that the absence of Toro protein leads to a two times decrease of the final amount of TorA enzyme. However, specific activity and biochemical properties of TorA enzyme were similar to those of the enzyme produced in the wild type. Excess of Toro protein restores the normal level of TorA enzyme, and also, leads to the appearance of a new cytoplasmic form of TorA on SDS-polyacrylamide gel electrophoresis using gentle conditions. This probably indicates a new folding state of the cytoplasmic TorA protein when Toro is overexpressed. BIAcore techniques demonstrated direct specific interaction between the TorA and Toro proteins. This interaction was enhanced when TorA was previously unfolded by heating, Finally, as TorA is a molybdoenzyme, we demonstrated that Toro can interact with TorA before the molybdenum cofactor has been inserted. As Toro homologue encoding genes are found in various TMAO reductase loci, we propose that Toro is a chaperone protein specific for the TorA enzyme. It belongs to a family of TorD-like chaperones present in several bacteria, and, probably, involved in TMAO reductase folding.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS)	Iobbi-Nivol, C (corresponding author), CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, 31 Chemin Joseph Aiguier,BP71, F-13402 Marseille 20, France.	iobbi@ibsm.cnrs-mrs.fr		Mejean, Vincent/0000-0001-6533-5846				Aubert C, 1998, BIOCHEMISTRY-US, V37, P2120, DOI 10.1021/bi971656g; Blasco F, 1998, MOL MICROBIOL, V28, P435, DOI 10.1046/j.1365-2958.1998.00795.x; BRAGG PD, 1983, BIOCHIM BIOPHYS ACTA, V725, P168, DOI 10.1016/0005-2728(83)90237-2; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CRASKE A, 1986, EUR J BIOCHEM, V158, P429, DOI 10.1111/j.1432-1033.1986.tb09771.x; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GRAHAM A, 1980, FEMS MICROBIOL LETT, V7, P145, DOI 10.1111/j.1574-6941.1980.tb01595.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; IobbiNivol C, 1996, BBA-PROTEIN STRUCT M, V1294, P77, DOI 10.1016/0167-4838(95)00271-5; Jourlin C, 1996, MOL MICROBIOL, V20, P1297, DOI 10.1111/j.1365-2958.1996.tb02648.x; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Knablein J, 1996, J MOL BIOL, V263, P40, DOI 10.1006/jmbi.1996.0554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XL, 1997, J BIOL CHEM, V272, P24266, DOI 10.1074/jbc.272.39.24266; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MERK AB, 1994, BIATECHNOLOGY HDB; MONCEY NJ, 1997, J BACTERIOL, V179, P7617; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; SILVESTRO A, 1989, BIOCHIM BIOPHYS ACTA, V999, P208, DOI 10.1016/0167-4838(89)90220-3; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; TAWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; Ujiiye T, 1996, BBA-BIOENERGETICS, V1277, P1, DOI 10.1016/S0005-2728(96)00101-6	30	111	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16615	16620		10.1074/jbc.273.26.16615	http://dx.doi.org/10.1074/jbc.273.26.16615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632735	hybrid			2022-12-27	WOS:000074436600106
J	van de Poll, MLM; van Vugt, MJH; Lenferink, AEG; van Zoelen, EJJ				van de Poll, MLM; van Vugt, MJH; Lenferink, AEG; van Zoelen, EJJ			Identification of the minimal requirements for binding to the human epidermal growth factor (EGF) receptor using chimeras of human EGF and an EGF repeat of Drosophila notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COAGULATION FACTOR-X; FACTOR-ALPHA; HIGH-AFFINITY; TGF-ALPHA; ESCHERICHIA-COLI; DOMAIN; PROTEOLYSIS; SEQUENCE; PROTEINS	Many proteins contain so-called epidermal growth factor (EGF)-like domains that share the characteristic spacing of cysteines and glycines with members of the EGF family. They are, however, functionally unrelated, despite the fact that the three-dimensional structure of these EGF-like domains, also, is often very similar to that of the EGF receptor agonists. In the present study, we linked an EGF-like repeat from the Drosophila Notch protein to the N- and C-terminal linear tail sequences of human EGF (hEGF), and we showed that this chimera (E1N6E) is unable to bind or activate the hEGF receptor. This recombinant protein was then used as a basic construct for identifying the minimal requirements for high affinity EGF receptor binding and activation. We selectively reintroduced a limited number of important hEGF-derived residues, and by using this unique approach, we were able to make hEGF/Notch chimeras that, compared with wild type hEGF, showed nearly 100% binding affinity and mitogenic activity on HER-14 cells expressing the hEGF receptor.	Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	van de Poll, MLM (corresponding author), Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	mvdpoll@sci.kun.nl						ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ARTEAGA CL, 1988, CANCER RES, V48, P5023; BARON M, 1992, PROTEIN SCI, V1, P81; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAMPION SR, 1993, PROTEIN ENG, V6, P651, DOI 10.1093/protein/6.6.651; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; KOIDE H, 1992, FEBS LETT, V302, P39, DOI 10.1016/0014-5793(92)80279-P; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; KOIDE H, 1994, BIOCHEMISTRY-US, V33, P7470, DOI 10.1021/bi00189a055; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE DC, 1993, ONCOGENES TUMOR SUPP, P233; Lenferink AEG, 1997, BIOCHEM J, V327, P859; McInnes C, 1996, J BIOL CHEM, V271, P32204, DOI 10.1074/jbc.271.50.32204; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; Puddicombe SM, 1996, J BIOL CHEM, V271, P30392, DOI 10.1074/jbc.271.48.30392; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; SELANDER M, 1990, BIOCHEMISTRY-US, V29, P8111, DOI 10.1021/bi00487a018; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; VANZOELEN EJJ, 1985, J CELL PHYSIOL, V123, P151, DOI 10.1002/jcp.1041230202; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6	35	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16075	16081		10.1074/jbc.273.26.16075	http://dx.doi.org/10.1074/jbc.273.26.16075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632659	hybrid			2022-12-27	WOS:000074436600030
J	Brondijk, THC; van der Rest, ME; Pluim, D; de Vries, Y; Stingl, K; Poolman, B; Konings, WN				Brondijk, THC; van der Rest, ME; Pluim, D; de Vries, Y; Stingl, K; Poolman, B; Konings, WN			Catabolite inactivation of wild-type and mutant maltose transport proteins in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-TRANSPORT; YEAST; GLUCOSE; ENDOCYTOSIS; TRANSFORMATION; KINASE	The maltose transporter of Saccharomyces cerevisiae is subject to rapid, irreversible inactivation in the presence of glucose. Loss of transport function was paralleled by a decrease in amount of transporter protein and most likely involves endocytosis and degradation of the protein in the vacuole, This (catabolite) inactivation of Mal61p was triggered not only by glucose but also by 2-deoxy-D-glucose, which cannot be metabolized beyond 2-deoxy-D-glucose phosphate. The signal that targets membrane proteins specifically for catabolite inactivation is unknown. To investigate whether or not specific modification of Mal61p triggers the inactivation putative protein kinase A and C phosphorylation sites were removed, and the transport activities and levels of the mutant proteins upon addition of glucose were followed in time. Three Mal61p mutants, i.e. S295A, T363A, and S487A, exhibited significantly reduced rates of inactivation in the presence of glucose. Likewise, in wild-type Mal61p the rate of inactivation and degradation of the protein paralleled each other in the case of T363A. On the contrary, for the S295A and S487A mutants the rates of protein degradation were slowed down more profoundly than was the loss of transport activity. These observations indicate that (i) some form of modification (e.,g. phosphorylation) of the protein precedes breakdown, (ii) the modification inactivates MaI61p, and (iii) the inactivation of Mal61p is not necessarily followed by proteolytic degradation.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	B.Poolman@biol.rug.nl	Konings, Wilhelmus N./C-7063-2013; Brondijk, Harma/AAD-6485-2019	Brondijk, Harma/0000-0002-0234-673X; Stingl, Kerstin/0000-0002-8338-717X				Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; BUSTURIA A, 1985, BIOCHIM BIOPHYS ACTA, V820, P324, DOI 10.1016/0005-2736(85)90128-2; CHENG Q, 1991, J BACTERIOL, V173, P1817, DOI 10.1128/jb.173.5.1817-1820.1991; DULEY JR, 1975, ANAL BIOCHEM, V64, P136; EILAM Y, 1990, J GEN MICROBIOL, V136, P2537, DOI 10.1099/00221287-136-12-2537; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Lucero P, 1997, FEMS MICROBIOL LETT, V147, P273, DOI 10.1016/S0378-1097(96)00538-1; LUCERO P, 1993, FEBS LETT, V333, P265; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Messing J, 1979, RECOMBINANT DNA TECH, V2, P43; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NOVAK S, 1990, J IND MICROBIOL, V6, P149, DOI 10.1007/BF01576435; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEINADO JM, 1986, BIOCHIM BIOPHYS ACTA, V856, P189, DOI 10.1016/0005-2736(86)90027-1; POSTMA E, 1990, J BACTERIOL, V171, P3539; RAMOS J, 1989, J BACTERIOL, V171, P3545, DOI 10.1128/jb.171.6.3545-3548.1989; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; RIBALLO E, 1994, BIOCHIM BIOPHYS ACTA, V1191, P143; ROOMANS GM, 1979, BIOCHIM BIOPHYS ACTA, V551, P187, DOI 10.1016/0005-2736(79)90364-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THEVELEIN JM, 1995, TRENDS BIOCHEM SCI, V20, P3, DOI 10.1016/S0968-0004(00)88938-0; VANDERREST ME, 1995, J BACTERIOL, V177, P5440, DOI 10.1128/jb.177.19.5440-5446.1995; Walsh MC, 1996, J BACTERIOL, V178, P2593, DOI 10.1128/jb.178.9.2593-2597.1996	30	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15352	15357		10.1074/jbc.273.25.15352	http://dx.doi.org/10.1074/jbc.273.25.15352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624116	hybrid, Green Published			2022-12-27	WOS:000074284200010
J	Kishimoto, H; Hoshino, S; Ohori, M; Kontani, K; Nishina, H; Suzawa, M; Kato, S; Katada, T				Kishimoto, H; Hoshino, S; Ohori, M; Kontani, K; Nishina, H; Suzawa, M; Kato, S; Katada, T			Molecular mechanism of human CD38 gene expression by retinoic acid - Identification of retinoic acid response element in the first intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYL CYCLASE; LYMPHOCYTE ANTIGEN CD38; NAD GLYCOHYDROLASE; MONOCLONAL-ANTIBODY; LEUKEMIA-CELLS; MYELOID CELLS; B-CELLS; SURFACE; DIFFERENTIATION; ACTIVATION	CD38 is a nonlineage-restricted type II transmembrane glycoprotein possessing ecto-NAD(+) glycohydrolase activity. Because of its unique expression pattern in lymphocyte differentiation, it appears to function as an immunoregulatory molecule. We previously reported that CD38 was specifically induced by all-trans-retinoic acid (RA) in human promyelocytic leukemia HL-60 cells. Here we studied the molecular mechanism of the RA-dependent induction of human CD38, The expression of CD38 mRNA by RA appeared to be caused by the transcriptional stimulation of the gene, since it was blocked by an RNA synthesis inhibitor, but not by a protein synthesis inhibitor. In search of the RA response element (RARE) possibly present in human CD38 gene promoter, we isolated and sequenced the genomic DNA covering the 5'-flanking region, exon I, and partial intron 1. Transient transfection experiments revealed that the responsiveness to RA was conferred through an RARE consisting of two direct repeat TGACCT-like hexamer motifs with a 5-nucleotide spacer, which was located in the first intron rather than the 5'-flanking region of the CD38 gene. This RARE interacted with heterodimer composed of RA receptor and retinoid X receptor in vitro. Thus, the RA-induced expression of the human CD38 gene was demonstrated to be mediated through the RARE located in the first intron.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Katada, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 113, Japan.			Hoshino, Shinichi/0000-0001-6135-7896				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUSIELLO CM, 1995, EUR J IMMUNOL, V25, P1477, DOI 10.1002/eji.1830250554; BHAN AK, 1981, J EXP MED, V154, P737, DOI 10.1084/jem.154.3.737; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; DIANZANI U, 1994, J IMMUNOL, V153, P952; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; FUNARO A, 1990, J IMMUNOL, V145, P2390; HEMMI H, 1982, BIOCHEM BIOPH RES CO, V109, P669, DOI 10.1016/0006-291X(82)91992-1; HOLTER W, 1985, CELL IMMUNOL, V90, P322, DOI 10.1016/0008-8749(85)90197-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HROMAS R, 1991, J BIOL CHEM, V266, P14183; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JANOSSY G, 1981, J IMMUNOL, V126, P1608; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Mehta K, 1997, BLOOD, V89, P3607, DOI 10.1182/blood.V89.10.3607.3607_3607_3614; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Nata K, 1997, GENE, V186, P285, DOI 10.1016/S0378-1119(96)00723-8; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SIEFF C, 1982, BLOOD, V60, P703; STASHENKO P, 1981, P NATL ACAD SCI-BIOL, V78, P3848, DOI 10.1073/pnas.78.6.3848; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Stoeckler JD, 1996, J IMMUNOL, V157, P4908; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TERSTAPPEN LWMM, 1990, J LEUKOCYTE BIOL, V48, P138, DOI 10.1002/jlb.48.2.138; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	38	97	104	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15429	15434		10.1074/jbc.273.25.15429	http://dx.doi.org/10.1074/jbc.273.25.15429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624127	hybrid			2022-12-27	WOS:000074284200021
J	Misko, TP; Highkin, MK; Veenhuizen, AW; Manning, PT; Stern, MK; Currie, MG; Salvemini, D				Misko, TP; Highkin, MK; Veenhuizen, AW; Manning, PT; Stern, MK; Currie, MG; Salvemini, D			Characterization of the cytoprotective action of peroxynitrite decomposition catalysts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL RESPIRATORY-CHAIN; TYROSINE NITRATION; OXIDATIVE DAMAGE; IN-VITRO; SUPEROXIDE; CELLS; RAT; INHIBITION; INDUCTION	The formation of the powerful oxidant peroxynitrite (PN) from the reaction of superoxide anion with nitric oxide has been shown to be a kinetically favored reaction contributing to cellular injury and death at sites of tissue inflammation. The PN molecule is highly reactive causing lipid peroxidation as well as nitration of both free and protein-bound tyrosine. We present evidence for the pharmacological manipulation of PN with decomposition catalysts capable of converting it to nitrate. hs target cells challenged with exogenously added synthetic PN, a series of metalloporphyrin catalysts (5,10,15,20-tetrakis(2,4,6-trimethyl-3,3-disulfonatophenyl)porphyrinato iron (III) (FeTMPS); 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron (III) (FeTPPS); 5,10,15,20-tetrakis(N-methyl-4'-pyridyl)porphyrinato iron (III) (FeTMPyP)) provided protection against PN-mediated injury with EC50 values for each compound 30-50-fold below the final concentration of PN added. Cytoprotection was correlated with a reduction in the level of measurable nitrotyrosine. In addition, we found our catalysts to be cytoprotective against endogenously generated PN in endotoxin-stimulated RAW 264.7 cells as well as in dissociated cultures of hippocampal neurons and glia that had been exposed to cytokines. Our studies thus provide compelling evidence for the involvement of peroxynitrite in cytokine-mediated cellular injury and suggest the therapeutic potential of PN decomposition catalysts in reducing cellular damage at sites of inflammation.	Searle R&D, Discovery Pharmacol, St Louis, MO 63167 USA; Monsanto Corp Res, St Louis, MO 63167 USA	Monsanto	Misko, TP (corresponding author), Searle R&D, Discovery Pharmacol, 800 N Lindbergh Blvd, St Louis, MO 63167 USA.			Misko, Thomas/0000-0001-7917-422X				Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Douki T, 1996, CHEM RES TOXICOL, V9, P3, DOI 10.1021/tx950126n; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Good PF, 1996, AM J PATHOL, V149, P21; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KASTEN TP, 1995, P SOC EXP BIOL MED, V208, P170; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Lee JB, 1997, BIOORG MED CHEM LETT, V7, P2913, DOI 10.1016/S0960-894X(97)10109-3; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MARTIN BL, 1990, J BIOL CHEM, V265, P7108; MEBMER UK, 1995, MOL PHARMACOL, V47, P757; MISKO TP, 1995, J NEUROIMMUNOL, V61, P195, DOI 10.1016/0165-5728(95)00091-F; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 1996, EUR J PHARMACOL, V303, P217, DOI 10.1016/0014-2999(96)00140-9; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; SKAPER SD, 1995, J NEUROCHEM, V64, P266; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; YAMADA KA, 1989, J NEUROSCI, V9, P3230; YERMILOV V, 1995, CARCINOGENESIS, V16, P2045, DOI 10.1093/carcin/16.9.2045; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; Zingarelli B, 1996, J IMMUNOL, V156, P350	52	212	220	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15646	15653		10.1074/jbc.273.25.15646	http://dx.doi.org/10.1074/jbc.273.25.15646			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624158	hybrid			2022-12-27	WOS:000074284200052
J	Hansen, PA; Wang, WC; Marshall, BA; Holloszy, JO; Mueckler, M				Hansen, PA; Wang, WC; Marshall, BA; Holloszy, JO; Mueckler, M			Dissociation of GLUT4 translocation and insulin-stimulated glucose transport in transgenic mice overexpressing GLUT1 in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; HEXOSAMINE BIOSYNTHESIS; RESPONSIVE TISSUES; PROTEIN; RESISTANCE; CLONING; IDENTIFICATION; ACTIVATION; WORTMANNIN	Overexpression of the human GLUT1 glucose transporter protein in skeletal muscle of transgenic mice results in large increases in basal glucose transport and metabolism, but impaired stimulation of glucose transport by insulin, contractions, or hypoxia (Gulve, E, A., Ren, J,-M,, Marshall, B, A., Gao, J,, Hansen, P, A., Holloszy, J. O., and Mueckler, M. (1994) J, Biol, Chem, 269, 18366-18370). This study examined the relationship between glucose transport and cell-surface glucose transporter content in isolated skeletal muscle from wild-type and GLUT1-overexpressing mice using 2-deoxyglucose, 3-O-methylglucose, and the 2-N-[4-(1-azi-2,2,2-trifluoroethyl)benzoyl]-1,3-bis (D-mannos-4-yloxy)-2-propylamine exofacial photolabeling technique. Insulin (2 milliunits/ml) stimulated a 3-fold increase in a-deoxyglucose uptake in extensor digitorum longus muscles of control mice (0.47 +/- 0.07 mu mol/ml/20 min in basal muscle versus 1.44 mu mol/ml/20 min in insulin-stimulated muscle; mean +/- S.E.), Insulin failed to increase a-deoxyglucose uptake above basal rates in muscles overexpressing GLUT1 (4.00 +/- 0.40 mu mol/ml/20 min in basal muscle versus 3.96 +/- 0.37 mu mol/ml/20 min in insulin-stimulated muscle). A similar lack of insulin stimulation in muscles overexpressing GLUT1 was observed using 3-O-methylglucose. However, the magnitude of the insulin-stimulated increase in cell-surface GLUT4 photolabeling was nearly identical (similar to 3-fold) in wild-type and GLUT1-overexpressing muscles. This apparently normal insulin-stimulated translocation of GLUT4 in GLUT1-overexpressing muscle was confirmed by immunoelectron microscopy. Our findings suggest that GLUT4 activity at the plasma membrane can be dissociated from the plasma membrane content of GLUT4 molecules and thus suggest that the intrinsic activity of GLUT4 is subject to regulation.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050332, R01DK038495, R01DK018986] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50332, DK38495, DK18986] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DUDEK RW, 1994, FEBS LETT, V339, P205, DOI 10.1016/0014-5793(94)80416-8; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HENRIKSEN EJ, 1991, ACTA PHYSIOL SCAND, V143, P381, DOI 10.1111/j.1748-1716.1991.tb09249.x; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUNOZ P, 1995, BIOCHEM J, V312, P393, DOI 10.1042/bj3120393; PAREKH B S, 1989, Peptide Research, V2, P249; REN JM, 1993, J BIOL CHEM, V268, P16113; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; Wang WC, 1996, J CELL BIOL, V135, P415, DOI 10.1083/jcb.135.2.415; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	40	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18173	18179		10.1074/jbc.273.29.18173	http://dx.doi.org/10.1074/jbc.273.29.18173			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660777	hybrid			2022-12-27	WOS:000074828500032
J	Rockman, HA; Choi, DJ; Akhter, SA; Jaber, M; Giros, B; Lefkowitz, RJ; Caron, MG; Koch, WJ				Rockman, HA; Choi, DJ; Akhter, SA; Jaber, M; Giros, B; Lefkowitz, RJ; Caron, MG; Koch, WJ			Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; GAMMA-SUBUNITS; G-PROTEINS; EXPRESSION; DESENSITIZATION; ACTIVATION	We studied the effect of alterations in the level of myocardial beta-adrenergic receptor kinase (beta ARK1) in two types of genetically altered mice. The first group is heterozygous for beta ARK1 gene ablation, beta ARK1(+/-), and the second is not only heterozygous for beta AR1 gene ablation but is also transgenic for cardiac-specific overexpression of a beta ARK1 COOH-terminal inhibitor pep tide, beta ARK1(+/-)/beta ARKct. In contrast to the embryonic lethal phenotype of the homozygous beta ARK1 knockout (Jaber, M., Koch, W. J., Rockman, H. A., Smith, B., Bond, R. A., Sulik, K., Ross, J., Jr., Lefkowitz, R. J., Caron, M. G,, and Giros, B. (1996) Proc. Natl. Acad Sci. U.S.A. 93, 12974-12979), beta ARK1(+/-) mice develop normally. Cardiac catheterization was performed in mice and showed a stepwise increase in contractile function in the beta ARK1(+/-) and beta ARK1(+/-)/beta ARKct mice with the greatest level observed in the beta ARK1(+/-)/beta ARKct animals. Contractile parameters were measured in adult myocytes isolated from both groups of gene-targeted animals. A significantly greater increase in percent cell shortening and rate of cell shortening following isoproterenol stimulation was observed in the beta ARK1(+/-) and beta ARK1(+/-)/beta ARKct myocytes compared with wild-type cells, indicating a progressive increase in intrinsic contractility. These data demonstrate that contractile function can be modulated by the level of beta ARK1 activity. This has important implications in disease states such as heart failure (in which beta ARK1 activity is increased) and suggests that beta ARK1 should be considered as a therapeutic target in this situation. Even partial inhibition of beta ARK1 activity enhances beta-adrenergic receptor signaling leading to improved functional catecholamine responsiveness.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Dept Med, Durham, NC 27710 USA; Duke Univ, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 2606,Room 472 MSRB, Durham, NC 27710 USA.		GIROS, Bruno/ABD-5790-2021; Lefkowitz, Robert/AAW-2649-2021	GIROS, Bruno/0000-0001-5876-9822; Jaber, Mohamed/0000-0003-2536-1913	NHLBI NIH HHS [HL 16037, HL 56687] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL056687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; ANZAI T, 1996, CIRCULATION, V94, P643; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Korzick DH, 1997, AM J PHYSIOL-HEART C, V272, pH590, DOI 10.1152/ajpheart.1997.272.1.H590; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LITTLE WC, 1985, CIRC RES, V56, P808, DOI 10.1161/01.RES.56.6.808; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; Ungerer M, 1996, CIRC RES, V79, P455, DOI 10.1161/01.RES.79.3.455; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250	26	139	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18180	18184		10.1074/jbc.273.29.18180	http://dx.doi.org/10.1074/jbc.273.29.18180			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660778	hybrid			2022-12-27	WOS:000074828500033
J	Anderson, VE; Gootz, TD; Osheroff, N				Anderson, VE; Gootz, TD; Osheroff, N			Topoisomerase IV catalysis and the mechanism of quinolone action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA CLEAVAGE; DRUG-INTERACTION DOMAINS; II-TARGETED DRUGS; ESCHERICHIA-COLI; EUKARYOTIC TOPOISOMERASE; STREPTOCOCCUS-PNEUMONIAE; DROSOPHILA-MELANOGASTER; STAPHYLOCOCCUS-AUREUS; ANTINEOPLASTIC DRUGS; IN-VITRO	Topoisomerase IV is.bacterial type II topoisomerase that is essential for proper chromosome segregation and is a target for quinolone-based antimicrobial agents. Despite the importance of this enzyme to the survival of prokaryotic cells and to the treatment of bacterial infections, relatively little is known about the details of its catalytic mechanism or the basis by which quinolones alter its enzymatic functions. Therefore, a series of experiments that analyzed individual steps of the topoisomerase IV catalytic cycle were undertaken to address these critical mechanistic issues. The following conclusions were drawn, First, equilibrium levels of DNA cleavage mediated by the bacterial enzyme were considerably (>10-fold) higher than those observed with its eukaryotic counterparts. To a large extent, this reflected decreased rates of DNA religation. Second, the preference of topoisomerase TV for catalyzing DNA decatenation over relaxation reflects increased rates of strand passage and enzyme recycling rather than a heightened recognition of intermolecular DNA helices, Third, quinolones stimulate topoisomerase IV-mediated DNA cleavage both by increasing rates of DNA scission and by inhibiting religation of cleaved DNA. Finally, quinolones inhibit the overall catalytic activity of topoisomerase TV primarily by interfering with enzyme-ATP interactions.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA; Pfizer Inc, Pfizer Cent Res, Dept Canc Immunol & Infect Dis, Groton, CT 06340 USA	Vanderbilt University; Vanderbilt University; Pfizer	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg I, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09385] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; BARRETT JF, 1989, ANTIMICROB AGENTS CH, V33, P1697, DOI 10.1128/AAC.33.10.1697; Blanche F, 1996, ANTIMICROB AGENTS CH, V40, P2714, DOI 10.1128/AAC.40.12.2714; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, ANTIMICROB AGENTS CH, V37, P2599, DOI 10.1128/AAC.37.12.2599; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Elsea SH, 1997, BIOCHEMISTRY-US, V36, P2919, DOI 10.1021/bi962488f; ELSEA SH, 1993, ANTIMICROB AGENTS CH, V37, P2179, DOI 10.1128/AAC.37.10.2179; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GILLIGAN PJ, 1986, Patent No. 4623650; Gootz TD, 1996, ANTIMICROB AGENTS CH, V40, P2691, DOI 10.1128/AAC.40.12.2691; Gootz TD, 1996, MED RES REV, V16, P433, DOI 10.1002/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W; Gootz Thomas D., 1993, P139; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; Hooper D., 1993, QUINOLONE ANTIMICROB, Vsecond; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HOSHINO K, 1953, ANTIMICROB AGENTS CH, V3826, P94; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LIU LF, 1983, J BIOL CHEM, V258, P5365; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; Menzel R, 1994, Adv Pharmacol, V29A, P39; Munoz R, 1996, ANTIMICROB AGENTS CH, V40, P2252, DOI 10.1128/AAC.40.10.2252; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; OSHEROFF N, 1994, CANC CHEMOTHER PHARM, V34, P19; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; Zechiedrich EL, 1997, GENE DEV, V11, P2580, DOI 10.1101/gad.11.19.2580; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; ZIMMER C, 1990, J BASIC MICROB, V30, P209, DOI 10.1002/jobm.3620300312	69	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17879	17885		10.1074/jbc.273.28.17879	http://dx.doi.org/10.1074/jbc.273.28.17879			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651393	hybrid			2022-12-27	WOS:000074816100086
J	Ikebe, M; Kambara, T; Stafford, WF; Sata, M; Katayama, E; Ikebe, R				Ikebe, M; Kambara, T; Stafford, WF; Sata, M; Katayama, E; Ikebe, R			A hinge at the central helix of the regulatory light chain of myosin is critical for phosphorylation-dependent regulation of smooth muscle myosin motor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD-MUSCLE; 3-DIMENSIONAL STRUCTURE; ENZYMATIC-PROPERTIES; 2-HEADED STRUCTURE; BOUNDARY ANALYSIS; PEPTIDE COMPLEX; CONFORMATION; CALMODULIN; KINASE; PROTEOLYSIS	The motor function of smooth muscle myosin is activated by phosphorylation of the regulatory light chain (RLC) at Ser(19). However, the molecular mechanism by which the phosphorylation activates the motor function is not yet understood. In the present study, we focused our attention on the role of the central helix of RLC for regulation. The flexible region at the middle of the central helix (Gly(95)-Pro(98)) was substituted or deleted to various extents, and the effects of the deletion or substitution on the regulation of the motor activity of myosin were examined. Deletion of Gly(95)-Asp(97), Gly(95)-Thr(96), or Thr(96)-Asp(97) decreased the actin-translocating activity of myosin a Little, but the phosphorylation-dependent regulation of the motor activity was not disrupted. In contrast, the deletion of Gly(95)-Pro(98) Of RLC completely abolished the actin translocating activity of phosphorylated myosin. However, the unregulated myosin long subfragment 1 containing this RLC mutant showed motor activity the same as that containing the wild type RLC, Since long subfragment 1 motor activity is unregulated by phosphorylation, i.e. constitutively active, these results suggest that the deletion of these residues at the central helix of RLC disrupts the phosphorylation-mediated activation mechanism but not the motor function of myosin itself. On the other hand, the elimination of Pro(98) or substitution of Gly(95)-Pro(98) by Ala resulted in the activation of actin translocating activity of dephosphorylated myosin, whereas it did not affect the motor activity of phosphorylated myosin, Together, these results clearly indicate the importance of the hinge at the central helix of RLC on the phosphorylation-mediated regulation of smooth muscle myosin.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Boston Biomed Res Inst, Muscle Res Grp, Boston, MA 02114 USA; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 108, Japan	University of Massachusetts System; University of Massachusetts Worcester; Boston Biomedical Research Institute; University of Tokyo	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.		Stafford, Walter/ABC-6553-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047530, R01HL056218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47530, HL 56218] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Cuda G, 1997, BIOPHYS J, V72, P1767, DOI 10.1016/S0006-3495(97)78823-4; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1986, J BIOL CHEM, V261, P36; IKEBE M, 1985, J BIOL CHEM, V260, P27; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAKES R, 1976, FEBS LETT, V70, P229, DOI 10.1016/0014-5793(76)80763-6; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAITA T, 1981, EUR J BIOCHEM, V117, P417, DOI 10.1111/j.1432-1033.1981.tb06354.x; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; ONISHI H, 1984, J BIOCHEM, V95, P899, DOI 10.1093/oxfordjournals.jbchem.a134685; ONISHI H, 1983, J BIOCHEM-TOKYO, V94, P1147, DOI 10.1093/oxfordjournals.jbchem.a134459; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016; Yphantis D, 1994, MODERN ANAL ULTRACEN, P209	50	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17702	17707		10.1074/jbc.273.28.17702	http://dx.doi.org/10.1074/jbc.273.28.17702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651368	hybrid			2022-12-27	WOS:000074816100061
J	Li, QS; Das Gupta, J; Hunt, AG				Li, QS; Das Gupta, J; Hunt, AG			Polynucleotide phosphorylase is a component of a novel plant poly(A) polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MESSENGER-RNA; ESCHERICHIA-COLI; BINDING PROTEINS; DEGRADATION; GENE; SEQUENCE; DECAY	We have isolated cDNA clones encoding a novel RNA-binding protein that is a component of a multisubunit poly(A) polymerase from pea seedlings. The encoded protein bears a significant resemblance to polynucleotide phosphorylases (PNPases) from bacteria and chloroplasts, More significantly, this RNA-binding protein is able to degrade RNAs with the resultant production of nucleotide diphosphates, and it can add extended polyadenylate tracts to RNAs using ADP as a donor for adenylate moieties, These activities are characteristic of PNPase, Antibodies raised against the cloned protein simultaneously immunoprecipitate both poly(A) polymerase and PNPase activity. We conclude from these studies that PNPase is the RNA-binding cofactor for this poly(A) polymerase and is an integral player in the reaction catalyzed by this enzyme. The identification of this RNA-binding protein as PNPase, which is a chloroplast-localized enzyme known to be involved in mRNA 3'-end determination and turnover (Hayes, R., Kudla, J., Schuster, G., Gabay, L., Maliga, P., and Gruissem, W. (1996) EMBO J, 15, 1132-1141), raises interesting questions regarding the subcellular location of the poly(A) polymerase under study, We have reexamined this issue, and we find that this enzyme can be detected in chloroplast extracts. The involvement of PNPase in poly adenylation in vitro provides a biochemical rationale for the link between chloroplast RNA polyadenylation and RNA turnover which has been noted by others (Lisitsky, I., Klaff, P,, and Schuster, G, (1996) Proc. Natl, Acad, Sci, U. S. A. 93, 13398-13403).	Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA	University of Kentucky	Hunt, AG (corresponding author), Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, N212A Agr Sci Ctr N, Lexington, KY 40546 USA.		Hunt, Arthur/A-8040-2009; Li, Qingshun/C-5603-2009	Li, Qingshun/0000-0003-4105-1480; Hunt, Arthur/0000-0002-0008-4158				Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DASGUPTA J, 1995, PLANT SCI, V110, P215; GANTT JS, 1986, MOL GEN GENET, V202, P186, DOI 10.1007/BF00331635; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; Li QS, 1996, J BIOL CHEM, V271, P19831, DOI 10.1074/jbc.271.33.19831; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; MCCLAREN RS, 1991, J MOL BIOL, V220, P81; MOGEN BD, 1992, MOL CELL BIOL, V12, P5406, DOI 10.1128/MCB.12.12.5406; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; OROZCO EM, 1986, METHOD ENZYMOL, V118, P232; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REGNIER P, 1987, J BIOL CHEM, V262, P63; REINER AM, 1969, J BACTERIOL, V97, P1437, DOI 10.1128/JB.97.3.1437-1443.1969; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sambrook J., 2002, MOL CLONING LAB MANU; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YANG JJ, 1994, PLANT SCI, V99, P161, DOI 10.1016/0168-9452(94)90173-2	23	31	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17539	17543		10.1074/jbc.273.28.17539	http://dx.doi.org/10.1074/jbc.273.28.17539			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651346	hybrid			2022-12-27	WOS:000074816100039
J	Marekov, LN; Steinert, PM				Marekov, LN; Steinert, PM			Ceramides are bound to structural proteins of the human foreskin epidermal cornified cell envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEIN-1; STRATUM-CORNEUM; CROSS-LINKING; LIPIDS; TRANSGLUTAMINASES; CORNEOCYTE; INVOLUCRIN; LORICRIN	An important component of barrier function in human epidermis is contributed by ceramides that are bound by ester linkages to undefined proteins of the cornified cell envelope (CE), In this paper, we have examined the protein targets for the ceramide attachment. By partial saponification of isolated foreskin epidermal CEs followed by limited proteolysis, we have recovered several lipopeptides. Biochemical and mass spectroscopic characterization revealed that all contained near stoichiometric amounts of ceramides of masses ranging from about 690 to 890 atomic mass units, of which six quantitatively major species were common. The array of ceramides was similar to that obtained from pig skin, the composition of which is known, thereby providing strong indirect data for their fatty acid and sphingosine compositions, The recovered peptides accounted for about 20% of the total foreskin CE ceramides, By amino acid sequencing, about 35% of the peptides were derived from ancestral glutamine glutamate-rich regions of involucrin, an important CE structural protein. Another 18% derived from rod domain sequences of periplakin and envoplakin, which are also known or suspected CE proteins. Other peptides were too short for unequivocal identification. Together, these data indicate that involucrin, envoplakin, periplakin, and possibly other structural proteins serve as substrates for the attachment of ceramides by ester linkages to the CE for barrier function in human epidermis.	NIAMSD, Lab Shin Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Steinert, PM (corresponding author), NIAMSD, Lab Shin Biol, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov						DOWNING DT, 1993, DERMATOLOGY GEN MED, P210; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Elias Peter M., 1996, Journal of Dermatology (Tokyo), V23, P756; ELIAS PM, 1991, ADV LIPID RES, V24, P1; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREEN H, 1992, MOL BIOL EVOL, V9, P977; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROSS M, 1974, J BIOL CHEM, V249, P3021; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; Holbrook K.A., 1993, DERMATOLOGY GEN MED, P97; Jarnik M, 1998, J CELL SCI, V111, P1051; Jarnik M, 1996, J CELL SCI, V109, P1381; LAZO ND, 1995, J INVEST DERMATOL, V105, P296, DOI 10.1111/1523-1747.ep12318985; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARTINET N, 1990, BIOCHEM J, V271, P305, DOI 10.1042/bj2710305; PONEC M, 1994, KERATINOCYTE HDB, P351; Reichert Uwe, 1993, P107; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SCHURER NY, 1991, ADV LIPID RES, V24, P27; SIMON M, 1994, KERATINOCYTE HDB, P275; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; STEVEN AC, 1994, J CELL SCI, V107, P693; SWARTZENDRUBER DC, 1987, J INVEST DERMATOL, V88, P709, DOI 10.1111/1523-1747.ep12470383; WERTZ PW, 1987, J INVEST DERMATOL, V89, P419, DOI 10.1111/1523-1747.ep12471781; WERTZ PW, 1989, COMP BIOCHEM PHYS B, V93, P265, DOI 10.1016/0305-0491(89)90080-1; WERTZ PW, 1989, J INVEST DERMATOL, V93, P169, DOI 10.1111/1523-1747.ep12277394; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; WERTZ PW, 1983, J LIPID RES, V24, P759; WERTZ PW, 1991, PHYSL BIOCH MOL BIOL, P205; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754	37	157	166	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17763	17770		10.1074/jbc.273.28.17763	http://dx.doi.org/10.1074/jbc.273.28.17763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651377	hybrid			2022-12-27	WOS:000074816100070
J	Solomon, C; Sebag, M; White, JH; Rhim, J; Kremer, R				Solomon, C; Sebag, M; White, JH; Rhim, J; Kremer, R			Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; D RESPONSE ELEMENT; THYROID-HORMONE; ACID RECEPTORS; CO-REPRESSOR; DIFFERENTIATION; BINDING; 1,25-DIHYDROXYVITAMIN-D3; CELLS; GENE	A partial resistance to the growth inhibitory influence of 1,25-dihydroxyvitamin D-3 is apparent when immortalized keratinocytes are transformed by the ras oncogene. The vitamin D receptor (VDR) was isolated, analyzed, and found to be identical in normal, immortalized, and ras-transformed keratinocytes. Subsequently, nuclear extracts from immortalized and ras-transformed keratinocytes were analyzed in gel mobility shift assays utilizing labeled vitamin D response elements or thyroid hormone response elements. A specific protein DNA complex that was shown to contain VDR using an anti-VDR antibody was identified in both types of extracts; however, the addition of an anti-retinoid X receptor (RXR) antibody identified RXR in the complex of both normal and immortalized keratinocyte cell extracts, but not in ras-transformed keratinocytes. Furthermore, transfection of ras-transformed keratinocytes with wild-type human RXR alpha rescued VDR.RXR and thyroid hormone receptor.RXR complexes as demonstrated by a supershift in the presence of the anti-RXR antibody. Both cell lines were found to express RXR alpha message in equal amounts. Western blot analysis revealed that RXR alpha protein from ras-transformed keratinocytes was indistinguishable from that from immortalized keratinocytes and from control cells. These results suggest a causal relationship between resistance to the growth inhibitory influences of 1,25-dihydroxyvitamin D-3 and disruption of the VDR.RXR complex in malignant keratinocytes.	McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; NCI, Mol Oncol Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kremer, R (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		white, john h/N-9782-2013	white, john h/0000-0002-4785-2687; Kremer, Richard/0000-0002-7053-2139				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DURST M, 1987, ONCOGENE, V1, P251; ELDER JT, 1992, J INVEST DERMATOL, V98, pS36, DOI 10.1111/1523-1747.ep12462180; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1994, MOL ENDOCRINOL, V8, P265, DOI 10.1210/me.8.3.265; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jin CH, 1996, MOL ENDOCRINOL, V10, P196, DOI 10.1210/me.10.2.196; Kephart DD, 1996, MOL ENDOCRINOL, V10, P408, DOI 10.1210/me.10.4.408; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; OMALLEY BW, 1984, J CLIN INVEST, V74, P307, DOI 10.1172/JCI111425; OZONO K, 1990, J BIOL CHEM, V265, P21881; PILLAI S, 1988, J BIOL CHEM, V263, P5390; SEBAG M, 1994, J INVEST DERMATOL, V103, P323, DOI 10.1111/1523-1747.ep12394802; SEBAG M, 1992, J BIOL CHEM, V267, P12162; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; SONE T, 1990, MOL ENDOCRINOL, V4, P623, DOI 10.1210/mend-4-4-623; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	29	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17573	17578		10.1074/jbc.273.28.17573	http://dx.doi.org/10.1074/jbc.273.28.17573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651351	hybrid			2022-12-27	WOS:000074816100044
J	Kuroda, T; Okuda, N; Saitoh, N; Hiyama, T; Terasaki, Y; Anazawa, H; Hirata, A; Mogi, T; Kusaka, I; Tsuchiya, T; Yabe, I				Kuroda, T; Okuda, N; Saitoh, N; Hiyama, T; Terasaki, Y; Anazawa, H; Hirata, A; Mogi, T; Kusaka, I; Tsuchiya, T; Yabe, I			Patch clamp studies on ion pumps of the cytoplasmic membrane of Escherichia coli - Formation, preparation, and utilization of giant vacuole-like structures consisting of everted cytoplasmic membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PROTEIN TRANSLOCATION; H+-ATPASE; DEGRADATION; F1-ATPASE; PROTEASES; EVOLUTION; SYSTEM; CELLS	Formation of giant protoplasts from normal Escherichia coli cells resulted in the formation of giant vacuole-type structures (which we designate as provacuoles) in the protoplasts. Electron microscopic observation revealed that these provacuoles were surrounded by a single membrane. We detected inner (cytoplasmic) membrane proteins in the provacuolar membrane but not outer membrane proteins. Biochemical analyses revealed that the provacuoles consist of everted cytoplasmic membranes. We applied the patch clamp method to the giant provacuoles. We have succeeded in measuring current that represents inward movement of H+ because of respiration and to ATP hydrolysis by the F0F1-ATPase. Such current was inhibited by inhibitors of the respiratory chain or F0F1-ATPase. This method is applicable for analyses of ion channels, ion pumps, or ion transporters in E. coli or other microorganisms.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 700, Japan; Saitama Univ, Dept Biochem, Urawa, Saitama 38, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Okayama University; Saitama University; Kyowa Kirin Ltd; University of Tokyo	Yabe, I (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.	yabe@bio.t.u-tokyo.ac.jp	KURODA, Teruo/B-2028-2011					AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6546; BRAUN V, 1972, P NATL ACAD SCI USA, V69, P970, DOI 10.1073/pnas.69.4.970; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CUI C, 1995, J MEMBRANE BIOL, V144, P31; EDA T, 1978, J BACTERIOL, V127, P1564; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GIBSON SAW, 1988, J GEN MICROBIOL, V134, P2231; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRATA H, 1986, J BIOL CHEM, V261, P9839; INGLEDEW WJ, 1984, MICROBIOL REV, V48, P222, DOI 10.1128/MMBR.48.3.222-271.1984; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; KUBALSKI A, 1995, BBA-BIOMEMBRANES, V1238, P177, DOI 10.1016/0005-2736(95)00126-N; KURODA T, 1994, J BIOCHEM-TOKYO, V116, P1030, DOI 10.1093/oxfordjournals.jbchem.a124624; KUSAKA I, 1967, J BACTERIOL, V96, P884; LEDERBERG J, 1958, J BACTERIOL, V75, P143, DOI 10.1128/JB.75.2.143-160.1958; MATSUDA H, 1984, J PHYSIOL-LONDON, V357, P553, DOI 10.1113/jphysiol.1984.sp015517; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MUNEYUKI E, 1989, J BIOL CHEM, V264, P6092; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; ONODA T, 1987, J GEN MICROBIOL, V133, P527; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; REINER AM, 1969, J BACTERIOL, V97, P1431, DOI 10.1128/JB.97.3.1431-1436.1969; Rosen B P, 1979, Methods Enzymol, V56, P233; RUTHE HJ, 1985, BIOCHIM BIOPHYS ACTA, V819, P105, DOI 10.1016/0005-2736(85)90200-7; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUZUKI H, 1978, MOL GEN GENET, V167, P1; TSURUOKA T, 1988, J BACTERIOL, V170, P5229, DOI 10.1128/jb.170.11.5229-5235.1988; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	38	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16897	16904		10.1074/jbc.273.27.16897	http://dx.doi.org/10.1074/jbc.273.27.16897			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642251	hybrid			2022-12-27	WOS:000074545200041
J	Pagano, A; Cinque, G; Bassi, R				Pagano, A; Cinque, G; Bassi, R			In vitro reconstitution of the recombinant photosystem II light-harvesting complex CP24 and its spectroscopic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; CHLOROPHYLL SPECTRAL FORMS; ESCHERICHIA-COLI; PIGMENT-BINDING; GAUSSIAN DECOMPOSITION; ENERGY-DISSIPATION; ANTENNA COMPLEXES; MEMBRANES; PLANTS; FLUORESCENCE	The light-harvesting chlorophyll alb protein CP24, a minor subunit of the photosystem ii antenna system, is a major violaxanthin-binding protein involved in the regulation of excited state concentration of chlorophyll a. This subunit is poorly characterized due to the difficulty in isolation and instability during purification procedures. We have used an alternative approach in order to gain information on the properties of this protein; the Lhcb6 cDNA has been overexpressed in bacteria in order to obtain the CP24 apoprotein, which was then reconstituted in vitro with xanthophylls, chlorophyll a, and chlorophyll b, yielding a pigment-protein complex with properties essentially identical to the native protein extracted from maize thylakoids. Although all carotenoids were supplied during refolding, the recombinant holoprotein exhibited high selectivity in xanthophyll binding by coordinating violaxanthin and lutein but not neoxanthin or beta-carotene. Each monomer bound a total of 10 chlorophyll a plus chlorophyll b and two xanthophyll molecules. Moreover, the protein could be refolded in the presence of different chlorophyll a to chlorophyll b ratios for yielding a family of recombinant proteins with different chlorophyll alb ratios but still binding the same total number of porphyrins. A peculiar feature of CP24 was its refolding capability in the absence of lutein, contrary to the case of other homologous proteins, thus showing higher plasticity in xanthophyll binding. These characteristics of CP24 are discussed with respect to its role in binding zeaxanthin in high light stress conditions. The spectroscopic analysis of a recombinant CP24 complex binding eight chlorophyll b molecules and a single chlorophyll a molecule by Gaussian deconvolution allowed the identification of four subbands peaking at wavelengths of 638, 645, 653, and 659 nm, which have an increased amplitude with respect to the native complex and therefore identify the chlorophyll b absorption in the antenna protein environment. Gaussian subbands at wavelengths 666, 673, 679, and 686 nm are depleted in the high chlorophyll b complex, thus suggesting they derive from chlorophyll a.	Univ Verona, Fac Sci, MM FF NN, I-37134 Verona, Italy	University of Verona	Bassi, R (corresponding author), Univ Verona, Fac Sci, MM FF NN, St Grazie, I-37134 Verona, Italy.	bassi@biotech.sci.univr.it	Pagano, Aldo/AAF-3974-2019; Cinque, Gianfelice/K-5599-2018	Pagano, Aldo/0000-0001-8035-9299; Cinque, Gianfelice/0000-0001-6801-8010; bassi, roberto/0000-0002-4140-8446				BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; Bassi R, 1996, NATO ADV SCI INST SE, V287, P41; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CAMMARATA KV, 1992, BIOCHEMISTRY-US, V31, P2779, DOI 10.1021/bi00125a019; CATTANEO R, 1995, BIOCHEMISTRY-US, V34, P15267, DOI 10.1021/bi00046a035; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; CROFTS AR, 1994, FEBS LETT, V352, P265, DOI 10.1016/0014-5793(94)00976-7; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DAINESE P, 1992, RES PHOTOSYNTHESIS, V1, P287; DAINESE P, 1992, DEV PHOTOSYNTHESIS R, V1, P199; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DIPAOLO ML, 1990, PLANTA, V181, P275, DOI 10.1007/BF00195877; DUNAHAY TG, 1986, PLANT PHYSIOL, V80, P429, DOI 10.1104/pp.80.2.429; FOWLER GJS, 1992, NATURE, V355, P848, DOI 10.1038/355848a0; GILLIE JK, 1989, J PHYS CHEM-US, V93, P1620, DOI 10.1021/j100341a085; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HEMELRIJK PW, 1992, BIOCHIM BIOPHYS ACTA, V1098, P159, DOI 10.1016/S0005-2728(05)80331-7; HENRYSSON T, 1989, BIOCHIM BIOPHYS ACTA, V977, P301, DOI 10.1016/S0005-2728(89)80084-2; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; JAHNS P, 1995, PLANT PHYSIOL BIOCH, V33, P683; JENNINGS RC, 1993, BIOCHEMISTRY-US, V32, P3203, DOI 10.1021/bi00064a002; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KWA SLS, 1992, BIOCHIM BIOPHYS ACTA, V1101, P143, DOI 10.1016/0005-2728(92)90198-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUARDT J, 1993, PLANTA, V191, P265, DOI 10.1007/BF00199759; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Press W., 1986, NUMERICAL RECIPES; REDDY NRS, 1994, J PHYS CHEM-US, V98, P4729, DOI 10.1021/j100068a040; ROS F, 1998, IN PRESS EUR J BIOCH; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER K, 1966, J AM CHEM SOC, V88, P2681, DOI 10.1021/ja00964a011; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SIMPSON DJ, 1979, CARLSBERG RES COMMUN, V44, P305, DOI 10.1007/BF02906493; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stepanov B.I., 1957, PHYS DOKL, V2, P81; THORNBER JP, 1993, BIOCHEM SOC T, V21, P15, DOI 10.1042/bst0210015; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; VISSCHERS RW, 1994, BBA-BIOENERGETICS, V1183, P483, DOI 10.1016/0005-2728(94)90075-2; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; YAMAMOTO HY, 1996, OXYGENIC PHOTOSYNTHE, P539, DOI DOI 10.1007/0-306-48127-8_30; ZUCCHELLI G, 1994, BIOCHEMISTRY-US, V33, P8982, DOI 10.1021/bi00196a016; ZUCCHELLI G, 1992, BIOCHIM BIOPHYS ACTA, V1099, P163, DOI 10.1016/0304-4173(92)90023-8; Zucchelli G, 1996, BIOCHEMISTRY-US, V35, P16247, DOI 10.1021/bi9613178	64	61	64	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17154	17165		10.1074/jbc.273.27.17154	http://dx.doi.org/10.1074/jbc.273.27.17154			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642283	hybrid			2022-12-27	WOS:000074545200073
J	Santamaria, I; Velasco, G; Pendas, AM; Fueyo, A; Lopez-Otin, C				Santamaria, I; Velasco, G; Pendas, AM; Fueyo, A; Lopez-Otin, C			Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; MOLECULAR-CLONING; LYSOSOMAL PROTEINASE; GENOMIC ORGANIZATION; TISSUE DISTRIBUTION; THIOL PROTEASE; PROCATHEPSIN-L; EXPRESSION; LOCALIZATION; PRECURSOR	We have identified and characterized a novel human cysteine proteinase of the papain family. A full-length cDNA for this enzyme was cloned from a human brain cDNA library. Nucleotide sequence analysis revealed that the isolated cDNA codes for a polypeptide of 303 amino acids, tentatively called cathepsin Z, that exhibits structural features characteristic of cysteine proteinases. Fluorescent in. situ hybridization experiments revealed that the human cathepsin Z gene maps to chromosome 20q13, a location that differs from all cysteine proteinase genes mapped to date. The cDNA encoding cathepsin Z was expressed in Escherichia coli as a fusion protein with glutathione S-transferase, and after purification, the recombinant protein was able to degrade the synthetic peptide benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin, used as a substrate for cysteine proteinases. Northern blot analysis demonstrated that cathepsin Z is widely expressed in human tissues, suggesting that this enzyme could be involved in the normal intracellular protein degradation taking place in all cell types. Cathepsin Z is also ubiquitously distributed in cancer cell lines and in primary tumors from different sources, suggesting that this enzyme may participate in tumor progression as reported for other cathepsins. Finally, on the basis of a series of distinctive structural features, including diverse peptide insertions and an unusual short propeptide, together with its unique chromosomal location among cysteine proteinases, we propose that cathepsin Z may be the first representative of a novel subfamily of this class of proteolytic enzymes.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain	University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain.	CLO@DWARF1.QUIMICA.UNIOVI.ES	López-Otín, Carlos/AAB-2106-2020; Fueyo, Antonio/ABH-3243-2020; Pendas, Alberto M/L-1017-2014; Velasco, Gloria/AAS-5842-2021; Santamaria, Inigo/H-6727-2015	López-Otín, Carlos/0000-0001-6964-1904; Fueyo, Antonio/0000-0002-7121-9398; Velasco, Gloria/0000-0001-8032-5056; Santamaria, Inigo/0000-0001-8718-5359; Pendas, Alberto M/0000-0001-9264-3721				BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; CHAUHAN SS, 1991, CANCER RES, V51, P1478; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOCHERTY K, 1982, P NATL ACAD SCI-BIOL, V79, P4613, DOI 10.1073/pnas.79.15.4613; Ferrando AA, 1997, J BIOL CHEM, V272, P33298, DOI 10.1074/jbc.272.52.33298; Ferrando AA, 1996, CANCER RES, V56, P1746; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GAL S, 1986, J BIOL CHEM, V261, P1760; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GOHDA E, 1981, J BIOL CHEM, V256, P2567; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; HONIG J, 1984, ANN HUM GENET, V48, P49, DOI 10.1111/j.1469-1809.1984.tb00833.x; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; Maniatis T., 1982, MOL CLONING LAB MANU; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MASON RW, 1985, BIOCHEM J, V226, P233, DOI 10.1042/bj2260233; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V214, P376, DOI 10.1016/0003-9861(82)90042-X; Rao NV, 1997, J BIOL CHEM, V272, P10260; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; Rood JA, 1997, GENOMICS, V41, P169, DOI 10.1006/geno.1997.4614; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santamaria I, 1998, CANCER RES, V58, P1624; SANTAMARIA I, 1998, IN PRESS GENOMICS; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1994, J BIOL CHEM, V269, P11530; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WANG X, 1987, CYTOGENET CELL GENET, V46, P710; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; Yokoyama C, 1996, GENOMICS, V36, P296, DOI 10.1006/geno.1996.0465; YU H, 1993, GENOMICS, V15, P219, DOI 10.1006/geno.1993.1040	62	110	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16816	16823		10.1074/jbc.273.27.16816	http://dx.doi.org/10.1074/jbc.273.27.16816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642240	hybrid			2022-12-27	WOS:000074545200030
J	Wu, WJ; Lin, R; Cerione, RA; Manor, D				Wu, WJ; Lin, R; Cerione, RA; Manor, D			Transformation activity of Cdc42 requires a region unique to Rho-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL-ONCOGENE PRODUCT; GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; RAS TRANSFORMATION; KINASE; GTPASES; ACTIVATION; IDENTIFICATION; CASCADE; PAK65	The Rho subfamily GTP-binding protein Cdc42 mediates actin cytoskeletal rearrangements and cell cycle progression and is essential for Ras transformation. Expression of a Cdc42 mutant (Cdc42(F28L)) that undergoes spontaneous activation (guanine nucleotide exchange) results in transformation of NIH3T3 fibroblasts. In this report, we show that deletion of residues 120-139 from Cdc42(F28L), which comprise an insert region unique to Rho subfamily proteins but is missing in other GTP-binding proteins, yields a Cdc42 molecule that still undergoes spontaneous GTP-GDP exchange and stimulates both actin cytoskeletal changes and the activation of the cellular targets pal-activated kinase and the c-Jun kinase (JNK1). However, this Cdc42 mutant is unable to transform cells. These findings indicate that the Rho subfamily insert region is dispensable for many of the known signaling pathways initiated by activated Cdc42 but is essential for its regulation of cell growth.	Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	Cornell University	Manor, D (corresponding author), Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA.	dm43@cornell.edu			NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1980, CELL CULTURE BIOCH L; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON ME, 1995, SCIENCE, V269, P53; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SUTCLIFF M, 1995, PROTEIN PEPTIDE LETT, V1, P84; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu WJ, 1997, J BIOL CHEM, V272, P26153, DOI 10.1074/jbc.272.42.26153; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	38	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16655	16658		10.1074/jbc.273.27.16655	http://dx.doi.org/10.1074/jbc.273.27.16655			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642217	hybrid			2022-12-27	WOS:000074545200007
J	Valiyaveetil, FI; Fillingame, RH				Valiyaveetil, FI; Fillingame, RH			Transmembrane topography of subunit a in the Escherichia coli F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; MEMBRANE TOPOLOGY; ALPHA-SUBUNIT; PROTEIN; PREDICTION; COMPONENT; MUTATIONS; FUSIONS; HELIX; PORE	Subunit a is the least understood of the three subunits that compose the F-0 sector in the Escherichia coli F0F1 ATP synthase. In this study, we have substituted Cys into predicted extramembranous loops of the protein and used chemical modification to obtain topographical information on the folding of subunit a. The extent of labeling of the substituted Cys residues by fluorescein-5'-maleimide was determined. The localization of reactive Cys residues was inferred from differences in the extent of labeling in inside out and right side out membrane vesicles. The NH2-terminal segment of subunit a was localized to the outside (periplasmic) surface and the COOH terminus to the cytoplasmic surface by these procedures. Loop residues in two periplasmic extramembranous loops and in two cytoplasmic extramembranous loops were also localized. The localization of two cytoplasmic Cys residues was confirmed by using 4-acetamido-4'-maleimidylstilbene-2,2 '-disulfonic acid to block fluorescein-5'-maleimide labeling. From the localization of the Cys residues, a model for the topography is proposed that consists of five transmembrane segments with the NH, terminus periplasmic and the COOH terminus cytoplasmic. The positions of second site suppressors, including several isolated here to the nonfunctional E219C and H245C substitutions, provide support for the topographical model proposed.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 587 Med Sci Bldg, Madison, WI 53706 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTENDORF KH, 1974, J BACTERIOL, V117, P888, DOI 10.1128/JB.117.2.888-899.1974; Barik S, 1996, Methods Mol Biol, V57, P203; BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; BOYD D, 1994, MEMBRANE PROTEIN STR, P144; CAFISO DS, 1994, MEMBRANE PROTEIN STR, P127; ContiFine BM, 1996, ANNU REV BIOPH BIOM, V25, P197; DECKERSHEBESTRE.G, 1996, ANNU REV MICROBIOL, V50, P971; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kimura T, 1997, J BIOL CHEM, V272, P580; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1989, PHYSLR EV, V68, P177; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P5032, DOI 10.1073/pnas.71.12.5032; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	39	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16241	16247		10.1074/jbc.273.26.16241	http://dx.doi.org/10.1074/jbc.273.26.16241			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632683	hybrid			2022-12-27	WOS:000074436600054
J	Betuing, S; Daviaud, D; Pages, C; Bonnard, E; Valet, P; Lafontan, M; Saulnier-Blache, JS				Betuing, S; Daviaud, D; Pages, C; Bonnard, E; Valet, P; Lafontan, M; Saulnier-Blache, JS			G beta gamma-independent coupling of alpha(2)-adrenergic receptor to p21(rhoA) in preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; TYROSINE PHOSPHORYLATION; ADP-RIBOSYLATION; FOCAL ADHESIONS; GENE-PRODUCT; RHO; STIMULATION; EXPRESSION	In preadipocytes, alpha(2)-adrenergic receptor (alpha(2)-AR) stimulation leads to a G(1)/G(0)-dependent rearrangement of actin cytoskeleton. This is characterized by a rapid cell spreading, the formation of actin stress fibers, and the increase in tyrosyl phosphorylation of the focal adhesion kinase (pp125(FAK)). These cellular events being tightly controlled by the small GTPase p21(rhoA), the existence of a G(1)/G(0)-dependent coupling of alpha(2)-AR to p21(rhoA) in preadipocytes was proposed. In alpha 2AF2 preadipocytes (a cell clone derived from the 3T3F442A preadipose cell line and which stably expresses the human alpha 2C10-adrenergic receptor) alpha(2)-adrenergic-dependent induction of cell spreading, formation of actin stress fibers, and increase in tyrosyI phosphorylation of pp125(FAK) were abolished by pretreatment of the preadipocytes with the C3 exoenzyme, a toxin which impairs p21(rhoA ) activity by ADP-ribosylation, Conversely, C3 exoenzyme had no effect on the alpha(2)-adrenergic-dependent increase in tyrosyl phosphorylation and shift of ERK2 mitogen-activated protein kinase, alpha(2)-Adrenergic stimulation also led to an increase in GDP/GTP exchange on p21(rhoA) as well as to an increase in the amount of p21(rhoA) I m the particulate fraction of alpha 2AF2 preadipocytes. Stable transfection of alpha 2AF2 preadipocytes with the COOH-terminal domain of beta ARK1 (beta ARK-CT) (a blocker of G beta gamma-action), strongly inhibited the cu,adrenergic-dependent increase in tyrosyl phosphorylation and shift of ERK2, without modification of the tyrosyl phosphorylation of pp125(FAK) and spreading of preadipocytes. These results show that alpha(2)-adrenergic-dependent reorganization of actin cytoskeleton requires the activation of p21(rhoA) in,preadipocytes. Conversely to the activation of the p21(ras)/mitogen-activated protein kinase pathway, the ai-adrenergic activation of p21(rhoA)-dependent pathways are independent of the beta gamma-subunits of heterotrimeric G proteins.	Universite Paul Sabatier, Inst Louis Bugnard, INSERM U317, CHU Rangueil, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Saulnier-Blache, JS (corresponding author), Universite Paul Sabatier, Inst Louis Bugnard, INSERM U317, CHU Rangueil, Batiment L3, F-31403 Toulouse 4, France.		Betuing, Sandrine/F-2967-2013; Valet, Philippe/N-7472-2017; Betuing, Sandrine/X-1957-2019; Betuing, Sandrine/X-2179-2018; Saulnier-Blache, Jean Sebastien/X-7729-2018	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARRY ST, 1994, J CELL SCI, V107, P2033; Betuing S, 1996, ENDOCRINOLOGY, V137, P5220, DOI 10.1210/en.137.12.5220; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Flinn HM, 1996, J CELL SCI, V109, P1133; Hein L, 1997, TRENDS CARDIOVAS MED, V7, P137, DOI 10.1016/S1050-1738(97)00034-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JinsiParimoo A, 1997, J BIOL CHEM, V272, P14556, DOI 10.1074/jbc.272.23.14556; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kranenburg O, 1997, J CELL SCI, V110, P2417; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI I, 1994, J CELL SCI, V107, P1853; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1995, METHOD ENZYMOL, V255, P149; SECKINE A, 1989, J BIOL CHEM, V264, P8602; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	33	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15804	15810		10.1074/jbc.273.25.15804	http://dx.doi.org/10.1074/jbc.273.25.15804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624180	hybrid			2022-12-27	WOS:000074284200074
J	Hodge, DR; Dunn, KJ; Pei, GK; Chakrabarty, MK; Heidecker, G; Lautenberger, JA; Samuel, KP				Hodge, DR; Dunn, KJ; Pei, GK; Chakrabarty, MK; Heidecker, G; Lautenberger, JA; Samuel, KP			Binding of c-Raf1 kinase to a conserved acidic sequence within the carboxyl-terminal region of the HIV-1 Nef protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GLUTATHIONE-S-TRANSFERASE; CD4 DOWN-REGULATION; HUMAN T-CELLS; SERINE PHOSPHORYLATION; PHYSICAL INTERACTION; PLASMA-MEMBRANE; GENE-PRODUCT; IN-VITRO; RAS-GTP	Nef is a membrane-associated cytoplasmic phosphoprotein that is well conserved among the different human (HIV-1 and HIV-8) and simian immunodeficiency viruses and has important roles in down-regulating the CD4 receptor and modulating T-cell signaling pathways. The ability to modulate T-cell signaling pathways suggests that Nef may physically interact with T-cell signaling proteins. In order to identify Nef binding proteins and map their site(s) of interaction, we targeted a highly conserved acidic sequence at the carboxyl-terminal region of Nef sharing striking similarity with an acidic sequence at the c-Raf1-binding site within the Ras effector region. Here, we used deletion and site-specific mutagenesis to generate mutant Nef proteins fused to bacterial glutathione S-transferase in in vitro precipitation assays and immunoblot analysis to map the specific interaction between the HIV-1(LAI) Nef and c-Raf1 to a conserved acidic sequence motif containing the core sequence Asp-Asp-X-X-X-Glu (position 174-179). Significantly, we demonstrate that substitution of the nonpolar glycine residue for either or both of the conserved negatively charged aspartic acid residues at positions 174 and 175 in the full-length recombinant Nef protein background completely abrogated binding of c-Raf1 in vitro. In addition, lysates from a permanent CEM T-cell line constitutively expressing the native HIV-1 Nef protein was used to coimmunoprecipitate a stable Nef c-Raf1 complex, suggesting that molecular interactions between Nef and c-Raf1, an important downstream transducer of cell signaling through the c-Raf1-MAP kinase pathway, occur in vivo. This interaction may account for the Nef-induced perturbations of T-cell signaling and activation pathways in vitro and in vivo.	Morgan State Univ, Dept Biol, Baltimore, MD 21251 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Leukocyte Biol, Frederick, MD 21702 USA; Natl Human Genome Res Lab, Lab Genet Dis Res, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Gen Divers, Frederick, MD 21702 USA; Frederick Canc Res & Dev Ctr, SAIC, Frederick, MD 21702 USA; Morgan State Univ, Dept Biol, Baltimore, MD 21239 USA	Morgan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Morgan State University	Samuel, KP (corresponding author), Morgan State Univ, Dept Biol, Spencer Hall,Rm 110,1700 Cold Spring Ln, Baltimore, MD 21251 USA.	ksamuel@moac.morgan.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011606] Funding Source: NIH RePORTER; NCRR NIH HHS [2P20RR011606-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Barnard D, 1995, ONCOGENE, V10, P1283; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; CHOWERS MY, 1995, VIROLOGY, V212, P451, DOI 10.1006/viro.1995.1502; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Iafrate A.J., 1997, EMBO J, V16, P673; KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; Miller Michael D., 1994, Trends in Microbiology, V2, P294, DOI 10.1016/0966-842X(94)90007-8; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NIEDERMAN TMJ, 1993, VIROLOGY, V197, P420, DOI 10.1006/viro.1993.1605; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; POULIN L, 1992, AIDS, V6, P787, DOI 10.1097/00002030-199208000-00003; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P8219, DOI 10.1093/nar/13.22.8219; Richard A, 1997, AIDS, V11, pF1, DOI 10.1097/00002030-199701000-00001; Rossi F, 1996, VIROLOGY, V217, P397, DOI 10.1006/viro.1996.0130; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; SAMUEL KP, 1987, FEBS LETT, V218, P81, DOI 10.1016/0014-5793(87)81023-2; SAMUEL KP, 1991, AIDS RES HUM RETROV, V7, P697, DOI 10.1089/aid.1991.7.697; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TERWILLIGER EF, 1991, P NATL ACAD SCI USA, V88, P10971, DOI 10.1073/pnas.88.23.10971; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; ZWEIG M, 1990, VIROLOGY, V179, P504, DOI 10.1016/0042-6822(90)90325-L	58	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15727	15733		10.1074/jbc.273.25.15727	http://dx.doi.org/10.1074/jbc.273.25.15727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624170	hybrid			2022-12-27	WOS:000074284200064
J	Kumar, A; Middleton, A; Chambers, TC; Mehta, KD				Kumar, A; Middleton, A; Chambers, TC; Mehta, KD			Differential roles of extracellular signal-regulated kinase-1/2 and p38(MAPK) in interleukin-1 beta- and tumor necrosis factor-alpha-induced low density lipoprotein receptor expression in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NERVE GROWTH-FACTOR; MAP KINASE; TRANSDUCTION PATHWAY; GENE-TRANSCRIPTION; INTERFERON-ALPHA; HEAT-SHOCK; CASCADE; PHOSPHORYLATION	The inflammatory cytokines interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF), elevated in inflammatory, malignant, and infectious diseases, induce low density lipoprotein (LDL) receptor transcription in HepG2 cells, and such are induction can account for hypocholesterolemia associated with these states. However, the signaling mechanisms of cytokine-mediated LDL receptor induction are largely unexplored, In the present studies, we examined the potential involvement of different mitogen-activated protein kinase (MAPK) pathways. Northern analysis demonstrated that IL-1 beta or TNF significantly increased LDL receptor transcript in HepG2 cells, whereas expression of another tightly regulated sterol-responsive squalene synthase gene was unaffected. IL-1 beta tread;ment resulted in transient activation of three MAPK cascades, namely p46/54(JNK), p38(MAPK), and ERK-1/2, with maximal activation of 20-, 25-, and 3-fold, respectively, occurring 15-30 min after cytokine addition. PD98059, a specific inhibitor of MAPK kinase activity, inhibited IL-lp-induced LDL receptor expression In contrast, SB202190, a specific inhibitor of p38(MAPK), enhanced IL-1 beta-induced LDL receptor expression, with a concomitant increase in ERK-1/2 activity. Similarly, TNF induced LDL receptor expression also required ERK-1/2 activation. Finally, sterols repressed IL-1 beta induced receptor expression, without affecting ERK-1/2 activation. These results show that IL-IP-or TNF-induced LDL receptor expression requires ERK-1/2 activation, that the p38(MAPK) pathway negatively regulates LDL receptor expression, and that sterols inhibit induction at a point downstream of ERK-1/2 in HepG2 cells.	Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Mehta, KD (corresponding author), Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, 4301 W Markham, Little Rock, AR 72205 USA.	mehtakamald@exchange.uams.edu			NHLBI NIH HHS [HL-51592-04] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1993, ONCOGENE, V8, P2015; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Dhawan P, 1997, NUCLEIC ACIDS RES, V25, P4132, DOI 10.1093/nar/25.20.4132; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DINARELLO CA, 1991, BLOOD, V77, P162; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EVANS RD, 1989, CLIN SCI, V77, P357, DOI 10.1042/cs0770357; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; FOA R, 1992, J CLIN ONCOL, V10, P954, DOI 10.1200/JCO.1992.10.6.954; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRIFFITH RL, 1988, J EXP MED, V168, P1041, DOI 10.1084/jem.168.3.1041; GROVE RI, 1991, J LIPID RES, V32, P1889; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GUAM G, 1995, J BIOL CHEM, V270, P21958; GUY GR, 1991, J BIOL CHEM, V266, P14343; JONASSON L, 1990, BIOCHIM BIOPHYS ACTA, V1053, P43, DOI 10.1016/0167-4889(90)90024-8; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Kumar A, 1997, NEUROSCI LETT, V231, P143, DOI 10.1016/S0304-3940(97)00549-1; KUMAR A, 1997, J LIPID RES, V38, P4220; Kusari AB, 1997, MOL ENDOCRINOL, V11, P1532, DOI 10.1210/me.11.10.1532; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; Mehta KD, 1996, J BIOL CHEM, V271, P33616, DOI 10.1074/jbc.271.52.33616; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Ridley SH, 1997, J IMMUNOL, V158, P3165; RIIKONEN P, 1992, J INFECT DIS, V166, P432, DOI 10.1093/infdis/166.2.432; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SCHECTMAN G, 1992, ARTERIOSCLER THROMB, V12, P1053, DOI 10.1161/01.ATV.12.9.1053; SEGER R, 1992, J BIOL CHEM, V267, P14373; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; STOUDEMIRE JB, 1991, BLOOD, V77, P750; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WILSON DE, 1989, J CLIN ONCOL, V7, P1573, DOI 10.1200/JCO.1989.7.10.1573; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	63	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15742	15748		10.1074/jbc.273.25.15742	http://dx.doi.org/10.1074/jbc.273.25.15742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624172	hybrid			2022-12-27	WOS:000074284200066
J	Chinpaisal, C; Lee, CH; Wei, LN				Chinpaisal, C; Lee, CH; Wei, LN			Mechanisms of the mouse orphan nuclear receptor TR2-11-mediated gene suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X RECEPTOR; TATA-BINDING PROTEIN; MOLECULAR-CLONING; RESPONSE ELEMENT; ACID RECEPTORS; CO-REPRESSOR; BETA-GENE; ACTIVATION; IDENTIFICATION	The mouse orphan nuclear receptor TR2-11 functions as a repressor for reporter genes containing a direct repeat-5 or direct repeat-4 hormone response element. The functional domains responsible for its suppressive activity are defined, including the DNA-binding domain and the ligand-binding domain. The C-terminal 30 amino acid residues can be deleted without compromising its suppressive activity, whereas a deletion for 40 amino acids completely abolishes the suppressive activity and receptor dimerization, and reduces the DNA binding affinity. Point mutation at three conserved leucine residues located on the predicted dimer interface abolishes the suppressive activity, receptor dimerization and its DNA binding property. However, mutation at two consecutive glutamate residues located within the hinge between the last two helices of the ligand-binding domain (helix 10 and helix 11 according to the human retinoid receptor X alpha structure) drastically reduces its DNA binding affinity and abrogates the suppressive activity without compromising its ability to dimerize, indicating that receptor dimerization property can be functionally uncoupled from its suppressive activity. A transferable, active silencing activity is encoded within the DEF segment of the receptor molecule, as evidenced by the suppression of a GAL4 reporter by a chimeric protein containing the DNA-binding domain of GAL4 and the DEF segment of TR2-11, Moreover, the C-terminal 49 amino acid sequence is required for this trans-suppressive activity. It is suggested that TR2-11 functions as a repressor, mediated by mechanisms requiring high affinity DNA binding, receptor dimerization, and active silencing.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	weixx009@maroon.tc.umn.edu			NIDA NIH HHS [DA11190] Funding Source: Medline; NIDDK NIH HHS [DK46866] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BAURGUET W, 1995, NATURE, V375, P377; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang LM, 1997, J BIOL CHEM, V272, P10144; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chinpaisal C, 1997, BIOCHEMISTRY-US, V36, P14088, DOI 10.1021/bi971598z; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Gaemers IC, 1997, ENDOCRINOLOGY, V138, P1544, DOI 10.1210/en.138.4.1544; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Joyeux A, 1997, MOL ENDOCRINOL, V11, P193, DOI 10.1210/me.11.2.193; Lee CH, 1996, MOL REPROD DEV, V44, P305, DOI 10.1002/(SICI)1098-2795(199607)44:3&lt;305::AID-MRD4&gt;3.0.CO;2-Q; Lee CH, 1997, J ENDOCRINOL, V152, P245, DOI 10.1677/joe.0.1520245; LEE CH, 1995, GENOMICS, V30, P46, DOI 10.1006/geno.1995.0007; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; Lee HJ, 1996, J BIOL CHEM, V271, P10405, DOI 10.1074/jbc.271.17.10405; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WU R, 1995, RECOMBINANT DNA METH, V2, P323; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N	39	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18077	18085		10.1074/jbc.273.29.18077	http://dx.doi.org/10.1074/jbc.273.29.18077			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660764	hybrid			2022-12-27	WOS:000074828500019
J	Gesbert, F; Guenzi, C; Bertoglio, J				Gesbert, F; Guenzi, C; Bertoglio, J			A new tyrosine-phosphorylated 97-kDa adaptor protein mediates interleukin-2-induced association of SHP-2 with p85-phosphatidylinositol 3-kinase in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; IL-2 RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; GAMMA-CHAIN; SH2 DOMAINS; BETA-CHAIN; ACTIVATION; BINDING	Interleukin (IL)-2 is a major cytokine that controls differentiation and proliferation of T lymphocytes. In this report we characterize an as yet unidentified 97-kDa protein that is a major tyrosine kinase substrate in IL-2-stimulated cells. pp97 was found to associate with the p85.p110 phosphatidylinositol 3-kinase complex, the Src homology 2 (SH2) domain-containing tyrosine phosphatase SHP-2, and the adaptor molecules CrkL and Grb2. We demonstrate that these interactions are directly mediated through the SH2 domains of CrkL, p85, and SHP-2 and through the SH3 domains of Grb2. pp97 was found to mediate the IL-2-induced interaction between p85 and both a phosphorylated and a non-phosphorylated form of SHP-2. In this study we show that pp97 behaves as a docking protein and associates with at least CrkL, p85, and SHP-2 in the same multimolecular complex. We thus characterized pp97 as a new tyrosine kinase substrate in human T lymphocytes which might play a central role in the regulation of several pathways activated by IL-2.	Fac Pharm Paris 11, INSERM, U461, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bertoglio, J (corresponding author), Fac Pharm Paris 11, INSERM, U461, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	j.bertoglio@cep.u-psud.fr		Gesbert, Franck/0000-0002-5800-8385				Adachi M, 1997, ONCOGENE, V14, P1629, DOI 10.1038/sj.onc.1200981; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORI T, 1987, BLOOD, V70, P1069; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITE MF, 1987, J BIOL CHEM, V262, P9769; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1994, J BIOL CHEM, V269, P5518	53	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18273	18281		10.1074/jbc.273.29.18273	http://dx.doi.org/10.1074/jbc.273.29.18273			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660791	hybrid			2022-12-27	WOS:000074828500046
J	Vassylyev, DG; Tomitori, H; Kashiwagi, K; Morikawa, K; Igarashi, K				Vassylyev, DG; Tomitori, H; Kashiwagi, K; Morikawa, K; Igarashi, K			Crystal structure and mutational analysis of the Escherichia coli putrescine receptor - Structural basis for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; PREFERENTIAL UPTAKE SYSTEM; ORNITHINE-BINDING PROTEIN; D-ASPARTATE RECEPTOR; SALMONELLA-TYPHIMURIUM; POLYAMINE TRANSPORT; ACTIVE-TRANSPORT; HYDROGEN-BONDS; POTD PROTEIN; SPERMIDINE	PotF protein is a periplasmic substrate-binding protein of the putrescine transport system in Escherichia coli. We hare determined the crystal structure of PotF protein in complex with the substrate at 2.3-Angstrom resolution, The PotF molecule has dimensions of 54 x 42 x 30 A and consists of two similar globular domains. The PotF structure is reminiscent of other periplasmic receptors with a highest structural homology to another polyamine-binding protein, PotD. Putrescine is tightly bound in the deep cleft between the two domains of PotF through 12 hydrogen bonds and 36 van der Waals interactions. The comparison of the PotF structure with that of PotD provides the insight into the differences in the specificity between the two proteins. The PotF structure, in combination with the mutational analysis, revealed the residues crucial for putrescine binding (Trp-37, Ser-85, Glu-185, Trp-244, Asp-247, and Asp-278) and the importance of water molecules for putrescine recognition.	Biomol Engn Res Inst, Osaka 5650874, Japan; Chiba Univ, Fac Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	Chiba University	Vassylyev, DG (corresponding author), Matsushita Elect Ind Co Ltd, Int Inst Adv Res, 3-4 Hikaridai, Kyoto 6190222, Japan.		Vassylyev, Dmitry/A-9005-2008	Igarashi, Kazuei/0000-0003-3751-3187				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1992, XPLOR VERSION 3 1 MA; Chao J, 1997, MOL PHARMACOL, V51, P861, DOI 10.1124/mol.51.5.861; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; Hsiao CD, 1996, J MOL BIOL, V262, P225, DOI 10.1006/jmbi.1996.0509; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG CH, 1991, J BIOL CHEM, V266, P23893; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; Kashiwagi K, 1997, J BIOL CHEM, V272, P6318, DOI 10.1074/jbc.272.10.6318; Kashiwagi K, 1996, J BIOL CHEM, V271, P12205, DOI 10.1074/jbc.271.21.12205; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; Kashiwagi K, 1996, MOL PHARMACOL, V49, P1131; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Maniatis T., 1982, MOL CLONING LAB MANU, P250; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Nickitenko AV, 1995, BIOCHEMISTRY-US, V34, P16585, DOI 10.1021/bi00051a006; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PEGG AE, 1988, CANCER RES, V48, P759; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO, P10; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sugiyama S, 1996, PROTEIN SCI, V5, P1984, DOI 10.1002/pro.5560051004; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; Vassylyev DG, 1998, ACTA CRYSTALLOGR D, V54, P132, DOI 10.1107/S0907444997009049; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Williams K, 1995, MOL PHARMACOL, V48, P1087; YAMAGUCHI K, 1985, MOL GEN GENET, V200, P362, DOI 10.1007/BF00425718; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	56	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17604	17609		10.1074/jbc.273.28.17604	http://dx.doi.org/10.1074/jbc.273.28.17604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651355	hybrid, Green Submitted			2022-12-27	WOS:000074816100048
J	Virolle, T; Monthouel, MN; Djabari, Z; Ortonne, JP; Meneguzzi, G; Aberdam, D				Virolle, T; Monthouel, MN; Djabari, Z; Ortonne, JP; Meneguzzi, G; Aberdam, D			Three activator protein-1-binding sites bound by the Fra-2 center dot JunD complex cooperate for the regulation of murine laminin alpha 3A (lama3A) promoter activity by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; HOMOZYGOUS NONSENSE MUTATION; PLASMINOGEN-ACTIVATOR; GENE-EXPRESSION; CHAIN GENE; HUMAN KERATINOCYTES; BASEMENT-MEMBRANES; AP1 SITES; BINDING; ADHESION	Several lines of evidence suggest a role for laminin 5 in skin wound healing. We report here that transforming growth factor-beta (TGF-beta), which elicits various responses during cutaneous healing, stimulates transcription of the mouse laminin alpha 3A (lama3A) gene. To identify the TGF-beta-responsive elements (TGF beta-REs) on the lama3A promoter, we have generated a series of 5'-deletions of the promoter upstream of the beta-galactosidase reporter gene. Transient cell transfection assays using mouse PAM212 keratinocytes revealed that TGF beta-REs lie between nucleotides -297 and -54 relative to the transcription start site. Insertion of the TGF beta-RE in front of the unresponsive minimal SV40 promoter conferred TGF-beta inducibility. Computer analysis of the promoter sequence identified three canonical activator protein-1 (AP-1) sites located at nucleotides -277 (AP-1A), -125 (AP-1B), and -69 (AP-1C). Site-directed mutagenesis of either the AP-1A or AP-1C site did not drastically alter the basal activity of the lama3A promoter, but reduced TGF-beta responsiveness by 50%. Simultaneous mutation of these two AP-1 sites resulted in a 65% decline in the response to TGF-beta, suggesting a cooperative contribution of each site to the overall promoter activity. In contrast, mutation of the AP-1B site markedly reduced the basal activity of the lama3A promoter, indicating that this AP-1 site is essential for gene expression. Mobility shift assays demonstrated specific binding of Fra-2 and JunD to the AP-1 sites, suggesting for the first time a possible regulatory function for the Fra-2 JunD AP-1 complex in a basal keratinocyte-specific gene.	Fac Med Nice, UFR Med, INSERM, U385, F-06107 Nice 2, France; Hop Archet, Serv Dermatol, F-06002 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Aberdam, D (corresponding author), Fac Med Nice, UFR Med, INSERM, U385, Av Valombrose, F-06107 Nice 2, France.		Aberdam, Daniel/G-3299-2013; Virolle, Thierry/E-5838-2016	Aberdam, Daniel/0000-0002-4019-5418; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Bahadoran P, 1997, BRIT J DERMATOL, V136, P35, DOI 10.1111/j.1365-2133.1997.tb08743.x; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Kagami S, 1996, EXP CELL RES, V229, P1, DOI 10.1006/excr.1996.0336; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KESKIOJA J, 1992, J INVEST DERMATOL, V99, P193, DOI 10.1111/1523-1747.ep12616826; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; McGrath JA, 1996, J INVEST DERMATOL, V106, P781, DOI 10.1111/1523-1747.ep12346349; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NAGLE RB, 1995, AM J PATHOL, V146, P1498; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; PYKE C, 1995, CANCER RES, V55, P4132; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rutberg SE, 1996, ONCOGENE, V13, P167; RYAN MC, 1994, J BIOL CHEM, V269, P22779; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; VAILLY J, 1995, J INVEST DERMATOL, V104, P462, DOI 10.1111/1523-1747.ep12605898; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; VIDAL F, 1995, GENOMICS, V30, P273, DOI 10.1006/geno.1995.9877; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WIKNER NE, 1990, J INVEST DERMATOL, V95, P607, DOI 10.1111/1523-1747.ep12505603; ZWAIN IH, 1994, MOL CELL NEUROSCI, V5, P229, DOI 10.1006/mcne.1994.1027	49	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17318	17325		10.1074/jbc.273.28.17318	http://dx.doi.org/10.1074/jbc.273.28.17318			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651314	hybrid			2022-12-27	WOS:000074816100007
J	Krapivinsky, G; Kennedy, ME; Nemec, J; Medina, I; Krapivinsky, L; Clapham, DE				Krapivinsky, G; Kennedy, ME; Nemec, J; Medina, I; Krapivinsky, L; Clapham, DE			G(beta gamma) binding to GIRK4 subunit is critical for G protein-gated K+ channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; POTASSIUM CHANNEL; I-KACH; EXPRESSION; CLONING; BRAIN; IDENTIFICATION; CIR	The cardiac G protein-gated K+ channel, I-KACh, is directly activated by G protein beta gamma subunits (G(beta gamma)). I-KACh is composed of two inward rectifier K+ channel subunits, GIRK1 and GIRK4. G(beta gamma) binds to both GIRK1 and GIRK4 subunits of the heteromultimeric I-KACh. Here we delineate the G(beta gamma) binding regions of I-KACh by studying direct G(beta gamma) interaction with native purified I-KACh, competition of this interaction with peptides derived from GIRK1 or GIRK4 amino acid sequences, mutational analysis of regions implicated in G(beta gamma) binding, and functional expression of mutated subunits in mammalian cells. Only two GIRK4 peptides, containing amino acids 209-225 or 226-245, effectively competed for G beta gamma binding. A single point mutation introduced into GIRK4 at position 216 (C216T) dramatically reduced the potency of the peptide in inhibiting G(beta gamma) binding and G(beta gamma) activation of expressed GIRK1/GIRK4(C216T) channels. Conversion of 5 amino acids in GIRK4 (226-245) to the corresponding amino acids found in the G protein-insensitive IRK1 channel, completely abolished peptide inhibition of G(beta gamma) binding to I-KACh and G(beta gamma) activation of GIRK1/mutant GIRK4 channels. We conclude from this data that G(beta gamma) binding to GIRK4 is critical for I-KACh activation.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Pediat Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Pediat Childrens Hosp, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/S-1123-2019; Medina, Igor/O-5532-2016; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Medina, Igor/0000-0001-6839-5414; 	PHS HHS [54873] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; HARTZELL HC, 1977, J PHYSIOL-LONDON, V271, P817, DOI 10.1113/jphysiol.1977.sp012027; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; Liao YJ, 1996, J NEUROSCI, V16, P7137; Loewi O, 1921, PFLUG ARCH GES PHYS, V189, P239, DOI 10.1007/BF01738910; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TUCKER SJ, 1996, AM J PHYSIOL, V40, P379; UEDA N, 1994, J BIOL CHEM, V269, P4388; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Woodward R, 1997, J BIOL CHEM, V272, P10823	34	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16946	16952		10.1074/jbc.273.27.16946	http://dx.doi.org/10.1074/jbc.273.27.16946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642257	hybrid			2022-12-27	WOS:000074545200047
J	Liu, R; Takayama, S; Zheng, Y; Froesch, B; Chen, GQ; Zhang, X; Reed, JC; Zhang, XK				Liu, R; Takayama, S; Zheng, Y; Froesch, B; Chen, GQ; Zhang, X; Reed, JC; Zhang, XK			Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACTIVATION FUNCTION AF-2; NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; CO-REPRESSOR; X RECEPTORS; PROTEIN; DEATH; MEDIATOR	BAG-1 (also known as RAP46) is an anti-apoptotic protein, which has been shown previously to interact with a number of nuclear hormone receptors, including receptors for glucocorticoid, estrogen, and thyroid hormone. We show here that BAG-I also interacts with retinoic acid receptor (RAR). Gel retardation assays demonstrated that in vitro translated BAG-1 protein could effectively inhibit the binding of RAR but not retinoid X receptor (RXR) to a number of retinoic acid (RA) response elements (RAREs), A glutathione S-transferase-BAG-1 fusion protein also specifically bound RAR but not RXR. Interaction of BAG-I and RAR could also be demonstrated by yeast two-hybrid assays. In transient transfection assays, co-transfection of BAG-1 expression plasmid inhibited the transactivation activity of RAR/RXR heterodimers but not RXR/RXR homodimers. When stably expressed in breast cancer cell lines, BAG-1 inhibited binding of RAR/RXR heterodimer to a number of RAREs and suppressed RA-induced growth inhibition and apoptosis. In addition, RA-induced suppression of Bcl-2 expression was abrogated by overexpression of BAG-1. These results demonstrate that BAG-1 can regulate retinoid activities through its interaction with RAR and suggest that elevated levels of BAG-I protein could potentially contribute to retinoid resistance in cancer cells.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Zhang, XK (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA067329, R01CA060988] Funding Source: NIH RePORTER; NCI NIH HHS [CA67329, CA60988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; Elstner E, 1996, CANCER RES, V56, P3570; Fanjul AN, 1996, CANCER RES, V56, P1571; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Gudas Lorraine J., 1994, P443; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1734; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong Waun Ki, 1994, P597; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOCHHAR DM, 1993, PROG CLIN BIOL RES, V383, P815; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Li Y, 1998, INT J CANCER, V75, P88, DOI 10.1002/(SICI)1097-0215(19980105)75:1<88::AID-IJC14>3.0.CO;2-9; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAGY L, 1995, MOL CELL BIOL, V15, P3540; ONATE SA, 1995, SCIENCE, V270, P1354; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PONZONI M, 1995, CANCER RES, V55, P853; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1998, IN PRESS CANC RES; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11456; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	105	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16985	16992		10.1074/jbc.273.27.16985	http://dx.doi.org/10.1074/jbc.273.27.16985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642262	hybrid			2022-12-27	WOS:000074545200052
J	Snyers, L; Umlauf, E; Prohaska, R				Snyers, L; Umlauf, E; Prohaska, R			Oligomeric nature of the integral membrane protein stomatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAND 7.2B; ORGANIZATION; CAVEOLAE; GENE; ERYTHROCYTES; EXPRESSION	The 32-kDa integral membrane protein stomatin (protein 7.2b) is not only an important component of the red cell membrane but can also be found in abundance in different tissues and cell lines. The protein is thought to be anchored to the membrane by a hydrophobic domain while both N and C termini are exposed to the cytoplasm. We have previously shown in the human cell line UAC that stomatin concentrates preferentially in plasma membrane folds and protrusions. There is also evidence that stomatin is linked to the cortical actin cytoskeleton, suggesting a role in cortical morphogenesis of the cell. In this study, we demonstrate that the fundamental structure of stomatin is oligomeric, Whereas interaction of stomatin with itself was suggested by cross-linking experiments, we show by density gradient centrifugation analysis that soluble homo-oligomeric complexes of this protein are present in Triton X-100 extracts of UAC cells. We also show the existence of these oligomers by co-immunoprecipitation of the endogenous stomatin and a recombinantly expressed myc-tagged stomatin, using an anti-myc antibody. The data indicate that these complexes comprise between 9 and 12 monomers of stomatin, Two C-terminally truncated forms of stomatin do not incorporate into these oligomers, suggesting an involvement of the C terminus in the homo-oligomeric interaction.	Univ Vienna, Inst Biochem, Bioctr, A-1030 Vienna, Austria	University of Vienna	Prohaska, R (corresponding author), Univ Vienna, Inst Biochem, Bioctr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	prohaska@bch.univie.ac.at						ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Barnes TM, 1996, J NEUROCHEM, V67, P46; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; Desneves J, 1996, BIOCHEM BIOPH RES CO, V224, P108, DOI 10.1006/bbrc.1996.0992; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; GALLAGHER PG, 1995, J BIOL CHEM, V270, P26358, DOI 10.1074/jbc.270.44.26358; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Snyers L, 1997, EUR J CELL BIOL, V73, P281; SNYERS L, 1994, EUR J BIOCHEM, V223, P411, DOI 10.1111/j.1432-1033.1994.tb19008.x; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Unfried I, 1995, GENOMICS, V30, P521, DOI 10.1006/geno.1995.1273; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6	25	111	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17221	17226		10.1074/jbc.273.27.17221	http://dx.doi.org/10.1074/jbc.273.27.17221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642292	hybrid			2022-12-27	WOS:000074545200082
J	Ammanamanchi, S; Kim, SJ; Sun, LZ; Brattain, MG				Ammanamanchi, S; Kim, SJ; Sun, LZ; Brattain, MG			Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2 '-deoxycytidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; TGF-BETA; MICROSATELLITE INSTABILITY; DNA METHYLATION; PROTEIN-KINASE; GENE; MECHANISM; BINDING; TRANSCRIPTION; INHIBITION	Previous studies suggest that estrogen receptor-positive (ER+) breast cancer cells acquire resistance to transforming growth factor-beta (`TGF-beta) because of reduced expression levels of TGF-beta receptor type II (RII). We now report that treatment of ER+ breast cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-2'-dC) leads to accumulation of RII transcript and protein in three different cell lines. RII induction restored TGF-beta response in MCF-7L breast cancer cells as indicated by the enhanced activity of a TGF-beta responsive promoter-reporter construct (p3TP-Lux). A transiently transfected RII promoter-reporter element (RII-chloramphenicol acetyltransferase) showed an increase in activity in the 5-aza-2'-dC-treated MCF-7L cells compared with untreated cells, suggesting the activation of a transactivator of RII transcription. Using electrophoretic mobility shift assays, the enhanced binding: of proteins from 5-aza-2'-dC-treated MCF-7L nuclear extracts to radiolabeled Sp1 oligonucleotides was demonstrated. An RII promoter-chloramphenicol acetyltransferase construct containing a mutation in the Sp1 site was not expressed in the 5-aza-2'-dC-treated MCF-7L cells, further demonstrating that induction of Sp1 activity by 5-aza-2'-dC in the MCF-7L cells was critical to RII expression. Northern analysis indicated that 5-aza-2'-dC treatment did not affect the Sp1 transcript levels. Western blot analysis revealed an increase of Sp1 protein in the 5-aza-2'-dC-treated MCF-7L cells, but there was no change in the c-Jun levels. Studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5-aza-2'-dC-treated MCF-7L extracts compared with untreated control extracts. These results indicate that the transcriptional repression of RII in the ER+ breast cancer cells is caused by suboptimal activity of Sp1, whereas treatment with 5-aza-2'-dC stabilizes the protein thus increasing steady-state Sp1 levels and thereby leads to enhanced RII transcription and subsequent restoration of TGF-beta sensitivity.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; NCI, Chemoprevent Lab, NIH, Bethesda, MD 20892 USA; Univ Kentucky, Coll Med, Dept Pharmacol, Lexington, KY 40536 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Kentucky	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA072001, R37CA038173, R01CA038173, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54807, CA 72001, CA 38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, CANCER RES, V48, P3898; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones PA, 1996, CANCER RES, V56, P2463; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim DH, 1997, J BIOL CHEM, V272, P688; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	39	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16527	16534		10.1074/jbc.273.26.16527	http://dx.doi.org/10.1074/jbc.273.26.16527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632722	hybrid			2022-12-27	WOS:000074436600093
J	Holloway, MP; Bram, RJ				Holloway, MP; Bram, RJ			Co-localization of calcium-modulating cyclophilin ligand with intracellular calcium pools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOMA CELLS; INTEGRAL MEMBRANE-PROTEINS; INTERNAL CA2+ RELEASE; BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; TRITON X-114; CALRETICULIN; INFLUX; IDENTIFICATION; THAPSIGARGIN	The calcium-modulating cyclophilin ligand (CAML) protein activates Ca2+ influx signaling when overexpressed in Jurkat T cells. Although CAML appears to directly participate in Ca2+-dependent signaling initiated by the transmembrane activator and CAML interactor cell surface receptor, its mechanism of action is unknown. To address this issue, we have determined its membrane topology, subcellular localization, and ability to mobilize intracellular Ca2+ pools. Fractionation of cell extracts on discontinuous sucrose gradients and indirect immunofluorescence indicate that CAML colocalizes with sarcoplasmic/endoplasmic reticulum calcium/ATPase-2 and calreticulin at membrane-bound cytosolic vesicles. Limited trypsin digests indicate that the hydrophilic NH2-terminal domain of CAML is directed toward the cytoplasm. Functionally, CAML overexpression was shown to deplete thapsigargin-sensitive intracellular Ca2+ pools. These data suggest that CAML may initiate Ca2+ signaling through activation of a capacitative Ca2+ influx pathway.	St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Dept Pediat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Bram, RJ (corresponding author), St Jude Childrens Res Hosp, Dept Expt Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	richard.bram@stjude.org			NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIAN JH, 1991, J BIOL CHEM, V266, P8801; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BOURGUIGNON LYW, 1986, J CELL PHYSIOL, V127, P146, DOI 10.1002/jcp.1041270118; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Bram RJ, 1996, GENE, V174, P307, DOI 10.1016/0378-1119(96)00081-9; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Sambrook J., 2002, MOL CLONING LAB MANU; Schwientek T, 1996, J BIOL CHEM, V271, P3398; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138	32	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16346	16350		10.1074/jbc.273.26.16346	http://dx.doi.org/10.1074/jbc.273.26.16346			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632697	hybrid			2022-12-27	WOS:000074436600068
J	Taylor, SV; Kelleher, NL; Kinsland, C; Chiu, HJ; Costello, CK; Backstrom, AD; McLafferty, FW; Begley, TP				Taylor, SV; Kelleher, NL; Kinsland, C; Chiu, HJ; Costello, CK; Backstrom, AD; McLafferty, FW; Begley, TP			Thiamin biosynthesis in Escherichia coli - Identification of this thiocarboxylate as the immediate sulfur donor in the thiazole formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; BIOTIN SYNTHASE; SALMONELLA-TYPHIMURIUM; PYRIMIDINE MOIETY; CONVERTING FACTOR; GENE-PRODUCT; LIPOIC ACID; ORIGIN; ATOM; MOLYBDOPTERIN	ThiFSGH and ThiI are required for the biosynthesis of the thiazole moiety of thiamin in Escherichia coli. The overproduction, purification, and characterization of ThiFS and the identification of two of the early steps in the biosynthesis of the thiazole moiety of thiamin are described here. ThiS isolated from E. coli thiI(+) is post-translationally modified by converting the carboxylic acid group of the carboxyl-terminal glycine into a thiocarboxylate. The thiI gene plays an essential role in the formation of the thiocarboxylate because ThiS isolated from a thiI(-) strain does not contain this modification. ThiF catalyzes the adenylation by ATP of the carboxyl-terminal glycine of ThiS. This reaction is likely to be involved in the activation of ThiS for sulfur transfer from cysteine or from a cysteine-derived sulfur donor.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA	Cornell University	Begley, TP (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Begley, Tadhg/B-5801-2015		NIDDK NIH HHS [DK44083] Funding Source: Medline; NIGMS NIH HHS [GM16609] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044083, R01DK044083, R56DK044083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016609, R37GM016609] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; Begley TP, 1996, NAT PROD REP, V13, P177, DOI 10.1039/np9961300177; BELLION E, 1976, BIOCHIM BIOPHYS ACTA, V437, P229, DOI 10.1016/0304-4165(76)90364-0; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; DAVID S, 1982, J CHEM SOC PERK T, V1, P2131; DEMOLL E, 1985, BIOCHEM BIOPH RES CO, V132, P217, DOI 10.1016/0006-291X(85)91010-1; ESTRAMAREIX B, 1972, BIOCHIM BIOPHYS ACTA, V273, P275, DOI 10.1016/0304-4165(72)90217-6; ESTRAMAREIX B, 1986, BIOCHEM BIOPH RES CO, V134, P1136, DOI 10.1016/0006-291X(86)90369-4; Estramareix B, 1996, NEW J CHEM, V20, P607; ESTRAMAREIX B, 1990, BIOCHIM BIOPHYS ACTA, V1035, P154, DOI 10.1016/0304-4165(90)90110-I; FLORENTIN D, 1994, CR ACAD SCI III-VIE, V317, P485; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; HAYDEN MA, 1992, J BIOL CHEM, V267, P9512; Himmeldirk K, 1998, J AM CHEM SOC, V120, P3581, DOI 10.1021/ja973835r; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSETT MN, 1972, J BIOL CHEM, V247, P1458; MARSHALL AG, 1985, J AM CHEM SOC, V107, P7893, DOI 10.1021/ja00312a015; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Miller J. H., 1972, EXPT MOL GENETICS, P433; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; REED KE, 1993, J BACTERIOL, V175, P1325, DOI 10.1128/JB.175.5.1325-1336.1993; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; RYALS J, 1982, J BACTERIOL, V151, P899, DOI 10.1128/JB.151.2.899-904.1982; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; STEWART V, 1988, J BACTERIOL, V170, P1589, DOI 10.1128/jb.170.4.1589-1597.1988; TAZUYA K, 1987, BIOCHIM BIOPHYS ACTA, V924, P210, DOI 10.1016/0304-4165(87)90089-4; TAZUYA K, 1987, BIOCHEM INT, V14, P769; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Webb E, 1997, J BACTERIOL, V179, P4399, DOI 10.1128/jb.179.13.4399-4402.1997; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WHITE RH, 1978, BIOCHIM BIOPHYS ACTA, V542, P340, DOI 10.1016/0304-4165(78)90029-6; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; [No title captured]	40	134	145	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16555	16560		10.1074/jbc.273.26.16555	http://dx.doi.org/10.1074/jbc.273.26.16555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632726	hybrid			2022-12-27	WOS:000074436600097
J	Hagg, P; Rehn, M; Huhtala, P; Vaisanen, T; Tamminen, M; Pihlajaniemi, T				Hagg, P; Rehn, M; Huhtala, P; Vaisanen, T; Tamminen, M; Pihlajaniemi, T			Type XIII collagen is identified as a plasma membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; ALPHA-1 CHAIN; EXPRESSION; GENE; TRANSCRIPTS; DOMAINS; COMPLEX; BINDING; CELLS; HEMIDESMOSOME	The complete primary structure of the mouse type XIII collagen chain was determined by cDNA cloning. Comparison of the mouse amino acid sequences with the previously determined human sequences revealed a high identity of 90%. Surprisingly, the mouse cDNAs extended further in the 5' direction than the previously identified human clones. The 5' sequences contained a new in-frame ATG codon for translation initiation which resulted in elongation of the N-terminal noncollagenous domain by 81 residues. These N-terminal sequences lack a typical signal sequence but include a highly hydrophobic segment that clearly fulfills the criteria for a transmembrane domain. The sequence data thus unexpectedly suggested that type XIII collagen may be located on the plasma membrane, with a short cytosolic N-terminal portion and a long collagenous extracellular portion. These sequence data prompted us to generate antipeptide antibodies against type XIII collagen in order to study the protein and its subcellular location. Western blotting of human tumor HT-1080 cell extract revealed bands of over 180 kDa. These appeared to represent disulfide-bonded multimeric polypeptide forms that resolved upon reduction into 85-95-kDa bands that are likely to represent a mixture of splice forms of monomelic type XIII collagen chains. These chains were shown to contain the predicted N-terminal extension and thus also the putative transmembrane segment. Immunoprecipitation of biotinylated type XIII collagen from surface-labeled HT-1080 cells, subcellular fractionation, and immunofluorescence staining were used to demonstrate that type XIII collagen molecules are indeed located in the plasma membranes of these cells.	Oulu Univ, Dept Biochem Med, FIN-90220 Oulu, Finland; Oulu Univ, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Oulu Univ, Dept Internal Med, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Oulu Univ, Dept Biochem Med, Kajaanintie 52A, FIN-90220 Oulu, Finland.			Pihlajaniemi, Taina/0000-0002-1664-9045				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLNER G, 1966, J CELL BIOL, V30, P97, DOI 10.1083/jcb.30.1.97; DOI T, 1993, J BIOL CHEM, V268, P2126; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAHAM JM, 1993, BIOMEMBRANE PROTOCOL; Harlow E., 1988, ANTIBODIES LAB MANUA; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; KENELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; MERION M, 1983, J CELL BIOL, V96, P644, DOI 10.1083/jcb.96.3.644; MORRISON LH, 1988, J CLIN INVEST, V81, P2023, DOI 10.1172/JCI113554; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; PIHALJANIEMI T, 1995, PROG NUCL ACID RES M, V50, P225; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PRPIC V, 1984, J BIOL CHEM, V259, P1382; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; TIKKA L, 1991, J BIOL CHEM, V266, P17713; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Wharton DC., 1967, METHOD ENZYMOL, P245	42	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15590	15597		10.1074/jbc.273.25.15590	http://dx.doi.org/10.1074/jbc.273.25.15590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624150	hybrid			2022-12-27	WOS:000074284200044
J	Gilmore, R; Coffey, MC; Lee, PWK				Gilmore, R; Coffey, MC; Lee, PWK			Active participation of Hsp90 in the biogenesis of the trimeric reovirus cell attachment protein sigma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTERONE-RECEPTOR COMPLEXES; HEPTAD REPEAT REGION; GLUCOCORTICOID RECEPTOR; CONFORMATIONAL-CHANGES; RETICULOCYTE LYSATE; BINDING; KINASE; PROTEIN-SIGMA-1; HETEROCOMPLEX; DOMAINS	The reovirus cell attachment protein, sigma 1, is a lollipop-shaped homotrimer with an N-terminal fibrous tail and a C-terminal globular head. Biogenesis of this protein involves two trimerization events: N-terminal trimerization, which occurs cotranslationally and is Hsp70/ATP-independent, and C-terminal trimerization, which occurs posttranslationally and is Hsp70/ATP-dependent. To determine if Hsp90 also plays a role in sigma 1 biogenesis, we analyzed sigma 1 synthesized in rabbit reticulocyte lysate. Coprecipitation experiments using anti-Hsp90 antibodies revealed that Hsp90 was associated with immature sigma 1 trimers (hydra-like intermediates with assembled N-termini and unassembled C termini) but not with mature trimers, The use of truncated sigma 1 further demonstrated that only the C-terminal half of sigma 1 associated with Hsp90. In the presence of the Hsp90 binding drug geldanamycin, N-terminal trimerization proceeded normally, but C-terminal trimerization was blocked. Geldanamycin did not inhibit the association of Hsp90 with sigma 1 but prevented the subsequent release of Hsp90 from the immature al complex. We also examined the status of p23, an Hsp90-associated co-chaperone. Like Hsp90, p23 only associated with immature sigma 1 trimers, and this association was mapped to the C-terminal half of sigma 1. However, unlike Hsp90, p23 was released from the sigma 1 complex upon the addition of geldanamycin. These results highlight an all-or-none concept of chaperone involvement in different oligomerization domains within a single protein and suggest a possible common usage of chaperones in the regulation of general protein folding and of steroid receptor activation.	Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada.							ALIQUE R, 1994, EMBO J, V13, P6099; BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Chavany C, 1996, J BIOL CHEM, V271, P4974; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; DUNCAN R, 1994, VIROLOGY, V203, P149, DOI 10.1006/viro.1994.1465; FERNANDES J, 1994, J BIOL CHEM, V269, P17043; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FREEMAN BC, 1996, SCIENCE, V274, P17188; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PWK, 1998, CURR TOP MICROBIOL, V233, P137; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; Leone G, 1996, J BIOL CHEM, V271, P8466, DOI 10.1074/jbc.271.14.8466; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; PRATT WB, 1996, STRESS INDUCIBLE CEL, P79; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; Uma S, 1997, J BIOL CHEM, V272, P11648; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Xu ZY, 1997, EUR J BIOCHEM, V246, P461, DOI 10.1111/j.1432-1033.1997.t01-1-00461.x	52	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15227	15233		10.1074/jbc.273.24.15227	http://dx.doi.org/10.1074/jbc.273.24.15227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614137	hybrid			2022-12-27	WOS:000074160400079
J	Adamski, FM; Zhu, MY; Bahiraei, F; Shieh, BH				Adamski, FM; Zhu, MY; Bahiraei, F; Shieh, BH			Interaction of eye protein kinase C and INAD in Drosophila - Localization of binding domains and electrophysiological characterization of a loss of association in transgenic flies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVERTEBRATE PHOTORECEPTORS; TRANSDUCTION; GENE; MECHANISMS; RECOVERY; TRP	Drosophila eye-specific protein kinase C (eye-PKC) is involved in light adaptation and deactivation. eye-PKC, NORPA (phospholipase CP), and transient-receptor-potential (TRP) (calcium channel) are integral components of a signal transduction complex organized by INAD, a protein containing five PDZ domains. We previously demonstrated the direct association between the third PDZ domain of INAD with TRP in addition to the carboxyl-terminal half of INAD with the last three residues of NORPA. In this work, the molecular interaction between eye-PKC and INAD is defined via the yeast two-hybrid and ligand overlay assays, We show that the second PDZ domain of INAD interacts with the last three residues in the carboxyl-terminal tail of eye-PKC, Thr-Ile-Ile. The association between eye PKC and INAD is disrupted by an amino acid substitution (Ile-700 to Asp) at the final residue of eye-PKC. In flies lacking endogenous eye-PKC (inaC(p215)), normal visual physiology is restored upon expression of wild-type eye-PKC, whereas the eye-PKCI700D mutant is completely inactive. Flies homozygous for inaC(p209) and InaD(p215), a mutation that causes a loss of the INAD-TRP association, were generated. These double mutants display a more severe response inactivation than either of the single mutants. Based on these findings, we conclude that the in vivo activity of eye-PKC depends on its association with INAD and that the sensitivity of photoreceptors is cooperatively regulated by the presence of both eye-PKC and TRP in the signaling complex.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Shieh, BH (corresponding author), Vanderbilt Univ, Dept Pharmacol, 402 Med Res Bldg 1, Nashville, TN 37232 USA.	shiehb@ctrvax.vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY009743] Funding Source: NIH RePORTER; NEI NIH HHS [EY09743] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; COSENS D, 1972, J INSECT PHYSIOL, V18, P627, DOI 10.1016/0022-1910(72)90190-4; DEER JLR, 1995, J BIOL CHEM, V270, P12623, DOI 10.1074/jbc.270.21.12623; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO, V33; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HILLMAN P, 1983, PHYSIOL REV, V63, P668, DOI 10.1152/physrev.1983.63.2.668; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Thummel CS, 1992, DROS INF SERV, V71, P150; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	31	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17713	17719		10.1074/jbc.273.28.17713	http://dx.doi.org/10.1074/jbc.273.28.17713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651370	Green Submitted, hybrid			2022-12-27	WOS:000074816100063
J	Baxter, BK; Smerdon, MJ				Baxter, BK; Smerdon, MJ			Nucleosome unfolding during DNA repair in normal and xeroderma pigmentosum (Group C) human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-C; TRANSCRIPTIONALLY ACTIVE CHROMATIN; EXCISION-REPAIR; HUMAN-FIBROBLASTS; AFFINITY-CHROMATOGRAPHY; REARRANGEMENT INVITRO; STRUCTURAL-CHANGES; PYRIMIDINE DIMERS; YEAST; PROTEIN	The fate of nucleosomes during nucleotide excision repair is unclear. We have used organomercurial chromatography to capture accessible thiol groups of proteins at (or near) nascent repair sites in normal and xeroderma pigmentosum (group C) human cells. The reactive groups include cysteine 110 of histone H3, which is exposed in unfolded nucleosomes. Immediately after UV irradiation and a short pulse labeling of repair patches, intact nuclei were digested with restriction enzymes to release similar to 18% of the chromatin into soluble fragments, which are enriched (similar to 4-fold) in a constitutively transcribed gene. Upon organomercurial affinity fractionation, similar to 1.8% of the soluble chromatin remains bound in high salt (0.5 M NaCl) and is released with dithiothreitol. In normal cell chromatin, this fraction is enriched in nascent repair patches (1.5-1.8 fold) over the unbound fraction. This enrichment decreases following short chase periods with a time course similar to the loss of enhanced nuclease sensitivity of these regions (t 1/2 approximate to 30 min). Much less enrichment of nascent repair patches is observed in the thiol-reactive fraction from XPC cells, which repair primarily the transcribed strand of active genes. These results suggest that transient nucleosome unfolding occurs during nucleotide excision repair in normal human cells, and this unfolding may require the XPC protein.	Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Dept Biochem & Biophys, POB 644660, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002614, R01ES002614, F32ES005699] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614, ES05699] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ALLFREY VG, 1991, METHOD CELL BIOL, V35, P315; BASSETJONES DP, 1996, NUCLEIC ACIDS RES, V24, P321; BOFFA LC, 1992, MOL CARCINOGEN, V5, P174, DOI 10.1002/mc.2940050303; CHEN TA, 1991, J BIOL CHEM, V266, P6489; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P1118; CHENCLELAND TA, 1993, J BIOL CHEM, V268, P23409; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; ELGIN SCR, 1995, CHROMATIN STRUCTURE; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; FRITZ LK, 1994, THESIS WASHINGTON ST; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GALE JM, 1988, BIOCHEMISTRY-US, V27, P949; HARLESS J, 1987, MUTAT RES, V183, P177, DOI 10.1016/0167-8817(87)90060-5; HUIJZER JC, 1992, BIOCHEMISTRY-US, V31, P5077, DOI 10.1021/bi00136a021; HUNTING DJ, 1985, BIOCHEMISTRY-US, V24, P3219, DOI 10.1021/bi00334a022; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEWIS B, 1997, GENES, V6, P650; LEYS EJ, 1981, MOL CELL BIOL, V1, P961, DOI 10.1128/MCB.1.11.961; LIEBERMAN MW, 1979, ENV CARCINOGENESIS, P345; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; NISSEN KA, 1986, J BIOL CHEM, V261, P8585; PARRISH DD, 1992, MUTAT RES, V273, P157, DOI 10.1016/0921-8777(92)90077-G; PARRISH DD, 1990, MUTAT RES, V235, P65, DOI 10.1016/0921-8777(90)90059-E; PARRISH DD, 1992, BIOCHEM BIOPH RES CO, V189, P782, DOI 10.1016/0006-291X(92)92270-8; RAMANATHAN B, 1989, J BIOL CHEM, V264, P11026; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; SMERDON MJ, 1979, BIOCHEMISTRY-US, V18, P3732, DOI 10.1021/bi00584a014; SMERDON MJ, 1986, J BIOL CHEM, V261, P244; SMERDON MJ, 1978, P NATL ACAD SCI USA, V75, P4238, DOI 10.1073/pnas.75.9.4238; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; SMERDON MJ, 1982, BIOCHEMISTRY-US, V21, P3879, DOI 10.1021/bi00259a024; SMERDON MJ, 1998, IN PRESS DNA DAMAGE; SMERDON MJ, 1998, IN PRESS PROGR NUCL; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; van Holde KE., 1989, SPRINGER SERIES MOL; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WALKER J, 1990, J BIOL CHEM, V265, P5736; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATKINS JF, 1985, BIOCHEMISTRY-US, V24, P7279, DOI 10.1021/bi00346a039; WATKINS JF, 1985, BIOCHEMISTRY-US, V24, P7288, DOI 10.1021/bi00346a040; Wolffe A., 1995, CHROMATIN STRUCTURE	59	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17517	17524		10.1074/jbc.273.28.17517	http://dx.doi.org/10.1074/jbc.273.28.17517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651343	hybrid			2022-12-27	WOS:000074816100036
J	Leppanen, A; Zhu, Y; Maaheimo, H; Helin, J; Lehtonen, E; Renkonen, O				Leppanen, A; Zhu, Y; Maaheimo, H; Helin, J; Lehtonen, E; Renkonen, O			Biosynthesis of branched polylactosaminoglycans - Embryonal carcinoma cells express midchain beta 1,6-N-acetylglucosaminyltransferase activity that generates branches to preformed linear backbones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-I; WHEAT-GERM-AGGLUTININ; HUMAN-SERUM; N-ACETYLLACTOSAMINOGLYCANS; GASTRIC-MUCOSA; LACTOSAMINOGLYCAN; IDENTIFICATION; ANTIGENS; PA1	Two types of beta 1,6-GlcNAc transferases (IGnT6) are involved in in vitro branching of polylactosamines: dIGnT6 (distally acting), transferring to the penultimate galactose residue in accepters like GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1- R, and cIGnT6 (centrally acting), transferring to the midchain galactoses in accepters of the type (GlcNAc beta 1-3)Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc beta 1-R. The roles of the two transferases in the biosynthesis of branched polylactosamine backbones have not been clearly elucidated. We report here that cIGnT6 activity is expressed in human (PA1) and murine (PC13) embryonal carcinoma (EC) cells, both of which contain branched polylactosamines in large amounts. In the presence of exogenous UDP-GlcNAc, lysates from both EC cells catalyzed the formation of the branched pentasaccharide Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4GlcNAc from the linear tetrasaccharide Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc. The PA1 cell lysates were shown to also catalyze the formation of the branched heptasaccharides Gal beta 1-4G1cNAc beta 1-3Gal beta 1-4GlcNAc beta 1-3(GlcNAc beta 1-6)Gal beta 1-4GlcNAc and Gal beta 1-4GlcNAc-beta 1-3(GlcNAc beta 1-6) Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4GlcNAc from the linear hexasaccharide Galpl-LiGlcNAcpl3Galpl-4GlcNAcpl3GalP1-4GlcNAc in reactions characteristic to cIGnT6, By contrast, dIGnT6 activity was not detected in the lysates of the two EC cells that were incubated with UDP-GlcNAc and the acceptor trisaccharide GlcNAc beta 1-3Gal beta 1-4GlcNAc. Hence, it appears likely that cIGnT6, rather than dIGnT6 is responsible for the synthesis of the branched polylactosamine chains in these cells.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Div Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Renkonen, O (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Lehtonen, Eero/AGJ-4027-2022	Lehtonen, Eero/0000-0002-8218-635X				BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3893; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1994, TRENDS GLYCOSCI GLYC, V6, P17; BROCKHAUSEN I, 1986, EUR J BIOCHEM, V157, P463, DOI 10.1111/j.1432-1033.1986.tb09690.x; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; GU J, 1992, J BIOL CHEM, V267, P2994; Helin J, 1997, FEBS LETT, V412, P637, DOI 10.1016/S0014-5793(97)00818-1; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; LEHTONEN E, 1983, EXP CELL RES, V144, P191, DOI 10.1016/0014-4827(83)90453-6; Leppanen A, 1997, BIOCHEMISTRY-US, V36, P7026, DOI 10.1021/bi9627673; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; PILLER F, 1984, J BIOL CHEM, V259, P3385; RASILO ML, 1982, EUR J BIOCHEM, V123, P397, DOI 10.1111/j.1432-1033.1982.tb19782.x; RENKONEN O, 1983, BIOCHEM SOC T, V11, P265, DOI 10.1042/bst0110265; RENKONEN O, 1991, GLYCOCONJUGATE J, V8, P361, DOI 10.1007/BF00731349; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; ROPP PA, 1991, J BIOL CHEM, V266, P23863; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SEPPO A, 1995, BIOCHEMISTRY-US, V34, P4655, DOI 10.1021/bi00014a019; SEPPO A, 1990, BIOCHEM CELL BIOL, V68, P44, DOI 10.1139/o90-006; VILKMAN A, 1992, CARBOHYD RES, V226, P155, DOI 10.1016/0008-6215(92)84061-V; WATANABE K, 1979, J BIOL CHEM, V254, P3221; YATES AD, 1983, CARBOHYD RES, V120, P251, DOI 10.1016/0008-6215(83)88020-3; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	31	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17399	17405		10.1074/jbc.273.28.17399	http://dx.doi.org/10.1074/jbc.273.28.17399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651325	hybrid			2022-12-27	WOS:000074816100018
J	Johnstone, RW; Kerry, JA; Trapani, JA				Johnstone, RW; Kerry, JA; Trapani, JA			The human interferon-inducible protein, IFI 16, is a repressor of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR DIFFERENTIATION ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; GENE; ACTIVATION; P202; LOCALIZATION; INHIBITION; BINDING; CLUSTER	IFI 16 is a member of a family of interferon-inducible proteins, including the human MNDA (myeloid nuclear differentiation antigen), the recently identified AIM-S (absent in melanoma), and the homologous murine molecules, p202, p204, and D3. IFI 16 contains a domain at the amino terminus capable of binding double-stranded DNA and a bipartite nuclear localization signal. No molecular or biological function has been assigned to any of the human family members, although a role in transcription regulation has been proposed. In the present study, we show IFI 16 fused to the GAL4 DNA binding domain can function as a transcriptional repressor. IFI 16-mediated repression is not dependent on the position or distance of IFI 16 binding, relative to the site of transcription initiation, and it can significantly repress when only one GAL4 DNA element is present in the promoter. We mapped the transcriptional repression domains to the 200 amino acid repeat regions common to all human and mouse family members. We also demonstrate that wild type IFI 16 can repress transcription of a reporter gene containing the minimal promoter region of the human cytomegalovirus UL54 gene. Thus, IFI 16 is a transcriptional repressor, with a modular structure typical of many known transcription regulators.	Austin Hosp, Austin Res Inst, Heidelberg, Vic 3084, Australia; Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA 23501 USA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Eastern Virginia Medical School	Johnstone, RW (corresponding author), Austin Hosp, Austin Res Inst, Studley Rd, Heidelberg, Vic 3084, Australia.	r.johnstone@ari.unimelb.edu.au	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUHL DM, 1989, J CELL PHYSIOL, V141, P148, DOI 10.1002/jcp.1041410122; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KERRY JA, 1994, J VIROL, V68, P4167, DOI 10.1128/JVI.68.7.4167-4176.1994; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Luu P, 1997, J VIROL, V71, P6683, DOI 10.1128/JVI.71.9.6683-6691.1997; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MADDEN SL, 1993, ONCOGENE, V8, P1713; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Min W, 1996, MOL CELL BIOL, V16, P359; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0	33	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17172	17177		10.1074/jbc.273.27.17172	http://dx.doi.org/10.1074/jbc.273.27.17172			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642285	hybrid			2022-12-27	WOS:000074545200075
J	Loechel, F; Gilpin, BJ; Engvall, E; Albrechtsen, R; Wewer, UM				Loechel, F; Gilpin, BJ; Engvall, E; Albrechtsen, R; Wewer, UM			Human ADAM 12 (meltrin alpha) is an active metalloprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASES; CONSTITUTIVE SECRETORY PATHWAY; CYSTEINE SWITCH; PRECURSOR PROTEINS; GENE FAMILY; DISINTEGRIN; ACTIVATION; CELL; STROMELYSIN-1; DROSOPHILA	The ADAMs (a disintegrin and metalloprotease) are a family of multidomain proteins with structural homology to snake venom metalloproteases. We recently described the cloning and sequencing of human ADAM 12 (meltrin alpha). In this report we provide evidence that the metalloprotease domain of ADAM 12 is catalytically active. We used the trapping mechanism of alpha(2)-macroglobulin to assay for protease activity of wild-type and mutant ADAM 12 proteins produced in a COS cell transfection system. We found that ADAM 12 is synthesized as a zymogen, with the prodomain maintaining the metalloprotease in a latent form, probably by means of a cysteine switch. The zymogen could be activated chemically by alkylation with N-ethylmaleimide. Cleavage of the prodomain at a site for a furin-like endopeptidase resulted in an ADAM 12 protein with proteolytic activity. The protease activity was sensitive to inhibition by 1,10-phenanthroline and could be eliminated by mutation of the critical glutamate residue at the active site. The demonstration that the ADAM 12 metalloprotease domain is functional may have important implications for future studies that explore the role of ADAM 12 protein in development and disease.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Burnham Inst, La Jolla, CA 92037 USA	University of Copenhagen; Sanford Burnham Prebys Medical Discovery Institute	Engvall, E (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	molera@inet.uni-c.dk	; Gilpin, Brent/E-3463-2013	Albrechtsen, Reidar/0000-0003-4180-1827; Gilpin, Brent/0000-0002-8109-2271				BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; HANSEN HB, 1995, CURR OPIN CELL BIOL, V7, P728; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; JENSEN LS, 1994, ANN NY ACAD SCI, V737, P172; Jia LG, 1996, TOXICON, V34, P1269, DOI 10.1016/S0041-0101(96)00108-0; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MILHIET PE, 1995, BIOCHEM J, V309, P683, DOI 10.1042/bj3090683; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NAGASE H, 1994, ANN NY ACAD SCI, V732, P294, DOI 10.1111/j.1749-6632.1994.tb24744.x; Nagase H, 1996, ZINC METALLOPROTEASE, P153; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PARK AJ, 1991, J BIOL CHEM, V266, P1584; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1995, PROTEIN SCI, V4, P823; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	42	170	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16993	16997		10.1074/jbc.273.27.16993	http://dx.doi.org/10.1074/jbc.273.27.16993			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642263	hybrid			2022-12-27	WOS:000074545200053
J	Delany, AM; Canalis, E				Delany, AM; Canalis, E			Dual regulation of stromelysin-3 by fibroblast growth factor-2 in murine osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOUSE STROMELYSIN-3; GENE-EXPRESSION; POSTTRANSCRIPTIONAL MECHANISMS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; MC3T3-E1 CELLS; BONE-CELLS; DIFFERENTIATION	Osteoblasts express stromelysin-3, a matrix metalloproteinase associated with normal remodeling processes and with stromal fibroblasts surrounding many invasive carcinomas. Fibroblast growth factors (FGFs) play an important role in skeletal development, fracture repair, and osteoblast function. The osteoblastic cell line MC3T3 was used to study the regulation of stromelysin-3 by FGF-2. Acutely, FGF-2 decreased stromelysin-3 mRNA levels, whereas prolonged treatment caused an induction of stromelysin-3 mRNA. RNA stability studies and nuclear run-off assays indicated that acute treatment with FGF-2 decreased stromelysin-3 mRNA stability but did not alter gene transcription. However, the induction of stromelysin-3 after prolonged treatment with FGF-2 resulted from increased gene transcription, with no effect on RNA stability. The stimulatory effect was protein synthesis-dependent, whereas the inhibitory effect was not. This study demonstrates dual regulation of stromelysin-3 by FGF-2: acute destabilization of stromelysin-3 mRNA, followed by induction of gene transcription. This complex regulation may be important in the function of stromelysin-3 in bone and in remodeling processes, such as wound and fracture repair.	St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Dept Med, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	Saint Francis Hospital & Medical Center; Saint Francis Hospital & Medical Center; University of Connecticut	Delany, AM (corresponding author), St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	adelany@stfranciscare.org			NIAMS NIH HHS [AR21707] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; ANDERSON IC, 1995, CANCER RES, V55, P4120; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Delany A. M., 1997, GROWTH FACTORS CYTOK; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; Delany AM, 1998, AM J PHYSIOL-CELL PH, V274, pC734, DOI 10.1152/ajpcell.1998.274.3.C734; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GREENBERG ME, 1993, CONTROL MESSENGER RN, P161; Guerin E, 1997, J BIOL CHEM, V272, P11088; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MEIKLE MC, 1992, J CELL SCI, V103, P1093; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; MURPHY G, 1993, J BIOL CHEM, V268, P15435; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; OKAZAKI R, 1992, J BONE MINER RES, V7, P1149; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; RIFAS L, 1994, ENDOCRINOLOGY, V134, P213, DOI 10.1210/en.134.1.213; RODAN SB, 1989, J BIOL CHEM, V264, P19934; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sato T, 1997, J CELL SCI, V110, P589; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Sokal R. R, 1981, BIOMETRY; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; VARGHESE S, 1995, ENDOCRINOLOGY, V136, P2156, DOI 10.1210/en.136.5.2156; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9	56	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16595	16600		10.1074/jbc.273.26.16595	http://dx.doi.org/10.1074/jbc.273.26.16595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632732	hybrid			2022-12-27	WOS:000074436600103
J	Kim, TSY; Reid, DM; Molday, RS				Kim, TSY; Reid, DM; Molday, RS			Structure-function relationships and localization of the Na/Ca-K exchanger in rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; OUTER SEGMENTS; NA+-CA2+ EXCHANGER; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; PLASMA-MEMBRANES; BOVINE; PROTEIN; PURIFICATION; RHODOPSIN	The structural and functional properties of the bovine rod photoreceptor Na/Ca-K exchanger and its distribution in vertebrate photoreceptor cells were studied using a panel of monoclonal antibodies. Antibodies that bind to distinct epitopes along the large hydrophilic N-terminal segment of the exchanger labeled the extracellular surface of the rod outer segment plasma membrane, whereas antibodies against a large hydrophilic loop between the two membrane domains labeled the intracellular side, Enzymatic deglycosylation studies indicated that the exchanger primarily contains O-linked sialo-oligosaccharides located within the N-terminal domain. Removal of the extracellular domain with trypsin or the large intracellular domain with kallikrein did not alter the Na+- or K+-dependent Ca2+ efflux activity of the exchanger when reconstituted into lipid vesicles. Anti-exchanger antibodies were also used to visualize the distribution of the exchanger in the retina by light and electron microscopy, The exchanger was localized to the plasma membrane of rod outer segments. No labeling was observed in the disk membranes, cone photoreceptor cells, or other retinal neurons, and only faint staining was seen in the rod inner segment. These results indicate that the O-linked glycosylated rod Na/Ca-K exchanger is specifically targeted to the plasma membrane of rod photoreceptors and has a topological organization similar to that reported for the cardiac Na/Ca exchanger. The large intracellular and extracellular domains do not directly function in the transport of ions across the rod outer segment plasma membrane, but instead may play a role in protein-protein interactions that maintain the spatial organization of the exchanger in the plasma membrane or possibly regulate transport activity of the exchanger.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@unixg.ubc.ca			NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAUER PJ, 1992, J PHYSIOL-LONDON, V451, P109, DOI 10.1113/jphysiol.1992.sp019156; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; CREPSO LM, 1990, NATURE, V345, P618; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAASE W, 1990, J NEUROSCI, V10, P1486; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; Molday RS, 1998, VISION RES, V38, P1315, DOI 10.1016/S0042-6989(97)00409-4; NICOLL DA, 1989, J BIOL CHEM, V264, P16207; NICOLL DA, 1991, AM J PHYSIOL, V260, pC1212, DOI 10.1152/ajpcell.1991.260.6.C1212; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; RATTO GM, 1988, J NEUROSCI, V8, P3240; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REEVES JP, 1980, SCIENCE, V208, P1461, DOI 10.1126/science.7384788; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1991, ANN NY ACAD SCI, V639, P10, DOI 10.1111/j.1749-6632.1991.tb17285.x; Schwarzer A, 1997, BIOCHEMISTRY-US, V36, P13667, DOI 10.1021/bi9710232; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Tucker JE, 1998, INVEST OPHTH VIS SCI, V39, P435; YAU KW, 1984, NATURE, V311, P661, DOI 10.1038/311661a0	38	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16561	16567		10.1074/jbc.273.26.16561	http://dx.doi.org/10.1074/jbc.273.26.16561			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632727	hybrid			2022-12-27	WOS:000074436600098
J	Rizo, J; Sudhof, TC				Rizo, J; Sudhof, TC			C-2-domains, structure and function of a universal Ca2+-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTEIN KINASE-C; SYNAPTOTAGMIN-I; PHOSPHOLIPASE-C; BINDING; EXPRESSION; 3-KINASE; HOMOLOGY; MULTIPLE; CLONING; RELEASE		Univ Texas, Hlth Sci Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas	Rizo, J (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037200, R29NS033731] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33731, NS37200] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAZIN WJ, 1995, NAT STRUCT BIOL, V2, P707, DOI 10.1038/nsb0995-707; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GERLOFF DL, 1995, PROTEINS, V22, P299, DOI 10.1002/prot.340220402; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kretsinger RH, 1996, NAT STRUCT BIOL, V3, P12, DOI 10.1038/nsb0196-12; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Ponting CP, 1996, PROTEIN SCI, V5, P162; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; UBACH J, 1998, IN PRESS EMBO J; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	50	682	706	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15879	15882		10.1074/jbc.273.26.15879	http://dx.doi.org/10.1074/jbc.273.26.15879			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632630	hybrid			2022-12-27	WOS:000074436600001
J	Song, W; Chen, JM; Dean, WL; Redinger, RN; Prough, RA				Song, W; Chen, JM; Dean, WL; Redinger, RN; Prough, RA			Purification and characterization of hamster liver microsomal 7 alpha-hydroxycholesterol dehydrogenase - Similarity to type I 11 beta-hydroxysteroid dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE; 7-OXOCHOLESTEROL; ISOFORM; TISSUES; KIDNEY	While studying the bile acid synthetic pathway of hamsters, we discovered an NADP(+)-dependent liver microsomal 7 alpha-hydroxycholesterol dehydrogenase (7 alpha-HCD) activity that was not observed in rat liver microsomal fractions. The hamster liver microsomal 7 alpha-HCD was purified to homogeneity using 2',5'-ADP and cholic acid-agarose affinity chromatography. 7 alpha-HCD displayed a molecular weight of approximately 34,000 on SDS-polyacrylamide gel electrophoresis; it is an intrinsic membrane protein of the hamster liver endoplasmic reticulum and exists as a multimeric aggregate in pure form. Partial N-terminal amino acid sequence analysis showed that 7 alpha-HCD had high sequence similarity to human Ilp-hydroxysteroid dehydrogenase (11 beta-HSD; 24/30 amino acid identity). The K-m values for corticosterone and 7 alpha-hydroxycholesterol were 1.2 and 1.9 mu M, respectively, for purified 7a-HCD; both reactions displayed identical V-max values (approximately 170 nmol/min/mg of protein). The IC50 of carbenoxolone, a competitive inhibitor of 11 beta-HSD, was 75 nM for 7 alpha-hydroxycholesterol dehydrogenation and 210 nM for corticosterone dehydrogenation. The tissue-specific expression in hamster was as follows: adrenal greater than or equal to liver > kidney > testis >> brain > lung. Microsomal 7 alpha-HCD is uniquely expressed in hamster liver and to some extent in human liver but not in rat liver. Western blot analysis with two antibodies elicited against an N-terminal peptide of the human 11 beta-HSD and purified hamster liver 7a-HCD, respectively, suggested the presence of multiple forms of 7 alpha-HCD in hamster liver, most likely due to the existence of a family of 11 beta-HSD proteins. Since 7-oxocholesterol is a potent inhibitor of cholesterol 7 alpha-hydroxylase, alternative mechanisms for regulation of bile acid synthesis may exist in human and hamster liver due to production of this metabolite and its potential as an oxysterol.	Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Dept Med, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Prough, RA (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.		Russell A, Prough/AAH-5907-2020	Prough, Russell/0000-0001-8901-8490	NATIONAL CANCER INSTITUTE [R01CA043839] Funding Source: NIH RePORTER; NCI NIH HHS [CA43839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; BJORKHEM I, 1986, ANAL BIOCHEM, V154, P497, DOI 10.1016/0003-2697(86)90021-7; BREUER O, 1993, EUR J BIOCHEM, V215, P705, DOI 10.1111/j.1432-1033.1993.tb18082.x; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; CANTFORT JV, 1972, LIFE SCI, V11, P773; Carey M.C., 1988, LIVER BIOL PATHOBIOL, V2nd, P573; EVDOKIMOVA NI, 1967, FARMAKOLOGIIA ALKALO, P222; Gontscharow N. P., 1971, J STEROID BIOCHEM, V2, P389; GONTSCHAROW VNP, 1975, ENDOKRINOLOGIE, V64, P213; GUSTAFSSON JA, 1974, EUR J BIOCHEM, V44, P225, DOI 10.1111/j.1432-1033.1974.tb03477.x; ICHIOKA H, 1968, GIFU DAIGAKU IGAKUBU, V15, P810; KOERNER DR, 1969, BIOCHIM BIOPHYS ACTA, V176, P377, DOI 10.1016/0005-2760(69)90196-9; LABRIE F, 1994, BAILLIERE CLIN ENDOC, V8, P451, DOI 10.1016/S0950-351X(05)80261-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONDER C, 1988, Steroids, V52, P515, DOI 10.1016/0039-128X(88)90118-3; MONDER C, 1993, VITAM HORM, V47, P187, DOI 10.1016/S0083-6729(08)60447-1; PETERSON RE, 1955, J CLIN INVEST, V34, P1779, DOI 10.1172/JCI103233; REMMER H, 1967, METHOD ENZYMOL, V10, P703; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; Smith, 1981, CHOLESTEROL AUTOXIDA; Song W, 1996, ARCH BIOCHEM BIOPHYS, V328, P272, DOI 10.1006/abbi.1996.0173; SONG W, 1991, BIOCHEM PHARMACOL, V41, P1439, DOI 10.1016/0006-2952(91)90559-N; STEWART PM, 1994, J CLIN ENDOCR METAB, V78, P1529, DOI 10.1210/jc.78.6.1529; STEWART PM, 1987, LANCET, V2, P821; STRANDVIK B, 1994, SCAND J CLIN LAB INV, V54, P1, DOI 10.3109/00365519409086503; YANG K, 1994, J STEROID BIOCHEM, V49, P245, DOI 10.1016/0960-0760(94)90016-7	28	36	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16223	16228		10.1074/jbc.273.26.16223	http://dx.doi.org/10.1074/jbc.273.26.16223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632680	hybrid			2022-12-27	WOS:000074436600051
J	Brown, V; Small, K; Lakkis, L; Feng, Y; Gunter, C; Wilkinson, KD; Warren, ST				Brown, V; Small, K; Lakkis, L; Feng, Y; Gunter, C; Wilkinson, KD; Warren, ST			Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; KH DOMAINS; GENE; REGION; RIBONUCLEOPROTEIN; TRANSCRIPTION; PURIFICATION; POLYMERASE; RIBOSOMES; SEQUENCES	Fragile X syndrome is caused by the transcriptional silencing of the FIMR1 gene due to a trinucleotide repeat expansion, The encoded protein, Fmrp, has been found to be a nucleocytoplasmic RNA-binding protein containing both KH domains and RGG boxes that associates with polyribosomes as a ribonucleoprotein particle. RNA binding has previously been demonstrated with in vitro-translated Fmrp; however, it remained uncertain whether the selective RNA binding observed was an intrinsic property of Fmrp or required an associated protein(s), Here, baculovirus-expressed and affinity-purified FLAG-tagged murine Fmrp was shown to bind directly to both ribonucleotide homopolymers and human brain mRNA, FLAG-Fmrp exhibited selectivity for binding poly(G) > poly(U) much greater than poly(C) or poly(A), Moreover, purified FLAG-Fmrp bound to only a subset of brain mRNA, including the 3' untranslated regions of myelin basic protein message and its own message. Recombinant isoform 4, lacking the RGG boxes but maintaining both KH domains, was also purified and was found to only weakly interact with RNA. FLAG-purified I304N Fmrp, harboring the mutation of severe fragile X syndrome, demonstrated RNA binding,:in contrast to previous suggestions. These data demonstrate the intrinsic property of Fmrp to selectively hindi RNA and show FLAG-Fmrp as a suitable reagent for structural. characterization and identification of cognate RNA ligands.	Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA	Emory University; Howard Hughes Medical Institute; Emory University; Emory University; Emory University	Warren, ST (corresponding author), Emory Univ, Sch Med, Howard Hughes Med Inst, 4035 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	swarren@bimcore.emory.edu	Gunter, Chris/AHA-7271-2022	Feng, Yue/0000-0002-7905-2182; Gunter, Chris/0000-0001-9369-7537	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, P01HD035576] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD35576, R37 HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; DOLGANOV GM, 1981, EUR J BIOCHEM, V114, P247, DOI 10.1111/j.1432-1033.1981.tb05143.x; Eberhart DE, 1996, COLD SPRING HARB SYM, V61, P679; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; MORENO CS, 1995, J IMMUNOL, V155, P4313; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POONIAN MS, 1971, BIOCHEMISTRY-US, V10, P424, DOI 10.1021/bi00779a011; REINES D, 1989, J BIOL CHEM, V264, P10799; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; Scandurro AB, 1997, KIDNEY INT, V51, P579, DOI 10.1038/ki.1997.83; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1995, NUCLEIC ACIDS RES, V2, P1193; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; SMALL K, 1995, MENTAL RETARDATION D, V1, P245; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tamanini F, 1996, HUM MOL GENET, V5, P809, DOI 10.1093/hmg/5.6.809; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WAGNER AF, 1971, BIOCHEM BIOPH RES CO, V45, P184, DOI 10.1016/0006-291X(71)90067-2; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582	37	138	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15521	15527		10.1074/jbc.273.25.15521	http://dx.doi.org/10.1074/jbc.273.25.15521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624140	hybrid			2022-12-27	WOS:000074284200034
J	Gerhardt, B; Kordas, TJ; Thompson, CM; Patel, P; Vida, T				Gerhardt, B; Kordas, TJ; Thompson, CM; Patel, P; Vida, T			The vesicle transport protein Vps33p is an ATP-binding protein that localizes to the cytosol in an energy-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; ENDOSOME-LIKE COMPARTMENT; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PREVACUOLAR COMPARTMENT; MEMBRANE-FUSION; GOLGI TRANSPORT; SHUTTLE VECTORS; GENE-PRODUCT; YEAST	Molecular mechanisms of vesicle transport between the prevacuolar compartment and the vacuole in yeast or the lysosome in mammalian cells are poorly understood. To learn more about the specificity of this intercompartmental step, we have examined the subcellular localization of a SEC1 homologue, Vps33p, a protein implicated to function in transport between the prevacuolar compartment and the vacuole, Following short pulses, 80-90% of newly synthesized Vps33p cofractionated with a cytosolic enzyme marker after making permeabilized yeast cells, However, during a chase, 20-40% of Vps33p fractionated with permeabilized cell membranes in a time-dependent fashion with a half-time of similar to 40 min. Depletion of cellular ATP increased the association rate to a half-time of similar to 4 min and caused 80-90% of newly synthesized Vps33p to be associated with permeabilized cell membranes. The association of Vps35p with permeabilized cell membranes was reversible after restoring cells with glucose before permeabilization. The N-ethylmaleimide-sensitive fusion protein homologue, Sec18p, a protein with known ATP binding and hydrolysis activity, displayed the same reversible energy-dependent sedimentation characteristics as Vps33p. We determined that the photosensitive analog 8-azido-[alpha-P-32]ATP, could bind directly to Vps33p with low affinity. Interestingly, excess unlabeled ATP could enhance photoaffinity labeling of 8-azido-[alpha-P-32]ATP to Vps33p, suggesting cooperative binding, which was not observed with excess GTP. Importantly, we did not detect significant photolabeling after deleting amino acid regions in Vps33p that show similarity to ATP interaction motifs, We visualized these events in living yeast cells after fusing the jellyfish green fluorescent protein (GFP) to the C terminus of full-length Vps33p, In metabolically active cells, the fully functional Vp33p-GFP fusion protein appeared to stain throughout the cytoplasm with one or two very bright fluorescent spots near the vacuole, After depleting cellular ATP, Vps33p-GFP appeared to localize with a punctate morphology, which was also reversible upon restoring cells with glucose. Overall, these data support a model where Vps33p cycles between soluble and particulate forms in an ATP-dependent manner, which may facilitate the specificity of transport vesicle docking or targeting to the yeast lysosome/vacuole.	Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA	University of Texas System	Vida, T (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052092] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52092] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BARBER R, 1992, SEC MESS PHOSPHOPROT, V14, P77; BRIDGER WA, 1983, CELL ATP TRANSPORT L, V5; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; COWLES CR, 1994, J CELL SCI, V107, P3449; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; Halachmi N, 1996, J NEUROCHEM, V66, P889; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; LACHER K, 1993, ARCH BIOCHEM BIOPHYS, V302, P391, DOI 10.1006/abbi.1993.1229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; MAURER PJ, 1981, BIOCHEMISTRY-US, V20, P6894, DOI 10.1021/bi00527a024; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; SALVUCCI ME, 1994, BIOCHEMISTRY-US, V33, P14879, DOI 10.1021/bi00253a027; SALVUCCI ME, 1993, J BIOL CHEM, V268, P14239; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1995, FEBS LETT, V369, P80, DOI 10.1016/0014-5793(95)00594-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOLFE KH, 1994, CURR GENET, V25, P379, DOI 10.1007/BF00351493	68	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15818	15829		10.1074/jbc.273.25.15818	http://dx.doi.org/10.1074/jbc.273.25.15818			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624182	hybrid			2022-12-27	WOS:000074284200076
J	Zurovec, M; Yang, CS; Kodrik, D; Sehnal, F				Zurovec, M; Yang, CS; Kodrik, D; Sehnal, F			Identification of a novel type of silk protein and regulation of its expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI SILKGLAND; GALLERIA-MELLONELLA L; MESSENGER-RNA; SERICIN; FIBROIN; GLAND; SEQUENCE; GENE; HORMONES; SITES	The silk of lepidopteran insects has been studied extensively as proteins of two categories the fibroins, which are produced in the posterior section of silk glands, and the sericins, which are secreted in the middle section. We now describe a third category that is named seroins to accentuate the fact that both the sericin- and the fibroin-producing cells participate in seroin secretion. Using a probe derived from the N-terminal sequences of a 23-kDa components of Galleria mellonella silk, we isolated silk gland-specific cDNA encoding 167 amino acids, of which 17 constitute the signal peptide. The following 14 residues match the N-terminal sequences of the 23- and 22.5-kDa silk proteins, The reaction of these proteins with concanavalin A and the presence of two glycosylation sites in the seroin peptide sequence indicate that seroin is secreted in two forms that both contain a mannose-rich sugar moiety, Seroin is distinguished from other silk proteins by high proline content (34 residues or 20.26% by weight), lack of cysteines, and the presence of two kinds of short amino acid repeats, The seroin gene is expressed in both the posterior and middle silk gland sections. The expression fluctuates during development in correlation with the feeding regime and the changes in hormone titers: seroin mRNA is high in the silk glands of feeding larvae, declines at ecdysis, reaches a maximum during cocoon spinning, and thereafter rapidly drops to an undetectable level. In vivo and in vitro experiments showed that the drop is caused by ecdysteroid hormones and is prevented by juvenile hormones. N-terminal sequencing of several silk proteins of Bombyx mori revealed that the 8- and 13-kDa proteins share 5 or 6 out of 10 identified amino acids with the N terminus of Galleria seroin and obviously represent seroin homologues, The result suggests that seroin-type proteins are a general component of lepidopteran silk.	Acad Sci Czech Republ, Inst Entomol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol Sci, Ceske Budejovice 370, Czech Republic	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Czech Academy of Sciences; University of South Bohemia Ceske Budejovice	Sehnal, F (corresponding author), Acad Sci Czech Republ, Inst Entomol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	sehnal@entu.cas.cz	Kodrik, Dalibor/H-1522-2014; Zurovec, Michal/H-2562-2014; Zurovec, Michal/AAE-8185-2021	Kodrik, Dalibor/0000-0001-6109-1979; Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X				Boman HG, 1996, SCAND J IMMUNOL, V43, P475, DOI 10.1046/j.1365-3083.1996.d01-76.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COUBLE P, 1983, DEV BIOL, V97, P398, DOI 10.1016/0012-1606(83)90096-9; COUBLE P, 1987, DEV BIOL, V124, P431, DOI 10.1016/0012-1606(87)90496-9; CYAMA F, 1984, J BIOCHEM-TOKYO, V96, P1689; FRUDHOMME JC, 1985, COMPREHENSIVE INSECT, V10, P571; GAMO T, 1977, INSECT BIOCHEM, V7, P285, DOI 10.1016/0020-1790(77)90026-9; GRUBHOFFER L, 1990, LECTINS BIOL BIOCH C, V7, P313; GRZELAK K, 1988, INSECT BIOCHEM, V18, P223, DOI 10.1016/0020-1790(88)90086-8; Jindra M, 1996, DEV GENES EVOL, V206, P305, DOI 10.1007/s004270050057; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KIMURA K, 1985, EXPERIENTIA, V41, P1167, DOI 10.1007/BF01951711; KODRIK D, 1992, ACTA ENTOMOL BOHEMOS, V87, P332; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; KULDOVA J, 1990, ACTA ENTOMOL BOHEMOS, V87, P332; LEHLE L, 1984, BIOCHIM BIOPHYS ACTA, V799, P246, DOI 10.1016/0304-4165(84)90267-8; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAILLE JJ, 1986, BIOCHIMIE, V68, P1165, DOI 10.1016/S0300-9084(86)80060-8; REMBOLD H, 1987, INSECT BIOCHEM, V17, P997, DOI 10.1016/0020-1790(87)90109-0; SASAKI T, 1973, BIOCHIM BIOPHYS ACTA, V310, P91, DOI 10.1016/0005-2795(73)90011-1; SEHNAL F, 1990, INT J INSECT MORPHOL, V19, P79, DOI 10.1016/0020-7322(90)90022-H; SEHNAL F, 1981, J INSECT PHYSIOL, V27, P535, DOI 10.1016/0022-1910(81)90041-X; SEHNAL F, 1966, Z WISS ZOOL ABT A, V174, P53; SEHNAL F, 1987, SERICOLOGIA, V27, P643; SHIMURA K, 1976, J BIOCHEM-TOKYO, V80, P693, DOI 10.1093/oxfordjournals.jbchem.a131328; SINOHARA H, 1979, COMP BIOCHEM PHYS B, V63, P87, DOI 10.1016/0305-0491(79)90239-6; SUZUKI Y, 1972, J MOL BIOL, V63, P409, DOI 10.1016/0022-2836(72)90437-8; TANAKA K, 1993, J BIOCHEM-TOKYO, V114, P1; TOKUTAKE S, 1980, J BIOCHEM-TOKYO, V187, P413; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yang CS, 1996, ARCH INSECT BIOCHEM, V32, P353, DOI 10.1002/(SICI)1520-6327(1996)32:3/4&lt;353::AID-ARCH8&gt;3.0.CO;2-; ZUROVEC M, 1995, MOL GEN GENET, V247, P1, DOI 10.1007/BF00425815; ZUROVEC M, 1992, INSECT BIOCHEM MOLEC, V22, P55, DOI 10.1016/0965-1748(92)90100-S; Zurovec M, 1998, MOL GEN GENET, V257, P264, DOI 10.1007/s004380050647	34	48	56	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15423	15428		10.1074/jbc.273.25.15423	http://dx.doi.org/10.1074/jbc.273.25.15423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624126	hybrid			2022-12-27	WOS:000074284200020
J	Beers, MF; Lomax, CA; Russo, SJ				Beers, MF; Lomax, CA; Russo, SJ			Synthetic processing of surfactant protein C by alevolar epithelial cells - The COOH terminus of proSP-C is required for post-translational targeting and proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SP-B; PULMONARY SURFACTANT; RAT LUNG; II CELLS; STRUCTURAL REQUIREMENTS; HYDROPHOBIC PROTEINS; IN-VITRO; PRECURSOR; IDENTIFICATION; LOCALIZATION	Surfactant protein C (SP-C) is synthesized by alveolar type II cells as a 21-kDa propeptide (proSP-C-21) which is proteolytically processed in subcellular compartments distal to the trans-Golgi network to yield a 35-residue mature form, Initial synthetic processing events for SP-C include post-translational cleavages of the COOH terminus of proSP-C-21, yielding two intermediates (16 and 6 kDa). To test the role of specific COOH-terminal domains in intracellular targeting and proteolysis of proSP-C-21, synthesis and processing of SP-C was evaluated using a lung epithelial cell line (A549) transfected with a eukaryotic expression vector containing either the full-length cDNA for rat SP-C (SP-C-wt) or one of six polymerase chain reaction (PCR)-generated COOH terminally truncated forms (Sp-C1-185, SP-C1-175, SP-C1-147, Sp-C1-120, SP-C1-72, and SP-C1-59), Using in vitro transcription/translation, each of the seven constructs produced a S-35-labeled product of appropriate length which could be immunoprecipitated by epitope specific proSP-C antisera, Immunoprecipitation of S-35-labeled A549 cell lysates from SP-C-wt transfectants demonstrated rapid synthesis of [S-35]proSP-C-21 with processing to SP-C-16 and SP-C-6 intermediates via cleavages of the COOH-terminal propeptide. Both the intermediates as well as the kinetics of processing in A549 cells were similar to that observed in rat type II cells. In contrast, constructs SP-C1-185, SP-C1-175, SP-C1-147, SP-C1-120, SP- C1-72, and SP-C1-59 were each translated but degraded without evidence of proteolytic processing. Fluorescence immunocytochemistry identified proSP-C-wt in cytoplasmic vesicles of A549 cells while all COOH-terminal deletional mutants were restricted to an endoplasmic reticulum/Golgi compartment identified by co-localization with fluorescein isothiocyanate-concanavalin A. We conclude that SP-C-wt expressed in A549 cells is directed to cytoplasmic vesicles where it is proteolytically processed in a manner similar to native type II cells and that amino acids Cys(186)-Ile(194) located at the COOH terminus of proSP-C-21 are necessary for correct intracellular targeting and subsequent cleavage events.	Univ Penn, Sch Med, Inst Environm Med, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Med, Div Pulm & Crit Care, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Beers, MF (corresponding author), Univ Penn, Sch Med, Inst Environm Med, 1 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	mfbeers@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, P50HL056401, K08HL002869] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19737, HL-02869, P50-HL56401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BALLARD PL, 1995, PEDIATRICS, V96, P1046; BEER SMF, 1995, AM J PHYSIOL, V269, pL744; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; BEERS MF, 1994, J BIOL CHEM, V269, P20318; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Comon P., 1995, IEEE ATHOS WORKSHOP, P217; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Gough NR, 1997, J CELL BIOL, V137, P1161, DOI 10.1083/jcb.137.5.1161; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KING RJ, 1982, J APPL PHYSIOL, V53, P1; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; ZEN K, 1994, MOL BIOL CELL A, V77	35	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15287	15293		10.1074/jbc.273.24.15287	http://dx.doi.org/10.1074/jbc.273.24.15287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614145	hybrid			2022-12-27	WOS:000074160400087
J	Liu, YX; Christou, H; Morita, T; Laughner, E; Semenza, GL; Kourembanas, S				Liu, YX; Christou, H; Morita, T; Laughner, E; Semenza, GL; Kourembanas, S			Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5 ' enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PERMEABILITY FACTOR; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVATION; MICROVASCULAR PERMEABILITY; MOLECULAR MECHANISMS; ERYTHROPOIETIN GENE; FACTOR EXPRESSION; ANGIOGENESIS; TENSION	Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and blood vessel remodeling. Its expression is up-regulated in vascular smooth muscle cells by a number of conditions, including hypoxia. Hypoxia increases the transcriptional rate of VEGF via a 28-base pair enhancer located in the 5'-upstream region of the gene. The gas molecules nitric oxide (NO) and carbon monoxide (CO) are important vasodilating agents. We report here that these biological molecules can suppress the hypoxia-induced production of VEGF mRNA and protein in smooth muscle cells. In transient expression studies, both NO and CO inhibited the ability of the hypoxic enhancer we have previously identified to activate gene transcription. Furthermore, electrophoretic mobility shift assays indicated decreased binding of hypoxia-inducible factor 1 (HIF-1) to this enhancer by nuclear proteins isolated from CO-treated cells, although HIF-1 protein levels were unaffected by CO, Given that both CO and NO activate guanylyl cyclase to produce cGMP and that a cGMP analog (8-Br-cGMP) showed a similar suppressive effect on the hypoxic induction of the VEGF enhancer, we speculate that the suppression of VEGF by these two gas molecules occurs via a cyclic GMP-mediated pathway.	Harvard Univ, Sch Med, Childrens Hosp, Dept Med,Div Dev & Newborn Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Med,Div Newborn Med, Boston, MA 02115 USA; Johns Hopkins Univ, Sch Med, Ctr Med Genet, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Ctr Med Genet, Dept Med, Baltimore, MD 21287 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Johns Hopkins University; Johns Hopkins University	Kourembanas, S (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Med,Div Dev & Newborn Biol, 300 Longwood Ave,Enders 9, Boston, MA 02115 USA.			Christou, Helen/0000-0002-3104-4570	NHLBI NIH HHS [R01 HL55338, HL-09008] Funding Source: Medline; NIDDK NIH HHS [R01 DK39869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009008, R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fritsch EF, 1986, MOL CLONING LAB MANU, V2nd; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KUBES P, 1993, AM J PHYSIOL, V265, pH1909, DOI 10.1152/ajpheart.1993.265.6.H1909; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	48	201	220	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15257	15262		10.1074/jbc.273.24.15257	http://dx.doi.org/10.1074/jbc.273.24.15257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614141	hybrid			2022-12-27	WOS:000074160400083
J	Salvador, JM; Inesi, G; Rigaud, JL; Mata, AM				Salvador, JM; Inesi, G; Rigaud, JL; Mata, AM			Ca2+ transport by reconstituted synaptosomal ATPase is associated with H+ countertransport and net charge displacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; MEMBRANE-VESICLES; CA-2+ PUMP; PIG BRAIN; PROTEOLIPOSOMES; LIPOSOMES; BACTERIORHODOPSIN; ELECTROGENICITY; CA2+-ATPASE	The synaptosomal plasma membrane Ca2+-ATPase (PMCA) purified from pig brain was reconstituted with liposomes prepared by reverse phase evaporation at a lipid to protein ratio of 150/1 (w/w), ATP-dependent Ca2+ uptake and H+ ejection by the reconstituted proteoliposomes were demonstrated by following light absorption and fluorescence changes undergone by arsenate III and 8-hydroxy-1,3,6-pyrene trisulfonate, respectively. Ca2+ uptake was increased up to 2-3-fold by the Hf ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone, consistent with relief of an inhibitory transmembrane pH gradient (Le. lumenal alkalinization) generated by Hf countertransport. The stoichiometric ratio of Ca2+/H+ countertransport was 1.0/0.6, and the ATP/Ca2+ coupling stoichiometry was yl at 25 degrees C. The electrogenic character of the Ca2+/H+ countertransport was demonstrated by measuring light absorption changes undergone by oxonol VI. It was shown that a 20 mV steady state potential (positive on the lumenal side) was formed as a consequence of net charge transfer associated with the 1/1 Ca2+/H+ countertransport, Calmodulin stimulated ATPase activity, Ca2+ uptake, and H+ ejection, demonstrating that these parameters are linked by the same mechanism of PMCA regulation.	Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol & Genet, E-06071 Badajoz, Spain; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Inst Curie, Sect Rech, CNRS, UMR 168, F-75231 Paris, France; CEA, LRC, F-75231 Paris, France	Universidad de Extremadura; University System of Maryland; University of Maryland Baltimore; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; CEA	Mata, AM (corresponding author), Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol & Genet, E-06071 Badajoz, Spain.		Mata, Ana M./J-8460-2014	Mata, Ana M./0000-0002-2887-7854; Salvador, Jesus Maria/0000-0002-1087-9675	NHLBI NIH HHS [P01-HL-27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carafoli E, 1997, CALCIUM AND CELLULAR METABOLISM, P73; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; GASSNER B, 1988, CELL CALCIUM, V2, P95; GILL DL, 1981, J BIOL CHEM, V256, P184; HAO LN, 1994, J BIOL CHEM, V269, P14268; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; MICHAELIS ML, 1994, ANN NY ACAD SCI, V747, P407; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; Pitard B, 1996, EUR J BIOCHEM, V235, P769, DOI 10.1111/j.1432-1033.1996.00769.x; RAEYMAEKERS L, 1993, J MUSCLE RES CELL M, V14, P141, DOI 10.1007/BF00115449; REGA AF, 1986, CA2PLUS PUMP PLASMA, P45; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; Salvador JM, 1998, ARCH BIOCHEM BIOPHYS, V351, P272, DOI 10.1006/abbi.1997.0562; Salvador JM, 1996, BIOCHEM J, V315, P183, DOI 10.1042/bj3150183; Scarpa A, 1979, Methods Enzymol, V56, P301; SORENSEN RG, 1981, J NEUROCHEM, V37, P1407, DOI 10.1111/j.1471-4159.1981.tb06309.x; WAISMAN DM, 1981, J BIOL CHEM, V256, P415; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1994, J BIOL CHEM, V269, P16656; YU X, 1993, FEBS LETT, V328, P301, DOI 10.1016/0014-5793(93)80948-T	26	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18230	18234		10.1074/jbc.273.29.18230	http://dx.doi.org/10.1074/jbc.273.29.18230			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660785	hybrid			2022-12-27	WOS:000074828500040
J	Gopal-Srivastava, R; Cvekl, A; Piatigorsky, J				Gopal-Srivastava, R; Cvekl, A; Piatigorsky, J			Involvement of retinoic acid retinoid receptors in the regulation of murine alpha B-crystallin small heat shock protein gene expression in the lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; ARGININOSUCCINATE LYASE; MOUSE EMBRYOGENESIS; DELTA-CRYSTALLIN; TRANSGENIC MICE; PAIRED DOMAIN; EYELESS GENE; MUTANT MICE	Crystallins are a diverse group of abundant soluble proteins that are responsible for the refractive properties of the transparent eye lens. me showed previously that Pax-6 can activate the alpha B-crystallin/small heat shock protein promoter via the lens specific regulatory regions LSR1 (-147/-118) and LSR2 (-78/-46). Here we demonstrate that retinoic acid can induce the accumulation of alpha B-crystallin in N/N1003A lens cells and that retinoic acid receptor heterodimers (retinoic acid receptor/retinoid X receptor; RAR/RXR) can transactivate LSR1 and LSR2 in cotransfection experiments. DNase I footprinting experiments demonstrated that purified RAR/RXR heterodimers will OCCUPY sequences resembling retinoic acid response elements within LSR1 and LSR2. Electrophoretic mobility shift assays using antibodies indicated that LSR1 and LSR2 can interact with endogenous RAR/RXR complexes in extracts of cultured lens cells. Pax-6 and RAR/RXR together had an additive effect on the activation of alpha B-promoter in the transfected lens cells. Thus, the alpha B-crystallin gene is activated by Pax-6 and retinoic acid receptors, making these transcription factors examples of proteins that have critical roles in early development as well as in the expression of proteins characterizing terminal differentiation.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, Bldg 6,Rm 201, Bethesda, MD 20892 USA.	joram@helix.nih.gov	Cvekl, Ales/B-2427-2013					BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; BALKAN W, 1992, DEV BIOL, V151, P622, DOI 10.1016/0012-1606(92)90200-Z; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; Eichele G, 1997, TRENDS GENET, V13, P343, DOI 10.1016/S0168-9525(97)01218-3; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GLASER T, 1992, NAT GENET, V8, P463; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; GOTO K, 1988, CELL DIFFER DEV, V24, P139, DOI 10.1016/0045-6039(88)90065-6; Grondona JM, 1996, DEVELOPMENT, V122, P2173; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Haynes JI, 1997, BIOCHEM BIOPH RES CO, V241, P407, DOI 10.1006/bbrc.1997.7833; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hyatt GA, 1996, DEVELOPMENT, V122, P195; Hyatt GA, 1997, INVEST OPHTH VIS SCI, V38, P1471; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; Li X, 1997, DEV GENET, V20, P258; LOHNES D, 1994, DEVELOPMENT, V120, P2723; MARTHA A, 1994, AM J HUM GENET, V54, P801; MEANS AL, 1902, ANNU REV BIOCHEM, V201, P95; Minucci S, 1998, MOL ENDOCRINOL, V12, P315, DOI 10.1210/me.12.3.315; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATEK CE, 1990, EXP EYE RES, V50, P345, DOI 10.1016/0014-4835(90)90135-H; PEREZCASTRO AV, 1993, DEVELOPMENT, V119, P363; PIATIGORSKY J, 1993, DEV DYNAM, V196, P267, DOI 10.1002/aja.1001960408; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1993, J BIOL CHEM, V268, P11894; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1992, DEVELOPMENT, V115, P973; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052	71	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17954	17961		10.1074/jbc.273.28.17954	http://dx.doi.org/10.1074/jbc.273.28.17954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651402	hybrid			2022-12-27	WOS:000074816100095
J	Tournois, C; Mutel, V; Manivet, P; Launay, JM; Kellermann, O				Tournois, C; Mutel, V; Manivet, P; Launay, JM; Kellermann, O			Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line - Involvement of arachidonic acid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DOPAMINE RELEASE; ACTIVATION; MIGRAINE; PHOSPHOLIPASE-A2; AGONIST; TERATOCARCINOMA; DIFFERENTIATION; PHARMACOLOGY; HYDROLYSIS	The study of signaling cascades and of functional interactions between 5-hydroxytryptamine (5-HT) receptor pathways with heterogenous brain cell populations remains an arduous task. We took advantage of a serotonergic cell Line to elucidate cross-talks between 5-HT receptors and to demonstrate the involvement of two 5-HT2 receptor subtypes in the regulation of 5-HT1B/1D function. The inducible 1C11 cell line has the unique property of acquiring within 4 days a complete serotonergic phenotype (1C11* cells), including three 5-HT receptors. 5-HT1B/1D and 5-HT2B receptors are expressed since day 2 of the serotonergic differentiation while 5-HT2A receptors are induced at day 4. We first established that 5-HT2B receptors are coupled with the phospholipase A2 (PLA2)-mediated release of arachidonic acid (AA) and that the activation of 5-HT2B receptors in 1C11*d2 cells inhibits the 5-HT1B/1D receptor function via a cyclooxygenase dependent AA metabolite. At day 4, this 5-HT2B-mediated inhibition of the 5-HT1B/1D function can be blocked upon concomitant 5-HT2A activation although a 5-HT2A/PLA2 positive coupling was evidenced. This suggests the existence in 1C11*d4 cells of pathway(s) for 5-HT2A receptors, distinct from PLC and PLA2. Finally, this study reveals the antagonistic roles of 5-HT2A and 5-HT2B receptors in regulating the function of 5-HT1B/1D, a receptor involved in neuropsychiatric disorders and migraine pathogenesis.	Inst Pasteur, CNRS, URA 1960, F-75724 Paris 15, France; Hoffmann La Roche Ag, Pharma Res Dept, CH-4002 Basel, Switzerland; Hop Lariboisiere, Serv Biochim, IFR 6, CR C Bernard, F-75010 Paris, France; Univ Paris 05, Fac Pharm, Biol Cellulaire Lab, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Roche Holding; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kellermann, O (corresponding author), Inst Pasteur, CNRS, URA 1960, 28 Rue Dr Roux, F-75724 Paris 15, France.	okellerm@pasteur.fr	Manivet, Philippe/AAA-1884-2021					Audia JE, 1996, J MED CHEM, V39, P2773, DOI 10.1021/jm960062t; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; Bazan N G, 1986, Adv Neurol, V44, P879; BERG KA, 1994, MOL PHARMACOL, V46, P477; Berg KA, 1996, MOL PHARMACOL, V50, P1017; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERTHOU L, 1992, EUR J CELL BIOL, V58, P377; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Branchek T, 1997, ANNU REP MED CHEM, V32, P1, DOI 10.1016/S0065-7743(08)61459-1; BREWERTON TD, 1988, CLIN PHARMACOL THER, V43, P605, DOI 10.1038/clpt.1988.83; BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; CLARK MA, 1987, J BIOL CHEM, V262, P4402; COHEN ML, 1987, J CARDIOVASC PHARM, V10, P176, DOI 10.1097/00005344-198708000-00007; DOENICKE A, 1988, LANCET, V1, P1309; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476-5381.1995.tb13240.x; FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187; FOZARD JR, 1989, TRENDS PHARMACOL SCI, V10, P307, DOI 10.1016/0165-6147(89)90061-8; FOZARD JR, 1992, CURR OPIN NEUROL NEU, V5, P496; GALLOWAY MP, 1993, SYNAPSE, V15, P90, DOI 10.1002/syn.890150109; GLENNON RA, 1993, DRUG NEWS PERSPECT, V6, P390; HOYER D, 1988, EUR J PHARMACOL, V147, P145, DOI 10.1016/0014-2999(88)90645-0; HOYER D, 1994, PHARMACOL REV, V46, P157; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Iyer RN, 1996, J PHARMACOL EXP THER, V277, P40; KAUFMAN MJ, 1995, J NEUROCHEM, V64, P199; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; KELLERMANN O, 1986, DIFFERENTIATION, V32, P74, DOI 10.1111/j.1432-0436.1986.tb00558.x; Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476-5381.1996.tb15519.x; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LORIC S, 1995, MOL PHARMACOL, V47, P458; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PALACIOS JM, 1990, ANN NY ACAD SCI, V600, P36, DOI 10.1111/j.1749-6632.1990.tb16871.x; PAZOS A, 1985, BRAIN RES, V346, P231, DOI 10.1016/0006-8993(85)90857-1; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAITERI M, 1986, J PHARMACOL EXP THER, V237, P644; SANDERSBUSH E, 1988, SERONTONIN RECEPTORS; Schmuck K, 1996, EUR J NEUROSCI, V8, P959, DOI 10.1111/j.1460-9568.1996.tb01583.x; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x	41	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17498	17503		10.1074/jbc.273.28.17498	http://dx.doi.org/10.1074/jbc.273.28.17498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651340	hybrid			2022-12-27	WOS:000074816100033
J	Brown, CL; Meise, KS; Plowman, GD; Coffey, RJ; Dempsey, PJ				Brown, CL; Meise, KS; Plowman, GD; Coffey, RJ; Dempsey, PJ			Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor - Release of a predominant N-glycosylated 43-kDa soluble form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; EPITHELIAL-CELLS; FACTOR RECEPTOR; PHORBOL-ESTER; COLORECTAL TUMORS; OVARIAN-CARCINOMA; MEMBRANE-PROTEINS; EGF PRECURSOR; TGF-ALPHA	Biosynthesis and processing of amphiregulin (AR) have been investigated in human colorectal (HCA-7, Caco-2) and mammary (MCF-7) cancer cell lines, as well as in Madin-Darby canine kidney cells stably expressing various human AR precursor (pro-AR) forms. Both cells expressing endogenous and transfected AR produce multiple cellular and soluble forms of AR with an N-glycosylated 50-kDa pro-AR form being predominant. Our results demonstrate that sequential proteolytic cleavage within the ectodomain of the 50-kDa pro-AR form leads to release of a predominant N-glycosylated 43-kDa soluble AR, as well as the appearance of other cellular and soluble AR forms. Cell surface biotinylation studies using a C-terminal epitope-tagged pro-AR indicate that all cell surface forms are membrane-anchored and support that AR is released by ectodomain cleavage of pro-AR at the plasma membrane. We also show that pro-AR ectodomain cleavage is a regulated process, which can be stimulated by phorbol 12-myristate 13-acetate and inhibited by the metalloprotease inhibitor, batimastat. In addition, we provide evidence that high molecular mass AR forms may retain the full-length N-terminal pro-region, which may influence the biological activities of these forms.	Vanderbilt Univ, Med Ctr, Dept Med, GI Div,Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Sugen Inc, Redwood City, CA 94063 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Coffey, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, GI Div,Sch Med, CC2218 Med Ctr N, Nashville, TN 37232 USA.		PLOWMAN, Greg D/E-2012-2011		NCI NIH HHS [CA46413] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; Adam RM, 1996, GROWTH FACTORS, V13, P193, DOI 10.3109/08977199609003221; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Culouscou JM, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046924; DAVIES B, 1993, CANCER RES, V53, P2087; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; DeLuca A, 1997, INT J CANCER, V73, P277, DOI 10.1002/(SICI)1097-0215(19971009)73:2<277::AID-IJC19>3.3.CO;2-J; DEMPSEY P, 1997, J CELL BIOL, V138, P1; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ESKO J, 1985, P NATL ACAD SCI USA, V82, P3179; ESKO JD, 1992, ADV EXP MED BIOL, V313, P97; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; JOHNSON G, 1992, J CELL BIOL, V113, P741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; LEE DC, 1995, PHARMACOL REV, V47, P51; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; Modrell B, 1992, GROWTH FACTORS, V7, P305, DOI 10.3109/08977199209046413; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PARRIES G, 1995, J BIOL CHEM, V270, P27954, DOI 10.1074/jbc.270.46.27954; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; PIEPKORN M, 1995, J INVEST DERMATOL, V105, P802, DOI 10.1111/1523-1747.ep12326567; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SAEKI T, 1992, CANCER RES, V52, P3467; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zushi S, 1997, INT J CANCER, V73, P917, DOI 10.1002/(SICI)1097-0215(19971210)73:6<917::AID-IJC26>3.0.CO;2-#	65	101	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17258	17268		10.1074/jbc.273.27.17258	http://dx.doi.org/10.1074/jbc.273.27.17258			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642297	hybrid			2022-12-27	WOS:000074545200087
J	Sicilia, RJ; Hibbs, ML; Bello, PA; Bjorge, JD; Fujita, DJ; Stanley, IJ; Dunn, AR; Cheng, HC				Sicilia, RJ; Hibbs, ML; Bello, PA; Bjorge, JD; Fujita, DJ; Stanley, IJ; Dunn, AR; Cheng, HC			Common in vitro substrate specificity and differential Src homology 2 domain accessibility displayed by two members of the Src family of protein-tyrosine kinases, c-Src and Hck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT MICE; MUTANT MICE; HEMATOPOIESIS; OSTEOPETROSIS; INACTIVATION; PP60(C-SRC); FYN	Hck and Src are members of the Src family of protein-tyrosine kinases that carry out distinct and overlapping functions in vivo (Lowell, C. A., Niwa, M., Soriano, P., and Varmus, H. E. (1996) Blood 87, 1780-1792), In an attempt to understand how Hck and Src can function both independently and in concert, we have compared 1) their in vitro substrate specificity and 2) the accessibility of their Src homology 2 (SH2) domain. Using several synthetic peptides, we have demonstrated that Hck and Src recognize similar structural features in the substrate peptides, suggesting that both kinases have the intrinsic ability to carry out overlapping cellular functions by phosphorylating similar cellular proteins in vivo. Using a phosphotyrosine-containing peptide that has previously been shown to bind the SH2 domain of Src family kinases with high affinity, we found that although Src could bind to the phosphopeptide, Hck showed no interaction. The inability of Hck to bind the phosphopeptide was not a result of a stable intramolecular interaction between its SH2 domain and C-terminal regulatory phosphotyrosine residue (Tyr-520), as most Hck molecules in the purified Hck preparation were not tyrosine-phosphorylated. In contrast to intact Hck, a recombinant truncation analog of Hck was able to bind the phosphopeptide with an affinity similar to that of the Src SH2 domain, suggesting that conformational constraints are imposed on intact Hck that limit accessibility of its SH2 domain to the phosphopeptide. Furthermore, the difference in SH2 domain accessibility is a potential mechanism that enables Src and Hck to perform their respective unique functions by 1) targeting them to different subcellular compartments, whereupon they phosphorylate different cellular proteins, and/or 2) facilitating direct binding to their cellular substrates.	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	University of Melbourne; Ludwig Institute for Cancer Research; University of Calgary	Cheng, HC (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.	Heung-Chin_Cheng.BioChem@muwaye.unimelb.edu.au	Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Cheng, Heung-Chin/0000-0002-4965-7148				AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ALLEN G, 1981, SEQUENCING PROTEINS, P53; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Cheng HC, 1996, BIOCHEMISTRY-US, V35, P11874, DOI 10.1021/bi9603940; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COURTNEIDGE SA, 1994, PROTEIN KINASES, P212; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, BLOOD, V87, P1780; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS HE, 1994, BLOOD, V83, P5; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	28	13	13	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16756	16763		10.1074/jbc.273.27.16756	http://dx.doi.org/10.1074/jbc.273.27.16756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642231	hybrid			2022-12-27	WOS:000074545200021
J	Ulrich, AS; Otter, M; Glabe, CG; Hoekstra, D				Ulrich, AS; Otter, M; Glabe, CG; Hoekstra, D			Membrane fusion is induced by a distinct peptide sequence of the sea urchin fertilization protein bindin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM ADHESIVE PROTEIN; PHOSPHOLIPID-VESICLES; MOLECULAR MECHANISMS; ABALONE SPERMATOZOA; LIPOSOMES; DOMAIN; DESIGN	Fertilization in the sea urchin is mediated by the membrane-associated acrosomal protein bindin, which plays a key role in the adhesion and fusion between sperm and egg. We have investigated the structure/function relationship of an 18-amino acid peptide fragment "B18," which represents the minimal membrane binding motif of the protein and resembles a putative fusion peptide. The peptide was found to mimic the behavior of its parent protein bindin with respect to (a) its high affinity for lipid bilayers, (b) the ability to aggregate and fuse vesicles, (c) the binding of Zn2+ by a histidine-rich motif, (d) the tendency to self-assemble, and (e), as indicated earlier, the adhesion to cell surface polysaccharides. Fluorescence and light scattering assays were used here to monitor peptide-induced lipid mixing, leakage, and aggregation of large unilamellar sphingomyelin/cholesterol vesicles. For these activities, B18 requires the presence of Zn2+ ions, with which it forms oligomeric complexes and assumes a partially cc-helical conformation, as observed by circular dichroism. We conclude that aggregation and fusion involves a "transcomplex" between peptides on apposing vesicles that are connected by Zn2+ bridges.	Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Groningen, Dept Physiol Chem, NL-9713 AV Groningen, Netherlands; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	Friedrich Schiller University of Jena; University of Groningen; University of California System; University of California Irvine	Ulrich, AS (corresponding author), Univ Jena, Inst Mol Biol, Winzerlaer Str 10, D-07745 Jena, Germany.		Ulrich, Anne S/H-5519-2013	Ulrich, Anne S/0000-0001-5571-9483				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; ARTS EGJM, 1993, EUR J BIOCHEM, V217, P1001, DOI 10.1111/j.1432-1033.1993.tb18331.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; DEANGELIS PL, 1990, BIOCHIM BIOPHYS ACTA, V1037, P100, DOI 10.1016/0167-4838(90)90107-Q; DEANGELIS PL, 1988, BIOCHEMISTRY-US, V27, P8189, DOI 10.1021/bi00421a030; DEANGELIS PL, 1990, PEPTIDE RES, V3, P1; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; GLABE C G, 1990, Technique (Philadelphia), V2, P138; GLABE CG, 1985, J CELL BIOL, V100, P794, DOI 10.1083/jcb.100.3.794; GLABE CG, 1985, J CELL BIOL, V100, P800, DOI 10.1083/jcb.100.3.800; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; Hofmann Angelika, 1994, Seminars in Developmental Biology, V5, P233, DOI 10.1006/sedb.1994.1031; HONG KL, 1986, BIOCHEMISTRY-US, V25, P543, DOI 10.1021/bi00351a004; HUGHSON FM, 1995, CURR OPIN STRUC BIOL, V5, P507, DOI 10.1016/0959-440X(95)80036-0; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KENNEDY L, 1989, BIOCHEMISTRY-US, V28, P9153, DOI 10.1021/bi00449a029; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; LENNARZ WJ, 1994, SEMIN DEV BIOL, V5; LoidlStahlhofen A, 1996, EUR BIOPHYS J BIOPHY, V25, P151, DOI 10.1007/s002490050026; LOPEZ A, 1993, DEV BIOL, V156, P24, DOI 10.1006/dbio.1993.1056; MATTHEWS DJ, 1995, CURR OPIN BIOTECH, V6, P419, DOI 10.1016/0958-1669(95)80071-9; Mauk R, 1997, DEV BIOL, V184, P31, DOI 10.1006/dbio.1997.8512; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MINOR JE, 1993, MOL BIOL CELL, V4, P375, DOI 10.1091/mbc.4.4.375; MIRAGLIA SJ, 1993, BIOCHIM BIOPHYS ACTA, V1145, P191, DOI 10.1016/0005-2736(93)90288-B; MIRAGLIA SJ, 1993, THESIS U CALIFORNIA; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Niidome T, 1997, J PEPT RES, V49, P563; Pecheur EI, 1998, BIOCHEMISTRY-US, V37, P2361, DOI 10.1021/bi972697f; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; Stears RL, 1997, DEV BIOL, V187, P200, DOI 10.1006/dbio.1997.8608; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SWANSON WJ, 1995, BIOCHEMISTRY-US, V34, P14202, DOI 10.1021/bi00043a026; VACQUIER VD, 1995, DEV GROWTH DIFFER, V37, P1; VIDAL M, 1995, J BIOL CHEM, V270, P17823, DOI 10.1074/jbc.270.30.17823; WASSARMAN PM, 1995, CURR OPIN CELL BIOL, V7, P658, DOI 10.1016/0955-0674(95)80107-3	44	72	77	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16748	16755		10.1074/jbc.273.27.16748	http://dx.doi.org/10.1074/jbc.273.27.16748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642230	hybrid			2022-12-27	WOS:000074545200020
J	Kuwana, T; Smith, JJ; Muzio, M; Dixit, V; Newmeyer, DD; Kornbluth, S				Kuwana, T; Smith, JJ; Muzio, M; Dixit, V; Newmeyer, DD; Kornbluth, S			Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FAS ANTIBODY; BCL-2 PROTECTS; CELL-DEATH; LAMIN-A; INHIBITION; PROTEASES; REQUIREMENT; ACTIVATION; EXTRACTS; PATHWAY	Apoptosis often involves the release of cytochrome c from mitochondria, leading to caspase activation. However, in apoptosis mediated by CD95 (Fas/APO-1), caspase-8 (FLICE/MACH/Mch5) is immediately activated and, in principle, could process other caspases directly. To investigate whether caspase-8 could also act through mitochondria, we added active caspase-8 to a Xenopus cell-free system requiring these organelles. Caspase-8 rapidly promoted the apoptotic program, culminating in fragmentation of chromatin and the nuclear membrane. In extracts devoid of mitochondria, caspase-8 produced DNA degradation, but left nuclear membranes intact. Thus, mitochondria were required for complete engagement of the apoptotic machinery. In the absence of mitochondria, high concentrations of caspase-8 were required to activate downstream caspases. However, when mitochondria were present, the effects of low concentrations of caspase-8 were vastly amplified through cytochrome c-dependent caspase activation. Caspase-8 promoted cytochrome c release indirectly, by cleaving at least one cytosolic substrate. Bcl-2 blocked apoptosis only at the lowest caspase-8 concentrations, potentially explaining why CD95-induced apoptosis can often evade inhibition by Bcl-2.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	La Jolla Institute for Immunology; Duke University; University of Michigan System; University of Michigan	Newmeyer, DD (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Muzio, Marta/J-9360-2018	Muzio, Marta/0000-0002-7761-759X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056518] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56518, GM50284] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asoh S, 1997, BIOCHEM BIOPH RES CO, V237, P659, DOI 10.1006/bbrc.1997.7210; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHIU VK, 1995, J IMMUNOL, V154, P2023; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lee RK, 1996, INT IMMUNOL, V8, P991, DOI 10.1093/intimm/8.7.991; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sutton VR, 1997, J IMMUNOL, V158, P5783; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang XH, 1996, CELL IMMUNOL, V173, P149, DOI 10.1006/cimm.1996.0260; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	323	329	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16589	16594		10.1074/jbc.273.26.16589	http://dx.doi.org/10.1074/jbc.273.26.16589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632731	hybrid			2022-12-27	WOS:000074436600102
J	Majello, B; Napolitano, G; De Luca, P; Lania, L				Majello, B; Napolitano, G; De Luca, P; Lania, L			Recruitment of human TBP selectively activates RNA polymerase II TATA-dependent promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; INITIATOR ELEMENTS; BINDING PROTEIN; GENE ACTIVATION; MAMMALIAN-CELLS; SEQUENCE; COMPLEX; HIV-1	An increasing body of evidence suggests that eukaryotic activators stimulate polymerase II transcription by facilitating the assembly of the functional basal machinery at the promoter. Here we describe experiments that provide added support for the idea that recruitment of TATA-binding protein (TBP) is a rate-limiting step for transcription activation in mammalian cells. We found that, in human cell lines, recruitment of TBP to a promoter, as a GAL4-TBP fusion protein, can provide a substantial activation of transcription. Activation mediated by the hTBP, tethered to promoter DNA, is strictly dependent upon the presence of a functional TATA element, and it directs faithful transcription initiation. Interestingly, GAL4-hTBP activation was not observed from initiator (Inr) -dependent TATA-less promoters. These results suggest that TBP binding to DNA is not a rate-limiting step for the initial stages of TFIID recruitment to initiator-dependent TATA-less promoters. Finally, we provide evidence that synergy between GAL4-hTBP and defined transcription domains is restricted to activators, such as VP16 and Tat, which are likely to function at steps subsequent to the TFIID recruitment. These findings strengthen the idea that recruitment of TBP represents an important mechanism of activation of TATA-dependent promoters, and on the other hand, they suggest that TBP-DNA interactions are largely dispensable for specific transcription of initiator dependent TATA-less promoters.	Univ Naples Federico II, Dipartimento Genet Biol Gen & Mol, I-80134 Naples, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Lania, L (corresponding author), Univ Naples, Dipartimento Genet Biol Gen & Mol, Via Mezzocannone 8, I-80134 Naples, Italy.		De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Majello, Barbara/0000-0003-2789-3585; Napolitano, Giuliana/0000-0002-1637-6016				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LILLIE JW, 1989, NATURE, V338, P38; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	57	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16509	16516		10.1074/jbc.273.26.16509	http://dx.doi.org/10.1074/jbc.273.26.16509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632719	hybrid			2022-12-27	WOS:000074436600090
J	Tanemura, M; Miyagawa, S; Koyota, S; Koma, M; Matsuda, H; Tsuji, S; Shirakura, R; Taniguchi, N				Tanemura, M; Miyagawa, S; Koyota, S; Koma, M; Matsuda, H; Tsuji, S; Shirakura, R; Taniguchi, N			Reduction of the major swine xenoantigen, the alpha-galactosyl epitope by transfection of the alpha 2,3-sialyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT REGULATORY PROTEINS; DECAY-ACCELERATING FACTOR; ANTI-GAL ANTIBODY; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; XENOGRAFT REJECTION; MOLECULAR-CLONING; CDNA SEQUENCE; EXPRESSION; XENOTRANSPLANTATION; GLYCOPROTEIN	alpha 2,3-Sialyltransferase represents a putative enzyme that reduces the Gal alpha 1-3Gal beta 1-4GlcNAc-R (the alpha-galactosyl epitope) by intracellular competition with alpha 1,3-galactosyltransferase for a common acceptor substrate. This study demonstrates that the overexpression of the alpha 2,3-sialyltransferase gene suppresses the antigenicity of swine endothelial cells to human natural antibodies by 77% relative to control cells and by 30% relative to cells transfected with alpha 1,2-fucosyltransferase, and in addition, it reduces the complement-mediated cell lysis by 75% compared with control cells and by 22% compared with cells transfected with alpha 1,2-fucosyltransferase. The mechanism by which the alpha-galactosyl epitope was reduced was also studied. Suppression of alpha 1,3-galactosyltransferase activity by 30-63% was observed in the transfectants with alpha 2,3-sialyltransferase, and mRNA expression of the alpha 1,3-galactosyltransferase gene was reduced as well. The data suggest that the alpha 2,3-sialyltransferase effectively reduced the cy-galactosyl epitope as well as or better than the alpha 1,2-fucosyltransferase did and that the reduction of the alpha-galactosyl epitope is due not only to substrate competition but also to an overall reduction of endogenous alpha 1,3-galactosyltransferase enzyme activity.	Osaka Univ, Sch Med, Biomed Res Ctr, Div Organ Transplantat, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Biochem, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg 1, Osaka 5650871, Japan; Inst Phys & Chem Res, Frontier Res Program, Wako, Saitama 3510100, Japan	Osaka University; Osaka University; Osaka University; RIKEN	Miyagawa, S (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Div Organ Transplantat, 2-2 Yamadaoka, Osaka 5650871, Japan.	miyagawa@orgtrp.med.osaka-u.ac.jp	Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; CALNE RY, 1970, TRANSPL P, V2, P550; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Hosenpud JD, 1997, J HEART LUNG TRANSPL, V16, P691; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; Mikata S, 1998, TRANSPLANTATION, V65, P363, DOI 10.1097/00007890-199802150-00011; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; MIYAGAWA S, 1988, TRANSPLANTATION, V46, P825, DOI 10.1097/00007890-198812000-00007; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; NISHIURA T, 1990, CANCER RES, V50, P5345; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PLATT JL, 1991, TRANSPLANTATION, V52, P937, DOI 10.1097/00007890-199112000-00001; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; Sambrook J, 1988, MOL CLONING LAB MANU; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; SEYA T, 1986, J EXP MED, V163, P837, DOI 10.1084/jem.163.4.837; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; SUIGITA Y, 1988, J BIOCH, V104, P633; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; Taniguchi N, 1996, GLYCOBIOLOGY, V6, P691, DOI 10.1093/glycob/6.7.691; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Waterworth PD, 1997, TRANSPL P, V29, P899, DOI 10.1016/S0041-1345(96)00224-2; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P4152; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	52	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16421	16425		10.1074/jbc.273.26.16421	http://dx.doi.org/10.1074/jbc.273.26.16421			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632707	hybrid			2022-12-27	WOS:000074436600078
J	Tarasova, NI; Stauber, RH; Michejda, CJ				Tarasova, NI; Stauber, RH; Michejda, CJ			Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE CHEMOATTRACTANT; RETROVIRAL VECTORS; HIV-1 ENTRY; INFECTION; SDF-1; 7-TRANSMEMBRANE; INTERNALIZATION; LESTR/FUSIN; CLONING; BLOCKS	A chimeric protein consisting of CXC-chemokine receptor 4 (CXCR4) and the green fluorescent protein (GFP) was used for studying receptor localization and trafficking in real time in stably transduced HeLa, U-937, GEM, and NIH/3T3 cells. CXCR4-GFP was fully active as a co-receptor in mediating human immunodeficiency virus (HIV) entry. Both CXCR4 and CXCR4-GFP were found to undergo significant spontaneous endocytosis, Only 51.5 +/- 7.8% of receptor molecules were found on the plasma membrane in CD4-positive cells, 43.9 +/- 8.5% were found in CD4-negative HeLa cells, 75.6 +/- 9.7% were found in U-937 cells, 72.5 +/- 7.9 were found in CEM cells, and almost none were found in in NIH/3T3 cells. Stromal cell-derived factor-1 alpha induced rapid endocytosis of cell surface receptor molecules. A significant part of CXCR4 was targeted to lysosomes upon binding of the ligands, and recycling of internalized CXCR4 was not efficient. Only about 30% of receptor molecules recycled back to the cell surface in HeLa cells, 5% recycled in U937, and 10% recycled in CEM cells, suggesting that the protective effect of chemokines against HIV infection can be attributed not only to competition for binding but also to depletion of the co-receptor molecules from the cell surface. Envelope glycoprotein gp120 of syncytia-inducing/lymphocyte tropic HIV-1 strains induced rapid internalization of CXCR4 in both CD4-negative and CD4-positive cells, suggesting that gp120 is a high affinity ligand of CXCR4.	NCI, Mol Aspects Drug Design Sect, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Inst Virol, D-91054 Erlangen, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Erlangen Nuremberg	Tarasova, NI (corresponding author), NCI, Mol Aspects Drug Design Sect, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Frederick, MD 21702 USA.			Tarasova, Nadya/0000-0002-4949-0069; Stauber, Roland/0000-0002-1341-4523				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BERGER EA, 1997, AIDS, V11, P3; Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bohm SK, 1997, BIOCHEM J, V322, P1; CONNOR RI, 1995, VIROLOGY, V206, P936; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YEE JK, 1994, METHOD CELL BIOL, V43, P99	26	147	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15883	15886		10.1074/jbc.273.26.15883	http://dx.doi.org/10.1074/jbc.273.26.15883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632631	hybrid			2022-12-27	WOS:000074436600002
J	Uchida, K; Kanematsu, M; Morimitsu, Y; Osawa, T; Noguchi, N; Niki, E				Uchida, K; Kanematsu, M; Morimitsu, Y; Osawa, T; Noguchi, N; Niki, E			Acrolein is a product of lipid peroxidation reaction - Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED MACROPHAGE DEGRADATION; SMOOTH-MUSCLE CELLS; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; ENDOTHELIAL-CELLS; MYELOPEROXIDASE; ALDEHYDES; CATALYST; ADDUCTS; LDL	Lipoprotein peroxidation, especially the modification of apolipoprotein B-100, has been implicated to play an important role in the pathogenesis of atherosclerosis. However, there have been few detailed insights into the chemical mechanism of derivatization of apolipoproteins during oxidation, In the present study, we provide evidence that the formation of the toxic pollutant acrolein (CH2=CH-CHO) and its conjugate with lysine residues is involved in the oxidative modification of human low density lipoprotein (LDL), Upon incubation with LDL, acrolein preferentially reacted with lysine residues. To determine the structure of acrolein-lysine adduct in protein, the reaction of acrolein with a lysine derivative was carried out. Employing N-alpha-acetyllysine, we detected a single product, which was identified to be a novel acrolein-lysine adduct, N-alpha-acetyl-N-epsilon-(3-formyl-3,4-dehydropiperidino)lysine. The acid hydrolysis of the adduct led to the derivative that was detectable with amino acid analysis. It was revealed that, upon in vitro incubation of LDL with acrolein, the lysine residues that had disappeared were partially recovered by N-epsilon-(3-formyl-3,4-dehydropiperidino)lysine. In addition, we found that the same derivative was detected in the oxidatively modified LDL with Cu2+ and that the adduct formation was correlated with LDL peroxidation assessed by the consumption of alpha-tocopherol and cholesteryl ester and the concomitant formation of cholesteryl ester hydroperoxide. Enzyme-linked immunosorbent assay that measures free acrolein revealed that a considerable amount of acrolein was released from the Cu2+-oxidized LDL. Furthermore, metal-catalyzed oxidation of arachidonate was associated with the formation of acrolein, indicating that polyunsaturated fatty acids including arachidonate represent potential sources of acrolein generated during the peroxidation of LDL. These results indicate that acrolein is not just a pollutant but also a lipid peroxidation product that could be ubiquitously generated in biological systems.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 153, Japan	Nagoya University; University of Tokyo	Niki, E (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@nuagr1.agr.nagoya-u.ac.jp		Uchida, Koji/0000-0003-3894-5299				Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GAN JC, 1987, RES COMMUN CHEM PATH, V55, P419; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HOBERMAN HD, 1988, J BIOCHEM TOXICOL, V3, P105, DOI 10.1002/jbt.2570030205; IZARD C, 1978, Mutation Research, V47, P115, DOI 10.1016/0165-1110(78)90016-7; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; JOHNSTONE RAW, 1959, CHEM REV, V59, P885, DOI 10.1021/cr50029a004; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; LENZ ML, 1990, J LIPID RES, V31, P1043; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; Noguchi N, 1996, ATHEROSCLEROSIS, V123, P227, DOI 10.1016/0021-9150(96)05811-X; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; POCKER Y, 1988, J BIOL CHEM, V263, P6169; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAMOS P, 1995, J LIPID RES, V36, P2113; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UCHIDA K, 1995, BIOCHEM BIOPH RES CO, V212, P1068, DOI 10.1006/bbrc.1995.2078; Uchida K, 1997, ARCH BIOCHEM BIOPHYS, V346, P45, DOI 10.1006/abbi.1997.0266; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	34	442	455	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16058	16066		10.1074/jbc.273.26.16058	http://dx.doi.org/10.1074/jbc.273.26.16058			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632657	hybrid			2022-12-27	WOS:000074436600028
J	Wilk, S; Wilk, E; Magnusson, RP				Wilk, S; Wilk, E; Magnusson, RP			Purification, characterization, and cloning of a cytosolic aspartyl aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST AMINOPEPTIDASE; BLEOMYCIN HYDROLASE; MOLECULAR-CLONING; BP-1/6C3 ANTIGEN; RAT; BRAIN; INHIBITORS; DNA; LOCALIZATION; METABOLISM	An aminopeptidase with a preference for N-terminal aspartyl and glutamyl residues but distinct from glutamyl aminopeptidase (EC 3.4.11.7) was purified to near homogeneity from rabbit brain cytosol. Its properties were similar to an enzyme described previously (Kelly, J. A, Neidle, E, L., and Neidle, A. (1983) J. Neurochem. 40, 1727-1734). Aspartyl aminopeptidase had barely detectable activity toward simple aminoacyl-naphthylamide substrates. Its activity was determined with the substrate Asp-Ala-Pro-naphthylamide in the presence of excess dipeptidyl-peptidase IV (EC 3.4.14,5). The native enzyme has a molecular mass of 440 kDa and migrates as a single band of 55 kDa after SDS-polyacrylamide gel electrophoresis. The sequences of three tryptic peptides were used to screen the GenBank(TM) data base of expressed sequence tags. Human and mouse clones described as "similar to a yeast vacuolar aminopeptidase" and containing full-length cDNAs were identified and sequenced. The human cDNA was expressed in Escherichia coli. The amino acid sequence has significant homology to yeast aminopeptidase I, placing it as the first identified mammalian member of the M18 family of metalloproteinases. Homologous sequences in Caenorhabditis elegans and in prokaryotes revealed three conserved histidines, three conserved glutamates and five conserved aspartates. Aspartyl aminopeptidase is found at relatively high levels in all mammalian tissues examined and is likely to play an important role in intracellular protein and peptide metabolism.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wilk, S (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-17392] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 1997, EUR J BIOCHEM, V245, P283, DOI 10.1111/j.1432-1033.1997.t01-1-00283.x; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; CHANG YH, 1989, J BIOL CHEM, V264, P6979; CHEUNG HS, 1971, BIOCHIM BIOPHYS ACTA, V242, P190, DOI 10.1016/0005-2744(71)90098-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FRIEDMAN TC, 1985, BIOCHEM BIOPH RES CO, V132, P787, DOI 10.1016/0006-291X(85)91201-X; GLENNER GG, 1962, NATURE, V194, P867, DOI 10.1038/194867a0; GLENNER GG, 1961, NATURE, V192, P338, DOI 10.1038/192338a0; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; HERSH LB, 1987, PEPTIDES, V8, P523, DOI 10.1016/0196-9781(87)90019-2; IRIBAR C, 1995, BRAIN RES, V687, P211, DOI 10.1016/0006-8993(95)00538-2; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KELLY JA, 1983, J NEUROCHEM, V40, P1727, DOI 10.1111/j.1471-4159.1983.tb08148.x; Kuda T, 1997, BIOCHEM BIOPH RES CO, V231, P526, DOI 10.1006/bbrc.1996.5920; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P148, DOI 10.1006/abbi.1995.0020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELBYE SW, 1971, J BIOL CHEM, V246, P2459; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; Migaud M, 1996, PEPTIDES, V17, P601, DOI 10.1016/0196-9781(96)00036-8; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROHM KH, 1984, H-S Z PHYSIOL CHEM, V365, P1235, DOI 10.1515/bchm2.1984.365.2.1235; ROHM KH, 1985, ARCH BIOCHEM BIOPHYS, V239, P216, DOI 10.1016/0003-9861(85)90829-X; Sambrook J., 2002, MOL CLONING LAB MANU; Song LJ, 1997, BRAIN RES, V744, P1, DOI 10.1016/S0006-8993(96)00952-3; Takeda A, 1996, J BIOCHEM-TOKYO, V120, P353; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WILK S, 1993, ADV NEUROIMMUNOL, V3, P195, DOI 10.1016/S0960-5428(05)80021-X; WILK S, 1969, BIOCHEMISTRY-US, V8, P3168, DOI 10.1021/bi00836a006; WILK S, 1995, METABOLISM BRAIN PEP, P215; WRIGHT JW, 1992, BRAIN RES REV, V17, P227, DOI 10.1016/0165-0173(92)90018-H; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	37	82	88	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15961	15970		10.1074/jbc.273.26.15961	http://dx.doi.org/10.1074/jbc.273.26.15961			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632644	hybrid			2022-12-27	WOS:000074436600015
J	Zhao, AC; Ansari, RA; Schmidt, MC; Khan, SA				Zhao, AC; Ansari, RA; Schmidt, MC; Khan, SA			An oligonucleotide inhibits oligomerization of a rolling circle initiator protein at the pT181 origin of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID REPLICATION; STAPHYLOCOCCUS-AUREUS; DNA; SEQUENCE; TERMINATION; SPECIFICITY; TOPOISOMERASE; HETERODIMER; MUTATIONS; ELEMENT	A large number of plasmids have been shown to replicate by a rolling circle (RC) mechanism. The initiators encoded by these plasmids have origin-specific, nicking-closing activity that is required for the initiation and termination of RC replication. Since the initiators of many RC plasmids are rate-limiting for replication, these proteins are usually inactivated after supporting one round of replication. In the case of the pT181 plasmid, inactivation of the initiator RepC protein occurs by the attachment of an oligonucleotide to its active tyrosine residue. We have generated the inactivated form of RepC, termed RepC*, in, vitro and investigated the effects of attachment of the oligonucleotide on its various biochemical activities. Our results demonstrate that while RepC* is inactive in nicking-closing and replication activities due to the blockage of its active tyrosine residue, it is competent in origin DNA binding and DNA religation activities. We have investigated the oligomeric state of RepC and RepC* and found that RepC exists as a dimer in solution and can oligomerize on the DNA, We have generated heterodimers in vitro between the wild-type and epitope-tagged RepC proteins. In electrophoretic mobility shift experiments, the initiator heterodimers generated a novel DNA-protein complex, demonstrating that it binds to DNA as a dimer, We have shown that a DNA binding mutant of RepC can be targeted to the origin in the presence of the wild-type protein primarily through a protein-protein interaction. Interestingly, RepC* is defective in its ability to oligomerize on the DNA. RepC* inhibited the DNA binding and replication activity of wild-type RepC to only a very limited extent, suggesting that it may play only a minor regulatory role in replication in vivo, Based on these and earlier results, we propose a model for the role of RepC during the initiation and termination of pT181 RC replication.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Room E 1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	Khan@med.pitt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031685] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAAS PD, 1988, CURR TOP MICROBIOL, V136, P31; BARGONETTI J, 1993, EMBO J, V12, P3659, DOI 10.1002/j.1460-2075.1993.tb06040.x; CARLETON S, 1984, EMBO J, V3, P2407, DOI 10.1002/j.1460-2075.1984.tb02147.x; DELSOLAR G, 1993, MOL MICROBIOL, V8, P789; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; DEMPSEY LA, 1992, J BIOL CHEM, V267, P24538; GRUSS A, 1989, MICROBIOL REV, V53, P231, DOI 10.1128/MMBR.53.2.231-241.1989; GUAN C, 1988, GENE, V67, P21; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; IORDANESCU S, 1995, MOL MICROBIOL, V16, P477; Jin RZ, 1996, J BIOL CHEM, V271, P31086, DOI 10.1074/jbc.271.49.31086; Jin RZ, 1997, J BACTERIOL, V179, P141, DOI 10.1128/jb.179.1.141-147.1997; Jin RZ, 1997, EMBO J, V16, P4456, DOI 10.1093/emboj/16.14.4456; KHAN SA, 1983, PLASMID, V10, P251, DOI 10.1016/0147-619X(83)90039-2; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; MURRAY RW, 1989, J BIOL CHEM, V264, P1051; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1989, CELL, V59, P395, DOI 10.1016/0092-8674(89)90300-0; RASOOLY A, 1994, EMBO J, V13, P5245, DOI 10.1002/j.1460-2075.1994.tb06856.x; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; REINBERG D, 1983, J BIOL CHEM, V258, P529; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THOMAS CD, 1988, BIOCHEM SOC T, V16, P758, DOI 10.1042/bst0160758; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x; Zhao AC, 1997, MOL MICROBIOL, V24, P535, DOI 10.1046/j.1365-2958.1997.3641730.x; Zhao AC, 1996, J BACTERIOL, V178, P5222, DOI 10.1128/jb.178.17.5222-5228.1996; ZINDER ND, 1985, MICROBIOL REV, V49, P101, DOI 10.1128/MMBR.49.2.101-106.1985	32	11	11	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16082	16089		10.1074/jbc.273.26.16082	http://dx.doi.org/10.1074/jbc.273.26.16082			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632660	hybrid			2022-12-27	WOS:000074436600031
J	Fan, CY; Pan, J; Usuda, N; Yeldandi, AV; Rao, MS; Reddy, JK				Fan, CY; Pan, J; Usuda, N; Yeldandi, AV; Rao, MS; Reddy, JK			Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase - Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; DIFFERENTIAL EXPRESSION; BETA-OXIDATION; PPAR-ALPHA; GENE; MOUSE; ACID; ADRENOLEUKODYSTROPHY; CLONING; MEMBER	Peroxisomal beta-oxidation system consists of fc,ur consecutive reactions to preferentially metabolize very long chain fatty acids. The first step of this system, catalyzed by acyl-CoA oxidase (AOX), converts fatty acyl-CoA to 2-trans-enoyl-CoA. Herein, we show that mice deficient in AOX exhibit steatohepatitis, increased hepatic H2O2 levels, and hepatocellular regeneration, leading to a complete reversal of fatty change by 6 to 8 months of age. The liver of AOX-/- mice with regenerated hepatocytes displays profound generalized spontaneous peroxisome proliferation and increased mRNA levels of genes that are regulated by peroxisome proliferator-activated receptor alpha (PPAR alpha). Hepatic adenomas and carcinomas develop in AOX-/- mice by 15 months of age due to sustained activation of PPAR alpha. These observations implicate acyl-CoA and other putative substrates for AOX, as biological ligands for PPAR alpha; thus, a normal AOX gene is indispensable for the physiological regulation of PPAR alpha.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@nwu.edu			NIGMS NIH HHS [GM 23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARSLAND A, 1991, BIOCHEM PHARMACOL, V41, P53, DOI 10.1016/0006-2952(91)90010-3; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; ASHBY J, 1994, HUM EXP TOXICOL S2, V13, P1; BERGE RK, 1985, BIOCHIM BIOPHYS ACTA, V837, P141, DOI 10.1016/0005-2760(85)90237-1; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; CHU RY, 1995, J BIOL CHEM, V270, P29636; deDuve C, 1996, ANN NY ACAD SCI, V804, P1; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; FAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; HUANG Q, 1995, INT J ONCOL, V6, P307; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kobayashi T, 1997, BIOCHEM BIOPH RES CO, V232, P631, DOI 10.1006/bbrc.1997.6340; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; POLLTHE BT, 1987, EUR J PEDIATR, V146, P477, DOI 10.1007/BF00441598; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHOONJANS K, 1995, J BIOL CHEM, V270, P16269; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; Tugwood JD, 1996, ANN NY ACAD SCI, V804, P252, DOI 10.1111/j.1749-6632.1996.tb18620.x; Usuda N, 1996, ANN NY ACAD SCI, V804, P297, DOI 10.1111/j.1749-6632.1996.tb18624.x; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	58	293	304	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15639	15645		10.1074/jbc.273.25.15639	http://dx.doi.org/10.1074/jbc.273.25.15639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624157	hybrid			2022-12-27	WOS:000074284200051
J	Groot-Kormelink, PJ; Luyten, WHML; Colquhoun, D; Sivilotti, LG				Groot-Kormelink, PJ; Luyten, WHML; Colquhoun, D; Sivilotti, LG			A reporter mutation approach shows incorporation of the "orphan" subunit beta 3 into a functional nicotinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; DESENSITIZATION; CHANNELS; FAMILY; DOMAIN	We have investigated whether the neuronal nicotinic subunit beta 3 can participate in the assembly of functional recombinant receptors, Although beta 3 is expressed in several areas of the central nervous system, it does not form functional receptors when expressed heterologously together with an alpha or another beta nicotinic subunit, We inserted into the human beta 3 subunit a reporter mutation (V273T), which, if incorporated into a functional receptor, would be expected to increase its agonist sensitivity and maximum response to partial agonists, Expressing the mutant beta 3(V273T) in Xenopus oocytes together with both the alpha 3 and the beta 4 subunits resulted in the predicted changes in the properties of the resulting nicotinic receptor when compared with those of alpha 3 beta 4 receptors. This indicated that some of the receptors incorporated the mutant beta 3 subunit, as part of a "triplet" alpha 3 beta 4 beta 3 receptor. The proportion of triplet receptors was dependent on the ratios of the alpha 3:beta 4:beta 3 cRNA injected. We conclude that, like the related alpha 5 subunit, the beta 3 subunit can form functional receptors only if expressed together with both alpha and beta subunits.	Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England; Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium	University of London; University College London; Johnson & Johnson	Sivilotti, LG (corresponding author), Univ London, Sch Pharm, Dept Pharmacol, 2939 Brunswick Sq, London WC1N 1AX, England.	sivilo@cua.ulsop.ac.uk	Colquhoun, David/C-1664-2008; Sivilotti, Lucia/D-8919-2011	Colquhoun, David/0000-0002-4263-017X; Sivilotti, Lucia/0000-0003-2510-8424				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Chang YC, 1996, J NEUROSCI, V16, P5415; COLQUHOUN D, 1987, PERSPECTIVES RECEPTO, P103; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; Fucile S, 1997, NEUROREPORT, V8, P2433, DOI 10.1097/00001756-199707280-00005; Fucile S, 1998, EUR J NEUROSCI, V10, P172, DOI 10.1046/j.1460-9568.1998.00001.x; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; Groot Kormelink P. J., 1997, FEBS LETT, V400, P309; LABARCA C, 1995, NATURE, V376, P415; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Lewis TM, 1997, J PHYSIOL-LONDON, V505, P299, DOI 10.1111/j.1469-7793.1997.299bb.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SIVILOTTI L, 1995, SCIENCE, V269, P1681, DOI 10.1126/science.7569892; Sivilotti LG, 1997, J PHYSIOL-LONDON, V500, P123, DOI 10.1113/jphysiol.1997.sp022004; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030	22	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15317	15320		10.1074/jbc.273.25.15317	http://dx.doi.org/10.1074/jbc.273.25.15317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624109	hybrid, Green Submitted			2022-12-27	WOS:000074284200003
J	Larsen, CM; Wadt, KAW; Juhl, LF; Andersen, HU; Karlsen, AE; Su, MSS; Seedorf, K; Shapiro, L; Dinarello, CA; Mandrup-Poulsen, T				Larsen, CM; Wadt, KAW; Juhl, LF; Andersen, HU; Karlsen, AE; Su, MSS; Seedorf, K; Shapiro, L; Dinarello, CA; Mandrup-Poulsen, T			Interleukin-1 beta-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ATF2; BETA-CELLS; MAP KINASE; INSULIN-SECRETION; IN-VITRO; SYNTHASE EXPRESSION; INDUCED APOPTOSIS; RINM5F CELLS; KAPPA-B; INHIBITOR	Interleukin-1 beta (IL-1 beta) is cytotoxic to rat pancreatic beta-cells by inhibiting glucose oxidation, causing DNA damage and inducing apoptosis, Nitric oxide (NO) is a necessary but not sufficient mediator of these effects. IL-1 beta induced kinase activity toward Elk-1, activation transcription factor 2, c-Jun, and heat shock protein 25 in rat islets. By Western blotting with phosphospecific antibodies and by immunocomplex kinase assay, IL-1 beta was shown to activate extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (p38) in islets and rat insulinoma cells. Specific ERK1/2 and p38 inhibitors individually reduced but in combination blocked IL-1 beta-mediated islet NO synthesis, and reverse transcription-polymerase chain reaction of inducible NO synthase mRNA showed that ERK1/2 and p38 controlled IL-1 beta-induced islet inducible NO synthase expression at the transcriptional level. Hyperosmolarity caused phosphorylation of Elk-1, activation transcription factor 2, and heat shock protein 25 and activation of ERK1/2 and p38 in islets comparable to that induced by IL-1 beta but did not lead to NO synthesis. Inhibition of p38 but not of ERK1/2 attenuated IL-1 beta-mediated inhibition of glucose-stimulated insulin release, We conclude that ERK1/2 and p38 activation is necessary but not sufficient for IL-1 beta-mediated beta-cell NO synthesis and that p38 is involved in signaling of NO-independent effects of IL-1 beta in beta-cells.	Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Hagedorn Res Inst, DK-2820 Gentofte, Denmark; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute; Vertex Pharmaceuticals; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Mandrup-Poulsen, T (corresponding author), Steno Diabet Ctr, DK-2820 Gentofte, Denmark.	tmpo@novo.dk	Dinarello, Charles/C-8524-2013	Andersen, Henrik Ullits/0000-0001-8048-9720; Mandrup-Poulsen, Thomas/0000-0002-3215-9273	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614, R56AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKABANE A, 1995, BIOCHEM BIOPH RES CO, V215, P524, DOI 10.1006/bbrc.1995.2496; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSEN HU, 1994, DIABETES, V43, P770, DOI 10.2337/diabetes.43.6.770; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRUNSTEDT J, 1984, METHODS DIABETES RES, P254; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Kinugawa K, 1997, CIRC RES, V81, P911; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANDRUPPOULSEN T, 1987, ACTA PATH MICRO IM C, V95, P55; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; RABINOVITCH A, 1990, J CLIN ENDOCR METAB, V71, P152, DOI 10.1210/jcem-71-1-152; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reimers JI, 1996, DIABETES, V45, P771, DOI 10.2337/diabetes.45.6.771; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SALDEEN J, 1994, BIOCHEM BIOPH RES CO, V203, P149, DOI 10.1006/bbrc.1994.2161; SANDLER S, 1989, ENDOCRINOLOGY, V124, P1492, DOI 10.1210/endo-124-3-1492; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; WELSH N, 1994, BIOSCIENCE REP, V14, P43, DOI 10.1007/BF01901637; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	57	153	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15294	15300		10.1074/jbc.273.24.15294	http://dx.doi.org/10.1074/jbc.273.24.15294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614146	hybrid			2022-12-27	WOS:000074160400088
J	McLachlin, DT; Bestard, JA; Dunn, SD				McLachlin, DT; Bestard, JA; Dunn, SD			The b and delta subunits of the Escherichia coli ATP synthase interact via residues in their C-terminal regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; H+-ATPASE; ADENOSINE-TRIPHOSPHATASE; MONOCLONAL-ANTIBODIES; CROSS-LINKING; ALPHA-SUBUNIT; F1F0 ATPASE; BINDING; F1-ATPASE; MEMBRANE	An affinity resin for the F-1 sector of the Escherichia coli ATP synthase was prepared by coupling the b subunit to a solid support through a unique cysteine residue in the N-terminal leader. b(24-156), a form of b lacking the N-terminal transmembrane domain, was able to compete with the affinity resin for binding of F-1. Truncated forms of b(24-156), in which one or four residues from the C terminus mere removed, competed poorly for F-1 binding, suggesting that these residues play an important role in b-F-1 interactions. Sedimentation velocity analytical ultracentrifugation revealed that removal of these C-terminal residues from b(24-156) resulted in a disruption of its association with the purified delta subunit of the enzyme. To determine whether these residues interact directly with delta, cysteine residues were introduced at various C-terminal positions of b and modified with the heterobifunctional cross-linker benzophenone-4-maleimide, Cross-links between b and delta were obtained when the reagent was incorporated at positions 155 and 158 (two residues beyond the normal C terminus) in both the reconstituted b(24-156)-F-1 complex and the membrane-bound F1F0 complex. CNBr digestion followed by peptide sequencing showed the site of cross-linking within the 177-residue delta 6 subunit to be C-terminal to residue 148, possibly at Met-158. These results indicate that the b and delta subunits interact via their C-terminal regions and that this interaction is instrumental in the binding of the F-1 sector to the b subunit of F-0.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.		Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; ANGOV E, 1991, J BACTERIOL, V173, P407, DOI 10.1128/jb.173.1.407-411.1991; ARIS JP, 1983, J BIOL CHEM, V258, P4599; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; COLLINSON IR, 1994, J MOL BIOL, V242, P408; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; ENGELBRECHT S, 1991, Z NATURFORSCH C, V46, P759; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, J BIOL CHEM, V258, P2882; JANS DA, 1985, J BACTERIOL, V162, P420, DOI 10.1128/JB.162.1.420-426.1985; JOSHI S, 1990, J BIOL CHEM, V265, P14518; Joshi S, 1997, BIOCHEMISTRY-US, V36, P10936, DOI 10.1021/bi9704109; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; Mao YQ, 1997, ARCH BIOCHEM BIOPHYS, V337, P8, DOI 10.1006/abbi.1996.9777; MCCLACHLIN DT, 1997, J BIOL CHEM, V272, P21233; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; MONTICELLO RA, 1994, J BACTERIOL, V176, P1383, DOI 10.1128/jb.176.5.1383-1389.1994; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Penefsky H S, 1979, Methods Enzymol, V56, P527; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAKUMI K, 1986, J BIOL CHEM, V261, P5761; Sambrook J., 2002, MOL CLONING LAB MANU; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; SCHAIRER HU, 1982, BIOSCIENCE REP, V2, P631, DOI 10.1007/BF01314228; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; STAFFORD WF, 1992, ANAL BIOCHEM, V161, P70; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198	56	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15162	15168		10.1074/jbc.273.24.15162	http://dx.doi.org/10.1074/jbc.273.24.15162			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614129	hybrid			2022-12-27	WOS:000074160400071
J	Srinivas, V; Zhu, X; Salceda, S; Nakamura, R; Caro, J				Srinivas, V; Zhu, X; Salceda, S; Nakamura, R; Caro, J			Hypoxia-inducible factor 1 alpha (HIF-1 alpha) is a non-heme iron protein - Implications for oxygen sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; TRANSCRIPTIONAL RESPONSE; ENHANCER ELEMENT; MECHANISM; CELLS	The hypoxia-inducible factor 1 complex (HIF-1) is involved in the transcriptional activation of several genes, like erythropoietin and vascular endothelial growth factor, that are responsive to the lack of oxygen. The HIF-1 complex is composed of two b-HLH proteins: HIF-1 beta, that is constitutively expressed, and HIF-1 alpha, that is present only in hypoxic cells. The HIF-1 alpha subunit is continuously synthesized and degraded by the ubiquitin-proteasome under oxic conditions. Hypoxia, transition metals, iron chelators, and several antioxidants stabilize the HIF-1 alpha protein, allowing the formation of the transcriptionally active HIF-1 complex. The mechanisms of oxygen sensing and the pathways leading to HIF-1 alpha stabilization are unclear. Because the involvement of a heme protein oxygen sensor has been postulated, we tested the heme sensor hypothesis by using a luciferase-expressing cell line (B-l), that is highly responsive to hypoxia, Exposure of B-l cells to carbon monoxide and heme synthesis inhibitors failed to show any effect on the hypoxia responsiveness of these cells, suggesting that heme proteins are not involved in hypoxia sensing. Measurement of iron in recombinantly expressed HIF-1 alpha protein revealed that this protein binds iron in vivo. Iron binding was localized to a 129-amino acid peptide between sequences 529 and 658 of the HIF-1 alpha protein. Although the exact structure of the iron center has not been yet defined, a 2:1 metal/protein molar ratio suggests a di-iron center, probably similar to the one found in hemerythrin. This finding is compatible with a model where redox: reaction may occur directly in the iron center of the HIF-1 alpha subunit, affecting its survival in oxic conditions.	Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA	Jefferson University	Caro, J (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, 1015 Walnut St, Philadelphia, PA 19107 USA.	carol@jeflin.tju.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034642] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-34642] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER H, 1995, NEWS PHYSIOL SCI, V10, P211; BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1985, J BIOL CHEM, V260, P9251; Biaglow JE, 1997, RADIAT RES, V148, P181, DOI 10.2307/3579576; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; ECKARDT KU, 1993, PFLUG ARCH EUR J PHY, V423, P356, DOI 10.1007/BF00374928; Ehleben W, 1997, KIDNEY INT, V51, P483, DOI 10.1038/ki.1997.67; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graven KK, 1998, AM J PHYSIOL-CELL PH, V274, pC347, DOI 10.1152/ajpcell.1998.274.2.C347; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; JIANG BH, 1996, J BIOL CHEM, V271, P1771; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ratcliffe PJ, 1997, NEPHROL DIAL TRANSPL, V12, P1842, DOI 10.1093/ndt/12.9.1842; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SLAVIN W, 1988, METHOD ENZYMOL, V158, P117, DOI 10.1016/0076-6879(88)58052-7; Steyermark A., 1961, QUANTITATIVE ORGANIC; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609	29	63	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18019	18022		10.1074/jbc.273.29.18019	http://dx.doi.org/10.1074/jbc.273.29.18019			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660756	hybrid			2022-12-27	WOS:000074828500011
J	Young, JC; Obermann, WMJ; Hartl, FU				Young, JC; Obermann, WMJ; Hartl, FU			Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RECEPTOR COMPLEXES; IMMUNOPHILIN; COMPONENT; FKBP52; CYCLE; HSP70; HIP	The molecular chaperone hsp90 in the eukaryotic cytosol interacts with a variety of protein cofactors, Several of these cofactors have protein domains containing tetratricopeptide repeat (TPR) motifs, which mediate binding to hsp90. Using a yeast two-hybrid screen, the 12-kDa C-terminal domain of human hspg90 alpha (C90) was found to mediate the interaction of hsp90 with TPR-containing sequences from the hsp90 cofactors FKBP51/54 and FKBP52. In addition, the mitochondrial outer membrane protein hTOM34p was identified as a TPR-containing putative partner protein of hsp90, In experiments with purified proteins, the TPR-containing cofactor p60 (Hop) was shown to form stable complexes with hsp90. A deletion mutant of hsp90 lacking the C90 domain was unable to bind p60, whereas deletion of the similar to 25-kDa N-terminal domain of hsp90 did not affect complex formation. Both p60 and FKBP52 bound specifically to the C90 domain fused to glutathione S-transferase and competed with each other for binding. In reticulocyte lysate, the C90 fusion protein recognized the TPR proteins p60, FKBP52, and Cyp40. Thus, our results identify the C90 domain as the specific binding site for a set of hsp90 cofactors having TPR domains.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Obermann, Wolfgang/AAN-3896-2020; Hartl, F. Ulrich/Y-8206-2019					ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HOHFELD J, 1995, CELL, V83, P589; Irmer H, 1997, J BIOL CHEM, V272, P2230; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Prapapanich V, 1996, MOL CELL BIOL, V16, P6200; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Wearsch PA, 1996, BIOCHEMISTRY-US, V35, P16760, DOI 10.1021/bi962068q; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X	33	207	214	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18007	18010		10.1074/jbc.273.29.18007	http://dx.doi.org/10.1074/jbc.273.29.18007			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660753	hybrid			2022-12-27	WOS:000074828500008
J	Shistik, E; Ivanina, T; Blumenstein, Y; Dascal, N				Shistik, E; Ivanina, T; Blumenstein, Y; Dascal, N			Crucial role of N terminus in function of cardiac L-type Ca2+ channel and its modulation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; SENSITIVE CALCIUM-CHANNEL; PHORBOL ESTER INCREASES; GATING CHARGE MOVEMENTS; BETA-SUBUNIT; XENOPUS-OOCYTES; SKELETAL-MUSCLE; VENTRICULAR MYOCYTES; AUXILIARY SUBUNITS; CARBOXYL-TERMINUS	The role of the cytosolic N terminus of the main subunit (alpha(1C)) of cardiac L-type voltage-dependent Ca2+ channel was studied in Xenopus oocyte expression system. Deletion of the initial 46 or 139 amino acids (a.a.) of rabbit heart alpha(1C) caused a 5-10-fold increase in the whole cell Ca2+ channel current carried by Ba2+ (I-Ba), as reported previously (Wei, X., Neely, A., Olcese, R., Lang, W., Stefani, E., and Birnbaumer, L. (1996) Recept. Channels 4, 205-215), The plasma membrane content of alpha(1C) protein, measured immunochemically, was not altered by the 46-a.a. deletion. Patch clamp recordings in the presence of a dihydropyridine agonist showed that this deletion causes a 5-10-fold increase in single channel open probability without changing channel density. Thus, the initial segment of the N terminus affects channel gating rather than expression. The increase in I-Ba caused by coexpression of the auxiliary beta(2A) subunit was substantially stronger in channels with full-length alpha(1C) than in 46- or 139-a.a. truncated mutants, suggesting an interaction between beta(2A) and N terminus. However, only the I-II domain linker of alpha(1C), but not to N or C termini, bound beta(2A) in vitro, The well documented increase of I-Ba caused by activation of protein kinase C (PKC) was fully eliminated by the 46-a.a. deletion. Thus, the N terminus of alpha(1C) plays a crucial role in channel gating and PKC modulation, We propose that PKC and beta subunit enhance the activity of the channel in part by relieving an inhibitory control exerted by the N terminus. Since PKC up-regulation of L-type Ca2+ channels has been reported in many species, we predict that isoforms of alpha(1C) subunits containing the initial N-terminal 46 a.a. similar to those of the rabbit heart alpha(1C) are widespread in cardiac and smooth muscle cells.	Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Dascal, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.	dascaln@post.tau.ac.il	Dascal, Nathan/O-3915-2015; Tuluc, Petronel/C-2527-2011	Dascal, Nathan/0000-0002-5397-4146; 				ASAI T, 1996, AM JPHYSL, V39, pH620; Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; Bendahhou S, 1997, AM J PHYSIOL-CELL PH, V272, pC592, DOI 10.1152/ajpcell.1997.272.2.C592; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOURINET E, 1992, PFLUG ARCH EUR J PHY, V421, P247, DOI 10.1007/BF00374834; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DOSEMECI A, 1988, CIRC RES, V62, P347, DOI 10.1161/01.RES.62.2.347; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GROSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HADLEY RW, 1992, AM J PHYSIOL, V262, pH472, DOI 10.1152/ajpheart.1992.262.2.H472; Hille B., 1992, IONIC CHANNELS EXCIT; Hirano Y, 1996, RECEPTOR CHANNEL, V4, P93; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Hughes AD, 1995, J VASC RES, V32, P353, DOI 10.1159/000159111; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JOSEPHSON IR, 1994, PFLUG ARCH EUR J PHY, V428, P485, DOI 10.1007/BF00374569; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIU QY, 1993, BIOCHEM BIOPH RES CO, V191, P796, DOI 10.1006/bbrc.1993.1287; MARINISSEN MJ, 1994, CELL SIGNAL, V6, P531, DOI 10.1016/0898-6568(94)90007-8; McHugh D, 1997, J PHYSIOL-LONDON, V500, P311, DOI 10.1113/jphysiol.1997.sp022022; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Olcese R, 1996, J PHYSIOL-LONDON, V497, P675, DOI 10.1113/jphysiol.1996.sp021799; Perets T, 1996, FEBS LETT, V384, P189, DOI 10.1016/0014-5793(96)00303-1; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SATOH H, 1992, GEN PHARMACOL, V23, P1097, DOI 10.1016/0306-3623(92)90293-S; SCHUHMANN K, 1994, FEBS LETT, V341, P208, DOI 10.1016/0014-5793(94)80458-3; SHEETS MF, 1995, J GEN PHYSIOL, V106, P617, DOI 10.1085/jgp.106.4.617; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SINGERLAHAT D, 1992, FEBS LETT, V306, P113, DOI 10.1016/0014-5793(92)80980-U; SINGERLAHAT D, 1994, RECEPTOR CHANNEL, V2, P215; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSENG GN, 1991, AM J PHYSIOL, V261, pH364, DOI 10.1152/ajpheart.1991.261.2.H364; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1991, J BIOL CHEM, V266, P21943; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	75	92	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17901	17909		10.1074/jbc.273.28.17901	http://dx.doi.org/10.1074/jbc.273.28.17901			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651396	hybrid			2022-12-27	WOS:000074816100089
J	Crowley, KS; Payne, RM				Crowley, KS; Payne, RM			Ribosome binding to mitochondria is regulated by GTP and the transit peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND CYTOPLASMIC POLYSOMES; SIGNAL-RECOGNITION PARTICLE; PROTEIN IMPORT; YEAST MITOCHONDRIA; ENDOPLASMIC-RETICULUM; MALATE-DEHYDROGENASE; OUTER-MEMBRANE; TRANSLOCATION; IDENTIFICATION; PURIFICATION	The association between ribosomes and the pore proteins at the endoplasmic reticulum membrane is important to co-translational translocation. To determine if a similar association occurs between the ribosome and mitochondrial membrane protein(s) during protein import in higher eukaryotes, we examined ribosome-mitochondria binding. By using spectral measurements, analysis of mitochondrial associated RNA, and electron microscopy, we demonstrated that ribosomes stably bind to purified rat liver mitochondria in vitro. Binding of ribosomes to mitochondria was markedly reduced by GTP and nearly abolished by the non-hydrolyzable GTP analogue, guanosine-5'-[thio]-triphosphate (GTP gamma S), but was only modestly reduced by GDP or ATP and unaffected by CTP. The initial rate of GTP hydrolysis by mitochondria was increased by ribosomes, whereas the rate of ATP hydrolysis by mitochondria was not affected. Ribosomes programmed with mRNA for 92 amino acids of the N terminus of mitochondrial malate dehydrogenase bound to mitochondria, but unlike unprogrammed rat liver ribosomes, neither GTP nor GDP disrupted binding; however, GTP gamma S did. These data show that receptors specific for ribosomes are present on the mitochondrial membrane, and a GTP-dependent process mediates this binding. The presence of a nascent chain alters these binding characteristics. These findings support the hypothesis that a co-translational translocation pathway exists for import of proteins into mitochondria.	Wake Forest Univ, Sch Med, Dept Pediat, Winston Salem, NC 27157 USA	Wake Forest University	Payne, RM (corresponding author), Wake Forest Univ, Sch Med, Dept Pediat, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mpayne@bgsm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG014223] Funding Source: NIH RePORTER; NIA NIH HHS [R03 AG14223] Funding Source: Medline; NIGMS NIH HHS [1F32 GM16826-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERKOVITCHYELLIN Z, 1992, CRIT REV BIOCHEM MOL, V27, P403, DOI 10.3109/10409239209082568; Bitte L, 1974, Methods Enzymol, V30, P563; Bloemendal H, 1974, Methods Enzymol, V30, P313; CASCARANO J, 1995, HEPATOLOGY, V22, P837, DOI 10.1016/0270-9139(95)90306-2; CHU TW, 1987, J BIOL CHEM, V262, P12806; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GRANT PM, 1986, NUCLEIC ACIDS RES, V14, P6053, DOI 10.1093/nar/14.15.6053; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; KELLEMS RE, 1972, J BIOL CHEM, V247, P8043; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; KELLEMS RE, 1974, J BIOL CHEM, V249, P3304; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Komiya T, 1996, J BIOL CHEM, V271, P22105, DOI 10.1074/jbc.271.36.22105; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; LITHGOW T, 1991, BIOCHEM BIOPH RES CO, V180, P1453, DOI 10.1016/S0006-291X(05)81359-2; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; ROISE D, 1988, J BIOL CHEM, V263, P4509; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sepuri NBV, 1998, J BIOL CHEM, V273, P1420, DOI 10.1074/jbc.273.3.1420; SHEPHARD EH, 1969, BIOCHEM J, V113, P429, DOI 10.1042/bj1130429; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUISSA M, 1982, J BIOL CHEM, V257, P3048; TAKEDA S, 1993, J BIOCHEM-TOKYO, V114, P684, DOI 10.1093/oxfordjournals.jbchem.a124237; THOMSON M, 1995, BIOCHIM BIOPHYS ACTA, V1248, P158; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X	41	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17278	17285		10.1074/jbc.273.27.17278	http://dx.doi.org/10.1074/jbc.273.27.17278			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642299	hybrid			2022-12-27	WOS:000074545200089
J	Hashimoto, Y; Katayama, H; Kiyokawa, E; Ota, S; Kurata, T; Gotoh, N; Otsuka, N; Shibata, M; Matsuda, M				Hashimoto, Y; Katayama, H; Kiyokawa, E; Ota, S; Kurata, T; Gotoh, N; Otsuka, N; Shibata, M; Matsuda, M			Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; PROLINE-RICH SEQUENCES; CELL ANTIGEN RECEPTOR; COMPLEXES IN-VIVO; SH3 DOMAIN; C-CRK; SIGNALING PATHWAYS; DEPENDENT MANNER; GRB2-SOS COMPLEX; ENDOGENOUS CRK	CrkII adaptor protein becomes tyrosine-phosphorylated upon various types of stimulation. We examined whether tyrosine 221, which has been shown to be phosphorylated by c-Abl, was phosphorylated also by other tyrosine kinases, such as epidermal growth factor (EGF) receptor. For this purpose, we developed an antibody that specifically recognizes Tyr(221)-phosphorylated CrkII, and we demonstrated that CrkII was phosphorylated on Tyr(221) upon EGF stimulation. When NRK cells were stimulated with EGF, the tyrosine-phosphorylated CrkII was detected at the periphery of the cells, where ruffling is prominent, suggesting that signaling to CrkII may be involved in EGF-dependent cytoskeletal reorganization. The EGF-dependent phosphorylation of CrkII was also detected in a c-Abl-deficient cell line. Moreover, recombinant CrkII protein was phosphorylated in vitro by EGF receptor. These results strongly suggest that EGF receptor directly phosphorylates CrkII. Mutational analysis revealed that the src homology 2 domain was essential for the phosphorylation of CrkII by EGF receptor but not by c-Abl, arguing that these kinases phosphorylate CrkII by different phosphorylation mechanisms. Finally, we found that the CrkII protein phosphorylated upon EGF stimulation did not bind to the phosphotyrosine-containing peptide and that CrkII initiated dissociation from EGF receptor within 3 min even with the sustained tyrosine phosphorylation of EGF receptor. This result implicated phosphorylation of Tyr(221) in the negative regulation of the src homology a-mediated binding of CrkII to EGF receptor.	Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 182, Japan; Med & Biol Labs, Nagano 396, Japan; Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo; National Center for Global Health & Medicine - Japan	Matsuda, M (corresponding author), Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 162, Japan.			Matsuda, Michiyuki/0000-0002-5876-9969				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARLOW E, 1988, ANTIBODIES LAB MANUA, P535; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Khwaja A, 1996, ONCOGENE, V12, P2491; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MATSUDA M, 1990, J BIOL CHEM, V265, P12000; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Ota S, 1998, CELL SIGNAL, V10, P283, DOI 10.1016/S0898-6568(97)00130-7; RANI CSS, 1997, J BIOL CHEM, V272, P1077; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Smit L, 1996, ONCOGENE, V13, P381; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Torres M, 1996, ONCOGENE, V12, P77; Wang BL, 1996, ONCOGENE, V13, P1379	40	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17186	17191		10.1074/jbc.273.27.17186	http://dx.doi.org/10.1074/jbc.273.27.17186			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642287	hybrid			2022-12-27	WOS:000074545200077
J	Langton, KP; Barker, MD; McKie, N				Langton, KP; Barker, MD; McKie, N			Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIMP GENE FAMILY; MOLECULAR-CLONING; IV COLLAGENASE; 21-KDA PROTEIN; EXPRESSION; COMPLEX; CDNA; TRANSFORMATION; FIBROBLASTS; ACTIVATION	A transient COS-7 cell expression system was used to investigate the functional domain arrangement of tissue inhibitor of metalloproteinases-3 (TIMP-3), specifically to assess the contribution of the amino- and carboxyl-terminal domains of the molecule to its matrix metalloproteinase (MMP) inhibitory and extracellular matrix (ECM) binding properties. Wild type TIMP-3 was entirely localized to the ECM in both its glycosylated (27 kDa) and unglycosylated (24 kDa) forms. A COOH-terminally truncated TIMP-3 molecule was found to be a non-ECM bound MMP inhibitor, whereas a chimeric TIMP molecule, consisting of the NH2-terminal domain of TIMP-2 fused to the COOH-terminal domain of TIMP-3, displayed ECM binding, albeit with a lower affinity than the wild type TIMP-3 molecule. Thus the functional domain arrangement of TIMP-3 is analogous to that seen in TIMP-1 and -2, namely that the NH2-terminal domain is responsible for MMP inhibition whereas the COOH-terminal domain is most important in mediating the specific functions of the molecule. A mutant TIMP-3 in which serine 181 was changed to a cysteine, found in Sorsby's fundus dystrophy, a hereditary macular degenerative disease, was also expressed in COS-7 cells. This gave rise to an additional 48-kDa species (possibly a TIMP-3 dimer) that retained its ability to inhibit MMPs and localize to the ECM, These data favor the hypothesis that the TIMP-3 mutations seen in Sorsby's fundus dystrophy contribute to disease progression by accumulation of mutant protein rather than by the loss of functional TIMP-3.	Univ Sheffield, Sch Med, Dept Pathol, Krebs Inst Biomol Res, Sheffield S10 2RX, S Yorkshire, England; Univ Newcastle Upon Tyne, Sch Med, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Sheffield; Newcastle University - UK	Barker, MD (corresponding author), Univ Sheffield, Sch Med, Dept Pathol, Krebs Inst Biomol Res, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.							Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Celentano DC, 1997, J CLIN PHARMACOL, V37, P991, DOI 10.1002/j.1552-4604.1997.tb04278.x; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fariss RN, 1997, AM J PATHOL, V150, P323; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; LECO KJ, 1994, J BIOL CHEM, V269, P9352; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, J RHEUMATOL, V19, P61; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763; SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67; STASKUS PW, 1991, J BIOL CHEM, V266, P449; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Thorgeirsson UP, 1996, IN VIVO, V10, P137; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WICK M, 1994, J BIOL CHEM, V269, P18953; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	38	99	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16778	16781		10.1074/jbc.273.27.16778	http://dx.doi.org/10.1074/jbc.273.27.16778			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642234	Green Accepted, hybrid			2022-12-27	WOS:000074545200024
J	Bose, S; Chapin, SJ; Seetharam, S; Feix, J; Mostov, KE; Seetharam, B				Bose, S; Chapin, SJ; Seetharam, S; Feix, J; Mostov, KE; Seetharam, B			Brefeldin A (BFA) inhibits basolateral membrane (BLM) delivery and dimerization of transcobalamin II receptor in human intestinal epithelial Caco-2 cells - BFA effects on BLM cholesterol content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MDCK CELLS; G-PROTEIN; INTRACELLULAR TRAFFICKING; ORGANELLE STRUCTURE; PLASMA-MEMBRANE; EXPRESSION; BINDING; SURFACE; RAT	Brefeldin A (BFA) treatment of Caco-2 cells (5 mu g/ml for 12 h) reduced by 90% the cholesterol, but not the phospholipid (PL), levels of the basolateral membrane (BLM), thus altering its PL/cholesterol molar ratio from 2.6 to 22.0, and decreasing its steady state fluorescent anisotropy (r(s)) from 0.27 to 0.15. BFA treatment for 12 h also resulted in complete loss of transcobalamin II receptor (TC II-R) activity/protein levels in the BLM and the disappearance of trans-Golgi network (TGN) morphology as revealed by confocal immunofluorescence microscopy using antibody to TGN 38. However, BFA treatment had no effect on either total cellular cholesterol, TC II-R activity, or PL levels. When cells treated with BFA for 12 h were exposed to BFA-free medium for 0-24 h, all of the effects were reversed, including reappearance of normal TGN morphology. TC H-R delivered to the BLM. during this period was progressively sialylated and changed its physical state from a monomer (8 h) to a dimer (12 h), coinciding with increased delivery (11-53 pmol) of cholesterol to the BLM and an increase in the BLM r(s) from 0.15 to 0.21. These results indicate that cholesterol, but not FL, delivery to the BLM of Caco-2 cells is BFA-sensitive, and cholesterol, by influencing the higher order of the BLM, is essential for TC II-R dimerization.	Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, MACC Fund Ctr, Dept Biochem, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, MACC Fund Ctr, Dept Biophys, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Vet Affairs Med Ctr, Milwaukee, WI 53226 USA; Univ Calif San Francisco, Dept Anat & Cell Biol, San Francisco, CA 94143 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Room 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.			mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1993, J BIOL CHEM, V268, P20380; Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; Bose S, 1997, J BIOL CHEM, V272, P20920, DOI 10.1074/jbc.272.33.20920; Bose S, 1997, J BIOL CHEM, V272, P3538, DOI 10.1074/jbc.272.6.3538; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DAMKE H, 1992, BIOCHEM BIOPH RES CO, V185, P719, DOI 10.1016/0006-291X(92)91685-J; DAMKE H, 1991, J BIOL CHEM, V266, P24829; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; HIDALGO J, 1992, EUR J CELL BIOL, V58, P214; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LAU KS, 1965, BLOOD-J HEMATOL, V26, P202, DOI 10.1182/blood.V26.2.202.202; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1125, P28, DOI 10.1016/0005-2760(92)90151-K; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1993, J CELL SCI, V104, P833; VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4; VANCE JE, 1991, J BIOL CHEM, V266, P8241; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOUNGDAHLTURNER P, 1978, J CLIN INVEST, V61, P133, DOI 10.1172/JCI108911	40	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16163	16169		10.1074/jbc.273.26.16163	http://dx.doi.org/10.1074/jbc.273.26.16163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632671	hybrid			2022-12-27	WOS:000074436600042
J	Ito, T; Hayashi, Y; Ohmori, S; Oda, S; Seo, H				Ito, T; Hayashi, Y; Ohmori, S; Oda, S; Seo, H			Molecular cloning of sucrase-isomaltase cDNA in the house musk shrew Suncus murinus and identification of a mutation responsible for isolated sucrase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCROSE INTOLERANT PATIENTS; MALTASE-GLUCOAMYLASE; RESIDUAL ISOMALTASE; BIOSYNTHESIS; TRANSPORT; SEQUENCE; RAT; COMPLEX; SUBUNIT; PROTEIN	Isolated sucrase deficiency has been demonstrated in a line of house musk shrew, Suncus murinus (laboratory name: suncus). This animal belongs to the order Insectivore and is phylogenetically different from ordinarily used laboratory animals. They are believed to have evolved with mainly animal food without sucrose. To study the molecular basis of the sucrase deficiency in suncus, we cloned 6.0-kilobase (kb) sucrase-isomaltase (SI, EC 3.2.1.48-10) cDNA from suncus intestinal cDNA library, The cDNA clone contained a 5442-base pair (bp)-long open reading frame preceded by an in frame termination codon. The deduced 1813-amino acid sequence showed 68.6, 71.2, and 74.7% similarity with those of rat, rabbit, and human, respectively. A cleavage site between isomaltase and sucrase as well as the region surrounding the catalytic sites for sucrase and isomaltase were conserved among the species. Out of 18 potential N-linked glycosylation sites, 5 were common among all 4 species. In the connecting segment which was enriched with O-linked glycosylation sites in the other species, only two sites were present in suncus. Northern blot analysis revealed that the 6.0-kb SI mRNA was expressed in the KAT line with intact sucrase-isomaltase activity. In contrast, 3.0-kb SI mRNA was expressed in suncus of the MI line with isolated sucrase deficiency. The 3.0-kb mRNA cosegregated with sucrase deficiency phenotype as an autosomal recessive trait. Sequence analysis revealed a a-nucleotide deletion at position 2767-2768, which results in a frameshift and an immature termination codon, The cDNA of the MI line diverged from that of the KAT line at position 2865, having an 18-bp unique sequence followed by a poly(A) tail. The mutant cDNA encodes 922 amino acid residues which preserves the region for isomaltase but lacks that for whole sucrase. While the cells transfected with the plasmids expressing SI in the RAT line showed both sucrase and isomaltase activity, the plasmids expressing MI line cDNA showed only isomaltase activity. Thus it was concluded that the mutation in the SI gene was responsible for isolated sucrase deficiency in the MI line.	Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adaptat, Nagoya, Aichi 46401, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Management, Nagoya, Aichi 46401, Japan	Nagoya University; Nagoya University	Hayashi, Y (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adaptat, Nagoya, Aichi 46401, Japan.		Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHANDRASENA G, 1994, GENE, V150, P355, DOI 10.1016/0378-1119(94)90452-9; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colbert E.H., 1969, EVOLUTION VERTEBRATE, V2nd; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GALAND G, 1989, COMP BIOCHEM PHYS B, V94, P1, DOI 10.1016/0305-0491(89)90002-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY GM, 1992, J NUTR, V122, P172, DOI 10.1093/jn/122.1.172; Gudmand-Hoyer E, 1984, Adv Nutr Res, V6, P233; GUDMANDHOYER E, 1987, SCAND J GASTROENTERO, V22, P24, DOI 10.3109/00365528708991851; GUNTAKA RV, 1993, MICROBIOL REV, V57, P511, DOI 10.1128/MMBR.57.3.511-521.1993; HAUERJENSEN M, 1987, PANCREAS, V2, P295, DOI 10.1097/00006676-198705000-00008; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1982, J BIOL CHEM, V257, P4522; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; ITO T, 1996, ANN RES I ENV MED, V47, P201; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Oda S, 1977, Jikken Dobutsu, V26, P273; ODA S, 1994, MAMM SCI, V34, P59; ODA S, 1991, EDITION FDN M MERIEU, P137; ODA S, 1985, SUNCUS; OHNO T, 1994, EXP ANIM TOKYO, V43, P111, DOI 10.1538/expanim1978.43.1_111; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERMAN JA, 1978, J PEDIATR-US, V93, P17, DOI 10.1016/S0022-3476(78)80592-7; Sambrook J., 2002, MOL CLONING LAB MANU; SEMENZA G, 1981, CLIN GASTROENTEROL, V10, P691; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; SKOVBJERG H, 1986, J PEDIATR GASTR NUTR, V5, P365, DOI 10.1097/00005176-198605000-00005; SKOVBJERG H, 1981, PEDIATR RES, V15, P214, DOI 10.1203/00006450-198103000-00004; STERCHI EE, 1990, BAILLIERE CLIN GASTR, V4, P79, DOI 10.1016/0950-3528(90)90040-N; TREEM WR, 1995, J PEDIATR GASTR NUTR, V21, P1, DOI 10.1097/00005176-199507000-00001; YOKOTA K, 1992, COMP BIOCHEM PHYS B, V103, P629, DOI 10.1016/0305-0491(92)90381-Z	37	9	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16464	16469		10.1074/jbc.273.26.16464	http://dx.doi.org/10.1074/jbc.273.26.16464			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632713	hybrid			2022-12-27	WOS:000074436600084
J	Sunahara, RK; Beuve, A; Tesmer, JJG; Sprang, SR; Garbers, DL; Gilman, AG				Sunahara, RK; Beuve, A; Tesmer, JJG; Sprang, SR; Garbers, DL; Gilman, AG			Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; ACTIVITY REQUIRES; ENZYME SUBUNITS; EXPRESSION; MUTANTS; FORM	The active sites of guanylyl and adenylyl cyclases are closely related. The crystal structure of adenylyl cyclase and modeling studies suggest that specificity for ATP or GTP is dictated in part by a few amino acid residues, invariant in each family, that interact with the purine ring of the substrate. By exchanging these residues between guanylyl cyclase and adenylyl cyclase, we can completely change the nucleotide specificity of guanylyl cyclase and convert adenylyl cyclase into a nonselective purine nucleotide cyclase. The activities of these mutant enzymes remain fully responsive to their respective stimulators, sodium nitroprusside and G(s)alpha. The specificity of nucleotide inhibitors of guanylyl and adenylyl cyclases that do not act competitively with respect to substrate are similarly altered, indicative of their action at the active sites of these enzymes.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	alfred.gilman@email.swmed.edu	Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371, R56DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; NAKANE M, 1990, J BIOL CHEM, V265, P16841; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; YOUNG C, 1997, PERSISTENCE VISION R; YUEN PST, 1994, J BIOL CHEM, V269, P791; ZHANG G, 1997, NATURE, V386, P284	28	182	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16332	16338		10.1074/jbc.273.26.16332	http://dx.doi.org/10.1074/jbc.273.26.16332			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632695	hybrid			2022-12-27	WOS:000074436600066
J	Tang, DM; Gururajan, R; Kidd, VJ				Tang, DM; Gururajan, R; Kidd, VJ			Phosphorylation of PITSLRE p110 isoforms accompanies their processing by caspases during Fas-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PROTEOLYTIC ACTIVATION; IDENTIFICATION; EXPRESSION; APOPTOSIS; FAMILY	A number of cellular proteins have been identified as caspase targets during cell death, including the PITSLRE protein kinases. These targets generally fall into one of three possible categories: 1) other caspases, 2) proteins that are inactivated during apoptosis, and 3) proteins that are required for execution of the cell death program. However, not all proteins are cleaved by caspases during apoptosis. Why only specific proteins are destined to be processed by caspases during cell death is currently not clear. Here we show that multiple caspase-like activities are involved in the processing of the PITSLRE p110 isoforms during Fas-induced apoptosis in Jurkat T-cells. Three p110 caspase cleavage sites have been mapped to the amino-terminal domain of p110 and verified by site-directed mutagenesis. Curiously, the mutagenesis studies revealed that cleavage of two juxtaposed caspase sites is necessary for the complete processing of this protein during cell death in vivo. Finally, we demonstrate that the PITSLRE p110 protein is rapidly phosphorylated during Fas-induced apoptosis in Jurkat cells and that phosphorylation of an aminoterminal portion of the protein may enhance caspase cleavage in this region.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.	vincent.kidd@stjude.org	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 44088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; LOYER P, 1998, IN PRESS J CELL SCI; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sauer K, 1996, MOL BIOL CELL, V7, P1759, DOI 10.1091/mbc.7.11.1759; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhu HJ, 1997, CELL DEATH DIFFER, V4, P590, DOI 10.1038/sj.cdd.4400284	35	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16601	16607		10.1074/jbc.273.26.16601	http://dx.doi.org/10.1074/jbc.273.26.16601			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632733	hybrid			2022-12-27	WOS:000074436600104
J	Wang, HN; Zhang, LX; Liddington, R; Fu, HI				Wang, HN; Zhang, LX; Liddington, R; Fu, HI			Mutations in the hydrophobic surface of an amphipathic groove of 14-3-3 zeta disrupt its interaction with Raf-1 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE; 14-3-3-PROTEINS ASSOCIATE; JURKAT CELLS; T-CELLS; PHOSPHORYLATION; ACTIVATION; CBL; TRANSDUCTION	14-3-3 proteins bind to a diverse group of regulatory molecules such as Raf-1, Cbl, and c-Bcr that are involved in signal transduction pathways. The crystal structure of 14-3-3 zeta reveals a conserved amphipathic groove that may mediate the association of 14-3-3 with diverse ligands. Consistently, mutations on the charged surface of the groove (Lys-49, Arg-56, and Arg-60) decrease the binding of 14-3-3 zeta to the ligands tested (Zhang, L., Wang, H., Liu, D., Liddington, R., and Fu, H. (1997) J. Biol. Chem. 272, 13717-13724). Here we report that mutations that altered the hydrophobic property of the groove, V176D, L216D, L220D, and L227D, disrupted the interaction of 14-3-3 zeta with Raf-l kinase. The reduced binding of the 14-3-3 zeta mutants to Raf-1 was apparently not because of gross structural changes in the mutants as judged by their ability to form dimers, by partial proteolysis profiles, and by circular dichroism analysis. These hydrophobic residues appeared to be required for the binding of 14-3-3 zeta to distinct activation states of Raf-1 because mutations V176D, L216D, L220D, and L227D reduced the interaction of 14-3-3 zeta with Raf-1 from both phorbol 12-myristate 13-acetate-stimulated and unstimulated Jurkat T cells. These same mutations also disrupted the association of 14-3-3 zeta with other regulatory molecules such as Cbl and c-Bcr, suggesting that the hydrophobic surface of the amphipathic groove represents part of a binding site shared by a number of 14-3-3-associated proteins. The conservation of the hydrophobic residues Val-176, Leu-216, Leu-220, and Leu-227 among known 14-3-3 family members implies their general importance in ligand binding.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Cell & Dev Biol, Atlanta, GA 30322 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Emory University; Emory University; University of Leicester	Fu, HI (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.	haianfu@bimcore.emory.edu		Zhang, Lixin/0000-0003-0894-9520	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Rommel C, 1996, ONCOGENE, V12, P609; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	47	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16297	16304		10.1074/jbc.273.26.16297	http://dx.doi.org/10.1074/jbc.273.26.16297			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632690	hybrid			2022-12-27	WOS:000074436600061
J	Yu, G; Chen, FS; Levesque, G; Nishimura, M; Zhang, DM; Levesque, L; Rogaeva, E; Xu, DH; Liang, Y; Duthie, M; St George-Hyslop, PH; Fraser, PE				Yu, G; Chen, FS; Levesque, G; Nishimura, M; Zhang, DM; Levesque, L; Rogaeva, E; Xu, DH; Liang, Y; Duthie, M; St George-Hyslop, PH; Fraser, PE			The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MISSENSE MUTATIONS; CHROMOSOME-1; GENE	The presenilin (PS) genes associated with Alzheimer disease encode polytopic transmembrane proteins which undergo physiologic endoproteolytic cleavage to generate stable NH2- and COOH-terminal fragments (NTF or CTF) which co-localize in intracellular membranes, but are tightly regulated in their stoichiometry and abundance. We have used linear glycerol velocity and discontinuous sucrose gradient analysis to investigate the distribution and native conformation of PS1 and PS2 during this regulated processing in cultured cells and in brain. The PS1 NTF and CTF co-localize in the endoplasmic reticulum (ER) and in the Golgi apparatus, where they are components of a similar to 250-kDa complex. This complex also contains beta-catenin but not beta-amyloid precursor protein (APP). In contrast, the PS1 holoprotein precursor is predominantly localized to the rough ER and smooth ER, where it is a component of a similar to 180-kDa native complex. PS2 forms similar but independent complexes. Restricted incorporation of the presenilin NTF and CTF along with a potentially functional ligand (beta-catenin) into a multimeric complex in the ER and Golgi apparatus may provide an explanation for the regulated accumulation of the NTF and CTF.	Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, PH (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med, Tanz Neurosci Bldg,6 Queens Pk Crescent, Toronto, ON M5S 3H2, Canada.							BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIND S, 1994, J BIOL CHEM, V269, P12784; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WEIDEMANN A, 1997, NAT MED, V3, P323; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	28	364	372	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16470	16475		10.1074/jbc.273.26.16470	http://dx.doi.org/10.1074/jbc.273.26.16470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632714	hybrid			2022-12-27	WOS:000074436600085
J	Benes, C; Roisin, MP; Van Tan, H; Creuzet, C; Miyazaki, J; Fagard, R				Benes, C; Roisin, MP; Van Tan, H; Creuzet, C; Miyazaki, J; Fagard, R			Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; MAP KINASE; GLUTAMATE-RECEPTOR; GROWTH-FACTOR; AMPA SUBTYPE; CALCIUM; ISLETS; STIMULATION; RAS; INHIBITION	MING is one of the few pancreatic beta cell lines that respond to physiological concentrations of glucose by secreting insulin, and little is known about the triggered molecular mechanisms. We report below that the response to glucose in the MIN6 cells includes an activation of the p42 and p44 mitogen-activated protein (MAP) kinases (ERK2 and ERK1), This activation also occurred with the antidiabetic sulfonylurea glibenclamide and kainate, a specific agonist of a subtype of the ionotropic glutamate receptors, which depolarize the cytoplasmic membrane. The requirement for a. calcium entry through the L-type voltage-gated channels and other characteristics of the regulation of the MAP kinase activity, such as the effect of the elevation of the cAMP concentration by forskolin, were similar to those: of the secretion of insulin. However, the activation of the MAP kinases is not required for the secretion of insulin, inasmuch as this effect of glucose was not abolished when the MAP kinases were prevented from activation by PD098059, an inhibitor of the MAP kinase kinase, However, as the MAP kinases were translocated into the nucleus, they might be implicated in the calcium-dependent transcriptional response of the cells to glucose and thus regulate the expression of the insulin gene.	Osaka Univ, Sch Med, Dept Physiol Chem & Nutr, Suita, Osaka 565, Japan; Univ Paris 05, UFR Cochin, Lab Signalisat Cellulaire & Parisites, F-75674 Paris, France	Osaka University; UDICE-French Research Universities; Universite Paris Cite	Fagard, R (corresponding author), Osaka Univ, Sch Med, Dept Physiol Chem & Nutr, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	fagard@infobiogen.fr	Miyazaki, Jun-ichi/N-1976-2015; Tuluc, Petronel/C-2527-2011	Miyazaki, Jun-ichi/0000-0003-2475-589X; 				AGBOTOUNOU WK, 1994, BIOCHEM PHARMACOL, V48, P505, DOI 10.1016/0006-2952(94)90280-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Baron C, 1996, J NEUROCHEM, V66, P1005; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GONOI T, 1994, J BIOL CHEM, V269, P16989; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P338; JOLLY YC, 1993, BIOCHEMISTRY-US, V32, P12209, DOI 10.1021/bi00096a034; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUMOTO K, 1995, ENDOCRINOLOGY, V136, P3784, DOI 10.1210/en.136.9.3784; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOSJOV S, 1989, J CLIN INVEST, V79, P616; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; Wheal H. V., 1991, EXCITATORY AMINO ACI; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	49	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15507	15513		10.1074/jbc.273.25.15507	http://dx.doi.org/10.1074/jbc.273.25.15507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624138	hybrid			2022-12-27	WOS:000074284200032
J	Boland, MP; O'Neill, LAJ				Boland, MP; O'Neill, LAJ			Ceramide activates NF kappa B by inducing the processing of p105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUNORUBICIN-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; TNF-ALPHA; HL-60 CELLS; NEUTRAL SPHINGOMYELINASE; ACIDIC SPHINGOMYELINASE; PROTEIN-KINASE; PRECURSOR P105	The role of ceramide as a second messenger in tumor necrosis factor (TNF)-mediated signal transduction has been much debated, It is supported by recent reports describing an expanding number of potential targets for this lipid, but is opposed by those describing how ceramide is not necessary for many TNF-mediated cellular events. In this paper, we directly compare the effects of the cell-permeable ceramide analogue, N-acetylsphingosine (C-2-ceramide), with TNF, on NF kappa B function, a transcription factor whose activation is central to many TNF-mediated effects. We describe how C-2-ceramide failed to drive kappa B-linked chloramphenicol acetyltransferase gene expression in either HL60 promyelocytic or Jurkat T lymphoma cells. Furthermore, it had no effect on TNF-mediated transcription of this reporter gene. However, electrophoretic mobility shift analysis following cell stimulation with this ceramide analogue revealed a dose-responsive activation of NF kappa B, which was mot apparent following cell treatment with the inactive dihydro form. Activated complexes from treated cells were shown to contain predominantly the p50 subunit, in contrast to complexes from TNF-treated cells, where both p50 and p65/ReIA subunits were present. The specific activation of p50 homodimeric complexes by C(2)ceramide, which are known to lack trans-activating activity, was strongly suggested from these data, Further investigations revealed that C-2-ceramide had only a marginal effect on I kappa B alpha degradation but strongly promoted the processing of p105 to its p50 product as revealed by immunoblot analysis. The increase in p50 arising from the processing of its p105 precursor was further established from p105/p50 ratios obtained by scanning densitometric analysis of bands from immunoblots. TNF, on the other hand, stimulated both I kappa B alpha degradation and p105 processing, in accordance with previous findings. Furthermore, the effect of TNF on NF kappa B activation was rapid, whereas C-2-ceramide required an optimal treatment time of 1 h. Interestingly, TNF was found to increase ceramide ire cells but only after a 1 h contact Lime. Our data therefore suggest that ceramide promotes the activation of NF kappa B complexes that lack transactivating activity by enhanced processing of p105.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin	Boland, MP (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.							Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BETTS JC, 1994, J BIOL CHEM, V269, P8455; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CIFONE MG, 1993, J EXP MED, V177, P1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higuchi M, 1996, J IMMUNOL, V157, P297; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIM MY, 1991, J BIOL CHEM, V266, P484; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V265, P1596; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P707; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, MOL CELL BIOL, V16, P5015; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	62	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15494	15500		10.1074/jbc.273.25.15494	http://dx.doi.org/10.1074/jbc.273.25.15494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624136	Green Published, hybrid			2022-12-27	WOS:000074284200030
J	Gao, L; Dong, LQ; Whitlock, JP				Gao, L; Dong, LQ; Whitlock, JP			A novel response to dioxin - Induction of ecto-ATPase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATOMA-CELLS; AH RECEPTOR; TRANSCRIPTIONAL REGULATION; CHROMATIN STRUCTURE; WILD-TYPE; MECHANISM; ACTIVATION; CYP1A1; TCDD; CYTOCHROME-P1-450	We used differential display to discover a mew gene that the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) regulates in mouse hepatoma cells. Its predicted amino acid sequence suggests that the gene encodes an ecto-ATPase that contains multiple glycosylation sites, conserved cysteine residues, and apyrase conserved regions. cDNA expression experiments in mouse hepatoma cells confirm that the new gene encodes an ecto-ATPase, Wild-type mouse hepatoma cells contain both constitutive and TCDD-inducible ecto-ATPase activity. Induction of ecto-ATPase gene expression by TCDD is direct and occurs at the transcriptional level. Studies in mutant hepatoma cells indicate that induction requires both the aromatic hydrocarbon receptor (AhR) and the AhR nuclear translocator (Arnt). Furthermore, induction requires AhR's transactivation domain, but not that of Arnt. Our findings reveal new aspects of dioxin's biological effects and TCDD-dependent gene regulation.	Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA	Stanford University	Whitlock, JP (corresponding author), Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003719] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03719] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BRUNS RF, 1990, ANN NY ACAD SCI, V603, P648; BURNSTOCK G, 1971, NATURE, V229, P282, DOI 10.1038/229282d0; BURNSTOCK G, 1985, METHOD PHARMACOL, V6, P193; Demby K B, 1996, Prog Clin Biol Res, V394, P113; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Dong LQ, 1997, J BIOL CHEM, V272, P29614, DOI 10.1074/jbc.272.47.29614; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FleschJanys D, 1996, J TOXICOL ENV HEALTH, V47, P363, DOI 10.1080/009841096161708; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; ISRAEL DI, 1983, J BIOL CHEM, V258, P390; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KANSAS GS, 1991, J IMMUNOL, V146, P2235; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; LI H, 1994, J BIOL CHEM, V269, P28098; LIANG P, 1992, SCIENCE, V257, P1319; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PLESNER L, 1995, INT REV CYTOL, V158, P141; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; STROM DK, 1992, ARCH BIOCHEM BIOPHYS, V294, P707, DOI 10.1016/0003-9861(92)90745-I; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; WALKER NJ, 1995, CARCINOGENESIS, V16, P1319, DOI 10.1093/carcin/16.6.1319; Wang XH, 1996, BIOCHEM BIOPH RES CO, V220, P784, DOI 10.1006/bbrc.1996.0481; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; WU L, 1993, NUCLEIC ACIDS RES, V21, P119, DOI 10.1093/nar/21.1.119	52	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15358	15365		10.1074/jbc.273.25.15358	http://dx.doi.org/10.1074/jbc.273.25.15358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624117	hybrid			2022-12-27	WOS:000074284200011
J	Sessa, G; D'Ascenzo, M; Loh, YT; Martin, GB				Sessa, G; D'Ascenzo, M; Loh, YT; Martin, GB			Biochemical properties of two protein kinases involved in disease resistance signaling in tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR KINASE; TYROSINE KINASE; GENE; TRANSDUCTION; THREONINE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; SPECIFICITY	In tomato plants, resistance to bacterial speck disease is mediated by a phosphorylation cascade, which is triggered by the specific recognition between the plant serine/threonine protein kinase Pto and the bacterial AvrPto protein, In the present study, we investigated in vitro biochemical properties of Pto, which appears to function as arm intracellular receptor for the AvrPto signal molecule. Pto and its downstream effector Pti1, which is also a serine/threonine protein kinase, were expressed in Escherichia coli as maltose-binding protein and glutathione S-transferase fusion proteins, respectively, The two kinases each autophosphorylated at multiple sites as determined by phosphopeptide mapping. In addition, Pto and PLi1 autophosphorylation occurred via an intramolecular mechanism, as their specific activity was not affected by their molar concentration in the assay, Moreover, an active glutathione S-transferase-Pto fusion failed to phosphorylate an inactive maltose-binding protein-Pto(K69Q) fusion excluding ale intermolecular mechanism of phosphorylation for Pto, Pti1 phosphorylation by Pto was also characterized and found to occur with a K-m of 4.1 mu M at sites similar to those autophosphorylated by Pti1, Pto and the product of the recessive allele pto phosphorylated Pti1 at similar sites, as observed by phosphopeptide mapping. This suggests that the inability of the kinase pto to confer resistance to bacterial speck disease in tomato is not caused by altered recognition specificity for Pti1 phosphorylation sites.	Purdue Univ, Dept Agron, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Martin, GB (corresponding author), Purdue Univ, Dept Agron, Lilly Hall Life Sci, W Lafayette, IN 47907 USA.		Martin, Gregory B/F-6262-2011	Martin, Gregory B/0000-0003-0044-6830				Alfano JR, 1996, PLANT CELL, V8, P1683, DOI 10.1105/tpc.8.10.1683; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DADD CA, 1993, BIOTECHNIQUES, V14, P266; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jia YL, 1997, PLANT CELL, V9, P61, DOI 10.1105/tpc.9.1.61; Jones DA, 1997, ADV BOT RES, V24, P89; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SchulzeMuth P, 1996, J BIOL CHEM, V271, P26684, DOI 10.1074/jbc.271.43.26684; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VandenAckerveken G, 1997, TRENDS MICROBIOL, V5, P394, DOI 10.1016/S0966-842X(97)01124-4; Zhou JM, 1997, EMBO J, V16, P3207, DOI 10.1093/emboj/16.11.3207; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	34	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15860	15865		10.1074/jbc.273.25.15860	http://dx.doi.org/10.1074/jbc.273.25.15860			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624187	hybrid			2022-12-27	WOS:000074284200081
J	Teng-umnuay, P; Morris, HR; Dell, A; Panico, M; Paxton, T; West, CM				Teng-umnuay, P; Morris, HR; Dell, A; Panico, M; Paxton, T; West, CM			The cytoplasmic F-box binding protein SKP1 contains a novel pentasaccharide linked to hydroxyproline in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; MASS-SPECTROMETRY; GLYCOPROTEIN; DISCOIDEUM; EXPRESSION; LECTIN; CDNA; FP21	SKP1 is involved in the ubiquitination of certain cell cycle and nutritional regulatory proteins for rapid turnover. SKP1 from Dictyostelium has been known to be modified by an oligosaccharide containing Fuc and Gal, which is unusual for a cytoplasmic or nuclear protein. To establish how it is glycosylated, SKP1 labeled with [H-3]FUC was purified to homogeneity and digested with endo-Lys-C. A single radioactive peptide was found after two-dimensional high performance Liquid chromatography, Analysis in a quadrupole time-of-flight mass spectrometer revealed a predominant ion with a novel mass. Tandem mass spectrometry analysis yielded a set of daughter ions which identified the peptide and showed that it was modified at Pro-143, A second series of daughter ions showed that Pro-143 was hydroxylated and derivatized with a potentially Linear pentasaccharide, Hex-->Hex-->Fuc-->Hex-->HexNAc-->(HyPro). The attachment site was confirmed by Edman degradation. Gas chromatography-mass spectrometry analysis of trimethylsilyl-derivatives of overexpressed SKP1 after methanolysis showed the HexNAc to be GlcNAc. Exoglycosidase digestions of the glycopeptide from normal SKP1 and from a fucosylation mutant, followed by matrix-assisted laser desorption time-of-flight mass spectrometry analysis, showed that the sugar chain consisted of D-Galp alpha 1-->6-D-Galp alpha 1-->L-FUCp alpha 1-->2-D-Galp beta 1-->3GlcNAc. Matrix-assisted laser-desorption time-of-flight mass spectrometry analysis of all SKP1 peptides resolved by reversed phase-high performance liquid chromatography showed that SKP1 was only partially hydroxylated at Pro-143 and that all hydroxylated SKP1 was completely glycosylated, Thus SKP1 is variably modified by an unusual linear pentasaccharide, suggesting the localization of a novel glycosylation pathway in the cytoplasm.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	State University System of Florida; University of Florida; Imperial College London	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	westcm@college.med.ufl.edu			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CHEN H, 1995, GENOMICS, V27, P389, DOI 10.1006/geno.1995.1068; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; ELWOOD PC, 1988, ANAL BIOCHEM, V175, P202, DOI 10.1016/0003-2697(88)90379-X; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FERGUSON TA, 1994, DEV GROWTH DIFFER, V36, P597; FINCHER GB, 1974, BIOCHEM J, V139, P535, DOI 10.1042/bj1390535; FREEZE HH, 1997, NEW COMPREHENSIVE BI, V29, P91; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; JACOB GS, 1994, METHOD ENZYMOL, V230, P280; Jung E, 1996, EMBO J, V15, P1238, DOI 10.1002/j.1460-2075.1996.tb00465.x; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Liang Y, 1997, GENE, V184, P163, DOI 10.1016/S0378-1119(96)00590-2; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; Medina L, 1998, GLYCOBIOLOGY, V8, P191, DOI 10.1093/glycob/8.2.191; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SOWDEN J, 1995, GENOMICS, V29, P145, DOI 10.1006/geno.1995.1225; Trinchera M, 1996, FEBS LETT, V395, P68, DOI 10.1016/0014-5793(96)01003-4; UroCoste E, 1997, NEUROREPORT, V8, P1675, DOI 10.1097/00001756-199705060-00023; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; Yoho ER, 1997, HEARING RES, V104, P47, DOI 10.1016/S0378-5955(96)00183-9; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang Y, 1997, GLYCOBIOLOGY, V7, P1153, DOI 10.1093/glycob/7.8.1153	44	65	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18242	18249		10.1074/jbc.273.29.18242	http://dx.doi.org/10.1074/jbc.273.29.18242			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660787	hybrid			2022-12-27	WOS:000074828500042
J	Dutra, MB; Ambesi, A; Slayman, CW				Dutra, MB; Ambesi, A; Slayman, CW			Structure-function relationships in membrane segment 5 of the yeast Pma1 H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; P-TYPE ATPASES; SARCOPLASMIC-RETICULUM; PLASMA-MEMBRANE; TRANSMEMBRANE DOMAIN; AMINO-ACIDS; SCANNING MUTAGENESIS; NEUROSPORA-CRASSA; ALPHA-SUBUNIT; CONSEQUENCES	Membrane segment 5 (M5) is thought to play a direct role in cation transport by the sarcoplasmic reticulum Ca2+-ATPase and the Na+,K+-ATPase of animal cells. In this study, we have examined M5 of the yeast plasma membrane H+-ATPase by alanine-scanning mutagenesis. Mutant enzymes were expressed behind an inducible heat-shock promoter in yeast secretory vesicles as described previously (Nakamoto, R, K,, Rao, R,, and Slayman, C, W, (1991) J, Biol, Chem, 266, 7940-7949), Three substitutions (R695A, H701A, and L706A) led to misfolding of the H+-ATPase as evidenced by extreme sensitivity to trypsin; the altered proteins were arrested in biogenesis, and the mutations behaved genetically as dominant lethals. The remaining mutants reached the secretory vesicles in sufficient amounts to be characterized in detail, One of them (Y691A) had no detectable ATPase activity and appeared, based on trypsinolysis in the presence and absence of ligands, to be blocked in the E-1-to-E-2 step of the reaction cycle. Alanine substitution at an adjacent position (V692A) had substantial ATPase activity (54%), but was likewise affected in the E-1-to-E-2 step, as evidenced by shifts in its apparent affinity for ATP, H+, and orthovanadate, Among the mutants that were sufficiently active to be assayed for ATP-dependent H+ transport by acridine orange fluorescence quenching, none showed an appreciable defect in the coupling of transport to ATP hydrolysis, The only residue for which the data pointed to a possible role in cation liganding was Ser-699, where removal of the hydroxyl group (S699A and S699C) led to a modest acid shift in the pH dependence of the ATPase, This change was substantially smaller than the 13-30-fold decrease in K+ affinity seen in corresponding mutants of the Na+,K+-ATPase (Arguello, J, M,, and Lingrel, J, B (1995) J, Biol, Chem, 270, 22764-22771), Taken together, the results do not give firm evidence for a transport site in M5 of the yeast H+-ATPase, but indicate a critical role for this membrane segment in protein folding and in the conformational changes that accompany the reaction cycle. It is therefore worth noting that the mutationally sensitive residues lie along one face of a putative alpha-helix.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Ambesi, A (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; Andersen JP, 1996, BBA-BIOENERGETICS, V1275, P118, DOI 10.1016/0005-2728(96)00060-6; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; Fiske CH, 1925, J BIOL CHEM, V66, P375; GEITZ RD, 1988, GENE, V74, P527; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Ohta H, 1997, BBA-BIOENERGETICS, V1319, P9, DOI 10.1016/S0005-2728(97)00007-8; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RAO R, 1996, MYCOTA, V3, P29; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r	40	25	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17411	17417		10.1074/jbc.273.28.17411	http://dx.doi.org/10.1074/jbc.273.28.17411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651327	hybrid			2022-12-27	WOS:000074816100020
J	Kostenis, E; Zeng, FY; Wess, J				Kostenis, E; Zeng, FY; Wess, J			Functional characterization of a series of mutant G protein alpha(q) subunits displaying promiscuous receptor coupling properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; HETEROTRIMERIC G-PROTEINS; G-BETA-GAMMA; PHOSPHOLIPASE-C; AMINO-TERMINUS; MUSCARINIC RECEPTOR; SYNTHETIC PEPTIDES; PALMITOYLATION; IDENTIFICATION; MYRISTOYLATION	The N termini of two G protein alpha subunits, alpha(q) and alpha(11), differ from those of other alpha subunits in that they display a unique, highly conserved six-amino acid extension (MTLESI(M)). We recently showed that an alpha(q) deletion mutant lacking these six amino acids (in contrast to wild type alpha(q)) was able to couple to several different G(s)- and G(L/o)-coupled receptors, apparently due to promiscuous receptor/G protein coupling (Kostenis, E., Degtyarev, M. Y., Conklin, B. R., and Wess, J. (1997) J. Biol. Chem. 272, 19107-19110). To study which specific amino acids within the N-terminal segment of alpha(q/11) are critical for constraining the receptor coupling selectivity of these subunits, this region of alpha(q) was subjected to systematic deletion and alanine scanning mutagenesis. All mutant alpha(q) constructs (or wild type alpha(q) as a control) were coexpressed (in COS-7 cells) with the m2 muscarinic or the D2 dopamine receptors, two prototypical G(L/o)-coupled receptors, and Ligand-induced increases in inositol phosphate production were determined as a measure of G protein activation. Surprisingly, all 14 mutant G proteins studied (but not wild type alpha(q)) gained the ability to productively interact with the two G(L/o)-linked receptors, Similar results were obtained when we examined the ability of selected mutant alpha(q) subunits to couple to the G(s)-coupled beta 2-adrenergic receptor, Additional experiments indicated that the functional promiscuity displayed by all investigated mutant alpha(q) constructs was not due to overexpression (as compared with wild type alpha(q)), lack of palmitoylation, or initiation of translation at a downstream ATG codon (codon seven). These data are consistent with the notion that the six-amino acid extension characteristic for alpha(q/11) subunits forms a tightly folded protein subdomain that is critical for regulating the receptor coupling selectivity of these subunits.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.							AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chen BW, 1996, BBA-BIOMEMBRANES, V1281, P125, DOI 10.1016/0005-2736(96)00039-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CULLEN BR, 1987, METHOD ENZYMOL, V152, P688; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; JUSTICE JM, 1995, J BIOL CHEM, V270, P6436, DOI 10.1074/jbc.270.12.6436; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	60	52	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17886	17892		10.1074/jbc.273.28.17886	http://dx.doi.org/10.1074/jbc.273.28.17886			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651394	hybrid			2022-12-27	WOS:000074816100087
J	Mikita, T; Daniel, C; Wu, PG; Schindler, U				Mikita, T; Daniel, C; Wu, PG; Schindler, U			Mutational analysis of the STAT6 SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CYTOKINE RECEPTORS; SIGNAL TRANSDUCERS; DNA-BINDING; SPECIFICITY; INTERFERON; PROTEIN; PEPTIDE; ACTIVATORS; MOTIFS	The SH2 domain of the STAT family of transcription factors is essential for STAT binding to phosphorylated cytoplasmic domains of activated cytokine receptors, Furthermore, the same domain mediates dimerization of activated STAT monomers, a prerequisite for DNA binding by this family of proteins. To identify amino acid residues within the STAT protein that mediate these various interactions, we have carried out an extensive mutational analysis of the Stat6 SH2 domain. Recombinant proteins carrying C-terminal deletions or double alanine substitutions were expressed in mammalian and insect cells and assayed for DNA binding, transcription activation, tyrosine phosphorylation, and the ability to interact with a tyrosine-phosphorylated peptide derived from the interleukin-4 receptor signaling chain. From these studies, we have identified amino acids that are required for both DNA binding and interleukin-4 receptor interaction, as well as residues that when mutated impair only one of the two functions. Our results suggest that the structural homology between the SH2 domain of Stat6 and that of the distantly related Src protein may be higher than predicted on the basis of primary amino acid sequence comparisons. However, the two types of SH2 domains may differ at their C-terminal ends.	Tularik Inc, San Francisco, CA 94080 USA		Schindler, U (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	uli@tularik.com						BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Inoue M, 1997, J BIOL CHEM, V272, P9550; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Mikita T, 1996, MOL CELL BIOL, V16, P5811; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17634	17642		10.1074/jbc.273.28.17634	http://dx.doi.org/10.1074/jbc.273.28.17634			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651359	hybrid			2022-12-27	WOS:000074816100052
J	Pardee, TS; Bangur, CS; Ponticelli, AS				Pardee, TS; Bangur, CS; Ponticelli, AS			The N-terminal region of yeast TFIIB contains two adjacent functional domains involved in stable RNA polymerase II binding and transcription start site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAINS; PROTEIN; SUBUNIT; MUTATIONS; INTERACTS; TATA; INITIATION; PROMOTERS; COMPLEX	The general transcription factor IIB (TFIIB) is required for accurate and efficient transcription of protein-coding genes by RNA polymerase II (RNAPII). To define functional domains in the highly conserved N-terminal region of TFIIB, we have analyzed 14 site-directed substitution mutants of yeast TFIIB for their ability to support cell viability, transcription in vitro, accurate start site selection in vitro and in vivo, and to form stable complexes with purified RNAPII in vitro. Mutations impairing the formation of stable TFIIB RNAPII complexes mapped to the zinc ribbon fold, whereas mutations conferring downstream shifts in transcription start site selection were identified at multiple positions within a highly conserved homology block adjacent and C-terminal to the zinc ribbon. These results demonstrate that the N-terminal region of yeast TFIIB contains two separable and adjacent functional domains involved in stable RNAPII binding and transcription start site selection, suggesting that downstream shifts in transcription start site selection do not result from impairment of stable TFIIB RNAPII binding. We discuss models for yeast start site selection in which TFIIB may affect the ability of preinitiation complexes to interact with downstream DNA or to affect start site recognition by a scanning polymerase.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Ctr Adv Mol Biol & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ponticelli, AS (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA.			Pardee, Timothy/0000-0002-1186-6948	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051124, R29GM051124] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51124] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PINTO I, 1994, J BIOL CHEM, V269, P30569; PONTICELLI AS, 1995, MOL CELL BIOL, V15, P983; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	32	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17859	17864		10.1074/jbc.273.28.17859	http://dx.doi.org/10.1074/jbc.273.28.17859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651390	hybrid			2022-12-27	WOS:000074816100083
J	Vaughan, M				Vaughan, M			G protein-coupled receptors minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vaughan, M (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.								0	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17297	17297		10.1074/jbc.273.28.17297	http://dx.doi.org/10.1074/jbc.273.28.17297			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651308	hybrid			2022-12-27	WOS:000074816100001
J	Fusetti, F; Erlandsen, H; Flatmark, T; Stevens, RC				Fusetti, F; Erlandsen, H; Flatmark, T; Stevens, RC			Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE; CRYSTAL-STRUCTURES; RAT-LIVER; MUTATION; IDENTIFICATION; EXPRESSION; MECHANISM; PROTEIN; IRON; HYPERPHENYLALANINEMIA	Phenylalanine hydroxylase (PheOH) catalyzes the conversion of L-phenylalanine to L-tyrosine, the rate-limiting step in the oxidative degradation of phenylalanine. Mutations in the human PheOH gene cause phenylketonuria, a common autosomal recessive metabolic disorder that in untreated patients often results in varying degrees of mental retardation. We have determined the crystal structure of human PheOH (residues 118-452), The enzyme crystallizes as a tetramer with each monomer consisting of a catalytic and a tetramerization domain. The tetramerization domain is characterized by the presence of a domain swapping arm that interacts with the other monomers forming an antiparallel coiled-coil. The structure is the first report of a tetrameric PheOH and displays an overall architecture similar to that of the functionally related tyrosine hydroxylase. In contrast to the tyrosine hydroxylase tetramer structure, a very pronounced asymmetry is observed in the phenylalanine hydroxylase, caused by the occurrence of two alternate conformations in the hinge region that leads to the coiled-coil helix. Examination of the mutations causing PKU shows that some of the most frequent mutations are located at the interface of the catalytic and tetramerization domains. Their effects on the structural and cellular stability of the enzyme are discussed.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Tromso, Prot Crystallog Grp, Dept Chem, N-9037 Tromso, Norway; Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; UiT The Arctic University of Tromso; University of Bergen	Stevens, RC (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	stevens@adrenaline.berkeley.edu	Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALASUBRAMANIAN S, 1994, BIOCHEMISTRY-US, V33, P8532, DOI 10.1021/bi00194a019; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CELIKEL R, 1991, J MOL BIOL, V218, P495, DOI 10.1016/0022-2836(91)90694-2; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; Daubner SC, 1997, BIOCHEMISTRY-US, V36, P11574, DOI 10.1021/bi9711137; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; Daubner SC, 1997, ARCH BIOCHEM BIOPHYS, V348, P295, DOI 10.1006/abbi.1997.0435; Davis MD, 1997, P NATL ACAD SCI USA, V94, P491, DOI 10.1073/pnas.94.2.491; DICKSON PW, 1994, J BIOL CHEM, V269, P20369; DILELLA AG, 1987, NATURE, V327, P333, DOI 10.1038/327333a0; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; Doskeland AP, 1996, BIOCHEM J, V319, P941, DOI 10.1042/bj3190941; EIKEN HG, 1992, HUM GENET, V88, P608, DOI 10.1007/BF02265283; Erlandsen H, 1997, FEBS LETT, V406, P171, DOI 10.1016/S0014-5793(97)00259-7; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; FLATMARK T, 1968, J BIOL CHEM, V243, P1623; FOLLING I, 1994, ACTA PAEDIATR, V83, P4, DOI 10.1111/j.1651-2227.1994.tb13440.x; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hoang L, 1996, NUCLEIC ACIDS RES, V24, P127, DOI 10.1093/nar/24.1.127; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kappock TJ, 1995, J BIOL CHEM, V270, P30532, DOI 10.1074/jbc.270.51.30532; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; Kobe B, 1997, PROTEIN SCI, V6, P1352, DOI 10.1002/pro.5560060626; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LICHTERKONECKI U, 1988, BIOCHEMISTRY-US, V27, P2881, DOI 10.1021/bi00408a032; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MARTINEZ A, 1993, EUR J BIOCHEM, V211, P259, DOI 10.1111/j.1432-1033.1993.tb19894.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKANO Y, 1991, GENOMICS, V9, P96, DOI 10.1016/0888-7543(91)90225-4; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; OKANO Y, 1991, EUR J PEDIATR, V150, P347, DOI 10.1007/BF01955938; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMSEY AJ, 1995, PROTEIN SCI, V4, P2082; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SHIMAN R, 1990, J BIOL CHEM, V265, P11633; SVENSSON E, 1994, J INHERIT METAB DIS, V17, P215, DOI 10.1007/BF00711621; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WANG T, 1991, P NATL ACAD SCI USA, V88, P2146, DOI 10.1073/pnas.88.6.2146	48	140	148	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16962	16967		10.1074/jbc.273.27.16962	http://dx.doi.org/10.1074/jbc.273.27.16962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642259	hybrid			2022-12-27	WOS:000074545200049
J	Han, CH; Freeman, JLR; Lee, TH; Motalebi, SA; Lambeth, JD				Han, CH; Freeman, JLR; Lee, TH; Motalebi, SA; Lambeth, JD			Regulation of the neutrophil respiratory burst oxidase - Identification of an activation domain in p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; CELL-FREE SYSTEM; ADENINE-DINUCLEOTIDE PHOSPHATE; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; SUPEROXIDE PRODUCTION; PLASMA-MEMBRANE; SH3 DOMAIN; FLAVOCYTOCHROME B(558); RECOMBINANT P47-PHOX	Superoxide generation by the neutrophil respiratory burst oxidase (NADPH oxidase) can be reconstituted in a cell-free system using flavocytochrome b(558) and the cytosolic proteins p47(phox), p67(phox), and Rac. p47(phox) functions as an adaptor protein; it increases the affinity of p67(phox) and Rac in the NADPH oxidase complex, but is not essential when high concentrations of these proteins are used (Freeman, J. L., and Lambeth, J. D. (1996) J, Biol. Chem. 271, 22578-22582), implying that p67(phox) and/or Rac directly regulates enzyme activity. Herein, we describe an activation domain in p67(phox) that is essential for NADPH oxidase activity. A series of C-terminal truncation mutants of p67(phox) showed that residues 211 to the C terminus (residue 526) are not needed for cell-free activity. However, shorter truncations were inactive, pointing to an activation domain within the region spanning residues 199-210, p67(phox) mutated at single amino acid residues within this region showed diminished activity, and p67(phox) V204A was completely inactive, The effects of mutations on activity were independent of p47(phox), and mutations did not affect the binding of p67(phox) to Rac. In the presence of wild-type p67(phox), the V204A mutant was a potent inhibitor of superoxide generation, and inhibition was partially reversed by high concentrations of p67(phox), but not by p47(phox) OF Rac, The V204A mutant competed with native p67(phox) for translocation to neutrophil plasma membrane, indicating that p67(phox) V204A assembles to form an inactive complex. The data imply a direct activation of flavocytochrome b(558) by an activation domain in p67(phox).	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22809] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; ISHIDA K, 1989, FEBS LETT, V243, P169, DOI 10.1016/0014-5793(89)80123-1; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KRECK ML, 1994, J BIOL CHEM, V269, P4161; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIGETI E, 1989, BIOCHEMISTRY-US, V28, P7116, DOI 10.1021/bi00443a050; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; PEMBER SO, 1983, BLOOD, V61, P1105; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1991, J BIOL CHEM, V266, P20990; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	54	182	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16663	16668		10.1074/jbc.273.27.16663	http://dx.doi.org/10.1074/jbc.273.27.16663			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642219	hybrid			2022-12-27	WOS:000074545200009
J	Jones, PC; Jiang, WP; Fillingame, RH				Jones, PC; Jiang, WP; Fillingame, RH			Arrangement of the multicopy H+-translocating subunit c in the membrane sector of the Escherichia coli F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLAR LOOP REGION; DIRECTED MUTAGENESIS; GENE DUPLICATION; F-0; PROTEINS; COMPLEX; F1-ATPASE; ROTATION; EPSILON; BINDING	The multicopy subunit c of the H+-transporting F1F0 ATP synthase of Escherichia coli is thought to fold across the membrane as a hairpin of two hydrophobic cu-helices. The conserved Asp(61), centered in the second transmembrane helix, is essential for H+ transport. In this study, we have made sequential Cys substitutions across both transmembrane helices and used disulfide cross-link formation to determine the oligomeric arrangement of the c subunits. Cross link formation between single Cys substitutions in helix 1 provided initial limitations on how the subunits could be arranged. Double Cys substitutions at positions 14/16, 16/18, and 21/23 in helix 1 and 70/72 in helix 2 led to the formation of cross-linked multimers upon oxidation. Double Cys substitutions in helix 1 and helix 2, at residues 14/72, 21/65, and 20/66, respectively, also formed cross-linked multimers. These results indicate that at least 10 and probably 12 subunits c interact in a front-to-back fashion to form a ring-like arrangement in F-0. Helix 1 packs at the interior and helix 2 at the periphery of the ring. The model indicates that the Asp(61) carboxylate is centered between the helical faces of adjacent subunit c at the center of a four-helix bundle.	Univ Wisconsin, Dept Biomol Chem, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med, 587 Med Sci Bldg, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1995, BIOCHEM SOC T, V23, P760, DOI 10.1042/bst0230760; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1989, J BIOL CHEM, V264, P6797; FRIEDL P, 1979, EUR J BIOCHEM, V100, P175, DOI 10.1111/j.1432-1033.1979.tb02046.x; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Harvey WR, 1997, J EXP BIOL, V200, P203; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Jones PC, 1995, BIOCHEM J, V312, P739, DOI 10.1042/bj3120739; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KLUGE C, 1993, BIOCHEMISTRY-US, V32, P10378, DOI 10.1021/bi00090a013; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	52	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17178	17185		10.1074/jbc.273.27.17178	http://dx.doi.org/10.1074/jbc.273.27.17178			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642286	hybrid			2022-12-27	WOS:000074545200076
J	Paunio, T; Kangas, H; Heinonen, O; Buc-Caron, MH; Robert, JJ; Kaasinen, S; Julkunen, I; Mallet, J; Peltonen, L				Paunio, T; Kangas, H; Heinonen, O; Buc-Caron, MH; Robert, JJ; Kaasinen, S; Julkunen, I; Mallet, J; Peltonen, L			Cells of the neuronal lineage play a major role in the generation of amyloid precursor fragments in gelsolin-related amyloidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINNISH TYPE FAF; FAMILIAL AMYLOIDOSIS; IN-VITRO; PROTEIN; PLASMA; DOMAIN; ASN-187; REVEALS; ACID; GENE	Gelsolin-related amyloidosis or familial amyloidosis, Finnish type (FAF) (OMIM No105120) is a hereditary amyloid disease caused by a mutation in a precursor protein for amyloid (gelsolin) and characterized by corneal dystrophy and polyneuropathy. In vitro expression of the FAF-mutant (Asp(187) --> Asn/Tyr) secretory gelsolin in COS cells leads to generation of an aberrant polypeptide presumably representing the precursor for tissue amyloid. Here, we provide evidence that this abnormal processing results from defective initial folding of the secreted FAF gelsolin due to the lack of the Cys(188)-Cys(201) disulfide bond, normally formed next to the FAF mutation site. We compared cells of different tissue origin and discovered a dramatic difference between the amount of cleavage of FAF gelsolin to the amyloid precursor in neuronal and non-neuronal cells. More than half of the mutant gelsolin was cleaved in PC12 and in vitro differentiated human neuronal progenitor cells. In contrast, human fibroblasts and Schwannoma cell cultures showed only a limited capacity to cleave FAF gelsolin, although the cleavage mechanism per se seems to be similar in the various cell types, The present findings of processing and distribution of secreted FAF gelsolin in the neuronal cells emphasize the role of neurons in the tissue pathogenesis of this amyloid polyneuropathy.	Univ Helsinki, Inst Biomed, Dept Human Mol Genet, SF-00300 Helsinki, Finland; CNRS, Lab Genet Neurotransmiss & Neurodegenerat Proc, F-75013 Paris, France; Haartman Inst, Dept Virol, Helsinki 00280, Finland; Natl Publ Hlth Inst, Dept Virol, SF-00300 Helsinki, Finland	University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Finland National Institute for Health & Welfare	Peltonen, L (corresponding author), Univ Helsinki, Inst Biomed, Dept Human Mol Genet, SF-00300 Helsinki, Finland.	Leena.Peltonen@ktl.fi						BUCCARON MH, 1995, NEUROBIOL DIS, V2, P37, DOI 10.1006/nbdi.1995.0004; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DELACHAPELLE A, 1992, NAT GENET, V2, P157, DOI 10.1038/ng1092-157; GHISO J, 1990, BIOCHEM J, V272, P827, DOI 10.1042/bj2720827; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; HALTIA M, 1990, BIOCHEM BIOPH RES CO, V167, P927, DOI 10.1016/0006-291X(90)90612-Q; HALTIA M, 1990, AM J PATHOL, V136, P1223; KAASINEN S, 1995, ACTA OTOLARYNGOL, V1, P25; Kangas H, 1996, HUM MOL GENET, V5, P1237, DOI 10.1093/hmg/5.9.1237; KIURU S, 1992, ACTA NEUROL SCAND, V86, P346, DOI 10.1111/j.1600-0404.1992.tb05099.x; KIVELA T, 1993, BRIT J OPHTHALMOL, V77, P799, DOI 10.1136/bjo.77.12.799; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Makishita H, 1996, AMYLOID, V3, P134, DOI 10.3109/13506129609014366; MAURY CPJ, 1990, BIOCHIM BIOPHYS ACTA, V1096, P84, DOI 10.1016/0925-4439(90)90016-I; Maury CPJ, 1997, LAB INVEST, V77, P299; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MAURY CPJ, 1994, LAB INVEST, V70, P558; MERETOJA J, 1969, Annals of Clinical Research, V1, P314; MERETOJA J, 1972, OPHTHALMOLOGICA, V165, P15, DOI 10.1159/000308469; MERETOJA J, 1971, ACTA PATH MICRO IM A, VA 79, P432; PAUNIO T, 1992, GENOMICS, V13, P237, DOI 10.1016/0888-7543(92)90235-K; PAUNIO T, 1994, AMYLOID, V1, P80, DOI 10.3109/13506129409148629; PAUNIO T, 1994, HUM MOL GENET, V3, P2223, DOI 10.1093/hmg/3.12.2223; Paunio T, 1997, FEBS LETT, V406, P49, DOI 10.1016/S0014-5793(97)00237-8; Ronni T, 1997, J IMMUNOL, V158, P2363; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; STARCK T, 1991, OPHTHALMOLOGY, V98, P1197; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Sunada Y, 1994, AMYLOID AMYLOIDOSIS, P623; Tienari PJ, 1996, EMBO J, V15, P5218, DOI 10.1002/j.1460-2075.1996.tb00907.x; Vouyiouklis DA, 1997, J NEUROCHEM, V69, P995; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; YIN HL, 1984, J BIOL CHEM, V259, P5271	36	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16319	16324		10.1074/jbc.273.26.16319	http://dx.doi.org/10.1074/jbc.273.26.16319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632693	hybrid			2022-12-27	WOS:000074436600064
J	Boge, M; Wyss, S; Bonifacino, JS; Thali, M				Boge, M; Wyss, S; Bonifacino, JS; Thali, M			Membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOPLASMIC DOMAIN; SORTING SIGNALS; PROTEIN; GP41; TAIL; ENDOCYTOSIS; ASSOCIATION; MECHANISM; MATRIX	The envelope glycoprotein (Env) of human immunodeficiency virus, type 1 (HIV-1) undergoes rapid internalization after its transport to the cell surface. Env internalization is dependent upon information contained within the cytosolic domain of the protein, Here, we report that the cytosolic domain of Env binds specifically to the medium chain, mu 2, of the clathrin-associated protein complex AP-2, as well as to the complete AP-2 complex. The Env cytosolic domain contains two highly conserved tyrosine-based motifs ((YSPL)-S-712 and (YHRL)-H-768), both of which are capable of binding to mu 2 when presented as short peptides, However, only the membrane-proximal motif (YSPL)-S-712 binds to mu 2 and is required for internalization in the context of the whole cytosolic domain of Env, A glycine residue (Gly(711)) adjacent to the (YSPL)-S-712 motif is also important for binding to mu 2/AP-2 and internalization. These observations suggest that the accessibility of the membrane-proximal GY(712)SPL to mu 2/AP-2 determines its function as a signal for recruitment of HIV-1 Env into clathrin-coated pits and its ensuing internalization.	CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Thali, M (corresponding author), CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland.	Markus.Thali@inst.hospvd.ch		Bonifacino, Juan S./0000-0002-5673-6370; Thali, Markus/0000-0001-8621-2095				Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Cosson P, 1996, EMBO J, V15, P5783, DOI 10.1002/j.1460-2075.1996.tb00964.x; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Egan MA, 1996, J VIROL, V70, P6547, DOI 10.1128/JVI.70.10.6547-6556.1996; Freed EO, 1996, J VIROL, V70, P341, DOI 10.1128/JVI.70.1.341-351.1996; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; HAFFAR OK, 1991, VIROLOGY, V180, P439, DOI 10.1016/0042-6822(91)90054-F; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; Lodge R, 1997, EMBO J, V16, P695, DOI 10.1093/emboj/16.4.695; LODGE R, 1994, J VIROL, V68, P4857, DOI 10.1128/JVI.68.8.4857-4861.1994; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Myers GK, 1995, HUMAN RETROVIRUSES A; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ROBEN P, 1994, J VIROL, V71, P6869; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; RODRIGUEZBOULAN E, 1993, J CELL SCI, P9; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROWELL JF, 1995, J IMMUNOL, V155, P473; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; THALI M, 1994, J VIROL, V68, P674, DOI 10.1128/JVI.68.2.674-680.1994; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I	31	162	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15773	15778		10.1074/jbc.273.25.15773	http://dx.doi.org/10.1074/jbc.273.25.15773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624176	hybrid			2022-12-27	WOS:000074284200070
J	Tolias, KF; Rameh, LE; Ishihara, H; Shibasaki, Y; Chen, J; Prestwich, GD; Cantley, LC; Carpenter, CL				Tolias, KF; Rameh, LE; Ishihara, H; Shibasaki, Y; Chen, J; Prestwich, GD; Cantley, LC; Carpenter, CL			Type I phosphatidylinositol-4-phosphate 5-kinases synthesize the novel lipids phosphatidylinositol 3,5-bisphosphate and phosphatidylinositol 5-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHOINOSITIDE KINASES; INOSITOL PHOSPHOLIPIDS; 4-PHOSPHATE 5-KINASE; HUMAN PLATELETS; PATHWAY; CELLS; PHOSPHORYLATION; POLYPHOSPHOINOSITIDES; 3,4-BISPHOSPHATE	Inositol phospholipids regulate a variety of cellular processes including proliferation, survival, vesicular trafficking, and cytoskeletal organization. Recently, two novel phosphoinositides, phosphatidylinositol-3,5-bisphosphate (PtdIns-3,5-P-2) and phosphatidylinositol-5-phosphate (PtdIns-5-P), have been shown to exist in cells. PtdIns-3,5-P-2, which is regulated by osmotic stress, appears to be synthesized by phosphorylation of PtdIns-3-P at the D-5 position. No evidence yet exists for how PtdIns-5-P is produced in cells. Understanding the regulation of synthesis of these molecules will be important for identifying their function in cellular signaling. To determine the pathway by which Ptdins-3,5-P-2 and PtdIns-5-P might be synthesized, we tested the ability of the recently cloned type I PtdIns-4-P 5-kinases (PIP5Ks) alpha and beta to phosphorylate PtdIns-3-P and PtdIns at the D-5 position of the inositol ring.We found that the type I PIP5Ks phosphorylate PtdIns-3-P to form Ptdins-3,B-P-2. The identity of the PtdIns-3,B-P-2 product was determined by anion exchange high performance liquid chromatography analysis and periodate treatment. PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3 were also produced from PtdIns-3-P phosphorylation by both isoforms. When expressed in mammalian cells, PIP5K I alpha and PIP5K I beta differed in their ability to synthesize PtdIns-3,5-P-2 relative to PtdIns-3,4-P-2. me also found that the type I PIP5Ks phosphorylate PtdIns to produce PtdIns-5-P and phosphorylate PtdIns-3,4-P-2 to produce PtdIns-3,4,5-P-3. Our findings suggest that type I PIP5Ks synthesize the novel phospholipids PtdIns-3,B-P-2 and PtdIns-5-P. The ability of PIP5Ks to produce multiple signaling molecules indicates that they may participate in a variety of cellular processes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA USA; Univ Tokyo, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Tokyo; Utah System of Higher Education; University of Utah	Tolias, KF (corresponding author), Harvard Inst Med, Div Signal Transduct, 330 Brookline Ave, Boston, MA 02115 USA.	ktolias@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Tolias, Kimberley/0000-0002-2092-920X	NIGMS NIH HHS [GM36624, R01 GM041890, GM54389] Funding Source: Medline; NINDS NIH HHS [NS 29632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM036624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FRUMAN DA, 1998, IN PRESS ANN REV BIO, V67; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; ISHIHARA H, 1996, J BIOL CHEM, V271, P2361; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Thum O, 1996, TETRAHEDRON LETT, V37, P9017, DOI 10.1016/S0040-4039(96)02117-X; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	36	114	118	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18040	18046		10.1074/jbc.273.29.18040	http://dx.doi.org/10.1074/jbc.273.29.18040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660759	hybrid			2022-12-27	WOS:000074828500014
J	Vanden Hoek, TL; Becker, LB; Shao, ZH; Li, CQ; Schumacker, PT				Vanden Hoek, TL; Becker, LB; Shao, ZH; Li, CQ; Schumacker, PT			Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; FREE-RADICALS; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; ISCHEMIA; ANION; CELLS; REPERFUSION	Reactive oxygen species (ROS) have been proposed to participate in the induction of cardiac preconditioning. However, their source and mechanism of induction are unclear. We tested whether brief hypoxia induces preconditioning by augmenting mitochondrial generation of ROS in chick cardiomyocytes. Cells were preconditioned with 10 min of hypoxia, followed by 1 h of simulated ischemia and 3 h of reperfusion. Preconditioning decreased cell death from 47 +/- 3% to 14 +/- 29. Return of contraction was observed in 3/3 preconditioned versus 0/6 non-preconditioned experiments. During induction, ROS oxidation of the probe dichlorofluorescin (sensitive to H2O2) increased similar to 2.5-fold. As a substitute for hypoxia, the addition of H2O2 (15 mu mol/liter) during normoxia also induced preconditioning-like protection. Conversely, the ROS signal during hypoxia mas attenuated with the thiol reductant 2-mercaptopropionyl glycine, the cytosolic Cu,Zn-superoxide dismutase inhibitor diethyldithiocarbamic acid, and the anion channel inhibitor 4,4'-diisothiocyanato-stilbene-2,2'-disulfonate, all of which also abrogated protection. ROS generation during hypoxia was attenuated by myxothiazol, but not by diphenyleneiodonium or the nitric-oxide synthase inhibitor L-nitroarginine. We conclude that hypoxia increases mitochondrial superoxide generation which initiates preconditioning protection. Furthermore, mitochondrial anion channels and cytosolic dismutation to H2O2 may be important steps for oxidant induction of hypoxic preconditioning.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Schumacker, PT (corresponding author), Univ Chicago, Dept Med, MC 6026,5841 S Maryland Ave, Chicago, IL 60637 USA.			Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL32646, HL03779, HL35440] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R55HL032646, R01HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BOND JM, 1991, RES COMMUN CHEM PATH, V71, P195; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Downey JM, 1996, ISCHAEMIA PRECONDITI, P21; DURANTEAU J, 1998, INPRESS J BIOL CHEM, V273; FERRARI R, 1993, EUR HEART J, V14, P25; FERRARI R, 1991, AM J CLIN NUTR, V53, pS215, DOI 10.1093/ajcn/53.1.215S; FISHER JR, 1967, DEV BIOL, V15, P289, DOI 10.1016/0012-1606(67)90028-0; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KITAKAZE M, 1995, J MOL CELL CARDIOL, V27, P2149, DOI 10.1016/S0022-2828(95)91335-1; LARSSON R, 1989, CANCER RES, V49, P5627; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; MISRA HP, 1979, J BIOL CHEM, V254, P1623; MOHAZZAB HK, 1997, CIRCULATION, V96, P614; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURRY CE, 1988, CIRCULATION S2, V78, P77; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; OSADA M, 1994, JPN CIRC J, V58, P259, DOI 10.1253/jcj.58.259; PAKY A, 1993, J APPL PHYSIOL, V74, P2868, DOI 10.1152/jappl.1993.74.6.2868; PATHAK SK, 1995, CIRCULATION S1, V92, P717; PRUTZ WA, 1984, RADIAT ENVIRON BIOPH, V23, P1, DOI 10.1007/BF01326731; RICHARD V, 1993, CARDIOVASC RES, V27, P2016, DOI 10.1093/cvr/27.11.2016; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TANAKA M, 1994, CARDIOVASC RES, V28, P980, DOI 10.1093/cvr/28.7.980; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; THIERBACH G, 1981, BIOCHIM BIOPHYS ACTA, V638, P282, DOI 10.1016/0005-2728(81)90238-3; Tritto I, 1997, CIRC RES, V80, P743, DOI 10.1161/01.RES.80.5.743; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek Terry L., 1997, Journal of Molecular and Cellular Cardiology, V29, P2441, DOI 10.1006/jmcc.1997.0481; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; ZHOU X, 1997, CIRCULATION, V93, P1177; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	45	586	601	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18092	18098		10.1074/jbc.273.29.18092	http://dx.doi.org/10.1074/jbc.273.29.18092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660766	hybrid			2022-12-27	WOS:000074828500021
J	Zhang, D; Paley, AJ; Childs, G				Zhang, D; Paley, AJ; Childs, G			The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EWS/FLI-1 FUSION GENE; RNA-BINDING PROTEIN; SPLICING FACTOR SF1; POLYMERASE-II; DOMAIN; IDENTIFICATION; PURIFICATION; HOMOLOGY; CONTAINS; TLS/FUS	The ZFM1 protein is both a transcriptional repressor and identical to the splicing factor SF1, ZFM1 was shown to interact with and repress transcription from the glycine, glutamine, serine, and threonine-rich transcription activation domain of the sea urchin transcription factor, stage-specific activator protein (SSAP), EWS, a human protein involved in cellular transformation in Ewing's sarcoma tumors, contains an NH2-terminal transcriptional activation domain (NTD) which resembles that of SSAP in both amino acid composition and the ability to drive transcription to levels higher than VP16 in most cell types. Here we report that ZFM1 also interacts with EWS in both two-hybrid assays and glutathione S-transferase pub-down experiments. The region on EWS which interacts with ZFM1 maps to 37 amino acids within its NTD. Overexpression of ZFM1 in HepG2 cells represses the transactivation of reporter gene expression driven by Gal4-EWS-NTD fusion protein and this repression correlates with ZFM1 binding to EWS, Furthermore, two proteins, TLS and hTAF(II)68, which hare extensive homology to EWS, also interact with ZFM1, Recently, it was discovered that EWS/TLS/hTAF(II)68 are each present in distinct TFIID populations and EWS and hTAF(II)68 were also found to be associated with the RNA polymerase II holoenzyme, The association of ZFM1 with these proteins implies that one normal cellular function for ZFM1 may be to negatively modulate transcription of target genes coordinated by these cofactors.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Childs, G (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030333] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30333] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arning S, 1996, RNA, V2, P794; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CALVIO C, 1995, RNA, V1, P724; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEANGELO DJ, 1995, MOL CELL BIOL, V15, P1254; DEANGELO DJ, 1993, MOL CELL BIOL, V13, P1746, DOI 10.1128/MCB.13.3.1746; DeFalco J, 1996, P NATL ACAD SCI USA, V93, P5802, DOI 10.1073/pnas.93.12.5802; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LESSNICK SL, 1995, ONCOGENE, V10, P423; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; OHNO T, 1994, ONCOGENE, V9, P3087; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Thompson AD, 1996, ONCOGENE, V13, P2649; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; Zhang D, 1998, J BIOL CHEM, V273, P6868, DOI 10.1074/jbc.273.12.6868; Zinszner H, 1997, J CELL SCI, V110, P1741	28	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18086	18091		10.1074/jbc.273.29.18086	http://dx.doi.org/10.1074/jbc.273.29.18086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660765	hybrid			2022-12-27	WOS:000074828500020
J	Huang, YD; Liu, XQ; Rall, SC; Mahley, RW				Huang, YD; Liu, XQ; Rall, SC; Mahley, RW			Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CORONARY-ARTERY DISEASE; III HYPERLIPOPROTEINEMIA; E POLYMORPHISM; APOPROTEIN-E; MYOCARDIAL-INFARCTION; PLASMA; PARTICLES; HYPERTRIGLYCERIDEMIA; HYPERCHOLESTEROLEMIA	Apolipoprotein (apo) E2 is often associated with low levels of low density lipoprotein (LDL) cholesterol and high levels of plasma triglycerides in humans. Mice expressing apoE2 also have low LDL levels. To evaluate the possible role of the LDL receptor in the cholesterol-lowering effect of apoE2, we bred transgenic mice expressing low levels of apoE2 with LDL receptor-null mice (hE(2+/0),LDLR-/-). Even in the absence of the LDL receptor, plasma total and LDL cholesterol levels decreased progressively with increasing levels of plasma apoE2, At plasma apoE2 levels >20 mg/dl, LDL cholesterol was similar to 45% lower than in LDLR-/- mice. Thus, the LDL cholesterol-lowering effect of apoE2 is independent of the LDL receptor. In contrast, plasma triglyceride levels increased (mostly in very low density lipoproteins (VLDL) and intermediate density Lipoproteins (IDL)) progressively as apoE2 levels increased. At plasma apoE2 levels >20 mg/dl, triglycerides were similar to 150% higher than in LDLR-/- mice. Furthermore, in apoE-null mice (hE2(+/0), mE(-/-)), apoE2 levels also correlated positively with plasma triglyceride levels, suggesting impaired lipolysis in both hE2(+/0),LDLR-/- and hE2(+/0),mE(-/-) mice. Incubating VLDL or IDL from the hE2(+/0),LDLR-/- or the hE2(+/0),mE(-/-) mice with mouse postheparin plasma inhibited lipoprotein lipase-mediated lipolysis of apoE2-containing VLDL and IDL by similar to 80 and similar to 70%, respectively, versus normal VLDL and IDL, This observation was confirmed by studies with triglyceride-rich emulsion particles, apoE2, and purified lipoprotein lipase, Furthermore, apoE2-containing VLDL had much less apoC-II than normal VLDL. Adding apoC-II to the incubation partially corrected the apoE2-impaired lipolysis in apoE2-containing VLDL or IDL and corrected it completely in apoE2-containing emulsion particles. Thus, apoE2 lowers LDL cholesterol by impairing lipoprotein lipase mediated lipolysis of triglyceride rich lipoproteins (mostly by displacing or masking apoC-II), Furthermore, the effects of apoE2 on both plasma cholesterol and triglyceride levels are dose dependent and act via different mechanisms. The increase in plasma cholesterol caused by apoE2 is due mostly to impaired clearance, whereas the increase in plasma triglycerides is caused mainly by apoE2-impaired Lipolysis of triglyceride-rich Lipoproteins.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Brunzell JD, 1995, METABOLIC BASIS INHE, P1913; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CHAIT A, 1977, LANCET, V1, P1176; CHUNG BH, 1983, J LIPID RES, V24, P1148; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CUMMING AM, 1984, CLIN GENET, V25, P310; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R; EISENBERG S, 1984, J LIPID RES, V25, P1017; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDBERG IJ, 1988, J CLIN INVEST, V81, P561, DOI 10.1172/JCI113354; GOMEZCORONADO D, 1993, BIOCHIM BIOPHYS ACTA, V1167, P70, DOI 10.1016/0005-2760(93)90219-Y; HAVEL RJ, 1980, J CLIN INVEST, V66, P1351, DOI 10.1172/JCI109988; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HOSPATTANKAR AV, 1984, J BIOL CHEM, V259, P318; Huang Y, 1997, ARTERIOSCL THROM VAS, V17, P2817, DOI 10.1161/01.ATV.17.11.2817; Huang YD, 1996, J BIOL CHEM, V271, P29146, DOI 10.1074/jbc.271.46.29146; Huang YD, 1997, J BIOL CHEM, V272, P22685, DOI 10.1074/jbc.272.36.22685; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; IVERIUS PH, 1972, J BIOL CHEM, V247, P6610; JI ZS, 1994, J BIOL CHEM, V269, P13421; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LUC G, 1994, ARTERIOSCLER THROMB, V14, P1412, DOI 10.1161/01.ATV.14.9.1412; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; SPOONER PJR, 1988, J BIOL CHEM, V263, P1444; Stengard JH, 1996, HUM GENET, V97, P677; UTERMANN G, 1984, HUM GENET, V65, P232, DOI 10.1007/BF00286508; UTERMANN G, 1980, AM J HUM GENET, V32, P339; UTERMANN G, 1979, CLIN GENET, V15, P63; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; Woollett LA, 1995, P NATL ACAD SCI USA, V92, P12500, DOI 10.1073/pnas.92.26.12500; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	50	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17483	17490		10.1074/jbc.273.28.17483	http://dx.doi.org/10.1074/jbc.273.28.17483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651338	hybrid			2022-12-27	WOS:000074816100031
J	Li, QL; Blau, CA; Clegg, CH; Rohde, A; Stamatoyannopoulos, G				Li, QL; Blau, CA; Clegg, CH; Rohde, A; Stamatoyannopoulos, G			Multiple epsilon-promoter elements participate in the developmental control of epsilon-globin genes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; LOCUS-CONTROL REGION; HIGH-LEVEL EXPRESSION; HUMAN GAMMA-GLOBIN; CHROMATIN STRUCTURE; ACTIVATION REGION; FACTOR-BINDING; SILENCER; SITE; TRANSCRIPTION	To delineate the regulation of the human epsilon-globin gene, we investigated epsilon-gene expression during the development of transgenic mice carrying constructs with epsilon-promoter truncations linked to a micro-locus control region (mu LCR). Expression levels were compared with those of mu LCR epsilon mice carrying a 2 kilobase epsilon-promoter and beta YAC controls. epsilon mRNA in the embryonic cells of mu LCR (-179)epsilon mice were as high as in mu LCR epsilon mice suggesting that the proximal epsilon-promoter contains most elements required for epsilon-gene activation. epsilon mRNA in adult alpha LCR (-179) epsilon mice was significantly lower than in the embryonic cells indicating that elements involved in epsilon-gene silencing are contained in the proximal epsilon promoter. Extension of the promoter sequence to -463 epsilon decreased epsilon-gene expression in the definitive erythroid cells, supporting previous evidence that the -179 to -463 epsilon region contains an epsilon-gene silencer. However, the epsilon-gene of the mu LCR(-463) epsilon mice was not silenced in the definitive cells of fetal and adult erythropoiesis indicating that additional silencing elements are located upstream of position -463 epsilon. These results provide in vivo evidence that multiple elements of the distal as well as the proximal promoter contribute to epsilon-gene silencing.	Univ Washington, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Div Hematol, Seattle, WA 98195 USA; Bristol Myers Squibb Pharmaceut Res Inst, Seattle, WA 98121 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Bristol-Myers Squibb	Stamatoyannopoulos, G (corresponding author), Univ Washington, Div Med Genet, Box 357720, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL53750, HL20899] Funding Source: Medline; NIDDK NIH HHS [DK45365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL020899, R01HL020899, P01HL053750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045365, R01DK045365, R37DK045365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; Dyer MA, 1996, MOL CELL BIOL, V16, P829; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FURUKAWA T, 1995, BLOOD CELL MOL DIS, V21, P168, DOI 10.1006/bcmd.1995.0019; GALE RE, 1979, NATURE, V280, P162, DOI 10.1038/280162a0; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; GUTMAN PD, 1992, GENE, V110, P197, DOI 10.1016/0378-1119(92)90648-9; HECHT F, 1966, SCIENCE, V152, P91, DOI 10.1126/science.152.3718.91; HUEHNS ER, 1964, NATURE, V201, P1095, DOI 10.1038/2011095a0; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; Li QL, 1997, P NATL ACAD SCI USA, V94, P2444, DOI 10.1073/pnas.94.6.2444; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; Liu QH, 1997, P NATL ACAD SCI USA, V94, P169, DOI 10.1073/pnas.94.1.169; NAVAS PA, 1998, IN PRESS MOL CELL BI; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETERS B, 1993, J BIOL CHEM, V268, P3430; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1992, BLOOD, V79, P861; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; SHIH DM, 1993, J BIOL CHEM, V268, P3066; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS, V2, P107; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TREPICCHIO WL, 1994, MOL CELL BIOL, V14, P3763, DOI 10.1128/MCB.14.6.3763; TREPICCHIO WL, 1993, MOL CELL BIOL, V13, P7457, DOI 10.1128/MCB.13.12.7457; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P11532	45	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17361	17367		10.1074/jbc.273.28.17361	http://dx.doi.org/10.1074/jbc.273.28.17361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651319	hybrid			2022-12-27	WOS:000074816100012
J	Wang, WQ; Merriam, DL; Moses, AS; Francis, GA				Wang, WQ; Merriam, DL; Moses, AS; Francis, GA			Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	70th Scientific Session of the American-Heart-Association Meeting	NOV 09-13, 1997	ORLANDO, FLORIDA	Amer Heart Assoc			CULTURED FIBROBLASTS; OXIDATIVE TYROSYLATION; POLYACRYLAMIDE GELS; PLASMA-LIPOPROTEINS; HDL; MACROPHAGES; ACYLTRANSFERASE; CELLS; MYELOPEROXIDASE; CHROMATOGRAPHY	Myeloperoxidase secreted by phagocytes in the artery wall may be a catalyst for lipoprotein oxidation, High density lipoprotein (HDL) oxidized by peroxidase-generated tyrosyl radical has a markedly enhanced ability to deplete cultured cells of cholesterol, We have investigated the structural modifications in tyrosylated HDL responsible for this effect. Spherical reconstituted HDL (rHDL) containing the whole apolipoprotein (apo) fraction of tyrosylated HDL reproduced the ability of intact tyrosylated HDL to enhance cholesterol efflux from cholesterol-loaded human fibroblasts when reconstituted with the whole lipid fraction of either HDL or tyrosylated HDL, Free apoAI or apoAII showed no increased capacity to induce cholesterol efflux from cholesterol-loaded fibroblasts following oxidation by tyrosyl radical, either in their lipid-free forms or in rHDL, The product of oxidation of a mixture of apoAI and apoAII (1:1 molar ratio) by tyrosyl radical, however, reproduced the enhanced ability of tyrosylated HDL to induce cholesterol efflux when reconstituted with the whole lipid fraction of HDL, HDL containing only apoAI or apoAII showed no enhanced ability to promote cholesterol efflux following oxidation by tyrosyl radical, whereas HDL containing both apoAI and apoAII did. rHDL containing apoAI-apoAII(monomer) and apoAI-(apoAII)(2) heterodimers showed a markedly increased ability to prevent the accumulation of LDL-derived cholesterol mass by sterol-depleted fibroblasts compared with other apolipoprotein species of tyrosylated HDL, These results indicate a novel product of HDL oxidation, apoAI-apoAII heterodimers, with a markedly enhanced capacity to deplete cells of the regulatory pool of free cholesterol and total cholesterol mass. The recent observation of tyrosyl radical-oxidized LDL in vivo suggests that a similar modification of HDL would significantly enhance its ability to deplete peripheral cells of cholesterol in the first step of reverse cholesterol transport.	Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Francis, GA (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, 328 HMRC, Edmonton, AB T6G 2S2, Canada.		应, 宁宁/G-9472-2011	Moses, Audric/0000-0002-2788-1739				ANDERSEN P, 1993, J IMMUNOL METHODS, V161, P29, DOI 10.1016/0022-1759(93)90195-D; BABIY AV, 1990, ATHEROSCLEROSIS, V81, P175, DOI 10.1016/0021-9150(90)90064-P; Banka CL, 1996, CURR OPIN LIPIDOL, V7, P139, DOI 10.1097/00041433-199606000-00005; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINTON EA, 1986, J BIOL CHEM, V261, P495; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cheung M C, 1986, Methods Enzymol, V129, P130; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHUNG BH, 1980, J LIPID RES, V21, P284; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; FIELDING CJ, 1995, J LIPID RES, V36, P211; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; Francis GA, 1997, ATHEROSCLEROSIS, V134, P366, DOI 10.1016/S0021-9150(97)89863-2; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; HEIDER JG, 1978, J LIPID RES, V19, P514; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hofer G, 1996, CLIN BIOCHEM, V29, P445, DOI 10.1016/0009-9120(96)00061-6; Hurtado I, 1996, ATHEROSCLEROSIS, V125, P39, DOI 10.1016/0021-9150(96)05840-6; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; KAPP OH, 1978, ANAL BIOCHEM, V91, P230, DOI 10.1016/0003-2697(78)90835-7; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1989, J BIOL CHEM, V264, P19942; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MCCALL M, 1995, ARTERIOSCL THROM VAS, V15, P1599, DOI 10.1161/01.ATV.15.10.1599; MCCALL MR, 1994, ARTERIOSCLER THROMB, V14, P248, DOI 10.1161/01.ATV.14.2.248; Mitchell G, 1995, METABOLIC MOL BASES, P1077; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Oram JF, 1996, J LIPID RES, V37, P2473; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; Scanu AM, 1979, BIOCH ATHEROSCLEROSI; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SKARLATOS SI, 1995, BBA-MOL BASIS DIS, V1270, P19, DOI 10.1016/0925-4439(94)00067-Z; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VADIVELOO PK, 1990, BIOCHIM BIOPHYS ACTA, V1045, P135, DOI 10.1016/0005-2760(90)90142-K; Viani P, 1996, BBA-MOL BASIS DIS, V1315, P78, DOI 10.1016/0925-4439(95)00094-1; Warnick G R, 1986, Methods Enzymol, V129, P101; WEISGRABER KH, 1980, J LIPID RES, V21, P316; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1990, EUR HEART J, V11, P88, DOI 10.1093/eurheartj/11.suppl_E.88; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811	53	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17391	17398		10.1074/jbc.273.28.17391	http://dx.doi.org/10.1074/jbc.273.28.17391			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651324	hybrid			2022-12-27	WOS:000074816100017
J	Bosilevac, JM; Gilchrist, CA; Jankowski, PE; Paul, S; Rees, AR; Hinrichs, SH				Bosilevac, JM; Gilchrist, CA; Jankowski, PE; Paul, S; Rees, AR; Hinrichs, SH			Inhibition of activating transcription factor 1- and cAMP-responsive element-binding protein-activated transcription by an intracellular single chain Fv fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODY FRAGMENTS; VARIABLE FRAGMENTS; TARGETED MUTATION; ESCHERICHIA-COLI; COMBINING SITES; T-LYMPHOCYTES; CREB; EXPRESSION; AFFINITY; INFECTION	Activating transcription factor 1 (ATF1) and cAMP-responsive element (CRE)-binding protein (CREB) activate transcription through CREs located in the promoters of cellular and viral genes. We previously described a monoclonal antibody (mAb41.4) that prevents ATF1 binding to DNA and reduces CRE-driven promoter activity in vitro (Orten, D. J., Strawhecker, J. M., Sanderson, S. D., Huang, D., Prytowsky, M. B., and Hinrichs, S. H. (1994) J. Biol. Chem. 269, 32254-32263). A single chain Fv (scFv) fragment from the mAb41.4-expressing hybridoma was generated to provide a means to investigate transcription factor function via intracellular expression of the scFv fragment. The affinity of scFv4 (subgroup: V-L kappa-III, V-H miscellaneous) for ATF1 was similar to that of the parental mAb and the Fab fragment, but it demonstrated greater inhibitory activity and reacted with CREB. scFv4 disrupted the binding of both ATF1 and CREB in electrophoretic mobility shift assays and reduced expression of CRE-driven expression in vitro. Transient expression of scFv had no effect on the non-CRE-containing adenovirus major late promoter. The proliferating cell nuclear antigen promoter, containing two CREs, was significantly more sensitive to inhibition by scFv than the cytomegalovirus immediate-early promoter, containing five CREs. Cotransfection of either ATF1 or CREB in the presence of scFv restored basal levels of expression. The intracellular expression of scFv provides a unique means to investigate the roles of the transcription factors ATF1 and CREB.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Bath, Dept Biochem, Bath BA2 7AY, Avon, England; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA	University of Nebraska System; University of Nebraska Medical Center; University of Bath; University of Texas System; University of Texas Health Science Center Houston	Hinrichs, SH (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, 600 S 42nd St, Omaha, NE 68198 USA.	shinrich@mail.unmc.edu		Bosilevac, Joseph/0000-0002-0258-6581				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; CHEN JX, 1992, MOL IMMUNOL, V29, P1121, DOI 10.1016/0161-5890(92)90045-Y; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; DESPLANCQ D, 1994, PROTEIN ENG, V7, P1027, DOI 10.1093/protein/7.8.1027; Duan LX, 1995, HUM GENE THER, V6, P1561, DOI 10.1089/hum.1995.6.12-1561; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Gao Q S, 1995, Methods Mol Biol, V51, P281; Gilchrist CA, 1995, ANTIBODY IMMUNOCONJ, V8, P281; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Grim J, 1996, AM J RESP CELL MOL, V15, P348, DOI 10.1165/ajrcmb.15.3.8810638; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HORWITZ MS, 1996, FIELDS VIROLOGY, V2, P1679; HSUEH YP, 1995, J IMMUNOL, V154, P5675; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KINGSTON R, 1994, CURRENT PROTOCOLS MO, V1; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MARTIN ACR, 1989, P NATL ACAD SCI USA, V86, P9268, DOI 10.1073/pnas.86.23.9268; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILSTEIN C, 1974, PROGR IMMUNOLOGY, V2, P157; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; OWENS RJ, 1994, J IMMUNOL METHODS, V168, P149, DOI 10.1016/0022-1759(94)90051-5; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; PEDERSEN JT, 1992, IMMUNOMETHODS, V1, P126; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Sambrook J, 1989, MOL CLONING LAB MANU, V3; Song BW, 1997, VIROLOGY, V235, P109, DOI 10.1006/viro.1997.8677; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; WEIGERT M, 1978, NATURE, V276, P785, DOI 10.1038/276785a0; WHITLOW M, 1994, PROTEIN ENG, V7, P1017, DOI 10.1093/protein/7.8.1017; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZAISS S, 1983, EUR J IMMUNOL, V13, P508, DOI 10.1002/eji.1830130614	48	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16874	16879		10.1074/jbc.273.27.16874	http://dx.doi.org/10.1074/jbc.273.27.16874			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642248	hybrid			2022-12-27	WOS:000074545200038
J	Gervais, FG; Thornberry, NA; Ruffolo, SC; Nicholson, DW; Roy, S				Gervais, FG; Thornberry, NA; Ruffolo, SC; Nicholson, DW; Roy, S			Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; V-SRC; PP125(FAK); EXPRESSION; ASSOCIATION; INHIBITION; POLYMERASE; 3-KINASE; DOMAIN; TUMORS	Focal adhesion kinase (Fak) is a non-receptor protein-tyrosine kinase that stimulates cell spreading and motility by promoting the formation of contact sites between the cell and the extracellular matrix (focal adhesions). It suppresses apoptosis by transducing survival signals that emanate from focal adhesions via the clustering of transmembrane integrins by components of the extracellular matrix. We demonstrate that Fak is cleaved by caspases at two distinct sites during apoptosis. The sites were mapped to DQTD(772), which was preferentially cleaved by caspase-3, and VSWD704, which was preferentially cleaved by caspase-6 and cytotoxic T lymphocyte-derived granzyme B. The cleavage of Fak. during apoptosis separates the tyrosine kinase domain from the focal adhesion targeting (FAT) domain. The carboxyl-terminal fragments that are generated suppress phosphorylation of endogenous Fak. and thus resemble a natural variant of Fak, FRNK, that inhibits Fak activity by preventing the localization of Fak to focal adhesions. The cleavage of Fak by caspases may thus play an important role in the execution of the suicide program by disabling the anti-apoptotic function of Fak, Interestingly, rodent Fak lacks an optimal caspase-3 consensus cleavage site although it is cleaved in murine cells undergoing apoptosis at an upstream site. This appears to be the first example of a caspase substrate where the cleavage sites are not conserved between species.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Roy, S (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.							CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P786; SCHLAEPFER DD, 1994, NATURE, V372, P786; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	27	172	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17102	17108		10.1074/jbc.273.27.17102	http://dx.doi.org/10.1074/jbc.273.27.17102			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642276	hybrid			2022-12-27	WOS:000074545200066
J	Ringerike, T; Stang, E; Johannessen, LE; Sandnes, D; Levy, FO; Madshus, IH				Ringerike, T; Stang, E; Johannessen, LE; Sandnes, D; Levy, FO; Madshus, IH			High-affinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE; CELLS; INTERNALIZATION; ENDOCYTOSIS; PHOSPHORYLATION; CYTOSKELETON; MEMBRANE; DOMAIN; GTPASE	Activation of the epidermal growth factor receptor (EGFR) kinase was analyzed in cells conditionally defective for clathrin-dependent endocytosis by overexpression of mutant dynamin (K44A). EGF-induced autophosphorylation of the EGFR on ice was strongly reduced in cells overexpressing mutant dynamin, and consistently, binding analyses showed that high-affinity EGFRs were lost. In the absence of mutant dynamin the cells displayed both high-and low-affinity EGFR. At 4 degrees C EGF-EGFR localized mainly outside coated pits regardless of expression of mutant dynamin. However, also low-affinity EGFR efficiently moved to coated pits upon incubating cells at 37 degrees C, Thus, expression of mutant dynamin disrupts high-affinity binding of EGF, but not ligand-induced recruitment of EGFR to clathrin-coated pits.	Univ Oslo, Inst Pathol, N-0316 Oslo, Norway; Univ Oslo, Natl Hosp, Inst Surg Res, N-0027 Oslo, Norway; Univ Oslo, Dept Pharmacol, N-0316 Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway; University of Oslo	Madshus, IH (corresponding author), Natl Hosp Norway, Inst Pathol, N-0027 Oslo, Norway.							BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HENEGOUWEN PMP, 1989, J CELL BIOCHEM, V39, P455; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KING AC, 1982, J BIOL CHEM, V257, P3053; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; VanderHeyden MAG, 1997, FEBS LETT, V410, P265, DOI 10.1016/S0014-5793(97)00599-1; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WEIGANT FAC, 1986, J CELL BIOL, V103, P87	31	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16639	16642		10.1074/jbc.273.27.16639	http://dx.doi.org/10.1074/jbc.273.27.16639			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642213	hybrid			2022-12-27	WOS:000074545200003
J	Westwick, JK; Lee, RJ; Lambert, QT; Symons, M; Pestell, RG; Der, CJ; Whitehead, IP				Westwick, JK; Lee, RJ; Lambert, QT; Symons, M; Pestell, RG; Der, CJ; Whitehead, IP			Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; JNK/SAPK SIGNALING PATHWAY; EXPRESSION CDNA CLONING; RAS TRANSFORMATION; SEQUENCE SIMILARITY; ONCOGENE FUNCTION; RHO; GENE; REGULATORS	The dbl family of oncogenes encodes a large, structurally related, family of growth-regulatory molecules that possess guanine nucleotide exchange factor activity for specific members of the Rho family of Pas-related GTPases. We have evaluated matched sets of weakly and strongly transforming versions of five Dbl family proteins (Lfc, Lsc, Ect2, Dbl, and Dbs) to determine their ability to stimulate signaling pathways that are activated by Rho family proteins, We found that the transforming potential of this panel did not correlate directly with their ability to activate Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. In contrast, transient stimulation of transcription from the cyclin DI promoter provided a strong correlation with transforming potential, and we found constitutive up-regulation of cyclin D1 protein in Dbl family protein-transformed cells, In addition, we observed that at least two Dbl family members (Lfc and Ect2) induced changes in the actin cytoskeleton and exhibited nuclear signaling profiles that are consistent with a broader range of in vivo substrate utilization than is predicted from their in vitro exchange specificities. In summary, although Dbl family proteins exhibit signaling profiles that are consistent with their in vivo activation of Rho proteins, stimulation of cyclin D1 transcription is the only activity that correlates with transforming potential, thus suggesting that deregulated cell cycle progression may be important for Dbl family protein transformation.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Whitehead, IP (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA063071, R01CA055008, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA42978, CA63071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, ONCOGENE, V9, P1057; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; OSLON MF, 1995, SCIENCE, V269, P1270; PASTERIS NG, 1994, CELL, V79, P669; Pepper Daniel S., 1997, Nature (London), V386, P177; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RON D, 1991, NEW BIOL, V3, P372; Sambrook J., 2002, MOL CLONING LAB MANU; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOKSOZ D, 1994, ONCOGENE, V9, P621; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WHITEHEAD I, 1995, J BIOL CHEM, V271, P18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZOHN IE, 1998, IN PRESS ONCOGENE	70	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16739	16747		10.1074/jbc.273.27.16739	http://dx.doi.org/10.1074/jbc.273.27.16739			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642229	hybrid, Green Published			2022-12-27	WOS:000074545200019
J	Akamatsu, E; Tanaka, T; Kato, J				Akamatsu, E; Tanaka, T; Kato, J			Transcription factor E2F and cyclin E Cdk2 complex cooperate to induce chromosomal DNA replication in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR DEVELOPMENTAL TRANSITION; MEIOTIC MATURATION; S-PHASE; RETINOBLASTOMA PROTEIN; CYTOPLASMIC CONTROL; DEPENDENT KINASES; CELL-CYCLES; LAEVIS; G(1); INHIBITORS	Although no chromosomal DNA replication actually occurs during Xenopus oocyte maturation, the capability develops during the late meiosis I (MI) phase in response to progesterone. This ability, however, is suppressed by Mos proteins and maturation/mitosis promoting factor during the second meiosis phase (meiosis II; MII) until fertilization. Inhibition of RNA synthesis by actinomycin D during early MI prevented induction of the replication ability, but did not interfere with initiation of the meiotic cell cycle progression characterized by oscillation of the maturation/mitosis promoting factor activity and germinal vesicle breakdown. Microinjection of recombinant proteins such as dominant-negative E2F or universal Gdk inhibitors, p21 and p27, but not wild type human E2F-1 or Cdk4-specific inhibitor, pig, into maturing oocytes during MI abolished induction of the DNA replication ability. Go-injection of human E2F-1 and cyclin E proteins into immature oocytes allowed them to initiate DNA replication even in the absence of progesterone treatment. Injection of cyclin E alone, which was sufficient to activate endogenous Cdk2 kinase, failed to induce DNA replication. Moreover, the activation of Cdk2 was not affected under the conditions where DNA replication was blocked by actinomycin D. Thus, like somatic cells, both activities of E2F and cyclin E-Cdk2 complex are required for induction of the DNA replication ability in maturing Xenopus oocytes, and enhancement of both activities enables oocytes to override DNA-replication inhibitory mechanisms that specifically lie in maturing oocytes.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Kato, J (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		Tanaka, Toshiaki/C-5567-2013	Tanaka, Toshiaki/0000-0002-9448-1452				BENBOW RM, 1975, P NATL ACAD SCI USA, V72, P2437, DOI 10.1073/pnas.72.6.2437; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRACHET J, 1967, EXP CELL RES, V48, P233, DOI 10.1016/0014-4827(67)90312-6; BRACHET J, 1974, MOL CELL BIOCHEM, V3, P189, DOI 10.1007/BF01686644; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Furuno N, 1997, EMBO J, V16, P3860, DOI 10.1093/emboj/16.13.3860; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GELFAND RA, 1983, DEV BIOL, V99, P427, DOI 10.1016/0012-1606(83)90292-0; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GURDON JB, 1967, P NATL ACAD SCI USA, V58, P545, DOI 10.1073/pnas.58.2.545; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFMANN F, 1996, GENE DEV, V10, P3949; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAMARCA MJ, 1975, DEV BIOL, V47, P384, DOI 10.1016/0012-1606(75)90292-4; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Murray A, 1993, CELL CYCLE INTRO; NEVINS JR, 1992, SCIENCE, V258, P424; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PHILPOTT A, 1994, MOL CELL BIOL, V14, P5000, DOI 10.1128/MCB.14.7.5000; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith L D, 1970, Curr Top Dev Biol, V5, P1, DOI 10.1016/S0070-2153(08)60051-4; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WEBB AC, 1975, DEV BIOL, V45, P44, DOI 10.1016/0012-1606(75)90239-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZIEGLER D, 1976, J CELL BIOL, V68, P620, DOI 10.1083/jcb.68.3.620	49	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16494	16500		10.1074/jbc.273.26.16494	http://dx.doi.org/10.1074/jbc.273.26.16494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632717	hybrid			2022-12-27	WOS:000074436600088
J	Rosenfeld, JM; Osborne, TF				Rosenfeld, JM; Osborne, TF			HLH106, a Drosophila sterol regulatory element-binding protein in a natural cholesterol auxotroph	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; RICH ACTIVATION MOTIF; TRANSCRIPTION FACTOR; SREBP-2; GENE; REDUCTASE; DOMAIN; CELLS	In mammalian cells, sterol regulatory element-binding proteins (SREBPs) coordinate metabolic flux through the cholesterol and fatty acid biosynthetic pathways in response to intracellular cholesterol levels. We describe experiments that evaluate the functional equivalence of mammalian SREBPs and the insect homologue of SREBP-1a, HLH106, in both mammalian and insect cell culture systems. HLH106 binds to both palindromic E-boxes and direct repeat sterol regulatory elements (SREs) efficiently, suggesting that it has a dual DNA binding specificity similar to the mammalian proteins, The amino-terminal "mature" protein activates transcription from mammalian SREs in both mammalian and Drosophila tissue culture cells. Additionally, HLH106 also requires a ubiquitous regulatory co-activator to efficiently activate transcription from mammalian SREs, These properties are shared with its mammalian counterparts. When expressed in mammalian cells, the carboxyl-terminal portion also localizes to perinuclear membranes similar to mammalian SREBPs. Furthermore, membrane-bound HLH106 is proteolytically processed in response to intracellular sterol levels in mammalian cells in an SREBP cleavage-activating protein-stimulated fashion, The presence of an SREBP homologue in Drosophila whose processing is regulated by intracellular sterol levels when expressed in mammalian cells suggests that related processing machinery exists in insect cells. This is notable, since insects are reportedly incapable of de novo sterol biosynthesis.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 19172 Jamboree Rd, Irvine, CA 92697 USA.	tfosborn@uci.edu			NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62203] Funding Source: Medline; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Karlson P, 1970, Biochem Soc Symp, V29, P145; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Maniatis T., 1982, MOL CLONING LAB MANU; MILLINDERVALLET.S, 1996, J BIOL CHEM, V271, P12247; Osborne TF, 1997, CURR BIOL, V7, pR172, DOI 10.1016/S0960-9822(97)70081-2; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Theopold U, 1996, P NATL ACAD SCI USA, V93, P1195, DOI 10.1073/pnas.93.3.1195; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	29	23	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16112	16121		10.1074/jbc.273.26.16112	http://dx.doi.org/10.1074/jbc.273.26.16112			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632664	hybrid			2022-12-27	WOS:000074436600035
J	Xu, J; Yeh, CH; Chen, SW; He, LM; Sensi, SL; Canzoniero, LMT; Choi, DW; Hsu, CY				Xu, J; Yeh, CH; Chen, SW; He, LM; Sensi, SL; Canzoniero, LMT; Choi, DW; Hsu, CY			Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha cycloheximide-induced cerebral endothelial cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED APOPTOSIS; TNF-ALPHA; SPHINGOLIPID BIOSYNTHESIS; MULTIPLE-SCLEROSIS; PROTEIN-SYNTHESIS; BRAIN INJURY; CYTOKINES; PATHWAY; SPHINGOSINE	Cytokines, including tumor necrosis factor-alpha (TNF-alpha), may elicit cytotoxic response through the sphingomyelin-ceramide signal transduction pathway by activation of sphingomyelinases and the subsequent release of ceramide: the universal lipid second messenger. Treatment of bovine cerebral endothelial cells (BCECs) with TNF-alpha for 16 h followed by cycloheximide (CHX) for 6 h resulted in an increase in ceramide accumulation, DNA fragmentation, and cell death. Application of a cell permeable ceramide analogue C-2 ceramide, but not the biologically inactive C-2 dihydroceramide, also induced DNA laddering and BCEC death in a concentration- and time-dependent manner, TNF-alpha/CHX-mediated ceramide production apparently is not a result of sphingomyelin hydrolysis because sphingomyelin content does not decrease in this death paradigm, In addition, an acidic sphingomyelinase inhibitor, desipramine, had no effect on TNF-alpha/CHX-induced cell. death, However, addition of fumonisin B1, a selective ceramide synthase inhibitor, attenuated TNF-alpha/CHX-induced intracellular ceramide elevation and BCEC death. Together, these findings suggest that ceramide plays at least a partial role in this paradigm of BCEC death. Our results show, for the first time, that ceramide derived from de novo synthesis is an alternative mechanism to sphingomyelin hydrolysis in the BCEC death process initiated by TNF-alpha/CHX.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hsu, CY (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	hsuc@neuro.wustl.edu	Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; Hsu, Chung Y./0000-0002-5632-2733; CANZONIERO, Lorella Maria Teresa/0000-0003-2255-5341	NINDS NIH HHS [NS 37230, NS 28995, NS 32636] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028995, R01NS037230, P01NS032636] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; CRUZ R, 1995, FASEB J, V9, pA127; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Gianani R, 1996, P NATL ACAD SCI USA, V93, P2257, DOI 10.1073/pnas.93.6.2257; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hsu CY, 1997, ANN NY ACAD SCI, V823, P148, DOI 10.1111/j.1749-6632.1997.tb48387.x; Hsu CY, 1996, NEUROTRAUMA, P1433; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Shaikh AY, 1997, NEUROSCI LETT, V229, P193, DOI 10.1016/S0304-3940(97)00307-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Slowik MR, 1997, LAB INVEST, V77, P257; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang JH, 1996, SHOCK, V6, P331, DOI 10.1097/00024382-199611000-00006; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; XU J, 1992, J NEUROCHEM, V58, P1930, DOI 10.1111/j.1471-4159.1992.tb10071.x; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	45	175	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16521	16526		10.1074/jbc.273.26.16521	http://dx.doi.org/10.1074/jbc.273.26.16521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632721	hybrid			2022-12-27	WOS:000074436600092
J	Hong, JX; Lee, FJS; Patton, WA; Lin, CY; Moss, J; Vaughan, M				Hong, JX; Lee, FJS; Patton, WA; Lin, CY; Moss, J; Vaughan, M			Phospholipid- and GTP-dependent activation of cholera toxin and phospholipase D by human ADP-ribosylation factor-like protein 1 (HARL1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; ARF-FAMILY; SELECTIVE AMPLIFICATION; CLONING; PURIFICATION; EXPRESSION; MEMBER; BRAIN; GENE; RIBOSYLTRANSFERASE	AY)P-ribosylation factors (ARFs), 20-kDa guanine nucleotide-binding proteins named for their ability to activate cholera toxin (CT) ADP-ribosyltransferase activity, have a critical role in vesicular transport slid activate a phospholipase D (PLD) isoform. Although ARF-like (ARL) proteins are very similar in sequence to ARFs, they were initially believed not to activate CT or PLD. mRNA for human ATL1. (hARL1), which is 57% identical in amino acid sequence to hARF1, is present in all tissues, with the highest amounts in kidney and pancreas and barely detectable amounts in brain. Relative amounts of hARL1 protein were similar to mRNA levels. Purified hARL1 (rARL1) synthesized in Escherichia coli had less activity toward PLD than did rARF1, although PLD activation by both proteins was guanosine guanosine 5'-(gamma-thio)triphosphate (GTP gamma S)-dependent. ARL1 stimulation of CT-catalyzed ADP-ribosylation was considerably less than that by rARF1 and was phospholipid dependent. GTP gamma S-binding by rARL1 was also phospholipid- and detergent-dependent, and in assays containing phosphatidylserine, was greater than that by rARF1. In vitro, the activities of rARL1 and rARF1 are similar. Rather than being a member of a separate subfamily, hARL1, which activates PLD and CT in a phospholipid-dependent manner, appears to be part of a continuum of ARF family proteins.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 100, Taiwan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Taiwan University	Lee, FJS (corresponding author), 7 Chung Shan S Rd, Taipei, Taiwan.			LEE, FANG-JEN/0000-0002-2167-2426				BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; Breiner M, 1996, BBA-GENE STRUCT EXPR, V1308, P1, DOI 10.1016/0167-4781(96)00081-4; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; Harlow E., 1988, ANTIBODIES LAB MANUA; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1995, GUIDEBOOK SMALL GTPA, P429; KIM J, 1996, THESIS KOREAN RES I; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LEE FJS, 1992, J BIOL CHEM, V267, P24441; Lowe SL, 1996, J CELL SCI, V109, P209; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1981, J BIOL CHEM, V256, P7830; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SMITH SA, 1995, GENOMICS, V28, P113, DOI 10.1006/geno.1995.1115; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WELSH CF, 1994, J BIOL CHEM, V269, P15583; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	31	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15872	15876		10.1074/jbc.273.25.15872	http://dx.doi.org/10.1074/jbc.273.25.15872			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624189	hybrid			2022-12-27	WOS:000074284200083
J	Mester, T; Field, JA				Mester, T; Field, JA			Characterization of a novel manganese peroxidase-lignin peroxidase hybrid isozyme produced by Bjerkandera species strain BOS55 in the absence of manganese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; WHITE-ROT FUNGUS; VERATRYL ALCOHOL; DEGRADING BASIDIOMYCETE; DEPENDENT PEROXIDASE; TRAMETES-VERSICOLOR; CERIPORIOPSIS-SUBVERMISPORA; CATALYTIC PROPERTIES; DICHOMITUS-SQUALENS; KINETIC-ANALYSIS	A novel manganese-dependent peroxidase (MnP) isozyme produced in manganese-free cultures of Bjerkandera sp. strain BOS55 was purified and characterized, The production of the enzyme was greatly stimulated by the exogenous addition of various physiological organic acids such as glycolate, glyoxylate, and oxalate, The physical properties of the enzyme are similar to those of MnP isozymes from different white rot fungi (M-r = 43,000, pi 3.88, and epsilon(407) (nm) = 123 mM(-1) cm(-1)). The Bjerkandera MnP was efficient ire the oxidation of Mn(II), as indicated by the kinetic constants (low K-m of 51 mu m and turnover number of 59 s(-1)). Furthermore, the isozyme was able to oxidize various substrates in the absence of manganese, such as 2,6-dimethoxyphenol, guaiacol, ABTS, 3-hydroxyanthranilic acid, and o- and p-anisidine. An interesting characteristic of the isozyme was its ability to oxidize nonphenolic substrates, veratryl alcohol and 1,4-dimethoxybenzene, without manganese addition. The affinity for veratryl alcohol (K-m = 116 mu M) and its turnover number (2.8 s(-1)) are comparable tee those of lignin peroxidase (LiP) isozymes from other white rot fungi, Manganese at concentrations greater than 0.1 mM severely inhibited the oxidation of veratryl alcohol. The results suggest that this single isozyme is a hybrid between MnP and LiP found in other white rot fungi. The N-terminal amino acid sequence showed a very high homology to those of both MnP and LiP isozymes from Trametes versicolor.	Wageningen Univ Agr, Dept Food Technol & Nutr Sci, Div Ind Microbiol, NL-6700 EV Wageningen, Netherlands	Wageningen University & Research	Mester, T (corresponding author), Wageningen Univ Agr, Dept Food Technol & Nutr Sci, Div Ind Microbiol, POB 8129, NL-6700 EV Wageningen, Netherlands.	Tunde.Mester@algemeen.im.wau.nl						Alic M, 1997, BBA-PROTEIN STRUCT M, V1338, P1, DOI 10.1016/S0167-4838(96)00235-X; BONNARME P, 1990, APPL ENVIRON MICROB, V56, P210, DOI 10.1128/AEM.56.1.210-217.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JA, 1991, J BACTERIOL, V173, P4101, DOI 10.1128/jb.173.13.4101-4106.1991; CANCEL AM, 1993, APPL ENVIRON MICROB, V59, P2909, DOI 10.1128/AEM.59.9.2909-2913.1993; D'Annibale A, 1996, J BIOTECHNOL, V48, P231, DOI 10.1016/0168-1656(96)01513-1; DEJONG E, 1994, FEMS MICROBIOL REV, V13, P153, DOI 10.1016/0168-6445(94)90078-7; Dutton MV, 1996, CAN J MICROBIOL, V42, P881, DOI 10.1139/m96-114; FARRELL RL, 1989, ENZYME MICROB TECH, V11, P322, DOI 10.1016/0141-0229(89)90014-8; FORRESTER IT, 1990, APPL MICROBIOL BIOT, V33, P359, DOI 10.1007/BF00164536; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; GOODWIN DC, 1995, BIOCHEMISTRY-US, V34, P5060, DOI 10.1021/bi00015a017; HAEMMERLI SD, 1987, FEBS LETT, V220, P149, DOI 10.1016/0014-5793(87)80893-1; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HAMMEL KE, 1994, BIOCHEMISTRY-US, V33, P13349, DOI 10.1021/bi00249a022; HU ZC, 1993, ENZYME MICROB TECH, V15, P567, DOI 10.1016/0141-0229(93)90018-W; JOHANSSON T, 1993, ARCH BIOCHEM BIOPHYS, V300, P49, DOI 10.1006/abbi.1993.1007; JOHANSSON T, 1993, ARCH BIOCHEM BIOPHYS, V300, P57, DOI 10.1006/abbi.1993.1008; KERSTEN PJ, 1987, J BACTERIOL, V169, P2195, DOI 10.1128/jb.169.5.2195-2201.1987; KHINDARIA A, 1994, ARCH BIOCHEM BIOPHYS, V314, P301, DOI 10.1006/abbi.1994.1446; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; KUAN IC, 1993, J BIOL CHEM, V268, P20064; KUAN IC, 1993, P NATL ACAD SCI USA, V90, P1242, DOI 10.1073/pnas.90.4.1242; LOBOS S, 1994, MICROBIOL-UK, V140, P2691, DOI 10.1099/00221287-140-10-2691; Martinez MJ, 1996, EUR J BIOCHEM, V237, P424, DOI 10.1111/j.1432-1033.1996.0424k.x; Matsubara M, 1996, APPL ENVIRON MICROB, V62, P4066, DOI 10.1128/AEM.62.11.4066-4072.1996; MAYFIELD MB, 1994, APPL ENVIRON MICROB, V60, P4303, DOI 10.1128/AEM.60.12.4303-4309.1994; Mester T, 1996, APPL MICROBIOL BIOT, V44, P778; Mester T, 1997, FEMS MICROBIOL LETT, V155, P161, DOI 10.1016/S0378-1097(97)00382-0; MESTER T, 1995, APPL ENVIRON MICROB, V61, P1881, DOI 10.1128/AEM.61.5.1881-1887.1995; MESTER T, 1998, IN PRESS HOLZFORSCHU; Moreira MT, 1997, APPL ENVIRON MICROB, V63, P1749, DOI 10.1128/AEM.63.5.1749-1755.1997; PEASE EA, 1989, J BIOL CHEM, V264, P13531; Perie FH, 1996, BBA-PROTEIN STRUCT M, V1297, P139, DOI 10.1016/S0167-4838(96)00096-9; PERIE FH, 1991, APPL ENVIRON MICROB, V57, P2240; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; ROY BP, 1993, APPL ENVIRON MICROB, V59, P1855, DOI 10.1128/AEM.59.6.1855-1863.1993; RUTTIMANNJOHNSON C, 1994, APPL ENVIRON MICROB, V60, P599; Sarkar S, 1997, BBA-PROTEIN STRUCT M, V1339, P23, DOI 10.1016/S0167-4838(96)00201-4; SHIMADA M, 1994, FEMS MICROBIOL REV, V13, P285, DOI 10.1111/j.1574-6976.1994.tb00049.x; Sundaramoorthy M, 1997, J BIOL CHEM, V272, P17574, DOI 10.1074/jbc.272.28.17574; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; ten Have R, 1998, FEBS LETT, V422, P391, DOI 10.1016/S0014-5793(98)00044-1; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1988, METHOD ENZYMOL, V161, P238; URZUA U, 1995, FEBS LETT, V371, P132, DOI 10.1016/0014-5793(95)00874-9; WARIISHI H, 1988, BIOCHEMISTRY-US, V27, P5365, DOI 10.1021/bi00414a061; WARIISHI H, 1992, J BIOL CHEM, V267, P23688; WOLFENDEN BS, 1982, J CHEM SOC PERK T 2, P805, DOI 10.1039/p29820000805; Zapanta LS, 1997, J BIOTECHNOL, V53, P93, DOI 10.1016/S0168-1656(96)01678-1	53	221	232	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15412	15417		10.1074/jbc.273.25.15412	http://dx.doi.org/10.1074/jbc.273.25.15412			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624124	hybrid			2022-12-27	WOS:000074284200018
J	Schmalfeldt, M; Dours-Zimmermann, MT; Winterhalter, KH; Zimmermann, DR				Schmalfeldt, M; Dours-Zimmermann, MT; Winterhalter, KH; Zimmermann, DR			Versican V-2 is a major extracellular matrix component of the mature bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LARGE AGGREGATING PROTEOGLYCAN; HYALURONATE-BINDING PROTEIN; PG-M; NEURITE OUTGROWTH; NERVOUS-TISSUE; AGGRECAN; CARTILAGE; EXPRESSION; GENE	We have isolated and characterized the proteoglycan isoforms of versican from bovine brain extracts. Our approach included (i) cDNA cloning and sequencing of the entire open reading frame encoding the bovine versican splice variants; (ii) preparation of antibodies against bovine versican using recombinant core protein fragments and synthetic peptides; (iii) isolation of versican isoforms by ammonium sulfate precipitation followed by anion exchange and hyaluronan affinity chromatography; and (iv) characterization by SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining or immunoblotting. Our results demonstrate that versican V-2 is, together with brevican, a major component of the mature brain extracellular matrix. Versicans V-0 and V-1 are only present in relatively small amounts. Versican V-2 migrates after chondroitinase ABC digestion with an apparent molecular mass of about 400 kDa, whereas it barely enters a 4-15% polyacrylamide gel without the enzyme treatment. The 400-kDa product is recognized by antibodies against the glycosaminoglycan-alpha domain and against synthetic NH2- and COOH-terminal peptides. Our preparations contain no major proteolytic products of versican, e.g, hyaluronectin or glial hyaluronate-binding protein. Having biochemical quantities of versican V-2 available will allow us to test its putative modulatory role in neuronal cell adhesion and axonal growth.	Univ Zurich, Inst Clin Pathol, Dept Pathol, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Biochem Lab 1, CH-8092 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zimmermann, DR (corresponding author), Univ Zurich, Inst Clin Pathol, Dept Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	dieterzi@pathol.unizh.ch						Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; DELPECH B, 1981, J NEUROCHEM, V36, P855, DOI 10.1111/j.1471-4159.1981.tb01672.x; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Domowicz M, 1996, INT J DEV NEUROSCI, V14, P191, DOI 10.1016/0736-5748(96)00007-X; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FRYER HJL, 1992, J BIOL CHEM, V267, P9874; FULOP C, 1993, J BIOL CHEM, V268, P17377; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HOCKFIELD S, 1990, COLD SPRING HARB SYM, V55, P505; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Li H, 1996, MOL BRAIN RES, V36, P309, DOI 10.1016/0169-328X(95)00269-X; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; NASO MF, 1994, J BIOL CHEM, V269, P32999; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1992, J BIOL CHEM, V267, P23883; PERIDES G, 1995, BIOCHEM J, V312, P377, DOI 10.1042/bj3120377; Rauch U, 1997, CELL TISSUE RES, V290, P349, DOI 10.1007/s004410050940; Rauch U, 1997, GENOMICS, V44, P15, DOI 10.1006/geno.1997.4853; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Rauch U, 1997, J BIOL CHEM, V272, P26905, DOI 10.1074/jbc.272.43.26905; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SNOW DM, 1991, DEVELOPMENT, V113, P1473; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	44	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15758	15764		10.1074/jbc.273.25.15758	http://dx.doi.org/10.1074/jbc.273.25.15758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624174	hybrid			2022-12-27	WOS:000074284200068
J	Gether, U; Kobilka, BK				Gether, U; Kobilka, BK			G protein-coupled receptors - II. Mechanism of agonist activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CONSTITUTIVELY ACTIVE MUTANTS; BETA-ADRENERGIC-RECEPTOR; TACHYKININ NK-1 RECEPTOR; TERNARY COMPLEX MODEL; CARBOXYLIC-ACID GROUP; CONFORMATIONAL-CHANGES; BETA(2)-ADRENERGIC RECEPTOR; HORMONE RECEPTOR; 7TM RECEPTORS; BINDING SITES		Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B157, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Univ Copenhagen, Panum Inst, Inst Med Physiol 12 5, Dept Cellular Physiol, DK-2200 Copenhagen, Denmark	Howard Hughes Medical Institute; Stanford University; Stanford University; University of Copenhagen	Kobilka, BK (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr B157, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Kobilka, Brian/0000-0001-5958-3990; Gether, Ulrik/0000-0002-0020-3807	NINDS NIH HHS [R0 1 NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BECKSICKINGER AG, 1996, DRUG DISCOV TODAY, V1, P501; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DELEAN A, 1980, J BIOL CHEM, V255, P7108; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKLIN TJ, 1983, J NEURAL TRANSM, P55; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUINTANA DG, 1995, BIOPHYS J, V69, P1077, DOI 10.1016/S0006-3495(95)79981-7; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROTHSCHILD KJ, 1983, SCIENCE, V219, P1333, DOI 10.1126/science.6828860; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SALAMON Z, 1994, BIOCHEMISTRY-US, V33, P13706, DOI 10.1021/bi00250a022; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276; WILLIAMS LT, 1977, J BIOL CHEM, V252, P7207; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZHOU W, 1994, MOL PHARMACOL, V45, P165	60	483	507	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17979	17982		10.1074/jbc.273.29.17979	http://dx.doi.org/10.1074/jbc.273.29.17979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660746	hybrid			2022-12-27	WOS:000074828500001
J	Seto-Young, D; Bandell, M; Hall, M; Perlin, DS				Seto-Young, D; Bandell, M; Hall, M; Perlin, DS			Differential exposure of surface epitopes in the beta-strand region of LOOP1 of the yeast H+-ATPase during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; FUNCTIONAL CONSEQUENCES; MUTATIONS; CLEAVAGE; BINDING; DOMAINS; STATES	The plasma membrane H+-ATPase of yeast assumes distinct conformational states during its catalytic cycle. To better understand structural changes in the LOOP1 domain, a catalytically important cytoplasmic loop segment Linking transmembrane segments 2 and 3, surface epitopes were examined at different stages of catalysis. A polyclonal rabbit antibody was prepared to a fusion protein consisting of LOOP1 and the maltose binding protein. This antibody was affinity-purified to produce a LOOP1-specific fraction that could be used in competition enzyme-linked immunosorbent assays to assess surface exposure of the LOOP1 epitopes. It was found that in an E-1 conformation stabilized with either adenosine 5'-(beta,gamma-imino)triphosphate (AMP-PNP) or ADP, less than 10% of the LOOP1 epitopes were accessible on native enzyme. However, when the enzyme was stabilized in an E-w-state with ATP plus vanadate, approximately 40% of the surface epitopes on LOOP1 became accessible to antibody. The remaining 60% of the LOOP1 epitopes were fully occluded in the native enzyme and never showed surface exposure. Enzyme-linked immunosorbent assays utilizing fusion proteins consisting of LOOP1 subdomains demonstrated that all of the available epitopes were contained in the beta-strand region (Glu-195-Val-267) of LOOP1, The epitopes that were differentially exposed during catalysis were included in regions upstream and downstream of the highly conserved TOES sequence. Our results suggest that during catalysis either the beta-strand region of LOOP1 or an interacting domain undergoes substantial structural rearrangement that facilitates epitope exposure.	Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA		Perlin, DS (corresponding author), Publ Hlth Res Inst City New York Inc, 455 1St Ave, New York, NY 10016 USA.		Perlin, David S/K-4013-2015		NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1982, J BIOL CHEM, V257, P421; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Bandell M, 1996, BBA-BIOMEMBRANES, V1280, P81, DOI 10.1016/0005-2736(95)00280-4; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GOFFEAU A, 1990, J BIOL CHEM, V265, P15503; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; SERRANO R, 1993, EUR J BIOCHEM, V212, P737, DOI 10.1111/j.1432-1033.1993.tb17712.x; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TUNWELL REA, 1991, BIOCHEM J, V279, P203, DOI 10.1042/bj2790203; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Wang GF, 1997, ARCH BIOCHEM BIOPHYS, V344, P309, DOI 10.1006/abbi.1997.0213; Yonekura K, 1997, BIOPHYS J, V72, P997, DOI 10.1016/S0006-3495(97)78752-6	35	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18282	18287		10.1074/jbc.273.29.18282	http://dx.doi.org/10.1074/jbc.273.29.18282			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660792	hybrid			2022-12-27	WOS:000074828500047
J	New, DR; Maggirwar, SB; Epstein, LG; Dewhurst, S; Gelbard, HA				New, DR; Maggirwar, SB; Epstein, LG; Dewhurst, S; Gelbard, HA			HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NF kappa B-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; CELLS; APOPTOSIS; EXPRESSION; NEUROTOXICITY; DISSOCIATION; MACROPHAGES; MORPHOLOGY; CULTURE	Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system may result in neuronal apoptosis in vulnerable brain regions, including cerebral cortex and basal ganglia. The mechanisms for neuronal loss are Likely to be multifactorial and indi rect, since HIV-1 productively infects brain-resident macrophages and microglia but does not cause cytolytic infection of neurons in the central nervous system. HIV-1 infection of macrophages and microglia leads to production and release of diffusible factors that result in neuronal cell death, including the HIV-1 regulatory protein Tat, We demonstrate in this report that recombinant Tat(1-86) and Tat peptides containing the basic region induce neuronal apoptosis in approximately 50% of vulnerable neurons in both rat and human neuronal cultures, and this apoptotic cell death is mediated by release of the pro-inflammatory cytokine tumor necrosis factor alpha, and by activation of glutamate receptors of the non-N-methyl-D-aspartate subtype, Finally, we show that Tat-induced apoptosis of human neuronal cell cultures occurs in the absence of activation of the transcription factor NF kappa B. These findings further define cellular pathways activated by Tat, that dysregulate production of tumor necrosis factor alpha, and lead to activation of glutamate receptors and neuronal death during HIV-1 infection of the central nervous system.	Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Dent Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Gelbard, HA (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Rochester, NY 14642 USA.		Gelbard, Harris/M-9260-2019	Dewhurst, Stephen/0000-0001-7729-7920; Epstein, Leon/0000-0003-4264-3867; Gelbard, Harris/0000-0001-5095-7976	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH057556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010307] Funding Source: NIH RePORTER; NIMH NIH HHS [P01 MH57556] Funding Source: Medline; NINDS NIH HHS [F32-NS10307] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEDLER JL, 1973, CANCER RES, V33, P2643; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVERALL IP, 1995, NAT MED, V1, P1174, DOI 10.1038/nm1195-1174; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KAWAMOTO JC, 1986, BRAIN RES, V384, P84, DOI 10.1016/0006-8993(86)91222-9; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIPTON SA, 1992, NEUROREPORT, V3, P913, DOI 10.1097/00001756-199210000-00023; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUNOZ E, 1994, J VIROL, V68, P8035; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; Perry SW, 1997, BIOTECHNIQUES, V22, P1102, DOI 10.2144/97226st01; Perry SW, 1997, BIOTECHNIQUES, V22, P1020, DOI 10.2144/97226bm01; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WHITE LA, 1994, J NEUROSCI, V14, P6744; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZAULI G, 1993, CANCER RES, V53, P4481	43	153	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17852	17858		10.1074/jbc.273.28.17852	http://dx.doi.org/10.1074/jbc.273.28.17852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651389	hybrid			2022-12-27	WOS:000074816100082
J	Shim, H; Hong, SB; Raushel, FM				Shim, H; Hong, SB; Raushel, FM			Hydrolysis of phosphodiesters through transformation of the bacterial phosphotriesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHOSPHATE DIESTER HYDROLYSIS; BINUCLEAR METAL CENTER; PSEUDOMONAS-DIMINUTA; 3-DIMENSIONAL STRUCTURE; ASPARTATE-AMINOTRANSFERASE; HISTIDINE; INACTIVATION; SPECIFICITY; MECHANISM	The phosphotriesterase from Pseudomonas diminuta catalyzes the hydrolysis of a wide array of phosphotriesters and related phosphonates, including organophosphate pesticides and military nerve agents. It has now been shown that this enzyme can also catalyze the hy drolysis of phosphodiesters, albeit at a greatly reduced rate. However, the enzymatic hydrolysis of ethyl-4-nitrophenyl phosphate (compound I) by the wild-type enzyme was >10(8) times faster than the uncatalyzed reaction (k(cat) = 0.06 s(-1) and K-m = 38 mM). Upon the addition of various alkylamines to the reaction mixture, the k(cat)/K-m for the phosphodiester (compound I) increased up to 200-fold. Four mutant enzymes of the phosphotriesterase were constructed in a preliminary attempt to improve phosphodiester hydrolysis activity of the native enzyme. Met-317, which is thought to reside in close proximity to the pro S-ethoxy arm of the paraoxon substrate, was mutated to arginine, alanine, histidine, and lysine, These mutant enzymes showed slight improvements in the catalytic hydrolysis of organophosphate diesters, The M317K mutant enzyme displayed the most improvement in catalytic activity (k(cat) = 0.34 s(-1) and K-m = 30 mM), The M317A mutant enzyme catalyzed the hydrolysis of the phosphodiester (compound I) in the presence of alkylamines up to 200 times faster than the wildtype enzyme in the absence of added amines, The neutralization of the negative charge on the oxygen atom of the phosphodiester by the ammonium cation within the active site is thought to be responsible for the rate enhancement by these amines in the hydrolytic reaction. These results demonstrate that an active site optimized for the hydrolysis of organophosphate triesters can be made to catalyze the hydrolysis of organophosphate diesters.	Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Raushel, FM (corresponding author), Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.		Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [GM 33894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER M, 1961, J BIOL CHEM, V236, P3014; BANZON JA, 1995, BIOCHEMISTRY-US, V34, P743, DOI 10.1021/bi00003a006; BANZON JA, 1995, BIOCHEMISTRY-US, V34, P750, DOI 10.1021/bi00003a007; BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; Birikh KR, 1997, EUR J BIOCHEM, V245, P1, DOI 10.1111/j.1432-1033.1997.t01-3-00001.x; BUNTON CA, 1975, J ORG CHEM, V40, P2313, DOI 10.1021/jo00904a011; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7444, DOI 10.1021/bi00244a011; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CHAE MY, 1993, J AM CHEM SOC, V115, P12173, DOI 10.1021/ja00078a069; CRONIN CN, 1987, J AM CHEM SOC, V109, P2222, DOI 10.1021/ja00241a072; Deal KA, 1996, INORG CHEM, V35, P2792, DOI 10.1021/ic951488l; Deal KA, 1996, J AM CHEM SOC, V118, P1713, DOI 10.1021/ja952306p; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; HAN MJ, 1997, J CHEM SOC CHEM COMM, P163; HENDRY P, 1989, J AM CHEM SOC, V111, P2521, DOI 10.1021/ja00189a025; Hettich R, 1997, J AM CHEM SOC, V119, P5638, DOI 10.1021/ja964319o; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; Kuo JM, 1997, BIOCHEMISTRY-US, V36, P1982, DOI 10.1021/bi962099l; KUO JM, 1994, BIOCHEMISTRY-US, V33, P4265, DOI 10.1021/bi00180a022; Kurpiewski MR, 1996, BIOCHEMISTRY-US, V35, P8846, DOI 10.1021/bi960261e; LEWIS VE, 1988, BIOCHEMISTRY-US, V27, P1591, DOI 10.1021/bi00405a030; MORROW JR, 1988, INORG CHEM, V27, P3387, DOI 10.1021/ic00292a025; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; OMBURO GA, 1993, BIOCHEMISTRY-US, V32, P9148, DOI 10.1021/bi00086a021; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; TAKAGASHI K, 1982, ENZYMES, V15, P458; Vanhooke JL, 1996, BIOCHEMISTRY-US, V35, P6020, DOI 10.1021/bi960325l; WTKINS LM, 1997, PROTEIN-STRUCT FUNCT, V29, P553	32	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17445	17450		10.1074/jbc.273.28.17445	http://dx.doi.org/10.1074/jbc.273.28.17445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651332	hybrid			2022-12-27	WOS:000074816100025
J	Takafuta, T; Wu, GX; Murphy, GF; Shapiro, SS				Takafuta, T; Wu, GX; Murphy, GF; Shapiro, SS			Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	39th Annual Meeting of the American-Society-of-Hematology	DEC 05-09, 1997	SAN DIEGO, CALIFORNIA	Amer Soc Hematol			ACTIN-BINDING-PROTEIN; NON-MUSCLE CELLS; SMOOTH-MUSCLE; IX COMPLEX; HUMAN-PLATELETS; DOMAIN; ABP-280; IDENTIFICATION; PURIFICATION; DYSTROPHIN	We have cloned and sequenced a 9.4-kilobase cDNA specifying a new 280-kDa protein interacting with the cytoplasmic tail of glycoprotein (Gp) Ib alpha and showing considerable homology to actin-binding protein 280 (ABP-280) and chicken retinal filamin. We term this protein human beta-filamin. The gene for beta-filamin localizes to chromosome 3p14.3-p21.1. beta-Filamin mRNA expression was observed in many tissues and in cultured human umbilical vein endothelial cells (HUVECs); only minimal expression was detected in platelets and the megakaryocytic cell line CHRF-288. Like ABP-280, beta-filamin contains an NH2-terminal actin-binding domain, a backbone of 24 tandem repeats, and two "hinge" regions. A polyclonal antibody to the unique beta-filamin first hinge sequence identifies a strong 280-kDa band in HUVECs but only a weak band in platelets, and stains normal human endothelial cells in culture and in situ. We have confirmed the interaction of beta-filamin and GpIb alpha in platelet and HUVEC lysates. In addition, using two-hybrid analysis with deletion mutants, we have localized the binding domain for GpIb alpha in beta-filamin to residues 1862-2148, an area homologous to the GpIb alpha binding domain in ABP-280. beta-Filamin is a new member of the filamin family that may have significance for GpIb alpha function in endothelial cells and platelets.	Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Shapiro, SS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, 1015 Walnut St, Philadelphia, PA 19107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL009163, R37HL009163] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09163] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BARRY CP, 1993, J BIOL CHEM, V268, P25577; BOXER LA, 1976, J CLIN INVEST, V57, P964, DOI 10.1172/JCI108373; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DAVIES PJA, 1978, J BIOL CHEM, V253, P4036; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1985, J BIOL CHEM, V260, P1970; Fucini P, 1997, NAT STRUCT BIOL, V4, P223, DOI 10.1038/nsb0397-223; GOMER RH, 1981, CELL, V23, P524, DOI 10.1016/0092-8674(81)90148-3; GOMER RH, 1983, J CELL BIOL, V96, P321, DOI 10.1083/jcb.96.2.321; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GORLIN JB, 1993, GENOMICS, V17, P496, DOI 10.1006/geno.1993.1354; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1975, J BIOL CHEM, V250, P5696; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; HU RJ, 1992, J BIOL CHEM, V267, P18715; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEEDMAN PJ, 1993, P NATL ACAD SCI USA, V90, P5994, DOI 10.1073/pnas.90.13.5994; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5616; MAESTRINI E, 1993, HUM MOL GENET, V2, P761, DOI 10.1093/hmg/2.6.761; MANGEAT PH, 1983, CELL MOTIL CYTOSKEL, V3, P657, DOI 10.1002/cm.970030530; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; NOEGEL AA, 1989, J CELL BIOL, V109, P607, DOI 10.1083/jcb.109.2.607; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; ROSENBERG S, 1981, J CELL BIOL, V91, P201, DOI 10.1083/jcb.91.1.201; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Tachikawa M, 1997, J BIOCHEM-TOKYO, V122, P314; TERASAKI AG, 1995, J CELL SCI, P857; WANG K, 1977, P NATL ACAD SCI USA, V74, P2021, DOI 10.1073/pnas.74.5.2021; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WANG K, 1977, BIOCHEMISTRY-US, V16, P1857, DOI 10.1021/bi00628a015; WEIHING RR, 1983, BIOCHEMISTRY-US, V22, P1839, DOI 10.1021/bi00277a015; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; Wu GX, 1997, BLOOD, V90, P2660, DOI 10.1182/blood.V90.7.2660.2660_2660_2669; Wu GX, 1996, BLOOD, V87, P2782, DOI 10.1182/blood.V87.7.2782.bloodjournal8772782; Zhang WJ, 1998, J NEUROSCI, V18, P914	48	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17531	17538		10.1074/jbc.273.28.17531	http://dx.doi.org/10.1074/jbc.273.28.17531			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651345	hybrid			2022-12-27	WOS:000074816100038
J	Buzzard, KA; Giaccia, AJ; Killender, M; Anderson, RL				Buzzard, KA; Giaccia, AJ; Killender, M; Anderson, RL			Heat shock protein 72 modulates pathways of stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-DEATH; BREAST-CANCER; ACTIVATION; HSP70; THERMOTOLERANCE; FIBROBLASTS; PROTEASES; INDUCTION; GENE	The resistance to stress-induced apoptosis conferred by the thermotolerant state or by exogenous expression of HSP72 was measured in mouse embryo fibroblasts. The induction of thermotolerance protects cells from heat, tumor necrosis factor alpha (TNF alpha), and ceramide-induced apoptosis but not from ionizing radiation. Because the development of thermotolerance is associated with increased levels of heat shock proteins, we determined whether constitutive expression of one of the major inducible heat shock proteins, HSP72, could also protect cells from stress-induced apoptosis. Cells expressing constitutive HSP72 were shown to have significantly reduced levels of apoptosis after heat, TNF alpha, and ceramide but not after ionizing radiation. Activation of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) was found to be strongly inhibited in thermotolerant cells after heat shock but not after other stresses. Cells that constitutively express HSP72 did not demonstrate decreased SAPK/JNK activation after any of these stresses. Thus, factors other than HSP72 that are induced in the thermotolerant state are able to reduce activation of SAPK/JNK after heat stress, Notably, the level of activation of SAPK/JNK did not correlate with the amount of apoptosis detected after different stresses. Constitutive HSP72 expression inhibited poly(ADP-ribose) polymerase cleavage in cells after heat shock and TNF alpha but not after ceramide or ionizing radiation. The results suggest either that SAPK/JNK activation is not required for apoptosis in mouse embryo fibroblasts or that HSP72 acts downstream of SAPK/JNK. Furthermore, the data support the concept that caspase activity, which can be down-regulated by HSP72, is a crucial step in stress-induced apoptosis. Based on data presented here and elsewhere, we propose that the heat shock protein family can be classified as a class of anti-apoptotic genes, in addition to the Bcl-2 and inhibitor of apoptosis protein families of genes.	Peter MacCallum Canc Inst, Trescowthick Res Labs, E Melbourne, Vic 3002, Australia; Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA	Peter Maccallum Cancer Center; Stanford University	Anderson, RL (corresponding author), Peter MacCallum Canc Inst, Locked Bag 1,ABeckett St, Melbourne, Vic 3000, Australia.	r.anderson@pmci.unimelb.edu.au	Anderson, Robin/K-6966-2019; Anderson, Robin/I-2306-2013; Anderson, Robin/S-1005-2017	Anderson, Robin/0000-0002-6841-7422				Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Garrido C, 1997, CANCER RES, V57, P2661; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; JAATTELA M, 1993, J IMMUNOL, V151, P4286; JAMEEL A, 1992, INT J CANCER, V50, P409, DOI 10.1002/ijc.2910500315; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIMURA E, 1993, J CLIN ONCOL, V11, P891, DOI 10.1200/JCO.1993.11.5.891; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NEALE ML, 1988, IMMUNOLOGY, V64, P81; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STRASSER A, 1995, CELL GROWTH DIFFER, V6, P1; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; TAVARIA M, 1997, GUIDEBOOK MOL CHAPER, P49; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1996, EXPERIENTIA, V52, P968, DOI 10.1007/BF01920106	49	257	278	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17147	17153		10.1074/jbc.273.27.17147	http://dx.doi.org/10.1074/jbc.273.27.17147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642282	hybrid			2022-12-27	WOS:000074545200072
J	Engel, LS; Hill, JM; Caballero, AR; Green, LC; O'Callaghan, RJ				Engel, LS; Hill, JM; Caballero, AR; Green, LC; O'Callaghan, RJ			Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOFT CONTACT-LENSES; ALKALINE PROTEASE; DEFICIENT MUTANTS; CYSTIC-FIBROSIS; TOXIN-A; ELASTASE; INFECTIONS; EPIDEMIOLOGY; KERATITIS; PROTEINS	Comparisons of virulence between a Pseudomonas parent strain and an isogenic mutant devoid of protease TV have demonstrated a significant role for this enzyme during infection. We have characterized purified Pseudomonas aeruginosa protease TV in terms of its biochemical and enzymatic properties, and found it to be a unique extracellular protease. The N-terminal decapeptide sequence of protease IV is not homologous with any published protein sequence. Protease IV has a molecular mass of 26 kDa, an isoelectric point of 8.70, and optimum enzymatic activity at pH 10.0 and 45 degrees C. Purified protease TV demonstrates activity for the carboxyl side of lysine-containing peptides and can digest a number of biologically important proteins, including immunoglobulin, complement components, fibrinogen, and plasminogen. Protease IV is not inhibited by thiol-, carboxyl-, or metalloproteinase inhibitors. The total loss of enzyme activity in the presence of N-p-tosyl-L-chloro-methyl ketone and the partial inhibition of enzyme activity by diisopropyl fluorophosphate or phenylmethylsulfonyl fluoride imply that protease TV is a serine protease. Inhibition by dithiothreitol and beta-mercaptoethanol suggests that intramolecular disulfide bonds are essential for enzyme activity. The characteristics of this enzyme suggest that inhibitors of serine proteases could be developed into a medication designed to arrest tissue damage during Pseudomonas infection.	Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, Ctr Eye,Sch Med, New Orleans, LA 70112 USA; Louisiana State Univ, Sch Med, Ctr Eye, Dept Ophthalmol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System	O'Callaghan, RJ (corresponding author), Louisiana State Univ, Med Ctr, Dept Microbiol Immunol & Parasitol, Ctr Eye,Sch Med, 1901 Perdido St, New Orleans, LA 70112 USA.				NEI NIH HHS [EY02377, EY08871, EY10974] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008871, R01EY010974, P30EY002377] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMS MH, 1959, BACTERIOPHAGES, P446; AQUINO VM, 1995, PEDIATR INFECT DIS J, V14, P140; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; Daring G., 1993, PSEUDOMONAS AERUGINO, P245; Dart JKG, 1995, EYE, V9, P679, DOI 10.1038/eye.1995.178; DIXON GH, 1958, J BIOL CHEM, V233, P1373; ELLIOTT BW, 1986, J BIOL CHEM, V261, P1259; Engel LS, 1998, INVEST OPHTH VIS SCI, V39, P662; FLANIGAN MJ, 1994, PERITON DIALYSIS INT, V14, P248; FLORES G, 1993, CLIN INFECT DIS, V16, P698; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GOLD AM, 1964, BIOCHEMISTRY-US, V3, P783, DOI 10.1021/bi00894a009; Holder I.A., 1993, PSEUDOMONAS AERUGINO, P275; Holland Simon P., 1993, P159; HOWE TR, 1984, INFECT IMMUN, V43, P1058, DOI 10.1128/IAI.43.3.1058-1063.1984; IMAYASU M, 1994, OPHTHALMOLOGY, V101, P371; JARVIS WR, 1992, J ANTIMICROB CHEMOTH, V29, P19, DOI 10.1093/jac/29.suppl_A.19; KERNACKI KA, 1995, INVEST OPHTH VIS SCI, V36, P1371; KESSLER E, 1993, J BIOL CHEM, V268, P7503; KILLINGSWORTH DW, 1989, ARCH OPHTHALMOL-CHIC, V107, P795, DOI 10.1001/archopht.1989.01070010817012; MOOS M, 1988, J BIOL CHEM, V263, P6005; O'Callaghan R.J., 1996, INVEST OPHTH VIS SCI, V37, P1; OHMAN DE, 1980, J INFECT DIS, V142, P547, DOI 10.1093/infdis/142.4.547; OHMAN DE, 1980, INFECT IMMUN, V28, P899; PAVLOVSKIS OR, 1979, INFECT IMMUN, V24, P181, DOI 10.1128/IAI.24.1.181-187.1979; ROLSTON KVI, 1992, CANCER INVEST, V10, P43, DOI 10.3109/07357909209032787; SHAW ELLIOTT, 1965, BIOCHEMISTRY, V4, P2219, DOI 10.1021/bi00886a039; STRAND CL, 1982, JAMA-J AM MED ASSOC, V248, P1615, DOI 10.1001/jama.248.13.1615; SUTER S, 1994, AM J RESP CRIT CARE, V150, pS118, DOI 10.1164/ajrccm/150.6_Pt_2.S118; TODER SD, 1992, 92 GEN M AM SOC MICR, pD51; TRUEB RM, 1994, PEDIATR DERMATOL, V11, P35, DOI 10.1111/j.1525-1470.1994.tb00071.x; TWINING SS, 1993, INVEST OPHTH VIS SCI, V34, P2699	34	129	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16792	16797		10.1074/jbc.273.27.16792	http://dx.doi.org/10.1074/jbc.273.27.16792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642237	hybrid			2022-12-27	WOS:000074545200027
J	Jansch, L; Kruft, V; Schmitz, UK; Braun, HP				Jansch, L; Kruft, V; Schmitz, UK; Braun, HP			Unique composition of the preprotein translocase of the outer mitochondrial membrane from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROTEIN IMPORT RECEPTOR; PROCESSING PEPTIDASE; POTATO MITOCHONDRIA; PRECURSOR PROTEINS; RESPIRATORY-CHAIN; COMPLEX; IDENTIFICATION; INSERTION; MACHINERY	Transport of most nuclear encoded mitochondrial proteins into mitochondria is mediated by heteropolymeric translocases in the membranes of the organelles. The translocase of the outer mitochondrial membrane (TOM) was characterized in fungi, and it was shown that TOM from yeast comprises nine different subunits, This publication is the first report on the preparation of the TOM complex from plant mitochondria. The protein complex from potato was purified by (a) blue native polyacrylamide gel electrophoresis and (b) by immunoaffinity chromatography, On blue native gels, the potato TOM complex runs close to cytochrome c oxidase at 230 kDa and hence only comprises about half of the size of fungal TOM complexes. Analysis of the TOM complex from potato by SDS-polyacrylamide gel electrophoresis allows separation of seven different subunits of 70, 36, 23, 9, 8, 7, and 6 kDa The 23-kDa protein is identical to the previously characterized potato TOM20 receptor, as shown by in vitro assembly of this protein into the 230-kDa complex, by immunoblotting and by direct protein sequencing Partial amino acid sequence data of the other subunits allowed us to identify sequence similarity between the 36-kDa protein and fungal TOM40, Sequence analysis of cDNAs encoding the 7-kDa protein revealed significant sequence homology of this protein to TOM7 from yeast. However, potato TOM7 has a N-terminal extension, which is very rich in basic amino acids. Counterparts to the TOM22 and TOM37 proteins from yeast seem to be absent in the potato TOM complex, whereas an additional low molecular mass subunit occurs. Functional implications of these findings are discussed.	Univ Hannover, Inst Angew Genet, D-30419 Hannover, Germany; Appl Biosyst, D-63225 Langen, Germany	Leibniz University Hannover; Thermo Fisher Scientific; Applied Biosystems	Braun, HP (corresponding author), Univ Hannover, Inst Angew Genet, Herrenhauser Str 2, D-30419 Hannover, Germany.		Braun, Hans-Peter/E-7149-2011	Braun, Hans-Peter/0000-0002-4459-9727				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; BAKER KP, 1990, NATURE, V348, P305; BRAUN HP, 1995, PLANTA, V195, P396, DOI 10.1007/BF00202597; BRAUN HP, 1992, MOL GEN GENET, V231, P217, DOI 10.1007/BF00279794; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; BURT WJE, 1994, FEBS LETT, V339, P139, DOI 10.1016/0014-5793(94)80401-X; Dekker PJT, 1996, BIOL CHEM, V377, P535; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HAUKE V, 1997, TRENDS CELL BIOL, V7, P103; HEINS L, 1994, J BIOL CHEM, V269, P26402; Heins L, 1996, PLANT J, V9, P829, DOI 10.1046/j.1365-313X.1996.9060829.x; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PERRYMAN RA, 1995, ARCH BIOCHEM BIOPHYS, V316, P659, DOI 10.1006/abbi.1995.1088; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PRASAD TK, 1992, PLANT MOL BIOL, V18, P873, DOI 10.1007/BF00019202; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; Szigyarto C, 1998, PLANT MOL BIOL, V36, P171, DOI 10.1023/A:1005977716814; WATTS FZ, 1992, PLANT MOL BIOL, V18, P23, DOI 10.1007/BF00018453	34	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17251	17257		10.1074/jbc.273.27.17251	http://dx.doi.org/10.1074/jbc.273.27.17251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642296	hybrid			2022-12-27	WOS:000074545200086
J	McCarthy, JV; Ni, J; Dixit, VM				McCarthy, JV; Ni, J; Dixit, VM			RIP2 is a novel NF-kappa B-activating and cell death-inducing kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; PROTEIN; APOPTOSIS; CD40; ANTIGEN; FAMILY; SIGNAL; INTERACTS	Through specific interactions with members of the tumor necrosis receptor (TNFR) family, adapter molecules such as the serine/threonine (Ser/Thr) kinase RIP mediate divergent signaling pathways including NF-KB activation and cell death. In this study, we have identified and characterized a novel 61-kDa protein kinase related to RIP that is a component of both the TNFR-1 and the CD40 signaling complexes. Receptor interacting protein-2 (RIP2) contains an N-terminal domain with homology to Ser/Thr kinases and a C-terminal caspase activation and recruitment domain (CARD), a homophilic interaction motif that mediates the recruitment of caspase death proteases. Overexpression of RIPS signaled both NF-KB activation and cell death. Mutational analysis revealed the pro-apoptotic function of RIPS to be restricted to its C-terminal CARD domain, whereas the intact molecule was necessary for NF-KB activation. RIPS interacted with other members of the TNFR-1 signaling complex, including inhibitor of apoptosis protein cIAP1 and with members of the TNFR-associated factor (TRAF) family, specifically TRAF1, TRAF5, and TRAF6, but not with TRAF2, TRAF3, or TRAF4. These TRAF interactions mediate the recruitment of RIPS to receptor signaling complexes.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Human Genome Sci Inc, Rockville, MD 20850 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Bldg 10,Rm 290, San Francisco, CA 94080 USA.	dixit@gene.com	mccarthy, justin/AAG-7550-2019; dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; mccarthy, justin/0000-0002-2667-7365				ADAMS MD, 1995, NATURE S, V377, P173; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LING NR, 1987, LEUCOCYTE TYPING, V3, P302; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	44	351	387	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16968	16975		10.1074/jbc.273.27.16968	http://dx.doi.org/10.1074/jbc.273.27.16968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642260	hybrid			2022-12-27	WOS:000074545200050
J	Mote, J; Reines, D				Mote, J; Reines, D			Recognition of a human arrest site is conserved between RNA polymerase II and prokaryotic RNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTOR; AMINO-ACID SUBSTITUTIONS; INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; NASCENT RNA; TERNARY COMPLEXES; TERMINATION EFFICIENCY; INTRINSIC TERMINATION; HYDROLYTIC CLEAVAGE; CRYSTAL-STRUCTURE	DNA sequences that arrest transcription by either eukaryotic RNA polymerase II or Escherichia coli RNA polymerase have been identified previously. Elongation factors SH and GreB are RNA polymerase-binding proteins that enable readthrough of arrest sites by these enzymes, respectively. This functional similarity has led to general models of elongation applicable to both eukaryotic and prokaryotic enzymes. Here we have transcribed with phage and bacterial RNA polymerases, a human DNA sequence previously defined as an arrest site for RNA polymerase II. The phage and bacterial enzymes both respond efficiently to the arrest signal in vitro at limiting levels of nucleoside triphosphates. The E. coli polymerase remains in a template-engaged complex for many hours, can be isolated, and is potentially active. The enzyme displays a relatively slow first-order loss of elongation competence as it dwells at the arrest site. Bacterial RNA polymerase arrested at the human site is reactivated by GreB in the same way that RNA polymerase II arrested at this site is stimulated by SII, Very efficient readthrough can be achieved by phage, bacterial, and eukaryotic RNA polymerases in the absence of elongation factors if 5-Br-UTP is substituted for UTP. These findings provide additional and direct evidence for functional similarity between prokaryotic and eukaryotic transcription elongation and readthrough mechanisms.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	dreines@emory.edu	excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NIGMS NIH HHS [GM46331, R01 GM046331] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Chamberlin M J, 1992, Harvey Lect, V88, P1; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Chen Y, 1996, J BIOL CHEM, V271, P5993, DOI 10.1074/jbc.271.11.5993; CHRISTIE GE, 1981, P NATL ACAD SCI-BIOL, V78, P4180, DOI 10.1073/pnas.78.7.4180; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; Deng L, 1997, J BIOL CHEM, V272, P695; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; Hartvig L, 1996, EMBO J, V15, P4767, DOI 10.1002/j.1460-2075.1996.tb00854.x; Heisler LM, 1996, J BIOL CHEM, V271, P14572, DOI 10.1074/jbc.271.24.14572; INMAN RB, 1962, J MOL BIOL, V5, P172, DOI 10.1016/S0022-2836(62)80082-5; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Labhart P, 1997, J BIOL CHEM, V272, P9055; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Landick R, 1996, SCIENCE, V273, P202, DOI 10.1126/science.273.5272.202; LUO Y, 1991, J BIOL CHEM, V266, P13303; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1991, J BIOL CHEM, V266, P10510; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Sastry SS, 1997, J BIOL CHEM, V272, P8644, DOI 10.1074/jbc.272.13.8644; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; Schnapp G, 1996, MOL GEN GENET, V252, P412, DOI 10.1007/s004380050245; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; THAYER GC, 1985, MOL GEN GENET, V199, P55, DOI 10.1007/BF00327509; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	82	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16843	16852		10.1074/jbc.273.27.16843	http://dx.doi.org/10.1074/jbc.273.27.16843			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642244	Green Accepted, hybrid			2022-12-27	WOS:000074545200034
J	Anderson, GW; Larson, RJ; Oas, DR; Sandhofer, CR; Schwartz, HL; Mariash, CN; Oppenheimer, JH				Anderson, GW; Larson, RJ; Oas, DR; Sandhofer, CR; Schwartz, HL; Mariash, CN; Oppenheimer, JH			Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) modulates expression of the Purkinje cell protein-2 gene - A potential role for COUP-TF in repressing premature thyroid hormone action in the developing brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ORPHAN RECEPTORS; RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; ROR-ALPHA; VITAMIN-D; BINDING; TRIIODOTHYRONINE; IDENTIFICATION; FAMILY; HYPOTHYROIDISM	The cerebellar Purkinje cell-specific PCP-2 gene is transcriptionally activated by thyroid hormone during the 2nd and 3rd weeks of postnatal life in the rat. In contrast, thyroid hormone has no detectable effects on PCP-2 expression in the fetal rat. We now present data that suggest that the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor (COUP-TF) represses triiodothyronine (T3)-dependent transcriptional activation of PCP-2 in the immature Purkinje cell. Gel shift assays show that the PCP-2 A1TRE and adjoining sequences (-295/-199 region) bind to rat and mouse brain nucleoproteins in a developmentally regulated fashion and that one of these nucleoproteins could be the orphan nucleoprotein COUP-TF. In support of this hypothesis, in vitro translated COUP-TF binds to the -295/-199 region and COUP-TF represses T3-dependent activation of the PCP-S promoter in transient transfection analyses. Finally, immunohistochemical studies reveal that COUP-TF is specifically expressed in the immature fetal and early neonatal Purkinje cell. and that this expression diminishes coincident with thyroid hormone induction of POP-a expression. Our findings are consistent with the hypothesis that the presence or absence of inhibitory proteins bound to the thyroid hormone response element of T3-responsive genes governs the responsivity of these genes to thyroid hormone during brain development.	Univ Minnesota, Dept Med, Div Endocrinol & Diabet, Thyroid Res Unit, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Oppenheimer, JH (corresponding author), Univ Minnesota, Dept Med, Div Endocrinol & Diabet, Thyroid Res Unit, Box 101 UMHC, Minneapolis, MN 55455 USA.				NIADDK NIH HHS [AM 19812] Funding Source: Medline; NIDDK NIH HHS [DK09295] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009295] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN J, 1997, RELATION ITS EVOLUTI, P99; ALTMAN J, 1997, RELATION ITS EVOLUTI, P173; ALTMAN J, 1997, DEV CEREBELLAR SYSTE, P379; Anderson GW, 1997, MOL CELL ENDOCRINOL, V131, P79, DOI 10.1016/S0303-7207(97)00095-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Brubaker K, 1996, DEV BRAIN RES, V93, P198, DOI 10.1016/0165-3806(96)00007-7; CALVO R, 1990, J CLIN INVEST, V86, P889, DOI 10.1172/JCI114790; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; DASILVA SL, 1995, MOL BRAIN RES, V30, P131, DOI 10.1016/0169-328X(94)00289-Q; DEESCOBAR GM, 1985, ENDOCRINOLOGY, V117, P1890, DOI 10.1210/endo-117-5-1890; DELONG R, 1989, IODINE BRAIN; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Hagen SG, 1996, J MOL NEUROSCI, V7, P245, DOI 10.1007/BF02737062; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Jacobson M., 1991, DEV NEUROBIOL, P401, DOI DOI 10.1007/978-1-4757-4954-0_10; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; LEGRAND J, 1967, ARCH ANAT MICROSC MO, V56, P291; Legrand J, 1986, THYROID HORMONE META, P503; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MARIASH CN, 1980, ENDOCRINOLOGY, V106, P22, DOI 10.1210/endo-106-1-22; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; NEUMAN K, 1995, J NEUROSCI RES, V41, P39, DOI 10.1002/jnr.490410106; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; QUI Y, 1994, P NATL ACAD SCI USA, V91, P4451; QUI Y, 1997, GENE DEV, V11, P1925; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SANDHOFER C, 1998, IN PRESS MOL CELL EN; SAWAYA BE, 1995, NUCLEIC ACIDS RES, V23, P2206, DOI 10.1093/nar/23.12.2206; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Schwartz HL, 1997, ENDOCRINOLOGY, V138, P3119, DOI 10.1210/en.138.8.3119; SHUPNIK MA, 1989, ENDOCR REV, V10, P459, DOI 10.1210/edrv-10-4-459; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; SURKS MI, 1972, J CLIN INVEST, V51, P3104, DOI 10.1172/JCI107137; TACHA DE, 1994, J HISTOTECHNOL, V17, P365, DOI 10.1179/his.1994.17.4.365; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; ZOU LL, 1994, J BIOL CHEM, V269, P13346	49	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16391	16399		10.1074/jbc.273.26.16391	http://dx.doi.org/10.1074/jbc.273.26.16391			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632703	hybrid			2022-12-27	WOS:000074436600074
J	Garcia, JJ; Capaldi, RA				Garcia, JJ; Capaldi, RA			Unisite catalysis without rotation of the gamma-epsilon domain in Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; CYSTEINE RESIDUES; ELEMENTARY STEPS; RATE CONSTANTS; BETA-SUBUNIT; F1-ATPASE; HYDROLYSIS; SITES	Unisite [gamma-P-32]ATP hydrolysis was studied in ECF1 from the mutant beta E381C after generating a single disulfide bond between beta and gamma subunits to prevent the rotation of the gamma/epsilon domain. The single beta-gamma cross-link was obtained by removal of the delta subunit from F-1 and then treating with CuCl2 as described previously (Aggeler, R,, Haughton, M, A., and Capaldi, R, k (1996) J. Biol, Chem. 270, 9185-9191), The mutant enzyme, beta E381C, had an increased overall rate of unisite hydrolysis of [gamma-P-32]ATP compared with the wild type ECF1 due to increases in the rate of ATP binding (k(+1)), P-i release (k(+3)), and ADP release (K+4). Release of bound substrate ([gamma-P-32]ATP) was also increased in the beta E381C mutant. Cross-linking between Cys-381 and the intrinsic Cys-87 of gamma caused a further increase in the rate of unisite catalysis, mainly by additional effects on nucleotide binding in the high affinity catalytic site (k(+1) and k(+4)), In delta-subunit-free ECF1 from wild type or beta E381C F-1, addition of an excess of ATP accelerated unisite catalysis. After cross-linking, unisite catalysis of beta E381C was not enhanced by the cold chase. The covalent linkage of gamma to beta increased the rate of unisite catalysis to that obtained by cold chase of ATP of the noncross-linked enzyme, It is concluded that the conversion of Glu-381 of beta to Cys induces an activated conformation of the high affinity catalytic site with low affinity for substrate and products. This state is stabilized by cross-linking the Cys at beta 381 to Cys-87 of gamma, We infer from the data that rotation of the gamma/epsilon rotor in ECF1 is not linked to unisite hydrolysis of ATP at the high affinity catalytic site but to ATP binding to a second or third catalytic site on the enzyme.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.				NHLBI NIH HHS [HL24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DEGOMEZPUYOU MT, 1995, J BIOL CHEM, V270, P16820, DOI 10.1074/jbc.270.28.16820; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Garcia JJ, 1997, J BIOENERG BIOMEMBR, V29, P61, DOI 10.1023/A:1022463822929; Garcia JJ, 1997, EUR J BIOCHEM, V249, P622, DOI 10.1111/j.1432-1033.1997.00622.x; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; GRUBER G, 1996, BIOCHEMISTRY-US, V35, P3877; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; Maldonado E, 1998, BBA-BIOENERGETICS, V1363, P70, DOI 10.1016/S0005-2728(97)00083-2; MUNEYUKI E, 1991, BIOCHIM BIOPHYS ACTA, V1058, P304, DOI 10.1016/S0005-2728(05)80251-8; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P11261; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1997, BIOPHYS CHEM, V68, P95, DOI 10.1016/S0301-4622(97)00018-5; XIAO R, 1994, J BIOL CHEM, V269, P19232; ZEIGLER M, 1994, J BIOL CHEM, V269, P4233; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381; [No title captured]	46	49	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15940	15945		10.1074/jbc.273.26.15940	http://dx.doi.org/10.1074/jbc.273.26.15940			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632641	hybrid			2022-12-27	WOS:000074436600012
J	Huss, JM; Kasper, CB				Huss, JM; Kasper, CB			Nuclear receptor involvement in the regulation of rat cytochrome P450 3A23 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; FUNCTION OXIDASE SYSTEM; TRANSCRIPTION FACTOR; COUP-TF; PREGNENOLONE 16-ALPHA-CARBONITRILE; TESTOSTERONE 6-BETA-HYDROXYLASE; HEPATIC CYTOCHROME-P-450; DEPENDENT EXPRESSION; LIVER MICROSOMES; ORPHAN RECEPTORS	Many genes of the cytochrome P450 3A (CYP3A) subfamily, including several human and rat isoforms, are inducible by glucocorticoids. In the rat CYP3A23 gene, a 110-base pair segment of the proximal 5'-flanking region mediates dexamethasone activation, Three binding sites (DexRE-1, DexRE-2, and Site A), identified by DNase I footprinting analysis, were characterized for their relative contribution to both basal activity and dexamethasone inducibility. Site-directed mutagenesis of DexRE-1 (-144 to -169) and DexRE-2 (-118 to -136) demonstrated that each contained a core imperfect AGGTCA direct repeat, which comprised a consensus nuclear receptor binding site, and was essential for dexamethasone responsiveness but was not required for basal activity. Competition gel shift and supershift analyses revealed that both sites can bind the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor. Site A (-85 to -110) was shown to be important for both basal activity and dexamethasone responsiveness. Point mutants displayed a reduced (2-3-fold) induction response, compared with 15-fold far wild-type, which was accompanied by a 40-60% drop in basal activity. Site A was shown to bind the liver-enriched nuclear receptor hepatocyte nuclear factor 4. Our studies demonstrate that the mechanism mediating glucocorticoid-inducible transcriptional activity of CYP3A23 involves multiple binding sites for members of the nuclear receptor superfamily.	Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Environm Toxicol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kasper, CB (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [T32-CA-09135, CA0920, CA22484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA000920, T32CA009135, P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA T, 1989, J BIOL CHEM, V264, P10388; BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; Cairns W, 1996, J BIOL CHEM, V271, P25269, DOI 10.1074/jbc.271.41.25269; CHEN D, 1994, DNA CELL BIOL, V13, P771, DOI 10.1089/dna.1994.13.771; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COOPER KO, 1993, ARCH BIOCHEM BIOPHYS, V301, P345, DOI 10.1006/abbi.1993.1154; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; GONZALEZ FJ, 1986, MOL CELL BIOL, V6, P2969, DOI 10.1128/MCB.6.8.2969; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HALPERT JR, 1988, ARCH BIOCHEM BIOPHYS, V263, P59, DOI 10.1016/0003-9861(88)90613-3; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huss JM, 1996, P NATL ACAD SCI USA, V93, P4666, DOI 10.1073/pnas.93.10.4666; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KOMORI M, 1994, J BIOCHEM-TOKYO, V116, P114, DOI 10.1093/oxfordjournals.jbchem.a124482; LU AYH, 1972, ARCH BIOCHEM BIOPHYS, V152, P457, DOI 10.1016/0003-9861(72)90239-1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; MIYATA M, 1994, ARCH BIOCHEM BIOPHYS, V314, P351, DOI 10.1006/abbi.1994.1453; NAGATA K, 1990, J BIOCHEM-TOKYO, V107, P718, DOI 10.1093/oxfordjournals.jbchem.a123115; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PRICHARD L, 1990, DRUG METAB DISPOS, V18, P595; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; RIBEIRO V, 1992, ARCH BIOCHEM BIOPHYS, V293, P147, DOI 10.1016/0003-9861(92)90377-9; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SIMMONS DL, 1989, ARCH BIOCHEM BIOPHYS, V271, P10, DOI 10.1016/0003-9861(89)90250-6; SIMMONS DL, 1987, J BIOL CHEM, V262, P326; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; TEHLADA MB, 1992, ARCH BIOCHEM BIOPHYS, V298, P715; THOMAS PE, 1977, MOL PHARMACOL, V13, P819; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; UMENSONO K, 1991, CELL, V65, P1255; VAMVAKOPOULOS NC, 1992, STEROIDS, V57, P282, DOI 10.1016/0039-128X(92)90061-D; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; Wright MC, 1996, MOL PHARMACOL, V50, P856; WRIGHTON SA, 1989, MOL PHARMACOL, V36, P97; WRIGHTON SA, 1985, BIOCHEMISTRY-US, V24, P2171, DOI 10.1021/bi00330a010; ZHOU XJ, 1993, BIOCHEM PHARMACOL, V45, P853, DOI 10.1016/0006-2952(93)90169-W	50	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16155	16162		10.1074/jbc.273.26.16155	http://dx.doi.org/10.1074/jbc.273.26.16155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632670	hybrid			2022-12-27	WOS:000074436600041
J	Lew, BM; Mills, KV; Paulus, H				Lew, BM; Mills, KV; Paulus, H			Protein splicing in vitro with a semisynthetic two-component minimal intein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Protein splicing elements, or inteins, catalyze their own excision from flanking polypeptide sequences, or exteins, thereby leading to the formation of new proteins in which the exteins are linked directly by a peptide bond. A trans-splicing system, using separately purified and expressed N- and C-terminal intein fragments of about 100 amino acids each, fused to appropriate exteins, was recently derived from the Mycobacterium tuberculosis RecA intein (Mills, K, V,, Lew, B, M,, Jiang, S,-Q,, and Paulus, H, (1998) Proc. Natl. Acad Sci, U, S, A. 95, 3543-3548), We have replaced the C-terminal intein fragment of this system with synthetic peptides comprising 35-50 of the C-terminal residues of the RecA intein, The N-terminal intein fragment and the synthetic peptide were reconstituted by renaturation from guanidinium chloride. In the absence of added reductants, a disulfide-linked dimer of the N-terminal fragment and the peptide accumulated and could be induced to splice by reduction of its disulfide bond. The intermediate and spliced products were identified by polyacrylamide gel electrophoresis, mass spectrometry, and derivatization with thiol-reactive biotin followed by Western blotting with a streptavidin-enzyme conjugate, This is the first example of protein splicing involving a synthetic intein fragment and opens the way for studying the active site structure and function of the intein by the use of different synthetic peptides, including ones with non-natural amino acids.	Boston Biomed Res Inst, Boston, MA 02114 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard University; Harvard Medical School	Paulus, H (corresponding author), Boston Biomed Res Inst, 20 Staniford St, Boston, MA 02114 USA.	paulus@bbri.harvard.edu	Wood, David W/B-2992-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055875] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM55875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAIKEN IM, 1973, J BIOL CHEM, V248, P884; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mills KV, 1998, P NATL ACAD SCI USA, V95, P3543, DOI 10.1073/pnas.95.7.3543; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Southworth MW, 1998, EMBO J, V17, P918, DOI 10.1093/emboj/17.4.918	13	39	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15887	15890		10.1074/jbc.273.26.15887	http://dx.doi.org/10.1074/jbc.273.26.15887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632632	hybrid			2022-12-27	WOS:000074436600003
J	Magrangeas, F; Pitiot, G; Dubois, S; Bragado-Nilsson, E; Cherel, M; Jobert, S; Lebeau, B; Boisteau, O; Lethe, B; Mallet, J; Jacques, Y; Minvielle, S				Magrangeas, F; Pitiot, G; Dubois, S; Bragado-Nilsson, E; Cherel, M; Jobert, S; Lebeau, B; Boisteau, O; Lethe, B; Mallet, J; Jacques, Y; Minvielle, S			Cotranscription and intergenic splicing of human galactose-1-phosphate uridylyltransferase and interleukin-11 receptor alpha-chain genes generate a fusion mRNA in normal cells - Implication for the production of multidomain proteins during evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; TRANSCRIPTIONAL INTERFERENCE; URIDYLTRANSFERASE GENE; NUCLEOTIDE-SEQUENCE; MEASLES-VIRUS; SUPERFAMILY; BINDING; ANTIGEN; DISEASE; IL11RA	In the past 10 years, much attention has been focused on transcription preinitiation complex formation as a target for regulating gene expression, and other targets such as transcription termination complex assemblage have been less intensively investigated. We established the existence of poly(A) site choice and fusion splicing of two adjacent genes, galactose-1-phosphate uridylyl-transferase (GALT) and interleukin-11 receptor alpha-chain (IL-11R alpha), in normal human cells. This 16-kilobase (kb) transcription unit contains two promoters (the first one is constitutive, and the second one, 8 kb downstream, is highly regulated) and two cleavage/polyadenylation signals separated by 12 kb, The promoter from the GALT gene yields two mRNAs, a 1,4-kb mRNA encoding GALT and a 3-kb fusion mRNA when the first poly(A) site is spliced out and the second poly(A) is used, The 3-kb mRNA codes for a fusion protein of unknown function, containing part of the GALT protein and the entire IL-11R alpha protein. The GALT promoter/IL-11R alpha poly(A) transcript results from leaky termination and alternative splicing. This feature of RNA polymerase (pol) II transcription, which contrasts with efficient RNA pol I and pol III termination, may be involved, together with chromosome rearrangements, in the generation of fusion proteins with multiple domains and would have major evolutionary implications in terms of natural processes to generate novel proteins with common motifs, Our results, together with accumulation of genomic informations, will stimulate new considerations and experiments in gene expression studies.	INSERM, U463, F-44035 Nantes, France; Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR 9923, F-75013 Paris, France; Univ Catholique Louvain, Cellular Genet Unit, B-1200 Brussels, Belgium; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite Catholique Louvain; Ludwig Institute for Cancer Research	Pitiot, G (corresponding author), Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR 9923, Bat CERVI,83 Bld Hop, F-75013 Paris, France.		Magrangeas, Florence/L-3080-2015; Minvielle, Stéphane/K-8251-2015; Chérel, Michel/F-8298-2013	Magrangeas, Florencce/0000-0002-5031-3748; Minvielle, Stephane/0000-0003-1389-312X				AFZAL MA, 1990, J GEN VIROL, V71, P615, DOI 10.1099/0022-1317-71-3-615; ANSARI LM, 1997, GENOME RES, V7, P268; BATEMAN E, 1988, CELL, V54, P985, DOI 10.1016/0092-8674(88)90113-4; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BHAT BM, 1986, J VIROL, V60, P54, DOI 10.1128/JVI.60.1.54-63.1986; Bousse T, 1997, VIROLOGY, V232, P44, DOI 10.1006/viro.1997.8524; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHEREL M, 1995, BLOOD, V86, P2534; Cherel M, 1996, GENOMICS, V32, P49, DOI 10.1006/geno.1996.0075; CHIN LS, 1993, VIROLOGY, V192, P473, DOI 10.1006/viro.1993.1063; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOWLING PC, 1986, J GEN VIROL, V67, P1987, DOI 10.1099/0022-1317-67-9-1987; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Gaschet J, 1996, BLOOD, V87, P2345, DOI 10.1182/blood.V87.6.2345.bloodjournal8762345; GATHOF BS, 1995, HUM GENET, V96, P721, DOI 10.1007/BF00210306; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Hardy RW, 1998, J VIROL, V72, P520, DOI 10.1128/JVI.72.1.520-526.1998; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; KALCKAR HM, 1991, ANNU REV BIOCHEM, V60, P1; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lebeau B, 1997, FEBS LETT, V407, P141, DOI 10.1016/S0014-5793(97)00326-8; LESLIE ND, 1992, GENOMICS, V14, P474, DOI 10.1016/S0888-7543(05)80244-7; Maxfield LF, 1997, J VIROL, V71, P8321, DOI 10.1128/JVI.71.11.8321-8329.1997; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEERA KP, 1978, CYTOGENET CELL GENET, V22, P207; MELLMAN WJ, 1965, J LAB CLIN MED, V66, P980; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; Nandurkar HH, 1996, ONCOGENE, V12, P585; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; RIMA BK, 1986, J GEN VIROL, V67, P1971, DOI 10.1099/0022-1317-67-9-1971; ROWLING C, 1997, CURR OPIN GENE DEV, V7, P416; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Segal S, 1989, METABOLIC BASIS INHE, P453; STAMATOYANNOPOU.G, 1994, HEMOGLOBIN SWITCHING, P107; SWAIN A, 1993, J VIROL, V67, P6265, DOI 10.1128/JVI.67.10.6265-6269.1993; VanLeuven F, 1996, GENOMICS, V31, P65, DOI 10.1006/geno.1996.0010; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WILDE A, 1984, J VIROL, V51, P71, DOI 10.1128/JVI.51.1.71-76.1984; WONG TC, 1987, J VIROL, V61, P584, DOI 10.1128/JVI.61.2.584-589.1987; YANG YC, 1992, BIOFACTORS, V4, P15	48	54	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16005	16010		10.1074/jbc.273.26.16005	http://dx.doi.org/10.1074/jbc.273.26.16005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632650	hybrid			2022-12-27	WOS:000074436600021
J	Majidi, M; Hubbs, AE; Lichy, JH				Majidi, M; Hubbs, AE; Lichy, JH			Activation of extracellular signal-regulated kinase 2 by a novel Abl binding protein, ST5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; SH3 DOMAIN; SUBSTRATE RECOGNITION; HUMAN CHROMOSOME-11; IDENTIFICATION; GRB2; GENE; TRANSDUCTION; MAP	The human ST5 gene encodes three proteins with predicted molecular masses of 126, 82, and 70 kDa. These widely expressed proteins share a C-terminal region that bears significant sequence homology to a group of GDP/GTP exchange proteins for the Rab3 family of small GTP binding proteins. The N-terminal region of the largest ST5 protein, p126, contains two proline-rich sequences, PR1 and PR2, with consensus motifs similar to Src homology 3 (SH3) binding regions and to mitogen-activated protein kinase (MAPK) phosphorylation sites. Based on these properties, we sought to investigate the activity of ST5 proteins in signal transduction pathways, In vitro, p126 displayed preferential binding to c-Abl SH3, as compared with other SH3 domains. This interaction was mediated by the PR2 sequence. In vivo, expression of p126, but not p82 or p70, activated MAPK/ERK2 in response to EGF in COS-7 cells. Expression of c-Abl with p126 greatly enhanced this activity. Deletion of PR1 blocked the ability of p126 to activate ERK2. Deletion of PR2 did not affect the basal activity, but blocked the stimulatory effect of c-Abl. Whereas p82 expression had no effect on ERK2 activation by p126, p70 completely abrogated this activity. These observations suggest that ST5 can function as a signaling protein and can provide a link between c-Abl and ERK2.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	Lichy, JH (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA.				NATIONAL CANCER INSTITUTE [R01CA064114] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA64114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; HARLOW E, 1988, ANTIBODIES; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lichy JH, 1996, NUCLEIC ACIDS RES, V24, P4700, DOI 10.1093/nar/24.23.4700; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MODI WS, 1991, CYTOGENET CELL GENET, V58, P1968; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD CW, 1993, AM J HUM GENET, V52, P915; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	30	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16608	16614		10.1074/jbc.273.26.16608	http://dx.doi.org/10.1074/jbc.273.26.16608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632734	hybrid			2022-12-27	WOS:000074436600105
J	Rusnati, M; Tulipano, G; Urbinati, C; Tanghetti, E; Giuliani, R; Giacca, M; Ciomei, M; Corallini, A; Presta, M				Rusnati, M; Tulipano, G; Urbinati, C; Tanghetti, E; Giuliani, R; Giacca, M; Ciomei, M; Corallini, A; Presta, M			The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; KAPOSIS-SARCOMA; TRANSGENIC MICE; ENDOTHELIAL-CELLS; SULFATED POLYSACCHARIDES; PLASMINOGEN-ACTIVATOR; STIMULATES GROWTH; PROMOTER ACTIVITY; RECEPTOR-BINDING	Heparin binds extracellular HIV-1 Tat protein and modulates its HIV long terminal repeat (LTR)-transactivating activity (M, Rusnati, D. Coltrini, P. Oreste, G. Zoppetti, A Albini, D. Noonan, F. d'Adda di Fagagna, M. Giacca, and M. Presta (1997) J. Biol. Chem. 272, 11313-11320). On this basis, the glutathione S-transferase (GST)-Tat(R49/52/53/55/56/57A) mutant, in which six arginine residues within the basic domain of Tat were mutagenized to alanine residues, was compared with GST-Tat for its capacity to bind immobilized heparin. Dissociation of the GST-Tat(R49/52/53/55/56/57A). heparin complex occurred at ionic strength significantly lower than that required to dissociate the GST-Tat heparin complex. Accordingly, heparin binds immobilized GST-Tat and GST-Tat(R49/52/53/55/56/57A) with a dissociation constant equal to 0.3 and 1.0 mu M, respectively. Also, the synthetic basic domain Tat-(41-60) competes with GST-Tat for heparin binding. Suramin inhibits [H-3]heparin/Tat interaction, I-125-GST-Tat internalization, and the LTR-transactivating activity of extracellular Tat in HL3T1 cells and prevents I-125-GST-Tat binding and cell proliferation in Tat-overexpressing T53 cells. The suramin derivative C-14-PNU 145156E binds immobilized GST-Tat with a dissociation constant 5 times higher than heparin and is unable to bind GST-Tat(R49/52/53/55/56/57A). Although heparin was an antagonist more potent than suramin, modifications of the backbone structure in selected suramin derivatives originated Tat antagonists whose potency was close to that shown by heparin. In conclusion, suramin derivatives bind the basic domain of Tat, prevent Tat/heparin and Tat/cell surface interactions, and inhibit the biological activity of extracellular Tat. Our data demonstrate that tailored polysulfonated compounds represent potent extracellular Tat inhibitors of possible therapeutic value.	Univ Brescia, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Pharmacia Upjohn, I-20014 Milan, Italy; Univ Ferrara, Inst Microbiol, I-44100 Ferrara, Italy; Univ Ferrara, Interdept Ctr Biotechnol, I-44100 Ferrara, Italy	University of Brescia; International Center for Genetic Engineering & Biotechnology (ICGEB); Pfizer; University of Ferrara; University of Ferrara	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Via Valsabbina 19, I-25123 Brescia, Italy.	presta@med.unibs.it	Presta, Marco/B-4345-2010; Giacca, Mauro/J-9287-2016; Rusnati, Marco/F-1168-2010	Giacca, Mauro/0000-0003-2927-7225; Rusnati, Marco/0000-0001-9968-5908; Urbinati, Chiara Eva/0000-0002-0138-7871; PRESTA, Marco/0000-0002-4398-8376				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Barton CH, 1996, J GEN VIROL, V77, P1643, DOI 10.1099/0022-1317-77-8-1643; BEHRENDT N, 1993, J BIOL CHEM, V268, P5985; BRADDOCK PS, 1994, BRIT J CANCER, V69, P890, DOI 10.1038/bjc.1994.172; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; CIOMEI M, 1994, BIOCHEM PHARMACOL, V47, P295, DOI 10.1016/0006-2952(94)90020-5; CLANTON DJ, 1995, ANTIVIR RES, V27, P335, DOI 10.1016/0166-3542(95)00017-G; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLTRINI D, 1993, EUR J BIOCHEM, V214, P51, DOI 10.1111/j.1432-1033.1993.tb17895.x; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DECLERCQ E, 1979, CANCER LETT, V8, P9, DOI 10.1016/0304-3835(79)90017-X; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Dewhurst S, 1996, MOL MED TODAY, V2, P16, DOI 10.1016/1357-4310(96)88754-5; ENDO S, 1989, VIRUS GENES, V2, P99; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; Goldstein G, 1996, NAT MED, V2, P960, DOI 10.1038/nm0996-960; Gregoire CJ, 1996, J BIOL CHEM, V271, P22641, DOI 10.1074/jbc.271.37.22641; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Hawkins Michael J., 1995, Current Opinion in Oncology, V7, P90; HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KIM CM, 1992, ONCOGENE, V7, P1525; KIM YS, 1993, J VIROL, V67, P3739, DOI 10.1128/JVI.67.7.3739-3747.1993; Lachgar A, 1996, BIOMED PHARMACOTHER, V50, P13, DOI 10.1016/0753-3322(96)85092-X; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOPALCO L, 1994, AIDS RES HUM RETROV, V10, P787, DOI 10.1089/aid.1994.10.787; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Maroder M, 1996, CELL IMMUNOL, V168, P49, DOI 10.1006/cimm.1996.0048; MCCLURE MO, 1992, AIDS RES HUM RETROV, V8, P19, DOI 10.1089/aid.1992.8.19; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; MONTEFIORI DC, 1990, J ANTIMICROB CHEMOTH, V25, P313, DOI 10.1093/jac/25.3.313; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; OPALENIK SR, 1995, J BIOL CHEM, V270, P17457, DOI 10.1074/jbc.270.29.17457; PESENTI E, 1992, BRIT J CANCER, V66, P367, DOI 10.1038/bjc.1992.272; Peterlin B. Matija, 1993, P75; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POCSIK E, 1992, LYMPHOKINE CYTOK RES, V11, P317; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PURI RK, 1992, CANCER RES, V52, P3787; PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C; Rusnati M, 1997, AIDS, V11, P727, DOI 10.1097/00002030-199706000-00005; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Sastry KJ, 1996, ONCOGENE, V13, P487; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; SOLA F, 1993, INVAS METAST, V13, P163; STEINAA L, 1994, ARCH VIROL, V139, P263, DOI 10.1007/BF01310790; STRIJBOS PJLM, 1995, NEUROSCI LETT, V197, P215, DOI 10.1016/0304-3940(95)11940-X; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VACCA A, 1994, BIOCHEM BIOPH RES CO, V205, P467, DOI 10.1006/bbrc.1994.2689; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WITVROUW M, 1994, ANTIVIR CHEM CHEMOTH, V5, P345, DOI 10.1177/095632029400500601; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; ZABRENETZKY VS, 1990, CANCER RES, V50, P5937; ZAULI G, 1993, MICROBIOLOGICA, V16, P115; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; ZAULI G, 1992, BLOOD, V80, P3036	95	103	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16027	16037		10.1074/jbc.273.26.16027	http://dx.doi.org/10.1074/jbc.273.26.16027			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632653	hybrid			2022-12-27	WOS:000074436600024
J	Messana, I; Angeletti, M; Castagnola, M; De Sanctis, G; Di Stasio, E; Giardina, B; Pucciarelli, S; Coletta, M				Messana, I; Angeletti, M; Castagnola, M; De Sanctis, G; Di Stasio, E; Giardina, B; Pucciarelli, S; Coletta, M			Thermodynamics of inositol hexakisphosphate interaction with human oxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HEMOGLOBIN; HUMAN DEOXYHEMOGLOBIN; BINDING; 2,3-DIPHOSPHOGLYCERATE	The interaction of inositol hexakisphosphate (IHP) with oxygenated human adult hemoglobin (Hb) was investigated at 25 degrees C. The affinity of IHP for oxygenated Hb is strongly pH-dependent, and potentiometric measurements of proton uptake and release upon IHP addition have shown that over the range between pH 8.0 and pH 6.0 in oxygenated Hb there are three groups of residues that change their pK(a) values after IHP addition, likely because of their interaction with negative charges of the heterotropic effector. On the basis of previous calculations on the electrostatic properties of human Hb (Matthew, J. B., Hanania, G, I. H., and Curd, F. R. N. (1979) Biochemistry 18, 1919-1928; Lee,.A W.-m., Karplus, M., Poyart, C., and Bursaux, E, (1988) Biochemistry 27, 1285-1301), two of these groups might be Val(1 beta) and His(143 beta), which are located in the beta(1)beta(2)dyad axis, where they have been also proposed to interact with 2,3-diphosphoglycerate, whereas the third group does not appear easily identifiable. Calorimetric measurements of the heat associated with IHP binding at different pH values over the same range indicate that IHP binding is mostly enthalpy-driven at pH < 7 and mostly entropy-driven at pH > 7.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Cattolica Sacro Cuore, CNR, Ctr Receptor Chem, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Inst Chem & Clin Chem, I-00168 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy; Univ Cagliari, Inst Biol Chem, I-0926 Cagliari, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Camerino; University of Cagliari; University of Rome Tor Vergata	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	massimo.coletta@uniroma2.it	di stasio, enrico/AAL-3082-2020; Angeletti, Mauro/C-2960-2014; Angeletti, Mauro/AAC-5597-2019; Coletta, Massimo/N-9049-2015; Castagnola, Massimo/AAB-2825-2019; Pucciarelli, Stefania/F-9168-2010; Coletta, Massimiliano/GSN-5927-2022; Messana, Irene/L-2478-2019; Castagnola, Massimo/AAM-6355-2021	Angeletti, Mauro/0000-0001-6719-5517; Angeletti, Mauro/0000-0001-6719-5517; Castagnola, Massimo/0000-0002-0959-7259; Messana, Irene/0000-0002-1436-6105; COLETTA, Massimiliano/0000-0002-5489-9467; Pucciarelli, Stefania/0000-0003-2137-5517				AMICONI G, 1981, J MOL BIOL, V152, P111, DOI 10.1016/0022-2836(81)90097-8; ANTONINI E, 1982, EUR J BIOCHEM, V121, P325, DOI 10.1111/j.1432-1033.1982.tb05789.x; ANTONINI E, 1965, J BIOL CHEM, V240, P1096; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ARNONE A, 1974, NATURE, V249, P34, DOI 10.1038/249034a0; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; CHRISTENSEN JJ, 1976, HDB PROTON IONISATIO; COLETTA M, 1995, J MOL BIOL, V249, P800, DOI 10.1006/jmbi.1995.0338; COLETTA M, 1993, BIOCHIM BIOPHYS ACTA, V1162, P309, DOI 10.1016/0167-4838(93)90295-3; de Bruin S H, 1973, Biochem Biophys Res Commun, V55, P193, DOI 10.1016/S0006-291X(73)80078-6; GILL SJ, 1980, J BIOL CHEM, V255, P7855; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; JOHNSON LF, 1969, CAN J CHEMISTRY, V47, P63, DOI 10.1139/v69-008; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; MATTHEW JB, 1979, BIOCHEMISTRY-US, V18, P1919, DOI 10.1021/bi00577a011; MCKINNON IR, 1984, ANAL BIOCHEM, V139, P134, DOI 10.1016/0003-2697(84)90398-1; NOLL LA, 1979, BIOCHEM BIOPH RES CO, V88, P1288, DOI 10.1016/0006-291X(79)91120-3; OHE H, 1980, BIOCHEMISTRY-US, V19, P4445; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; Riggs A., 1981, Methods in Enzymology, V76, P5; ROBERT CH, 1988, BIOCHEMISTRY-US, V27, P6835, DOI 10.1021/bi00418a028; RUSSU IM, 1990, BIOCHEMISTRY-US, V29, P3785, DOI 10.1021/bi00467a027; SHIH DTB, 1987, J MOL BIOL, V195, P419, DOI 10.1016/0022-2836(87)90660-7; Wyman J., 1990, BINDING LINKAGE; ZUIDERWEG ERP, 1981, EUR J BIOCHEM, V118, P95, DOI 10.1111/j.1432-1033.1981.tb05490.x; ZUIDERWEG ERP, 1981, EUR J BIOCHEM, V118, P85, DOI 10.1111/j.1432-1033.1981.tb05489.x	29	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15329	15334		10.1074/jbc.273.25.15329	http://dx.doi.org/10.1074/jbc.273.25.15329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624112	hybrid			2022-12-27	WOS:000074284200006
J	Norden, B; Wittung-Stafshede, P; Ellouze, C; Kim, HK; Mortensen, K; Takahashi, M				Norden, B; Wittung-Stafshede, P; Ellouze, C; Kim, HK; Mortensen, K; Takahashi, M			Base orientation of second DNA in RecA center dot DNA filaments - Analysis by combination of linear dichroism and small angle neutron scattering in flow-oriented solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FLUORESCENCE SPECTROSCOPY; 3-STRANDED DNA; PROTEIN; COMPLEXES; BINDING; RECOMBINATION; STOICHIOMETRY; TRIPLER	To gain insight into the mechanism of pairing two complementary DNA strands by the RecA protein, we have determined the nucleobase orientation of the first and the second bound DNA strands in the RecA DNA filament by combined measurements of linear dichroism and small angle neutron scattering on flow-oriented samples. An etheno-modified DNA, poly(d epsilon A) was adapted as the first DNA and an oligo(dT) as the second DNA, making it possible to distinguish between the linear dichroism signals of the two DNA strands, The results indicate that binding of the second DNA does not alter the nucleobase orientation of the first bound strand and that the bases of the second DNA are almost coplanar to the bases of the first strand although somewhat more tilted (60 degrees relative to the fiber axis compared with 70 degrees for the first DNA strand). Similar results were obtained for the RecA DNA complex formed with unmodified poly(dA) and oligo(dT). An almost coplanar orientation of nucleobases of two DNA strands in a RecA-DNA filament would facilitate scanning for, and recognition of, complementary base sequences. The slight deviation from co-planarity could increase the free energy of the duplex to facilitate dissociation in case of mismatching base sequences.	Ctr Univ Paris Sud, Inst Curie, F-91405 Orsay, France; Chalmers Univ Technol, Dept Phys Chem, S-41296 Gothenburg, Sweden; CNRS, Unite Mixte Rech 216, F-91405 Orsay, France; Riso Natl Lab, Dept Phys, DK-4000 Roskilde, Denmark	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Chalmers University of Technology; Centre National de la Recherche Scientifique (CNRS); Technical University of Denmark	Takahashi, M (corresponding author), Ctr Univ Paris Sud, Inst Curie, Bat 110, F-91405 Orsay, France.	Masa.Takahashi@curie.u-psud.fr	Mortensen, Kell/A-5066-2009; wittung-stafshede, pernilla/AAV-4392-2021; Norden, Bengt/ABE-3675-2020	Mortensen, Kell/0000-0002-8998-9390; wittung-stafshede, pernilla/0000-0003-1058-1964; Norden, Bengt/0000-0002-7946-200X				CHABBERT M, 1991, J BIOL CHEM, V266, P5395; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; HAGMAR P, 1992, J MOL BIOL, V226, P1193, DOI 10.1016/0022-2836(92)91061-S; HOLMEN A, 1994, J PHYS CHEM-US, V98, P13460, DOI 10.1021/j100102a006; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; KIM SK, 1995, BBA-GENE STRUCT EXPR, V1264, P129, DOI 10.1016/0167-4781(95)00137-6; KUBISTA M, 1988, NUCLEOS NUCLEOT, V7, P783, DOI 10.1080/07328318808056330; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; NORDEN B, 1985, APPL SPECTROSC, V39, P647, DOI 10.1366/0003702854250356; NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; RADHAKRISHNAN I, 1993, STRUCTURE, V1, P135, DOI 10.1016/0969-2126(93)90028-F; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; Simonson T., 1994, Journal of Molecular Recognition, V7, P199, DOI 10.1002/jmr.300070307; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; Takahashi Masayuki, 1994, Journal of Molecular Recognition, V7, P221, DOI 10.1002/jmr.300070311; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WITTUNG P, 1995, FEBS LETT, V368, P64, DOI 10.1016/0014-5793(95)00600-E; WITTUNG P, 1994, J BIOL CHEM, V269, P5799; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	25	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15682	15686		10.1074/jbc.273.25.15682	http://dx.doi.org/10.1074/jbc.273.25.15682			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624163	hybrid			2022-12-27	WOS:000074284200057
J	Qi, WW; Loh, E; Vilaire, G; Bennett, JS				Qi, WW; Loh, E; Vilaire, G; Bennett, JS			Regulation of alpha IIb beta 3 function in human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IIB-IIIA COMPLEX; PLATELET INTEGRIN ALPHA-IIB-BETA-3; STIMULATED LIGAND-BINDING; SIGNAL-TRANSDUCTION; CHEMOATTRACTANT RECEPTORS; FIBRINOGEN RECEPTOR; SELECTIVE INHIBITOR; LEUKOCYTE ADHESION; ADP-RIBOSYLATION	We studied the function of the platelet integrin alpha IIb beta 3 using a B lymphocyte model in which alpha II beta 3 can be induced to interact with fibrinogen using phorbol myristate acetate (PMA). To determine whether a G protein-coupled receptor could also activate alpha IIb beta 3 in lymphocytes, we coexpressed the human formyl peptide receptor (fPR) and alpha IIb beta 3, finding that the fPR agonist formyl Met-Leu-Phe (fMLP)-stimulated lymphocyte adherence to immobilized fibrinogen and binding of soluble fibrinogen to the lymphocyte surface. The response to fMLP, but not PMA, was abrogated by pertussis toxin, indicating that the fPR was coupled to the G-protein G alpha(i), whereas the protein kinase C inhibitor bisindolyl-maleimide I inhibited the response to both fMLP and PMA, indicating that signaling from the fPR included protein kinase C, On the other hand, the tyrosine kinase inhibitor genistein, the Syk inhibitor piceatannol, and the RhoA inhibitor C3 exoenzyme had no effect, implying that neither tyrosine phosphorylation nor the GTPase RhoA were involved. Furthermore, whereas micromolar concentrations of cytochalasin D inhibited the PMA-stimulated interaction of alpha IIb beta 3 with fibrinogen, nanomolar concentrations actually induced fibrinogen binding to unstimulated cells. Our studies demonstrate that alpha IIb beta 3 expressed in B lymphocytes can be activated by a physiologic agonist and outline an activating pathway that includes G alpha(i), protein kinase C, and the actin cytoskeleton.	Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Bennett, JS (corresponding author), 1005 Stellar Chance Labs, Div Hematol Oncol, 422 Curie Blvd, Philadelphia, PA 19014 USA.				NHLBI NIH HHS [HL51258, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL051258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; AKIYAMA T, 1991, METHODS ENZYMOLOGY B, P362; Allen WE, 1997, J CELL SCI, V110, P707; Bennett JS, 1996, TRENDS CARDIOVAS MED, V6, P31, DOI 10.1016/1050-1738(95)00126-3; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Brass Lawrence F., 1995, P1536; BRASS LF, 1986, J BIOL CHEM, V261, P6838; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HONDA S, 1994, J IMMUNOL, V152, P4026; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Leng L., 1997, Blood, V90, p430A; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; Loh E, 1996, J BIOL CHEM, V271, P30233, DOI 10.1074/jbc.271.47.30233; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER CL, 1998, IMMUNITY, V5, P155; MORII N, 1992, J BIOL CHEM, V267, P20921; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SILVER SM, 1987, BLOOD, V69, P1031; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WEISEL JW, 1992, J BIOL CHEM, V267, P16637	50	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15271	15278		10.1074/jbc.273.24.15271	http://dx.doi.org/10.1074/jbc.273.24.15271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614143	hybrid			2022-12-27	WOS:000074160400085
J	Hehner, SP; Hofmann, TG; Ratter, F; Dumont, A; Droge, W; Schmitz, ML				Hehner, SP; Hofmann, TG; Ratter, F; Dumont, A; Droge, W; Schmitz, ML			Tumor necrosis factor-alpha-induced cell killing and activation of transcription factor NF-kappa B are uncoupled in L929 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; DEATH; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; INHIBITION; RECEPTOR	The induction of transcription factor NF-kappa B has been shown to counteract tumor necrosis factor (TNF)-alpha-induced cell death in various cell types. In this study, we investigated the role of NF-kappa B for TNF-alpha-triggered cell death in the widely used mouse cell line L929 by various approaches. Inhibition of the mitochondrial permeability transition by bongkrekic acid impaired TNF-alpha-induced cell death without affecting the activity of NF-kappa B. The reduction of NF-kappa B-mediated gene expression by the synthetic steroid dexamethasone was associated with a decrease in TNF-alpha-mediated cell killing, suggesting that NF-KB does not protect L929 cells from TNF-alpha-induced cell death. This concept was reinforced by experiments employing L929 cell lines stably overexpressing a transdominant negative form of I kappa B-alpha. These cell lines were unable to activate NF-kappa B and to inducibly express the IL-6 gene, but they showed the same susceptibility toward TNF-alpha-mediated cell death as L929 wild-type cells.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAICHWAL WR, 1997, CURR BIOL, V7, pR94; Baker SJ, 1996, ONCOGENE, V12, P1; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	29	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18117	18121		10.1074/jbc.273.29.18117	http://dx.doi.org/10.1074/jbc.273.29.18117			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660769	hybrid			2022-12-27	WOS:000074828500024
J	Xu, H; Lee, KW; Goldfarb, M				Xu, H; Lee, KW; Goldfarb, M			Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRS-1 PTB DOMAIN; INSULIN-RECEPTOR; BETA-RECEPTOR; SH2 DOMAINS; PC12 CELLS; BINDING; RAS; SUBSTRATE-1; DIFFERENTIATION; STIMULATION	Fibroblast growth factors (FGFs) stimulate tyrosine phosphorylation of a membrane-anchored adapter protein, FRS2/SNT-1, promoting its association with Shp-2 tyrosine phosphatase and upstream activators of Ras, Using the yeast two-hybrid protein-protein interaction assay, we show that FRS2/SNT-1 and a newly isolated SNT-2 protein directly bind to FGF receptor-1 (FGFR-1). A juxtamembrane segment of FGFR-1 and the phosphotyrosine-binding domain of SNTs are both necessary and sufficient for interaction in yeast and in vitro, and FGFR-mediated SNT tyrosine phosphorylation in vivo requires these segments of receptor and SNT. Our findings establish SNTs as direct protein links between FGFR-1 and multiple downstream pathways. The SNT binding motif of FGFR-1 is distinct from previously described phosphotyrosine-binding domain recognition motifs, lacking both tyrosine and asparagine residues.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Grad Program Mol Cellular Biochem & Dev Sci, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Goldfarb, M (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, Box 1126,1 Gustave Levy Pl, New York, NY 10029 USA.		Lee, Kyung/AAD-5009-2021	Lee, Kyung/0000-0002-9756-1765	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM055666, T32GM008553] Funding Source: NIH RePORTER; NIGMS NIH HHS [R21-GM55666, T32-GM08553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CASE RD, 1994, J BIOL CHEM, V269, P10467; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU S, 1995, J BIOL CHEM, V270, P14863	31	142	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17987	17990		10.1074/jbc.273.29.17987	http://dx.doi.org/10.1074/jbc.273.29.17987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660748	hybrid			2022-12-27	WOS:000074828500003
J	Felberg, J; Johnson, P				Felberg, J; Johnson, P			Characterization of recombinant CD45 cytoplasmic domain proteins - Evidence for intramolecular and intermolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE-ACTIVITY; PHOSPHOTYROSINE PHOSPHATASE; CATALYTIC DOMAINS; KINASE PP56LCK; SH2 DOMAINS; RECEPTOR; ACTIVATION; PHOSPHORYLATION; EXPRESSION; PURIFICATION	CD45 is a transmembrane two-domain tyrosine phosphatase required for efficient signal transduction initiated by lymphocyte antigen receptors. As with most transmembrane two-domain phosphatases, the role of the second phosphatase domain is unclear. In this study, recombinant CD45 cytoplasmic domain proteins purified from bacteria were used to evaluate the function of the individual phosphatase domains, A recombinant protein expressing the membrane-proximal region, first phosphatase domain, and spacer region of CD45 (rD1) was catalytically active and found to exist primarily as a dimer, In contrast to this, a recombinant protein expressing the spacer region, the second phosphatase do main and the carboxy tail of CD45 (rD2) existed as a monomer and had no catalytic activity against any of the substrates tested, Comparison of rD1 with the recombinant protein expressing the entire cytoplasmic domain of CD45 (rD1/D2) indicated that rD1/D2 was 2-3-fold more catalytically active, was more thermostable, and existed primarily as a monomer, Limited trypsin digestion of rD1/D2 provided evidence for a noncovalent association between an N-terminal 27-kDa fragment and a C-terminal 53-kDa fragment, suggesting an intramolecular interaction. Furthermore, rD1 was found to specifically associate with rD2 in an in vitro binding assay. Taken together, these data provide evidence for an intramolecular interaction occurring in the cytoplasmic domain of CD45. In the absence of the C-terminal region containing the second phosphatase domain, intermolecular interactions occur, resulting in dimer formation.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; IIDA N, 1994, J BIOL CHEM, V269, P28576; ITOH M, 1992, J BIOL CHEM, V267, P12356; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JOHNSON P, 1997, WEIRS HDB EXPT IMMUN, V2; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; Lorenzo HK, 1997, FEBS LETT, V411, P231, DOI 10.1016/S0014-5793(97)00703-5; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; NG DHW, 1995, J IMMUNOL METHODS, V179, P177, DOI 10.1016/0022-1759(94)00281-Z; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; Ng DHW, 1997, BIOCHEM J, V327, P867; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAN XH, 1993, J BIOL CHEM, V268, P6835; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	44	74	76	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17839	17845		10.1074/jbc.273.28.17839	http://dx.doi.org/10.1074/jbc.273.28.17839			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651387	hybrid			2022-12-27	WOS:000074816100080
J	Fortune, JM; Osheroff, N				Fortune, JM; Osheroff, N			Merbarone inhibits the catalytic activity of human topoisomerase II alpha by blocking DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INTERACTION DOMAINS; EXPLOITING MECHANISTIC DIFFERENCES; CELL LUNG-CANCER; PHASE-II; ONCOLOGY-GROUP; BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; ANTICANCER DRUGS; ANTITUMOR AGENT	Merbarone is a catalytic inhibitor of topoisomerase II that is in clinical trials as an anticancer agent. Despite the potential therapeutic value of this drug, the mechanism by which it blocks topoisomerase II activity has not been delineated. Therefore, to determine the mechanistic basis for the inhibitory action of merbarone, the effects of this drug on individual steps of the catalytic cycle of human topoisomerase II alpha were assessed. Concentrations of merbarone that inhibited catalytic activity greater than or equal to 80% had no effect on either enzyme DNA binding or ATP hydrolysis. In contrast, the drug was a potent inhibitor of enzyme-mediated DNA scission (in the absence or presence of ATP), and the inhibitory profiles of merbarone for DNA cleavage and relaxation were similar. These data indicate that merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage. Merbarone inhibited DNA scission in a global (rather than site-specific) fashion but did not appear to intercalate into DNA or bind in the minor groove. Since the drug competed with etoposide (a cleavage-enhancing agent that binds directly to topoisomerase II), it is proposed that merbarone exerts its inhibitory effects through interactions with the enzyme and that the drug shares an interaction domain on topoisomerase II with cleavage-enhancing agents.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Oncol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Med Res Bldg 1, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu			NCI NIH HHS [5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJANI JA, 1994, CANCER INVEST, V12, P488, DOI 10.3109/07357909409021408; Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; BAGULEY BC, 1978, NUCLEIC ACIDS RES, V5, P161, DOI 10.1093/nar/5.1.161; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; BREWER AD, 1985, BIOCHEM PHARMACOL, V34, P2047, DOI 10.1016/0006-2952(85)90335-1; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; CAIN BF, 1978, J MED CHEM, V21, P658, DOI 10.1021/jm00205a013; Capranico G, 1997, TRENDS PHARMACOL SCI, V18, P323; Capranico G, 1994, Cancer Chemother Biol Response Modif, V15, P67; CHANG AY, 1993, J NATL CANCER I, V85, P388, DOI 10.1093/jnci/85.5.388; CHEN M, 1993, CANCER RES, V53, P5946; CHEN M, 1995, CANCER RES, V55, P1509; COONEY DA, 1985, BIOCHEM PHARMACOL, V34, P3395, DOI 10.1016/0006-2952(85)90368-5; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DRAKE FH, 1989, CANCER RES, V49, P2578; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; HAMNMONDS TR, 1997, J BIOL CHEM, V272, P32696; Hasinoff BB, 1997, MOL PHARMACOL, V52, P839, DOI 10.1124/mol.52.5.839; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; JENSEN PB, 1990, CANCER RES, V50, P3311; Kallio M, 1997, ENVIRON MOL MUTAGEN, V29, P16, DOI 10.1002/(SICI)1098-2280(1997)29:1<16::AID-EM3>3.0.CO;2-B; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KRAUT EH, 1992, INVEST NEW DRUG, V10, P347, DOI 10.1007/BF00944194; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Lassota P, 1996, J BIOL CHEM, V271, P26418, DOI 10.1074/jbc.271.42.26418; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1994, ADV PHARM, V29; Look KY, 1996, AM J CLIN ONCOL-CANC, V19, P7, DOI 10.1097/00000421-199602000-00002; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; Meczes EL, 1997, CANCER CHEMOTH PHARM, V39, P367, DOI 10.1007/s002800050585; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; Nitiss JL, 1996, ANN NY ACAD SCI, V803, P32, DOI 10.1111/j.1749-6632.1996.tb26374.x; Nitiss JL, 1996, EUR J CANCER, V32A, P958, DOI 10.1016/0959-8049(96)00056-1; OSHEROFF N, 1994, CANCER CHEMOTH PHARM, V34, pS19, DOI 10.1007/BF00684859; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6410, DOI 10.1021/bi00344a015; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; Sato M, 1997, BIOCHEM BIOPH RES CO, V235, P571, DOI 10.1006/bbrc.1997.6851; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SPADARI S, 1986, ANTICANCER RES, V6, P935; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TANABE K, 1991, CANCER RES, V51, P4903; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WOYNAROWSKI JM, 1989, MOL PHARMACOL, V35, P177; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	78	227	232	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17643	17650		10.1074/jbc.273.28.17643	http://dx.doi.org/10.1074/jbc.273.28.17643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651360	hybrid			2022-12-27	WOS:000074816100053
J	Juin, P; Pelletier, M; Oliver, L; Tremblais, K; Gregoire, P; Meflah, K; Vallette, FM				Juin, P; Pelletier, M; Oliver, L; Tremblais, K; Gregoire, P; Meflah, K; Vallette, FM			Induction of a caspase-3-like activity by calcium in normal cytosolic extracts triggers nuclear apoptosis in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; CHROMATIN CONDENSATION; ICE/CED-3 PROTEASE; BCL-2; DEATH; INHIBITOR; CA2+	Calcium is involved in several steps of the apoptotic process. In nuclei, endonucleases are presumed to be the main targets of calcium; however, little is known about its role during the cytosolic phase of apoptosis. We used a cell-free system to address this question. Our results show that CaCl2 triggered nuclear apoptosis (i.e. typical morphological change and DNA fragmentation) at concentrations of 5 mM. This concentration was lowered 10-fold by the co-incubation with cytosolic extracts from nonapoptotic cells. Apoptotic changes induced by the incubation of nuclei with CaCl2 in the presence of these cytosols were strongly reduced in the presence of an inhibitor of caspase-3 and to a lesser extent by an inhibitor of caspase-1. We also show that calcium-induced apoptosis is affected by protease inhibitors such as N-tosyl-L-phenylalanine chloromethyl ketone, but not by calpain or several lysosomal protease inhibitors. The addition of CaCl2 to the cell-free system increased a caspase-3 activity in nonapoptotic cytosols as shown by specific antibodies and an enzymatic assay. No activation of a caspase-3-like activity by the addition of cytochrome c was observed in these extracts under similar conditions. The enhanced caspase-3 activity induced by calcium was inhibited by protease inhibitors affecting morphological nuclear apoptosis except for those responsible for the degradation of lamin A. These results suggest that CaCl2 could trigger, in normal cells, an apoptotic cascade through the activation of cytosolic caspase-3 activity.	Inst Biol, INSERM, U 419, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Vallette, FM (corresponding author), Inst Biol, INSERM, U 419, 9 Quai Moncousu, F-44035 Nantes 01, France.		JUIN, Philippe P/H-3636-2014; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018; Oliver, Lisa J/L-3070-2015; JUIN, Philippe/Q-1338-2019	JUIN, Philippe P/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; Oliver, Lisa J/0000-0002-5588-7564; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois/0000-0003-0802-0519				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHATEL JM, 1993, P NATL ACAD SCI USA, V90, P2476, DOI 10.1073/pnas.90.6.2476; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marin MC, 1996, ONCOGENE, V12, P2259; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; McConkey DJ, 1996, J BIOL CHEM, V271, P22398, DOI 10.1074/jbc.271.37.22398; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sukharev SA, 1997, CELL DEATH DIFFER, V4, P457, DOI 10.1038/sj.cdd.4400263; SUN DY, 1994, J EXP MED, V179, P559, DOI 10.1084/jem.179.2.559; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TOUNEKTI O, 1995, EXP CELL RES, V217, P506, DOI 10.1006/excr.1995.1116; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	36	102	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17559	17564		10.1074/jbc.273.28.17559	http://dx.doi.org/10.1074/jbc.273.28.17559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651349	hybrid			2022-12-27	WOS:000074816100042
J	Kawabata, S; Kohara, A; Tsutsumi, R; Itahana, H; Hayashibe, S; Yamaguchi, T; Okada, M				Kawabata, S; Kohara, A; Tsutsumi, R; Itahana, H; Hayashibe, S; Yamaguchi, T; Okada, M			Diversity of calcium signaling by metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TRANSDUCTION; OSCILLATIONS; ACTIVATION; ENTRY	During prolonged application of glutamate (20 min), patterns of increase in intracellular Ca2+ concentration ([Ca2+](i)) were studied in HEK-293 cells expressing metabotropic glutamate receptor, mGluR1 alpha or mGluR5a, Stimulation of mGluR1 alpha induced an increase in [Ca2+](i), that consisted of an initial transient peak with a subsequent steady plateau or an oscillatory increase in [Ca2+](i). The transient phase was largely attributed to Ca2+ mobilization from the intracellular Ca2+ stores, but the sustained phase was solely due to Ca2+ influx through the mGluR1 alpha receptor-operated Ca2+ channel. Prolonged stimulation of mGluR5a continuously induced [Ca2+](i) oscillations through mobilization of Ca2+ from the intracellular Ca2+ stores, Studies on mutant receptors of mGluR1 alpha and mGluR5a revealed that the coupling mechanism in the sustained phase of Ca2+ response is determined by oscillatory/non-oscillatory patterns of the initial Ca2+ response but not by the receptor identity. In mGluR1 alpha-expressing cells, activation of protein kinase C selectively desensitized the pathway for intracellular Ca2+ mobilization, but the mGluR1 alpha-operated Ca2+ channel remained active. In mGluR5a-expressing cells, phosphorylation of mGluR5a by protein kinase C, which accounts for the mechanism of mGluR5a controlled [Ca2+](i) oscillations, might prevent desensitization and result in constant oscillatory mobilization of Ca2+ from intracellular Ca2+ stores. Our results provide a novel concept in which oscillatory/non-oscillatory mobilizations of Ca2+ induce different coupling mechanisms during prolonged stimulation of mGluRs.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Neurosci Res Lab, Tsukuba, Ibaraki 305, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Lab, Tsukuba, Ibaraki 305, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Chem Lab, Tsukuba, Ibaraki 305, Japan	Astellas Pharmaceuticals; Astellas Pharmaceuticals; Astellas Pharmaceuticals	Okada, M (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Neurosci Res Lab, 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan.							ABE T, 1992, J BIOL CHEM, V267, P13361; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chen JG, 1997, J NEUROSCI, V17, P7278; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HALLAM TJ, 1989, TRENDS PHARMACOL SCI, V10, P8, DOI 10.1016/0165-6147(89)90092-8; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; JENSEN AM, 1990, J NEUROSCI, V10, P1165; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; Nakahara K, 1997, J NEUROCHEM, V69, P1467; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Towart R, 1979, BRIT J PHARMACOL, V67, p409P	23	61	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17381	17385		10.1074/jbc.273.28.17381	http://dx.doi.org/10.1074/jbc.273.28.17381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651322	hybrid			2022-12-27	WOS:000074816100015
J	Kawata, Y; Mizukami, Y; Fujii, Z; Sakumura, T; Yoshida, K; Matsuzaki, M				Kawata, Y; Mizukami, Y; Fujii, Z; Sakumura, T; Yoshida, K; Matsuzaki, M			Applied pressure enhances cell proliferation through mitogen-activated protein kinase activation in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; GLOMERULAR CAPILLARY HYPERTENSION; SIGNAL-TRANSDUCTION PATHWAYS; TERNARY COMPLEX-FORMATION; SERUM RESPONSE ELEMENT; MAP KINASE; TRANSCRIPTION FACTOR; RENAL ABLATION; CYCLIN D1; GENE-EXPRESSION	progressive renal diseases lead to prolonged glomerular hypertension, which induces the proliferation of mesangial cells. This proliferation is thought to be involved in the development of renal injury. Here we investigate mitogen-activated protein kinase (MAPK) activation and cell proliferation in mesangial cells under conditions of high pressure. After pressure-load, the phosphorylation level of MAPK (at Tyr-204) increases rapidly with a peak at I min, although the amount of MAPK remains almost constant during pressure-load, To confirm the activation of MAPK, we carried out an immunoprecipitation-kinase assay. MAPK activity during pressure-load shows kinetics similar to that of the tyrosine phosphorylation. In contrast, c-Jun N-terminal kinase 1 (JNK1) phosphorylation falls below basal levels in response to high pressure. Immunocytochemical observations show phosphorylated MAPK in the nucleus at 10 min. The expression of c-Fos, a nuclear transcription factor, is induced by high pressure, and the induction is significantly inhibited by PD98059 (50 mu M), an upstream MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitor of MAPK. The expression of the c-Jun that is induced by JNR1 activation remains unchanged during pressure-load. MAPK phosphorylation and cell proliferation by applied pressure are significantly inhibited by genistein, a tyrosine kinase inhibitor in a dose-dependent manner, but not by protein kinase C inhibitors, chelerythrine and GF109203X, Genistein also blocks pressure-induced tyrosine phosphorylation of proteins with molecular masses of 35, 53, and 180 kDa. To clarify the physiological role in MAPK activation under high pressure conditions, we transfected antisense MAPK DNA into mesangial cells. The antisense DNA (2 mu M) inhibited MAPK expression by 80% compared with expression in the presence of sense or scrambled DNA, and significantly blocked pressure-induced cell proliferation. Treatment of cells with: MEK inhibitor also produced a similar result. MEK inhibitor strongly suppresses DNA synthesis induced by pressure-load. Cyclin D1 expression is significantly increased under high pressure conditions, and the increase is blocked by treatment with MEK inhibitor. These findings show that pressure-load, a novel activator of MAPK, induces the activation of tyrosine kinases, and enhances the proliferation of mesangial cells, probably through cyclin D1 expression.	Yamaguchi Univ, Dept Legal Med, Yamaguchi 7558505, Japan; Yamaguchi Univ, Dept Internal Med, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University	Mizukami, Y (corresponding author), Yamaguchi Univ, Dept Legal Med, 1144 Kogushi, Yamaguchi 7558505, Japan.			Mizukami, Yoichi/0000-0002-3290-0754				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; Bianchini L, 1997, J BIOL CHEM, V272, P271; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bokemeyer D, 1997, J CLIN INVEST, V100, P582, DOI 10.1172/JCI119568; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CORTES P, 1994, KIDNEY INT, V45, pS11; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DWORKIN LD, 1986, J CLIN INVEST, V77, P797, DOI 10.1172/JCI112377; DWORKIN LD, 1984, J CLIN INVEST, V73, P1448, DOI 10.1172/JCI111349; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; HARPER PA, 1984, KIDNEY INT, V26, P875, DOI 10.1038/ki.1984.231; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HISHIKAWA K, 1994, J CLIN INVEST, V93, P1975, DOI 10.1172/JCI117189; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JIANG W, 1993, ONCOGENE, V8, P3447; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; Kawata Y, 1998, BBA-MOL CELL RES, V1401, P195, DOI 10.1016/S0167-4889(97)00112-2; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRIZ W, 1990, KIDNEY INT, V38, pS2; KRIZ W, 1995, J AM SOC NEPHROL, V5, P1731; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUKAS J, 1995, ONCOGENE, V10, P2125; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OFSTAD J, 1992, KIDNEY INT, V41, pS8; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; PURKERSON ML, 1988, J CLIN INVEST, V81, P69, DOI 10.1172/JCI113312; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SELVA E, 1993, J BIOL CHEM, V268, P2250; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Suzuki H, 1996, J BIOL CHEM, V271, P18981, DOI 10.1074/jbc.271.31.18981; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; YAN MH, 1994, NATURE, V372, P798; YOSHIDA K, 1988, BIOCHEM J, V249, P487, DOI 10.1042/bj2490487; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X; YOSHIDA K, 1987, J BIOL CHEM, V262, P16048; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521	73	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16905	16912		10.1074/jbc.273.27.16905	http://dx.doi.org/10.1074/jbc.273.27.16905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642252	hybrid			2022-12-27	WOS:000074545200042
J	Chen, ZG; Blandl, T; Prorok, M; Warder, SE; Li, LP; Zhu, Y; Pedersen, LG; Ni, F; Castellino, FJ				Chen, ZG; Blandl, T; Prorok, M; Warder, SE; Li, LP; Zhu, Y; Pedersen, LG; Ni, F; Castellino, FJ			Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; GAMMA-CARBOXYGLUTAMATE; H-1-NMR SPECTRA; SPECTROSCOPY; PEPTIDES; PROTEINS; COSY; ASSIGNMENT; RESOLUTION; CONSTANTS	The apo- and metal-bound solution conformations of synthetic conantokin-G (con-G, G(1)E gamma gamma L(5)Q gamma NQ gamma(10)- LIR gamma (KSN)-S-15-CONH2, gamma = gamma-carboxyglutamic acid), an antagonist of N-methyl-D-aspartate receptor-derived neuronal ion channels, have been examined by one- and two-dimensional H-1 NMR at neutral pH. A complete structure for the Mg2+-loaded peptide was defined by use of distance geometry calculations and was found to exist as an cc-helix that spans the entire peptide. The a-helical nature of Mg2+/con-G was also supported by the small values (<5.5 Hz) of the (3)J(HN alpha) coupling constants measured for amino acid residues 3-5, 8, 9, and 11-16, and the small values (<4 ppb/K) of the temperature coefficients observed for the alpha NH protons of residues 5-17. This conformation contrasted with that obtained for apo-con-G, which was nearly structureless in solution. Docking of Mg2+ into con-G was accomplished by use of the genetic algorithm/molecular dynamics simulation method, employing the NMR-derived Mg2+-loaded structure for initial coordinates in the midpoint calculations. For the 3 Mg2+/con-G model, it was found that binding of one Mg2+ ion is stabilized by oxygen atoms from three gamma-carboxylates of Gla(3), Gla(4), and Gla(7); another Mg2+ is coordinated by two oxygen atoms, one from each of the gamma-carboxylates of Gla(7); and a third metal ion through three donor oxygen atoms of gamma-carboxylates from Gla(10) and Gla(14). As shown from direct metal binding measurements to mutant con-G) peptides, these latter two Gla residues probably stabilized the tightest binding Mg2+ ion. Circular dichroism studies of these same peptide variants demonstrated that all Gla residues contribute to the adoption of the Mg2+-dependent alpha-helical conformation in con-G. The data obtained in this investigation provide a molecular basis for the large conformational alteration observed in apo-con-G as a result of divalent cation binding and allow assessment of the roles of individual Gla residues in defining certain of the structure-function properties of con-G.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Natl Res Council Canada, Biotechnol Res Inst, Biomol NMR Lab, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; NIEHS, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of Notre Dame; National Research Council Canada; National Research Council Canada; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu	Li, Leping/F-6497-2019; Pedersen, Lee G/E-3405-2013; Ni, Feng/AAN-6388-2020	Li, Leping/0000-0003-4208-0259; Pedersen, Lee G/0000-0003-1262-9861; 	NHLBI NIH HHS [HL-27995, HL-19982] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blandl T, 1997, BIOCHEM J, V328, P777, DOI 10.1042/bj3280777; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; HAACK JA, 1990, J BIOL CHEM, V265, P6025; KADKHODAEI M, 1993, J MAGN RESON SER A, V105, P104, DOI 10.1006/jmra.1993.1257; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; Li LP, 1997, BIOCHEMISTRY-US, V36, P2132, DOI 10.1021/bi962250r; Lin CH, 1997, FEBS LETT, V407, P243, DOI 10.1016/S0014-5793(97)00354-2; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MYERS RA, 1990, J TOXICOL-TOXIN REV, V9, P179, DOI 10.3109/15569549009033113; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; NI F, 1992, BIOCHEMISTRY-US, V31, P2545, DOI 10.1021/bi00124a015; NI F, 1995, J MOL BIOL, V252, P656, DOI 10.1006/jmbi.1995.0527; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PEARLMAN DA, 1995, AMBER; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; VASQUEZ M, 1988, J BIOMOL STRUCT DYN, V5, P757, DOI 10.1080/07391102.1988.10506426; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhou LM, 1996, J NEUROCHEM, V66, P620	35	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16248	16258		10.1074/jbc.273.26.16248	http://dx.doi.org/10.1074/jbc.273.26.16248			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632684	Green Published			2022-12-27	WOS:000074436600055
J	Gerstin, EH; McMahon, T; Dadgar, J; Messing, RO				Gerstin, EH; McMahon, T; Dadgar, J; Messing, RO			Protein kinase C delta mediates ethanol-induced up-regulation of L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; RAT-BRAIN; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; PHYSICAL-DEPENDENCE; ALCOHOL-CONSUMPTION; MOLECULAR-CLONING; SENSORY NEURONS; PREFERRING RATS; DOWN-REGULATION	Brief ethanol exposure inhibits L-type, voltage-gated calcium channels in neural cells, whereas chronic exposure increases the number of functional channels. In PC12 cells, this adaptive response is mediated by protein kinase C (PKC), but the PKC isozyme responsible is unknown. Since chronic ethanol exposure increases expression of PKC delta and PKC epsilon, we investigated the role these isozymes play in up-regulation of L-type channels by ethanol, Incubation with the PKC inhibitor GF 109203X or expression of a PKC delta fragment that inhibits phorbol ester-induced PKC delta translocation largely prevented ethanol-induced increases in dihydropyridine binding and K+-stimulated Ca-45(2+) uptake. A corresponding PKC epsilon fragment had no effect on this response. These findings indicate that PKC delta mediates up-regulation of L-type channels by ethanol, Remaining responses to ethanol in cells expressing the PKC delta fragment were not inhibited by GF 109203X, indicating that PKC delta-independent mechanisms also contribute. PKC delta overexpression increased binding sites for dihydropyridine and L-channel antagonists, but did not increase R+-stimulated Ca-45(2+) uptake, possibly because of homeostatic responses that maintain base-line levels of channel function, Since L-type channels modulate drinking behavior and contribute to neuronal hyperexcitability during alcohol withdrawal, these findings suggest an important role for PKC delta in alcohol consumption and dependence.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Grad Program Biomed Sci, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Messing, RO (corresponding author), Bldg 1,Rm 101,1001 Potrero Ave, San Francisco, CA 94110 USA.	romes@itsa.ucsf.edu	Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; BONE GHA, 1989, PSYCHOPHARMACOLOGY, V99, P386, DOI 10.1007/BF00445563; BRENNAN CH, 1990, NEUROPHARMACOLOGY, V29, P429, DOI 10.1016/0028-3908(90)90163-L; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOMBO G, 1994, EUR J PHARMACOL, V265, P167, DOI 10.1016/0014-2999(94)90427-8; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; DELORME EM, 1986, BRAIN RES, V397, P189, DOI 10.1016/0006-8993(86)91385-5; DOLIN S, 1987, NEUROPHARMACOLOGY, V26, P275, DOI 10.1016/0028-3908(87)90220-6; FADDA F, 1992, ALCOHOL CLIN EXP RES, V16, P449, DOI 10.1111/j.1530-0277.1992.tb01398.x; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goldstein DB, 1983, PHARM ALCOHOL; GRANT AJ, 1993, BRAIN RES, V600, P280, DOI 10.1016/0006-8993(93)91384-5; GREENBERG DA, 1986, J PHARMACOL EXP THER, V238, P1021; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HARRIS RA, 1980, J PHARMACOL EXP THER, V213, P562; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; LESLIE SW, 1983, J PHARMACOL EXP THER, V225, P571; Li WQ, 1996, ONCOGENE, V13, P731; LINDBLAD B, 1976, JAMA-J AM MED ASSOC, V236, P1600, DOI 10.1001/jama.236.14.1600; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LITTLETON JM, 1990, PSYCHOPHARMACOLOGY, V100, P387, DOI 10.1007/BF02244612; Liu HY, 1996, J NEUROSCI, V16, P7557; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSA E, 1995, MOL PHARMACOL, V47, P707; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MESSING RO, 1986, P NATL ACAD SCI USA, V83, P6213, DOI 10.1073/pnas.83.16.6213; MESSING RO, 1990, J NEUROCHEM, V55, P1383, DOI 10.1111/j.1471-4159.1990.tb03150.x; Miettinen S, 1996, J NEUROSCI, V16, P6236; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MULLIKINKILPATRICK D, 1995, J PHARMACOL EXP THER, V272, P489; MULLIKINKILPATRICK D, 1995, MOL PHARMACOL, V47, P997; NIKODIJEVIC B, 1994, J NEUROSCI RES, V37, P71, DOI 10.1002/jnr.490370110; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OAKES SG, 1982, DEV BRAIN RES, V5, P251, DOI 10.1016/0165-3806(82)90123-7; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PANZA G, 1985, NEUROPHARMACOLOGY, V24, P1113, DOI 10.1016/0028-3908(85)90200-X; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; RAMKUMAR V, 1988, EUR J PHARMACOL, V146, P73, DOI 10.1016/0014-2999(88)90488-8; REZVANI AH, 1991, ALCOHOL ALCOHOLISM, V26, P161, DOI 10.1093/oxfordjournals.alcalc.a045097; REZVANI AH, 1990, PROG NEURO-PSYCHOPH, V14, P623, DOI 10.1016/0278-5846(90)90013-7; Roivainen R, 1994, MOL BASIS ALCOHOL US, P29; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SKATTEBOL A, 1987, BIOCHEM PHARMACOL, V36, P2227, DOI 10.1016/0006-2952(87)90156-0; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TWOMBLY DA, 1990, J PHARMACOL EXP THER, V254, P1029; URSO T, 1981, LIFE SCI, V28, P1053, DOI 10.1016/0024-3205(81)90752-9; Victor M, 1953, RES PUBL ASSOC RES N, V32, P526; WANG XM, 1994, J NEUROSCI, V14, P5453; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	63	64	64	5	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16409	16414		10.1074/jbc.273.26.16409	http://dx.doi.org/10.1074/jbc.273.26.16409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632705	hybrid			2022-12-27	WOS:000074436600076
J	Jackson, DT; Froehlich, JE; Keegstra, K				Jackson, DT; Froehlich, JE; Keegstra, K			The hydrophilic domain of Tic110, an inner envelope membrane component of the chloroplastic protein translocation apparatus, faces the stromal compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; IMPORT MACHINERY; SMALL SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; PRECURSOR PROTEINS; PEA-CHLOROPLASTS; OUTER-MEMBRANE; IDENTIFICATION; TRANSPORT	It has previously been found that Tic110, an integral protein of the chloroplast inner envelope membrane, is a component of the chloroplastic protein import apparatus. However, conflicting reports exist concerning the topology of this protein within the inner envelope membrane. In this report, we provide,evidence that indicates that the large (>90-kDa) hydrophilic domain of Tic110 is localized within the chloroplast stroma. Trypsin, a protease that cannot penetrate the permeability barrier of the inner envelope membrane, degrades neither Tic110 nor other proteins exposed to the stromal compartment but is able to digest proteins exposed to the intermembrane space between the two envelope membranes. Previous reports indicating that trypsin is able to degrade Tic110 were influenced by incomplete quenching of protease activity.When trypsin is not sufficiently quenched, it is able to digest Tic110, but only after chloroplasts have been ruptured. It is therefore necessary to employ adequate quenching protocols, such as the one reported here, whenever trypsin is utilized as an analytical tool. Based on a stromal localization for the majority of Tic110, we propose that this protein may be involved in the recruitment of stromal factors, possibly molecular chaperones, to the translocation apparatus during protein import.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA	Michigan State University	Keegstra, K (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.							Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Bruce BD, 1994, PLANT MOL BIOL MAN J, VJ1, P1; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DAUM G, 1982, J BIOL CHEM, V257, P3028; ETEMADI AH, 1980, BIOCHIM BIOPHYS ACTA, V604, P347; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HIGHFIELD PE, 1978, NATURE, V271, P420, DOI 10.1038/271420a0; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MOORE T, 1993, PLANT MOL BIOL, V21, P525, DOI 10.1007/BF00028809; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; NIELSEN EE, 1997, THESIS MICHIGAN STAT, P131; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WU CB, 1994, J BIOL CHEM, V269, P32264	38	137	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16583	16588		10.1074/jbc.273.26.16583	http://dx.doi.org/10.1074/jbc.273.26.16583			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632730	hybrid			2022-12-27	WOS:000074436600101
J	Cao, ZY; Jefferson, DM; Panjwani, N				Cao, ZY; Jefferson, DM; Panjwani, N			Role of carbohydrate-mediated adherence in cytopathogenic mechanisms of Acanthamoeba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTAMOEBA-HISTOLYTICA; CORNEAL EPITHELIUM; CELL-CULTURE; CASTELLANII; PROTEASES; PATHOGENICITY; TROPHOZOITES; PROTEINASE; EXPRESSION; VIRULENCE	Acanthamoeba keratitis is a vision-threatening corneal infection. The mannose-binding protein of Acanthamoeba is thought to mediate adhesion of parasites to host cells. We characterized the amoeba lectin with respect to its carbohydrate binding properties and the role in amoeba-induced cytopathic effect (CPE), Sugar inhibition assays revealed that the amoeba lectin has the highest affinity for alpha-Man and Man(alpha 1-3)Man units. In vitro cytopathic assays indicated that mannose-based saccharides which inhibit amoeba adhesion to corneal epithelial cells were also potent inhibitors of amoeba-induced CPE, Another major finding was that N-acetyl-D-glucosamine (GlcNAc) which does not inhibit adhesion of amoeba to host cells is also an inhibitor of amoeba-induced CPE. The Acanthamoebae are thought to produce CPE by secreting cytotoxic proteinases. By zymography, one metalloproteinase and three serine proteinases were detected in the conditioned media obtained after incubating amoebae with the host cells. The addition of free alpha-Man and GlcNAc to the co-culture media inhibited the secretion of the metalloproteinase and serine proteinases, respectively. In summary, we have shown that the lectin-mediated adhesion of the Acanthamoeba to host cells is a prerequisite for the amoeba-induced cytolysis of target cells and have implicated a contact-dependent metalloproteinase in the cytopathogenic mechanisms of Acanthamoeba.	Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Panjwani, N (corresponding author), Tufts Univ, Sch Med, Dept Ophthalmol, 136 Harrison Ave, Boston, MA 02111 USA.	NPanjwani@infonet.tufts.edu			NATIONAL EYE INSTITUTE [R01EY009349] Funding Source: NIH RePORTER; NEI NIH HHS [EY07088, EY09349] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALIZADEH H, 1994, INFECT IMMUN, V62, P1298, DOI 10.1128/IAI.62.4.1298-1303.1994; ALIZADEH H, 1997, DIS CORNEA, V2, P1267; BADENOCH PR, 1995, INT J PARASITOL, V25, P229, DOI 10.1016/0020-7519(94)00075-Y; BONALDO MC, 1991, EXP PARASITOL, V73, P44, DOI 10.1016/0014-4894(91)90006-I; BORNES JT, 1970, J PARASITOL, V56, P904; CURSONS RTM, 1978, J CLIN PATHOL, V31, P1, DOI 10.1136/jcp.31.1.1; DEJONCKHEERE JF, 1980, APPL ENVIRON MICROB, V39, P681, DOI 10.1128/AEM.39.4.681-685.1980; DEJONCKHEERE JF, 1981, J PROTOZOOL, V28, P56; HADAS E, 1993, TROP MED PARASITOL, V44, P197; HARE DF, 1989, EXP PARASITOL, V68, P168, DOI 10.1016/0014-4894(89)90094-5; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; JAMES GT, 1978, ANAL BIOCHEM, V86, P574, DOI 10.1016/0003-2697(78)90784-4; JUMBLATT MM, 1983, INVEST OPHTH VIS SCI, V24, P1139; KEENE WE, 1990, EXP PARASITOL, V71, P199, DOI 10.1016/0014-4894(90)90022-5; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN DFP, 1991, EYE, V5, P70, DOI 10.1038/eye.1991.14; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Martinez AJ, 1997, BRAIN PATHOL, V7, P583, DOI 10.1111/j.1750-3639.1997.tb01076.x; MCCOY JJ, 1994, INFECT IMMUN, V62, P3045, DOI 10.1128/IAI.62.8.3045-3050.1994; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MITRA MM, 1995, MOL BIOCHEM PARASIT, V73, P157, DOI 10.1016/0166-6851(94)00109-Z; MITRO K, 1994, EXP PARASITOL, V78, P377, DOI 10.1006/expr.1994.1041; MOORE MB, 1991, CORNEA, V10, P291, DOI 10.1097/00003226-199107000-00003; MORTON LD, 1991, INFECT IMMUN, V59, P3819, DOI 10.1128/IAI.59.10.3819-3822.1991; PANJWANI N, 1995, J BIOL CHEM, V270, P14015, DOI 10.1074/jbc.270.23.14015; PANJWANI N, 1990, INVEST OPHTH VIS SCI, V31, P689; Panjwani N, 1997, INVEST OPHTH VIS SCI, V38, P1858; PERRONE RD, 1995, AM J PHYSIOL-GASTR L, V269, pG335, DOI 10.1152/ajpgi.1995.269.3.G335; Petri WA, 1996, J INVEST MED, V44, P24; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; PRESTON TM, 1984, J GEN MICROBIOL, V130, P2317; PRINA E, 1990, INFECT IMMUN, V58, P1730, DOI 10.1128/IAI.58.6.1730-1737.1990; RAGLAND BD, 1994, EXP PARASITOL, V79, P460, DOI 10.1006/expr.1994.1107; REED SL, 1989, J CLIN MICROBIOL, V27, P2772, DOI 10.1128/JCM.27.12.2772-2777.1989; STANLEY SL, 1995, J BIOL CHEM, V270, P4121, DOI 10.1074/jbc.270.8.4121; VANKLINK F, 1992, CURR EYE RES, V11, P1207, DOI 10.3109/02713689208999546; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VISVESVARA GS, 1975, J PROTOZOOL, V22, P245, DOI 10.1111/j.1550-7408.1975.tb05860.x; Yang ZT, 1997, INFECT IMMUN, V65, P439, DOI 10.1128/IAI.65.2.439-445.1997	41	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15838	15845		10.1074/jbc.273.25.15838	http://dx.doi.org/10.1074/jbc.273.25.15838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624184	hybrid			2022-12-27	WOS:000074284200078
J	Desrivieres, S; Cooke, FT; Parker, PJ; Hall, MN				Desrivieres, S; Cooke, FT; Parker, PJ; Hall, MN			MSS4, a phosphatidylinositol-4-phosphate 5-kinase required for organization of the actin cytoskeleton in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; 4-PHOSPHATE 5-KINASE; YEAST SACCHAROMYCES; PHOSPHATIDIC-ACID; ALPHA-ACTININ; CELL-CYCLE; PATHWAY; HOMOLOG; GENE	The Saccharomyces cerevisiae protein MSS4 is essential and homologous to mammalian phosphatidylinositol-4-phosphate (PI(4)P) 5-kinases. Here, we demonstrate that MSS4 is a lipid kinase. MSS4 has dual substrate specificity in vitro, converting PI(4)P to PI(4,5)P-2 and to a lesser extent PI(S)P to PI(3, 4)P-2; no activity was detected with PI or PI(S)P as a substrate. Cells overexpressing MSS4 contain an elevated level specifically of PI(4,5)P,, whereas mss4 mutant cells have only approximately 10% of the normal amount of this phosphorylated phosphoinositide. Furthermore, cells lacking MSS4 are unable to form actin cables and to properly localize their actin cytoskeleton during polarized cell growth. Overexpression of RHO2, encoding a Rho-type GTPase involved in regulation of the actin cytoskeleton, restores growth and polarized distribution of actin in an mss4 mutant. These results suggest that MSS4 is the major PI(4)P B-kinase in yeast and provide a link between phosphoinositide metabolism and organization of the actin cytoskeleton in vivo.	Univ Basel, Biozentrum, Dept Biochem, CH-4056 Basel, Switzerland; Imperial Canc Res Fund, London WC2A 3PX, England	University of Basel; Cancer Research UK	Hall, MN (corresponding author), Univ Basel, Biozentrum, Dept Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	hall@ubaclu.unibas.ch	Desrivieres, Sylvane/B-7399-2011; Parker, Peter j/D-5192-2013; Desrivières, Sylvane/ABC-4336-2021	Desrivieres, Sylvane/0000-0002-9120-7060; Desrivières, Sylvane/0000-0002-9120-7060; Hall, Michael N/0000-0002-2998-0757; parker, peter/0000-0002-6218-2933				ADAMS AE, 1984, J CELL BIOL, V9, P934; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Helliwell SB, 1998, GENETICS, V148, P99; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SCHMIDT A, 1998, IN PRESS ANN REV CEL; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	53	172	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15787	15793		10.1074/jbc.273.25.15787	http://dx.doi.org/10.1074/jbc.273.25.15787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624178	hybrid, Green Accepted			2022-12-27	WOS:000074284200072
J	Paakkonen, K; Annila, A; Sorsa, T; Pollesello, P; Tilgmann, C; Kilpelainen, I; Karisola, P; Ulmanen, I; Drakenberg, T				Paakkonen, K; Annila, A; Sorsa, T; Pollesello, P; Tilgmann, C; Kilpelainen, I; Karisola, P; Ulmanen, I; Drakenberg, T			Solution structure and main chain dynamics of the regulatory domain (residues 1-91) of human cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HETERONUCLEAR NMR-SPECTROSCOPY; CHEMICAL-SHIFT ANISOTROPY; MODEL-FREE APPROACH; SKELETAL-MUSCLE; CALCIUM-BINDING; BACKBONE DYNAMICS; RELAXATION; PROTEINS; CONTRACTION	The three-dimensional structure of calcium-loaded regulatory, i.e. N-terminal, domain (1-91) of human cardiac troponin C (cNTnC) was determined by NMR in water/trifluoroethanol (91:9 v/v) solution. The single-calcium-loaded cardiac regulatory domain is in a "closed"? conformation with comparatively little exposed hydrophobic surface. Difference distance matrices computed from the families of Ca2+-cNTnC, the apo and two-calcium forms of the skeletal TnC (sNTnC) structures reveal similar relative orientations for the N, A, and D helices, The B and C helices are closer to the NAD framework in Ca2+-cNTnC and in apo-sNTnC than in 2 . Ca2+-sNTnC, However, there is an indication of a conformational exchange based on broad N-15 resonances for several amino acids measured at several temperatures. A majority of the amides in the alpha-helices and in the calcium binding loop exhibit very fast motions with comparatively small amplitudes according to the Lipari-Szabo model. A few residues at the N and C termini are flexible. Data were recorded from nonlabeled and N-15-labeled samples, and backbone dynamics was investigated by N-15 T-1,T- T-2, and heteronuclear nuclear Overhauser effect as well as by relaxation interference measurements.	VTT Chem Technol, FIN-02044 VTT, Finland; Orion Corp, Orion Pharma, R&D, FIN-02101 Espoo, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	VTT Technical Research Center Finland; Orion Corporation; University of Helsinki	Annila, A (corresponding author), VTT Chem Technol, POB 1401, FIN-02044 VTT, Finland.		Pollesello, Piero/I-6884-2019	Pollesello, Piero/0000-0001-6994-768X; Tilgmann, Carola/0000-0001-6241-2359				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; Dong WJ, 1997, J BIOL CHEM, V272, P19229, DOI 10.1074/jbc.272.31.19229; Evenas J, 1997, BIOCHEMISTRY-US, V36, P3448, DOI 10.1021/bi9628275; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GOLDMAN M, 1984, J MAGN RESON, V60, P437, DOI 10.1016/0022-2364(84)90055-6; HERZBERG O, 1986, CIBA F SYMP, V122, P120; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Jansson M, 1996, J BIOMOL NMR, V7, P131; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SCHULZKI HD, 1990, EUR J BIOCHEM, V189, P683, DOI 10.1111/j.1432-1033.1990.tb15537.x; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SLUPSKY CM, 1995, PROTEIN SCI, V4, P1279, DOI 10.1002/pro.5560040704; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162	35	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15633	15638		10.1074/jbc.273.25.15633	http://dx.doi.org/10.1074/jbc.273.25.15633			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624156	hybrid			2022-12-27	WOS:000074284200050
J	Dammeier, J; Beer, HD; Brauchle, M; Werner, S				Dammeier, J; Beer, HD; Brauchle, M; Werner, S			Dexamethasone is a novel potent inducer of connective tissue growth factor expression - Implications for glucocorticoid therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; INDUCIBLE GENE; WOUND REPAIR; FACTOR-BETA; IDENTIFICATION	Due to its potent effect on fibroblast proliferation and extracellular matrix deposition, connective tissue growth factor (CTGF) seems to play an important role in the pathogenesis of fibrotic disease. Since glucocorticoids are frequently used for the therapy of these disorders, we determined a potential effect of these steroids on CTGF expression. In cultured fibroblasts, a striking induction of CTGF expression was observed after dexamethasone treatment and occurred in a time- and dose-dependent manner, This effect was obviously not mediated by the CTGF inducer transforming growth factor-beta 1, since expression of this factor was down-regulated by the glucocorticoid. Most importantly, CTGF expression levels also increased substantially in various tissues and organs by systemic glucocorticoid treatment of mice, After cutaneous injury, a strong induction of CTGF expression was seen in the wounds of nontreated mice, However, no further increase in the levels of CTGF mRNA occurred in wounded skin compared with unwounded skin of glucocorticoid-treated animals, suggesting the presence of other factors in the wound that might compensate for the effect of the steroids. Tumor necrosis factor-alpha was identified as a possible mediator of this effect because this factor suppressed CTGF expression in cultured fibroblasts and also blocked the glucocorticoid-induced CTGF production by these cells. These findings indicate that glucocorticoids stimulate CTGF expression in normal tissues and organs but not in highly inflamed areas.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Werner, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	werner@biochem.mpg.de		Beer, Hans-Dietmar/0000-0002-8085-713X; Dammeier, Johanna/0000-0002-6040-2779; Werner, Sabine/0000-0001-7397-8710				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; Bemelmans MHA, 1996, CRIT REV IMMUNOL, V16, P1; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EHRLICH HP, 1968, ANN SURG, V167, P324, DOI 10.1097/00000658-196803000-00004; Franklin TJ, 1997, INT J BIOCHEM CELL B, V29, P79, DOI 10.1016/S1357-2725(96)00121-5; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Grotendorst G R, 1997, Expert Opin Investig Drugs, V6, P777, DOI 10.1517/13543784.6.6.777; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LOMBES M, 1995, CIRCULATION, V92, P175, DOI 10.1161/01.CIR.92.2.175; OBRIAN TP, 1990, MOL CELL BIOL, V4, P637; Oemar BS, 1997, CIRCULATION, V95, P831; REED BR, 1985, J AM ACAD DERMATOL, V13, P919, DOI 10.1016/S0190-9622(85)70242-3; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SHULL S, 1995, LUNG, V173, P71, DOI 10.1007/BF02981467; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Wahl S, 1989, ANTIINFLAMMATORY STE, P280; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	28	121	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18185	18190		10.1074/jbc.273.29.18185	http://dx.doi.org/10.1074/jbc.273.29.18185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660779	hybrid			2022-12-27	WOS:000074828500034
J	Dron, M; Dandoy-Dron, F; Guillot, F; Benboudjema, L; Hauw, JJ; Lebon, P; Dormont, D; Tovey, MG				Dron, M; Dandoy-Dron, F; Guillot, F; Benboudjema, L; Hauw, JJ; Lebon, P; Dormont, D; Tovey, MG			Characterization of the human analogue of a Scrapie-responsive gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; EXPRESSION; PROTEIN; BRAIN	We have recently described a novel mRNA denominated ScRG-1, the level of which is increased in the brains of Scrapie-infected mice (Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J.-P., Lasmezas, C., Dormont, D., Tovey, M. G., and Dron, M. (1998) J. Biol. Chem, 273, 7691-7697), The increase in ScRG-1 mRNA in the brain follows the accumulation of PrPSc, the proteinase K-resistant form of the prion protein (PrP), and precedes the widespread neuronal death that occurs in late stage disease. In the present study, we have isolated a cDNA encoding the human counterpart of ScRG-1, Comparison of the human and mouse transcripts firmly established that both sequences encode a highly conserved protein of 98 amino acids that contains a signal peptide, suggesting that the protein may be secreted. Examination of the distribution of human ScRG-1 mRNA in adult and fetal tissues revealed that the gene was expressed primarily in the central nervous system as a 0.7-kilobase message and was under strict developmental control.	Lab Viral Oncol, CNRS, UPR 9045, IFC1, F-94801 Villejuif, France; Grp Hosp Pitie Salpetriere, INSERM, U360,Assoc Claude Bernard, Lab Neuropathol Raymond Escourolle, F-75651 Paris 13, France; Hop St Vincent de Paul, Virol Lab, F-75674 Paris 14, France; CEA, Lab Neurovirol, F-92265 Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CEA	Tovey, MG (corresponding author), Lab Viral Oncol, CNRS, UPR 9045, IFC1, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.		DRON, Michel/M-7093-2017	Tovey, Michael/0000-0002-3058-0494				Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; CAMPBELL IL, 1994, J VIROL, V68, P2383, DOI 10.1128/JVI.68.4.2383-2387.1994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5291; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DUGUID J, 1993, P NATL ACAD SCI USA, V90, P114, DOI 10.1073/pnas.90.1.114; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; LEMERE CA, 1995, AM J PATHOL, V146, P848; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Raeber AJ, 1997, EMBO J, V16, P6057, DOI 10.1093/emboj/16.20.6057; RIGIER R, 1997, NAT MED, V3, P1383; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X	12	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18015	18018		10.1074/jbc.273.29.18015	http://dx.doi.org/10.1074/jbc.273.29.18015			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660755	hybrid			2022-12-27	WOS:000074828500010
J	Palmer, CNA; Axen, E; Hughes, V; Wolf, CR				Palmer, CNA; Axen, E; Hughes, V; Wolf, CR			The repressor protein, Bm3R1, mediates an adaptive response to toxic fatty acids in Bacillus megaterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING PROTEIN; ESCHERICHIA-COLI; ACTIVATED RECEPTOR; TRANSCRIPTIONAL REGULATOR; PEROXISOME PROLIFERATORS; OMEGA-HYDROXYLATION; SOLUBLE SYSTEM; BETA-OXIDATION; GENE; CYTOCHROME-P-450	Bm3R1 is a helix-turn-helix transcriptional repressor from Bacillus megaterium whose binding to DNA is inhibited by fatty acids and a wide range of compounds that modulate lipid metabolism. The inactivation of Bm3R1/DNA binding activity results in the activation of transcription of the operon encoding a fatty acid hydroxylase, cytochrome P450 102, The metabolic role of this operon is unknown. It is possible that it is involved in the synthesis of modified fatty acids as part of normal cellular metabolism or may represent a protective mechanism by which B, megaterium detoxifies harmful foreign lipids. In this report we demonstrate that poly unsaturated fatty acids (PUFA) activate the transcription of the CYP102 operon, These PUFA are the most potent activators of the CYP102 operon observed to date, and we show that their effects are due to binding directly to Bm3R1, In addition, cultures that have been treated with the CYP102 inducer, nafenopin, are protected against PUFA toxicity. Resistance to PUFA toxicity is also seen in a Bm3R1-deficient strain that constitutively expresses CYP102, The resistant phenotype of this Bm3R1 mutant strain is reversed by specific chemical inactivation of CYP102, These data demonstrate that Bm3R1 can act as a direct sensor of toxic fatty acids and, in addition, provide the first direct evidence of fatty acids binding to a prokaryotic transcription factor.	Univ Dundee, Ninewells Hosp & Med Sch, ICRF, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Wolf, CR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, ICRF, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland.		Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560				BELL DR, 1992, EUR J BIOCHEM, V206, P979, DOI 10.1111/j.1432-1033.1992.tb17009.x; BUCHANAN JF, 1978, BIOCHEM BIOPH RES CO, V85, P1254, DOI 10.1016/0006-291X(78)91138-5; Burr GO, 1930, J BIOL CHEM, V86, P0587; Capdevila JH, 1996, J BIOL CHEM, V271, P22663, DOI 10.1074/jbc.271.37.22663; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ENGLISH N, 1994, J BIOL CHEM, V269, P26836; English N, 1996, BIOCHEM J, V316, P279, DOI 10.1042/bj3160279; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FULCO AJ, 1967, BIOCHIM BIOPHYS ACTA, V144, P701, DOI 10.1016/0005-2760(67)90065-3; GEBREMEDHIN D, 1993, J VASC RES, V30, P53, DOI 10.1159/000158975; GIBSON G, 1993, PEROXISOMES BIOL IMP; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; KANEDA T, 1977, BACTERIOL REV, V41, P391, DOI 10.1128/MMBR.41.2.391-418.1977; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1997, P NATL ACAD SCI USA, V94, P4312; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MIURA Y, 1974, J BIOL CHEM, V249, P1880; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SAGAR PS, 1995, PROSTAG LEUKOTR ESS, V53, P287, DOI 10.1016/0952-3278(95)90129-9; SHA RS, 1993, J BIOL CHEM, V268, P7885; SHAW GC, 1992, J BIOL CHEM, V267, P5515; Shaw GC, 1995, BIOCHEM MOL BIOL INT, V37, P1197; Shaw GC, 1996, CURR MICROBIOL, V32, P124, DOI 10.1007/s002849900022; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SHIRANE N, 1993, BIOCHEMISTRY-US, V32, P13732, DOI 10.1021/bi00212a044; STRAUCH MA, 1992, MOL MICROBIOL, V6, P2909, DOI 10.1111/j.1365-2958.1992.tb01750.x; VONEULER VS, 1936, J PHYSIOL-LONDON, V88, P208; WEISSBART D, 1992, BIOCHIM BIOPHYS ACTA, V1124, P135, DOI 10.1016/0005-2760(92)90089-E; WEN LP, 1987, J BIOL CHEM, V262, P6676; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOU SY, 1989, J BIOL CHEM, V264, P16489	41	31	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18109	18116		10.1074/jbc.273.29.18109	http://dx.doi.org/10.1074/jbc.273.29.18109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660768	hybrid			2022-12-27	WOS:000074828500023
J	Park, YC; Bedouelle, H				Park, YC; Bedouelle, H			Dimeric tyrosyl-tRNA synthetase from Bacillus stearothermophilus unfolds through a monomeric intermediate - A quantitative analysis under equilibrium conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; SUBUNIT INTERFACE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MOLTEN GLOBULE; FOLDED STATE; PROTEIN; STABILITY; ENZYME	Tyrosyl-tRNA synthetase from Bacillus stearother-mophilus comprises an N-terminal domain (residues 1-319), which is dimeric and forms tyrosyladenylate, and a C-terminal domain (residues 320-419), which binds the anticodon arm of tRNA(Tyr). The N-terminal domain has the characteristic fold of the class I amino-acyl-tRNA synthetases. The unfolding of the N-terminal domain by urea at 25 degrees C under equilibrium conditions was monitored by its intensities of Light emission at 330 and 350 nm, the ratio of these intensities, its ellipticity at 229 nm, and its partition coefficient, in spectrofluorometry, circular dichroism, and size-exclusion chromatography experiments, respectively. These experiments showed the existence of an equilibrium between the native dimeric state of the N-terminal domain, a monomeric intermediate state, and the unfolded state. The intermediate was compact and had secondary structure, and its tryptophan residues were partially buried. These properties of the intermediate and its inability to bind 1-anilino-8-naphthalenesulfonate showed that it was not in a molten globular state. The variation of free energy Delta G(H2O) and its coefficient m of dependence on the concentration of urea were, respectively, 13.8 +/- 0.2 kcal mol-l and 0.9 +/- 0.1 kcal.mol(-1).M-1 for the dissociation of the native dimer and 13.9 +/- 0.6 kcal.mol(-1) and 2.5 +/- 0.1 kcal.mol(-1).M-1 for the unfolding of the monomeric intermediate.	Inst Pasteur, Unite Biochim Cellulaire, CNRS, URA 1129,Grp Ingn Prot, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bedouelle, H (corresponding author), Inst Pasteur, Unite Biochim Cellulaire, CNRS, URA 1129,Grp Ingn Prot, 28 Rue Docteur Roux, F-75724 Paris 15, France.							Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BEDOUELLE H, 1986, NATURE, V320, P371, DOI 10.1038/320371a0; Blondel A, 1996, PROTEIN ENG, V9, P231, DOI 10.1093/protein/9.2.231; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; CLARK AC, 1993, J BIOL CHEM, V268, P10773; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; EFTINK MR, 1994, BIOCHEMISTRY-US, V33, P10220, DOI 10.1021/bi00200a002; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; GRISLEY JK, 1997, BIOCHEMISTRY-US, V36, P14366; GuezIvanier V, 1996, J MOL BIOL, V255, P110, DOI 10.1006/jmbi.1996.0010; HAUGLAND RP, 1991, HDB FLUORESCENT PROB; HIBBARD LS, 1978, BIOCHEMISTRY-US, V17, P5460, DOI 10.1021/bi00618a021; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; JONES DH, 1985, BIOCHEMISTRY-US, V24, P5852, DOI 10.1021/bi00342a024; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Pace C N, 1986, Methods Enzymol, V131, P266; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; VIDALCROS A, 1992, J MOL BIOL, V223, P801, DOI 10.1016/0022-2836(92)90991-R; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; WARD WHJ, 1987, BIOCHEMISTRY-US, V26, P4131, DOI 10.1021/bi00387a058; WAYE MMY, 1983, EMBO J, V2, P1827, DOI 10.1002/j.1460-2075.1983.tb01665.x; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	35	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18052	18059		10.1074/jbc.273.29.18052	http://dx.doi.org/10.1074/jbc.273.29.18052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660761	hybrid			2022-12-27	WOS:000074828500016
J	Pikuleva, IA; Babiker, A; Waterman, MR; Bjorkhem, I				Pikuleva, IA; Babiker, A; Waterman, MR; Bjorkhem, I			Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; RABBIT LIVER-MITOCHONDRIA; SMOOTH-MUSCLE CELLS; STEROL 27-HYDROXYLASE; CEREBROTENDINOUS XANTHOMATOSIS; SIDE-CHAIN; CHENODEOXYCHOLIC ACIDS; 26-HYDROXYCHOLESTEROL; 27-HYDROXYCHOLESTEROL; 26-HYDROXYLATION	The primary physiological significance of cytochrome P450c27 (CYP27) has been associated with its role in the degradation of the side chain of C-27 steroids in the hepatic bile acid biosynthesis pathway, which begins with 7 alpha-hydroxylation of cholesterol in liver. However, recognition that in humans P450c27 is a widely or ubiquitously expressed mitochondrial P450, and that there are alternative pathways of bile acid synthesis which begin with 27-hydroxylation of cholesterol catalyzed by P450c27, suggests the need to reevaluate the role of this enzyme and its catalytic properties. 27-Hydroxycholesterol was thought to be the only product formed upon reaction of P450c27 with cholesterol. However, the present study demonstrates that recombinant human P450c27 is also able to further oxidize 27-hydroxycholesterol giving first an aldehyde and then 3 beta-hydroxy-5-cholestenoic acid. Kinetic data indicate that in a reconstituted system, after 27-hydroxycholesterol is formed from cholesterol, it is released from the P450 and then competes with cholesterol for reentry the enzyme active site for further oxidation, Under subsaturating substrate concentrations, the efficiencies of oxidation of 27-hydroxycholesterol and 3 beta-hydroxy-5-cholestenal to the acid by human P450c27 are greater than the efficiency of hydroxylation of cholesterol to 27-hydroxycholesterol indicating that the first hydroxylation step in the overall conversion of cholesterol into 3 beta-hydroxy-5-cholestenoic acid is rate-limiting. Interestingly, 3 beta-hydroxy-5-cholestenoic acid was found to be further metabolized by the recombinant human P450c27, giving two monohydroxylated products with the hydroxyl group introduced at different positions on the steroid nucleus.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Huddinge Hosp, Karolinska Inst, Dept Clin Chem, S-14188 Huddinge, Sweden	Vanderbilt University; Karolinska Institutet	Pikuleva, IA (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.			Pikuleva, Irina/0000-0001-9742-6232; Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R37GM037942] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM37942] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KE, 1972, J CLIN INVEST, V51, P112, DOI 10.1172/JCI106780; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARINGER L, 1971, STEROIDS, V18, P381, DOI 10.1016/0039-128X(71)90052-3; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1988, J LIPID RES, V29, P629; AXEN E, 1994, P NATL ACAD SCI USA, V91, P10014, DOI 10.1073/pnas.91.21.10014; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; BARANOWSKI A, 1982, ATHEROSCLEROSIS, V41, P255, DOI 10.1016/0021-9150(82)90190-3; BJORKHEM I, 1973, EUR J BIOCHEM, V36, P201, DOI 10.1111/j.1432-1033.1973.tb02902.x; BJORKHEM I, 1992, BIOCHIM BIOPHYS ACTA, V1128, P73, DOI 10.1016/0005-2760(92)90259-X; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; CALI JJ, 1991, J BIOL CHEM, V266, P7774; Crisby M, 1997, BBA-LIPID LIPID MET, V1344, P278, DOI 10.1016/S0005-2760(96)00152-X; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V153, P267, DOI 10.1016/S0006-291X(88)81217-8; Diczfalusy U, 1996, SCAND J CLIN LAB INV, V56, P9; GUSTAFSSON J, 1978, J BIOL CHEM, V253, P199; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HARIKKHAN R, 1990, J STEROID BIOCHEM, V36, P351, DOI 10.1016/0022-4731(90)90228-K; HOLMBERGBETSHOL.I, 1995, J STEROID BIOCHEM, V55, P115; HOLMBERGBETSHOLTZ I, 1993, J BIOL CHEM, V268, P11079; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JAVITT NB, 1990, J LIPID RES, V31, P1527; JAVITT NB, 1982, J LIPID RES, V23, P627; Kimura T, 1978, Methods Enzymol, V52, P132; Lee C, 1996, J LIPID RES, V37, P1356; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; LUND E, 1992, J BIOL CHEM, V267, P25092; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; MARTIN KO, 1993, J LIPID RES, V34, P581; Martin KO, 1997, J LIPID RES, V38, P1053; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OFTEBRO H, 1980, J CLIN INVEST, V65, P1418, DOI 10.1172/JCI109806; PAL S, 1983, J LIPID RES, V24, P1281; PENG SK, 1985, ATHEROSCLEROSIS, V54, P121, DOI 10.1016/0021-9150(85)90172-8; PENG SK, 1978, ARCH PATHOL LAB MED, V102, P57; PETRACK B, 1993, J LIPID RES, V34, P643; Pikuleva IA, 1996, ARCH BIOCHEM BIOPHYS, V334, P183, DOI 10.1006/abbi.1996.0445; PILULEVA IA, 1997, ARCH BIOCHEM BIOPHYS, V343, P123; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; Reiss AB, 1997, J LIPID RES, V38, P1254; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SEGEL IH, 1993, ENZYME KINETICS, P47; Selley ML, 1996, THROMB RES, V83, P449, DOI 10.1016/0049-3848(96)00154-5; SHODA J, 1993, HEPATOLOGY, V17, P395; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; SWELL L, 1980, J LIPID RES, V21, P455; TUCKEY RC, 1993, EUR J BIOCHEM, V217, P209, DOI 10.1111/j.1432-1033.1993.tb18235.x; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; VOET D, 1990, BIOCHEMISTRY-US, P338; WIKVALL K, 1984, J BIOL CHEM, V259, P3800; ZHOU Q, 1993, P SOC EXP BIOL MED, V202, P75	55	87	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18153	18160		10.1074/jbc.273.29.18153	http://dx.doi.org/10.1074/jbc.273.29.18153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660774	hybrid			2022-12-27	WOS:000074828500029
J	Saha, P; Thome, KC; Yamaguchi, R; Hou, ZH; Weremowicz, S; Dutta, A				Saha, P; Thome, KC; Yamaguchi, R; Hou, ZH; Weremowicz, S; Dutta, A			The human homolog of Saccharomyces cerevisiae CDC45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; S-PHASE; BUDDING YEAST; FISSION YEAST; CELL-CYCLE; INITIATION; GENE; COMPLEX; PROTEIN; CLONING	In budding yeast Saccharomyces cerevisiae CDC45 is an essential gene required for initiation of DNA replication. A structurally related protein Tsd2 is necessary for DNA replication in Ustilago maydis. We have identified and cloned the gene for a human protein homologous to the fungal proteins. The human gene CDC45L is 30 kilobases long and contains 15 introns, The 16 exons encode a protein of 566 amino acids. The human protein is 52 and 49.5% similar to CDC45p and Tsd2p, respectively. The level of CDC45L mRNA peaks at G(1)-S transition, but total protein amount remains constant throughout the cell cycle. Consistent with a role of CDC45L protein in the initiation of DNA replication it co-immunoprecipitates from cell extracts with a putative replication initiator protein, human ORC2L, In addition, subcellular fractionation indicates that the association of the protein with the nuclear fraction becomes labile as S phase progresses. The CDC45L gene is located to chromosome 22q11.2 region by cytogenetics and by fluorescence in situ hybridization, This region, known as DiGeorge syndrome critical region, is a minimal area of 2 megabases, which is consistently deleted in DiGeorge syndrome and related disorders. The syndrome is marked by parathyroid hypoplasia, thymic aplasia, or hypoplasia and congenital cardiac abnormalities, CDC45L is the first gene mapped to the DiGeorge syndrome critical region interval whose loss may negatively affect cell proliferation.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Yamaguchi, Ryuji/0000-0002-1706-7063; Saha, Partha/0000-0002-4514-6391	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA060499, R01 CA060499-05, CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Gong WK, 1996, HUM MOL GENET, V5, P789, DOI 10.1093/hmg/5.6.789; HADY C, 1997, GENE AMST, V187, P239; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; MORROW B, 1995, AM J HUM GENET, V56, P1391; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Onel K, 1997, MOL GEN GENET, V253, P463, DOI 10.1007/s004380050344; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sirotkin H, 1997, GENOMICS, V42, P245, DOI 10.1006/geno.1997.4734; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; ZHOU C, 1989, J BIOL CHEM, V264, P9022; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	31	49	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18205	18209		10.1074/jbc.273.29.18205	http://dx.doi.org/10.1074/jbc.273.29.18205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660782	hybrid			2022-12-27	WOS:000074828500037
J	Raats, CJI; Bakker, MAH; Hoch, W; Tamboer, WPM; Groffen, AJA; van den Heuvel, LPWJ; Berden, JHM; van den Born, J				Raats, CJI; Bakker, MAH; Hoch, W; Tamboer, WPM; Groffen, AJA; van den Heuvel, LPWJ; Berden, JHM; van den Born, J			Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DENSITY-LIPOPROTEIN-RECEPTOR; CELL-ADHESION MOLECULES; EPIDERMAL GROWTH-FACTOR; TORPEDO ELECTRIC ORGAN; EXTRACELLULAR-MATRIX; ALPHA-DYSTROGLYCAN; ACETYLCHOLINE-RECEPTORS; NEUROMUSCULAR-JUNCTION; MONOCLONAL-ANTIBODY	We determined the specificity of two hamster monoclonal antibodies and a sheep polyclonal antiserum against heparan sulfate proteoglycan isolated from rat glomerular basement membrane. The antibodies were characterized by enzyme-linked immunosorbent assay on various basement membrane components and immunoprecipitation with heparan sulfate proteoglycan with or without heparitinase pre-treatment. These experiments showed that the antibodies specifically recognize approximately 150-, 105-, and 70-kDa core proteins of rat glomerular basement membrane heparan sulfate proteoglycan. Recently, we showed that agrin is a major heparan sulfate proteoglycan in the glomerular basement membrane (Groffen, A. J. A., Ruegg, M. A., Dijkman, H. B. P. M., Van der Velden, T. J., Buskens, C. A., van den Born, J., Assmann, It. J. M., Monnens, L. A. H., Veerkamp, J. H., and van den Heuvel, L. P. W. J. (1998) J. Histochem. Cytochem. 46, 19-27). Therefore, we tested whether our antibodies recognize agrin. To this end, we evaluated staining of Chinese hamster ovary cells transfected with constructs encoding full-length or the C-terminal half of rat agrin by analysis on a fluorescence-activated cell sorter. Both hamster monoclonals and the sheep antiserum clearly stained cells transfected with the construct encoding full-length agrin, whereas wild type cells and cells transfected with the construct encoding the C-terminal part of agrin were not recognized. A panel of previously characterized monoclonals, directed against C-terminal agrin, clearly stained cells transfected with either of the constructs but not wild type cells. This indicates that both hamster monoclonals and the sheep antiserum recognize epitopes on the N-terminal half of agrin. By immunohistochemistry on rat renal tissue, we compared distribution of N-terminal agrin with that of C-terminal agrin. The monoclonal antibodies against C-terminal agrin stained almost exclusively the glomerular basement membrane, whereas the anti-N-terminal agrin antibodies recognized all renal basement membranes, including tubular basement membranes. Based on these results, we hypothesize that full-length agrin is predominantly expressed in the glomerular basement membrane, whereas in most other renal basement membranes a truncated isoform of agrin is predominantly found that misses (part of) the C terminus, which might be due to alternative splicing and/or posttranslational processing. The possible significance of this finding is discussed.	Univ Nijmegen St Radboud Hosp, Div Nephrol 545, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Entwicklungsbiol, Dept Biochem, D-72076 Tubingen, Germany	Radboud University Nijmegen; Radboud University Nijmegen; Max Planck Society	Raats, CJI (corresponding author), Univ Nijmegen St Radboud Hosp, Div Nephrol 545, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van den Heuvel, Lambertus/AAM-1772-2021; Groffen, A.J.A./C-1118-2009; Berden, J.H.M./H-8009-2014; van den Heuvel, L.P.W.J./H-8044-2014	van den Heuvel, Lambertus/0000-0003-3917-6727; Groffen, A.J.A./0000-0003-0046-4027; van den Heuvel, L.P.W.J./0000-0003-3917-6727				BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; FARQUHAR MG, 1985, NEPHROLOGY, P580; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GODFREY EW, 1988, J CELL BIOL, V106, P1263, DOI 10.1083/jcb.106.4.1263; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Groffen AJ, 1998, J HISTOCHEM CYTOCHEM, V46, P19, DOI 10.1177/002215549804600104; Groffen AJA, 1997, EUR J BIOCHEM, V247, P175, DOI 10.1111/j.1432-1033.1997.00175.x; HAGEN SG, 1993, J BIOL CHEM, V268, P7261; HIRANO Y, 1989, J NEUROSCI, V9, P1555; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hopf C, 1996, J BIOL CHEM, V271, P5231; Hopf C, 1997, EUR J NEUROSCI, V9, P1170, DOI 10.1111/j.1460-9568.1997.tb01471.x; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOONAN DM, 1993, KIDNEY INT, V43, P53, DOI 10.1038/ki.1993.10; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Raats CJI, 1997, J BIOL CHEM, V272, P26734, DOI 10.1074/jbc.272.42.26734; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SHIMOMURA H, 1987, DIABETES, V36, P374, DOI 10.2337/diabetes.36.3.374; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; VANDENBORN J, 1994, J HISTOCHEM CYTOCHEM, V42, P89, DOI 10.1177/42.1.8263327; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; WALLACE BG, 1990, J NEUROSCI, V10, P3576	50	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17832	17838		10.1074/jbc.273.28.17832	http://dx.doi.org/10.1074/jbc.273.28.17832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651386	hybrid, Green Published			2022-12-27	WOS:000074816100079
J	Deb, TB; Wong, L; Salomon, DS; Zhou, GC; Dixon, JE; Gutkind, JS; Thompson, SA; Johnson, GR				Deb, TB; Wong, L; Salomon, DS; Zhou, GC; Dixon, JE; Gutkind, JS; Thompson, SA; Johnson, GR			A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors - A specific role for SHP-2 in MAP, but not c-jun amino-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; INSULIN; SEVENLESS; SHPTP2; CELLS; PHOSPHORYLATION; STIMULATION; EXPRESSION; HEREGULIN	The ErbB family of receptors, which include the epidermal growth factor receptor (EGFR), ErbB2, ErbB3, and ErbB4 mediate the actions of a family of bioactive polypeptides. EGF signals through EGFR, whereas heregulin (HRG) signaling is initiated through binding to either ErbB3 or ErbB4. In this report we studied the role of protein-tyrosine phosphatase SHP-2 in ErbB-mediated activation of mitogen-activated protein kinase (MAPK) by overexpressing SHP-2 mutants in COS-7 cells. We demonstrate that enzymatic activity and both NH2- and COOH-terminal SH2 domains of SHP-2 are required for EGF-induced MAPK activation, but not for c-Jun amino-terminal kinase stimulation or MAPK activation which occurred in response to myristoylated son of sevenless, activated Ras, or phorbol ester. Dominant-negative forms of SHP-2 had no effect on EGF-stimulated interaction of GRB2 with EGFR or SHC, nor did they influence phosphorylation of SHC and SHC/EGFR association. The same mutant SHP-2 structures that inhibited EGF-mediated stimulation of MAPK also blocked HRG alpha/beta-induced MAPK activation. EGF or HRG beta caused SHP-2 SH2 domains to engage multiple phosphotyrosine proteins, and mutation of either domain disrupted these associations. These results demonstrate that SHP-2 performs a common and essential function(s) in ligand-stimulated MAPK activation by the ErbB family of receptors.	US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA; NCI, NIH, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; NIDR, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; Berlex Biosci, Dept Prot Chem & Biophys, Richmond, CA 94804 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Johnson, GR (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bldg 29A,Rm 3B-16,8800 Rockville Pike, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	25	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16643	16646		10.1074/jbc.273.27.16643	http://dx.doi.org/10.1074/jbc.273.27.16643			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642214	hybrid			2022-12-27	WOS:000074545200004
J	Yeung, YG; Wang, Y; Einstein, DB; Lee, PSW; Stanley, ER				Yeung, YG; Wang, Y; Einstein, DB; Lee, PSW; Stanley, ER			Colony-stimulating factor-1 stimulates the formation of multimeric cytosolic complexes of signaling proteins and cytoskeletal components in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR; CELL-LINE; F-ACTIN; PHALLOIDIN BINDING; CSF-1; ACTIVATION; PHOSPHORYLATION; MOUSE	Stimulation of macrophages with colony-stimulating factor-1 (CSF-1) results in the protein tyrosine phosphorylation of the CSF-1 receptor (CSF-1R) and many other, primarily cytosolic, proteins. Stimulation by CSF-1 at 4 degrees C was used to facilitate the purification and identification of the proteins of the cytosolic anti-phosphotyrosine (PY)-reactive fraction (alpha PY-RF) involved in downstream signaling pathways. Confocal microscopy revealed that the PY proteins are in close proximity to the CSF-1R at the plasma membrane. The alpha PY-RF contained pre-existing complexes of PY proteins and non-PY proteins which generally increased in size and PY protein content following CSF-1 stimulation. PY proteins identified by microsequencing and Western blotting include Cbl, STAT3, STAT5a, STAT5b, SHP-1, She, and two novel proteins pp57 and pp37. Other proteins included cytoskeletal/contractile proteins (paxillin, vimentin, elongation factor-1 alpha, F-actin, tropomyosin, and myosin regulatory light chain), Ras family signaling proteins (p85 (phosphoinositide 3-kinase), Vav, Ras-GTPase-activating protein SH3 domain-binding protein, and Grb2), DnaJ-like protein, and glyceraldehyde-3-phosphate dehydrogenase. CSF-1 induced the de novo recruitment of Cbl, STAT3, STAT5a, STAT5b, p85, SHP-1, She, vimentin, and Grb2 to complexes and caused preexisting complexes involving Vav, elongation factor-1 alpha, and F-actin to increase in size. These studies indicate that CSF-l-induced protein tyrosine phosphorylation is associated with the reorganization of complexes of cytoskeletal, signaling, and other proteins that mediate CSF-l-regulated motility and growth.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, ER (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rstanley@aecom.yu.edu	Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NCI NIH HHS [CA 26504] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen WE, 1997, J CELL SCI, V110, P707; Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BOOCOCK CA, 1989, J CELL SCI, V93, P447; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BUSCHER D, 1993, ONCOGENE, V8, P3323; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; Chan AY, 1998, J CELL SCI, V111, P199; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DE LA CRUZ EM, 1994, BIOCHEMISTRY-US, V33, P14387, DOI 10.1021/bi00252a003; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; Edmonds BT, 1996, J CELL SCI, V109, P2705; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; NAITO M, 1991, AM J PATHOL, V139, P657; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Parker F, 1996, MOL CELL BIOL, V16, P2561; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; Pollard JW., 1996, ADV D BIOCH, V4, P153; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; STANLEY ER, 1994, CYTOKINE HDB, P387; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Webb SE, 1996, J CELL SCI, V109, P793; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YEUNG YG, 1987, P NATL ACAD SCI USA, V84, P1268, DOI 10.1073/pnas.84.5.1268; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	60	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17128	17137		10.1074/jbc.273.27.17128	http://dx.doi.org/10.1074/jbc.273.27.17128			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642280	hybrid			2022-12-27	WOS:000074545200070
J	Arakane, F; Kallen, CB; Watari, H; Foster, JA; Sepuri, NBV; Pain, D; Stayrook, SE; Lewis, M; Gerton, GL; Strauss, JF				Arakane, F; Kallen, CB; Watari, H; Foster, JA; Sepuri, NBV; Pain, D; Stayrook, SE; Lewis, M; Gerton, GL; Strauss, JF			The mechanism of action of steroidogenic acute regulatory protein (StAR) - StAR acts on the outside of mitochondria to stimulate steroidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FUNCTIONAL-ACTIVITY; LEYDIG-CELLS; EXPRESSION; PHOSPHORYLATION; PHOSPHOPROTEIN; IDENTIFICATION; BIOSYNTHESIS; GENE	Steroidogenic acute regulatory protein (StAR) plays an essential role in steroidogenesis, facilitating delivery of cholesterol to cytochrome P450(scc) on the inner mitochondrial membrane. StAR is synthesized in the cytoplasm and is subsequently imported by mitochondria and processed to a mature form by cleavage of the NH,terminal mitochondrial targeting sequence. To explore the mechanism of StAR action, we produced 6-histidine-tagged N-62 StAR (His-tag StAR) constructs lacking the NH2-terminal 62 amino acids that encode the mitochondrial targeting sequence and examined their steroidogenic activity in intact cells and on isolated mitochondria, His-tag StAR proteins stimulated pregnenolone synthesis to the same extent as wild-type StAR when expressed in COS-1 cells transfected with the cholesterol side-chain cleavage system. His-tag StAR was diffusely distributed in the cytoplasm of transfected COS-1 cells whereas wild-type StAR was localized to mitochondria, There was no evidence at the light or electron microscope levels for selective localization of His-tag StAR protein to mitochondrial membranes. In vitro import assays demonstrated that wild-type StAR preprotein was imported and processed to mature protein that was protected from subsequent trypsin treatment. In contrast, His-tag StAR was not imported and protein associated with mitochondria was sensitive to trypsin, Using metabolically labeled COS-1 cells transfected with wild-type or His-tag StAR constructs, we confirmed that wild-type StAR preprotein was imported and processed by mitochondria, whereas His-tag StAR remained largely cytosolic and unprocessed To determine whether cytosolic factors are required for StAR action, we developed an assay system using washed mitochondria isolated from bovine corpora lutea and purified recombinant His-tag StAR proteins expressed in Escherichia coli. Recombinant His-tag StAR stimulated pregnenolone production in a dose- and time-dependent manner, functioning at nanomolar concentrations. A point mutant of StAR (A218V) that causes lipoid congenital adrenal hyperplasia was incorporated into the His-tag protein. This mutant was steroidogenically inactive in COS-1 cells and on isolated mitochondria. Our observations conclusively document that StAR acts on the outside of mitochondria, independent of mitochondrial import, and in the absence of cytosol, The ability to produce bioactive recombinant StAR protein paves the way for refined structural studies of StAR and StAR mutants.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Strauss, JF (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, 778 Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	jstrauss@mail.med.upenn.edu	Gerton, George L/A-1039-2007; Sepuri, Naresh/AAF-2704-2020	Gerton, George L/0000-0001-9894-5640; Stayrook, Steven/0000-0002-1677-8293; Kallen, Caleb/0000-0002-4156-6719	NICHD NIH HHS [HD-06274] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; ARAKANE F, 1998, J SOC GYNECOL INVE S, V5, pA50; BELFIORE CJ, 1994, J STEROID BIOCHEM, V51, P283, DOI 10.1016/0960-0760(94)90041-8; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; CARON MK, 1997, P NATL ACAD SCI USA, V94, P11540; CHEN ZJ, 1994, ENDOCRINOLOGY, V134, P2360, DOI 10.1210/en.134.6.2360; Cherradi N, 1997, J BIOL CHEM, V272, P7899, DOI 10.1074/jbc.272.12.7899; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; GRADI A, 1995, BBA-LIPID LIPID MET, V1258, P228, DOI 10.1016/0005-2760(95)00140-8; HARTIGAN JA, 1995, J STEROID BIOCHEM, V53, P95, DOI 10.1016/0960-0760(95)00026-V; JUENGEL JL, 1995, ENDOCRINOLOGY, V136, P5423, DOI 10.1210/en.136.12.5423; King SR, 1996, ENDOCR RES, V22, P505, DOI 10.1080/07435809609043739; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; KOWLURU R, 1995, MOL CELL ENDOCRINOL, V107, P181, DOI 10.1016/0303-7207(94)03441-U; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Nakae J, 1997, HUM MOL GENET, V6, P571, DOI 10.1093/hmg/6.4.571; PAAVOLA LG, 1983, J CELL BIOL, V97, P593, DOI 10.1083/jcb.97.3.593; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAYNE AH, 1995, BIOL REPROD, V52, P217, DOI 10.1095/biolreprod52.2.217; Pollack SE, 1997, J CLIN ENDOCR METAB, V82, P4243, DOI 10.1210/jc.82.12.4243; PON LA, 1986, J BIOL CHEM, V261, P3309; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; STOCCO DM, 1993, J STEROID BIOCHEM, V46, P337, DOI 10.1016/0960-0760(93)90223-J; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295	30	166	168	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16339	16345		10.1074/jbc.273.26.16339	http://dx.doi.org/10.1074/jbc.273.26.16339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632696	hybrid			2022-12-27	WOS:000074436600067
J	Labbe-Jullie, C; Barroso, S; Nicolas-Eteve, D; Reversat, JL; Botto, JM; Mazella, J; Bernassau, JM; Kitabgi, P				Labbe-Jullie, C; Barroso, S; Nicolas-Eteve, D; Reversat, JL; Botto, JM; Mazella, J; Bernassau, JM; Kitabgi, P			Mutagenesis and modeling of the neurotensin receptor NTR1 - Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROKININ-1 RECEPTOR; ANGIOTENSIN-II; SUBSTANCE-P; AMINO-ACID; LIGAND; SITE; PEPTIDE; EXPRESSION; EPITOPES; DOPAMINE	The two neurotensin receptor subtypes known to date, NTR1 and NTR2, belong to the family of G-protein-coupled receptors with seven putative transmembrane domains (TM). SR 48692, a nonpeptide neurotensin antagonist, is selective for the NTR1. In the present study we attempted, through mutagenesis and computer-assisted modeling, to identify residues in the rat NTR1 that are involved in antagonist binding and to provide a tentative molecular model of the SR 48692 binding site. The seven putative TMs of the NTR1 were defined by sequence comparison and alignment of bovine rhodopsin and G-protein-coupled receptors. Thirty-five amino acid residues within or flanking the TMs were mutated to alanine. Additional mutations were performed for basic residues. The wild type and mutant receptors were expressed in COS M6 cells and tested for their ability to bind I-125-NT and [H-3]SR 48692. A tridimensional model of the SR 48692 binding site was constructed using frog rhodopsin as a template. SR 48692 was docked into the receptor, taking into account the mutagenesis data for orienting the antagonist. The model shows that the antagonist binding pocket lies near the extracellular side of the transmembrane helices within the first two helical turns. The data identify one residue in TM 4, three in TM 6, and four in TM 7 that are involved in SR 48692 binding, Two of these residues, Arg(327) in TM 6 and Tyr(351) in TM 7, play a key role in antagonist/receptor interactions. The former appears to form an ionic link with the carboxyIic group of SR 48692, as further supported by structure-activity studies using SR 48692 analogs. The data also show that the agonist and antagonist binding sites in the rNTR1 are different and help formulate hypotheses as to the structural basis for the selectivity of SR 48692 toward the NTR1 and NTR2.	Univ Nice, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Sanofi Rech, Ctr Montpellier, F-34184 Montpellier 04, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis; Sanofi France	Kitabgi, P (corresponding author), Univ Nice, CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	kitabgi@ipmc.cnrs.fr	Mazella, Jean/A-6767-2012	Labbe-Jullie, Catherine/0000-0001-6398-3807				BALDWIN JM, 1997, J MOL BIOL, V213, P899; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BHOGAL N, 1994, J BIOL CHEM, V269, P27269; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BISSETTE G, 1976, NATURE, V262, P607, DOI 10.1038/262607a0; Botto JM, 1997, MOL BRAIN RES, V46, P311, DOI 10.1016/S0169-328X(97)00006-5; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLINESCHMIDT BV, 1982, ANN NY ACAD SCI, V400, P283, DOI 10.1111/j.1749-6632.1982.tb31576.x; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; Cusack B, 1996, J BIOL CHEM, V271, P15054, DOI 10.1074/jbc.271.25.15054; DUBUC I, 1994, BRIT J PHARMACOL, V112, P352, DOI 10.1111/j.1476-5381.1994.tb13077.x; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Gully D, 1995, FUNDAM CLIN PHARM, V9, P513, DOI 10.1111/j.1472-8206.1995.tb00528.x; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; JI H, 1994, J BIOL CHEM, V269, P16533; KITABGI P, 1989, NEUROCHEM INT, V14, P111, DOI 10.1016/0197-0186(89)90110-1; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LAZARUS LH, 1977, J BIOL CHEM, V252, P7180; Mazella J, 1996, J NEUROSCI, V16, P5613; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Pang YP, 1996, J BIOL CHEM, V271, P15060, DOI 10.1074/jbc.271.25.15060; Perlman S, 1997, MOL PHARMACOL, V51, P301, DOI 10.1124/mol.51.2.301; Quere L, 1996, J CHEM SOC PERK T 2, P2639, DOI 10.1039/p29960002639; Rostene W, 1997, ANN NY ACAD SCI, V814, P125, DOI 10.1111/j.1749-6632.1997.tb46151.x; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WATLING KJ, 1993, TRENDS PHARMACOL SCI, V14, P81, DOI 10.1016/0165-6147(93)90067-T; WOODRUFF GN, 1991, ANNU REV PHARMACOL, V31, P469	41	66	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16351	16357		10.1074/jbc.273.26.16351	http://dx.doi.org/10.1074/jbc.273.26.16351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632698	hybrid			2022-12-27	WOS:000074436600069
J	Petosa, C; Masters, SC; Bankston, LA; Pohl, J; Wang, BC; Fu, HI; Liddington, RC				Petosa, C; Masters, SC; Bankston, LA; Pohl, J; Wang, BC; Fu, HI; Liddington, RC			14-3-3 zeta binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; PROTEIN-KINASE; 14-3-3-PROTEINS; ASSOCIATION; PROGRAM; BCR	14-3-3 proteins bind a variety of molecules involved in signal transduction, cell cycle regulation and apoptosis. 14-3-3 binds ligands such as Raf-1 kinase and Bad by recognizing the phosphorylated consensus motif, RSX-pSXP, but must bind unphosphorylated ligands, such as glycoprotein Ib and Pseudomonas aeruginosa exoenzyme S, via a different motif. Here we report the crystal structures of the zeta isoform of 14-3-3 in complex with two peptide ligands: a Raf-derived phosphopeptide (pS-Raf-259, LSQRQRSTpSTPNVHMV) and an unphosphorylated peptide derived from phage display (R18, PH-CVPRDLSWLDLEANMCLP) that inhibits binding of exoenzyme S and Raf-1. The two peptides bind within a conserved amphipathic groove on the surface of 14-3-3 at overlapping but distinct sites. The phosphoserine of pS-Raf-259 engages a cluster of basic residues (Lys(49) Arg(56), Arg(60), and Arf(127)), whereas R18 binds via the amphipathic sequence, WLDLE, with its two acidic groups coordinating the same basic cluster. 14-3-3 is dimeric, and its two peptide-binding grooves are arranged in an antiparallel fashion, 30 Angstrom apart. The ability of each groove to bind different peptide motifs suggests how 14-3-3 can act in signal transduction by inducing either homodimer or heterodimer formation in its target proteins.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Grad Program Mol Therapeut & Toxicol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Cleveland, OH 44109 USA	University of Leicester; Emory University; Emory University; Emory University; Case Western Reserve University; MetroHealth System	Liddington, RC (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.	RCL6@LEICESTER.AC.UK	Wang, Binghe/D-4257-2009	Wang, Binghe/0000-0002-2200-5270; Petosa, Carlo/0000-0002-9975-1167	NIGMS NIH HHS [GM08602, GM53165] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165, R29GM053165, T32GM008602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Craparo A, 1997, J BIOL CHEM, V272, P11663; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	33	274	284	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16305	16310		10.1074/jbc.273.26.16305	http://dx.doi.org/10.1074/jbc.273.26.16305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632691	hybrid			2022-12-27	WOS:000074436600062
J	Weng, QP; Kozlowski, M; Belham, C; Zhang, AH; Comb, MJ; Avruch, J				Weng, QP; Kozlowski, M; Belham, C; Zhang, AH; Comb, MJ; Avruch, J			Regulation of the p70 S6 kinase by phosphorylation in vivo - Analysis using site-specific anti-phosphopeptide antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; RAPAMYCIN; INSULIN; ACTIVATION; P70(S6K); WORTMANNIN; INHIBITION	The p70 S6 kinase is activated by diverse stimuli through a multisite phosphorylation directed at three separate domains as follows: a cluster of (Ser/Thr) Pro sites in an autoinhibitory segment in the noncatalytic carboxyl-terminal tail; Thr-252 in the activation loop of the catalytic domain; and Ser-394 and Thr-412 in a segment immediately carboxyl-terminal to the catalytic domain. Phosphorylation of Thr-252 in vitro by the enzyme phosphatidylinositol 3-phosphate-dependent kinase-1 or mutation of Thr-412 --> Glu has each been shown previously to engender some activation of the p70 S6 kinase, whereas both modifications together produce 20-30-fold more activity than either alone. We employed phospho-specific anti-peptide antibodies to examine the relative phosphorylation at several of these sites in wild type and various p70 mutants, in serum-deprived cells, and in response to activators and inhibitors of p70 S6 kinase activity. Substantial phosphorylation of p70 Thr-252 and Ser-434 was present in serum-deprived cells, whereas Thr-412 and Thr-444/Ser-447 were essentially devoid of phospho-specific immunoreactivity, Activation of p70 by insulin was accompanied by a coordinate increase in phosphorylation at all sites examined, together with a slowing in mobility on SDS-PAGE of a portion of p70 polypeptides. Upon addition of rapamycin or wortmannin to insulin-treated cells, the decrease in activity of p70 was closely correlated with the disappearance of anti-Thr-412(P) immunoreactivity and the most slowly migrating p70 polypeptides, whereas considerable phosphorylation at Ser-434 and Thr-252 persisted after the disappearance of 40 S kinase activity. The central role of Thr-412 phosphorylation in the regulation of kinase activity was further demonstrated by the close correlation of the effects of various deletions and point mutations on p70 activity and Thr-412 phosphorylation. In conclusion, although p70 activity depends on a disinhibition from the carboxyl-terminal tail and the simultaneous phosphorylation at both Thr-252 and Thr-412, p70 activity in vivo is most closely related to the state of phosphorylation at Thr-412.	Massachusetts Gen Hosp, Dept Biol Mol, Diabet Res Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Diabet Res Lab, 50 Blossom St, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu			NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1997, CURR BIOL, V8, P69; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333	24	324	332	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16621	16629		10.1074/jbc.273.26.16621	http://dx.doi.org/10.1074/jbc.273.26.16621			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632736	hybrid			2022-12-27	WOS:000074436600107
J	Humke, EW; Ni, J; Dixit, VM				Humke, EW; Ni, J; Dixit, VM			ERICE, a novel FLICE-activatable caspase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; CELL-DEATH; GRANZYME-B; CYSTEINE PROTEASE; POLY(ADP-RIBOSE) POLYMERASE; PROTEOLYTIC ACTIVATION; ICE/CED-3 PROTEASE; APOPTOTIC ACTIVITY; MOLECULAR-CLONING	Programmed cell death, or apoptosis, is a process of fundamental importance to cellular homeostasis in metazoan organisms (Ellis, R. E., Yuan, J., and Horvitz, H. R. (1991) Annu. Rev. Cell Biol. 7, 663-698). The caspase family of mammalian proteases, related to the nematode death protein CED-3, plays a crucial role in apoptosis and inflammation. We report here the isolation and characterization of a new caspase, tentatively termed ERICE (Evolutionarily Related Interleukin-lp Converting Enzyme). Based on phylogenetic analysis, ERICE (caspase-13) is a member of the ICE subfamily of caspases which includes caspase-1 (ICE), caspase-4 (ICErel-II, TX, ICH-2), and caspase-5 (ICErel-III, TY). Overexpression of ERICE induces apoptosis of 293 human embryonic kidney cells and MCF7 breast carcinoma cells. Like other members of the subfamily, ERICE is not activated by the serine protease granzyme B, a caspase-activating component of cytotoxic T cell granules. Therefore, ERICE most likely does not play a role in granzyme B-induced cell death. ERICE, however, was activated by caspase-8 (FLICE, MACH, Mch-B), the apical caspase activated upon engagement of death receptors belonging to the tumor necrosis factor family. This is consistent with a potential role for ERICE in this receptor-initiated death pathway.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Univ Michigan, Sch Med, Dept Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Human Genome Sci, Rockville, MD 20850 USA	Roche Holding; Genentech; University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Bldg 10,Rm 290,M-S 40, S San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013671] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG13671] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07863-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; Crouch DH, 1996, ONCOGENE, V12, P2689; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ni J, 1997, J BIOL CHEM, V272, P10853; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry N A, 1997, Adv Pharmacol, V41, P155, DOI 10.1016/S1054-3589(08)61058-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN Y, 1995, Patent No. 00160	63	96	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15702	15707		10.1074/jbc.273.25.15702	http://dx.doi.org/10.1074/jbc.273.25.15702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624166	hybrid			2022-12-27	WOS:000074284200060
J	Sharma, KK; Kumar, GS; Murphy, AS; Kester, K				Sharma, KK; Kumar, GS; Murphy, AS; Kester, K			Identification of 1,1 '-bi(4-anilino)naphthalene-5,5 '-disulfonic acid binding sequences in alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; LENS CRYSTALLINS; A-CRYSTALLIN; QUATERNARY STRUCTURE; CROSS-LINKING; ASCORBIC-ACID; B-CRYSTALLIN; TISSUES	The hydrophobic binding sites in alpha-crystallin were evaluated using fluorescent probes 1,1'-bi(4-anilino)naphthalenesulfonic acid (bis-ANS), 8-anilino-1-naphthalene sulfonate; (ANS), and 1-azidonaphthalene 5-sulfonate (1,5-AZNS). The photolysis of bis-ANS-alpha-crystallin complex resulted in incorporation of the probe to both alpha A- and alpha B-subnnits, Prior binding of denatured alcohol dehydrogenase to alpha-crystallin significantly decreased the photoincorporation of bis-ANS to alpha-crystallin. Localization of bis-ANS incorporated into alpha A-cryskallin resulted in the identification of residues QSLFR and HFSPEDLTVK as the fluorophore binding regions, In alpha B-crystallin, sequences DRFSVNLNVK and VLGDVIEVHGK were found to be the Ibis-ANS binding regions, Of the bis-ANS binding sequences, HFSPEDLTVK of alpha-A-crystallin and DRFSVNLNVK and VLGDVIEVHGK of alpha B-crystallin were earlier identified as part of the sequences involved in their interaction with target proteins during the molecular chaperone-like action. The hydrophobic probe, 1,5-AZNS, also interacted with both subunits of alpha-crystallin. Localization of 1,5-AZNS binding site in alpha B-crystallin lead to the identification of HFSPEEK sequence as the interacting site in this subunit of alpha-crystallin, Glycated alpha-crystallin displayed decreased ANS fluorescence and loss of chaperone-like function, suggesting the involvement of glycation site as well as ANS binding site ire chaperone-like activity display.	Univ Missouri, Mason Eye Inst, Dept Ophthalmol, Columbia, MO 65212 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Mason Eye Inst, Dept Ophthalmol, Columbia, MO 65212 USA.		Kumar, Dr Suresh/HHZ-2615-2022; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Gopinatha Suresh/W-1461-2019	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604; 	NATIONAL EYE INSTITUTE [R01EY011981] Funding Source: NIH RePORTER; NEI NIH HHS [EY 11981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; Bloemendal M, 1995, EXP EYE RES, V61, P757, DOI 10.1016/S0014-4835(05)80027-2; Borkman RF, 1996, EXP EYE RES, V62, P141, DOI 10.1006/exer.1996.0018; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; Clark JI, 1996, P NATL ACAD SCI USA, V93, P15185, DOI 10.1073/pnas.93.26.15185; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DOCKTER ME, 1983, BIOCHEMISTRY-US, V22, P3954, DOI 10.1021/bi00285a035; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; MERK KB, 1993, J BIOL CHEM, V268, P1046; ORTWERTH BJ, 1992, BIOCHIM BIOPHYS ACTA, V1117, P207, DOI 10.1016/0304-4165(92)90081-5; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; PRABHAKARAM M, 1992, EXP EYE RES, V55, P451, DOI 10.1016/0014-4835(92)90118-C; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; Sharma KK, 1997, FASEB J, V11, pA908; SHARMA KK, 1995, EXP EYE RES, V61, P413; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STEVENS DJ, 1980, J BIOL CHEM, V255, P379; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; WANG KY, 1994, J BIOL CHEM, V269, P13601	43	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15474	15478		10.1074/jbc.273.25.15474	http://dx.doi.org/10.1074/jbc.273.25.15474			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624133	hybrid			2022-12-27	WOS:000074284200027
J	Belkin, AM; Retta, SF				Belkin, AM; Retta, SF			beta D-1 integrin inhibits cell cycle progression in normal myoblasts and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CYTOPLASMIC DOMAIN; RAS TRANSFORMATION; EXPRESSION; PROTEIN; DIFFERENTIATION; ACTIVATION; SUBUNIT; PROLIFERATION; LOCALIZATION	Integrins are alpha beta heterodimeric transmembrane receptors involved in the regulation of cell growth and differentiation. The beta(1) integrin subunit is widely expressed in vivo and is represented by four alternatively spliced cytoplasmic domain isoforms, beta(1)D is a muscle-specific variant of beta(1) integrin and a predominant beta(1) isoform in striated muscles. In the present study we showed that expression of the exogenous beta(1)D integrin in C2C12 myoblasts and NIH 3T3 or REF 52 fibroblasts inhibited cell proliferation. Unlike the case of the common beta(1)A isoform, adhesion of beta(1)D-transfected C2C12 myoblasts specifically via the expressed integrin did not activate mitogen-activated protein kinases, The beta(1)D-induced growth inhibitory signal was shown to occur late in the G(1) phase of the cell cycle, before the G(1)-S transition. Ha-(12R)Ras, but not (Delta 22W)Raf-1 oncogene, was able to overcome completely the beta(1)D-triggered cell growth arrest in NIH 3T3 fibroblasts, Since perturbation of the beta(1)D amino acid sequence in beta(1)A/beta(1)D chimeric integrins decreased the growth inhibitory signal, the entire cytoplasmic domain of beta(1)D appeared to be important for this function, However, an interleukin-2 receptor-beta(1)D chimera containing the cytoplasmic domain of beta(1)D still efficiently inhibited cell growth, showing that the ectodomain and the ligand-binding site in beta(1)D were not required for the growth inhibitory signal. Together, our data showed a new specific function for the alternatively spliced beta(1)D integrin isoform, Since the onset of beta(1)D expression during myodifferentiation coincides with the timing of myoblast withdrawal from the cell cycle, the growth inhibitory properties of beta(1)D demonstrated in this study might reflect the major function for this integrin in commitment of differentiating skeletal muscle cells in vivo.	Amer Red Cross, Dept Biochem, Rockville, MD 20855 USA; Univ Palermo, Inst Biol, I-90133 Palermo, Italy; Univ Turin, Dept Genet Biol & Med Chem, I-10126 Turin, Italy	American Red Cross; University of Palermo; University of Turin	Belkin, AM (corresponding author), Amer Red Cross, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	belkina@usa.redcross.org	Retta, Saverio Francesco/Q-4770-2019	Retta, Saverio Francesco/0000-0001-9761-2959	NATIONAL CANCER INSTITUTE [R29CA077697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA77697] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BURRIDGE K, 1992, J CELL BIOL, V119, P793; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Clark GJ, 1996, ONCOGENE, V12, P169; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; Lin TH, 1997, J BIOL CHEM, V272, P8849; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	35	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15234	15240		10.1074/jbc.273.24.15234	http://dx.doi.org/10.1074/jbc.273.24.15234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614138	hybrid, Green Published			2022-12-27	WOS:000074160400080
J	Stewart, RJ; Fredenburgh, JC; Weitz, JI				Stewart, RJ; Fredenburgh, JC; Weitz, JI			Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMODUS-ROTUNDUS; ONE-CHAIN; PULMONARY-EMBOLISM; LYS-PLASMINOGEN; INTACT FIBRIN; FINGER DOMAIN; BINDING; THROMBOLYSIS; SITE; CLONING	Vampire bat plasminogen activator (b-PA) causes less fibrinogen (Fg) consumption than tissue-type plasminogen activator (t-PA). Herein, we demonstrate that this occurs because the complex of D-dimer noncovalently linked to fragment E ((DD)E), the most abundant degradation product of cross-linked fibrin, as well as Fg, stimulate plasminogen (Pg) activation by t-PA more than b-PA. To explain these findings, we characterized the interactions of t-PA b-PA Lys-Pg, and Glu-Pg with Pg and (DD)E using right angle Light scattering spectroscopy. In addition, interactions with fibrin were determined by clotting Fg in the presence of various amounts of t-PA, b-PA, Lys-Pg, or Glu-Pg and quantifying unbound material in the supernatant after centrifugation, Glu-Pg and Lys-Pg bind fibrin with K-d values of 13 and 0.13 mu M, respectively. t-PA binds fibrin through two classes of sites with K-d values of 0.05 and 2.6 mu M, respectively, The second kringle (K-2) of t-PA mediates the low affinity binding that is eliminated with epsilon-amino-n-caproic acid. In contrast, b-PA binds fibrin through a single kringle-independent site with a K-d of 0.15 mu M. t-PA competes with b-PA for fibrin binding, indicating that both activators share the same finger-dependent site on fibrin, Glu-Pg binds (DD)E with a K-d of 5.4 mu M. Lys-Pg binds to (DD)E and Fg with K-d values of 0.03 and 0.23 mu M, respectively, t-PA binds to (DD)E and Fg with K-d values of 0.02 and 0.76 mu M, respectively; interactions were eliminated with epsilon-amino-n caproic acid, consistent with K-2-dependent binding. Because it lacks a K-2-domain, b-PA does not bind to either (DD)E or Fg, thereby explaining why b-PA is more fibrin-specific than t-PA.	Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	weitzj@fhs.mcmaster.ca	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				BACHMANN F, 1995, FIBRINOLYSIS, V9, P9, DOI 10.1016/S0268-9499(05)80003-7; BAKKER AHF, 1995, J BIOL CHEM, V270, P12355, DOI 10.1074/jbc.270.21.12355; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERGUM PW, 1992, J BIOL CHEM, V267, P17726; Blanchoin L, 1996, J BIOL CHEM, V271, P12380, DOI 10.1074/jbc.271.21.12380; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; BRINGMANN P, 1995, J BIOL CHEM, V270, P25596, DOI 10.1074/jbc.270.43.25596; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; COLLEN D, 1992, ANN NY ACAD SCI, V667, P259, DOI 10.1111/j.1749-6632.1992.tb51623.x; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GARDELL SJ, 1990, BLOOD, V76, P2560; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GARDELL SJ, 1991, CIRCULATION, V84, P244, DOI 10.1161/01.CIR.84.1.244; GULBA DC, 1995, FIBRINOLYSIS, V9, P91, DOI 10.1016/S0268-9499(08)80020-3; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HIGGINS DL, 1986, ARCH BIOCHEM BIOPHYS, V249, P418, DOI 10.1016/0003-9861(86)90018-4; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; KLEMENT G, 1995, THROMB HAEMOSTASIS, V73, P1339; KRATZSCHMAR J, 1991, GENE, V105, P229, DOI 10.1016/0378-1119(91)90155-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lijnen H. Roger, 1995, P1588; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; LOSCALZO J, 1988, J CLIN INVEST, V82, P1391, DOI 10.1172/JCI113743; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MELLOTT MJ, 1995, THROMB HAEMOSTASIS, V73, P478; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; Schleuning Wolf-Dieter, 1992, V667, P395; STRINGER HAR, 1994, THROMB HAEMOSTASIS, V72, P900; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VAUGHAN DE, 1987, CIRCULATION, V75, P1200, DOI 10.1161/01.CIR.75.6.1200; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; WEITZ JI, 1993, J CLIN INVEST, V91, P1343, DOI 10.1172/JCI116335; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069; WITT W, 1992, BLOOD, V79, P1213	42	37	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18292	18299		10.1074/jbc.273.29.18292	http://dx.doi.org/10.1074/jbc.273.29.18292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660794	hybrid			2022-12-27	WOS:000074828500049
J	Ericsson, J; Edwards, PA				Ericsson, J; Edwards, PA			CBP is required for sterol-regulated and sterol regulatory element-binding protein regulated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; MUTANT HAMSTER-CELLS; NF-Y; COACTIVATOR; PROMOTER; GENES; CREB; CHOLESTEROL	Cells were transfected with luciferase reporter genes, under the control of promoters derived from either the farnesyl diphosphate (FPP) synthase, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, or low density lipoprotein receptor genes. The increase in luciferase activity that occurred when cells were either incubated in sterol-depleted medium or cotransfected with a cDNA encoding sterol regulatory element-binding protein (SREBP)-1a was prevented by coexpression of wild type E1A or a Gal4-CBP (1-451) fusion protein. The inhibitory effect of E1A was overcome by coexpression of CBP. The increase in reporter gene activity noted above was not affected when the cells were cotransfected with cDNAs that encoded either a mutant E1A that is unable to interact with the transcriptional activator CBP or Gal4-CBP fusion proteins encoding separate fragments of CBP, which span the remainder of the CBP molecule, A preformed SREBP-1a:[P-32]DNA complex bound specifically to membrane-immobilized GST-CBP fusion proteins that contained amino terminal portions of CBP, In order to investigate the role of CBP in the regulation of endogenous genes, we isolated stable transformants that express Ga14-CBP(1-451) in response to added doxycycline. Induction of endogenous FPP synthase and HMG-CoA synthase mRNAs, in response to cellular cholesterol depletion, was prevented when cells expressed Ga14-CBP(1-451), We conclude that when cells are incubated in the absence of sterols, the transcriptional activation of the HMG-CoA synthase, HMG-CoA reductase, FPP synthase, and low density lipoprotein receptor genes is dependent on a specific interaction between SREBP, which is bound to the promoter DNA, and the amino terminal domain (amino acids 1-451) of CBP.	Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257, Los Angeles, CA 90095 USA.	pedwards@medicine.medsch.UCLA.edu	Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eckner R, 1996, BIOL CHEM, V377, P685; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guan GM, 1997, J BIOL CHEM, V272, P10295; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jackson SM, 1996, J LIPID RES, V37, P1712; JCKSON SM, 1998, J LIPID RES, V39, P767; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WANG XD, 1993, J BIOL CHEM, V268, P14497; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	34	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17865	17870		10.1074/jbc.273.28.17865	http://dx.doi.org/10.1074/jbc.273.28.17865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651391	hybrid			2022-12-27	WOS:000074816100084
J	Ishikawa, K; Ishida, H; Koyama, Y; Kawarabayasi, Y; Kawahara, J; Matsui, E; Matsui I				Ishikawa, K; Ishida, H; Koyama, Y; Kawarabayasi, Y; Kawahara, J; Matsui, E; Matsui, I			Acylamino acid-releasing enzyme from the thermophilic archaeon Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-PEPTIDE HYDROLASE; RAT-LIVER; ACYLPEPTIDE HYDROLASE; PROLYL OLIGOPEPTIDASE; AMINO-ACIDS; PROTEIN; PURIFICATION; SEQUENCE; RESIDUE; FAMILY	When the genome of the thermophilic archaeon Pyrococcus horikoshii was sequenced, a gene homologous to the mammalian gene for an acylamino acid-releasing enzyme (EC 3.4.19.1) was found in which the enzyme's proposed active residues were conserved. The P. horikoshii gene comprised an open reading frame of 1,896 base pairs with an ATG initiation codon and a TAG termination codon, encoding a 72,390-Da protein of 632 amino acid residues. This gene was overexpressed in Escherichia coli with the pET vector system, and the resulting enzyme showed the anticipated amino-terminal sequence and high hydrolytic activity for acylpeptides. This enzyme was concluded to be the first acylamino acid-releasing enzyme from an organism other than a eukaryotic cell. The existence of the enzyme in archaea suggests that the mechanisms of protein degradation or initiation of protein synthesis or both in archaea may be similar to those in eukaryotes. The enzyme was stable at 90 degrees C, with its Optimum temperature over 90 degrees C. The specific activity of the enzyme increased 7-14-fold with heat treatment, suggesting the modification of the enzyme's structure for optimal hydrolytic activity by heating. This enzyme is expected to be useful for the removal of N(alpha)-acylated residues in short peptide sequence analysis at high temperatures.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Natl Inst Mat & Chem Res, Tsukuba, Ibaraki 305, Japan; Natl Inst Technol & Evaluat, Tokyo 151, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Ishikawa, K (corresponding author), Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.	ishikawa@nibh.go.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BOYEN A, 1996, THERMOPHILES 1996, P178; BROWN JL, 1976, J BIOL CHEM, V251, P1009; DOI E, 1981, ANAL BIOCHEM, V118, P173, DOI 10.1016/0003-2697(81)90175-5; GADE W, 1978, J BIOL CHEM, V253, P5012; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; ISHIKAWA K, 1997, NATURE BIOTECH SHORT, V8, P63; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; KAMATA T, 1973, J COLLOID INTERF SCI, V43, P89, DOI 10.1016/0021-9797(73)90351-2; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; LIEW CC, 1970, NATURE, V226, P414, DOI 10.1038/226414a0; MARKS N, 1983, J NEUROCHEM, V41, P201, DOI 10.1111/j.1471-4159.1983.tb13670.x; MATSUI E, 1997, NATURE BIOTECH SHORT, V8, P65; MITA M, 1989, J BIOCH, V106, P548; MIYAGI M, 1995, J BIOCHEM-TOKYO, V118, P771, DOI 10.1093/oxfordjournals.jbchem.a124979; NARITA K, 1969, BIOCHEM BIOPH RES CO, V37, P327, DOI 10.1016/0006-291X(69)90738-4; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PIKE ER, 1975, J CHEM PHYS, V62, P3188, DOI 10.1063/1.430867; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P1354; SWINBANKS D, 1995, NATURE, V374, P583; TSUNASAWA S, 1984, METHOD ENZYMOL, V106, P165; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; TSUNASAWA S, 1983, J BIOCHEM-TOKYO, V93, P1217, DOI 10.1093/oxfordjournals.jbchem.a134248; YOSHIDA A, 1970, P NATL ACAD SCI USA, V67, P1600, DOI 10.1073/pnas.67.3.1600	33	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17726	17731		10.1074/jbc.273.28.17726	http://dx.doi.org/10.1074/jbc.273.28.17726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651372	hybrid			2022-12-27	WOS:000074816100065
J	Roth, M; Helm-Kruse, S; Friedrich, T; Jeltsch, A				Roth, M; Helm-Kruse, S; Friedrich, T; Jeltsch, A			Functional roles of conserved amino acid residues in DNA methyltransferases investigated by site-directed mutagenesis of the EcoRV adenine-N-6-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODIFICATION METHYLASE; SEQUENCE MOTIFS; HHAI METHYLTRANSFERASE; RECOGNITION SEQUENCE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; COFACTOR ANALOGS; NUCLEIC-ACID; BINDING; ADENINE	All DNA methyltransferases (MTases) have similar catalytic domains containing nine blocks of conserved amino acid residues. We have investigated by site directed mutagenesis the function of 17 conserved residues in the EcoRV alpha-adenine-N(6-)DNA methyltransferase, The structure of this class of MTases has been predicted recently. The variants were characterized with respect to their catalytic activities and their abilities to bind to DNA and the S-adenosylmethionine (AdoMet) cofactor. Amino acids located in motifs X, I, and II are shown to be involved in AdoMet binding (Lys(16), Glu(37), Phe(39), and Asp(58)). Some of the mutants defective in AdoMet binding are also impaired in DNA binding, suggesting allosteric interactions between the AdoMet and DNA binding site. Asp(78) (motif III), which was supposed to form a hydrogen bond to the AdoMet on the basis of the structure predictions, turned out not to be important for AdoMet binding, suggesting that motif III has not been identified correctly. R128A and N130A having mutations in the putative DNA binding domain, are unable to bind to DNA, Residues located in motifs TV, V, VI, and VIII are involved in catalysis (Asp(193), Tyr(196), Asp(211), Ser(229), Trp(231), and Tyr(258)), some of them presumably in binding the flipped target base, because mutations at these residues fail to significantly interfere with DNA and AdoMet binding but strongly reduce catalysis. Our results are in substantial agreement with the structure prediction for EcoRV alpha-adenine-N-6-methyltransferase and x-ray structures of other MTases.	Justus Liebig Univ, Fachbereich Biol, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen	Jeltsch, A (corresponding author), Justus Liebig Univ, Fachbereich Biol, Inst Biochem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.		Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290				ADAMS RLP, 1995, BIOESSAYS, V17, P139, DOI 10.1002/bies.950170209; Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Ahmad I, 1996, J MOL BIOL, V259, P229, DOI 10.1006/jmbi.1996.0315; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; Bokar JA, 1997, RNA, V3, P1233; Cal S, 1997, J BIOL CHEM, V272, P490; Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P3167, DOI 10.1093/nar/20.12.3167; Friedrich T, 1998, BIOL CHEM, V379, P475, DOI 10.1515/bchm.1998.379.4-5.475; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; GUYOT JB, 1993, NUCLEIC ACIDS RES, V21, P3183, DOI 10.1093/nar/21.14.3183; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; Hornby D P, 1993, Methods Mol Biol, V16, P201, DOI 10.1385/0-89603-234-5:201; Hough RF, 1997, RNA, V3, P356; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Jeltsch A, 1996, PROTEIN ENG, V9, P413, DOI 10.1093/protein/9.5.413; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; Kong HM, 1997, NUCLEIC ACIDS RES, V25, P3687, DOI 10.1093/nar/25.18.3687; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NOYERWEIDNER M, 1993, DNA METHYLATION MOL, P40; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; OGara M, 1996, J MOL BIOL, V263, P597, DOI 10.1006/jmbi.1996.0601; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; REICH NO, 1990, J BIOL CHEM, V265, P8966; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10734, DOI 10.1021/bi00034a005; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WILLCOCK DF, 1994, EMBO J, V13, P3902, DOI 10.1002/j.1460-2075.1994.tb06701.x; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; WU JC, 1987, J BIOL CHEM, V262, P4778; Yoder JA, 1996, BIOL CHEM, V377, P605	45	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17333	17342		10.1074/jbc.273.28.17333	http://dx.doi.org/10.1074/jbc.273.28.17333			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651316	hybrid			2022-12-27	WOS:000074816100009
J	Suy, S; Mitchell, JB; Ehleiter, D; Haimovitz-Friedman, A; Kasid, U				Suy, S; Mitchell, JB; Ehleiter, D; Haimovitz-Friedman, A; Kasid, U			Nitroxides tempol and tempo induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FLOW CYTOMETRIC DETECTION; TUMOR-NECROSIS-FACTOR; C-JUN; MAP KINASE; PHOSPHATIDYLSERINE EXPRESSION; SPHINGOMYELIN PATHWAY; INDUCED APOPTOSIS; TERMINAL KINASES; OXIDATIVE DAMAGE	Tempol and tempo are stable free radical nitroxides that possess antioxidant properties. In this study, we examined the effects of these compounds on components of the mitogen-activated protein kinase signal transduction cascade. Tempo treatment (15 min), of MDA-MB 231 human breast cancer cells resulted in significant levels of tyrosine phosphorylation of several as yet unidentified proteins compared with equimolar concentration of tempol (10 mM). Both compounds caused tyrosine phosphorylation and activation of Raf-l protein kinase (30 min, 2-3-fold). Interestingly, however, only tempol caused increased extracellular signal-regulated kinase 1 activity (2 h, similar to 3-fold). On the other hand, tempo, but not tempol, potently activated stress-activated protein kinase (2 h, >3-fold). Consistent with these data, tempol was found to be noncytotoxic, whereas tempo induced apoptotic cell death (2 h, >50%). Tempo treatment also resulted in significant elevation of ceramide levels at 30 min (54% over control) and 1 h (71% over control) posttreatment, preceding stress-activated protein kinase activation and apoptosis. These data suggest that in the absence of an environmental oxidative stress, tempol and tempo elicit distinct cellular signaling pathways. The recognition of the molecular mechanisms of nitroxide action may have important implications for biological effectiveness of these compounds.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; NCI, Div Radiat Biol, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med, E208,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA58984, CA74175, CA68322/OD68322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058984, P01CA074175, R55CA068322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BENNETT HF, 1987, MAGNET RESON MED, V4, P93, DOI 10.1002/mrm.1910040202; BENNETT HF, 1987, INVEST RADIOL, V22, P502, DOI 10.1097/00004424-198706000-00011; BERLINER LJ, 1979, SPIN LABELLING, V2; BERLINGER LJ, 1976, SPIN LABELING THEORY; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; DEGRAFF WG, 1992, FREE RADICAL BIO MED, V13, P479, DOI 10.1016/0891-5849(92)90142-4; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; FADOK VA, 1992, J IMMUNOL, V148, P2207; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; GOFFMAN T, 1992, INT J RADIAT ONCOL, V22, P803, DOI 10.1016/0360-3016(92)90528-P; HAHN SM, 1995, CAN J PHYSIOL PHARM, V73, P399, DOI 10.1139/y95-051; HAHN SM, 1992, RADIAT RES, V132, P87, DOI 10.2307/3578338; HAHN SM, 1992, CANCER RES, V52, P1750; HAHN SM, 1994, CANCER RES, V54, pS2006; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HEO DS, 1989, CANCER RES, V49, P5167; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KADIS U, 1996, NATURE, V382, P813; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kocherginsky N., 1995, NITROXIDE SPIN LABEL, P15; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; MYERS ML, 1985, CIRCULATION, V72, P915, DOI 10.1161/01.CIR.72.4.915; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; QUINTANILHA AT, 1977, P NATL ACAD SCI USA, V74, P570, DOI 10.1073/pnas.74.2.570; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; SAMUNI A, 1990, ADV EXP MED BIOL, V264, P85; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; STRZALKA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P312, DOI 10.1016/0003-9861(90)90449-9; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WU J, 1994, INSULIN ACTION EFFEC, P151; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	80	49	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17871	17878		10.1074/jbc.273.28.17871	http://dx.doi.org/10.1074/jbc.273.28.17871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651392	hybrid			2022-12-27	WOS:000074816100085
J	Crookes, WJ; Olsen, LJ				Crookes, WJ; Olsen, LJ			The effects of chaperones and the influence of protein assembly on peroxisomal protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TARGETING SIGNAL; IN-VIVO; 3-KETOACYL-COA THIOLASE; MOLECULAR CHAPERONES; PLANT PEROXISOMES; CARBOXY TERMINUS; ISOCITRATE LYASE; BIOGENESIS; RECEPTOR	Peroxisomal proteins are synthesized in the cytoplasm and post-translationally translocated into the organelle. The role of chaperones and protein folding in peroxisomal protein transport is still unclear. Translocation of proteins into mitochondria requires that precursor proteins assume an extended conformation; cytosolic chaperones are thought to help maintain this conformation. In contrast, peroxisomal protein import does not require unfolding of the targeted protein. However, the molecular chaperones Hsp70 and Hsp40 may be important for translocation. We present several lines of evidence that show that plant peroxisomal protein import is enhanced by chaperones. First, peroxisomes isolated from heat-shocked pumpkin seedling tissues exhibited increased protein import relative to control peroxisomes. Second, antibodies raised against wheat germ cytosolic Hsp70 and Escherichia coli Hsp40 inhibited import of the peroxisomal protein isocitrate lyase. To our knowledge, this is the first time that Hsp90 has been directly implicated in a protein transport event. Third, peroxisomal proteins were immunoprecipitated by wheat germ Hsp70 antibodies. We also present results that suggest that the efficiency of peroxisomal protein import is influenced by the structure of the targeted protein; monomeric isocitrate lyase was imported more efficiently than oligomeric isocitrate lyase. Taken together, these data demonstrate that the assembly state of peroxisomal proteins and the chaperones that may mediate those states are both important for efficient peroxisomal protein import.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Olsen, LJ (corresponding author), Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA.			Goodson, Wendy/0000-0001-5147-9291				ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; BEHARI R, 1993, J BIOL CHEM, V268, P7315; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; Brickner DG, 1997, PLANT PHYSIOL, V113, P1213, DOI 10.1104/pp.113.4.1213; Brickner DG, 1998, PLANT PHYSIOL, V116, P309, DOI 10.1104/pp.116.1.309; Corpas FJ, 1997, EUR J CELL BIOL, V73, P49; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; ETTINGER WF, 1990, ARCH BIOCHEM BIOPHYS, V281, P139, DOI 10.1016/0003-9861(90)90423-V; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Freedman Robert B., 1992, P455; Gietl C, 1996, PHYSIOL PLANTARUM, V97, P599, DOI 10.1111/j.1399-3054.1996.tb00521.x; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; Goodfriend Joyce D., 1992, MEMBRANE BIOGENESIS, P221; GOODMAN JM, 1984, J BIOL CHEM, V259, P8485; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAUCKE V, 1997, TRENDS CELL BIOL, V7, P13; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KINDL H, 1992, CELL BIOCHEM FUNCT, V10, P153, DOI 10.1002/cbf.290100304; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1973, J CELL BIOL, V59, P507, DOI 10.1083/jcb.59.2.507; Lee MS, 1997, PLANT CELL, V9, P185, DOI 10.1105/tpc.9.2.185; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Miernyk JA, 1997, TRENDS PLANT SCI, V2, P180; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; OLSEN LJ, 1993, PLANT CELL, V5, P941, DOI 10.1105/tpc.5.8.941; OLSEN LJ, 1995, ANNU REV PLANT PHYS, V46, P123, DOI 10.1146/annurev.pp.46.060195.001011; OLSEN LJ, 1998, IN PRESS PLANT MOL B, V377; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PREISIGMULLER R, 1994, EUR J BIOCHEM, V219, P57, DOI 10.1111/j.1432-1033.1994.tb19914.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Subramani S, 1996, CURR OPIN CELL BIOL, V8, P513, DOI 10.1016/S0955-0674(96)80029-9; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; WALTON PA, 1994, J CELL BIOL, V125, P1037, DOI 10.1083/jcb.125.5.1037; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Wimmer B, 1997, P NATL ACAD SCI USA, V94, P13624, DOI 10.1073/pnas.94.25.13624; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	55	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17236	17242		10.1074/jbc.273.27.17236	http://dx.doi.org/10.1074/jbc.273.27.17236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642294	hybrid			2022-12-27	WOS:000074545200084
J	Hrycyna, CA; Ramachandra, M; Ambudkar, SV; Ko, YH; Pedersen, PL; Pastan, I; Gottesman, MM				Hrycyna, CA; Ramachandra, M; Ambudkar, SV; Ko, YH; Pedersen, PL; Pastan, I; Gottesman, MM			Mechanism of action of human P-glycoprotein ATPase activity - Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITES; MULTIDRUG TRANSPORTER; VANADATE; MYOSIN; RESISTANCE; PHOTOCLEAVAGE; ANTIBODIES; PROTEINS; CELLS; MUTANTS	Human P-glycoprotein (P-gp), an ATP-dependent efflux pump responsible for cross-resistance of human cancers to a variety of lipophilic compounds, is composed of two homologous halves, each containing six transmembrane domains and an ATP-binding/utilization domain. To determine whether each site can hydrolyze ATP simultaneously, we used an orthovanadate (Vi)-induced ADP-trapping technique (P-gp.MgADP.Vi). In analogy with other ATPases, a photochemical peptide bond cleavage reaction occurs within the Walker A nucleotide binding domain consensus sequence (GX(4)GK(T/S)) when the molecule is trapped with Vi in an inhibited catalytic transition state (P-gp.MgADP.Vi) and incubated in the presence of ultraviolet light. Upon reconstitution into proteoliposomes, histidine-tagged purified P-gp from baculovirus-infected insect cells had drug-stimulated ATPase activity. Reconstituted P-gp was incubated with either ATP or 8-azido-ATP in the presence or absence of Vi under ultraviolet (365 nm) light on ice for 60 min. The resultant products were separated by SDS-polyacrylamide gel electrophoresis and subjected to immunoblotting with seven different human P-gp-specific antibodies covering the entire length of the molecule. Little to no degradation of P-gp was observed in the absence of Vi. In the presence of Vi, products of approximately 28, 47, 94, and 110 kDa were obtained, consistent with predicted molecular weights from cleavage at either of the ATP sites but not both sites, An additional Vi-dependent cleavage site was detected at or near the trypsin site in the linker region of P-gp. These results suggest that both the amino-and carboxyl-terminal ATP sites can hydrolyze ATP. However, there is no evidence that ATE can be hydrolyzed simultaneously by both sites.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Gottesman, MM (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1A-09,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	mgottesman@nih.gov	Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Ramachandra, Murali/0000-0003-4039-1491				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1991, BIOTECHNIQUES, V10, P202; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1992, BIOCHEMISTRY-US, V31, P491, DOI 10.1021/bi00117a027; CREMO CR, 1991, METHOD ENZYMOL, V196, P442; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GIBBONS IR, 1991, METHOD ENZYMOL, V196, P428; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Muller M, 1996, J BIOL CHEM, V271, P1877; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	28	108	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16631	16634		10.1074/jbc.273.27.16631	http://dx.doi.org/10.1074/jbc.273.27.16631			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642211	hybrid			2022-12-27	WOS:000074545200001
J	Rawal, N; Pangburn, MK				Rawal, N; Pangburn, MK			C5 convertase of the alternative pathway of complement - Kinetic analysis of the free and surface-bound forms of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C3-C5 CONVERTASE; 3RD COMPONENT; FLUID PHASE; CLASSICAL PATHWAY; SERINE PROTEASES; HUMAN C3; ACTIVATION; SYSTEM; BINDING; C4B	Although proteolytic activation of the complement protein C5 initiates important defensive and occasionally pathological inflammatory reactions, the enzymatic properties of the enzymes responsible for this cleavage have never been examined. We have studied the kinetic parameters of the C5 convertase of the alternative pathway of complement, either bound to a zymosan surface or in its monomeric soluble form. C5 convertase enzymatic activity was measured as a function of C5 concentration by quantitating production of C5b,6 under physiological conditions of temperature, pH, and ionic strength. The C5 convertases appeared to follow Michaelis-Menten kinetics and exhibited similar catalytic rate constants (k(cat)). However, the surface-bound enzyme, ZymC3b,Bb had a K-m (1.4 mu M) that was 17 times lower than that of the soluble monomeric form of the enzyme, C3b,Bb (K-m = 24 mu M). The k(cat) for the cell-bound enzyme, ZymC3b,Bb was 0.0048 s(-1) and that for soluble C3b,Bb was 0.0110 s(-1). Both forms of the enzyme had a low turnover number at V-max (0.23 to 0.68 C5/min/enzyme). Substituting Mg2+ for Ni2+ did not alter the kinetic parameters but lowered the half-life of the enzyme by 5-7-fold. The kinetic data presented demonstrate that the fluid phase C5 convertase, C3b,Bb, can cleave C5 without the aid of a second C3b molecule. The results also show that the greater enzymatic activity previously observed for the surface-bound C5 convertases is not due to higher catalytic efficiency but is solely due to higher affinity for the substrate C5. In blood, C5 concentrations are 3-4-fold below the K-m determined for the surface-bound C5 convertase suggesting a direct correlation between the local C5 concentration and production of the anaphylatoxin C5a and the cytolytic C5b-9 complex.	Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Pangburn, MK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA.				NIDDK NIH HHS [DK-35081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BHAKDI S, 1988, J IMMUNOL, V141, P3117; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278; DAHA MR, 1976, J IMMUNOL, V117, P630; DALMASSO AP, 1998, COMPLEMENT SYSTEM, P471; DESSAUER A, 1984, ACTA PATH MICRO IM C, V92, P75; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1983, J BIOL CHEM, V258, P629; DISCIPIO RG, 1981, BIOCHEM J, V199, P497, DOI 10.1042/bj1990497; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; GLOVER GI, 1988, MOL IMMUNOL, V25, P1261, DOI 10.1016/0161-5890(88)90040-5; GOTZE O, 1974, J EXP MED, V139, P44, DOI 10.1084/jem.139.1.44; GOTZE O, 1971, J EXP MED          2, V134, P90; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HETLAND G, 1986, SCAND J IMMUNOL, V24, P603, DOI 10.1111/j.1365-3083.1986.tb02176.x; Higgins PJ, 1997, J IMMUNOL, V158, P2872; HOMEISTER JW, 1994, ANNU REV PHARMACOL, V34, P17, DOI 10.1146/annurev.pa.34.040194.000313; HONG KS, 1991, J IMMUNOL, V146, P1868; ISENMAN DE, 1980, J IMMUNOL, V124, P326; ISSEKUTZ AC, 1990, INT J IMMUNOPHARMACO, V12, P1, DOI 10.1016/0192-0561(90)90062-R; KAM CM, 1992, J IMMUNOL, V149, P163; KIM YU, 1992, J BIOL CHEM, V267, P4171; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KITAMURA H, 1986, IMMUNOLOGY, V58, P459; KOZONO H, 1990, J BIOL CHEM, V265, P14444; LESAVRE PH, 1979, J IMMUNOL, V123, P529; MASAKI T, 1991, J IMMUNOL, V147, P927; MATIS LA, 1995, NAT MED, V1, P839, DOI 10.1038/nm0895-839; MEDICUS RG, 1976, P NATL ACAD SCI USA, V73, P612, DOI 10.1073/pnas.73.2.612; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; MOORE FD, 1994, ADV IMMUNOL, V56, P267, DOI 10.1016/S0065-2776(08)60454-X; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; ROTHER K, 1998, COMPLEMENT SYSTEM, P462; ROTHMAN BL, 1994, IMMUNOPHARM IMMUNOT, V16, P525, DOI 10.3109/08923979409019738; SAHU A, 1994, BIOCHEM J, V302, P429, DOI 10.1042/bj3020429; Sahu A, 1996, J IMMUNOL, V157, P884; Sahu A, 1996, BIOCHEM PHARMACOL, V51, P797, DOI 10.1016/0006-2952(95)02398-4; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; VANDENBERG CW, 1990, J IMMUNOL METHODS, V133, P199, DOI 10.1016/0022-1759(90)90360-8; VOGEL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7707, DOI 10.1073/pnas.78.12.7707; VOGT W, 1978, IMMUNOLOGY, V34, P29; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562	48	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16828	16835		10.1074/jbc.273.27.16828	http://dx.doi.org/10.1074/jbc.273.27.16828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642242	hybrid			2022-12-27	WOS:000074545200032
J	Wang, WY; Gorrell, A; Hou, ZL; Honzatko, RB; Fromm, HJ				Wang, WY; Gorrell, A; Hou, ZL; Honzatko, RB; Fromm, HJ			Ambiguities in mapping the active site of a conformationally dynamic enzyme by directed mutation - Role of dynamics in structure-function correlations in Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURES; MOLECULAR-CLONING; SEQUENCE; BINDING; PURA; GENE	On the basis of ligated crystal structures, Asn(21), Asn(38), Thr(42), and Arg(419) are not involved in the chemical mechanism of adenylosuccinate synthetase from Escherichia coli, yet these residues are well conserved across species. Purified mutants (Asp(21) --> Ala, Asn(38) --> Ala, Asn(38) --> Asp, Asn(38) --> Glu, Thr(42) --> Ala, and Arg(419) --> Leu) were studied by kinetics, circular dichroism spectroscopy, and equilibrium ultracentrifugation. Asp(21) and Ar-419 are not part of the active site, yet mutations at positions 21 and 419 lower k(cat) 20- and 10-fold, respectively. Thr(42) interacts only through its backbone amide with the guanine nucleotide, yet its mutation to alanine significantly increases K-m for all substrates. Asn(38) hydrogen-bonds directly to the 5'-phosphoryl group of IMP, yet its mutation to alanine and glutamate has no effect on K-m values, but reduces k(cat) by 100-fold. The mutation Asn(38) --> Asp causes 10-57-fold increases in K-m for all substrates along with a 30-fold decrease in k(cat). At pH 5.6, however, the Asn(38) --> Asp mutant is more active, yet binds IMP 100-fold more weakly, than the wild-type enzyme. Proposed mechanisms of ligand-induced conformational change and subunit aggregation can account for the properties of mutant enzymes reported here. The results underscore the difficulty of using directed mutations alone as a means of mapping the active site of an enzyme.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.	hjfromm@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P355; Bouyoub A, 1996, J MOL BIOL, V261, P144, DOI 10.1006/jmbi.1996.0448; Boyer, 1970, ENZYMES, P341, DOI DOI 10.1016/S1874-6047(08)60170-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; Kang C, 1996, J BIOL CHEM, V271, P29722, DOI 10.1074/jbc.271.47.29722; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MCRORIE DD, 1993, SELFASSOCIATING SYST, P8; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1997, J BIOL CHEM, V272, P15200, DOI 10.1074/jbc.272.24.15200; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHABES AV, 1993, J BIOL CHEM, V268, P20191; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; Wang WY, 1997, J BIOL CHEM, V272, P7078, DOI 10.1074/jbc.272.11.7078; Wang WY, 1997, J BIOL CHEM, V272, P16911, DOI 10.1074/jbc.272.27.16911; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	29	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16000	16004		10.1074/jbc.273.26.16000	http://dx.doi.org/10.1074/jbc.273.26.16000			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632649	hybrid			2022-12-27	WOS:000074436600020
J	Duncan, JA; Gilman, AG				Duncan, JA; Gilman, AG			A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; NITRIC-OXIDE SYNTHASE; MOLECULAR-CLONING; PLASMA-MEMBRANE; COENZYME-A; H-RAS; PALMITOYLATION; ACTIVATION; RECEPTOR; PURIFICATION	Thioacylation is one of a handful of reversible covalent protein modifications, but the enzymes responsible for addition and removal of long chain fatty acids from protein cysteine residues in vivo have not yet been identified. The alpha subunits of some heterotrimeric G proteins cycle between thioacylated and deacylated states in a receptor-regulated fashion. We have identified, purified, and characterized an enzyme acyl-protein thioesterase that deacylates G alpha proteins and at least some other thioacyl protein substrates, including Ha-RAS. The action of this enzyme oil thioacylated heterotrimeric G(s) is regulated by activation of the G protein. Although native and recombinant acyl-protein thioesterases act as both acyl-protein thioesterases and lysophospholipases in vitro, we demonstrate by transfection that the enzyme can accelerate the turnover of thioacyl groups on G(s)alpha in vivo.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Duncan, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497, GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HRYCYNA CA, 1993, PHARMACOL THERAPEUT, V59, P281, DOI 10.1016/0163-7258(93)90071-K; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Laposata M, 1996, LIPIDS, V31, pS217, DOI 10.1007/BF02637079; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE KS, 1994, J BIOL CHEM, V269, P19725; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Loudon RP, 1997, J BIOL CHEM, V272, P27422, DOI 10.1074/jbc.272.43.27422; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOLLNER S, 1995, FEBS LETT, V371, P241, DOI 10.1016/0014-5793(95)00864-6; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PATTERSON SI, 1995, METHOD ENZYMOL, V250, P284; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schriner JE, 1996, GENOMICS, V34, P317, DOI 10.1006/geno.1996.0292; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	45	300	305	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15830	15837		10.1074/jbc.273.25.15830	http://dx.doi.org/10.1074/jbc.273.25.15830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624183	hybrid			2022-12-27	WOS:000074284200077
J	Hunziker, W; Peters, PJ				Hunziker, W; Peters, PJ			Rab17 localizes to recycling endosomes and regulates receptor-mediated transcytosis in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; BASOLATERAL ENDOCYTIC PATHWAYS; POLARIZED CACO-2 CELLS; MDCK CELLS; PLASMA-MEMBRANE; APICAL ENDOSOME; G-PROTEIN; WILD-TYPE; TRANSPORT	The small GTPase Rab17 is restricted to epithelial cells and its expression is induced during cell polarization. This observation has led to the suggestion that the protein may function in transcytosis, a pathway connecting the apical and basolateral endocytic systems. To analyze whether Rab17 plays a Pole in transcellular transport, we generated Madin-Darby canine kidney (MDCK) cell lines stably coexpressing wild-type or mutant Rab17 and the transcytotic polymeric immunoglobulin receptor (pIgR), Rab17 expressed in MDCK cells was found on small vesicles and tubules in the apical region of the cells. A significant fraction of the Rab17-positive structures was accessible to dimeric IgA internalized from the apical or basolateral cell surface via the pIgR. Furthermore, basolateral to apical transcytosis of dimeric IgA was impaired in MDCK cells overexpressing Rab17. Our data provides morphological and biochemical evidence for a role of Rab17 in the regulation of transcellular traffic through apical recycling endosomes in epithelial cells.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	University of Lausanne; Utrecht University	Hunziker, W (corresponding author), Univ Lausanne, Inst Biochem, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Walter.Hunziker@ib.unil.ch	Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; 				APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; DEHOOP M, 1995, J CELL BIOL, V130, P1447, DOI 10.1083/jcb.130.6.1447; EOLZ RW, 1994, J BIOL CHEM, V269, P10229; FUJITA M, 1990, J CELL SCI, V97, P385; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1998, J MAMMARY GLAND BIOL, V3, P287, DOI 10.1023/A:1018715511178; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	42	79	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15734	15741		10.1074/jbc.273.25.15734	http://dx.doi.org/10.1074/jbc.273.25.15734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624171	hybrid			2022-12-27	WOS:000074284200065
J	Kometiani, P; Li, J; Gnudi, L; Kahn, BB; Askari, A; Xie, ZJ				Kometiani, P; Li, J; Gnudi, L; Kahn, BB; Askari, A; Xie, ZJ			Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes - The roles of Ras and mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL HYPERTROPHY; ANGIOTENSIN-II; VENTRICULAR MYOCYTES; DEPENDENT PATHWAYS; TYROSINE KINASE; IN-VITRO; POTENTIAL ROLE; S6 KINASE; EXPRESSION; CASCADE	We showed before that in neonatal rat cardiac myocytes partial inhibition of Na+/K+-ATPase by nontoxic concentrations of ouabain causes hypertrophic growth and transcriptional regulations of genes that are markers of cardiac hypertrophy, In view of the suggested roles of Ras and p42/44 mitogen-activated protein kinases (MAPKs) as key mediators of cardiac hypertrophy, the aim of this work was to explore their roles in ouabain-initiated signal pathways regulating four growth-related genes of these myocytes, i.e. these for c-Fos, skeletal alpha-actin, atrial natriuretic factor, and the alpha(3)-subunit of Na+/K+-ATPase, Ouabain caused rapid activations of Ras and p42/44 MAPKs; the latter was sustained longer than 90 min. Using high efficiency adenoviral-mediated expression of a dominant-negative Ras mutant, and a specific inhibitor of MAPK kinase (MEK), activation of Ras-Raf-MEK-p42/44 MAPK cascade by ouabain was shown. The effects of the mutant Ras, an inhibitor of Ras farnesylation, and the MEK inhibitor on ouabain-in duced changes in mRNAs of the four genes indicated that (a) skeletal alpha-actin induction was dependent on Rat; but not on p42/44 MAPKs, (b) alpha(3) repression was depend ent on the Ras-p42/44 MAPK cascade, and (c) induction of c-fos or atrial natriuretic factor gene occurred partly through the Ras-p42/44 MAPK cascade, and partly through pathways independent of Ras and p42/44 MAPKs, All ouabain effects required extracellular Ca2+ and were attenuated by a Ca2+/calmodulin antagonist or a protein kinase C inhibitor. The findings show that (a) signal pathways linked to sarcolemmal Na+/K+-ATPase share early segments involving Ca2+ and protein kinase C, but diverge into multiple branches only some of which involve Pas, or p42/44 MAPKs, or both; and (b) there are significant differences between this network and the related gene regulatory pathways activated by other hypertrophic stimuli, including those whose responses involve increases in intracellular free Ca2+ through different mechanisms.	Med Coll Ohio, Dept Pharmacol, Toledo, OH 43614 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Xie, ZJ (corresponding author), Med Coll Ohio, Dept Pharmacol, 3035 Arlington Ave, Toledo, OH 43614 USA.	xie@opus.mco.edu		gnudi, luigi/0000-0002-6353-630X	NHLBI NIH HHS [HL-36573] Funding Source: Medline; NIDDK NIH HHS [R01 DK043051] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdellatif M, 1997, J BIOL CHEM, V272, P525; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Askari FK, 1997, FEBS LETT, V405, P5, DOI 10.1016/S0014-5793(97)00087-2; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; GOTOH H, 1993, BIOCHEM BIOPH RES CO, V194, P72, DOI 10.1006/bbrc.1993.1786; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; Huang LY, 1997, J MOL CELL CARDIOL, V29, P3157, DOI 10.1006/jmcc.1997.0546; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; KIM D, 1987, CIRC RES, V60, P185, DOI 10.1161/01.RES.60.2.185; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Perry G, 1997, NEW ENGL J MED, V336, P525; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	57	262	267	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15249	15256		10.1074/jbc.273.24.15249	http://dx.doi.org/10.1074/jbc.273.24.15249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614140	hybrid, Green Submitted			2022-12-27	WOS:000074160400082
J	Jung, K; Altendorf, K				Jung, K; Altendorf, K			Truncation of amino acids 12-128 causes deregulation of the phosphatase activity of the sensor kinase KdpD of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY COMPONENTS; POTASSIUM-TRANSPORT; CONTROL EXPRESSION; OPERON EXPRESSION; TURGOR PRESSURE; KDPABC OPERON; PROTEIN; BINDING; SIGNAL; SYSTEM	The kdpFABC operon, which encodes the structural genes for the high affinity K+ transport complex KdpFABC, is regulated by the sensor kinase KdpD and the response regulator KdpE. KdpD is a bifunctional enzyme catalyzing the autophosphorylation by ATP and the dephosphorylation of the corresponding response regulator KdpE. Here, we demonstrate that the phosphatase activity of KdpD is dependent on ATP, whereas GTP, ITP, CTP, ADP, and GDP have no effect. The phosphatase activity requires only ATP binding, because nonhydrolyzable analogs (adenosine-5'-[gamma-thio]triphos phate and adenosine-5'-[beta,gamma-imido]triphosphate) work as well. However, KdpD proteins missing amino acids 12-128 are characterized by a phosphatase activity that is independent of ATP. These proteins are still able to respond to K+ starvation, but an increase in osmolarity is no longer sensed. Comparison of different KdpD sequences reveals a conserved motif in this amino acid region that is very similar to a classical ATP-binding site (Walker A motif), Replacement of the conserved Gly(37), Lys(38) and Thr(39) residues in the consensus ATP-binding sequence results in a KdpD protein that causes a kdp-FABC expression pattern comparable with that seen with KdpD proteins missing amino acids 12-128. However, in vitro phosphatase activity is comparable with that of wild-type KdpD. These results suggest that amino acids 12-128 of KdpD are important for its activity and that an additional ATP-binding site in the N-terminal region seems to be involved in modulation of the phosphatase activity.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.							AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; ALTENDORF K, 1996, BIOMEMBR, V5, P403; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Beier D, 1996, MOL GEN GENET, V252, P169, DOI 10.1007/BF02173217; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; CHARLES TC, 1993, J BACTERIOL, V175, P6614, DOI 10.1128/jb.175.20.6614-6625.1993; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; Jung K, 1997, J BIOL CHEM, V272, P10847; JUNG K, 1998, IN PRESS BIOCH BIOPH; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; Miller JH., 1992, SHORT COURSE BACTERI, P72; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OHWADA T, 1987, ARCH BIOCHEM BIOPHYS, V259, P157, DOI 10.1016/0003-9861(87)90481-4; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; Puppe W, 1996, J BIOL CHEM, V271, P25027, DOI 10.1074/jbc.271.40.25027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIEBERS A, 1992, ALKALI CATION TRANSP, P225; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	43	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17406	17410		10.1074/jbc.273.28.17406	http://dx.doi.org/10.1074/jbc.273.28.17406			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651326	hybrid			2022-12-27	WOS:000074816100019
J	Medkova, M; Cho, WW				Medkova, M; Cho, WW			Mutagenesis of the C2 domain of protein kinase C-alpha - Differential roles of Ca2+ ligands and membrane binding residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC PHOSPHOLIPASE A(2); LIPID-BINDING; HIGH-AFFINITY; ANNEXIN-V; MONOLAYERS; PHOSPHATIDYLSERINE; SYNAPTOTAGMIN; CALCIUM; BOVINE; DIACYLGLYCEROL	The C2 domains of conventional protein kinase C (PKC) have been implicated in their Ca2+-dependent membrane binding. The C2 domain of PKC-alpha contains several Ca2+ ligands that bind multiple Ca2+ ions and other putative membrane binding residues. To understand the roles of individual Ca2+ ligands and protein-bound Ca2+ ions in the membrane binding and activation of PKC-alpha, we mutated five putative Ca2+ Ligands (D187N, D193N, D246N, D248N, and D254N) and measured the effects of mutations on vesicle binding, enzyme activity and monolayer penetration of PKC-alpha. Altered properties of these mutants indicate that individual Ca2+ ions and their ligands have different roles in the membrane binding and activation of PKC-alpha. The binding of Ca2+ to Asp(187), Asp(193), and Asp(246) of PKC-alpha is important for the initial binding of protein to membrane surfaces, On the other hand, the binding of another Ca2+ to Asp(187), Asp(246), Asp(248) and Asp(254) induces the conformational change of PKC-alpha, which in turn triggers its membrane penetration and activation. Among these Ca2+ ligands, Asp(246) was shown to be most essential for both membrane binding and activation of PKC-alpha, presumably due to its coordination to multiple Ca2+ ions. Furthermore, to identify the residues in the C2 domain that are involved in membrane binding of PKC-alpha, we mutated four putative membrane binding residues (Trp(245), Trp(247), Arg(249) and Arg(252)). Membrane binding and enzymatic properties of two double site mutants (W245A/W247A and R249A/R252A) indicate that Arg(249) and Arg(252) are involved in electrostatic interactions of PRC-alpha with anionic membranes, whereas Trp(245) and Trp247 participate in its penetration into membranes and resulting hydrophobic interactions. Taken together, these studies provide the first experimental evidence for the role of C2 domain of conventional PKC as a membrane docking unit as web as a module that triggers conformational changes to activate the protein.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, WW (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NIGMS NIH HHS [GM53987, GM52598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GAINES JGL, 1966, INSOLUBLE MONOLAYERS, P208; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; KATES M, 1986, TECHNIQUES LIPIDOLOG, P113; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MOREAU H, 1988, BIOCHEMISTRY-US, V27, P2319, DOI 10.1021/bi00407a012; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; Mukhopadhyay S, 1996, BBA-BIOMEMBRANES, V1279, P58, DOI 10.1016/0005-2736(95)00201-4; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHEN Z, 1994, BIOCHEMISTRY-US, V33, P11598, DOI 10.1021/bi00204a022; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	48	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17544	17552		10.1074/jbc.273.28.17544	http://dx.doi.org/10.1074/jbc.273.28.17544			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651347	hybrid			2022-12-27	WOS:000074816100040
J	Zhang, WQ; Shields, JM; Sogawa, K; Fujii-Kuriyama, Y; Yang, VW				Zhang, WQ; Shields, JM; Sogawa, K; Fujii-Kuriyama, Y; Yang, VW			The gut-enriched Kruppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; INDUCIBLE EXPRESSION; NUCLEAR PROTEINS; GENE STRUCTURE; CACCC ELEMENT; ZINC FINGERS; SP1; BINDING; FAMILY; IDENTIFICATION	The gut-enriched Kruppel-like factor (GKLF) is a newly identified zinc finger-containing transcription factor. Recent studies indicate that GKLF binds to a core DNA sequence of 5'-(G/A) (G/A)GG(C/T)G(C/T)-3', which is found in an endogenous cis element, the basic transcription element (BTE) of the cytochrome P-450LA1 (CYP1A1) promoter. The present study characterizes the ability of GKLF to regulate CYP1A1 expression. By electrophoretic mobility gel shift assay (EMSA) and methylation interference assay, GKLF was found to bind BTE in a manner similar to several other transcription factors known to interact with BTE including Spl and BTEB. Cotransfection studies in Chinese hamster ovary cells showed that GKLF inhibited the CYP1A1 promoter in a dose and BTE dependent manner. The same exper iments also revealed that BTE was responsible for a significant portion of the CYP1A1 promoter activity. EMSA of nuclear extracts from Chinese hamster ovary cells showed that Spl and Sp3 were two major proteins that interacted with BTE. Additional cotransfection studies showed that GKLF inhibited Spl mediated activation of the CYP1A1 promoter. In contrast, GKLF enhanced Sp3-dependent suppression of the same promoter. Moreover, the ability of GKLF to inhibit Sp1-dependent transactivation was in part due to physical interaction of the two proteins. These findings indicate that GKLF is a negative regulator of the CYP1A1 promoter in a BTE-dependent fashion and that this inhibitory effect is in part mediated by physical interaction with Sp1.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Tohoku Univ, Dept Chem, Sendai, Miyagi 980, Japan	Johns Hopkins University; Johns Hopkins University; Tohoku University	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Ross 918,720 Rutland Ave, Baltimore, MD 21205 USA.	vyang@welchlink.welch.jhu.edu			NCI NIH HHS [R01 CA084197, R01 CA084197-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230-04, DK44484, R01 DK052230, DK09345, DK52230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009345, R01DK052230, P01DK044484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; BEALE EG, 1992, BIOTECHNIQUES, V12, P320; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHUNG I, 1995, MOL PHARMACOL, V47, P677; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GARGIABLANCO MA, 1989, GENE DEV, V3, P739, DOI 10.1101/gad.3.6.739; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HASHIMOTO H, 1993, EUR J BIOCHEM, V218, P585, DOI 10.1111/j.1432-1033.1993.tb18412.x; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Itoh S, 1997, BBA-GENE STRUCT EXPR, V1350, P155, DOI 10.1016/S0167-4781(96)00215-1; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PERKINS AC, 1995, NATURE, V375, P318; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SOGAWA K, 1993, J BIOCHEM, V114, P605, DOI 10.1093/oxfordjournals.jbchem.a124224; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; SUWA Y, 1985, J BIOL CHEM, V260, P7980; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TRABER PG, 1992, BIOCHIM BIOPHYS ACTA, V1171, P167, DOI 10.1016/0167-4781(92)90117-I; TRABER PG, 1992, AM J PHYSIOL, V263, pG215, DOI 10.1152/ajpgi.1992.263.2.G215; TRABER PG, 1988, J BIOL CHEM, V263, P9449; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	68	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17917	17925		10.1074/jbc.273.28.17917	http://dx.doi.org/10.1074/jbc.273.28.17917			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651398	Green Accepted, hybrid			2022-12-27	WOS:000074816100091
J	Bridges, A; Gruenke, L; Chang, YT; Vakser, IA; Loew, G; Waskell, L				Bridges, A; Gruenke, L; Chang, YT; Vakser, IA; Loew, G; Waskell, L			Identification of the binding site on cytochrome P450 2B4 for cytochrome b(5) and cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; RABBIT LIVER; NADPH-CYTOCHROME-P450 REDUCTASE; LYSINE RESIDUES; EXPRESSION; PURIFICATION; PROTEIN; RESOLUTION	A model of cytochrome P450 2B4, which was constructed by homology modeling with the four known crystal structures of the cytochromes P450 (Chang, T.-T., Stiffelman, O. B., Vakser, I. A, Loew, G. H., Bridges, A, and Waskell, L. (1997) Protein Eng. 10, 119-129), was used to select amino acids predicted, by computer docking studies and numerous previous biochemical and site-directed mutagenesis studies, to be involved in binding the heme domain of cytochrome b(5),. Twenty-four amino acid residues located on both the distal and the proximal surface of the molecule were chosen for mutagenesis. These 24 mutant proteins were expressed in Escherichia coli, purified, and characterized with respect to their ability to bind cytochrome b(5), and support substrate oxidation. Seven mutants, R122A, R126A, R133A, F135A, M137A, K139A, and K433A, all on the proximal surface of cytochrome P450 2B4 near the heme ligand, were identified that exhibited decreased ability to bind cytochrome b(5),. All of the mutants except K433A are located in either the C or C*: helices or their termini. In addition, these seven mutants and two additional mutants on the proximal surface of cytochrome P450, R422A and R443A, were shown to exhibit decreased binding to cytochrome P450 reductase. These studies indicate that the binding sites for cytochrome b(5), and cytochrome P450 reductase are, as predicted, located on the proximal surface of cytochrome P450 2B4 and are partially overlapping but not identical.	Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Dept Anesthesia, San Francisco, CA 94121 USA; Mol Res Inst, Palo Alto, CA 94304 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical University of South Carolina	Waskell, L (corresponding author), Vet Adm Med Ctr, Anesthesia Serv 129, 4150 Clement St, San Francisco, CA 94121 USA.	waskell@quicmail.ucsf.edu			NIGMS NIH HHS [GM35533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035533] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1975, J BIOL CHEM, V250, P747; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BORDERS CL, 1994, PROTEIN SCI, V3, P541; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; Chang YT, 1997, PROTEIN ENG, V10, P119, DOI 10.1093/protein/10.2.119; CINTI DL, 1975, BIOCHIM BIOPHYS ACTA, V410, P32, DOI 10.1016/0005-2744(75)90205-3; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COON MJ, 1992, FASEB J, V6, P669, DOI 10.1096/fasebj.6.2.1537454; DAVYDOV DR, 1992, ARCH BIOCHEM BIOPHYS, V297, P304, DOI 10.1016/0003-9861(92)90677-O; Durley RCE, 1996, ACTA CRYSTALLOGR D, V52, P65, DOI 10.1107/S0907444995007827; Estabrook R W, 1978, Methods Enzymol, V52, P212; ESTABROOK RW, 1971, BIOCHEM BIOPH RES CO, V42, P132, DOI 10.1016/0006-291X(71)90372-X; FREEMAN JE, 1994, BIOCHEMISTRY-US, V33, P13963, DOI 10.1021/bi00251a002; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GASSER R, 1988, MOL PHARMACOL, V33, P22; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P374, DOI 10.1006/abbi.1995.1177; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GORSKY LD, 1986, DRUG METAB DISPOS, V14, P89; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; GUO ZY, 1994, ARCH BIOCHEM BIOPHYS, V312, P436, DOI 10.1006/abbi.1994.1330; HARADA N, 1984, J BIOL CHEM, V259, P3005; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; INGELMANSUNDBERG M, 1980, BIOCHEM BIOPH RES CO, V97, P582, DOI 10.1016/0006-291X(80)90303-4; JANSSON I, 1990, ARCH BIOCHEM BIOPHYS, V283, P285, DOI 10.1016/0003-9861(90)90644-E; JOHN GH, 1994, ARCH BIOCHEM BIOPHYS, V314, P367, DOI 10.1006/abbi.1994.1455; JUVONEN RO, 1992, BIOCHEMISTRY-US, V31, P11519, DOI 10.1021/bi00161a033; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNERER M, 1995, BBA-GEN SUBJECTS, V1245, P107, DOI 10.1016/0304-4165(95)00075-M; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIWA GT, 1979, J BIOL CHEM, V254, P5695; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMATA Y, 1994, FEBS LETT, V346, P241, DOI 10.1016/0014-5793(94)00482-X; OMATA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1090, DOI 10.1006/bbrc.1994.1817; Omura T., 1967, METHOD ENZYMOL, P556, DOI [DOI 10.1016/0076-6879(67)10096-7, 10.1016/0076-6879(67)10096-7.]; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; REID LS, 1982, J AM CHEM SOC, V104, P841, DOI 10.1021/ja00367a032; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; RODGERS KK, 1991, J MOL BIOL, V221, P1453, DOI 10.1016/0022-2836(91)90945-3; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SHEN SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P83, DOI 10.1016/0003-9861(92)90140-R; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; TARTOF KD, 1987, FOCUS, V9, P12; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; VERGERES G, 1993, ARCH BIOCHEM BIOPHYS, V305, P231, DOI 10.1006/abbi.1993.1416; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; WADA A, 1992, J BIOL CHEM, V267, P22877; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WASKELL LA, 1991, METHOD ENZYMOL, V206, P523; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIKAWA K, 1992, BIOCHIM BIOPHYS ACTA, V1122, P41, DOI 10.1016/0167-4838(92)90124-V	69	251	260	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17036	17049		10.1074/jbc.273.27.17036	http://dx.doi.org/10.1074/jbc.273.27.17036			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642268	hybrid			2022-12-27	WOS:000074545200058
J	He, QY; Mason, AB; Woodworth, RC; Tam, BM; MacGillivray, RTA; Grady, JK; Chasteen, ND				He, QY; Mason, AB; Woodworth, RC; Tam, BM; MacGillivray, RTA; Grady, JK; Chasteen, ND			Mutations at nonliganding residues Tyr-85 and Glu-83 in the N-lobe of human serum transferrin - Functional second shell effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HALF-MOLECULE; CRYSTAL-STRUCTURE; HEN OVOTRANSFERRIN; HUMAN LACTOFERRIN; ANION-BINDING; IRON RELEASE; SITE; RESOLUTION; PH; SPECTROSCOPY	The x-ray crystal structure of the N-lobe of human serum transferrin has shown that there is a hydrogen bond network, the so-called "second shell," around the transferrin iron binding site. Tyrosine at position 85 and glutamic acid at position 83 are two nonliganding residues in this network in the human serum transferrin N-lobe (hTF/2N). Mutation of each of these two amino acids has a profound effect on the metal binding properties of hTF/2N. When Tyr-85 is mutated to phenylalanine, iron release from the resulting mutant Y85F is much more facile than from the parent protein. Elimination of the hydrogen bond between Tyr-85 and Lys-296 appears to interfere with the "di-lysine (Lys-206-Lys-296) trigger," which affects the iron binding stability of the protein. Surprisingly, mutation of Glu-83 to alanine leads to the absence of one of the normal iron binding ligands; introduction of a monovalent anion is able to restore the normal first coordination sphere. The missing ligand appears to be His-249, as revealed by comparison of the metal binding behaviors of mutants H249Q and E83A and structural analysis. Glu-83 has a strong H bond linkage with His-249 in apo-hTF/2N, which helps to hold the His-249 in the proper position for iron binding. Disabling Glu 83 by mutation to an alanine seriously disturbs the H bond network, allowing His-249 to move away. A monovalent anion can help reestablish the normal network by providing a negative charge near the position of Glu-83 to reach charge balance, so that ligand His-249 is available again for iron binding.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	University of Vermont; University of British Columbia; University System Of New Hampshire; University of New Hampshire	He, QY (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Given Bldg, Burlington, VT 05405 USA.		He, Qing-Yu/H-7078-2014; Mason, Anne B/A-6754-2008	He, Qing-Yu/0000-0003-0503-9492; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021739] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 21739] Funding Source: Medline; PHS HHS [R37 20194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; Baker HM, 1996, BIOCHEMISTRY-US, V35, P9007, DOI 10.1021/bi960288y; BALDWIN GS, 1993, COMP BIOCHEM PHYS B, V106, P203, DOI 10.1016/0305-0491(93)90028-4; CHASTEEN ND, 1990, IRON TRANSPORT STORA, P67; CHENG YG, 1995, BIOCHEMISTRY-US, V34, P14879, DOI 10.1021/bi00045a032; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; Faber HR, 1996, J MOL BIOL, V256, P352; GABER BP, 1974, J AM CHEM SOC, V96, P6868, DOI 10.1021/ja00829a010; GRADY JK, 1995, BIOCHEM J, V309, P403, DOI 10.1042/bj3090403; Griffiths E, 1987, IRON INFECTION, P1; Harris D., 1989, IRON CARRIERS IRON P, P239; He QY, 1997, BIOCHEM J, V328, P439, DOI 10.1042/bj3280439; He QY, 1997, BIOCHEMISTRY-US, V36, P14853, DOI 10.1021/bi9719556; He QY, 1997, BIOCHEMISTRY-US, V36, P5522, DOI 10.1021/bi963028p; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; LIN LN, 1993, BIOCHEM J, V293, P517, DOI 10.1042/bj2930517; MACGILLIVRAY RT, 1998, IN PRESS BIOCHEMISTR; Mason A B, 1991, Protein Expr Purif, V2, P214, DOI 10.1016/1046-5928(91)90074-S; Mason AB, 1996, BIOCHEM J, V319, P361, DOI 10.1042/bj3190361; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; PATCH MG, 1981, INORG CHIM A-BIOINOR, V56, pL71, DOI 10.1016/S0020-1693(00)88536-9; PECORARO VL, 1981, BIOCHEMISTRY-US, V20, P7033, DOI 10.1021/bi00527a040; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; SMITH RM, 1976, CRITICAL STABILITY C, V3, P139; SMITH RM, 1976, CRITICAL STABILITY C, V4, P139; SMITH RM, 1976, CRITICAL STABILITY C, V5, P139; TAN AT, 1969, BIOCHEMISTRY-US, V8, P3711, DOI 10.1021/bi00837a033; WOODWORTH RC, 1991, BIOCHEMISTRY-US, V30, P10824, DOI 10.1021/bi00109a002; WOODWORTH RC, 1975, PROTEINS IRON STORAG, P39; ZAK O, 1995, BIOCHEMISTRY-US, V34, P14428, DOI 10.1021/bi00044a020; ZUCCOLA HJ, 1993, THESIS GEORGIA I TEC	36	36	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17018	17024		10.1074/jbc.273.27.17018	http://dx.doi.org/10.1074/jbc.273.27.17018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642266	hybrid			2022-12-27	WOS:000074545200056
J	Klok, EJ; van Genesen, ST; Civil, A; Schoenmakers, JGG; Lubsen, NH				Klok, EJ; van Genesen, ST; Civil, A; Schoenmakers, JGG; Lubsen, NH			Regulation of expression within a gene family - The case of the rat gamma b- and gamma d-crystallin promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; LENS EPITHELIAL EXPLANTS; MAF NUCLEAR ONCOPROTEIN; DNA METHYLATION; CHLORAMPHENICOL ACETYLTRANSFERASE; FIBER DIFFERENTIATION; CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; BINDING-PROTEIN	The six closely related and clustered rat gamma-crystallin genes, the gamma A- to gamma F-crystallin genes, are simultaneously activated in the embryonic lens but differentially shut down during postnatal development with the gamma B-crystallin gene, the last one to be active. We show here that developmental silencing of the gamma D-crystallin promoter correlates with delayed demethylation during lens fiber cell differentiation. Methylation silencing of the gamma D-crystallin promoter is a general effect and does not require the methylation of a specific CpG, nor does methylation interfere with factor binding to the proximal activator. In later development, the gamma D-crystallin promoter is also shut down earlier by a repressor that footprints to the -91/-78 region. A factor with identical properties is present in brain. Hence, a ubiquitous factor has been recruited as a developmental regulator by the lens. All gamma-crystallin promoters tested contain upstream silencers, but at least the gamma B-crystallin silencer is distinct from the gamma D-crystallin silencer. The gamma-crystallin promoters were found to share a proximal activator (the gamma-box; around -50), which behaves as a MARE. The gamma B-box is recognized with much lower avidity than the gamma D-box. By swapping elements between the gamma B- and the gamma D-crystallin promoter, we show that activation by the gamma B-box requires a directly adjacent -46/-38 AP-1 consensus site. These experiments also uncovered another positive element in the gamma D-crystallin promoter, around -10. In the context of the gamma D-crystallin promoter, this element is redundant; in the context of the gamma B-crystallin promoter, it can replace the -46/-38 element.	Catholic Univ Nijmegen, Dept Mol Biol, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Lubsen, NH (corresponding author), Catholic Univ Nijmegen, Dept Mol Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	nhl@sci.kun.nl	Lubsen, Nicolette H./B-8426-2011					AMMENDOLA R, 1990, MOL CELL BIOL, V10, P387, DOI 10.1128/MCB.10.1.387; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BRAKENHOFF RH, 1991, NUCLEIC ACIDS RES, V19, P1279, DOI 10.1093/nar/19.6.1279; Chamberlain CG, 1997, PROG RETIN EYE RES, V16, P443, DOI 10.1016/S1350-9462(96)00034-1; Chamberlain CG, 1989, GROWTH FACTORS, V1, P125, DOI 10.3109/08977198909029122; Collignon J, 1996, DEVELOPMENT, V122, P509; DENDUNNEN JT, 1986, J MOL BIOL, V189, P37, DOI 10.1016/0022-2836(86)90379-7; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; Dirks RPH, 1996, DEV BIOL, V173, P14, DOI 10.1006/dbio.1996.0003; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KRUCZEK I, 1983, P NATL ACAD SCI-BIOL, V80, P7586, DOI 10.1073/pnas.80.24.7586; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOK S, 1985, MOL CELL BIOL, V5, P2221, DOI 10.1128/MCB.5.9.2221; LOVICU FJ, 1989, EXP EYE RES, V49, P479, DOI 10.1016/0014-4835(89)90056-0; LOVICU FJ, 1992, INVEST OPHTH VIS SCI, V33, P2269; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCAVOY JW, 1986, CURR EYE RES, V5, P711, DOI 10.3109/02713688609015139; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; OGINO H, 1996, EXP EYE RES, V62, P226; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PEEK R, 1992, DEV BIOL, V152, P152, DOI 10.1016/0012-1606(92)90165-D; PEEK R, 1990, NUCLEIC ACIDS RES, V18, P1189, DOI 10.1093/nar/18.5.1189; PEEK R, 1992, NUCLEIC ACIDS RES, V20, P4865, DOI 10.1093/nar/20.18.4865; PEEK R, 1991, NUCLEIC ACIDS RES, V19, P77, DOI 10.1093/nar/19.1.77; RICHARDSON NA, 1990, EXP EYE RES, V50, P203, DOI 10.1016/0014-4835(90)90232-J; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; VANLEEN RW, 1987, DEV BIOL, V120, P457, DOI 10.1016/0012-1606(87)90249-1; VOORTER CEM, 1990, EXP EYE RES, V50, P429, DOI 10.1016/0014-4835(90)90144-J; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679; YU CCK, 1990, DEVELOPMENT, V110, P131	52	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17206	17215		10.1074/jbc.273.27.17206	http://dx.doi.org/10.1074/jbc.273.27.17206			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642290	hybrid			2022-12-27	WOS:000074545200080
J	Kubo, A; Minamino, N; Isumi, Y; Katafuchi, T; Kangawa, K; Dohi, K; Matsuo, H				Kubo, A; Minamino, N; Isumi, Y; Katafuchi, T; Kangawa, K; Dohi, K; Matsuo, H			Production of adrenomedullin in macrophage cell line and peritoneal macrophage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; LOW-DENSITY-LIPOPROTEIN; INTERFERON-GAMMA; IFN-GAMMA; RAW-264.7 MACROPHAGES; HYPOTENSIVE PEPTIDE; RAT ADRENOMEDULLIN; MURINE MACROPHAGES; ENDOTHELIAL-CELLS	We demonstrate that adrenomedullin (AM) is produced and secreted from cultured murine monocyte/macrophage cell line (RAW 264.7) as well as mouse peritoneal macrophage. Immunoreactive (IR) AM secreted from RAW 264.7 cells was chromatographically identified to be native AM. To elucidate the regulation mechanism of AM production in macrophage, we examined the effects of various substances inducing differentiation or activation of monocyte/macrophage. Phorbol ester (TPA), retinoic acid (RA), lipopolysaccharide (LPS), and interferon-gamma (IFN-gamma) increased AM production 1.5-7-fold in RAW 264.7 cells in a dose- as well as time-dependent manner. By LPS stimulation, the AM mRNA level in RAW 264.7 cells was augmented up to 7-fold after 14 h incubation. RA exerted a synergistic effect when administered with TPA, LPS, or IFN-gamma, whereas IFN-gamma completely suppressed AM production in RAW 264.7 cells stimulated with LPS. Dexamethasone, hydrocortisone, estradiol, and transforming growth factor-beta dose-dependently suppressed AM production in RAW 264.7 cells. AM production was also investigated in mouse peritoneal macrophage. Primary mouse macrophage secreted IR-AM at a rate similar to that of RAW 264.7 cells, and its production was enhanced 9-fold by LPS stimulation. AM was found to increase basal secretion of tumor necrosis factor alpha (TNF-alpha) from RAW 264.7 cells, whereas AM suppressed the secretion of TNF-alpha and interleukin-6 from that stimulated with LPS. Thus, macrophage should be recognized as one of the major sources of AM circulating in the blood. Especially in cases of sepsis and inflammation, AM production in macrophage is augmented, and the secreted AM is deduced to function as a modulator of cytokine production.	Natl Cardiovasc Ctr, Res Inst, Suita, Osaka 5658565, Japan; Nara Med Univ, Dept Internal Med 1, Kashihara, Nara 6340813, Japan	National Cerebral & Cardiovascular Center - Japan; Nara Medical University	Minamino, N (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	minamino@ri.ncvc.go.jp						AKESON AL, 1991, J LIPID RES, V32, P1699; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Boyte WR, 1996, SHOCK, V6, P218, DOI 10.1097/00024382-199609010-00011; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chujor CSN, 1996, EUR J IMMUNOL, V26, P1253, DOI 10.1002/eji.1830260611; DI RM, 1990, BIOCHEM BIOPH RES CO, V172, P1246; DIAZGUERRA MJM, 1996, J BIOL CHEM, V271, P32038; DILLEHAY DL, 1988, J LEUKOCYTE BIOL, V44, P353, DOI 10.1002/jlb.44.5.353; FRENDSCHO MH, 1990, CLIN EXP IMMUNOL, V82, P404; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GRENETT HE, 1990, NUCLEIC ACIDS RES, V18, P6455, DOI 10.1093/nar/18.21.6455; HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391; HAUSMANN EHS, 1994, INFECT IMMUN, V62, P3625, DOI 10.1128/IAI.62.9.3625-3632.1994; HAYASHI T, 1991, AM J PHYSIOL, V261, pC106, DOI 10.1152/ajpcell.1991.261.1.C106; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirata Y, 1996, J CLIN ENDOCR METAB, V81, P1449, DOI 10.1210/jc.81.4.1449; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Isumi Y, 1998, ENDOCRINOLOGY, V139, P838, DOI 10.1210/en.139.3.838; KAMOI H, 1995, BIOCHEM BIOPH RES CO, V211, P1031, DOI 10.1006/bbrc.1995.1914; Kano H, 1996, J HYPERTENS, V14, P209, DOI 10.1097/00004872-199602000-00009; KITAMURA K, 1992, BIOCHEM BIOPH RES CO, V185, P134, DOI 10.1016/S0006-291X(05)80966-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kubo A, 1998, FEBS LETT, V426, P233, DOI 10.1016/S0014-5793(98)00349-4; LAMBERT LE, 1989, CELL IMMUNOL, V120, P401, DOI 10.1016/0008-8749(89)90208-6; MARTINEZ A, 1995, ENDOCRINOLOGY, V136, P4099, DOI 10.1210/en.136.9.4099; MCDOWELL MA, 1995, J IMMUNOL, V155, P4933; MIGLIORINI P, 1991, J IMMUNOL METHODS, V139, P107, DOI 10.1016/0022-1759(91)90357-L; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MINAMINO N, 1995, BIOCHEM BIOPH RES CO, V211, P686, DOI 10.1006/bbrc.1995.1866; Nishio K, 1997, CRIT CARE MED, V25, P953, DOI 10.1097/00003246-199706000-00010; Okazaki T, 1996, GENOMICS, V37, P395, DOI 10.1006/geno.1996.0576; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; RINEHART JJ, 1982, J IMMUNOL, V129, P1436; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAKATA J, 1993, BIOCHEM BIOPH RES CO, V195, P921, DOI 10.1006/bbrc.1993.2132; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; SATO A, 1992, HYPERTENSION, V19, P109, DOI 10.1161/01.HYP.19.1.109; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SHOJI H, 1995, BIOCHEM BIOPH RES CO, V215, P531, DOI 10.1006/bbrc.1995.2497; SNYDER DS, 1982, J IMMUNOL, V129, P1803; SPENGLER RN, 1989, INFECT IMMUN, V57, P2837, DOI 10.1128/IAI.57.9.2837-2841.1989; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUGO S, 1995, BIOCHEM BIOPH RES CO, V207, P25, DOI 10.1006/bbrc.1995.1148; SUGO S, 1995, FEBS LETT, V369, P311, DOI 10.1016/0014-5793(95)00769-6; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; VEY E, 1992, J IMMUNOL, V149, P2040; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	55	153	156	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16730	16738		10.1074/jbc.273.27.16730	http://dx.doi.org/10.1074/jbc.273.27.16730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642228	hybrid			2022-12-27	WOS:000074545200018
J	Vandergon, TL; Riggs, CK; Gorr, TA; Colacino, JM; Riggs, AF				Vandergon, TL; Riggs, CK; Gorr, TA; Colacino, JM; Riggs, AF			The mini-hemoglobins in neural and body wall tissue of the nemertean worm, Cerebratulus lacteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLLUSK SCAPHARCA-INAEQUIVALVIS; PHORONIS-ARCHITECTA PHORONIDA; PARAMECIUM-CAUDATUM; PROTOZOAN MYOGLOBIN; NUCLEOTIDE-SEQUENCE; STRUCTURAL-ANALYSIS; PETROMYZON-MARINUS; CRYSTAL-STRUCTURE; GLOBIN GENES	Hemoglobin (Hb) occurs in circulating red blood cells, neural tissue, and body wall muscle tissue of the nemertean worm, Cerebratubus lacteus. The neural and body wall tissue each express single major Hb components for which the amino acid sequences have been deduced from cDNA and genomic DNA. These 109-residue globins form the smallest stable Hbs known. The globin genes have three exons and two introns with splice sites in the highly conserved positions of most globin genes. Alignment of the sequences with those of other globins indicates that the A, B, and H helices are about one-half the typical length. Phylogenetic analysis indicates that shortening results in a small tendency of globins to group together regardless of their actual relationships. The neural and body wall Hbs in situ are half-saturated with O-2 at 2.9 and 4.1 torr, respectively. The Hill coefficient for the neural Hb in situ, similar to 2.8, suggests that the neural Hb self-associates in the deoxy state at least to tetramers at the 2-3 mM (heme) concentration estimated in the cells. The Hb must dissociate upon oxygenation and dilution because the weight-average molecular mass of the HbO(2) in vitro is only about 18 kDa at 2-3 mu M heme concentration. Calculations suggest that the Hb can function as an O-2 store capable of extending neuronal activity in an anoxic environment for 5-30 min.	Univ Texas, Dept Zool, Austin, TX 78712 USA; Clemson Univ, Dept Biol Sci, Clemson, SC 29631 USA	University of Texas System; University of Texas Austin; Clemson University	Vandergon, TL (corresponding author), Univ Texas, Dept Zool, Austin, TX 78712 USA.	tvanderg@pepperdine.edu		Gorr, Thomas/0000-0002-6023-4234	NIGMS NIH HHS [GM35847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN HT, 1966, PHYSIOL REV, V46, P212, DOI 10.1152/physrev.1966.46.2.212; ANTOINE M, 1984, NATURE, V310, P795, DOI 10.1038/310795a0; ARENTS G, 1989, J MOL BIOL, V210, P149, DOI 10.1016/0022-2836(89)90297-0; ARONSON HEG, 1994, PROTEIN SCI, V3, P1706, DOI 10.1002/pro.5560031009; ARVANITAKI A, 1960, B I OCEANOG, V57, P1; ATKINSON HJ, 1975, J EXP BIOL, V62, P1; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bevington P. R, 1969, DATA REDUCTION ERROR; BLESSING MH, 1972, COMP BIOCHEM PHYSIOL, V41, P475, DOI 10.1016/0300-9629(72)90005-9; Bonaventura J., 1973, COMP PHYSL, P493; CHALAZONITIS N, 1965, C R SOC BIOL, V159, P240; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; COBB JA, 1992, J BIOL CHEM, V267, P1183; COLACINO JM, 1984, COMP BIOCHEM PHYS A, V79, P363, DOI 10.1016/0300-9629(84)90528-0; COLACINO JM, 1987, J THEOR BIOL, V126, P437, DOI 10.1016/S0022-5193(87)80150-9; COUTURE M, 1994, MOL GEN GENET, V243, P184; DESANCTIS G, 1988, J MOL BIOL, V200, P725, DOI 10.1016/0022-2836(88)90483-4; DESANCTIS G, 1994, P NATL ACAD SCI USA, V91, P11507, DOI 10.1073/pnas.91.24.11507; DESANCTIS G, 1992, J MOL BIOL, V222, P637; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; DONAHUE RA, 1992, THESIS U TEXAS AUSTI; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5 D; FERMI G, 1981, ATLAS MOL STRUCTURES, V2, P26; FOX HM, 1957, NATURE, V179, P148, DOI 10.1038/179148a0; FOX HM, 1955, PROC R SOC SER B-BIO, V143, P203, DOI 10.1098/rspb.1955.0005; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; GAREY JR, 1986, J BIOL CHEM, V261, P6446; GERSTEIN M, 1994, J MOL BIOL, V236, P1067, DOI 10.1016/0022-2836(94)90012-4; HARDISON RC, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P272; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; HOMBRADOS I, 1983, BIOCHIMIE, V65, P247, DOI 10.1016/S0300-9084(83)80276-4; HONZATKO RB, 1985, J MOL BIOL, V184, P147, DOI 10.1016/0022-2836(85)90049-X; HYLDIGNIELSEN JJ, 1982, NUCLEIC ACIDS RES, V10, P689, DOI 10.1093/nar/10.2.689; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KENNEDY D, 1960, J GEN PHYSIOL, V44, P277, DOI 10.1085/jgp.44.2.277; KHOSLA C, 1988, MOL GEN GENET, V214, P158, DOI 10.1007/BF00340195; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; KOLATKAR PR, 1994, J MOL BIOL, V237, P87, DOI 10.1006/jmbi.1994.1211; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSMANN J, 1986, NATURE, V324, P166, DOI 10.1038/324166a0; Lankester E.R, 1872, P ROY SOC LONDON, V21, P70; MANWELL C, 1960, ARCH BIOCHEM BIOPHYS, V89, P194, DOI 10.1016/0003-9861(60)90042-4; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; MOENS L, 1992, FEBS LETT, V312, P105, DOI 10.1016/0014-5793(92)80915-4; OLLIS DL, 1983, AUST J CHEM, V36, P451, DOI 10.1071/CH9830451; PETRUZZELLI R, 1985, FEBS LETT, V184, P328, DOI 10.1016/0014-5793(85)80632-3; POLUHOWICH JJ, 1970, COMP BIOCHEM PHYSIOL, V36, P817, DOI 10.1016/0010-406X(70)90537-2; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; QIU Y, 1997, THESIS U TEXAS AUSTI; RITCHIE JM, 1979, J PHYSIOL-LONDON, V287, P315, DOI 10.1113/jphysiol.1979.sp012661; ROBERTS MS, 1984, COMP BIOCHEM PHYS B, V77, P237, DOI 10.1016/0305-0491(84)90250-5; ROYER WE, 1989, J BIOL CHEM, V264, P21052; SACK JS, 1978, HEMOGLOBIN, V2, P153, DOI 10.3109/03630267809074782; SCHINDELMEISER I, 1979, COMP BIOCHEM PHYS B, V64, P149, DOI 10.1016/0305-0491(79)90153-6; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P75, DOI 10.1016/0167-4781(93)90245-9; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; THOMAS PW, 1994, THESIS U TEXAS AUSTI; TROTMAN CNA, 1991, J BIOL CHEM, V266, P13789; TSUBAMOTO Y, 1990, EUR J BIOCHEM, V193, P55, DOI 10.1111/j.1432-1033.1990.tb19303.x; TURBEVILLE JM, 1992, MOL BIOL EVOL, V9, P235; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P57; VANDERGON TL, 1989, COMP BIOCHEM PHYS B, V94, P31, DOI 10.1016/0305-0491(89)90006-0; VANDERGON TL, 1991, PHYSIOL ZOOL, V64, P1561, DOI 10.1086/physzool.64.6.30158231; VANDERGON TL, 1989, AM ZOOL, V29, P59; VANDERGON TL, 1990, AM ZOOL, V31, P72; VARNDELL IM, 1980, J EXP MAR BIOL ECOL, V45, P157, DOI 10.1016/0022-0981(80)90057-X; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VERNET G, 1973, COMP BIOCHEM PHYSIOL, V44, P1053, DOI 10.1016/0300-9629(73)90242-9; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Weber R.E., 1978, P393; WITTENBERG BA, 1965, BIOCHEM J, V96, P363, DOI 10.1042/bj0960363; WITTENBERG JB, 1965, BIOCHIM BIOPHYS ACTA, V109, P518, DOI 10.1016/0926-6585(65)90177-9; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; YAMAUCHI K, 1992, BIOCHIM BIOPHYS ACTA, V1171, P81, DOI 10.1016/0167-4781(92)90142-M; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	87	40	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16998	17011		10.1074/jbc.273.27.16998	http://dx.doi.org/10.1074/jbc.273.27.16998			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642264	hybrid			2022-12-27	WOS:000074545200054
J	Halfon, S; Ford, J; Foster, J; Dowling, L; Lucian, L; Sterling, M; Xu, YM; Weiss, M; Ikeda, M; Liggett, D; Helms, A; Caux, C; Lebecque, S; Hannum, C; Menon, S; McClanahan, T; Gorman, D; Zurawski, G				Halfon, S; Ford, J; Foster, J; Dowling, L; Lucian, L; Sterling, M; Xu, YM; Weiss, M; Ikeda, M; Liggett, D; Helms, A; Caux, C; Lebecque, S; Hannum, C; Menon, S; McClanahan, T; Gorman, D; Zurawski, G			Leukocystatin, a new class II cystatin expressed selectively by hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE CYSTATIN; CYSTEINE PROTEINASE-INHIBITOR; RAY CRYSTAL-STRUCTURE; PAPAIN; REGION; GENE; IDENTIFICATION; ORGANIZATION; TRUNCATION; MECHANISM	We describe a new cystatin in both mice and humans, which we termed leukocystatin. This protein has all the features of a Class II secreted inhibitory cystatin but contains lysine residues in the normally hydrophobic binding regions. As determined by cDNA library Southern blots, this cystatin is expressed selectively in hematopoietic cells, although fine details of the distribution among these cell types differ between the human and mouse mRNAs. In addition, we have determined the genomic organization of mouse leukocystatin, and we found that in contrast to most cystatins, the leukocystatin gene contains three introns. The recombinant proteins corresponding to these cystatins were expressed in Escherichia coli as N-terminal glutathione S-transferase or FLAG(TM) fusions, and studies showed that they inhibited papain and cathepsin L but with affinities lower than other cystatins. The unique features of leukocystatin suggests that this cystatin plays a role in immune regulation through inhibition of a unique target in the hematopoietic system.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Biol Mol, Palo Alto, CA 94304 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA; Lab Immunol Res, F-69572 Dardilly, France	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Zurawski, G (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Biol Mol, 901 Calif Ave, Palo Alto, CA 94304 USA.			Caux, Christophe/0000-0003-2438-833X; lebecque, serge/0000-0003-4006-8061				ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BALBIN M, 1994, J BIOL CHEM, V269, P23156; Bieth J., 1974, BAYER S, P463; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Bolin LM, 1997, J NEUROSCI, V17, P5493; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; GOLLOB KJ, 1994, J IMMUNOL, V152, P5180; Hakansson K, 1996, COMP BIOCHEM PHYS B, V114, P303, DOI 10.1016/0305-0491(96)00025-9; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; Misaka T, 1996, EUR J BIOCHEM, V240, P609, DOI 10.1111/j.1432-1033.1996.0609h.x; MURPHY E, 1993, J IMMUNOL METHODS, V162, P211, DOI 10.1016/0022-1759(93)90386-L; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Ni J, 1997, J BIOL CHEM, V272, P10853; Pennacchio LA, 1996, GENOME RES, V6, P1103, DOI 10.1101/gr.6.11.1103; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; SAITOH E, 1993, CRIT REV ORAL BIOL M, V4, P487, DOI 10.1177/10454411930040033301; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SATO N, 1992, GENE, V114, P257, DOI 10.1016/0378-1119(92)90584-C; SHIBUYA K, 1995, J BIOCHEM, V118, P635, DOI 10.1093/oxfordjournals.jbchem.a124957; SHIBUYA K, 1995, BIOCHEMISTRY-US, V34, P12185, DOI 10.1021/bi00038a012; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Williams J W, 1979, Methods Enzymol, V63, P437	38	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16400	16408		10.1074/jbc.273.26.16400	http://dx.doi.org/10.1074/jbc.273.26.16400			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632704	hybrid			2022-12-27	WOS:000074436600075
J	Herrmann, C; Ahmadian, MR; Hofmann, F; Just, I				Herrmann, C; Ahmadian, MR; Hofmann, F; Just, I			Functional consequences of monoglucosylation of Ha-Ras at effector domain amino acid threonine 35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; GTPASE-ACTIVATING PROTEINS; CLOSTRIDIUM-DIFFICILE; EXCHANGE FACTOR; RHO-PROTEINS; BINDING PROTEINS; GLUCOSYLATION; NEUROFIBROMIN; COMPLEX; KINASE	Monoglucosylation of low molecular mass GTPases is an important post-translational modification by which microbes interfere with eukaryotic cell signaling. Ha-Ras is monoglucosylated at effector domain amino acid threonine 35 by Clostridium sordellii lethal toxin, resulting in a blockade of the downstream mitogen-activated protein kinase cascade. To understand the molecular consequences of this modification, effects of glucosylation on each step of the GTPase cycle of Ras were analyzed. Whereas nucleotide binding was not significantly altered, intrinsic GTPase activity was markedly decreased, and GTPase stimulation by the GTPase-activating protein p120(GAP) and neurofibromin NF-1 was completely blocked, caused by failure to bind to glucosylated Ras. Guanine nucleotide exchange factor (Cdc25)-catalyzed GTP loading was decreased, but not completely inhibited. A dominant-negative property of modified Ras to sequester exchange factor was not detectable. However, the crucial step in downstream signaling, Ras-effector coupling, was completely blocked. The K-d for the interaction between Ras.GTP and the Ras-binding domain of Raf was 15 nM, whereas glucosylation increased the K-d to >1 mM. Because the affinity of Ras.GDP for Raf (K-d = 22 mu M) is too low to allow functional interaction, a glucose moiety at threonine 35 of Ras seems to block completely the interaction with Raf. The net effect of lethal toxin-catalyzed glucosylation of Ras is the complete blockade of Ras downstream signaling.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany	University of Freiburg; Max Planck Society	Just, I (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	justingo@ruf.uni-freiburg.de						ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; AKTORIES K, 1993, GTPASES BIOL, V1, P87; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN SY, 1994, ONCOGENE, V9, P2691; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hofmann F, 1996, BIOCHEM BIOPH RES CO, V227, P77, DOI 10.1006/bbrc.1996.1470; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1993, J BIOL CHEM, V268, P923; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KNOOP FC, 1993, CLIN MICROBIOL REV, V6, P251, DOI 10.1128/CMR.6.3.251-265.1993; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Wittinghofer A, 1997, FEBS LETT, V410, P63, DOI 10.1016/S0014-5793(97)00321-9	39	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16134	16139		10.1074/jbc.273.26.16134	http://dx.doi.org/10.1074/jbc.273.26.16134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632667	hybrid			2022-12-27	WOS:000074436600038
J	Moutoussamy, S; Renaudie, F; Lago, F; Kelly, PA; Finidori, J				Moutoussamy, S; Renaudie, F; Lago, F; Kelly, PA; Finidori, J			Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED TYROSYL PHOSPHORYLATION; SERUM RESPONSE ELEMENT; C-FOS PROMOTER; TRANSCRIPTION FACTOR; INSULIN-RECEPTOR; EXPRESSION CLONING; INTERFERON-GAMMA; GENE-EXPRESSION; TERNARY COMPLEX; KINASE	The cloning of receptor targets procedure, used so far to identify proteins associated with tyrosine kinase receptors was modified to clone SH2 proteins able to bind to the growth hormone receptor (GHR). The cytoplasmic region of GHR, a member of the cytokine receptor superfamily does not contain tyrosine kinase activity. It was thus phosphorylated in bacteria by the Elk tyrosine kinase and radiolabeled to screen a mouse expression library. With this probe, we identified Shc and the p85 subunit of phosphatidylinositol 3-kinase as direct targets of the receptor. The other proteins identified, Csk, Shb, Grb4, and Grb10 are new potential transducers for cytokine receptors, We show in Huh-7 hepatoma cells that Grb10 and GHR associate under GH stimulation, Co-transfections in 293 cells further show that Grb10 interacts with both the GHR and Jak2, Functional tests demonstrate that Grb10 inhibits transcription of two reporter genes containing, respectively, the serum response element of c-fos and the GH response element 2 of the Spi2.1 gene, whereas it has no effect on a reporter gene containing only Stat5 binding elements. Our results suggest that Grb10 is a new target for a member of the cytokine receptor family that down-regulates some GH signaling pathways downstream of Jak2 and independently of Stat5.	Fac Med Necker, INSERM, U344, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Finidori, J (corresponding author), Fac Med Necker, INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.		Kelly, Paul/A-7951-2008					ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; DINERSTEIN H, 1995, MOL ENDOCRINOL, V9, P1701, DOI 10.1210/me.9.12.1701; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; EDMONDSON SR, 1995, ENDOCRINOLOGY, V136, P4602, DOI 10.1210/en.136.10.4602; ESPOSITO N, 1994, MOL CELL ENDOCRINOL, V103, P13, DOI 10.1016/0303-7207(94)90064-7; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; HANSEN H, 1996, J BIOL CHEM, V271, P23588; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Karlsson T, 1996, ONCOGENE, V13, P955; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LECOM A, 1994, J BIOL CHEM, V269, P21532; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1995, METHOD ENZYMOL, V255, P360; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; MULLIS PE, 1991, MOL CELL ENDOCRINOL, V76, P125, DOI 10.1016/0303-7207(91)90267-V; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLER C, 1994, J BIOL CHEM, V269, P12320; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WELSH M, 1994, ONCOGENE, V9, P19; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU XO, 1995, ENDOCRINOLOGY, V136, P4551, DOI 10.1210/en.136.10.4551; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	56	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15906	15912		10.1074/jbc.273.26.15906	http://dx.doi.org/10.1074/jbc.273.26.15906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632636	hybrid			2022-12-27	WOS:000074436600007
J	Irie, A; Koyama, S; Kozutsumi, Y; Kawasaki, T; Suzuki, A				Irie, A; Koyama, S; Kozutsumi, Y; Kawasaki, T; Suzuki, A			The molecular basis for the absence of N-glycolylneuraminic acid in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MOUSE-LIVER CYTOSOL; ACETYLNEURAMINIC ACID; SIALIC-ACID; IMMUNOGLOBULIN SUPERFAMILY; GLYCOLYNEURAMINIC ACID; CELL GLYCOLIPIDS; HYDROXYLATION; BIOSYNTHESIS; GANGLIOSIDES	N-Glycolylneuraminic acid (NeuGc) is abundantly expressed in most mammals, but it is not detectable in humans. The expression of NeuGc is controlled by cytidine monophospho-N-acetylneuraminic acid (CMPNeuAc) hydroxylase activity. We previously cloned a cDNA for mouse CMP-NeuAc hydroxylase and found that the human genome contains a homologue, We report here the molecular basis for the absence of NeuGc in humans. We cloned a cDNA for human CMP-NeuAc hydroxylase from a HeLa cell cDNA library. The cDNA encodes a 486-amino acid protein, and its deduced amino acid sequence lacks a domain corresponding to the N-terminal 104 amino acids of the mouse CMP-NeuAc hydroxylase protein, although the human protein is highly identical (93%) to the rest of the mouse hydroxylase protein. The N-terminal truncation of the human hydroxylase is caused by deletion of a 92-base pair-long exon in human genomic DNA. The human by. droxylase expressed in COS-7 cells exhibited no enzymatic activity, and a mouse hydroxylase mutant, which lacks the N-terminal domain, was also inactive. A chimera composed of the human hydroxylase and the N-terminal domain of the mouse hydroxylase displayed the enzyme activity. These results indicate that the human homologue of CMP-NeuAc hydroxylase is inactive because it lacks an N-terminal domain that is essential for enzyme activity. The absence of NeuGc in human glycoconjugates is due to a partial deletion in the gene that encodes CMP-NeuAc hydroxylase.	Tokyo Metropolitan Inst Med Sci, Dept Membrane Biochem, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sakyo Ku, Kyoto 6068304, Japan	Tokyo Metropolitan Institute of Medical Science; Kyoto University	Suzuki, A (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Membrane Biochem, Bunkyo Ku, Tokyo 1138613, Japan.	asuzuki@rinshoken.or.jp						BOUHOURS D, 1988, J BIOL CHEM, V263, P15540; BUSCHER HP, 1977, EUR J BIOCHEM, V77, P297, DOI 10.1111/j.1432-1033.1977.tb11668.x; DENEKE CF, 1984, INFECT IMMUN, V45, P522, DOI 10.1128/IAI.45.2.522-524.1984; FURUKAWA K, 1988, J BIOL CHEM, V263, P18507; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; HAMANAKA S, 1979, J BIOCHEM-TOKYO, V86, P695, DOI 10.1093/oxfordjournals.jbchem.a132573; HASHIMOTO Y, 1984, J BIOCHEM-TOKYO, V96, P1777, DOI 10.1093/oxfordjournals.jbchem.a135010; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; HIGASHI H, 1977, BIOCHEM BIOPH RES CO, V79, P388, DOI 10.1016/0006-291X(77)90169-3; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KAWANO T, 1995, J BIOL CHEM, V270, P16458, DOI 10.1074/jbc.270.27.16458; KAWANO T, 1993, GLYCOCONJUGATE J, V10, P109, DOI 10.1007/BF00731194; KAWANO T, 1994, J BIOL CHEM, V269, P9024; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Koyama S, 1996, GLYCOCONJUGATE J, V13, P353, DOI 10.1007/BF00731467; KOZUTSUMI Y, 1991, J BIOCHEM, V110, P429, DOI 10.1093/oxfordjournals.jbchem.a123598; KOZUTSUMI Y, 1990, J BIOCHEM, V108, P704, DOI 10.1093/oxfordjournals.jbchem.a123268; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LEPERS A, 1990, EUR J BIOCHEM, V193, P715, DOI 10.1111/j.1432-1033.1990.tb19391.x; Marquina G, 1996, CANCER RES, V56, P5165; MERRICK JM, 1978, INT ARCH ALLER A IMM, V57, P477, DOI 10.1159/000232140; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHAUER R, 1971, H-S Z PHYSIOL CHEM, V352, P1282, DOI 10.1515/bchm2.1971.352.2.1282; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P374; Schlenzka W, 1996, FEBS LETT, V385, P197, DOI 10.1016/0014-5793(96)00384-5; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; SHAW L, 1989, BIOCHEM J, V263, P355, DOI 10.1042/bj2630355; SMIT H, 1984, INFECT IMMUN, V46, P578, DOI 10.1128/IAI.46.2.578-584.1984; SUZUKI Y, 1987, BIOCHIM BIOPHYS ACTA, V903, P417, DOI 10.1016/0005-2736(87)90048-4; TAKEMATSU H, 1994, J BIOCHEM-TOKYO, V115, P381, DOI 10.1093/oxfordjournals.jbchem.a124347; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YASUE S, 1978, J BIOCHEM-TOKYO, V83, P1101, DOI 10.1093/oxfordjournals.jbchem.a131999	38	280	297	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15866	15871		10.1074/jbc.273.25.15866	http://dx.doi.org/10.1074/jbc.273.25.15866			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624188	hybrid			2022-12-27	WOS:000074284200082
J	Saxena, M; Williams, S; Gilman, J; Mustelin, T				Saxena, M; Williams, S; Gilman, J; Mustelin, T			Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; PHOSPHORYLATION; ACTIVATION; KINASE; CD45; INVOLVEMENT; INHIBITION; EXPRESSION; P72(SYK)	The hematopoietic tyrosine phosphatase (HePTP) is predominantly expressed in thymocytes and T lymphocytes and at lower levels in other hematopoietic cells. Expression of the gene is enhanced by the T cell growth factor interleukin-2, suggesting a role for HePTP in T cell proliferation or differentiation. We report that HePTP blocks T cell antigen receptor (TCR)-induced transcriptional activation of a reporter gene drivels by a nuclear factor of activated T cells(NFAT)/AP-1 element taken from the interleukin-2 genre promotes. This effect was specific to HePTP and was abolished by a mutation (C270S) that impaired its phosphatase activity. Co-expression of HePTP also reduced TCR-induced activation of the mitogen-activated protein kinase Erk2 and the TCR-induced appearance of phosphorylated Erk. In contrast, HePTP did not affect the activation of the N-terminal e-Jun kinase, Jnk. Together these findings suggest that HePTP plays an active negative role in TCR signaling by dephosphorylating one or several signaling molecules between the receptor and the mitogen-activated protein kinase pathway.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Mustelin, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.			Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI141481, R01AI041481, R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35603, AI41481] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAICHI M, 1994, ONCOGENE, V9, P3031; ADAICHI M, 1994, FEBS LETT, V338, P47; ADAICHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FONATSCH C, 1991, CANCER GENET CYTOGEN, V56, P243, DOI 10.1016/0165-4608(91)90177-V; IMBODEN JB, 1995, CURR BIOL, V5, P727, DOI 10.1016/S0960-9822(95)00145-X; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; MAMAEV N, 1988, CANCER GENET CYTOGEN, V35, P21, DOI 10.1016/0165-4608(88)90116-1; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6502; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Schultz Leonard D., 1993, Cell, V73, P1445; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SWIETER M, 1995, J BIOL CHEM, V270, P21902, DOI 10.1074/jbc.270.37.21902; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; ZANKE B, 1994, LEUKEMIA, V8, P236; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	29	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15340	15344		10.1074/jbc.273.25.15340	http://dx.doi.org/10.1074/jbc.273.25.15340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624114	hybrid			2022-12-27	WOS:000074284200008
J	Yeilding, NM; Procopio, WN; Rehman, MT; Lee, WMF				Yeilding, NM; Procopio, WN; Rehman, MT; Lee, WMF			c-myc mRNA is down-regulated during myogenic differentiation by accelerated decay that depends on translation of regulatory coding elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; PROTEIN-SYNTHESIS; POSTTRANSCRIPTIONAL REGULATION; CELL-DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTORS; DAUDI CELLS; F9 CELLS; TRANSCRIPTION	Murine C2C12 myoblasts induced to differentiate into multinucleated myotubes decrease their levels of c-myc mRNA 3-10-fold through posttranscriptional mechanisms that recognize regulatory elements contained in protein-coding sequences in exons 2 and 3 of the mRNA, To determine the mechanism by which these elements mediate c-myc mRNA down-regulation, we examined the regulation of mutant MYC and human beta-globin-MYC fusion mRNAs, Regulation of mRNAs containing MYC exon 2 or 3 is abolished by insertion of an upstream termination codon indicating that regulatory function depends on their translation. Exploiting this translation dependence, we show that pharmacologic inhibition of translation with cycloheximide abolishes the down-regulation of regulated MYC and globin-MYC mRNAs and induces their levels in differentiating C2C12 cells. We exclude the possibility that this induction in mRNA levels results from cycloheximide effects on transcription or processing of parts of the RNA other than the regulatory elements, leading to the conclusion that cycloheximide induction results from mRNA stabilization. We show that the magnitude of cycloheximide induction can be used to estimate turnover rates of mRNAs whose decay is translation-dependent. By using cycloheximide inducibility to examine turnover rates of MYC and globin-MYC mRNAs, we show that the MYB:exon 2 and exon 3 regulatory elements, but not MYC 3'-untranslated region or chloramphenicol acetyltransferase coding sequences, mediate accelerated mRNA decay in differentiating, but not undifferentiated, C2C12 cells. We show that these regulatory elements must be translated to confer accelerated mRNA decay and that increased turnover occurs in the cytoplasm and not in the nucleus. Finally, using cycloheximide induction to examine mRNA half-lives, we show that mRNA turnover is increased sufficiently by mechanisms targeting the exon 2 and 3 regulatory elements to account for the magnitude of c-myc mRNA down-regulation during differentiation. We conclude from these results that c-myc mRNA downregulation during myogenic differentiation is due to translation-dependent mechanisms that target mRNAs containing myc exon 2 and 3 regulatory elements for accelerated decay.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Lee, WMF (corresponding author), Univ Penn, Dept Med, 663 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	leemingf@mail.med.upenn.edu			NIAMS NIH HHS [AR01956] Funding Source: Medline; NIGMS NIH HHS [GM47147] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047147] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLAU HM, 1985, SCIENCE, V230, P458; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DONY C, 1985, NATURE, V317, P637; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GROSSO LE, 1985, CANCER RES, V45, P847; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; LASKI FA, 1982, NUCLEIC ACIDS RES, V10, P4609, DOI 10.1093/nar/10.15.4609; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; Pistoi S, 1996, MOL CELL BIOL, V16, P5107; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THEODORAKIS NG, 1996, TRANSLATIONAL CONTRO, P631; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WISDOM R, 1990, J BIOL CHEM, V265, P19015; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	41	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15749	15757		10.1074/jbc.273.25.15749	http://dx.doi.org/10.1074/jbc.273.25.15749			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624173	hybrid			2022-12-27	WOS:000074284200067
J	Muzzin, O; Campbell, EA; Xia, LL; Severinova, E; Darst, SA; Severinov, K				Muzzin, O; Campbell, EA; Xia, LL; Severinova, E; Darst, SA; Severinov, K			Disruption of Escherichia coli HepA, an RNA polymerase-associated protein, causes UV sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE HELICASES; DNA; EXPRESSION; FAMILY; CHROMATOGRAPHY; RECOMBINATION; SIMILARITY; ELONGATION; REPAIR; SNF2	During the development of purification procedures for Escherichia coli RNA polymerase (RNAP), we noticed the consistent co-purification of a 110-kDa polypeptide. Here, we report the identification of the 110-kDa protein as the product of the hepA gene, a member of the SNF2 family of putative helicases. We have cloned the hepA gene and overexpressed and purified the HepA protein. We show in vitro that RNAP preparations have an ATPase activity only in the presence of HepA and that HepA binds core RNAP competitively with the promoter specificity sigma(70) subunit with a 1:1 stoichiometry and a dissociation constant (K-d) Of 75 nM. An E. coli strain with a disruption in the hepA gene shows sensitivity to ultraviolet light.	Rockefeller Univ, New York, NY 10021 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08855 USA	Rockefeller University; Rutgers State University New Brunswick	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockvax.rockefeller.edu	Severinov, Konstantin/C-8545-2016	Campbell, Elizabeth/0000-0002-1332-128X				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P852; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; IWASAKI H, 1991, MOL GEN GENET, V226, P24, DOI 10.1007/BF00273583; KOLSTO AB, 1993, J MOL BIOL, V230, P684, DOI 10.1006/jmbi.1993.1185; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305; ZOU C, 1994, J MOL BIOL, V236, P1283, DOI 10.1016/0022-2836(94)90057-4	22	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15157	15161		10.1074/jbc.273.24.15157	http://dx.doi.org/10.1074/jbc.273.24.15157			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614128	hybrid			2022-12-27	WOS:000074160400070
J	Watkins, PA; Lu, JF; Steinberg, SJ; Gould, SJ; Smith, KD; Braiterman, LT				Watkins, PA; Lu, JF; Steinberg, SJ; Gould, SJ; Smith, KD; Braiterman, LT			Disruption of the Saccharomyces cerevisiae FAT1 gene decreases very long-chain fatty acyl-CoA synthetase activity and elevates intracellular very long-chain fatty acid concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; PEROXISOMAL MEMBRANE-PROTEIN; PICHIA-PASTORIS; PTS1 RECEPTOR; RAT; EXPRESSION; YEAST; ACTIVATION; OXIDATION; CLONING	Activation of fatty acids to their coenzyme A derivatives is necessary for subsequent metabolism, Very long-chain fatty acids, which accumulate in tissues of patients with X-Linked adrenoleukodystrophy, are activated by very long-chain acyl-CoA synthetase (VLCS) normally found in peroxisomes and microsomes, We identified a candidate yeast VLCS gene (FAT1), previously identified as encoding a fatty acid transport protein, by its homology to rat liver peroxisomal VLCS, Disruption of this gene decreased, but did not abolish, cellular VLCS activity. Fractionation studies showed that VLCS activity, but not long-chain acyl-CoA synthetase activity, was reduced to about 40% of wild-type level in both 27,000 x g supernatant and pellet fractions. Separation of organelles in the pellet fraction by density gradient centrifugation revealed that VLCS activity was associated with peroxisomes and microsomes but not mitochondria, FAT1 deletion strains exhibited decreased growth on medium containing dextrose, oleic acid, and cerulenin, an inhibitor of fatty acid synthesis. FAT1 deletion strains grown on either dextrose or oleic acid medium accumulated very long-chain fatty acids. Compared wth wild-type yeast, C22:0, C24:0, and C26:0 levels were increased approximately 20-, 18-, and 3-fold in deletion strains grown on dextrose, and 2-, 7-, and B-fold in deletion strains grow on oleate. Long-chain fatty acid levels in wild-type and deletion strains were not significantly different.All biochemical defects in FAT1 deletion strains were restored to normal after functional complementation with the FAT1 gene. The level of VLCS activity measured in both wild-type and deletion yeast strains transformed with FAT1 cDNA paralleled the level of expression of the transgene. The extent of both the decrease in peroxisomal VLCS activity and the very long-chain fatty acid accumulation in the yeast FAT1 deletion model resembles that observed in cells from X-linked adrenoleukodystrophy patients. These studies suggest that the FAT1 gene product has VLCS activity that is essential for normal cellular very long-chain fatty acid homeostasis.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.			Watkins, Paul A./0000-0002-3246-1405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010533] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24061, HD10981] Funding Source: Medline; NINDS NIH HHS [NS10533] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Brachmann CB, 1998, YEAST, V14, P115; Braiterman LT, 1998, HUM MOL GENET, V7, P239, DOI 10.1093/hmg/7.2.239; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Folch J, 1957, J BIOL CHEM, V226, P457; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KALISH JE, 1995, BIOCHEM BIOPH RES CO, V206, P335, DOI 10.1006/bbrc.1995.1046; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KNAZEK RA, 1983, J CLIN INVEST, V72, P245, DOI 10.1172/JCI110963; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KOK F, 1995, HUM MUTAT, V6, P104, DOI 10.1002/humu.1380060203; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Reuber B. E., 1997, American Journal of Human Genetics, V61, pA54; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Shani N, 1996, P NATL ACAD SCI USA, V93, P11901, DOI 10.1073/pnas.93.21.11901; Shani N., 1996, Molecular Biology of the Cell, V7, p433A; Shani N., 1994, American Journal of Human Genetics, V55, pA138; Sherman F, 1979, METHODS YEAST GENETI; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH I, 1993, J BIOL CHEM, V268, P9972; Steinberg SJ, 1997, AM J HUM GENET, V61, pA262; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; WANG TW, 1994, J BIOL CHEM, V269, P24480; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; WATKINS PA, 1995, ANN NEUROL, V38, P472, DOI 10.1002/ana.410380322; WHITCOMB RW, 1988, J CLIN INVEST, V81, P185, DOI 10.1172/JCI113292; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	58	129	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18210	18219		10.1074/jbc.273.29.18210	http://dx.doi.org/10.1074/jbc.273.29.18210			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660783	hybrid			2022-12-27	WOS:000074828500038
J	Graddis, TJ; Brasel, K; Friend, D; Srinivasan, S; Wee, SF; Lyman, SD; March, CJ; McGrew, JT				Graddis, TJ; Brasel, K; Friend, D; Srinivasan, S; Wee, SF; Lyman, SD; March, CJ; McGrew, JT			Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELLS; PROGENITOR CELLS; HUMAN HOMOLOG; GROWTH-FACTOR; STEM-CELLS; YEAST; EXPRESSION; CLONING; VARIANTS	FLT3 ligand (FLT3L) stimulates primitive hematopoietic cells by binding to and activating the FLT3 receptor (FLT3R), We carried out a structure-activity study of human FLT3L in order to define the residues involved in receptor binding. We developed a rapid method to screen randomly mutagenized FLT3L using a FLT3R-Fc fusion protein to probe the relative binding activities of mutated ligand, Approximately 60,000 potential mutants were screened, and the DNA from 59 clones was sequenced. Thirty-one single amino acid substitutions at 24 positions of FLT3L either enhanced or reduced activity in receptor binding and cell proliferation assays. Eleven representative proteins were purified and analyzed for receptor affinity, specific activity, and physical properties. Receptor affinity and bioactivity were highly correlated. FLT3L affinity for receptor improved when four individual mutations that enhance FLT3L receptor affinity were combined in a single molecule. A model of FLT3L three-dimensional structure was generated based on sequence alignment and x-ray structure of macrophage colony-stimulating factor. Most residues implicated in receptor binding are widely dispersed in the primary structure of FLT3L, yet they localize to a surface patch in the tertiary model. A mutation that maps to and is predicted to disrupt the proposed dimerization interface between FLT3L monomers exhibits a Stokes radius that is concentration-dependent, suggesting that this mutation disrupts the FLT3L dimer.	Immunex Res & Dev Corp, Dept Cell Sci, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Prot Chem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Immunobiol, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Biochem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Analyt Chem, Seattle, WA 98101 USA; Immunex Res & Dev Corp, Dept Mol Biol, Seattle, WA 98101 USA		McGrew, JT (corresponding author), Immunex Res & Dev Corp, Dept Cell Sci, 51 Univ St, Seattle, WA 98101 USA.							BRASEL K, 1995, LEUKEMIA, V9, P1212; Escobar S, 1995, BLOOD, V86, P74; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; Hsu YR, 1997, J BIOL CHEM, V272, P6406, DOI 10.1074/jbc.272.10.6406; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; Leung DW, 1989, TECHNIQUE, V1, P11; LYMAN SD, 1995, ONCOGENE, V10, P149; LYMAN SD, 1995, INT J HEMATOL, V62, P63; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1995, BLOOD, V86, P4091, DOI 10.1182/blood.V86.11.4091.bloodjournal86114091; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PARK LS, 1986, J BIOL CHEM, V261, P4177; PRICE V, 1987, GENE, V55, P287, DOI 10.1016/0378-1119(87)90288-5; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SRINIVASAN S, 1993, PROTEIN SCI, V2, P277; TAYLOR EW, 1994, J BIOL CHEM, V269, P31171; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x	29	23	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17626	17633		10.1074/jbc.273.28.17626	http://dx.doi.org/10.1074/jbc.273.28.17626			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651358	hybrid			2022-12-27	WOS:000074816100051
J	Kurbanov, FT; Choe, JY; Honzatko, RB; Fromm, HJ				Kurbanov, FT; Choe, JY; Honzatko, RB; Fromm, HJ			Directed mutations in the poorly defined region of porcine liver fructose 1,6-bispbosphatase significantly affect catalysis and the mechanism of AMP inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; 2,6-BISPHOSPHATE; 1,6-BISPHOSPHATASE; BISPHOSPHATASE; COOPERATIVITY; PROTEIN; BINDING; SITE	Asn(64), Asp(68), Lys(71), Lys(72), and Asp(74) of porcine liver fructose-1,6-bisphosphatase (FBPase) are conserved residues and part of a loop for which no electron density has been observed in crystal structures. Yet mutations of the above dramatically affect catalytic rates and/or AMP inhibition. The Asp(74) --> Ala and Asp(74) --> Asn mutant enzymes exhibited 50,000- and 2,000-fold reductions, respectively, in k(cat) relative to wild-type FBPase. The pH optimum for the catalytic activity of the Asp(74), Glu, Asp(68) --> Glu, Asn(64) --> Gln, and Asn(64) --> Ala mutant enzymes shifted from pH 7.0 (wild-type enzyme) to pH 8.5, whereas the Lys(71) --> Ala mutant and Lys(71,72) --> Met double mutant had optimum activity at pH 7.5. Mg2+ cooperativity, K-m for fructose 1,6-bisphosphate, and K-i for fructose 2,6-bisphosphate were comparable for the mutant and wild-type enzymes. Nevertheless, for the Asp(74) --> Glu, Asp(68) --> Glu, Asn(64) --> Gln, and Asn(64) --> Ala mutants, the binding affinity for Mg2+ decreased by 40-125-fold relative to the wild type enzyme. In addition, the Asp(74) --> Glu and Asn(64) --> Ala mutants exhibited no AMP cooperativity, and the kinetic mechanism of AMP inhibition with respect to Mg2+ was changed from competitive to noncompetitive. The double mutation Lys(71,72) --> Met increased K-i for AMP by 175-fold and increased Mg2+ affinity by 2-fold relative to wild-type FBPase. The results reported here strongly suggest that loop 51-72 is important for catalytic activity and the mechanism of allosteric inhibition of FBPase by AMP.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, 1210 Mol Biol Bldg, Ames, IA 50011 USA.	hjfromm@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENCOVIC ST, 1982, ADV ENZYMOL RELAT AR, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHATTERJEE T, 1985, J BIOL CHEM, V260, P3553; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; KE H, 1989, J MOL BIOL, V212, P513; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, NONLINEAR REGRESSION, P13; LIANG JY, 1992, P NATL ACAD SCI USA, V89, P2404, DOI 10.1073/pnas.89.6.2404; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; LU G, 1997, J BIOL CHEM, V270, P5076; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; MACGREGOR JS, 1982, ARCH BIOCHEM BIOPHYS, V217, P652, DOI 10.1016/0003-9861(82)90547-1; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S, 1982, ARCH BIOCHEM BIOPHYS, V218, P609, DOI 10.1016/0003-9861(82)90386-1; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4307, DOI 10.1021/bi00013a020; ZHANG RL, 1995, BIOCHEMISTRY-US, V34, P8190, DOI 10.1021/bi00025a026; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	36	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17511	17516		10.1074/jbc.273.28.17511	http://dx.doi.org/10.1074/jbc.273.28.17511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651342	hybrid			2022-12-27	WOS:000074816100035
J	Rother, KI; Imai, Y; Caruso, M; Beguinot, F; Formisano, P; Accili, D				Rother, KI; Imai, Y; Caruso, M; Beguinot, F; Formisano, P; Accili, D			Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; SELECTIVE INHIBITOR WORTMANNIN; RECEPTOR SUBSTRATE-1 IRS1; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; TARGETED DISRUPTION; HEMATOPOIETIC-CELLS; GLYCOGEN-SYNTHASE	Insulin receptor substrates (IRSs) are tyrosine-phosphorylated following stimulation with insulin, insulinlike growth factors (IGFs), and interleukins. A key questionis whether different IRSs play different roles to mediate insulin's metabolic and growth-promoting effects. In a novel system of insulin receptor-deficient hepatocytes, insulin fails to (i) stimulate glucose phosphorylation, (ii) enhance glycogen synthesis, (iii) suppress glucose production, and (iv) promote mitogenesis, However, insulin's ability to induce IRS-1 and gab-1 phosphorylation and binding to phosphatidylinositol (PI) 3-kinase is unaffected, by virtue of the compensatory actions of IGF-1 receptors, In contrast, phosphorylation of IRS-2 and generation of IRS-2/PI 3-kinase complexes are markedly reduced. Thus, absence of insulin receptors selectively reduces IRS-2, but not IRS-1 phosphorylation, and the impairment of IRS-S activation is associated with lack of insulin effects. To address whether phosphorylation of additional IRSs is also affected, we analyzed phosphotyrosine-containing proteins in PI 3-kinase immunoprecipitates from insulin-treated cells, However, these experiments indicate that IRS-1 and IRS-2 are the main PI 3-kinase bound proteins in hepatocytes, These data identify IRS-2 as the main effector of both the metabolic and growth-promoting actions of insulin through PI 3-kinase in hepatocytes, and IRS-1 as the main substrate mediating the mitogenic actions of IGF-1 receptors.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC 27514 USA; Univ Naples, Sch Med, Dipartimento Biol & Patol Cellulare, Naples, Italy; Univ Naples, Sch Med, CNR, Ctr Endocrinol & Oncol Sperimentale, Naples, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Accili, D (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10D 18, Bethesda, MD 20892 USA.		Formisano, Pietro/J-4237-2018	Formisano, Pietro/0000-0001-7020-6870; Imai, Yumi/0000-0001-5046-4223				Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; Accili D, 1997, TRENDS ENDOCRIN MET, V8, P101, DOI 10.1016/S1043-2760(97)00031-3; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; CHOU JY, 1985, METHOD ENZYMOL, V109, P385; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EFSTRATIADIS A, 1996, EXP CLIN ENDOCR S2, V104, P4; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IYNEDJIAN PB, 1995, J CLIN INVEST, V95, P1966, DOI 10.1172/JCI117880; Joshi RL, 1996, EMBO J, V15, P1542, DOI 10.1002/j.1460-2075.1996.tb00498.x; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; MOSES AC, 1995, DIABETES RES CLIN PR, V28, pS185, DOI 10.1016/0168-8227(95)01084-Q; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NIKOLICRORDORF T, 1995, J BIOL CHEM, V270, P3662; OKADA T, 1994, J BIOL CHEM, V269, P3568; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; Sciacchitano S, 1997, ENDOCRINOLOGY, V138, P4931, DOI 10.1210/en.138.11.4931; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	63	135	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17491	17497		10.1074/jbc.273.28.17491	http://dx.doi.org/10.1074/jbc.273.28.17491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651339	hybrid, Green Published			2022-12-27	WOS:000074816100032
J	Stachowiak, O; Dolder, M; Wallimann, T; Richter, C				Stachowiak, O; Dolder, M; Wallimann, T; Richter, C			Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-FREE-RADICALS; NITRIC-OXIDE; SARCOPLASMIC-RETICULUM; HYDROGEN-PEROXIDE; BINDING; MUSCLE; HEART; SUPEROXIDE; CA2+; RESPIRATION	The reaction of peroxynitrite (PN) with sarcomeric mitochondrial creatine kinase (Mi(b)-CK; EC 2.7.3.2) was observed at different stages of complexity (i) with purified Mi-CK, (ii) with enzyme bound on isolated mitoplasts, and (iii) within intact respiring mitochondria. Creatine-stimulated respiration was abolished by PN concentrations likely to be physiological and far before the respiratory chain itself was affected, thus demonstrating that Mi-CK is a prime target for inactivation by PN in intact mitochondria. The inactivation by PN of Mi CK was reversed by 22% with 2-mercaptoethanol. More remarkable protective effects were noticed with the full set of CK substrates, e.g. 30 and 50% protection with MgATP plus creatine and MgADP plus phosphocreatine, respectively, but not with each substrate alone. These data indicate an involvement of the active-site Cys-278 residue of Mi CK in this process. Furthermore, changes in endogenous tryptophan fluorescence intensity and spectral changes after reaction of Mi-CK with PN suggest additional modifications of Trp and Tyr residues. PN-inactivated Mi-CK can no longer be efficiently converted into dimers by incubation with reagents inducing a transition state analog complex at the active site. Thus, obviously, upon reaction of octameric Mi-CK with PN, the octamer-dimer equilibrium of Mi-CK is also affected. The consequences for cellular energy homeostasis and calcium handling are discussed.	ETH Zurich, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; ETH Zurich, Biochem Lab 1, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Wallimann, T (corresponding author), ETH Zurich, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	walliman@cell.biol.ethz.ch	Wallimann, Theo/C-6047-2008	Wallimann, Theo/0000-0003-4957-5836				AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590, DOI 10.1152/ajpheart.1991.261.2.H590; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY MR, 1995, BIOCHEMISTRY-US, V34, P2006, DOI 10.1021/bi00006a022; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; EPPENBERGER HM, 1981, J CELL BIOL, V89, P185, DOI 10.1083/jcb.89.2.185; Forstner M, 1996, J MOL STRUCT, V383, P217, DOI 10.1016/S0022-2860(96)09289-7; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; Gross WL, 1996, P NATL ACAD SCI USA, V93, P5604, DOI 10.1073/pnas.93.11.5604; HAMMAN BL, 1995, AM J PHYSIOL-HEART C, V269, pH1030, DOI 10.1152/ajpheart.1995.269.3.H1030; KAUL N, 1993, J PHARMACOL TOX MET, V30, P55, DOI 10.1016/1056-8719(93)90008-3; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; KORGE P, 1994, AM J PHYSIOL, V267, pC357, DOI 10.1152/ajpcell.1994.267.2.C357; KORGE P, 1993, ARCH BIOCHEM BIOPHYS, V304, P420, DOI 10.1006/abbi.1993.1370; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P87, DOI 10.1016/0005-2728(88)90111-9; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MCCORD JM, 1994, CURR TOP BIOENERG, V17, P173; Mekhfi H, 1996, CIRC RES, V78, P1016, DOI 10.1161/01.RES.78.6.1016; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Padmaja S, 1996, REDOX REP, V2, P173, DOI 10.1080/13510002.1996.11747045; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramezanian MS, 1996, CHEM RES TOXICOL, V9, P232, DOI 10.1021/tx950135w; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SCHLAME M, 1985, BIOMED BIOCHIM ACTA, V44, P1083; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Stachowiak O, 1996, BIOCHEMISTRY-US, V35, P15522, DOI 10.1021/bi961838v; STACHOWIAK O, 1998, IN PRESS MOL CELL BI; STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089; SUZUKI YJ, 1992, FREE RADICAL RES COM, V16, P131, DOI 10.3109/10715769209049166; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; Wolosker H, 1996, FEBS LETT, V392, P274, DOI 10.1016/0014-5793(96)00829-0; YUAN GX, 1992, BIOCHIM BIOPHYS ACTA, V1140, P78, DOI 10.1016/0005-2728(92)90022-T	54	155	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16694	16699		10.1074/jbc.273.27.16694	http://dx.doi.org/10.1074/jbc.273.27.16694			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642223	hybrid			2022-12-27	WOS:000074545200013
J	Wang, CC; Lu, SC; Chen, HL; Liao, TH				Wang, CC; Lu, SC; Chen, HL; Liao, TH			Porcine spleen deoxyribonuclease II - Covalent structure, cDNA sequence, molecular cloning, and gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC DEOXYRIBONUCLEASE; LYSOSOMAL-ENZYMES; DNASE-II; PURIFICATION	Porcine spleen DNase II, a lysosomal acid hydrolase, is a noncovalently linked alpha.beta heterodimer (Liao, T.-H, (1985) J, Biol, Chem, 260, 10708-10713), The cu subunit, after disulfide cleavage, yields two chains, alpha 1 and alpha 2. The complete amino acid sequences of the alpha 1, beta, and alpha 2 chains were elucidated by protein sequencing, and the pairings of one interchain disulfide between alpha 1 and alpha 2 and of three intrachain disulfides in a2 were assigned. Six carbohydrate attachment sites, two in beta and four in alpha 2, were detected by sugar analyses. The cDNA of DNase II was amplified using primers synthesized on the basis of the amino acid sequences determined. The amplified fragments shown to be a cDNA sequence of 1,292 bases. This cDNA sequence has an open reading frame encoding a 364-amino acid polypeptide containing a putative transmembrane peptide at the NH2-end, two small connecting peptides in the middle, and a peptide at the COOH terminus, These are evidently removed to form mature DNase II. Thus, all three chains in the sequence alpha 1, beta, and alpha 2 are coded by the same cDNA, When Chinese hamster ovary cells were transfected with a cloned plasmid with an inserted cDNA fragment encoding the entire reading frame, the expressed protein was released into the growth medium as an active form of DNase II.	Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei, Taiwan	National Taiwan University; National Taiwan University	Liao, TH (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, 1,Sect 1,JenAi Rd, Taipei, Taiwan.			Chen, Hui-Ling/0000-0002-2572-0595				BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bernardi G., 1971, HYDROLYSIS, P271; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; BOYER MJ, 1993, ADV CANCER RES, V60, P269; CHANG HC, 1990, ARCH BIOCHEM BIOPHYS, V280, P320, DOI 10.1016/0003-9861(90)90336-W; CHANG YM, 1994, BIOTECHNOL APPL BIOC, V19, P129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; FLORINCHRISTENSEN M, 1989, EUR J CELL BIOL, V48, P1; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; KOIZUMI T, 1995, EXP ANIM TOKYO, V44, P169, DOI 10.1538/expanim.44.169; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUKURUZINSKA MA, 1987, ANN REV BIOCH, V56, P15; LIAO TH, 1989, BIOCHIM BIOPHYS ACTA, V1007, P15, DOI 10.1016/0167-4781(89)90124-3; LIAO TH, 1985, J BIOL CHEM, V260, P708; Liao TH, 1997, J FORMOS MED ASSOC, V96, P481; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; MANIATIS T, 1982, MOL CLONING LAB MANU, P11; MORDIER SB, 1995, EUR J BIOCHEM, V229, P35, DOI 10.1111/j.1432-1033.1995.0035l.x; NAKAMURA Y, 1989, MECH AGEING DEV, V50, P215, DOI 10.1016/0047-6374(89)90101-2; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Ord T, 1997, ARCH BIOCHEM BIOPHYS, V339, P64, DOI 10.1006/abbi.1996.9870; OSHIMA RG, 1973, J BIOL CHEM, V248, P7522; PAUDEL HK, 1986, J BIOL CHEM, V261, P6006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shen Pei-Ming, 1993, Journal of the Chinese Biochemical Society, V22, P99; SUZUKI Y, 1995, JPN J CLIN MED, V53, P2887; TORRIGLIA A, 1995, J BIOL CHEM, V270, P28579, DOI 10.1074/jbc.270.48.28579; Yasuda T, 1998, J BIOL CHEM, V273, P2610, DOI 10.1074/jbc.273.5.2610	30	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17192	17198		10.1074/jbc.273.27.17192	http://dx.doi.org/10.1074/jbc.273.27.17192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642288	hybrid			2022-12-27	WOS:000074545200078
J	Wong, HN; Ward, MA; Bell, AW; Chevet, E; Bains, S; Blackstock, WP; Solari, R; Thomas, DY; Bergeron, JJM				Wong, HN; Ward, MA; Bell, AW; Chevet, E; Bains, S; Blackstock, WP; Solari, R; Thomas, DY; Bergeron, JJM			Conserved in vivo phosphorylation of calnexin at casein kinase II sites as well as a protein kinase C proline-directed kinase site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; MASS-SPECTROMETRY; MEMBRANE-PROTEIN; QUALITY-CONTROL; CALRETICULIN; ASSOCIATION; BINDING; GLYCOPROTEINS; PEPTIDES	Calnexin is a lectin-like chaperone of the endoplasmic reticulum (ER) that couples temporally and spatially N-linked oligosaccharide modifications with the productive folding of newly synthesized glycoproteins. Calnexin was originally identified as a major type I integral membrane protein substrate of kinase(s) associated with the ER, Casein kinase II (CK2) was subsequently identified as an ER-associated kinase responsible for the in vitro phosphorylation of calnexin in microsomes (Ou, W-J,, Thomas, D. Y., Bell, A. W., and Bergeron, J, J, M, (1992) J. Biol. Chem. 267, 23789-23796). We now report on the in vivo sites of calnexin phosphorylation, After (PO4)-P-32 labeling of HepG2 and Madin-Darby canine kidney cells, immunoprecipitated calnexin was phosphorylated exclusively on serine residues. Using nonradiolabeled cells, we subjected calnexin immunoprecipitates to in gel tryptic digestion followed by nanoelectrospray mass spectrometry employing selective scans specific for detection of phosphorylated fragments. Mass analyses identified three phosphorylated sites in calnexin from either HepG2 or Madin-Darby canine kidney cells. The three sites were localized to the more carboxyl-terminal half of the cytosolic domain: S(534)DAE (CK2 motif), S(544)QEE (CK2 motif), and (SPR)-P-563. We conclude that CK2 is a kinase that phosphorylates calnexin in vivo as well as in microsomes in vitro, Another yet to be identified kinase (protein kinase C and/or proline-directed kinase) is directed toward the most COOH-terminaI serine residue. Elucidation of the signaling cascade responsible for calnexin phosphorylation at these sites in vivo may define a novel regulatory function for calnexin in cargo folding and transport to the ER exit sites.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England	McGill University; McGill University; National Research Council Canada; GlaxoSmithKline	Bergeron, JJM (corresponding author), McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada.	eh14@musica.mcgill.ca	chevet, eric/E-4992-2016; Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	chevet, eric/0000-0001-5855-4522; Thomas, David/0000-0002-8854-762X				ALLEN G, 1989, SEQUENCING PROTEINS; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Betts JC, 1997, J BIOL CHEM, V272, P12922, DOI 10.1074/jbc.272.20.12922; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAPPS GG, 1994, J BIOL CHEM, V269, P11634; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; COVEY T, 1991, ADV LIF SCI, P249; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DAVID V, 1993, J BIOL CHEM, V268, P9585; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; LE AQ, 1994, J BIOL CHEM, V269, P7514; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PARLATI F, 1995, EMBO J, V14, P3064, DOI 10.1002/j.1460-2075.1995.tb07309.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Schaller J, 1997, RAPID COMMUN MASS SP, V11, P418, DOI 10.1002/(SICI)1097-0231(19970228)11:4<418::AID-RCM795>3.0.CO;2-R; SCHUE V, 1994, BIOCHEM BIOPH RES CO, V203, P22, DOI 10.1006/bbrc.1994.2143; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Tanaka H, 1997, GENE, V204, P159, DOI 10.1016/S0378-1119(97)00537-4; TECTOR M, 1994, J BIOL CHEM, V269, P25816; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WATANABE D, 1994, J BIOL CHEM, V269, P7744; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	52	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17227	17235		10.1074/jbc.273.27.17227	http://dx.doi.org/10.1074/jbc.273.27.17227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642293	hybrid			2022-12-27	WOS:000074545200083
J	Albini, A; Benelli, R; Giunciuglio, D; Cai, T; Mariani, G; Ferrini, S; Noonan, DM				Albini, A; Benelli, R; Giunciuglio, D; Cai, T; Mariani, G; Ferrini, S; Noonan, DM			Identification of a novel domain of HIV Tat involved in monocyte chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; GROWTH-FACTOR; ENDOTHELIAL-CELLS; TRANSGENIC MICE; IN-VIVO; PROTEIN; TYPE-1; BINDING; INDUCTION	Human immunodeficiency virus (HIV) Tat is chemotactic for monocytes and dendritic cells, an activity that could play a hey role in the expansion of HIV infection of accessory cells. To date, domains of Tat previously found to interact with cell surface molecules have shown only partial chemotactic activity toward monocytes. Using overlapping Tat peptides, we identify a novel region of Tat with a potent chemotactic activity for monocytes, reaching levels equal to Tat itself. This peptide also provokes monocyte polarization similar to Tat and is able to compete with Tat for induction of monocyte migration. Specific high affinity (k(d) = 3 x 10(-9) M) cell surface binding sites on monocyte cell surfaces for this region of Tat are demonstrated. These data indicate that the majority of Tat effects on monocytes are mediated by a novel region in the cysteine-rich and core domains. These domains are highly conserved among different HIV isolates, suggesting an important role in the establishment of HIV infection.	Ist Nazl Ric Canc, Ctr Biotechnol Avanzate, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Med Interna, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Albini, A (corresponding author), Ist Nazl Ric Canc, Ctr Biotechnol Avanzate, Largo Rosanna Benzi N10, I-16132 Genoa, Italy.	albini@sirio.cba.unige.it	Benelli, Roberto/AAF-3143-2019; Noonan, Douglas M/A-8620-2010	Benelli, Roberto/0000-0002-9769-0954; Noonan, Douglas M/0000-0001-8058-0719; Mariani, Giuliano/0000-0002-1900-4488; Albini, Adriana/0000-0002-9624-5103; Ferrini, Silvano/0000-0001-7254-2616				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Benelli R, 1998, AIDS, V12, P261, DOI 10.1097/00002030-199803000-00003; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FRANCHINI G, 1987, BLOOD, V69, P437; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JEANG KT, 1994, HUMAN RETROVIRUSES A; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARTINET Y, 1994, J IMMUNOL METHODS, V174, P209, DOI 10.1016/0022-1759(94)90024-8; MCPHEE DA, 1988, FEBS LETT, V233, P393, DOI 10.1016/0014-5793(88)80468-X; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WEEKS BS, 1993, J BIOL CHEM, V268, P5279; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898	41	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15895	15900		10.1074/jbc.273.26.15895	http://dx.doi.org/10.1074/jbc.273.26.15895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632634	hybrid			2022-12-27	WOS:000074436600005
J	Bhisutthibhan, J; Pan, XQ; Hossler, PA; Walker, DJ; Yowell, CA; Carlton, J; Dame, JB; Meshnick, SR				Bhisutthibhan, J; Pan, XQ; Hossler, PA; Walker, DJ; Yowell, CA; Carlton, J; Dame, JB; Meshnick, SR			The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA; ENDOPEROXIDES; HEMOZOIN; CULTURE; BINDING; INVITRO; HEMIN	Artemisinin and its derivatives are important new antimalarial drugs. When Plasmodium falciparum-infected erythrocytes are incubated with [10-H-3]dihydroartemisinin, several malaria-specific proteins become labeled. One of these proteins is the P. falciparum translationally controlled tumor protein (TCTP) homolog. In vitro, dihydroartemisinin reacts covalently with recombinant TCTP in the presence of hemin. The association between drug and protein increases with increasing drug concentration, plateauing at approximately 1 drug/TCTP molecule. By Scatchard analysis, there appear to be 2 hemin binding sites on TCTP with dissociation constants of similar to 18 mu M, When the single cysteine moiety is blocked by pretreatment with iodoacetamide, hemin binding is not affected, whereas drug binding is reduced by two-thirds. Thus, TCTP reacts with artemisinin in situ and in vitro in the presence of hemin and appears to bind to hemin, The function of the malarial TCTP and the role of this reaction in the mechanism of action of artemisinin await elucidation.	Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Florida, Coll Vet Med, Dept Infect Dis, Gainesville, FL 32610 USA	University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Meshnick, SR (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.	meshnick@umich.edu		Dame, John B./0000-0002-5772-5454	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI026848, R01AI026848, R22AI026848] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26848] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASAWAMAHASAKDA W, 1994, ANTIMICROB AGENTS CH, V38, P1854, DOI 10.1128/AAC.38.8.1854; ASAWAMAHASAKDA W, 1994, MOL BIOCHEM PARASIT, V67, P183, DOI 10.1016/0166-6851(94)00128-6; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cumming J N, 1997, Adv Pharmacol, V37, P253; Dame JB, 1996, MOL BIOCHEM PARASIT, V79, P1, DOI 10.1016/0166-6851(96)02641-2; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; GACHET Y, 1997, BIOCHEM SOC T, V25, P269; HAGHIGHAT NG, 1992, MOL BIOCHEM PARASIT, V51, P99, DOI 10.1016/0166-6851(92)90205-X; HARLOW B, 1988, ANTIBODIES LAB MANUA, P288; HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0; Kamchonwongpaisan S, 1997, AM J TROP MED HYG, V56, P7, DOI 10.4269/ajtmh.1997.56.7; KEMP DJ, 1985, NATURE, V315, P347, DOI 10.1038/315347a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Meshnick SR, 1996, MICROBIOL REV, V60, P301, DOI 10.1128/MMBR.60.2.301-315.1996; MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B; MESHNICK SR, 1994, LANCET, V344, P1441; Robert A, 1997, J AM CHEM SOC, V119, P5968, DOI 10.1021/ja970412g; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; Sullivan AD, 1996, PARASITOLOGY, V112, P285, DOI 10.1017/S003118200006580X; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	26	196	216	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16192	16198		10.1074/jbc.273.26.16192	http://dx.doi.org/10.1074/jbc.273.26.16192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632675	hybrid			2022-12-27	WOS:000074436600046
J	Chang, MY; Olin, KL; Tsoi, C; Wight, TN; Chait, A				Chang, MY; Olin, KL; Tsoi, C; Wight, TN; Chait, A			Human monocyte-derived macrophages secrete two forms of proteoglycan-macrophage colony-stimulating factor that differ in their ability to bind low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; MOLECULAR-WEIGHT; ARTERIAL PROTEOGLYCANS; PLASMA-LIPOPROTEINS; BLOOD MONOCYTES; GROWTH-FACTOR; FACTOR-I; EXPRESSION; ATHEROSCLEROSIS	This study evaluated whether human monocyte-derived macrophages synthesize specific types of proteoglycans with lipoprotein-binding capability that could contribute to lipid retention in the arterial wall. After labeling with either [S-36]SO4 or [S-36]methionine, macrophages secreted a high molecular mass proteoglycan, with glycosaminoglycan chains of similar to 18 kDa and core protein bands of similar to 100 and 55 kDa, Both core protein bands were recognized by an antibody to PG-100, an antibody that recognizes the proteoglycan form of macrophage colony-stimulating factor PG-100/PG-MCSF), The interaction between PG-100/PG-MCSF and low density lipoproteins (LDL) was examined by gel mobility shift. In this system, PG-100/PG-MCSF was resolved further into two forms. The two forms had the same core proteins but differed in their overall size and glycosaminoglycan content. The larger form contained glycosaminoglycan chains that were entirely chondroitin ABC lyase-sensitive, whereas the smaller form contained chains that were sensitive to both chondroitin ABC lyase and heparinase, Both forms bound native LDL with high affinity, but the larger form bound LDL with higher affinity than the smaller form. The glycosaminoglycan chains of PG-100/PG-MCSF, but not the core proteins, were responsible for binding to native LDL, Mildly oxidized LDL and methyl-LDL, which have an electrophoretic charge similar to that of native LDL, also bound PG-100/PG-MCSF. In contrast, extensively oxidized LDL and acetyl-LDL, which are more electronegative than native LDL, did not bind to either form of PG-100/PG-MCSF. The demonstration of two forms of human monocyte-derived macrophage PG-100/PG-MCSF which bind LDL may represent an additional role for macrophages in the extracellular trapping of lipoproteins in atherosclerosis.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chait, A (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIDDK NIH HHS [DK 02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVES CS, 1988, ATHEROSCLEROSIS, V73, P113, DOI 10.1016/0021-9150(88)90032-9; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Buege J A, 1978, Methods Enzymol, V52, P302; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CHAIT A, 1982, METABOLISM, V31, P721, DOI 10.1016/0026-0495(82)90204-9; CHANG MY, 1995, CIRCULATION S1, V92, P288; CHRISTNER JE, 1988, ARTERIOSCLEROSIS, V8, P535, DOI 10.1161/01.ATV.8.5.535; CHUNG BH, 1980, J LIPID RES, V21, P284; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; EDWARDS IJ, 1993, J LIPID RES, V34, P1155; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; HEINECKE JW, 1991, ARTERIOSCLER THROMB, V11, P1643, DOI 10.1161/01.ATV.11.6.1643; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HORIGUCHI J, 1988, MOL CELL BIOL, V8, P3951, DOI 10.1128/MCB.8.9.3951; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; INOUE I, 1992, ATHEROSCLEROSIS, V93, P245, DOI 10.1016/0021-9150(92)90261-E; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISMAIL NAE, 1994, ATHEROSCLEROSIS, V105, P79, DOI 10.1016/0021-9150(94)90010-8; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; LEE MT, 1990, J LEUKOCYTE BIOL, V47, P275, DOI 10.1002/jlb.47.3.275; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; MAYNE R, 1986, ARTERIOSCLEROSIS, V6, P585, DOI 10.1161/01.ATV.6.6.585; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; OOSHIMA A, 1981, SCIENCE, V213, P666, DOI 10.1126/science.7256267; OWENS RT, 1991, ATHEROSCLEROSIS, V91, P229, DOI 10.1016/0021-9150(91)90170-8; PARTENHEIMER A, 1995, J IMMUNOL, V155, P5557; RADHAKRISHNAMURTHY B, 1990, EUR HEART J, V11, P148, DOI 10.1093/eurheartj/11.suppl_E.148; REZVIN A, 1989, BIOTECHNIQUES, V7, P346; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schonherr E, 1997, ARCH BIOCHEM BIOPHYS, V339, P353, DOI 10.1006/abbi.1996.9854; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STOUDEMIRE JB, 1991, BLOOD, V77, P750; SUZU S, 1994, J CLIN INVEST, V94, P1637, DOI 10.1172/JCI117506; SUZU S, 1992, J BIOL CHEM, V267, P4345; SUZU S, 1992, J BIOL CHEM, V267, P16812; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; UHLINHANSEN L, 1993, BLOOD, V82, P2880; UHLINHANSEN L, 1992, BLOOD, V80, P1058; VIJAYAGOPAL P, 1994, BIOCHEM J, V301, P675, DOI 10.1042/bj3010675; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WIESER M, 1989, BLOOD, V73, P1105; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; YAMADA N, 1992, P SOC EXP BIOL MED, V200, P240	58	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15985	15992		10.1074/jbc.273.26.15985	http://dx.doi.org/10.1074/jbc.273.26.15985			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632647	hybrid			2022-12-27	WOS:000074436600018
J	Chatterjee-Kishore, M; Kishore, R; Hicklin, DJ; Marincola, FM; Ferrone, S				Chatterjee-Kishore, M; Kishore, R; Hicklin, DJ; Marincola, FM; Ferrone, S			Different requirements for signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; PEPTIDASE ACTIVITIES; T-CELLS; GAMMA; PROTEASOMES; IRF-1; TAP1; IFN; ELEMENTS; LMP2	The components of the antigen processing machinery, low molecular mass polypeptide (LMP) 2 and transporter associated with antigen processing (TAP) 1, are encoded by closely linked genes within the major histocompatibility complex class II subregion. Although the two genes share a bi-directional promoter, LMP2 and TAP1 have differential cellular expression. TAP1 is expressed constitutively. However, LMP2 expression requires induction by interferon-gamma in most cells. The regulatory elements within the LMP2/TAP1 promoter and the transcription factors that bind these elements have been defined, However, how these transactivators regulate differential TAP1 and LMP2 gene transcription is not known. We have addressed this question by analyzing three human melanoma cell lines with distinct phenotypes of LMP2 and TAP1 expression.Whereas binding of either interferon regulatory factor 1 or Stat1 to the overlapping interferon consensus sequence-2/GAS is sufficient for regulating transcription of the TAP1 gene, binding of both factors is required for LMP2 gene transcription. This conclusion is supported by restoration of LMP2 gene transcription following transfection of wild type Stat1 alpha or interferon regulatory factor 1 cDNA into cells lacking these transcription factors. The flexibility in the regulation of the TAP1 gene may reflect its role in maintaining immune surveillance. Furthermore, lack of LMP2 gene transcription in quiescent human cells suggests that LMP2 expression reflects a state of cell activation.	New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA; NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	New York Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ferrone, S (corresponding author), New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.				NATIONAL CANCER INSTITUTE [R01CA067108] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HANIEL A, 1995, J BIOL CHEM, V270, P11209, DOI 10.1074/jbc.270.19.11209; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HICKLIN DJ, 1996, IMMUNOLOGY HUMAN MEL, P95; HOMBACH J, 1995, J EXP MED, V182, P1615, DOI 10.1084/jem.182.5.1615; Kishore R, 1998, TISSUE ANTIGENS, V51, P129; Min W, 1996, J IMMUNOL, V156, P3174; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NGUYEN H, 1995, ONCOGENE, V11, P537; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Nonaka M, 1997, J IMMUNOL, V159, P734; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Seliger B, 1997, CLIN CANCER RES, V3, P573; Singal DP, 1996, INT J CANCER, V68, P629, DOI 10.1002/(SICI)1097-0215(19961127)68:5<629::AID-IJC13>3.0.CO;2-X; Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8; TANAKA K, 1994, J LEUKOCYTE BIOL, V56, P571, DOI 10.1002/jlb.56.5.571; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEBERNORT RM, 1996, BLOOD, V1, P809; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	34	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16177	16183		10.1074/jbc.273.26.16177	http://dx.doi.org/10.1074/jbc.273.26.16177			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632673	hybrid			2022-12-27	WOS:000074436600044
J	Feick, P; Gilhaus, S; Schulz, I				Feick, P; Gilhaus, S; Schulz, I			Pervanadate stimulates amylase release and protein tyrosine phosphorylation of paxillin and p125(FAK) in differentiated AR4-2J pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SWISS 3T3 CELLS; RAT ADIPOCYTES; PHORBOL ESTER; GROWTH-FACTOR; CROSS-TALK; SECRETION; BOMBESIN; INSULIN; CHOLECYSTOKININ	We have studied the role of protein tyrosine phosphorylation in amylase secretion from differentiated AR4-2J cells, The secretagogue bombesin, the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), and the protein-tyrosine phosphatase inhibitor pervanadate induced tyrosine phosphorylation of different proteins, including paxillin and p125(FAK), which was reduced or blocked by the tyrosine kinase inhibitors genistein and tyrphostin B56, respectively. Both PMA and pervanadate continuously increased amylase secretion with a similar time course, reaching the level of bombesin-induced amylase release after 60 min. Their effects were not additive and could be inhibited by preincubation of AR4-2J cells with genistein or tyrphostin B56, respectively. Inhibition of protein kinase C with Ro 31-8220 nearly abolished the effects of PMA, but had no effect on either pervanadate-induced protein tyrosine phosphorylation or amylase secretion, An increase in cytosolic free Ca2+ concentration by thapsigargin or A23187 caused a rapid increase in amylase release within the initial 5 min, In the presence of PMA or pervanadate, amylase secretion was further stimulated to levels comparable to those induced by bombesin after 30 min of stimulation. Inhibition of PMA-induced amylase secretion by Ro 31-8220 was less at elevated cytosolic free Ca2+ concentrations than without Ca2+. Furthermore, an increase in cytosolic free Ca2+ concentration had no effect on protein tyrosine phosphorylation in either the absence or presence of PMA or pervanadate, We therefore conclude that in the cascade of events that lead to bombesin-induced protein secretion from AR4-2J cells, protein tyrosine phosphorylation occurs downstream of protein kinase C activation, A further step in secretion that is Ca2+-dependent occurs distal to protein tyrosine phosphorylation.	Univ Saarlandes, Inst Physiol 2, D-66421 Homburg, Germany	Saarland University	Schulz, I (corresponding author), Univ Saarlandes, Inst Physiol 2, D-66421 Homburg, Germany.							BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEPONT JJHHM, 1984, FEBS LETT, V170, P64, DOI 10.1016/0014-5793(84)81369-1; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; Garcia LJ, 1997, BIOCHEM J, V327, P461; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; KIMURA T, 1986, AM J PHYSIOL, V250, pG698, DOI 10.1152/ajpgi.1986.250.5.G698; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGSDON CD, 1986, J BIOL CHEM, V261, P2096; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; MAY JM, 1979, J BIOL CHEM, V254, P9017; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PIIPER A, 1994, AM J PHYSIOL, V266, pG363, DOI 10.1152/ajpgi.1994.266.3.G363; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SCHULZ I, 1989, HDB PHYSL GASTROINTE, V3, P443; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHECHTER Y, 1993, ENDEAVOUR, V17, P27, DOI 10.1016/0160-9327(93)90008-Q; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	43	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16366	16373		10.1074/jbc.273.26.16366	http://dx.doi.org/10.1074/jbc.273.26.16366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632700	hybrid			2022-12-27	WOS:000074436600071
J	Helman, D; Staten, NR; Grosclaude, J; Daniel, N; Nespoulous, C; Djiane, J; Gertler, A				Helman, D; Staten, NR; Grosclaude, J; Daniel, N; Nespoulous, C; Djiane, J; Gertler, A			Novel recombinant analogues of bovine placental lactogen - G133K and G133R provide a tool to understand the difference between the action of prolactin and growth hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; ESCHERICHIA-COLI; TYROSINE KINASE; EXTRACELLULAR DOMAIN; RATIONAL DESIGN; NB2 CELLS; PROTEINS; BINDING; PROLIFERATION; MUTAGENESIS	Two new analogues of bovine placental lactogen (bPL), bPL(G133K) and bPL(G133R), were expressed in Escherichia coli, refolded, and purified to a native form. Binding experiments, which are likely to represent the binding to site 1 only, to intact FDC-P1 cells transfected with rabbit (rb) growth hormone receptor (GHR) or with human (h) GHR, to Nb2 rat lymphoma cells, or to rabbit mammary gland membranes prolactin receptor (PRLR), revealed only small or no reduction in binding capacity, The complex formation between these analogues and receptor extracellular domains (R-ECD) of various hormones was determined by gel filtration. Wild type bPL yielded 1:2 complex with hGHR-ECD, rat PRLR-ECD, and rbPRLR-ECD, whereas both analogues formed only 1:1 complexes with all R-ECDs tested. Real time kinetics experiments demonstrated that the ability of the analogues to form homodimeric complexes was compromised in both PRLR- and GHR-ECDs. The biological activity transduced through lactogenic receptors in in vitro bioassays in rabbit mammary gland acini culture and in Nb2 cells was almost fully retained, whereas the activity transduced through somatogenic receptors in FDC-P1 cells transfected with rbGHRs or with hGHRs was abolished, Both analogues exhibited antagonistic activity in the latter cells. To explain the discrepancy between the effect of the mutation on the signal transduced by PLR versus GHRs we suggest that: 1) the mutation impairs the ability of site 2 of bPL to form a stable homodimeric complex with both lactogenic and somatogenic receptors by a drastic shortening of the half-life of 2:1 complex; 2) the transient existence of the homodimeric complex is still sufficient to initiate the signal transduced through lactogenic receptors but not through somatogenic receptors; and 3) one possible reason for this difference is that JAK2, which serves as a mediator of both receptors, is already associated with lactogenic receptors prior to hormone binding-induced receptor dimerization, whereas in somatogenic receptors the JAK2 receptor association occurs subsequently to receptor dimerization.	Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; INRA, Unite Endocrinol Mol, F-78352 Jouy En Josas, France; INRA, Unite Virol & Immunol Mol, F-78352 Jouy En Josas, France; INRA, Unite Biochim & Struct Prot, F-78352 Jouy En Josas, France; Monsanto Co, Dept Biol Mol, St Louis, MO 63198 USA; Monsanto Co, Div Anim Sci, St Louis, MO 63198 USA	Hebrew University of Jerusalem; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Monsanto; Monsanto	Gertler, A (corresponding author), Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel.	gertler@agri.huji.ac.il						ANTHONY RV, 1995, J REPROD FERTIL, P83; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BINDER L, 1989, MOL ENDOCRINOL, V3, P923, DOI 10.1210/mend-3-6-923; BYATT JC, 1990, ENDOCRINOLOGY, V127, P1041, DOI 10.1210/endo-127-3-1041; CHEN WY, 1995, MOL ENDOCRINOL, V9, P292, DOI 10.1210/me.9.3.292; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHRISTINGER HW, 1998, IN PRESS ACTA CRYS D; COLLIER RJ, 1995, INTERCELLULAR SIGNALLING IN THE MAMMARY GLAND, P13; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; Daniel N, 1996, MOL CELL ENDOCRINOL, V118, P25, DOI 10.1016/0303-7207(95)03763-2; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; DJIANE J, 1982, ENDOCRINOLOGY, V110, P791, DOI 10.1210/endo-110-3-791; FORSYTH IA, 1986, J DAIRY SCI, V69, P886, DOI 10.3168/jds.S0022-0302(86)80479-9; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1992, J BIOL CHEM, V267, P12655; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; Gertler A, 1997, J MAMMARY GLAND BIOL, V2, P69, DOI 10.1023/A:1026377614430; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; Helman D, 1997, ENDOCRINOLOGY, V138, P4069, DOI 10.1210/en.138.10.4069; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KANE JF, 1992, NUCLEIC ACIDS RES, V20, P6707, DOI 10.1093/nar/20.24.6707; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1995, HORM RES, V42, P133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; NESPOULOUS C, 1992, PLANTA, V186, P551, DOI 10.1007/BF00198035; OBUKOWICZ MG, 1992, APPL ENVIRON MICROB, V58, P1511, DOI 10.1128/AEM.58.5.1511-1523.1992; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rowlinson SW, 1996, ENDOCRINOLOGY, V137, P90, DOI 10.1210/en.137.1.90; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; RUI H, 1992, J BIOL CHEM, V267, P24076; Sakal E, 1997, FEBS LETT, V410, P289, DOI 10.1016/S0014-5793(97)00581-4; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SHAMAY A, 1990, MOL CELL ENDOCRINOL, V69, P217, DOI 10.1016/0303-7207(90)90015-Z; Smit LS, 1997, ENDOCRINOLOGY, V138, P3426, DOI 10.1210/en.138.8.3426; TARTOF KD, 1987, FOCUS, V9, P12; TCHELET A, 1993, PEDIAT AD E, V24, P114; VASHDI D, 1992, FEBS LETT, V305, P101, DOI 10.1016/0014-5793(92)80873-F; VashdiElberg D, 1996, J BIOL CHEM, V271, P5558, DOI 10.1074/jbc.271.10.5558	43	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16067	16074		10.1074/jbc.273.26.16067	http://dx.doi.org/10.1074/jbc.273.26.16067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632658	hybrid			2022-12-27	WOS:000074436600029
J	Howland, DS; Trusko, SP; Savage, MJ; Reaume, AG; Lang, DM; Hirsch, JD; Maeda, N; Siman, R; Greenberg, BD; Scott, RM; Flood, DG				Howland, DS; Trusko, SP; Savage, MJ; Reaume, AG; Lang, DM; Hirsch, JD; Maeda, N; Siman, R; Greenberg, BD; Scott, RM; Flood, DG			Modulation of secreted beta-amyloid precursor protein and amyloid beta peptide in brain by cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E GENOTYPE; CENTRAL-NERVOUS-SYSTEM; CARBOXYL-TERMINAL DERIVATIVES; FAMILIAL ALZHEIMER-DISEASE; GOLGI-APPARATUS; CEREBROSPINAL-FLUID; DEFICIENT MICE; BLOOD-PRESSURE; TYPE-4 ALLELE; CELLS	The effects of dietary cholesterol on brain amyloid precursor protein (APP) processing were examined using an APP gene-targeted mouse, genetically humanized in the amyloid beta-peptide (A beta) domain and expressing the Swedish familial Alzheimer's disease mutations. These mice express endogenous levels of APP holoprotein and abundant human A beta. Increased dietary cholesterol led to significant reductions in brain levels of secreted APP derivatives, including sAPP alpha, sAPP beta, A beta 1-40, and A beta 1-42, while having little to no effect on cell-associated species, including full-length APP and the COOH-terminal APP processing derivatives. The changes in levels of sAPP and A beta in brain all were negatively correlated with serum cholesterol levels and levels of serum and brain apoE, These results demonstrate that secreted APP processing derivatives and A beta can be modulated in the brain of an animal by diet and provide evidence that cholesterol plays a role in the modulation of APP processing in vivo. APP gene-targeted mice lacking apoE, also have high serum cholesterol levels but do not show alterations in APP processing, suggesting that effects of cholesterol on APP processing require the presence of apoE.	Cephalon Inc, W Chester, PA 19380 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA	Teva Pharmaceutical Industries; Cephalon Inc.; University of North Carolina; University of North Carolina Chapel Hill	Flood, DG (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.	dflood@cephalon.com	Taylor, Graham/A-4027-2012					Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Beffert U., 1996, Society for Neuroscience Abstracts, V22, P2117; BERTRAND P, 1995, MOL BRAIN RES, V33, P174, DOI 10.1016/0169-328X(95)00097-C; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BLENNOW K, 1994, NEUROREPORT, V5, P2534, DOI 10.1097/00001756-199412000-00032; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bullido MJ, 1998, NAT GENET, V18, P69, DOI 10.1038/ng0198-69; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRIADO M, 1982, BIOCHEMISTRY-US, V21, P3622, DOI 10.1021/bi00258a015; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FOLCH J, 1957, J BIOL CHEM, V226, P497; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Guillaume D, 1996, J NEUROCHEM, V66, P2410; GUILLAUME D, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P385; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; JARVIK GP, 1994, GENET EPIDEMIOL, V11, P375, DOI 10.1002/gepi.1370110407; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; KLEIN I, 1978, BIOCHIM BIOPHYS ACTA, V506, P42, DOI 10.1016/0005-2736(78)90433-9; Koo EH, 1996, J CELL SCI, V109, P991; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LEHTIMAKI T, 1995, HUM GENET, V95, P39; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; ONER P, 1991, RES COMMUN CHEM PATH, V72, P337; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POIRIER J, 1990, ADV BEHAV BIOL, V38, P191; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; ROUSER G, 1972, ADV LIPID RES, V10, P236; SAKAKIHARA Y, 1985, J NEUROCHEM, V44, P1535, DOI 10.1111/j.1471-4159.1985.tb08792.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1462; Savage MJ, 1998, J NEUROSCI, V18, P1743; SAVAGE MJ, 1994, NEUROSCIENCE, V60, P607, DOI 10.1016/0306-4522(94)90490-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIMAN R, 1993, J BIOL CHEM, V268, P16602; SIMAN R, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P675; SINHA AK, 1977, J BIOL CHEM, V252, P3310; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; Sparks DL, 1997, NUTR METAB CARDIOVAS, V7, P255; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; SPARKS DL, 1995, NEUROSCI LETT, V187, P142, DOI 10.1016/0304-3940(95)11357-6; Srivastava RAK, 1996, MOL CELL BIOCHEM, V155, P153, DOI 10.1007/BF00229312; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; UTERMANN G, 1979, CLIN GENET, V15, P27; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang YY, 1996, NEUROBIOL AGING, V17, P869, DOI 10.1016/S0197-4580(96)00076-0	90	229	242	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16576	16582		10.1074/jbc.273.26.16576	http://dx.doi.org/10.1074/jbc.273.26.16576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632729	hybrid, Green Published			2022-12-27	WOS:000074436600100
J	Li, S; Choksi, S; Shan, SM; Hu, XY; Gao, JM; Korngold, R; Huang, ZW				Li, S; Choksi, S; Shan, SM; Hu, XY; Gao, JM; Korngold, R; Huang, ZW			Identification of the CD8 DE loop as a surface functional epitope - Implications for major histocompatibility complex class I binding and CD8 inhibitor design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-T; PROTEIN STRUCTURES; ALPHA-3 DOMAIN; MHC CLASS; MOLECULES; RECOGNITION; IMMUNOGLOBULIN; GENE	We used an approach of protein surface epitope mapping by synthetic peptides to analyze the surface structure-function relationship of the CD8 protein. Small synthetic peptide mimics of the CD8 DE loop were shown to effectively block CD8 binding to major histocompatibility complex (MHC) class I molecules and possess significant inhibitory activity on in vitro CD8(+) T cell function. These results suggested that the DE loop region of the CD8 protein is an important functional epitope mediating CD8-MHC class I interaction and the activation of CD8(+) T cells, a finding that is consistent with the recently reported crystal structure of the CDS-MHC class I complex. The structural basis for the biological activity of the DE loop peptide was further analyzed in a series of analogs containing alanine substitutions. This study provides support for the concept of bioactive peptide design based on protein surface epitopes and suggests that such an approach may be applicable to other protein-protein complexes, particularly those of immunoglobulin superfamily molecules.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University	Huang, ZW (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, 233 S 10th St, Philadelphia, PA 19107 USA.	zhuang@nana.jci.tju.edu	Korngold, Robert/AAF-2686-2020					Choksi S, 1998, NAT MED, V4, P309, DOI 10.1038/nm0398-309; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; Huang ZW, 1997, MED CHEM RES, V7, P137; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; LI S, 1998, IN PRESS IMMUNOL TOD; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MISICKA A, 1994, J MED CHEM, V37, P141, DOI 10.1021/jm00027a017; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; NAKANISHI H, 1993, GENE, V137, P51, DOI 10.1016/0378-1119(93)90250-7; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SANDERS SK, 1991, J EXP MED, V174, P371, DOI 10.1084/jem.174.2.371; Satoh T, 1996, BIOCHEM BIOPH RES CO, V224, P438, DOI 10.1006/bbrc.1996.1045; Satoh T, 1997, J BIOL CHEM, V272, P12175, DOI 10.1074/jbc.272.18.12175; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TYKOCINSKI ML, 1984, J IMMUNOL, V133, P2261; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150	32	15	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16442	16445		10.1074/jbc.273.26.16442	http://dx.doi.org/10.1074/jbc.273.26.16442			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632710	hybrid			2022-12-27	WOS:000074436600081
J	Yamashita, J; Yoshimasa, T; Arai, H; Hiraoka, J; Takaya, K; Miyamoto, Y; Ogawa, Y; Itoh, H; Nakao, K				Yamashita, J; Yoshimasa, T; Arai, H; Hiraoka, J; Takaya, K; Miyamoto, Y; Ogawa, Y; Itoh, H; Nakao, K			Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER ELEMENTS; SENSITIVE METHOD; B RECEPTOR; ANTAGONIST; CLONING; BQ-123; CELLS; CDNA; BINDING; INTRON	Previously, we succeeded in molecular cloning of the cDNA and the gene for human endothelin-A receptor (ET-AR). In the present study, we define cis-elements in the 5'-flanbing region of the ET-AR gene. Deletion analyses were performed in A7r5 cells, rat vascular smooth muscle cell line, and Chinese hamster ovary cells using ET-AR promoter-luciferase gene constructs including 5 kilobases of the 5'-Banking region. These analyses demonstrated the existence of one negative regulatory element (-2.0 kilobases to -857 bases) and two positive regulatory elements (-137 to -53 and -53 to +251). Gel mobility shift assay revealed a nuclear protein binding to the region (-104 to -78) (RI). DNase I footprinting analysis showed a footprint spanning from -91 to -83 whose sequence is CCCCACCTT (ETA-PI). When a plasmid including R1 fragments (R1 decoy) was co-transfected into A7r5 cells with ET-AR (-137 to 251)-luciferase gene construct, it significantly reduced the luciferase activity in a dose-dependent manner. Moreover, RI decoy down-regulated the endogenous ET-AR mRNA in A7r5 cells by a maximum of 75%. Thus, we identified cia-elements that regulate basal transcriptional activity of the ET-AR gene and proved the feasibility to suppress the expression of the ET-AR gene by the DNA decoy strategy using the positive regulatory element we identified.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 606, Japan; Grad Sch Human & Environm Studies, Kyoto 606, Japan	Kyoto University	Yoshimasa, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 606, Japan.	taka@kuhp.kyoto-u.ac.jp	Miyamoto, Yoshihiro/L-8583-2013	Miyamoto, Yoshihiro/0000-0002-1337-0508; Ogawa, Yoshihiro/0000-0002-0834-2836				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; Dimondo JP, 1996, DNA SEQUENCE, V6, P285, DOI 10.3109/10425179609020875; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GROVER GJ, 1993, CARDIOVASC RES, V27, P1613, DOI 10.1093/cvr/27.9.1613; HAGA N, 1989, J CLIN BIOCHEM NUTR, V7, P175; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOSODA K, 1992, J BIOL CHEM, V267, P18797; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; JONATHAN DS, 1988, J BIOL CHEM, V263, P8300; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MIHARA SI, 1994, J PHARMACOL EXP THER, V268, P1122; MINO N, 1992, EUR J PHARMACOL, V221, P77; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; RAINES EW, 1993, BRIT HEART J, V69, P30; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHANKE JT, 1994, NUCLEIC ACIDS RES, V22, P5425, DOI 10.1093/nar/22.24.5425; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374	30	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15993	15999		10.1074/jbc.273.26.15993	http://dx.doi.org/10.1074/jbc.273.26.15993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632648	hybrid			2022-12-27	WOS:000074436600019
J	Bugos, RC; Hieber, AD; Yamamoto, HY				Bugos, RC; Hieber, AD; Yamamoto, HY			Xanthophyll cycle enzymes are members of the lipocalin family, the first identified from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIOLAXANTHIN DE-EPOXIDASE; RETINOL-BINDING PROTEIN; CHLOROPHYLL-A FLUORESCENCE; SECONDARY STRUCTURE; ZEAXANTHIN-EPOXIDASE; MOLECULAR-STRUCTURE; BETA-LACTOGLOBULIN; CHLOROPLAST; LETTUCE; BIOSYNTHESIS	Violaxanthin de-epoxidase and zeaxanthin epoxidase catalyze the addition and removal of epoxide groups in carotenoids of the xanthophyll cycle in plants. The xanthophyll cycle is implicated in protecting the photosynthetic apparatus from excessive light. Two new sequences for violaxanthin de-epoxidase from tobacco and Arabidopsis are described. Although the mature proteins are well conserved, the transit peptides of these proteins are divergent, in contrast to transit peptides from other proteins targeted to the thylakoid lumen. Sequence analyses of both violaxanthin de-epoxidase and zeaxanthin epoxidase establish the xanthophyll cycle enzymes as members of the lipocalin family of proteins. The lipocalin family is a diverse group of proteins that bind small hydrophobic (lipophilic) molecules and share a conserved tertiary structure of eight P-strands forming a barrel configuration. This is the first reported identification of lipocalin proteins in plants.	Univ Hawaii, Dept Plant Mol Physiol, Honolulu, HI 96822 USA	University of Hawaii System	Yamamoto, HY (corresponding author), Univ Hawaii, Dept Plant Mol Physiol, 3190 Maile Way, Honolulu, HI 96822 USA.							Barker A, 1997, MICROBIOL-SGM, V143, P1805, DOI 10.1099/00221287-143-6-1805; Bouvier F, 1996, J BIOL CHEM, V271, P28861, DOI 10.1074/jbc.271.46.28861; BRATT CE, 1995, PHOTOSYNTH RES, V45, P169, DOI 10.1007/BF00032588; BUCH K, 1995, FEBS LETT, V376, P45, DOI 10.1016/0014-5793(95)01243-9; Bugos RC, 1996, P NATL ACAD SCI USA, V93, P6320, DOI 10.1073/pnas.93.13.6320; Burbidge A, 1997, J EXP BOT, V48, P1749, DOI 10.1093/jexbot/48.314.1749; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; Flower DR, 1996, BIOCHEM J, V318, P1; GILMORE AM, 1994, FEBS LETT, V350, P271, DOI 10.1016/0014-5793(94)00784-5; GILMORE AM, 1995, P NATL ACAD SCI USA, V92, P2273, DOI 10.1073/pnas.92.6.2273; Gilmore AM, 1996, PHOTOSYNTH RES, V48, P171, DOI 10.1007/BF00041007; GILMORE AM, 1993, PHOTOSYNTH RES, V35, P67, DOI 10.1007/BF02185412; GILMORE AM, 1992, P NATL ACAD SCI USA, V89, P1899, DOI 10.1073/pnas.89.5.1899; HAGER A, 1969, PLANTA, V89, P224, DOI 10.1007/BF00385028; HAGER A, 1975, BER DEUT BOT GES, V88, P27; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Marin E, 1996, EMBO J, V15, P2331, DOI 10.1002/j.1460-2075.1996.tb00589.x; MOHANTY N, 1995, AUST J PLANT PHYSIOL, V22, P231, DOI 10.1071/PP9950231; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; Rockholm DC, 1996, PLANT PHYSIOL, V110, P697, DOI 10.1104/pp.110.2.697; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SIEFERMANN D, 1974, BIOCHIM BIOPHYS ACTA, V357, P144, DOI 10.1016/0005-2728(74)90119-4; SIEFERMANN D, 1975, ARCH BIOCHEM BIOPHYS, V171, P70, DOI 10.1016/0003-9861(75)90008-9; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; TAKEGUCH.CA, 1968, BIOCHIM BIOPHYS ACTA, V153, P459, DOI 10.1016/0005-2728(68)90087-X; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1978, ARCH BIOCHEM BIOPHYS, V190, P514, DOI 10.1016/0003-9861(78)90305-3; YAMAMOTO HY, 1972, PLANT PHYSIOL, V49, P224, DOI 10.1104/pp.49.2.224; YAMAMOTO HY, 1972, BIOCHIM BIOPHYS ACTA, V267, P538, DOI 10.1016/0005-2728(72)90182-X	46	117	136	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15321	15324		10.1074/jbc.273.25.15321	http://dx.doi.org/10.1074/jbc.273.25.15321			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624110	hybrid			2022-12-27	WOS:000074284200004
J	Janicke, RU; Ng, P; Sprengart, ML; Porter, AG				Janicke, RU; Ng, P; Sprengart, ML; Porter, AG			Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; TUMOR-CELLS; LAMIN-A; PROTEASE; SPECTRIN; PROTEINASE; EXECUTION; DISTINCT	Although the commonly activated death protease caspase-3 appears not to be essential for apoptosis during development except in the brain, it was not shown whether substrates known tea he cleaved by caspase-3 are still proteolyzed in its absence, We have addressed this question with MCF-7 breast carcinoma cells that we recently showed lack caspase-3 owing to the functional deletion of the CASP-3 gene. Tumor necrosis factor-or staurosporine-induced apoptosis of caspase-3-deficient MCF-7 cells resulted in cleavage of the death substrates PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45, but not alpha-fodrin. In contrast, all these substrates including alpha-fodrin were cleaved in apoptotic HeLa cells expressing caspase-3. Introduction of CASP-3 cDNA, but not CASP-10 cDNA, into MCF-7 cells restored alpha-fodrin cleavage. In addition, tumor necrosis factor-os staurosporine-induced apoptosis of MCF-7 cells stably expressing pso-caspase-3 also resulted in alpha-fodrin cleavage. Although the specific caspase inhibitory peptides Z-VAD-fmk and Z-DEVD-fmk prevented apoptosis of MCF-7 cells, we were unable to detect activation of caspases 2 and 7, which are known tee be inhibited by Z-DEVD-fmk, Together our results suggest that caspase-3 is essential for cleavage of Lu-fodrin, but dispensable for the cleavage of PARP, Rb, PAK2, DNA-PKcs, gelsolin, and DFF-45 and imply that one or more caspases other theta caspases 2, 3, and 7 is activated and plays a crucial role in the cleavage of these substrates in MCF-7 cells.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Janicke, RU (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.			Duriez, Patrick/0000-0003-1814-2552				BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9	48	431	441	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15540	15545		10.1074/jbc.273.25.15540	http://dx.doi.org/10.1074/jbc.273.25.15540			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624143	hybrid			2022-12-27	WOS:000074284200037
J	Helms, JB; Helms-Brons, D; Brugger, B; Gkantiragas, I; Eberle, H; Nickel, W; Nurnberg, B; Gerdes, HH; Wieland, FT				Helms, JB; Helms-Brons, D; Brugger, B; Gkantiragas, I; Eberle, H; Nickel, W; Nurnberg, B; Gerdes, HH; Wieland, FT			A putative heterotrimeric G protein inhibits the fusion of COPI-coated vesicles - Segregation of heterotrimeric G proteins from COPI-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; GOLGI MEMBRANES; EPITHELIAL-CELLS; ALPHA-SUBUNITS; TRANSPORT; COATOMER; ACTIVATION; COMPLEXES; FLUORIDE	Heterotrimeric G proteins have been implicated in the regulation of intracellular protein transport, but their mechanism of action remains unclear, bn vivo, secretion of chromogranin B, tagged with the green fluorescent protein, was inhibited by the addition of a general activator of trimeric G proteins (AlF4-) to stably transfected Vero cells and resulted in an accumulation of the tagged protein in the Gels apparatus. In an in vitro assay that reconstitutes intra-Golgi protein transport, we find that a membrane-bound and AlF4--sensitive factor is involved in the fusion reaction. To determine whether this effect is mediated by a heterotrimeric G protein localized to COPI-coated transport vesicles, we determined the presence of G proteins on these vesicles and found that they were segregated relative to the donor membranes. Because G proteins do not have an obvious sorting, retention, or retrieval signal, we considered the possibility that other interactions might be responsible for this segregation. In agreement with this, we found that trimeric G proteins from isolated Golgi membranes were partially insoluble in Triton X-100. Identification of the proteins that interact with the heterotrimeric G proteins in the Golgi-derived detergent-insoluble complex might help to reveal the regulation of protein secretion mediated by heterotrimeric G proteins.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany; Free Univ Berlin, Klinikum Rudolf Virchow, Inst Pharmakol, D-14195 Berlin, Germany; Heidelberg Univ, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg	Helms, JB (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	Helms@urz.uni-heidelberg.de		Nurnberg, Bernd/0000-0002-5995-6555				Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BEG ZH, 1978, P NATL ACAD SCI USA, V75, P3678, DOI 10.1073/pnas.75.8.3678; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; DENKER BM, 1992, J BIOL CHEM, V267, P6272; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; KAHN RA, 1991, J BIOL CHEM, V266, P15595; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Wacker I, 1997, J CELL SCI, V110, P1453; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Yamaguchi T, 1997, J BIOL CHEM, V272, P25260, DOI 10.1074/jbc.272.40.25260; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	48	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15203	15208		10.1074/jbc.273.24.15203	http://dx.doi.org/10.1074/jbc.273.24.15203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614134	hybrid			2022-12-27	WOS:000074160400076
J	Iwamoto, Y; Chin, YE; Peng, XB; Fu, XY				Iwamoto, Y; Chin, YE; Peng, XB; Fu, XY			Identification of a membrane-associated inhibitor(s) of epidermal growth factor-induced signal transducer and activator of transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; DNA-BINDING ACTIVITY; INTERFERON-ALPHA; CYTOKINE RECEPTORS; SH3 DOMAINS; PHOSPHORYLATION; PATHWAY; PROMOTER; FAMILY; STAT3	Many growth factors, including epidermal growth factor (EGF), can activate the signal transducer and activator of transcription (STAT) signaling pathway. Here, we demonstrate that STAT activation by EGF treatment is conditional. EGF activates STAT1 and STAT3 in A431 but not in HeLa and PC12 cells. Using a reconstituted in vitro STAT activation system, we have identified and partially purified a potential inhibitor (s) that is membrane-associated and can block STAT activation induced by EGF in vitro. However, this inhibitor has no effect on STAT complexes after they are formed. We have further shown that this inhibitor(s) also exists in many other cancer cell lines, suggesting that blocking the STAT activation during growth factor signal transduction may play a significant role in the development of many kinds of cancers.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Fu, XY (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA.				NIAID NIH HHS [R01AI34522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	41	10	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18198	18204		10.1074/jbc.273.29.18198	http://dx.doi.org/10.1074/jbc.273.29.18198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660781	hybrid			2022-12-27	WOS:000074828500036
J	Lazari, RDM; Bertrand, JE; Nakamura, K; Liu, XB; Krupnick, JG; Benovic, JL; Ascoli, M				Lazari, RDM; Bertrand, JE; Nakamura, K; Liu, XB; Krupnick, JG; Benovic, JL; Ascoli, M			Mutation of individual serine residues in the C-terminal tail of the lutropin/choriogonadotropin receptor reveal distinct structural requirements for agonist-induced uncoupling and agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; LEYDIG TUMOR-CELLS; MEDIATED ENDOCYTOSIS; LUTEINIZING-HORMONE; BETA-ARRESTIN; INDUCED PHOSPHORYLATION; CYTOPLASMIC TAIL; PROTEIN; DESENSITIZATION	We have previously mapped the agonist-induced phosphorylation of the rat lutropin/choriogonadotropin receptor (rLHR) to a locus of four serines (Ser(635), Ser(639), Ser(649), and Ser(652)) located in the C-terminal tail. The removal or mutation of this locus delays the time course of agonist-induced uncoupling of the rLHR from its effector system without affecting the overall magnitude of uncoupling, and it retards the endocytosis of the agonist-receptor complex. We have now prepared and analyzed four new rLHR mutants in which each of these serines were individually mutated to alanines, The data presented show that each mutation reduces agonist-promoted rLHR phosphorylation by 20-40%. Mutation of Ser(635) or Ser(639) delayed the time course of agonist-induced uncoupling to about the same extent as the simultaneous mutation of all four serines. Mutation of Ser(635) or Ser(639) also retarded agonist-induced internalization, but the magnitude of this decrease was less than that induced by the simultaneous mutation of all four serines, Mutation of Ser(649) had no effect on agonist-induced uncoupling but retarded agonist-induced internalization to the same extent as the simultaneous mutation of all four serines. R Mutation of Ser(652) has little or no effect on either of these two parameters. Co-transfection studies with dominant-negative arrestins and dominant-negative dynamin reveal that, despite differences in their rates of internalization, rLHR-wild-type, rLHR-S639A, and rLHR-S649A are internalized by an arrestin- and dynamin-dependent pathway. These data show that the structural requirements needed for the agonist-induced uncoupling and internalization of the rLHR are distinct.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Iowa; Jefferson University	Ascoli, M (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-512 BSB, Iowa City, IA 52242 USA.				NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40629] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NIGMS NIH HHS [GM-47417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1987, ENDOCRINOLOGY, V120, P1161, DOI 10.1210/endo-120-3-1161; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HOELSCHER SR, 1991, ENDOCRINOLOGY, V128, P2837, DOI 10.1210/endo-128-6-2837; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RODRIGUEZ MC, 1990, ENDOCRINOLOGY, V127, P674, DOI 10.1210/endo-127-2-674; ROSEMBLIT N, 1988, ENDOCRINOLOGY, V123, P2284, DOI 10.1210/endo-123-5-2284; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; STRICKLAND TW, 1981, ENDOCRINOLOGY, V109, P1933, DOI 10.1210/endo-109-6-1933; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG H, 1991, J BIOL CHEM, V266, P780; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	42	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18316	18324		10.1074/jbc.273.29.18316	http://dx.doi.org/10.1074/jbc.273.29.18316			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660797	hybrid			2022-12-27	WOS:000074828500052
J	Rudolph, MG; Bayer, P; Abo, A; Kuhlmann, J; Vetter, IR; Wittinghofer, A				Rudolph, MG; Bayer, P; Abo, A; Kuhlmann, J; Vetter, IR; Wittinghofer, A			The Cdc42/Rac interactive binding region motif of the Wiskott Aldrich syndrome protein (WASP) is necessary but not sufficient for tight binding to Cdc42 and structure formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR-SPECTROSCOPY; MOLECULAR-CLONING; HUMAN RAF-1; KINASE; RAS; GTPASE; FAMILY; IDENTIFICATION; EFFECTOR; DOMAIN	Wiskott Aldrich syndrome is a rare hereditary disease that affects cell morphology and signal transduction in hematopoietic cells, Different size fragments of the Wiskott Aldrich syndrome protein, W4, W7 and W13, were expressed in Escherichia coli or obtained from proteolysis, ALI contain the GTPase binding domain (GBD), also called Cdc42/Rac interactive binding region (CRIB), found in many putative downstream effecters of Rac and Cdc42. We have developed assays to measure the binding interaction between these fragments and Cdc42 employing fluorescent N-methylanthraniloyl-guanine nucleotide analogues. The fragments bind with submicromolar affinities in a GTP-dependent manner, with the largest fragment having the highest affinity, showing that the GBD/CRIB motif is necessary but not sufficient for tight binding. Rate constants for the interaction with W13 have been determined via surface plasmon resonance, and the equilibrium dissociation constant obtained from their ratio agrees with the value obtained by fluorescence measurements. Far UV circular dichroism spectra show significant secondary structure only for W13, supported by fluorescence studies using intrinsic protein fluorescence and quenching by acrylamide, Proton and N-15 NMR measurements show that the GBD/CRIB motif has no apparent secondary structure and that the region C-terminal to the GBD/ CRIB region is cu-helical, The binding of Cdc42 induces a structural rearrangement of residues in the GBD/CRIB motif, or alternatively, the Wiskott Aldrich syndrome protein fragments have an ensemble of conformations, one of which is stabilized by Cdc42 binding. Thus, in contrast to Ras effecters, which have no conserved sequence elements but a defined domain structure with ubiquitin topology, Rac/Cdc42 effecters have a highly conserved binding region but no defined domain structure in the absence of the GTP-binding protein. Deviating from common belief GBD/CRIB is neither a structural domain nor sufficient for tight binding as regions outside this motif are necessary for structure formation and tight interaction with Rho/Rac proteins.	Max Planck Inst Mol Physiol, Abt Sturkturelle Biol & Phys Biochem, D-44139 Dortmund, Germany; Onyx Pharmaceut, Richmond, CA 94608 USA	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Sturkturelle Biol & Phys Biochem, Rheinlanddamm 201, D-44139 Dortmund, Germany.		Bayer, Peter/B-8803-2009	Bayer, Peter/0000-0003-0435-7202; Rudolph, Markus/0000-0003-0447-1101				Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BIRKS JB, 1970, PHOTOPHYSICS AROMATI, P443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Woody R. W., 1994, CIRCULAR DICHROISM P, P473; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YANG JT, 1986, CALCULATION PROTEIN, P208; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999	46	112	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18067	18076		10.1074/jbc.273.29.18067	http://dx.doi.org/10.1074/jbc.273.29.18067			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660763	hybrid			2022-12-27	WOS:000074828500018
J	Chen, ME; Lin, SH; Chung, LWK; Sikes, RA				Chen, ME; Lin, SH; Chung, LWK; Sikes, RA			Isolation and characterization of PAGE-1 and GAGE-7 - New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYTIC T-LYMPHOCYTES; SYNTHETIC PEPTIDE; MESSENGER-RNA; TUMOR-CELLS; MAGE GENES; DIFFERENTIAL DISPLAY; EPITHELIAL-CELLS; BONE FIBROBLASTS; GROWTH-INVIVO; FAMILY	The LNCaP progression model of human prostate cancer consists of lineage-related sublines that differ in their androgen sensitivity and metastatic potential. A differential display polymerase chain reaction was employed to evaluate mRNA expression differences between the LNCaP sublines in order to define the differences in gene expression between the androgen-sensitive, nontumorigenic LNCaP cell line and the androgen-insensitive, metastatic LNCaP sublines, C4-2 and C4-2B. An amplicon, BG16.21, was isolated that showed increased expression in the androgen-independent and metastatic LNCaP sublines, C4-2 and C4-2B. Hybridization screening of a lambda gt11 expression library with BG16.21 revealed two transcripts, both homologous to BG16.21 at the 3' end, A GenBank(TM) data base search using the GCG Wisconsin software package revealed the shorter similar to 600-bp transcript (designated GAGE-7) to be a new member of the GAGE family, The second similar to 700-bp transcript was a novel gene (designated PAGE-1, "prostate associated gene") with only 45% homology to GAGE gene family members. RNA blot analysis demonstrated that GAGE-7 mRNA was expressed at equal levels in all lineage related prostate cancer cell sublines, while PAGE-1 mRNA levels were elevated 5-fold in C4-2 and C4-2B as compared with LNCaP cells, Neither GAGE-7 nor PAGE-1 demonstrated any regulation by androgens in the prostate cancer cell lines used in this study. PAGE-1 and GAGE-7 expression was found to be restricted to testes (high) and placenta (low) on human multiple tissue Northern blots. As GAGE/MAGE antigens were reported preciously to be targets for tumor-specific cytotoxic lymphocytes in melanoma, these results suggest that PAGE-1 and GAGE-7 may be related to prostate cancer progression and may serve as potential targets for novel therapies.	Univ Virginia, Hlth Sci Ctr, Dept Urol, Mol Urol & Therapeut Program, Charlottesville, VA 22908 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Virginia; University of Texas System; UTMD Anderson Cancer Center	Sikes, RA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Urol, Mol Urol & Therapeut Program, Box 422, Charlottesville, VA 22908 USA.				NCI NIH HHS [CA64863, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064863, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMARCOSTESEC A, 1994, BIOCHEM BIOPH RES CO, V204, P710, DOI 10.1006/bbrc.1994.2517; AUSUBEL FM, 1994, PREPARING DNA SMALL, V1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRASSEUR F, 1992, INT J CANCER, V52, P839, DOI 10.1002/ijc.2910520528; CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105; CHANG SM, 1989, ENDOCRINOLOGY, V125, P2719, DOI 10.1210/endo-125-5-2719; CHEN Q, 1994, CANC IMMUNOL IMMUNOL, V34, P385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG LWK, 1989, INT J CANCER, V43, P1179, DOI 10.1002/ijc.2910430636; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; DePlaen E, 1997, GENOMICS, V40, P305, DOI 10.1006/geno.1996.4566; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; DING M, 1994, BIOCHEM BIOPH RES CO, V202, P549, DOI 10.1006/bbrc.1994.1963; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; GLEAVE M, 1991, CANCER RES, V51, P3753; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; Harlow E., 1988, ANTIBODIES LAB MANUA; HOON DSB, 1995, J IMMUNOL, V154, P730; Huggins C, 1941, CANCER RES, V1, P293; HUGGINS C, 1946, JAMA-J AM MED ASSOC, V131, P576, DOI 10.1001/jama.1946.02870240008003; INOUE H, 1995, INT J CANCER, V64, P76, DOI 10.1002/ijc.2910640115; KOCHER T, 1995, CANCER RES, V55, P2236; KURPISZ M, 1988, J IMMUNOL METHODS, V115, P195, DOI 10.1016/0022-1759(88)90288-8; Li J, 1996, CLIN CANCER RES, V2, P1619; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAHANA W, 1993, J IMMUNOL METHODS, V161, P187, DOI 10.1016/0022-1759(93)90294-H; MUSCATELLI F, 1995, P NATL ACAD SCI USA, V92, P4987, DOI 10.1073/pnas.92.11.4987; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PATARD JJ, 1995, INT J CANCER, V64, P60, DOI 10.1002/ijc.2910640112; RIMOLDI D, 1993, INT J CANCER, V54, P527, DOI 10.1002/ijc.2910540329; RUSSO V, 1995, INT J CANCER, V64, P216, DOI 10.1002/ijc.2910640313; SALGALLER ML, 1994, CANCER IMMUNOL IMMUN, V39, P105, DOI 10.1007/s002620050101; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schook LB, 1987, MONOCLONAL ANTIBODY; Serrano A, 1996, INT J CANCER, V68, P464, DOI 10.1002/(SICI)1097-0215(19961115)68:4<464::AID-IJC11>3.0.CO;2-5; SHICHIO S, 1995, INT J CANCER, V64, P158, DOI 10.1002/ijc.2910640303; SIKES RA, 1992, CANCER RES, V52, P3174; TAKAHASHI K, 1995, CANCER RES, V55, P3478; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; THALMANN GN, 1994, CANCER RES, V54, P2577; VALABHJI A, 1996, FUTURE ONCOLOGY, V2, P282; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WEBER J, 1994, CANCER RES, V54, P1766; WEYNANTS P, 1994, INT J CANCER, V56, P826, DOI 10.1002/ijc.2910560612; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; YAMASAKI S, 1995, CANCER IMMUNOL IMMUN, V40, P268; ZAKUT R, 1993, CANCER RES, V53, P5	52	69	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17618	17625		10.1074/jbc.273.28.17618	http://dx.doi.org/10.1074/jbc.273.28.17618			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651357	hybrid			2022-12-27	WOS:000074816100050
J	Fisher, M; Zamir, A; Pick, U				Fisher, M; Zamir, A; Pick, U			Iron uptake by the halotolerant alga Dunaliella is mediated by a plasma membrane transferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOPLANKTON; BINDING; MECHANISM; RELEASE; SALINA; SITES; SALT	A 150-kDa transferrin-like protein (Ttf) is associated with the plasma membrane of the halotolerant unicellular alga Dunaliella salina (Fisher, M., Gokhman, I., pick, U., and Zamir, A. (1997) J. Biol. Chem. 272, 1565-1570), The Ttf level rises with medium salinity or upon iron depletion. Evidence that Ttf is involved in iron uptake by Dunaliella is presented here. Algal iron uptake exhibits characteristics resembling those of animal transferrins: high specificity and affinity for Fe3+ ions, strict dependence on carbonate/bicarbonate ions, and very low activity in acidic pH. Reducing the level of Ttf by mild proteolysis of whole cells is accompanied by lowered uptake activity. Conversely, accumulation of high levels of Ttf is correlated with an enhancement of iron uptake. Kinetically, iron uptake consists of two steps: an energy-independent binding of iron to the cell surface and an energy-dependent internalization. Salinities as high as 3.5 M NaCl do not inhibit iron uptake or decrease the apparent affinity for Fe3+ ions, implying that Ttf activity is not affected by high salt, These results indicate that transferrins, hitherto identified only in animals, are present and function in iron transport also in plant systems.	Weizmann Inst Sci, Dept Biol Chem, IL-71600 Rehovot, Israel	Weizmann Institute of Science	Pick, U (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-71600 Rehovot, Israel.							AZARI P, 1970, ARCH BIOCHEM BIOPHYS, V138, P32, DOI 10.1016/0003-9861(70)90280-8; CHASTEEN ND, 1981, BIOCHEM J, V193, P717, DOI 10.1042/bj1930717; CHASTEEN ND, 1983, ADV INORG BIOCHEM, V5, P210; EGAN TJ, 1992, INORG CHEM, V31, P1994, DOI 10.1021/ic00037a005; Fisher M, 1996, J BIOL CHEM, V271, P17718, DOI 10.1074/jbc.271.30.17718; Fisher M, 1997, J BIOL CHEM, V272, P1565, DOI 10.1074/jbc.272.3.1565; HUDSON RJM, 1990, LIMNOL OCEANOGR, V35, P1002, DOI 10.4319/lo.1990.35.5.1002; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; KOLBER ZS, 1994, NATURE, V371, P145, DOI 10.1038/371145a0; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MARTIN RB, 1986, J INORG BIOCHEM, V28, P181, DOI 10.1016/0162-0134(86)80081-2; SADKA A, 1991, PLANT PHYSIOL, V95, P822, DOI 10.1104/pp.95.3.822; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; WELCH S, 1992, TRANSFERRIN IRON CAR; ZAK O, 1995, BIOCHEMISTRY-US, V34, P14428, DOI 10.1021/bi00044a020	15	64	72	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17553	17558		10.1074/jbc.273.28.17553	http://dx.doi.org/10.1074/jbc.273.28.17553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651348	hybrid			2022-12-27	WOS:000074816100041
J	Wu, JJ; Eyre, DR				Wu, JJ; Eyre, DR			Matrilin-3 forms disulfide-linked oligomers with matrilin-1 in bovine epiphyseal cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN; CROSS-LINKING; COILED COILS; COLLAGEN; EXPRESSION; MATURATION; SITES; GENE	A comparison of noncollagenous matrix proteins from different types of bovine cartilage by SDS polyacrylamide gel electrophoresis showed a prominent 240-kDa component in extracts of epiphyseal but not tracheal tissue. On amino-terminal sequence analysis, it gave two sequences. One matched the NH2 terminus of cartilage matrix protein (CMP) as reported for tracheal cartilage. The other did not match any known protein sequence. Further analysis of the 240-kDa protein after reduction of disulfides resolved two bands on SDS-polyacrylamide gel electrophoresis, Isolation and sequence analysis of tryptic peptides confirmed that one was bovine GRIP and the other a CMP homolog. A data base search identified the latter as matrilin-3, a molecule recently predicted from human and mouse cDNA sequences (Wagener, R,, Kobbe, B., and Paulsson, M. (1997) FEBS Lett. 413, 129-134). Matrilin-3 and GRIP (matrilin-1) were prominent in equimolar amounts in fetal bovine epiphyseal cartilage and absent from adult articular cartilage. Adult tracheal cartilage contained almost exclusively CMP. Although the mechanism of polymeric assembly is unknown, the matrilin-3 chain appears to function in the matrix linked to matrilin-1 in the form of disulfide-bonded heteromeric molecules. The results indicate a molecular stoichiometry of (matrilin-1)(2)(matrilin-3)(2).	Univ Washington, Dept Orthopaed, Orthopaed Res Labs, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wu, JJ (corresponding author), Univ Washington, Dept Orthopaed, Orthopaed Res Labs, Box 356500, Seattle, WA 98195 USA.	wujj@u.washington.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R01AR037318, R37AR036794] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37318, R37 AR037318, R01 AR036794, AR36794] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Deak F, 1997, J BIOL CHEM, V272, P9268; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; JENKINS RN, 1990, J BIOL CHEM, V265, P19624; KISS I, 1989, J BIOL CHEM, V264, P8126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUNDLOS S, 1994, DEV DYNAM, V199, P241, DOI 10.1002/aja.1001990308; NIYIBIZI C, 1987, T ORTHOP RES SOC, V12, P111; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; PAULSSON M, 1984, BIOCHEM J, V221, P623, DOI 10.1042/bj2210623; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; TONDRAVI MM, 1993, PROG CLIN BIOL RES, V383, P515; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; WU JJ, 1992, J BIOL CHEM, V267, P23007; WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373; Zeineldin R, 1997, BIOCHEM J, V328, P665, DOI 10.1042/bj3280665	28	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17433	17438		10.1074/jbc.273.28.17433	http://dx.doi.org/10.1074/jbc.273.28.17433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651330	hybrid			2022-12-27	WOS:000074816100023
J	Chen, CY; Liou, J; Forman, LW; Faller, DV				Chen, CY; Liou, J; Forman, LW; Faller, DV			Differential regulation of discrete apoptotic pathways by Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; CELL-SURFACE ANTIGEN; MATURE T-CELLS; NIH 3T3 CELLS; DEATH DOMAIN; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; MOLECULAR-CLONING	The products of the ras genes are known to regulate cell proliferation and differentiation; recently, they have been found to play a role in apoptosis, The expression of oncogenic p21(ras) in a number of cell types, including Jurkat (a human T lymphoblastoid cell line) and murine fibroblasts, makes the cells susceptible to apoptosis following suppression of protein kinase C (PKC) activity (PKC/Ras-mediated apoptosis), Engagement of Fas antigen, a potent effector of apoptosis, activates cellular p21(ras), which may be required for completion of the cell death program. To further investigate the role of p21(ras) in the regulation of apoptosis, the cellular mechanisms employed in these two apoptotic processes in which Ras activity is involved (PKC/Ras-related and Fas-triggered apoptosis), was explored. Increasing p21(ras) activity by expressing v-ras or by treatment with an antisense oligonucleotide to the GTPase-activating protein was found to accelerate the Fas-mediated apoptotic process in Jurkat and mouse LF cells. PKC/Ras-related apoptosis was associated with, and required, cell cycle progression, accompanied by the expression of the G(1)/S cyclins, In contrast, Fas engagement, although inducing a vigorous and PKC-independent activation of endogenous p21(ras), did not alter cell cycle progression, nor did it require such progression for apoptosis, Both the protein synthesis inhibitor cycloheximide and cyclin E antisense oligonucleotides partially abolished PKC/Ras-mediated apoptosis but had only a moderate effect on Fas-induced apoptosis, In contrast, the CED-3/interleukin-1 beta-converting enzyme (ICE) protease inhibitor Z-VADfmk efficiently suppressed Fas-induced apoptosis and only marginally inhibited PKC/Ras-mediated apoptosis, Induction of both pathways resulted in activation of the Jun NH2-terminal kinase/JUN signaling system. These results suggest that different cell death programs, such as PKC/Ras-mediated and Ras-mediated apoptosis, may be interconnected via p21(ras) and perhaps Jun NH2-terminal kinase/JUN, In response to various death stimuli, p21(ras) may act as a common intermediate regulator in the transduction of apoptotic signals.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, 80 E Concord St,Room K-701, Boston, MA 02118 USA.	dfaller@bu.edu			NCI NIH HHS [CA50459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chen CY, 1996, MOL CELL BIOL, V16, P6582; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; FU T, 1991, EXP CELL RES, V203, P230; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Itano Y, 1996, J NEUROCHEM, V67, P131; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOKA P, 1991, J IMMUNOL, V146, P2417; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leszczynski D, 1996, CANCER J - FRANCE, V9, P308; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Messmer UK, 1997, BRIT J PHARMACOL, V121, P625, DOI 10.1038/sj.bjp.0701156; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; RuizRuiz MD, 1997, EUR J IMMUNOL, V27, P1442, DOI 10.1002/eji.1830270622; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIMOTO Y, 1992, EXP CELL RES, V213, P203; TAKAHASHI T, 1994, CELL, V76, P966; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; Weiss E, 1997, INT J ONCOL, V10, P1119; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	74	48	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16700	16709		10.1074/jbc.273.27.16700	http://dx.doi.org/10.1074/jbc.273.27.16700			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642224	hybrid			2022-12-27	WOS:000074545200014
J	Sato, T; Watanabe, S; Ishii, E; Tsuji, K; Nakahata, T				Sato, T; Watanabe, S; Ishii, E; Tsuji, K; Nakahata, T			Induction of the erythropoietin receptor gene and acquisition of responsiveness to erythropoietin by stem cell factor in HML/SE, a human leukemic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROID-DIFFERENTIATION; GM-CSF; INTERLEUKIN-3; GATA-1; PROLIFERATION; TRANSCRIPTION; ESTABLISHMENT; PROGENITORS; EXPRESSION	HML/SE is a cytokine-dependent cell line established from childhood acute megakaryoblastic leukemia. Granulocyte-macrophage colony-stimulating factor or stem cell factor (SCF) alone could stimulate proliferation of HML/SE cells, however interleukin-3, interleukin-6, granulocyte colony-stimulating factor and thrombopoietin could not. Although erythropoietin (EPO) alone stimulated neither proliferation nor differentiation of HML/SE cells, it did stimulate proliferation of HML/SE cells and production of hemoglobin in the presence of SCF. SCF activated the human EPO receptor promoter and induced EPO receptor gene expression. Given these results, we speculate that HML/SE cells acquired responsiveness to EPO via the EPO receptor induced by SCF. Mutation analysis of putative transcription factor binding sites in the human EPO receptor promoter suggested that Spl, rather than the GATA-1 binding site, contributed to the induction of the hEPOR gene. Although it is well documented that hematopoietic stem cells and primitive progenitors require both an early-acting cytokine and a lineage-specific cytokine to differentiate to a certain lineage, related mechanisms are not well understood. HML/SE may serve as an excellent model system to analyze functions of early-acting cytokine SCF and lineage-specific cytokine EPO related to proliferation and differentiation of hematopoietic stem cells.	Univ Tokyo, Dept Clin Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Dept Mol & Dev Biol, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Nagano Childrens Hosp, Dept Hematol & Oncol, Nagano 39982, Japan	University of Tokyo; University of Tokyo	Nakahata, T (corresponding author), Univ Tokyo, Dept Clin Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; CHIBA S, 1991, BLOOD, V78, P2261; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; DALYOT N, 1993, NUCLEIC ACIDS RES, V21, P4031, DOI 10.1093/nar/21.17.4031; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOIKE K, 1986, J CLIN INVEST, V77, P894, DOI 10.1172/JCI112387; KOMATSU N, 1991, CANCER RES, V51, P341; Ma F, 1998, BRIT J HAEMATOL, V100, P427, DOI 10.1046/j.1365-2141.1998.00553.x; METCALF D, 1993, BLOOD, V82, P3515; Migliaccio AR, 1996, INT J HEMATOL, V64, P1; MINEGISHI N, 1994, J BIOL CHEM, V269, P27700; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOGUCHI CT, 1991, BLOOD, V78, P2548; OGAWA M, 1993, BLOOD, V81, P2844; OKUMURA N, 1992, BLOOD, V80, P642; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SONODA Y, 1988, P NATL ACAD SCI USA, V85, P4360, DOI 10.1073/pnas.85.12.4360; Sui XW, 1996, J EXP MED, V183, P837, DOI 10.1084/jem.183.3.837; Tajima S, 1996, J EXP MED, V184, P1357, DOI 10.1084/jem.184.4.1357; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; WATANABE S, 1995, MOL BIOL CELL, V6, P627, DOI 10.1091/mbc.6.6.627; WATANABE S, 1995, EUR J IMMUNOL, V25, P126, DOI 10.1002/eji.1830250122; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	32	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16921	16926		10.1074/jbc.273.27.16921	http://dx.doi.org/10.1074/jbc.273.27.16921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642254	hybrid			2022-12-27	WOS:000074545200044
J	Schnappauf, G; Krappmann, S; Braus, GH				Schnappauf, G; Krappmann, S; Braus, GH			Tyrosine and tryptophan act through the same binding site at the dimer interface of yeast chorismate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; R-STATE; BIOSYNTHESIS; PATHWAY	Tyrosine and tryptophan are the regulators of the dimeric yeast chorismate mutase. Biochemical studies reveal two binding sites per molecule for both effecters, tyrosine or tryptophan, A single binding site is built up by helix 8 and helices 4 and 5 of two different subunits, The binding sites have been analyzed in the active enzyme by site directed mutagenesis of critical codons of the coding gene, AR07, Gly-141 and Ser-142, which both reside on helix 8, are involved in the binding of tyrosine or tryptophan presumably by interacting specifically with the amino- and carboxylate-groups of these amino acid effecters. Interaction with Thr-145 of helix 8 is required for a strong tyrosine binding to the allosteric site. Replacement of Arg-75, which connects helices 4 and 5 or of Arg-76, which is part of helix 5 by alanine residues, resulted in unregulated enzymes. These two residues are bonded to the carboxylate group and phenolic hydroxyl group of tyrosine, respectively, but do not interact with tryptophan by hydrogen bonding in the crystal structures. Phenylalanine, which has low binding affinity slightly activated the chorismate mutase, A T145V mutant chorismate mutase, however, showed increased activation by phenylalanine. Our results support a mechanism by which tyrosine contracts the allosteric site by interacting with its phenolic hydroxyl group. Tryptophan works in an inverse way by opening the allosteric site through the steric size of its side chain.	Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Braus, GH (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.		Braus, Gerhard H/G-3999-2012; Krappmann, Sven/K-2615-2012; Braus, Gerhard/ABC-6293-2021	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626; Krappmann, Sven/0000-0002-8299-7777				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUS GH, 1991, MICROBIOL REV, V55, P349, DOI 10.1128/MMBR.55.3.349-370.1991; DIMROTH P, 1986, METHOD ENZYMOL, V125, P530; EBERHARD J, 1993, FEBS LETT, V334, P233, DOI 10.1016/0014-5793(93)81718-F; FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163; Ganem B., 1996, ANGEW CHEM INT EDIT, V35, P936, DOI [10.1002/anie.19960936, DOI 10.1002/ANIE.199609361]; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; GRAF R, 1995, J BACTERIOL, V177, P1645, DOI 10.1128/jb.177.6.1645-1648.1995; Haslam E., 1974, SHIKIMATE PATHWAY; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AY, 1995, CHEM BIOL, V2, P195, DOI 10.1016/1074-5521(95)90269-4; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWELL JO, 1990, BIOPHYS CHEM, V37, P183, DOI 10.1016/0301-4622(90)88018-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHEINI T, 1990, BIOCHEMISTRY-US, V29, P3660, DOI 10.1021/bi00467a011; SCHMIDHEINI T, 1989, J BACTERIOL, V171, P1245, DOI 10.1128/jb.171.3.1245-1253.1989; Strater N, 1997, STRUCTURE, V5, P1437, DOI 10.1016/S0969-2126(97)00294-3; Strater N, 1996, P NATL ACAD SCI USA, V93, P3330, DOI 10.1073/pnas.93.8.3330; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814	21	20	20	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17012	17017		10.1074/jbc.273.27.17012	http://dx.doi.org/10.1074/jbc.273.27.17012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642265	hybrid			2022-12-27	WOS:000074545200055
J	Zhou, KM; Wang, Y; Gorski, JL; Nomura, N; Collard, J; Bokoch, GM				Zhou, KM; Wang, Y; Gorski, JL; Nomura, N; Collard, J; Bokoch, GM			Guanine nucleotide exchange factors regulate specificity of downstream signaling from Rac and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DBL-ONCOGENE PRODUCT; PLECKSTRIN HOMOLOGY DOMAINS; GTP-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; TERMINAL REGION; RHO; MEMBRANE; EFFECTOR	The Rac and Cdc42 GTPases regulate diverse cellular behaviors involving the actin cytoskeleton, gene transcription, and the activity of multiple protein and lipid kinases, All of these pathways can potentially become activated when GTP-Rac or GTP-Cdc42 is formed in response to external cell signals, yet it is evident that each activity must also be able to be controlled individually. The mechanisms by which such specificity of GTPase signaling in response to upstream stimuli is achieved remains unclear, We investigated the action of several well characterized guanine nucleotide exchange factors (GEF(Rho)) to activate Rac- and/or Cdc42-dependent kinase pathways. Coexpression studies in COS-7 cells revealed that the ability of individual guanine nucleotide exchange factors (GEFs) to activate the pal-activated kinase PAK1 could be dissociated from activation of c-Jun amino-terminal kinase, even though activation of both pathways requires the action of the GEFs on Rac and/or Cdc42. In contrast, expression of constitutively active forms of Rac or Cdc42 effectively stimulated both downstream kinases. We conclude that GEFs can be important determinants of downstream signaling specificity for members of the Rho GTPase family.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Netherlands Canc Inst, NL-1066 CS Amsterdam, Netherlands	Scripps Research Institute; Scripps Research Institute; University of Michigan System; University of Michigan; Netherlands Cancer Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.	bokoch@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHARMAWARDHANE S, 1995, CURR OPIN HEMATOL, V4, P12; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PASTERIS NG, 1994, CELL, V79, P669; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1989, ONCOGENE, V4, P1067; SELF AJ, 1993, ONCOGENE, V8, P655; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	55	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16782	16786		10.1074/jbc.273.27.16782	http://dx.doi.org/10.1074/jbc.273.27.16782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642235	hybrid			2022-12-27	WOS:000074545200025
J	Chu, ZL; DiDonato, JK; Hawiger, J; Ballard, DW				Chu, ZL; DiDonato, JK; Hawiger, J; Ballard, DW			The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates I kappa B kinases containing IKK alpha and IKK beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; TRANSCRIPTION FACTORS; EXPRESSION; SIGNAL; HTLV; UBIQUITINATION; PROTEINS; MICE; GENE; PROTEOLYSIS	The Tax oncoprotein of human T-cell leukemia virus type 1 (HTLV1) chronically activates transcription factor NF-kappa B by a mechanism involving degradation of I kappa B alpha, an NF-kappa B-associated cytoplasmic inhibitor. Tax-induced breakdown of I kappa B alpha requires phosphorylation of the inhibitor at Ser-32 and Ser-36, which is also a prerequisite for the transient activation of NF-kappa B in cytokine-treated T lymphocytes. However, it remained unclear how Tax interfaces with the cellular NF-kappa B/I kappa B signaling machinery to generate a chronic rather than a transient NF-kappa B response. We now demonstrate that Tax associates with cytokine-inducible I kappa B kinase (IKK) complexes containing catalytic subunits IKK alpha and IKK beta, which mediate phosphorylation of I kappa B alpha at Ser-32 and Ser-36, Unlike their transiently activated counterparts in cytokine-treated cells, Tax-associated forms of Wt are constitutively active in either Tax transfectants or HTLV1-infected T lymphocytes. Moreover, point mutations in Tax that ablate its IKK-binding function also prevent Tax-mediated activation of IKK and NF-kappa B, Together, these findings suggest that the persistent activation of NF-kappa B in HTLV1-infected T-cells is mediated by a direct Tax/IKK coupling mechanism.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 802 Rudolph Light Hall, Nashville, TN 37232 USA.	dean.ballard@mcmail.vanderbilt.edu			NCI NIH HHS [T32 CA09385] Funding Source: Medline; NHLBI NIH HHS [R01 HL45994] Funding Source: Medline; NIAID NIH HHS [R01 AI33839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Esslinger CW, 1997, J IMMUNOL, V158, P5075; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYOSHI I, 1981, GANN, V72, P978; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	40	131	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15891	15894		10.1074/jbc.273.26.15891	http://dx.doi.org/10.1074/jbc.273.26.15891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632633	hybrid			2022-12-27	WOS:000074436600004
J	Nagy, AK; Knowles, AF; Nagami, GT				Nagy, AK; Knowles, AF; Nagami, GT			Molecular cloning of the chicken oviduct ecto-ATP-diphosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; TOXOPLASMA-GONDII; PURIFICATION; PROTEIN; CD39; DIPHOSPHATASE; ANTIBODIES; APYRASE; MUSCLE; COMMON	The chicken oviduct ecto-ATP diphosphohydrolase (ATPDase), a member of the ecto-ATPase family, was purified to homogeneity previously (Strobel, R. S., Nagy, A. K., Knowles, A, F,, Buegel, J., and Rosenberg, M. O. (1996) J. Biol. Chem. 271, 16323-16331), It is an 80-kDa glycoprotein with high specific activity (approximately 1,000 mu mol/min/mg with MgATP as the substrate) and hydrolyzes both nucleoside triphosphates and diphosphates. Using amino acid sequence information obtained from the purified enzyme, two partial cDNA clones were obtained using reverse transcriptase-polymerase chain reaction and library screening. This is the second ecto-ATPase family member and the first ecto-ATPDase to be cloned hom information derived from purified proteins. The deduced primary sequence of the chicken oviduct ecto-ATPDase indicates a protein of 493 amino acid residues with a molecular mass of 54 kDa. The predicted orientation shows it to be anchored to the membrane by two transmembranous segments near the NH2 and COOH termini with very short intracytoplasmic peptides at either end. The bulk of the protein is extracellular and contains 12 potential N-glycosylation sites, several potential phosphorylation sites, and five sequences that are conserved in seven other related membrane proteins, Four of the conserved sequences, designated as apyrase conserved regions, are present in both ecto-ATPases and soluble E-type ATPases, The fifth conserved region, which occurs near the COOH terminus of the eight proteins, is observed only in the membrane-bound ecto-ATPases. Unexpectedly, sequence comparison revealed that the chicken oviduct ecto-ATPDase is equally distant from the two ecto-ATPases, which exhibit low activity toward ADP, and the four putative ecto-ATPDases, which are closely related to CD39.	W Los Angeles Vet Affairs Med Ctr, Nephrol Sect 111L, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; San Diego State Univ, Dept Chem, San Diego, CA 92182 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California State University System; San Diego State University	Nagami, GT (corresponding author), W Los Angeles Vet Affairs Med Ctr, Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; Beaudoin A.R, 1996, BIOMEMBRANES, V5, P369; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Caldwell C, 1997, BIOCHEM BIOPH RES CO, V238, P728, DOI 10.1006/bbrc.1997.7377; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORIDIS S, 1995, EUR J BIOCHEM, V234, P66, DOI 10.1111/j.1432-1033.1995.066_c.x; ENGELHARDT WA, 1957, P INT S ENZ CHEM TOK, V2, P163; GREEN N, 1982, CELL, V28, P103; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Hsieh HL, 1996, PLANT MOL BIOL, V30, P135, DOI 10.1007/BF00017808; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KANSAS GS, 1991, J IMMUNOL, V146, P2235; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KNOWLES AF, 1983, BIOCHIM BIOPHYS ACTA, V731, P88, DOI 10.1016/0005-2736(83)90401-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LewisCarl S, 1997, J BIOL CHEM, V272, P23645, DOI 10.1074/jbc.272.38.23645; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; NAGAMI G, 1992, LUMINESCENCE TOPICS, V1, P1; Nagy AK, 1997, ECTO-ATPASES, P1; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLESNER L, 1995, INT REV CYTOL, V158, P141; PLESNER L, 1997, ECTO ATPASES RECENT; ROBERTSON MW, 1988, MOL IMMUNOL, V25, P103, DOI 10.1016/0161-5890(88)90057-0; ROWE M, 1982, INT J CANCER, V29, P373, DOI 10.1002/ijc.2910290403; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; SEVIGNY J, 1997, AM J PHYSIOL, V272, P1076; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; Stout JG, 1996, BIOCHEMISTRY-US, V35, P8289, DOI 10.1021/bi960563g; STROBEL R, 1993, THESIS U MINNESOTA; Strobel RS, 1996, J BIOL CHEM, V271, P16323, DOI 10.1074/jbc.271.27.16323; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; YAGI K, 1992, CHEM PHARM BULL, V40, P2143; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	45	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16043	16049		10.1074/jbc.273.26.16043	http://dx.doi.org/10.1074/jbc.273.26.16043			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632655	hybrid			2022-12-27	WOS:000074436600026
J	Factor, VM; Kiss, A; Woitach, JT; Wirth, PJ; Thorgeirsson, SS				Factor, VM; Kiss, A; Woitach, JT; Wirth, PJ; Thorgeirsson, SS			Disruption of redox homeostasis in the transforming growth factor-alpha c-myc transgenic mouse model of accelerated hepatocarcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERY ENDOTHELIAL-CELLS; REACTIVE-OXYGEN; HYDROGEN-PEROXIDE; THIOREDOXIN REDUCTASE; MITOCHONDRIAL-DNA; FACTOR-BETA; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; HUMAN-FIBROBLASTS; OXIDATIVE DAMAGE	In previous studies we have demonstrated that transforming growth factor (TGF)-alpha/c-myc double transgenic mice exhibit an enhanced rate of cell proliferation, accumulate extensive DNA damage, and develop multiple liver tumors between 4 and 8 months of age. To clarify the biochemical events that mag be responsible for the genotoxic and carcinogenic effects observed in this transgenic model, several parameters of redox homeostasis in the liver were examined prior to development of hepatic tumors, By 2 months of age, production of reactive oxygen species, determined by the peroxidation-sensitive fluorescent dye, 2',7'-dichlorofluorescin diacetate, was significantly elevated in TGF-alpha/c-myc transgenic hepatocytes versus either wild type or c-myc single transgenic cells, and occurred in parallel with an increase in Lipid peroxidation. Concomitantly with a rise in oxidant levels, antioxidant defenses were decreased, including total glutathione content and the activity of glutathione peroxidase, whereas thioredoxin reductase activity was not changed. However; hepatic tumors which developed in TGF-alpha/c-myc mice exhibited an increase in thioredoxin reductase activity and a very low activity of glutathiolae peroxidase. Furthermore, specific deletions were detected in mtDNA as early as 5 weeks of age in the transgenic mice. These data provide experimental evidence that co-expression of TGF-alpha and c-myc transgenes in mouse liver promotes overproduction of reactive oxygen species and thus creates an oxidative stress environment. This phenomenon may account for the massive DNA damage and acceleration of hepatocarcinogenesis observed in the TGF-alpha/c-myc mouse model.	NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, NIH, 37 Convent Dr,MSC4255,Bldg 37,Rm 3C28, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov						Ahmad S., 1995, OXIDATIVE STRESS ANT, P238, DOI DOI 10.1007/978-1-4615-9689-9_7; AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x; AMES BN, 1991, PROG CLIN BIOL RES, V369, P1; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BASS DA, 1983, J IMMUNOL, V130, P1910; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brunk U.T., 1981, AGE PIGMENTS 1981, P243; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cahill A, 1997, BIOCHEM BIOPH RES CO, V235, P286, DOI 10.1006/bbrc.1997.6774; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8; DAS SK, 1991, AM J PHYSIOL, V261, pL249, DOI 10.1152/ajplung.1991.261.4.L249; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; DIANZANI MU, 1993, CRIT REV ONCOL HEMAT, V15, P125, DOI 10.1016/1040-8428(93)90052-6; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Factor VM, 1997, HEPATOLOGY, V26, P1434; Filser N, 1997, BIOCHEM BIOPH RES CO, V233, P102, DOI 10.1006/bbrc.1997.6409; FRAMPTON J, 1987, NUCLEIC ACIDS RES, V15, P3671, DOI 10.1093/nar/15.9.3671; FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Kao CY, 1996, BIOCHEM BIOPH RES CO, V222, P64, DOI 10.1006/bbrc.1996.0698; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lee CM, 1997, FREE RADICAL BIO MED, V22, P1259, DOI 10.1016/S0891-5849(96)00546-1; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Luetteke N C, 1990, Semin Cancer Biol, V1, P265; Mansouri A, 1997, J HEPATOL, V27, P96, DOI 10.1016/S0168-8278(97)80286-3; Mansouri A, 1997, GASTROENTEROLOGY, V113, P599, DOI 10.1053/gast.1997.v113.pm9247482; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MURAKAMI H, 1993, CANCER RES, V53, P1719; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NEWMAN MJ, 1990, P NATL ACAD SCI USA, V87, P5543, DOI 10.1073/pnas.87.14.5543; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; POWERS SK, 1992, J APPL PHYSIOL, V72, P1068, DOI 10.1152/jappl.1992.72.3.1068; RETEL J, 1993, MUTAT RES, V299, P165, DOI 10.1016/0165-1218(93)90094-T; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rubin H, 1996, P NATL ACAD SCI USA, V93, P1825, DOI 10.1073/pnas.93.5.1825; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; Sargent LM, 1996, CANCER RES, V56, P2137; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; Sharrow S., 1991, CURRENT PROTOCOLS IM; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SWAIM MW, 1988, J LEUKOCYTE BIOL, V43, P365, DOI 10.1002/jlb.43.4.365; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Woitach JT, 1997, J CELL BIOCHEM, V64, P651; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7	81	145	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15846	15853		10.1074/jbc.273.25.15846	http://dx.doi.org/10.1074/jbc.273.25.15846			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624185	hybrid			2022-12-27	WOS:000074284200079
J	Nagata, K; Driessens, M; Lamarche, N; Gorski, JL; Hall, A				Nagata, K; Driessens, M; Lamarche, N; Gorski, JL; Hall, A			Activation of G(1) progression, JNK mitogen-activated protein kinase, and actin filament assembly by the exchange factor FGD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; SIGNALING PATHWAY; STRESS FIBERS; CDC42 GTPASES; JUN KINASE; RHO; RAC; FAMILY; POLYMERIZATION; FILOPODIA	Cdc42 has been shown to control bifurcating pathways leading to filopodia formation/G(1) cell cycle progression and to JNK mitogen-activated protein kinase activation. To dissect these pathways further, the cellular effects induced by a Cdc42 guanine nucleotide exchange factor, FGD1, have been examined. All exchange factors acting on the Rho GTPase family have juxtaposed Dbl homology (DH) and pleckstrin homology (PH) domains. We report here that FGD1 triggers G(1) cell cycle progression and filopodia formation in Swiss 3T3 fibroblasts as well as JNK mitogen-activated protein kinase activation in COS cell transfection assays. FGD1-induced filopodia formation is Cdc42-dependent, and both the DH and PH domains are essential. Although expression of the FGD1 DH domain alone does not activate Cdc42 and induce filopodia, it does trigger both the JNK cascade in COS cells and G(1) progression in quiescent Swiss 3T3 cells. We conclude that FGD1 can trigger G(1) progression independently of actin polymerization or integrin adhesion complex assembly. Furthermore, since FGD1 activates JNK and G(1) progression in a Cdc42-independent manner, it must have additional, as yet unidentified, targets.	Univ London Univ Coll, MRC, Mol Cell Biol Lab,Canc Res Campaign, Oncogene & Signal Transduct Grp, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA	University of London; University College London; University of London; University College London; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hall, A (corresponding author), Univ London Univ Coll, MRC, Mol Cell Biol Lab,Canc Res Campaign, Oncogene & Signal Transduct Grp, Gower St, London WC1E 6BT, England.							Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1145; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PASTERIS NG, 1994, CELL, V79, P669; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TOKSOZ D, 1994, ONCOGENE, V9, P621; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169	33	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15453	15457		10.1074/jbc.273.25.15453	http://dx.doi.org/10.1074/jbc.273.25.15453			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624130	hybrid			2022-12-27	WOS:000074284200024
J	Abuladze, N; Lee, I; Newman, D; Hwang, J; Boorer, K; Pushkin, A; Kurtz, I				Abuladze, N; Lee, I; Newman, D; Hwang, J; Boorer, K; Pushkin, A; Kurtz, I			Molecular cloning, chromosomal localization, tissue distribution, and functional expression of the human pancreatic sodium bicarbonate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-REGULATORY MECHANISMS; PROXIMAL CONVOLUTED TUBULE; CENTRAL-NERVOUS-SYSTEM; GUINEA-PIG PANCREAS; RETINAL GLIAL-CELLS; INTRACELLULAR PH; BASOLATERAL MEMBRANE; NA-HCO3 COTRANSPORT; EXOCRINE SECRETION; INTERLOBULAR DUCTS	We report the cloning, sequence analysis, tissue distribution, functional expression, and chromosomal localization of the human pancreatic sodium bicarbonate cotransport protein (pancreatic NBC (pNBC)), The transporter was identified by searching the human expressed sequence tag data base. An I.M.A.G.E. clone W39298 was identified, and a polymerase chain reaction probe was generated to screen a human pancreas cDNA library. pNBC encodes a 1079-residue polypeptide that differs at the N terminus from the recently cloned human sodium bicarbonate cotransporter isolated from kidney (kNBC) (Burnham, C. E., Amlal, H., Wang, Z., Shull, G, E,, and Soleimani, M. (1997) J. Biol. Chem. 272, 19111-19114), Northern blot analysis using a probe specific for the N terminus of pNBC revealed an similar to 7.7-kilobase transcript expressed predominantly in pancreas, with less expression in kidney, brain, liver, prostate, colon, stomach, thyroid, and spinal chord. In contrast, a probe to the unique 5' region of kNBC detected an similar to 7.6-kilobase transcript only in the kidney. In situ hybridization studies in pancreas revealed expression in the acini and ductal cells. The gene was mapped to chromosome 4q21 using fluorescent in situ hybridization. Expression of pNBC in Xenopus laevis oocytes induced sodium bicarbonate cotransport, These data demonstrate that pNBC encodes the sodium bicarbonate cotransporter in the mammalian pancreas. pNBC is also expressed at a lower level in several other organs, whereas kNBC is expressed uniquely in kidney.	Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Div Nephrol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kurtz, I (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Sch Med, Div Nephrol, 10833 Le Conte Ave,Rm 7-155 Factor Bldg, Los Angeles, CA 90095 USA.	IKurtz@med1.medsch.ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046976] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABULADZE N, 1998, AM J PHYSIOL, V43, P628; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; ALPERN RJ, 1987, J GEN PHYSIOL, V89, P581, DOI 10.1085/jgp.89.4.581; ARRUDA JAL, 1992, AM J PHYSIOL, V262, pF560; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; CASE RM, 1989, CURR OPIN GASTROEN, V5, P665, DOI 10.1097/00001574-198910000-00012; CASE RM, 1972, J PHYSIOL-LONDON, V223, P649, DOI 10.1113/jphysiol.1972.sp009867; DART C, 1992, J PHYSIOL-LONDON, V451, P365, DOI 10.1113/jphysiol.1992.sp019169; DEITMER JW, 1987, J PHYSIOL-LONDON, V388, P261, DOI 10.1113/jphysiol.1987.sp016614; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; DeOndarza J, 1997, AM J PHYSIOL-GASTR L, V272, pG124, DOI 10.1152/ajpgi.1997.272.1.G124; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; FREEDMAN SD, 1994, ANN NY ACAD SCI, V713, P199, DOI 10.1111/j.1749-6632.1994.tb44066.x; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRAY MA, 1993, AM J PHYSIOL, V264, pC591, DOI 10.1152/ajpcell.1993.264.3.C591; GUGGINO WB, 1983, J MEMBRANE BIOL, V71, P227, DOI 10.1007/BF01875464; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P169, DOI 10.1113/jphysiol.1996.sp021582; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P179, DOI 10.1113/jphysiol.1996.sp021583; JACOBSON HR, 1981, AM J PHYSIOL, V240, pF54, DOI 10.1152/ajprenal.1981.240.1.F54; KURTZ I, 1989, J CLIN INVEST, V83, P616, DOI 10.1172/JCI113925; KURTZ I, 1987, J CLIN INVEST, V80, P928, DOI 10.1172/JCI113184; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LUBMAN RL, 1995, RESP PHYSIOL, V100, P15, DOI 10.1016/0034-5687(94)00114-F; MACHEN TE, 1989, ANN NY ACAD SCI, V574, P447; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; NAKHOUL NL, 1990, AM J PHYSIOL, V258, pF371, DOI 10.1152/ajprenal.1990.258.2.F371; NEWMAN EA, 1991, GLIA, V4, P424, DOI 10.1002/glia.440040411; Newman EA, 1996, J NEUROSCI, V16, P159; NOVAK I, 1993, PFLUG ARCH EUR J PHY, V425, P272, DOI 10.1007/BF00374178; Romero M. F., 1996, Journal of the American Society of Nephrology, V7, P1259; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SASAKI S, 1988, J CLIN INVEST, V81, P1004, DOI 10.1172/JCI113410; SASAKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P45, DOI 10.1016/0167-4889(92)90098-V; SCHWARTZ GJ, 1983, AM J PHYSIOL, V245, pF382, DOI 10.1152/ajprenal.1983.245.3.F382; STUENKEL EL, 1988, AM J PHYSIOL, V254, pG925, DOI 10.1152/ajpgi.1988.254.6.G925; VAZHAIKKURICHI M, 1991, J CLIN INVEST, V88, P1379; VEEL T, 1992, ACTA PHYSIOL SCAND, V144, P239, DOI 10.1111/j.1748-1716.1992.tb09292.x; VILLANGER O, 1995, GASTROENTEROLOGY, V108, P850, DOI 10.1016/0016-5085(95)90460-3; WEINTRAUB WH, 1989, AM J PHYSIOL, V257, pG317, DOI 10.1152/ajpgi.1989.257.3.G317; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1994, AM J PHYSIOL, V36, pC385	45	203	213	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17689	17695		10.1074/jbc.273.28.17689	http://dx.doi.org/10.1074/jbc.273.28.17689			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651366	hybrid			2022-12-27	WOS:000074816100059
J	Matheson, NR; Travis, J				Matheson, NR; Travis, J			Purification and characterization of a novel peptidase (IImes) from mesquite (Prosopis velutina) pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANGIOTENSIN-II; CATHEPSIN-B; ALLERGENS; RAGWEED; ASTHMA; ENDOPEPTIDASE; NEUROPEPTIDES; RESPONSES; BINDING	Although the mesquite plant (Prosopis velutina) is not as widely distributed as some other allergenic species, its pollen can induce serious pollinosis in areas where it is localized. We previously isolated and characterized a peptidase from mesquite pollen with trypsin-like specificity (peptidase I-mes) (Matheson, N., Schmidt, J., and Travis, J. (1995) Am, J. Respir. Cell Mol. Biol. 12, 441-448). Now we have characterized a second enzyme with specificity for hydrophobic residues (mesquite pollen peptidase IImes). This enzyme has a molecular mass near 92 kDa and activity that was not affected by reducing or chelating agents but was inhibited by specific synthetic serine proteinase inhibitors and the aminopeptidase inhibitor bestatin. However, it was not inhibited by human plasma proteinase inhibitors, nor did it inactivate any of those tested. The enzyme possessed amidolytic activity against p-nitroanilide substrates most effectively after alanine residues and also displayed aminopeptidase activity against non-p-nitroanilide peptides with a preference for phenylalanine. This specificity for hydrophobic amino acid residues was corroborated by inhibition studies with chloromethyl ketone and organophosphonate inhibitors. More interesting from a physiological point of view is that the bioactive peptides, angiotensins I and II and vasoactive intestinal peptide, were also hydrolyzed rapidly, indicating an ability of peptidase IImes to act also as an oligopeptidase. Because these bioactive peptides play a role in the inflammatory responses in allergic asthma, our data suggest that the purified mesquite pollen peptidase IImes may be involved in the degradation of neuro- and vasoactive peptides during pollen-initiated allergic reactions.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	jtravis@uga.cc.uga.edu						ALBANI D, 1991, PLANT MOL BIOL, V16, P501, DOI 10.1007/BF00023417; ALLEN RL, 1992, PLANT MOL BIOL, V20, P343, DOI 10.1007/BF00014505; ASHWELL JD, 1986, NATURE, V320, P176, DOI 10.1038/320176a0; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; Bagarozzi DA, 1996, J BIOL CHEM, V271, P26227, DOI 10.1074/jbc.271.42.26227; Bagarozzi DA, 1998, AM J RESP CELL MOL, V18, P363, DOI 10.1165/ajrcmb.18.3.2825; BARNES PJ, 1987, J ALLERGY CLIN IMMUN, V79, P285, DOI 10.1016/0091-6749(87)90143-6; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BARNES PJ, 1986, LANCET, V1, P242; BARNES PJ, 1993, ALLERGY PRINCIPLES P, V1, P243; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P11; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P39; CASALE TB, 1988, AM J RHINOL, V2, P121; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; DEBONO E, 1963, CLIN SCI, V25, P123; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FROSSARD N, 1989, J PHARMACOL EXP THER, V248, P292; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V97, P1097, DOI 10.1016/0006-291X(80)91488-6; Guo ZJ, 1998, PHYTOCHEMISTRY, V47, P547, DOI 10.1016/S0031-9422(97)00441-X; HARTUNG HP, 1986, J IMMUNOL, V136, P3856; HOLGATE ST, 1993, ALLERGY PRINCIPLES P, V1, P267; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; KNOX RB, 1973, J CELL SCI, V12, P421; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LEWIS WH, 1980, AIRBORNE ALLERGIC PO, P45; LEWIS WH, 1980, ALLERGY IMMUNOLOGY M, P124; MATHESON N, 1995, AM J RESP CELL MOL, V12, P441, DOI 10.1165/ajrcmb.12.4.7695924; MCKAY MJ, 1983, BIOCHEM J, V213, P467, DOI 10.1042/bj2130467; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLO F, 1990, MOL IMMUNOL, V27, P151, DOI 10.1016/0161-5890(90)90110-L; ROSENSTREICH DL, 1981, CELLULAR FUNCTIONS I, P138; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANISZ AM, 1988, ANN NY ACAD SCI, V527, P478; TANIAI M, 1988, FEBS LETT, V239, P329, DOI 10.1016/0014-5793(88)80945-1; TURCICH MP, 1993, PLANT MOL BIOL, V23, P1061, DOI 10.1007/BF00021820; VILIALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523; ZUBAY GL, 1995, PRINCIPLES BIOCH, P144	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16771	16777		10.1074/jbc.273.27.16771	http://dx.doi.org/10.1074/jbc.273.27.16771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642233	hybrid			2022-12-27	WOS:000074545200023
J	Tamai, E; Shimamoto, T; Tsuda, M; Mizushima, T; Tsuchiya, T				Tamai, E; Shimamoto, T; Tsuda, M; Mizushima, T; Tsuchiya, T			Conversion of temperature-sensitive to -resistant gene expression due to mutations in the promoter region of the melibiose operon in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; REGULATORY REGION; MELAB PROMOTER; PROTEIN; TRANSPORT; CARRIER	The melibiose utilization system of Escherichia coli W3133, a derivative of K12, is nonfunctional between 37 and 42 degrees C, The reason for this temperature sensitivity was thought to be that the melibiose transporter (MelB) of W3133 cells was temperature-sensitive. A mutant W3133-2 has been isolated as a temperature-resistant strain that can utilize melibiose between 37 and 42 degrees C, However, we found that the melibiose transporter of the W3133-2 was still temperature-sensitive. Half-life activities of the melibiose transporter at 37 degrees C (or 40 degrees C) in both E. coli W3133 and W3133-2 were exactly the same. Furthermore, we found that the nucleotide sequence of coding region of the melB structural gene (the second gene of the melibiose operon) of W3133-2 was exactly the same as that of W3133, Activity of cu-galactosidase (product of the first gene, melA, of the melibiose operon) of W3133 cells grown at 40 degrees C was very low, although that of W3133-2 cells grown at 40 degrees C was high. These observations suggested that expression of the melibiose operon in W3133 is also temperature-sensitive. In fact, we found that the expression in W3133 cells was temperature-sensitive, while that in W3133-2 cells was temperature-resistant, by analyzing mRNA levels using the Northern blot method. Furthermore, we identified mutations in the promoter region of the melibiose operon of W3133-2 that resulted in the elongation of an 18 nucleotide inverted repeat sequence to a 28-nucleotide repeat sequence present immediately upstream of the -35 region. This may stabilize a possible stem structure due to the inverted repeat at 37-42 degrees C.	Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 7008530, Japan; Okayama Univ, Ctr Gene Res, Okayama 7008530, Japan	Okayama University; Okayama University	Tsuchiya, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Microbiol, Okayama 7008530, Japan.		Shimamoto, Tadashi/A-7109-2018	Shimamoto, Tadashi/0000-0002-5538-0595; TAMAI, EIJI/0000-0002-0338-5095				AIBA H, 1981, J BIOL CHEM, V256, P1905; ALBERTS B, 1983, MOL BIOL CELL, P611; BERNS KI, 1965, J MOL BIOL, V11, P476, DOI 10.1016/S0022-2836(65)80004-3; BURSTEIN C, 1971, BIOCHIM BIOPHYS ACTA, V230, P52, DOI 10.1016/0304-4165(71)90053-5; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; HANATANI M, 1984, J BIOL CHEM, V259, P1807; Keen J, 1996, BIOCHEM J, V318, P443, DOI 10.1042/bj3180443; KENNEDY EP, 1970, LACTOSE OPERON, P49; LEVINTHAL M, 1971, J BACTERIOL, V105, P1047, DOI 10.1128/JB.105.3.1047-1052.1971; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; MANIATIS T, 1982, MOL CLONING LABORATO, P440; NAGAO Y, 1988, BIOCHEM BIOPH RES CO, V151, P236, DOI 10.1016/0006-291X(88)90584-0; OHTANI K, 1995, J NEUROCHEM, V65, P605; PRESTIDGE LS, 1965, BIOCHIM BIOPHYS ACTA, V100, P591, DOI 10.1016/0304-4165(65)90029-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT R, 1968, J BACTERIOL, V96, P462, DOI 10.1128/JB.96.2.462-471.1968; SHIMAMOTO T, 1984, BIOCHEM BIOPH RES CO, V121, P41, DOI 10.1016/0006-291X(84)90685-5; SHIMAMOTO T, 1994, J BIOCHEM-TOKYO, V115, P1185, DOI 10.1093/oxfordjournals.jbchem.a124477; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TSUCHIYA T, 1978, J MEMBRANE BIOL, V42, P45, DOI 10.1007/BF01870393; WEBSTER C, 1987, GENE, V59, P253, DOI 10.1016/0378-1119(87)90333-7; WEBSTER C, 1989, GENE, V83, P207, DOI 10.1016/0378-1119(89)90106-6; WILLIAMS J, 1994, BIOCHEM J, V300, P757, DOI 10.1042/bj3000757; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YAZYU H, 1984, J BIOL CHEM, V259, P4320	25	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16860	16864		10.1074/jbc.273.27.16860	http://dx.doi.org/10.1074/jbc.273.27.16860			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642246	hybrid			2022-12-27	WOS:000074545200036
J	Feldman, JD; Vician, L; Crispino, M; Tocco, G; Marcheselli, VL; Bazan, NG; Baudry, M; Herschman, HR				Feldman, JD; Vician, L; Crispino, M; Tocco, G; Marcheselli, VL; Bazan, NG; Baudry, M; Herschman, HR			KID-1, a protein kinase induced by depolarization in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; REPRESENTATIONAL DIFFERENCE ANALYSIS; PC12 PHEOCHROMOCYTOMA CELLS; PLATELET-ACTIVATING-FACTOR; 3' UNTRANSLATED REGION; IMMEDIATE-EARLY GENE; MESSENGER-RNA; MEMBRANE DEPOLARIZATION; SYNAPTIC ACTIVITY	Membrane depolarization leads to changes in gene expression that modulate neuronal plasticity. Using representational difference analysis, we have identified a previously undiscovered cDNA,KID-1 (kinase induced by depolarization), that is induced by membrane depolarization or forskolin, but not by neurotrophins or growth factors, in PC12 pheochromocytoma cells, KID-1 is an immediate early gene that shares a high degree of sequence similarity with the family of PIM-1 serine/threonine protein kinases, Recombinant KID-1 fusion protein is able to catalyze both histone phosphorylation and autophosphorylation, KID-1 mRNA is present in a number of unstimulated tissues, including brain. In response to kainic acid and electroconvulsive shock-induced seizures, KID-1 is induced in specific regions of the hippocampus and cortex.	Univ Calif Los Angeles, Ctr Hlth Sci, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA; Louisiana State Univ, Med Ctr, Ctr Neurosci, New Orleans, LA 70112 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Southern California; Louisiana State University System	Herschman, HR (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Inst Mol Biol, 611 Circle Dr E, Los Angeles, CA 90095 USA.		Bazan, Nicolas/AAN-4121-2020; Crispino, Marianna/ABD-3702-2020	Bazan, Nicolas/0000-0002-9243-5444; CRISPINO, Marianna/0000-0002-5797-8830	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018427, R01NS028660] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01870] Funding Source: Medline; NINDS NIH HHS [NS28660, NS18427] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARENANDER AT, 1993, NEUROTROPHIC FACTORS, P1; Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu CC, 1997, P NATL ACAD SCI USA, V94, P2507, DOI 10.1073/pnas.94.6.2507; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; deOrtiz SP, 1996, MOL BRAIN RES, V38, P1, DOI 10.1016/0169-328X(95)00263-R; DOMEN J, 1993, BLOOD, V82, P1445; Edman CF, 1997, BIOCHEM J, V323, P113, DOI 10.1042/bj3230113; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KUJUBU DA, 1987, ONCOGENE, V1, P257; LASLOP A, 1994, NEUROSCIENCE, V59, P477, DOI 10.1016/0306-4522(94)90611-4; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; Marcheselli VL, 1996, J BIOL CHEM, V271, P24794, DOI 10.1074/jbc.271.40.24794; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MELEGA WP, 1984, P NATL ACAD SCI USA, V81, P6536; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; PADMA R, 1991, CANCER RES, V51, P2486; Palaty CK, 1997, J BIOL CHEM, V272, P10514; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; Sambrook J., 2002, MOL CLONING LAB MANU; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHREIBER SS, 1993, NEUROSCI LETT, V153, P17, DOI 10.1016/0304-3940(93)90066-T; SCHREIBER SS, 1993, NEUROREPORT, V5, P269, DOI 10.1097/00001756-199312000-00022; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THOMPSON ME, 1992, MOL BRAIN RES, V12, P195, DOI 10.1016/0169-328X(92)90084-O; Tocco G, 1996, MOL BRAIN RES, V40, P229, DOI 10.1016/0169-328X(96)00055-1; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Vician L, 1997, J NEUROSCI RES, V50, P32, DOI 10.1002/(SICI)1097-4547(19971001)50:1<32::AID-JNR4>3.0.CO;2-M; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; VONLOHUIZEN M, 1989, CELL, V56, P673; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333	56	83	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16535	16543		10.1074/jbc.273.26.16535	http://dx.doi.org/10.1074/jbc.273.26.16535			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632723	hybrid			2022-12-27	WOS:000074436600094
J	Hanner, M; Vianna-Jorge, R; Kamassah, A; Schmalhofer, WA; Knaus, HG; Kaczorowski, GJ; Garcia, ML				Hanner, M; Vianna-Jorge, R; Kamassah, A; Schmalhofer, WA; Knaus, HG; Kaczorowski, GJ; Garcia, ML			The beta subunit of the high conductance calcium-activated potassium channel - Identification of residues involved in charybdotoxin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNEL; AORTIC SMOOTH-MUSCLE; FUNCTIONAL RECONSTITUTION; MODULATION; EXPRESSION; VOLTAGE; BRAIN; HSLO; SITE	Coexpression of alpha and beta subunits of the high conductance Ca2+-activated K+ (maxi-K) channel leads to a 50-fold increase in the affinity for I-125-charybdotoxin (I-125-ChTX) as compared with when the alpha subunit is expressed alone (Hanner, M., Schmalhofer, W. A., Munujos, P., Knaus, H.-G., Kaczorowski, G. J., and Garcia, M. L. (1997) Proc. Natl. Acad Sci. U. S. A. 94, 2853-2858). To identify those residues in the P subunit that are responsible for this change in binding affinity, Ala scanning mutagenesis was carried out along the extracellular loop of beta and the resulting effects on I-125-ChTX binding were determined after coexpression with the alpha subunit, Mutagenesis of each of the four Cys residues present in the loop causes a large reduction in toxin binding affinity, suggesting that these residues could be forming disulfide bridges. The existence of two disulfide bridges in the extracellular loop of beta was demonstrated after comparison of reactivities of native beta and single-Cys-mutated subunits to N-biotin-maleimide. Negatively charged residues in the loop of beta, when mutated individually or in combinations, had no effect on toxin binding with the exception of Glu(94), whose alteration modifies kinetics of ligand association and dissociation. Further mutagenesis studies targeting individual residues between Cys(76) and Cys(103) indicate that four positions, Leu(90), Tyr(91), Thr(93), and Glu(94) are critical in conferring high affinity I-125-ChTX binding to the alpha.beta subunit complex. Mutations at these positions cause large effects on the kinetics of ligand association and dissociation, but they do not alter the physical interaction of beta with the alpha subunit. All these data, taken together, suggest that the large extracellular loop of the maxi-K channel beta subunit has a restricted conformation. Moreover, they are consistent with the view that four residues appear to be important for inducing an appropriate conformation within the alpha subunit that allows high affinity ChTX binding.	Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA; Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria	Merck & Company; University of Innsbruck	Garcia, ML (corresponding author), Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA.	maria_garcia@merck.com	Vianna-Jorge, Rosane/AAC-7301-2020; Vianna-Jorge, Rosane/A-1230-2013	Vianna-Jorge, Rosane/0000-0001-5407-4695; Vianna-Jorge, Rosane/0000-0001-5407-4695				ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIANGIACOMO KM, 1995, BIOCHEMISTRY-US, V34, P15849, DOI 10.1021/bi00048a031; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; Hanner M, 1998, BIOPHYS J, V74, pA112; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; Koch Robert O. A., 1996, Society for Neuroscience Abstracts, V22, P1754; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Koschak A, 1997, BIOCHEMISTRY-US, V36, P1943, DOI 10.1021/bi962074m; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Meera P., 1995, Biophysical Journal, V68, pA3; MUNUJOS P, 1995, BIOCHEMISTRY-US, V34, P10771, DOI 10.1021/bi00034a009; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; SUN TY, 1994, BIOCHEMISTRY-US, V33, P9992, DOI 10.1021/bi00199a024; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185	26	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16289	16296		10.1074/jbc.273.26.16289	http://dx.doi.org/10.1074/jbc.273.26.16289			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632689	hybrid			2022-12-27	WOS:000074436600060
J	Li, Y; Sternweis, PM; Charnecki, S; Smith, TF; Gilman, AG; Neer, EJ; Kozasa, T				Li, Y; Sternweis, PM; Charnecki, S; Smith, TF; Gilman, AG; Neer, EJ; Kozasa, T			Sites for G alpha binding on the G protein beta subunit overlap with sites for regulation of phospholipase C beta and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; GAMMA-SUBUNITS; CRYSTAL-STRUCTURE; SF9 CELLS; LIMITED PROTEOLYSIS; PURIFICATION; COMPLEX; MUTAGENESIS; RESOLUTION; TRANSDUCIN	Heterotrimeric G proteins, composed of alpha and beta gamma subunits, forward signals from transmembrane receptors to intracellular effector enzymes and ion channels. Free beta gamma activates downstream targets, but its action is terminated by association with GDP-liganded alpha subunits. Because alpha can inhibit activation of many effectors by beta gamma, it is likely that the alpha subunit binding surfaces on beta gamma overlap the surfaces necessary for effector activation. To test this hypothesis, we mutated residues on beta shown to contact a in the recently published crystal structures of the alpha beta gamma heterotrimer (Wall, M. A., Coleman, D. E., Lee, E., Iniguez-Lluhi, J. A. Posner, B. A., Gilman, A. G., and Sprang, S. R. (1995) Cell 83, 1047-1058; Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319.). The alpha subunit binds to the flat, top surface of the toroidal beta subunit and also extends a helix along the side of the beta subunit at blade I. We mutated four residues on the top surface of beta (H beta(1)[L117A], H beta(1)[D228R], H beta(1)[D246S], and H beta(1)[W332A]) and two residues on the side of beta that contacts alpha (H beta(1)[N88A/K89A]). Each of the mutant proteins was able to form py dimers, but they differed in their ability to bind a and to activate phospholipase C beta(2) (PLC beta(2)), PLC beta(3), and adenylyl cyclase II. Mutation of residues along the side of the torus at blade I diminish affinity for alpha but do not prevent activation of any of the effectors. Mutations on the a binding surface differentially affected PLC beta(2), PLC beta(3), and adenylyl cyclase II. Residues that affect PLC beta and adenylyl cyclase II activity are found on opposite sides of the central tunnel, suggesting that PLC and adenylyl cyclase, like the a subunit, make many contacts on the top surface. None of the mutations affected the ability of beta gamma to inhibit adenylyl cyclase I. We conclude that alpha, PLC beta(2), PLC beta(3), and adenylyl cyclase II share an interaction on the top surface of beta. The importance of individual residues is different for a binding and for effector activation and differs even between closely related isoforms of the same effector.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Boston Univ, Biomol Engn Res Ctr, Boston, MA 02111 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Neer, EJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.				NIGMS NIH HHS [GM34497, GM362569] Funding Source: Medline; NLM NIH HHS [P1 LM05252] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLANK JL, 1993, J BIOL CHEM, V268, P25184; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CASEY PJ, 1991, METHOD ENZYMOL, V195, P315; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DENKER BM, 1992, J BIOL CHEM, V267, P6272; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SUMMERS MD, 1987, MANNUAL METHODS BACU, V1555; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	35	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16265	16272		10.1074/jbc.273.26.16265	http://dx.doi.org/10.1074/jbc.273.26.16265			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632686	hybrid			2022-12-27	WOS:000074436600057
J	Rivers, A; Gietzen, KF; Vielhaber, E; Virshup, DM				Rivers, A; Gietzen, KF; Vielhaber, E; Virshup, DM			Regulation of casein kinase I epsilon and casein kinase I delta by an in vivo futile phosphorylation cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; 40 DNA-REPLICATION; REPAIR; FAMILY; YEAST; GENE	Casein kinase I delta (CKI delta) and casein kinase I epsilon (CKI epsilon) have been implicated in the response to DNA damage, but the understanding of how these kinases are regulated remains incomplete. In vitro, these kinases rapidly autophosphorylate, predominantly on their carboxyl-terminal extensions, and this autophosphorylation markedly inhibits kinase activity (Cegielska, A., Gietzen, K. F., Rivers, A., and Virshup, D. M. (1998) J. Biol. Chem. 273, 1357-1364). However, we now report that while these kinases are able to autophosphorylate in vivo, they are actively maintained in the dephosphorylated, active state by cellular protein phosphatases. Treatment of cells with the cell-permeable serine/threonine phosphatase inhibitors okadaic acid or calyculin A leads to rapid increases in kinase intramolecular autophosphorylation. Since CKI autophosphorylation decreases kinase activity, this dynamic autophosphorylation/dephosphorylation cycle provides a mechanism for kinase regulation in vivo.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84132 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, 50 N Med Dr,5C334 Hlth Sci Ctr, Salt Lake City, UT 84132 USA.		Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [R01 CA71074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHEN J, 1994, J BIOL CHEM, V269, P7957; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HO U, 1997, P NATL ACAD SCI USA, V94, P581; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MANNO S, 1995, J BIOL CHEM, V270, P5659, DOI 10.1074/jbc.270.10.5659; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Santos JA, 1996, J CELL SCI, V109, P1847; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WOLD MS, 1989, J BIOL CHEM, V264, P2801; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	25	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15980	15984		10.1074/jbc.273.26.15980	http://dx.doi.org/10.1074/jbc.273.26.15980			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632646	hybrid			2022-12-27	WOS:000074436600017
J	Ahmed, S; Prigmore, E; Govind, S; Veryard, C; Kozma, R; Wientjes, FB; Segal, AW; Lim, L				Ahmed, S; Prigmore, E; Govind, S; Veryard, C; Kozma, R; Wientjes, FB; Segal, AW; Lim, L			Cryptic Rac-binding and p21(Cdc42HS/Rac)-activated kinase phosphorylation sites of NADPH oxidase component p67(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; ACTIN STRESS FIBERS; PROTEIN N-CHIMAERIN; HUMAN NEUTROPHILS; TYROSINE KINASE; 2-HYBRID SYSTEM; CDC42 GTPASES; SH3 DOMAINS; ACTIVATION; RHO	Rad is a member of the Rho family of small molecular mass GTPases that act as molecular switches to control actin-based cell morphology as well as cell growth and differentiation. Rac1 and Rac2 are specifically required for superoxide formation by components of the NADPH oxidase, In binding assays, Rad interacts directly with p67(phox), but not with the other oxidase components: cytochrome b, p40(phox), or p47(phox) (Prigmore, E., Ahmed, S., Best, A., Kozma, R., Manser, E., Segal, A. W., and Lim, L. (1995) J. Biol. Chem. 270, 10717-10722), Here, the Rac1/2 interaction with p67(phox) has been characterized further. Rac1 and Rac2 can bind to p67(phox) amino acid residues 170-199, and the N terminus (amino acids 1-192) of p67(phox) can be used as a specific inhibitor of Rac signaling. Deletion of p67(phox) C-terminal sequences (amino acids 193-526), the C-terminal SH3 domain (amino acids 470-526), or the polyproline-rich motif (amino acids 226-236) stimulates Rad binding by similar to 8-fold. p21(Cdc42Hs/Rac)-activated kinase (PAK) phosphorylates p67(phox) amino acid residues adjacent to the Rac1/2-binding site, and this phosphorylation is stimulated by deletion of the C-terminal SH3 domain or the polyproline-rich motif, These data suggest a role for cryptic Rac-binding and PAK phosphorylation sites of p67(phox) in control of the NADPH oxidase.	Inst Neurol, Dept Neurochem, London WC1N 1PJ, England; Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 119076, Singapore; Univ London Univ Coll, Dept Med, London WC1E 6JJ, England	University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Lim, L (corresponding author), Inst Neurol, Dept Neurochem, 1 Wakefield St, London WC1N 1PJ, England.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768; Segal, Anthony/0000-0001-7602-9043; Veryard, Claire/0000-0002-6637-1686	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; AHMED S, 1993, J BIOL CHEM, V268, P10709; BENNA JE, 1994, J BIOL CHEM, V269, P6729; Best A, 1996, J BIOL CHEM, V271, P3756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fuchs A, 1996, BBA-MOL CELL RES, V1312, P39, DOI 10.1016/0167-4889(96)00020-1; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; HAYWORTH PG, 1994, J BIOL CHEM, V269, P30749; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leusen JHW, 1996, J EXP MED, V184, P1243, DOI 10.1084/jem.184.4.1243; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YAMMAGUCHI M, 1985, BIOCHEM BIOPH RES CO, V216, P203	51	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15693	15701		10.1074/jbc.273.25.15693	http://dx.doi.org/10.1074/jbc.273.25.15693			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624165	hybrid			2022-12-27	WOS:000074284200059
J	Homma, K; Terui, S; Minemura, M; Qadota, H; Anraku, Y; Kanaho, Y; Ohya, Y				Homma, K; Terui, S; Minemura, M; Qadota, H; Anraku, Y; Kanaho, Y; Ohya, Y			Phosphatidylinositol-4-phosphate 5-kinase localized on the plasma membrane is essential for yeast cell morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; ACID PHOSPHOLIPIDS; GUANINE-NUCLEOTIDE; BREFELDIN-A; 4,5-BISPHOSPHATE; GENE; MUTANTS; PROFILIN	Phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P-2), an important element in eukaryotic signal transduction, is synthesized either by phosphatidylinositol-4-phosphate 5-kinase (PtdIns(4)P 5K) from phosphatidylinositol 4-phosphate (PtdIns(4)P) or by phosphatidylinositol-5-phosphate 4-kinase (PtdIns(S)P 4K) from phosphatidylinositol B phosphate (PtdIns(B)P). Two Saccharomyces cerevisiae genes, MSS4 and FAB1, are homologous to mammalian PtdIns(4)P 5Ks and PtdIns(S)P 4:Ks. We show here that MSS4 is a functional homolog of mammalian PtdIns(4)P 5K but not of PtdIns(B)P 4K in vivo. We constructed a hemagglutinin epitope-tagged form of Mss4p and found that Mss4p has PtdIns(4)P SK activity. Immunofluorescent and fractionation studies of the epitope-tagged Mss4p suggest that Mss4p is localized on the plasma membrane, whereas Fab1p is reportedly localized on the vacuolar membrane. A temperature-sensitive mss4-1 mutant was isolated, and its phenotypes at restrictive temperatures were found to include increased cell size, round shape, random distribution of actin patches, and delocalized staining of cell wall chitin. Thus, biochemical and genetic analyses on Mss4p indicated that yeast PtdIns(4)P 5K localized on the plasma membrane is required for actin organization.	Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2260026, Japan; Univ Tokyo, Japan Sci & Technol Corp, Grad Sch Sci,Unit Proc & Combined Circuit, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); University of Tokyo	Ohya, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@biol.s.u-tokyo.ac.jp						ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; AMEH LE, 1997, NATURE, V390, P192; BELDE PJM, 1993, FEBS LETT, V323, P113, DOI 10.1016/0014-5793(93)81460-H; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kaiser C., 1994, METHODS YEAST GENETI; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; Ohya Y, 1996, MOL GEN GENET, V252, P1, DOI 10.1007/BF02173199; OSTRANDER DB, 1995, J BIOL CHEM, V270, P27045, DOI 10.1074/jbc.270.45.27045; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; SCHUMAKER KS, 1987, J BIOL CHEM, V262, P3944; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; TERUI T, 1994, J BIOL CHEM, V269, P28130; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	53	136	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15779	15786		10.1074/jbc.273.25.15779	http://dx.doi.org/10.1074/jbc.273.25.15779			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624177	hybrid			2022-12-27	WOS:000074284200071
J	Jiang, XC; D'Armiento, J; Mallampalli, RK; Mar, J; Yan, SF; Lin, M				Jiang, XC; D'Armiento, J; Mallampalli, RK; Mar, J; Yan, SF; Lin, M			Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CHOLESTEROL; SURFACTANT; CONVERSION; EXCHANGE; DISEASE; CELLS	The lung is the major site expressing plasma phospholipid transfer protein (PLTP) mRNA in humans and mice, suggesting that this protein might have an important role in maintaining normal function of this organ. In the lung of human collagenase transgenic mice, an emphysematous animal model, PLTP mRNA was 3-fold higher than in control mice. However, the mRNA in other tissues was not changed. To further assess the expression and function of PLTP, we measured PLTP mRNA level in lung tissue of two emphysematous patients and found that the mRNA was I-fold higher than in control subjects. In situ hybridization on mouse lung suggested positive staining in alveolar type II epithelial cells. In addition, immortalized rat alveolar pre-type II epithelial cells and freshly isolated mature rat alveolar type II epithelial cells both highly expressed PLTP mRNA, and the former cells actively secreted PLTP activity into the medium. To examine the possible mechanisms leading to high levels of PLTP expression in vivo, we exposed the pre-type II cells to hypoxia and demonstrated induction of PLTP mRNA and a coordinate increase in secreted PLTP activity. Thus, the PLTP gene is highly expressed in alveolar type II epithelial cells and is induced during hypoxia and in emphysema. These observations suggest that a hypoxic stimulus occurring in emphysema may be a novel mechanism that contributes to enhanced expression of PLTP.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Med Ctr, Dept Vet Affairs, Iowa City, IA 52242 USA	Columbia University; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Jiang, XC (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th ST, New York, NY 10032 USA.				NHLBI NIH HHS [HL54591, HL55584] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055584, R29HL055584, P01HL054591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BARLOW Y, 1985, THORAX, V40, P214; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; DAY JR, 1994, J BIOL CHEM, V269, P9388; FINLEY TN, 1972, NEW ENGL J MED, V286, P223, DOI 10.1056/NEJM197202032860501; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; FUJIWARA T, 1980, LANCET, V1, P55; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GUILLEMIN K, 1997, CELL, V81, P9; HIGHENBOTTAM T, 1987, EUR J RESP DIS S153, V71, P222; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Kurashima K, 1997, CLIN EXP ALLERGY, V27, P337; Longo CA, 1997, AM J RESP CELL MOL, V16, P605, DOI 10.1165/ajrcmb.16.5.9160843; MALLAMPALLI RK, 1992, IN VITRO CELL DEV-AN, V28A, P181; Mallampalli RK, 1997, J CLIN INVEST, V99, P2020, DOI 10.1172/JCI119370; MASON R J, 1987, European Journal of Respiratory Diseases Supplement, V71, P229; POWNALL HJ, 1991, J LIPID RES, V32, P793; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SHENOI A, 1992, ACTA PAEDIATR, V81, P150, DOI 10.1111/j.1651-2227.1992.tb12192.x; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; STRANG LB, 1977, NEONATAL RESPIRATION, P181; TALL AR, 1983, J BIOL CHEM, V258, P2174; TALL AR, 1985, J LIPID RES, V26, P842; TISI GM, 1981, METABOLISM, V30, P340, DOI 10.1016/0026-0495(81)90113-X; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TU AY, 1993, J BIOL CHEM, V268, P23098; VOYNOYASENETSKAYA TA, 1993, P NATL ACAD SCI USA, V90, P4256, DOI 10.1073/pnas.90.9.4256; Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699; WALSH A, 1989, J BIOL CHEM, V264, P6488; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837	32	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15714	15718		10.1074/jbc.273.25.15714	http://dx.doi.org/10.1074/jbc.273.25.15714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624168	hybrid			2022-12-27	WOS:000074284200062
J	Koppel, AM; Raper, JA				Koppel, AM; Raper, JA			Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; SEMAPHORIN-III; BINDING; FAMILY; SYSTEM; CD100	Chick collapsin-1, the first identified vertebrate member of the semaphorin family of axon guidance proteins, repels specific growth cones, Like all family members, collapsin-1 contains within its sequence a semaphorin domain that is necessary for specifying activity. Two additional structural domains of collapsin-1, the immunoglobulin (Ig) domain and the basic tail, each potentiate collapsin-1 activity. We identify in this study another structural feature of collapsin-1 that is necessary for its function, Collapsin-1 covalently dimerizes, and dimerization is necessary for collapse activity. This dimerization is mediated through a cysteine at residue 723, between the Ig domain and basic tail. The semaphorin domain alone is not active since it cannot dimerize, The collapsing activity of the semaphorin domain can be reconstituted when made as a chimeric construct with an immunoglobin Fc domain, which promotes dimerization.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania	Raper, JA (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.							Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; HEROLD C, 1995, INT IMMUNOL, V7, P1, DOI 10.1093/intimm/7.1.1; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Koppel AM, 1997, NEURON, V19, P531, DOI 10.1016/S0896-6273(00)80369-4; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MIYAZAKI J, 1989, GENE, V79, P269; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; YING SY, 1989, J STEROID BIOCHEM, V33, P705	24	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15708	15713		10.1074/jbc.273.25.15708	http://dx.doi.org/10.1074/jbc.273.25.15708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624167	hybrid			2022-12-27	WOS:000074284200061
J	Lee, SR; Kwon, KS; Kim, SR; Rhee, SG				Lee, SR; Kwon, KS; Kim, SR; Rhee, SG			Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN REDUCTASE; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; CATALYTIC ROLE; HUMAN-PLACENTA; PURIFICATION; PHOSPHORYLATION; SEQUENCE; H2O2; DEPHOSPHORYLATION	Stimulation of various cells with growth factors results in a transient increase in the intracellular concentration of H2O2 that is required for growth factor-induced protein tyrosine phosphorylation. The effect of H2O2 produced in response to epidermal growth factor (EGF) on the activity of protein-tyrosine phosphatase PB (PTP1B) was investigated in A431 human epidermoid carcinoma cells. H2O2 inactivated recombinant PTP1B in vitro by oxidizing its catalytic site cysteine, most likely to sulfenic acid. The oxidized enzyme was reactivated more effectively by thioredoxin than by glutaredoxin or glutathione at their physiological concentrations. Oxidation by H2O2 prevented modification of the catalytic cysteine of PTP1B by iodoacetic acid, suggesting that it should be possible to monitor the oxidation state of PTP1B in cells by measuring the incorporation of radioactivity into the enzyme after lysis of the cells in the presence of radiolabeled iodoacetic acid. The amount of such radioactivity associated with PTP1B immunoprecipitated from A431 cells that lead been stimulated with EGF for 10 min was 27% less than that associated with PTP1B from unstimulated cells. The amount of iodoacetic acid-derived radioactivity associated with PTP1B reached a minimum PO min after stimulation of cells with EGF and returned to base line values by 40 min, suggesting that the oxidation of PTP1B is reversible in cells. These results indicate that the activation of a receptor tyrosine kinase by binding of the corresponding growth factor may not be sufficient to increase the steady state level of protein tyrosine phosphorylation in cells and that concurrent inhibition of protein-tyrosine phosphatases by N2O2 might also be required.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122, Bethesda, MD 20892 USA.	sgrhee@helix.nih.gov						ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Fialkow L, 1997, J IMMUNOL, V158, P5409; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GALISTEO EM, 1993, BIOCHIMIE, V75, P803; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Lee SR, 1997, FASEB J, V11, pA1356; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; POT DA, 1991, J BIOL CHEM, V266, P19688; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; STONE RL, 1994, J BIOL CHEM, V269, P31323; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TONISSEN KF, 1989, NUCLEIC ACIDS RES, V17, P3973, DOI 10.1093/nar/17.10.3973; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	54	795	826	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15366	15372		10.1074/jbc.273.25.15366	http://dx.doi.org/10.1074/jbc.273.25.15366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624118	hybrid			2022-12-27	WOS:000074284200012
J	Loughnan, M; Bond, T; Atkins, A; Cuevas, J; Adams, DJ; Broxton, NM; Livett, BG; Down, JG; Jones, A; Alewood, PF; Lewis, RJ				Loughnan, M; Bond, T; Atkins, A; Cuevas, J; Adams, DJ; Broxton, NM; Livett, BG; Down, JG; Jones, A; Alewood, PF; Lewis, RJ			alpha-conotoxin EpI, a novel sulfated peptide from Conus episcopatus that selectively targets neuronal nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE SULFATION; SOLID-PHASE SYNTHESIS; CHANNELS; ANTAGONIST; SPECIFICITY; RESIDUES; BLOCKADE; CURRENTS; VENOM; CELLS	We have isolated and characterized ol-conotoxin EpI, a novel sulfated peptide from the venom of the molluscivorous snail, Conus episcopatus, The peptide was classified as an cy-conotoxin based on sequence, disulfide connectivity, and pharmacological target. EpI has ho mology to sequences of previously described cu-conotoxins, particularly PnIA, PnIB, and ImI, However, EpI differs from previously reported conotoxins in that it has a sulfotyrosine residue, identified by amino acid analysis and mass spectrometry, Native EpI was shown to coelute with synthetic EpI, The peptide sequence is consistent with most, but not all, recognized criteria for predicting tyrosine sulfation sites in proteins and peptides, The activities of synthetic EpI and its unsulfated analogue [Tyr(15)]EpI were similar. Both peptides caused competitive inhibition of nicotine action on bovine adrenal chromaffin cells (neuronal nicotinic ACh receptors) but had no effect on the rat phrenic nerve-diaphragm (muscle nicotinic ACh receptors), Both EpI and [Tyr(15)]EpI partly inhibited acetylcholine-evoked currents in isolated parasympathetic neurons of rat intracardiac ganglia, These results indicate that EPI and [Tyr(15)]EpI selectively inhibit alpha 3 beta 2 and alpha 3 beta 4 nicotinic acetylcholine receptors.	Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	University of Queensland; University of Queensland; University of Melbourne	Lewis, RJ (corresponding author), Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.		Adams, David/J-9125-2014; Cuevas, Javier/I-4941-2012; Loughnan, Marion/B-4508-2009; Milne, Trudy J/G-2630-2011; Lewis, Richard/T-8763-2019; Adams, David John/K-3578-2019; Lewis, Richard J/E-8674-2013	Adams, David/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Lewis, Richard J/0000-0003-3470-923X; Alewood, Paul/0000-0001-7454-6522; Atkins, Annette/0000-0003-2558-7058				Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLOUNT K, 1992, TOXICON, V30, P835, DOI 10.1016/0041-0101(92)90381-E; BROXTON NM, 1996, P AUST NEUROSCI SOC, V7, P164; BULBRING E, 1946, BRIT J PHARM CHEMOTH, V1, P38; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; CamposCaro A, 1997, J NEUROCHEM, V68, P488; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P656; Coggan JS, 1997, J NEUROSCI, V17, P5798; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; Criado M, 1997, J NEUROSCI, V17, P6554; Cuevas J, 1996, J PHYSIOL-LONDON, V493, P503, DOI 10.1113/jphysiol.1996.sp021399; CUEVAS J, 1994, BRIT J PHARMACOL, V111, P663, DOI 10.1111/j.1476-5381.1994.tb14789.x; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P469, DOI 10.1146/annurev.ph.57.030195.002345; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P215, DOI 10.1113/jphysiol.1991.sp018466; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; GIBSON BW, 1990, BIOLOGICAL MASS SPECTROMETRY /, P315; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harvey SC, 1997, MOL PHARMACOL, V51, P336, DOI 10.1124/mol.51.2.336; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; Hu SH, 1996, STRUCTURE, V4, P417, DOI 10.1016/S0969-2126(96)00047-0; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KAISER E, 1980, ANAL CHIM ACTA, V118, P149, DOI 10.1016/S0003-2670(01)93726-2; Kulak JM, 1997, J NEUROSCI, V17, P5263; Lewis R., 1996, TODAYS LIFE SCI, V8, P16; LIVETT BG, 1987, IN VITRO METHODS STU, P171; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; PAUWELS S, 1989, BIOCHIM BIOPHYS ACTA, V996, P82, DOI 10.1016/0167-4838(89)90098-8; Poth K, 1997, J NEUROSCI, V17, P586; PRITCHARD CI, 1986, BIOCHEM SOC T, V14, P1286, DOI 10.1042/bst0141286; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; YAGAMI T, 1993, CHEM PHARM BULL, V41, P376; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	49	103	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15667	15674		10.1074/jbc.273.25.15667	http://dx.doi.org/10.1074/jbc.273.25.15667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624161	hybrid, Green Published			2022-12-27	WOS:000074284200055
J	Meyer, O; Kirpotin, D; Hong, KL; Sternberg, B; Park, JW; Woodle, MC; Papahadjopoulos, D				Meyer, O; Kirpotin, D; Hong, KL; Sternberg, B; Park, JW; Woodle, MC; Papahadjopoulos, D			Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STERICALLY STABILIZED LIPOSOMES; TRANSFECTION; LIPIDS; CELLS	Modification of liposome surface with polyethylene glycol was used to improve oligodeoxyribonucleotide (ODN) loading, stability of the resulting complexes, and specificity of cellular delivery of ODN by cationic liposomes. Liposomes composed of a cationic lipid (DOTAP, DOGS, DDAB), a neutral lipid (DOPE), and a phospholipid derivative of polyethylene glycol (PEG-PE) formed a complex with 18-mer phosphorothioate up to ODN/lipid molar ratio of 0.25, The complexes showed intact vesicular structures similar to original liposomes and their size (100-130 nm) was unchanged after several weeks of storage, whereas complexes lacking PEG-PE showed progressive aggregation and/or precipitation. After exposure to human plasma, PEG-modified cationic liposomes retained over 60% of the originally bound ODN, PEG-coated complexes resulted in 4-13-fold enhancement of the ODN uptake by human breast cancer cells in serum-supplemented growth medium, relative to free ODN, Complexes containing conjugated anti-HER2 F(ab') fragments at the distal termini of PEG chains efficiently delivered ODN primarily irate che cytoplasm and nuclei of HERS overexpressing cancer cells and greatly enhanced the biological activity of antisense ODN. The development of PEG-modified cationic liposomes may lead to improved ODN potency in vivo.	Calif Pacific Med Ctr, Res Inst, Liposome Res Lab, San Francisco, CA 94115 USA; Genet Therapy Inc, Gaithersburg, MD 20878 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Novartis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Papahadjopoulos, D (corresponding author), Calif Pacific Med Ctr, Res Inst, Liposome Res Lab, 2200 Webster St, San Francisco, CA 94115 USA.	papah@cooper.cpmc.org	Hong, Kunlun/E-9787-2015	Hong, Kunlun/0000-0002-2852-5111; Kirpotin, Dmitri/0000-0002-1726-4040	NCI NIH HHS [P50CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H; BAGG A, 1993, ONCOGENES TUMOR SUPP, P141; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; HALDAR S, 1994, CANCER RES, V54, P2095; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; HUNSTON DL, 1975, ANAL BIOCHEM, V63, P99, DOI 10.1016/0003-2697(75)90193-1; JAASKELAINEN I, 1994, BBA-BIOMEMBRANES, V1195, P115, DOI 10.1016/0005-2736(94)90017-5; KENWORTHY AK, 1995, BIOPHYS J, V68, P1903, DOI 10.1016/S0006-3495(95)80368-1; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MORRISON WR, 1964, ANAL BIOCHEM, V7, P281; NAGEL KM, 1993, PHARMACOTHERAPY, V13, P177; OLON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P19; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PAPAHADJOPOULOS D, 1995, LIPOSOMES TOOLS BASI, P177; PARK JW, 1995, P NATL ACAD SCI USA, V92, P1327, DOI 10.1073/pnas.92.5.1327; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Sternberg B., 1992, LIPOSOME TECHNOLOGY, P363; THIERRY AR, 1995, DELIVERY STRATEGIES, P199; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; WOODLE MC, 1992, BIOPHYS J, V61, P902, DOI 10.1016/S0006-3495(92)81897-0; Woodle MC, 1997, NUCLEOS NUCLEOT NUCL, V16, P1731, DOI 10.1080/07328319708006265; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C; YUAN F, 1995, CANCER RES, V55, P3752; Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195	29	195	217	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15621	15627		10.1074/jbc.273.25.15621	http://dx.doi.org/10.1074/jbc.273.25.15621			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624154	Green Published, hybrid			2022-12-27	WOS:000074284200048
J	Morozov, I; Lotan, O; Joseph, G; Gorzalczany, Y; Pick, E				Morozov, I; Lotan, O; Joseph, G; Gorzalczany, Y; Pick, E			Mapping of functional domains in p47(phox) involved in the activation of NADPH oxidase by "peptide walking"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE-C; CYTOSOLIC COMPONENTS; HUMAN-NEUTROPHILS; SH3 DOMAINS	The superoxide generating NADPH oxidase. of phagocytes consists, in resting cells, of a membrane-associated electron transporting flavocytochrome (cytochrome b(559)) and four cytosolic proteins as follows: p47(phox), p67(phox), p40(phox), and the small GTPase, Rac(1 or 2). Activation of the oxidase is consequent to the assembly of a membrane-localized multimolecular complex consisting of cytochrome b(559) and the cytosolic components. We used "peptide walking" (Joseph, G., and Pick, E. (1995) J. Biol. Chem. 270, 29079-29082) for mapping domains in the amino acid sequence of p47(phox) participating in the molecular events leading to the activation of NADPH oxidase, Ninety-five overlapping pentadecapeptides, with a four-residue offset between neighboring peptides, spanning the complete p47(phox) sequence, were tested for the ability to inhibit NADPH oxidase activation in a cell-free system. This consisted of solubilized macrophage membranes, recombinant p47(phox), p67(phox), and Rad, and lithium dodecyl sulfate, as the activator. Eight functional domains were identified and labeled a-h. These were (N- and C-terminal residue numbers are given for each domain) as follows: a (21-35); b (105-119): c (149-159); d (193-207); e (253-267); f (305-319); g (325-339), and h (373-387). Four of these domains (c, d? e, and g) correspond to or form parts of regions shown before to participate in NADPH oxidase assembly. Thus, domain c corresponds to a region on the N-terminal boundary of the first src homology 3 (SH3) domain, whereas domains d and e represent more precisely defined sites within the full-length first and second SH3 domains, respectively. Domain g overlaps an extensively investigated arginine-rich region. Domains a and b, in the N-terminal half of p47(phox), and domains f and h, in the C-terminal half, represent newly identified entities, for which there is no earlier experimental evidence of involvement in NADPH oxidase activation. "Peptide walking" was also applied to the identification of domains in p47(phox) mediating binding to p67(phox). This was done by quantifying, by enzyme-linked immunosorbent assay, the binding of p67(phox), in solution, to a series of 95 overlapping biotinylated p47(phox) peptides, attached to streptavidin-coated 96-well plates. A single proline-rich domain (residues 357-371) was found to bind p67(phox) in the absence and presence of lithium dodecyl sulfate.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, JF Cohnheim Minerva Ctr Phagocyte Res, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, JF Cohnheim Minerva Ctr Phagocyte Res, IL-69978 Tel Aviv, Israel.		; Pick, Edgar/B-1795-2008	Morozov, Giora/0000-0002-2605-6075; Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; IYER SS, 1994, J BIOL CHEM, V269, P22405; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALECH HL, 1993, CLIN RES, V41, P323; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; PARK JW, 1992, J BIOL CHEM, V267, P17327; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; TOPORIK A, 1998, IN PRESS BIOCHEMISTR; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VALERIO RM, 1991, ANAL BIOCHEM, V197, P168, DOI 10.1016/0003-2697(91)90374-3; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Wientjes FB, 1996, BIOCHEM J, V317, P919, DOI 10.1042/bj3170919; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185	70	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15435	15444		10.1074/jbc.273.25.15435	http://dx.doi.org/10.1074/jbc.273.25.15435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624128	hybrid			2022-12-27	WOS:000074284200022
J	Serra-Pages, C; Medley, QG; Tang, M; Hart, A; Streuli, M				Serra-Pages, C; Medley, QG; Tang, M; Hart, A; Streuli, M			Liprins, a family of LAR transmembrane protein-tyrosine phosphatase-interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; AXON GUIDANCE; COILED COILS; ASSOCIATION; DROSOPHILA; EXPRESSION; ISOFORMS; KINASES; DELTA; SUPERFAMILY	LAR family transmembrane protein-tyrosine phosphatases function in axon guidance and mammary gland development. In cultured cells, LAR binds to the intracellular, coiled coil LAB-interacting protein at discrete ends of focal adhesions, implicating these proteins in the regulation of cell-matrix interactions. We describe seven LAB-interacting protein-like genes in humans and Caenorhabditis elegans that form the liprin gene family, Based on sequence similarities and binding characteristics, liprins are subdivided into alpha-type and beta-type liprins. The C-terminal, non-coiled coil regions of alpha-liprins bind to the membrane-distal phosphatase domains of LAR family members, as well as to the C-terminal, non-coiled coil region of beta-liprins. Both alpha- and beta-liprins homodimerize via their N-terminal, coiled coil regions. Liprins are thus multivalent proteins that potentially form complex structures. Some liprins have broad mRNA tissue distributions, whereas others are predominately expressed in the brain. Go-expression studies indicate that liprin-alpha 2 alters LAR cellular localization and induces LAR clustering. We propose that liprins function to localize LAR family tyrosine phosphatases at specific sites on the plasma membrane, possibly regulating their interaction with the extracellular environment and their association with substrates.	Dana Farber Canc Inst, Div Tumor Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Streuli, M (corresponding author), Dana Farber Canc Inst, Div Tumor Immunol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA055547] Funding Source: NIH RePORTER; NCI NIH HHS [CA55547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AICHER B, 1997, J CELL BIOL, V138, P381; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Desai CJ, 1997, DEVELOPMENT, V124, P1941; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; NobenTrauth K, 1997, BBA-GENE STRUCT EXPR, V1352, P133, DOI 10.1016/S0167-4781(97)00050-X; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; STOKER AW, 1994, MECH DEVELOP, V46, P201, DOI 10.1016/0925-4773(94)90071-X; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAN H, 1993, J BIOL CHEM, V268, P24880	39	224	243	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15611	15620		10.1074/jbc.273.25.15611	http://dx.doi.org/10.1074/jbc.273.25.15611			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624153	hybrid			2022-12-27	WOS:000074284200047
J	Wolters, PJ; Raymond, WW; Blount, JL; Caughey, GH				Wolters, PJ; Raymond, WW; Blount, JL; Caughey, GH			Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-C; MOLECULAR-CLONING; ACTIVATION; TRYPTASE; GRANULES; LUNG; INHIBITION; PROTEASE; HEPARIN; COMPLEX	Dipeptidyl peptidase I (DPPI) is a cysteine protease found predominantly in myelomonocytic cells, cytotoxic T-cells, and mast cells. Recent studies identify an intracellular role for mast cell-DPPI (MC-DPPI) by activating prochymase and protryptase to their mature forms, To better define MC-DPPI and to explore the possibility of extracellular roles, we purified MC-DPPI from mastocytoma cells. We found the dog C2 mastocytoma cell line to be the richest source yet described for DPPI, purifying up to 200 mu g of enzyme per g of cells. Dog MC-DPPI has an M-r of similar to 175,000 and consists of four subunits, each composed of a propeptide, light chain, and heavy chain. The heavy chain is N-glycosylated and is heterogeneously processed to three different forms. NH2-terminal sequences of the heavy chain and propeptide are identical to those predicted from a cDNA clone we sequenced from a mastocytoma cDNA library. The dog cDNA-derived sequence is 86% identical to that of human DPPI. Dog mastocytoma cells incubated with 12-O-tetradecanoylphorbol-13-acetate increase expression of MC-DPPI mRNA. MC-DPPI maintains its activity for dipeptide substrates at a neutral to alkaline pH. Cells stimulated with ionophore or substance P secrete MCDPPI in parallel with the granule-associated mediators tryptase and histamine. Thus, dog mastocytoma cells secrete DPPI that is active at the pH of extracellular fluids, suggesting that MC-DPPI may act outside the cell.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Caughey, GH (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	ghc@itsa.ucsf.edu	Wolters, Paul/A-7181-2009		NHLBI NIH HHS [HL-24136, HL-07185, HL-54774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054774, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARIZONO N, 1990, LAB INVEST, V62, P626; Authier F, 1996, FEBS LETT, V389, P55, DOI 10.1016/0014-5793(96)00368-7; BARRETT AJ, 1986, BIOMED BIOCHIM ACTA, V45, P1367; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; CAUGHEY GH, 1988, IMMUNOLOGY, V63, P399; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DAGROSA RM, 1988, BIOCHEM BIOPH RES CO, V157, P770, DOI 10.1016/S0006-291X(88)80316-4; DEVINNEY R, 1990, AM J RESP CELL MOL, V3, P413, DOI 10.1165/ajrcmb/3.5.413; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; DOLENC I, 1995, J BIOL CHEM, V270, P21626, DOI 10.1074/jbc.270.37.21626; DOUGHTY MJ, 1987, BIOCHEM CELL BIOL, V65, P617, DOI 10.1139/o87-082; DVORAK AM, 1993, MAST CELL HLTH DIS, P1; ISHIDOH K, 1991, J BIOL CHEM, V266, P16312; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; LYNTH GW, 1988, THROMB HAEMOSTASIS, V59, P372; Maniatis T., 1982, MOL CLONING LAB MANU; MCDONALD JK, 1969, J BIOL CHEM, V244, P2693; MCDONALD JK, 1966, J BIOL CHEM, V241, P1494; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; METRIONE RM, 1975, BIOCHEMISTRY-US, V14, P5249, DOI 10.1021/bi00695a002; MIZUOCHI T, 1994, IMMUNOL LETT, V43, P189, DOI 10.1016/0165-2478(94)90221-6; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; PHARM CTN, 1997, J BIOL CHEM, V272, P10695; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Rao NV, 1997, J BIOL CHEM, V272, P10260; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SERAFIN WE, 1991, P NATL ACAD SCI USA, V88, P5984, DOI 10.1073/pnas.88.14.5984; SHIMIZU Y, 1997, ASTHMA, P353; SLOANE BF, 1990, SEMIN CANCER BIOL, V1, P153; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Thiele DL, 1997, J IMMUNOL, V158, P5200; Ulbricht B, 1996, EXP CELL RES, V226, P255, DOI 10.1006/excr.1996.0226; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VARUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330, DOI 10.1021/bi00429a058	41	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15514	15520		10.1074/jbc.273.25.15514	http://dx.doi.org/10.1074/jbc.273.25.15514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624139	hybrid			2022-12-27	WOS:000074284200033
J	Zeitlmann, L; Knorr, T; Knoll, M; Romeo, C; Sirim, P; Kolanus, W				Zeitlmann, L; Knorr, T; Knoll, M; Romeo, C; Sirim, P; Kolanus, W			T cell activation induced by novel gain-of-function mutants of Syk and ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR ZETA-CHAIN; DOMAIN-CONTAINING PROTEINS; TANDEM SH2 DOMAINS; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; EXPRESSION SYSTEM; BINDING; PHOSPHORYLATION; TCR	The Syk family tyrosine kinases play a crucial role in antigen receptor-mediated signal transduction, but their regulation and cellular targets remain incompletely defined. Following receptor engagement, phosphorylation of tyrosine residues within ZAP-70 and Syk is thought to control both kinase activity and recruitment of modulatory factors. We report here the characterization of novel mutants of ZAP-70 and Syk, in which conserved C-terminal tyrosine residues have been replaced by phenylalanines (ZAP YF-C, Syk YF-C), Both mutant kinases display a prominent gain-of-function phenotype in Jurkat T cells, as demonstrated by lymphokine promoter activation, tyrosine phosphorylation of potential targets in vivo, and elevated intracellular calcium mobilization. While the presence of p56-Lck was required for ZAP YF-C-induced signaling, Syk YF-C showed enhanced functional activity in Lck-deficient JCaM1 Jurkat cells. Our results implicate the C terminus of Syk family kinases as an important regulatory region modulating T cell activation.	Univ Munich, Mol Biol Lab, Genzentrum, D-81377 Munich, Germany; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	University of Munich; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kolanus, W (corresponding author), Univ Munich, Mol Biol Lab, Genzentrum, Feodor Lynen Str 25, D-81377 Munich, Germany.	kolanus@lmb.uni-muenchen.de	Zeitlmann, Lutz/AAF-3586-2019					ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KATZAV S, 1994, J BIOL CHEM, V269, P32579; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; Kong GH, 1996, MOL CELL BIOL, V16, P5026; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	48	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15445	15452		10.1074/jbc.273.25.15445	http://dx.doi.org/10.1074/jbc.273.25.15445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624129	hybrid			2022-12-27	WOS:000074284200023
J	Taylor, BS; de Vera, ME; Ganster, RW; Wang, Q; Shapiro, RA; Morris, SM; Billiar, TR; Geller, DA				Taylor, BS; de Vera, ME; Ganster, RW; Wang, Q; Shapiro, RA; Morris, SM; Billiar, TR; Geller, DA			Multiple NF-kappa B enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-SPECIFIC REGULATION; ADHESION MOLECULE-1; INFLAMMATORY CYTOKINES; FUNCTIONAL-ANALYSIS; HUMAN HEPATOCYTES; EPITHELIAL-CELLS; INTERFERON-GAMMA; PROMOTER; EXPRESSION; TRANSCRIPTION	The human inducible nitric oxide synthase (iNOS) gene is overexpressed in a number of human inflammatory diseases. Previously, we observed that the human iNOS gene is transcriptionally regulated by cytokines and demonstrated that the cytokine-responsive regions are upstream of -3.8 kilobase pairs (kb), Therefore, the purpose of this study was to further localize the functional enhancer elements and to assess the role of the transcription factor NF-kappa B in both human liver (AKN-1) and human lung (A549) epithelial cell lines. The addition of NF-kappa B inhibitors significantly suppressed cytokine-stimulated iNOS mRNA expression and NO synthesis, indicating that NF-kappa B is involved in the induction of the human iNOS gene. Analysis of the first 4.7 kb of the 5'-flanking region demonstrated basal promoter activity and failed to show any cytokine-inducible activity. However, promoter constructs extending to -5.8 and -7.2 kb revealed 2-3-fold and 4-5-fold induction, respectively, in the presence of cytokines, DNA sequence analysis from -3.8 to -7.2 kh identified five putative NF-kappa B cis-regulatory transcription factor binding sites upstream of -4.7 kb. Site-directed mutagenesis of these sites revealed that the NF-kappa B motif at -5.8 kb is required for cytokine-indluced promoter activity, while the sites at -5.2, -5.5, and -6.1 kb elicit a cooperative effect. Electromobility shift assays using a site-specific oligonucleotide and nuclear extracts from cells stimulated with cytokine-mixture, tumor necrosis factor-alpha or interleukin-1 beta, but not interferon-gamma, exhibited inducible DNA binding activity for NF-kappa B. These data indicate that NF-kappa B activation is required for cytokine induction of the human iNOS gene and identifies four NF-kappa B enhancer elements upstream in the human iNOS promoter that confer inducibility to tumor necrosis factor-alpha and interleukin-1 beta.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Taylor, BS (corresponding author), Univ Pittsburgh, Dept Surg, 497 Scaife Hall, Pittsburgh, PA 15261 USA.	bsta@med.pitt.edu	Morris, Sidney M/I-3440-2015		NIGMS NIH HHS [GM-44100, GM-52021, GM-37753] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052021, R37GM044100, R01GM044100, R01GM052021, R01GM037753, R29GM044100] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHENG Q, 1994, J BIOL CHEM, V269, P13551; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GELLER DA, 1995, J IMMUNOL, V155, P4890; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HARBRECHT BG, 1995, SHOCK, V4, P332, DOI 10.1097/00024382-199511000-00004; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINN SC, 1997, AM J PHYSIOL, V35, pG1499; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NUNOKAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P802, DOI 10.1006/bbrc.1994.1522; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Spitsin SV, 1997, MOL MED, V3, P315, DOI 10.1007/BF03401810; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	64	352	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15148	15156		10.1074/jbc.273.24.15148	http://dx.doi.org/10.1074/jbc.273.24.15148			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614127	hybrid			2022-12-27	WOS:000074160400069
J	Fuller, SJ; Gillespie-Brown, J; Sugden, PH				Fuller, SJ; Gillespie-Brown, J; Sugden, PH			Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MUSCLE-SPECIFIC GENES; CARDIAC MYOCYTES; TYROSINE KINASE; GROWTH-FACTOR; ANGIOTENSIN-II; MYOCARDIAL-CELLS; MOLECULAR CHARACTERIZATION; ADRENERGIC STIMULATION; ENHANCED EXPRESSION	In response to hormones and growth factors, cultured neonatal ventricular myocytes increase in profile, exhibit myofibrillogenesis, and re-express genes whose expression is normally restricted to the fetal stage of ventricular development. These include atrial natriuretic factor (ANF), beta-myosin heavy chain (beta-MHC), and skeletal muscle (SkM)-alpha-actin. By using luciferase reporter plasmids, we examined whether oncogenes that activate the extracellular signal-regulated kinase cascade (src(F527), Ha-ras(V12), and v-raf) increased expression of "fetal" genes. Transfection of myocytes with src(F527) stimulated expression of ANF, SkM-alpha-actin, and beta-MHC by 62-, 6.7-, and 50-fold, respectively, but did not induce DNA synthesis. Stimulation of ANF expression by src(F527) was greater than by Ha-ras(V12), which in turn was greater than by v-raf. General gene expression was also increased but to a lesser extent. The response to src(F527) was inhibited by dominant-negative Ha-ras(N17). Myocyte area was increased by src(F527), Ha-ras(V12), and v-raf, and although it altered myocyte morphology by causing a pseudopodial appearance, src(F527) did not detectably increase myofibrillogenesis either alone or in combination with Ha-ras(V12). A kinase-dead src mutant increased myocyte size to a much lesser extent than src(F527), and also did not inhibit ANF-luciferase expression in response to phenylephrine. We conclude that members of the Src family of tyrosine kinases may be important in mediating the transcriptional changes occurring during cardiac myocyte hypertrophy and that Ras and Raf may be downstream effectors.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst Div, Sect Cardiac Med, London SW3 6LY, England	Imperial College London	Fuller, SJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst Div, Sect Cardiac Med, Dovehouse St, London SW3 6LY, England.	stephen.fuller@ic.ac.uk		Brown, Judith/0000-0003-4092-9685				Abdellatif M, 1997, J BIOL CHEM, V272, P525; ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Clerk A, 1996, BIOCHEM J, V317, P109, DOI 10.1042/bj3170109; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Fuller SJ, 1997, BIOCHEM J, V323, P313, DOI 10.1042/bj3230313; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sambrook J., 1989, MOL CLONING LABORATO, P33; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	80	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18146	18152		10.1074/jbc.273.29.18146	http://dx.doi.org/10.1074/jbc.273.29.18146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660773	hybrid			2022-12-27	WOS:000074828500028
J	Hagg, PM; Muona, A; Lietard, J; Kivirikko, S; Pihlajaniemi, T				Hagg, PM; Muona, A; Lietard, J; Kivirikko, S; Pihlajaniemi, T			Complete exon-intron organization of the human gene for the alpha 1 chain of type XV collagen (COL15A1) and comparison with the homologous Col18a1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL ORGANIZATION; XVIII COLLAGEN; THROMBOSPONDIN GENE; SEQUENCE STATISTICS; CORRESPONDING GENE; SPLICE JUNCTIONS; TISSUE; SITES; CHROMOSOME-10; LOCALIZATION	The human gene for the (yl chain of type XV collagen (COL15A1) is about 145 kilobases in size and contains 42 exons. The promoter is characterized by the lack of a TATAA motif and the presence of several Spl binding sites, some of which appeared to be functional in transfected HeLa cells. Comparison with Co118a1, which encodes the alpha 1(XVIII) collagen chain homologous with alpha 1(XV), indicates marked structural homology spread throughout the two genes. The mouse Co118a1 contains one exon more than COL15A1, due to the fact that COL15A1 lacks sequences corresponding to exon 3 of Col18a1, which encodes a cysteine-rich sequence motif. Twenty-five of the exons of the two genes are almost identical in size, six of them contain conserved split codons, and the locations of the respective exon-intron junctions are identical or almost identical in the two genes. The homologous exons include the closely adjacent first pair of exons and the exons encoding a thrombospondin-l homology found in the N-terminal noncollagenous domain 1, which are followed by the most variable part of the two genes, covering the C-terminal half of their noncollagenous domain 1 and the beginning of the collagenous portion, after which most of the exons are homologous. The lengths of the introns are not similar in these genes, with two exceptions, namely the first intron, which is very short, less than 100 base pairs, and the second intron, which is very large, about 50 kilobases, in both genes. It can be concluded that COL15A1 and Col18a1 are derived from a common ancestor.	Oulu Univ, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Oulu Univ, Dept Med Biochem, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Oulu Univ, Bioctr, Collagen Res Unit, Kajaanintie 52 A, FIN-90220 Oulu, Finland.	taina.pihlajaniemim@oulu.fi		Pihlajaniemi, Taina/0000-0002-1664-9045				APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; Chu Mon-Li, 1993, P149; Hagg PM, 1997, GENOMICS, V45, P31, DOI 10.1006/geno.1997.4884; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO S, 1994, J BIOL CHEM, V269, P4773; KIVIRIKKO S, 1995, AM J PATHOL, V147, P1500; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LEE SB, 1995, BIOCHEM J, V310, P15, DOI 10.1042/bj3100015; MURAGAKI Y, 1994, J BIOL CHEM, V269, P4042; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; REHN M, 1994, J BIOL CHEM, V269, P13929; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; SAITTA B, 1992, J BIOL CHEM, V267, P6188; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERS RH, 1990, ASTRON ASTROPHYS REV, V2, P1, DOI 10.1007/BF00873540; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SOININEN R, 1989, J BIOL CHEM, V264, P13565; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; YOSHIOKA H, 1995, J BIOL CHEM, V270, P418, DOI 10.1074/jbc.270.1.418	38	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17824	17831		10.1074/jbc.273.28.17824	http://dx.doi.org/10.1074/jbc.273.28.17824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651385	hybrid			2022-12-27	WOS:000074816100078
J	Hugl, SR; White, MF; Rhodes, CJ				Hugl, SR; White, MF; Rhodes, CJ			Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent - Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT ISLETS; PROTEIN-KINASE; TISSUE-CULTURE; HORMONE; PROLIFERATION; BIOSYNTHESIS; PROLACTIN; REPLICATION; MECHANISMS; SECRETION	Nutrients and certain growth factors stimulate pancreatic beta-cell mitogenesis, however, the appropriate mitogenic signal transduction pathways have not been defined, In the glucose sensitive pancreatic beta-cell line, INS-I, it was found that glucose (6-18 mM) independently increased INS-1 cell proliferation (>20-fold at 15 mM glucose). Insulin-like growth factor I (IGF-I)-induced INS-1 cell proliferation was glucose-dependent only in the physiologically relevant concentration range (6-18 mm glucose), The combination of IGF-I and glucose was synergistic, increasing INS-1 cell-proliferation >20-fold at 15 mM glucose + 10 nM IGF-I, Glucose metabolism and phosphatidylinositol S'-kinase (PI 3'-kinase) activation were necessary for both glucose and IGF-I-stimulated INS-1 cell proliferation, IGF-I and 15 mM glucose increased tyrosine phosphorylation mediated recruitment of Grb2/mSOS and PI 3'-kinase to IRS-2 and pp60, Glucose and IGF-I also induced Shc association with Grb2/ mSOS, Glucose (3-18 mM) and IGF-I, independently of glucose, activated mitogen-activated protein kinase but this did not correlate with IGF-I-induced beta-cell proliferation, In contrast, p70(S6K) was activated with increasing glucose concentration (between 6 and 18 mM), and potentiated by IGF I in the same glucose concentration range which correlated with INS-1 cell proliferation rate. Thus, glucose and IGF-I-induced beta-cell proliferation were mediated via a signaling mechanism that was facilitated by mitogen-activated protein kinase but de pendent on IRS-mediated induction of PI 3'-kinase activity and downstream activation of p70S6K. The glucose dependence of IGF-I mediated INS-1 cell proliferation emphasizes beta-cell signaling mechanisms are rather unique in being tightly linked to glycolytic metabolic flux.	Univ Texas, SW Med Ctr, Dept Internal Med, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Rhodes, CJ (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Gifford Labs Diabet Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	rhodes02@utsw.swmed.edu			NIDDK NIH HHS [DK 50610] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK050610, R01DK050610] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BONNERWEIR S, 1992, DIABETES NUTR MET S1, V5, P1; BRELJE TC, 1991, ENDOCRINOLOGY, V128, P45, DOI 10.1210/endo-128-1-45; BROCKENBROUGH JS, 1988, DIABETES, V37, P232, DOI 10.2337/diabetes.37.2.232; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHICK WL, 1973, DIABETES, V22, P687, DOI 10.2337/diab.22.9.687; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HELLERSTROM C, 1991, DIABETES, V40, P89, DOI 10.2337/diab.40.2.S89; HELLERSTROM C, 1991, ACTA PAEDIATR SCAND, P55; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kadowaki Takashi, 1996, Endocrine Journal, V43, pS33, DOI 10.1507/endocrj.43.Suppl_S33; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1989, EXP CLIN ENDOCRINOL, V93, P277; OGREID D, 1994, EUR J BIOCHEM, V221, P1089, DOI 10.1111/j.1432-1033.1994.tb18828.x; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Scharfmann R, 1990, Diabetes Res, V15, P137; SCHUPPIN GT, 1998, IN PRESS DIABETES; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; Sjoholm A, 1997, DIABETES, V46, P1141, DOI 10.2337/diabetes.46.7.1141; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; SWENNE I, 1980, DIABETES, V29, P686, DOI 10.2337/diab.29.9.686; SWENNE I, 1987, DIABETES, V36, P288, DOI 10.2337/diabetes.36.3.288; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; WELSH M, 1988, P NATL ACAD SCI USA, V85, P116, DOI 10.1073/pnas.85.1.116; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	46	207	212	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17771	17779		10.1074/jbc.273.28.17771	http://dx.doi.org/10.1074/jbc.273.28.17771			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651378	hybrid			2022-12-27	WOS:000074816100071
J	Qiu, YC; Benet, LZ; Burlingame, AL				Qiu, YC; Benet, LZ; Burlingame, AL			Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PARACETAMOL-INDUCED HEPATOTOXICITY; ISOLATED MOUSE HEPATOCYTES; GLUTATHIONE-S-TRANSFERASE; TIME-OF-FLIGHT; COMMON ARYLATING INTERMEDIATE; ACETYL-PARA-BENZOQUINONEIMINE; 56-KDA SELENIUM-BINDING; BOUND LIVER PROTEINS; OXIDATIVE STRESS; COVALENT BINDING	Liver toxicity following an overdose of acetaminophen is frequently considered a model for drug-induced hepatotoxicity. Extensive studies over many years have established that such toxicity is web correlated with liver protein arylation by acetaminophen metabolites. Identification of protein targets for covalent modifications is a challenging but necessary step in understanding how covalent binding could lead to liver toxicity. Previous approaches suffered from technical limitations, and thus over the last 10 years heroic efforts were required to determine the identity of only a few target proteins. We present a new mass spectrometry-based strategy for identification of all target proteins that now provides a comprehensive survey of the suite of Liver proteins modified. After administration of radiolabeled acetaminophen to mice, the proteins in the liver tissue lysate were separated by two-dimensional polyacrylamide gel electrophoresis. In-gel digestion of the radiolabeled gel spots gave a set of tryptic peptides, which were analyzed by matrix-assisted laser desorption ionization mass spectrometry. Interrogation of data bases based on experimentally determined molecular a-eights of peptides and product ion tags from postsource decay mass spectra was employed for the determination of the identities of modified liver proteins. Using this method, more than 20 new drug-labeled proteins have been identified.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Burlingame, AL (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Benet, Leslie Z/K-8286-2016		NCRR NIH HHS [RR 01614] Funding Source: Medline; NIGMS NIH HHS [GMS 36633] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036633] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMSON GM, 1993, BIOCHEM PHARMACOL, V45, P2289, DOI 10.1016/0006-2952(93)90201-7; ADAMSON GM, 1989, BIOCHEM PHARMACOL, V38, P3323, DOI 10.1016/0006-2952(89)90630-8; Adessi C, 1997, ELECTROPHORESIS, V18, P127, DOI 10.1002/elps.1150180124; Anderson NG, 1996, ELECTROPHORESIS, V17, P443, DOI 10.1002/elps.1150170303; ANDERSSON BS, 1990, CHEM-BIOL INTERACT, V75, P201, DOI 10.1016/0009-2797(90)90118-7; ANIYA Y, 1993, JPN J PHARMACOL, V62, P9, DOI 10.1254/jjp.62.9; ANSHER SS, 1983, HEPATOLOGY, V3, P932; ARNAIZ SL, 1995, FREE RADICAL BIO MED, V19, P303, DOI 10.1016/0891-5849(95)00023-Q; BARTOLONE JB, 1989, TOXICOL APPL PHARM, V99, P240, DOI 10.1016/0041-008X(89)90006-9; BARTOLONE JB, 1987, BIOCHEM PHARMACOL, V36, P1193, DOI 10.1016/0006-2952(87)90069-4; BARTOLONE JB, 1988, BIOCHEM PHARMACOL, V37, P4763, DOI 10.1016/0006-2952(88)90350-4; BARTOLONE JB, 1989, FUND APPL TOXICOL, V13, P859, DOI 10.1016/0272-0590(89)90339-4; BARTOLONE JB, 1992, TOXICOL APPL PHARM, V113, P19, DOI 10.1016/0041-008X(92)90004-C; BIRGE RB, 1990, TOXICOL APPL PHARM, V105, P472, DOI 10.1016/0041-008X(90)90150-S; BOELSTERLI UA, 1993, DRUG METAB REV, V25, P395, DOI 10.3109/03602539308993981; BRUNO MK, 1992, TOXICOL APPL PHARM, V112, P282, DOI 10.1016/0041-008X(92)90198-2; BULERA SJ, 1995, TOXICOL APPL PHARM, V134, P313, DOI 10.1006/taap.1995.1197; BURCHAM PC, 1990, TOXICOL LETT, V50, P37, DOI 10.1016/0378-4274(90)90250-P; BURCHAM PC, 1991, J BIOL CHEM, V266, P5049; BURLINGAME AL, 1996, MASS SPECTROMETRY BI, P546; Chang PWG, 1997, J CELL BIOCHEM, V64, P217, DOI 10.1002/(SICI)1097-4644(199702)64:2<217::AID-JCB5>3.0.CO;2-#; CHIEN CI, 1994, BBA-PROTEIN STRUCT M, V1204, P175, DOI 10.1016/0167-4838(94)90006-X; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; CLAUSER KR, 1996, P 44 ASMS C MASS SPE, P365; COMPORTI M, 1989, CHEM-BIOL INTERACT, V72, P1, DOI 10.1016/0009-2797(89)90016-1; CORCORAN GB, 1980, MOL PHARMACOL, V18, P536; DAHLIN DC, 1982, J MED CHEM, V25, P885, DOI 10.1021/jm00350a001; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; DONNELLY PJ, 1994, ARCH TOXICOL, V68, P110, DOI 10.1007/s002040050043; Ellouk-Achard S, 1995, Arch Toxicol Suppl, V17, P209; Epstein LB, 1996, ELECTROPHORESIS, V17, P1655, DOI 10.1002/elps.1150171103; ESTERLINE RL, 1989, BIOCHEM PHARMACOL, V38, P2387, DOI 10.1016/0006-2952(89)90481-4; GERSON RJ, 1985, BIOCHEM BIOPH RES CO, V126, P1129, DOI 10.1016/0006-291X(85)90303-1; Gibson JD, 1996, CHEM RES TOXICOL, V9, P580, DOI 10.1021/tx950153d; Goldin RD, 1996, J PATHOL, V179, P432; GUPTA S, 1995, TOXICOLOGIST, V153; HAENEN GRMM, 1991, ARCH BIOCHEM BIOPHYS, V287, P48, DOI 10.1016/0003-9861(91)90386-W; HALL SC, 1993, P NATL ACAD SCI USA, V90, P1927, DOI 10.1073/pnas.90.5.1927; Halmes NC, 1996, CHEM RES TOXICOL, V9, P541, DOI 10.1021/tx950158a; HARVISON PJ, 1988, CHEM RES TOXICOL, V1, P47, DOI 10.1021/tx00001a009; HAYES JD, 1990, BIOCHEM J, V272, P281, DOI 10.1042/bj2720281; HINSON JA, 1981, LIFE SCI, V29, P107, DOI 10.1016/0024-3205(81)90278-2; HINSON JA, 1994, DRUG METAB REV, V26, P395, DOI 10.3109/03602539409029805; HOLME JA, 1984, BIOCHEM PHARMACOL, V33, P401, DOI 10.1016/0006-2952(84)90232-6; HOLTZMAN JL, 1995, DRUG METAB REV, V27, P277, DOI 10.3109/03602539509029827; HONG M, 1994, TOXICOLOGIST, V427; HORIE T, 1995, J TOXICOL SCI, V20, P13; ISHII T, 1993, J BIOL CHEM, V268, P18633; JOLLOW DJ, 1973, J PHARMACOL EXP THER, V187, P195; KAMIYAMA T, 1993, TOXICOL LETT, V66, P7, DOI 10.1016/0378-4274(93)90073-7; KASTER JK, 1996, TOXICOLOGIST, V30, P280; KATYARE SS, 1989, BRIT J PHARMACOL, V96, P51, DOI 10.1111/j.1476-5381.1989.tb11783.x; KELLER RJ, 1991, DRUG METAB DISPOS, V19, P184; KYLE ME, 1987, BIOCHEM BIOPH RES CO, V149, P889, DOI 10.1016/0006-291X(87)90491-8; Landin JS, 1996, TOXICOL APPL PHARM, V141, P299; LANFEAR J, 1993, CARCINOGENESIS, V14, P335, DOI 10.1093/carcin/14.3.335; LASKEY RA, 1984, RADIOISTOPE DETECTIO, V2; LASKIN DL, 1986, TOXICOL APPL PHARM, V86, P204, DOI 10.1016/0041-008X(86)90051-7; LASKIN DL, 1995, HEPATOLOGY, V21, P1045, DOI 10.1002/hep.1840210424; LASKIN DL, 1986, TOXICOL APPL PHARM, V86, P216, DOI 10.1016/0041-008X(86)90052-9; MANAUTOU JE, 1995, J TOXICOL ENV HEALTH, V46, P263, DOI 10.1080/15287399509532034; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Matsui NM, 1997, ELECTROPHORESIS, V18, P409, DOI 10.1002/elps.1150180315; Medzihradszky KF, 1997, INT J MASS SPECTROM, V160, P357, DOI 10.1016/S0168-1176(96)04525-9; Medzihradszky KF, 1996, J AM SOC MASS SPECTR, V7, P1, DOI 10.1016/1044-0305(95)00621-4; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MEYERS LL, 1988, TOXICOL APPL PHARM, V93, P378, DOI 10.1016/0041-008X(88)90040-3; MILLER JA, 1994, CANCER LETT, V83, P9, DOI 10.1016/0304-3835(94)90292-5; MILLER JA, 1994, CANCER RES, V54, pS1879; MINER DJ, 1979, BIOCHEM PHARMACOL, V28, P3285, DOI 10.1016/0006-2952(79)90123-0; MITCHELL AE, 1995, CHEM RES TOXICOL, V8, P1054, DOI 10.1021/tx00050a009; MYERS TG, 1995, CHEM RES TOXICOL, V8, P403, DOI 10.1021/tx00045a012; NAKAE D, 1988, ARCH BIOCHEM BIOPHYS, V267, P651, DOI 10.1016/0003-9861(88)90073-2; NELSON SD, 1995, DRUG METAB REV, V27, P147, DOI 10.3109/03602539509029821; NELSON SD, 1990, SEMIN LIVER DIS, V10, P267, DOI 10.1055/s-2008-1040482; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OZDEMIRLER G, 1994, J APPL TOXICOL, V14, P297, DOI 10.1002/jat.2550140410; PARMAR DV, 1995, EUR J PHARM-ENVIRON, V293, P225, DOI 10.1016/S0922-4106(05)80047-1; POTTER WZ, 1974, PHARMACOLOGY, V12, P129, DOI 10.1159/000136531; Pumford NR, 1997, J PHARMACOL EXP THER, V280, P501; PUMFORD NR, 1990, BIOCHEM PHARMACOL, V40, P573, DOI 10.1016/0006-2952(90)90558-3; PUMFORD NR, 1992, BIOCHEM BIOPH RES CO, V182, P1348, DOI 10.1016/0006-291X(92)91881-P; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; RAMSAY RR, 1989, ARCH BIOCHEM BIOPHYS, V273, P449, DOI 10.1016/0003-9861(89)90504-3; RASHED MS, 1990, DRUG METAB DISPOS, V18, P765; Righetti PG, 1997, ANAL BIOCHEM, V247, P1, DOI 10.1006/abio.1997.2000; ROBERTS DW, 1991, AM J PATHOL, V138, P359; ROBERTS DW, 1987, J PHARMACOL EXP THER, V241, P527; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUSE JC, 1995, J AM SOC MASS SPECTR, V6, P822, DOI 10.1016/1044-0305(95)00325-8; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Stimson E, 1997, INT J MASS SPECTROM, V169, P231, DOI 10.1016/S0168-1176(97)00227-9; STRUBELT O, 1992, BIOCHEM PHARMACOL, V44, P163, DOI 10.1016/0006-2952(92)90050-S; TIRMENSTEIN MA, 1990, J BIOL CHEM, V265, P3059; VANDERZEE J, 1988, CHEM-BIOL INTERACT, V65, P15, DOI 10.1016/0009-2797(88)90027-0; VANDESTRAAT R, 1987, BIOCHEM PHARMACOL, V36, P2065, DOI 10.1016/0006-2952(87)90132-8; VERMEULEN NPE, 1992, DRUG METAB REV, V24, P367, DOI 10.3109/03602539208996298; VESTAL ML, 1995, RAPID COMMUN MASS SP, V9, P1044, DOI 10.1002/rcm.1290091115; WU XW, 1989, P NATL ACAD SCI USA, V86, P9412, DOI 10.1073/pnas.86.23.9412; [No title captured]	102	242	254	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17940	17953		10.1074/jbc.273.28.17940	http://dx.doi.org/10.1074/jbc.273.28.17940			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651401	hybrid			2022-12-27	WOS:000074816100094
J	Roesijadi, G; Bogumil, R; Vasak, M; Kagi, JHR				Roesijadi, G; Bogumil, R; Vasak, M; Kagi, JHR			Modulation of DNA binding of a tramtrack zinc finger peptide by the metallothionein-thionein conjugate pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; METAL-BINDING; TUMOR-CELLS; PROTEIN; DROSOPHILA; CADMIUM; DOMAINS; GENE; SPECIFICITY; EXPRESSION	The ability of metallothionein (MT) to modulate DNA binding by a two-finger peptide of Tramtrack (TTK), a CCHH zinc transcription factor, was investigated using metal bound and metal-deficient forms of rabbit MT-2 and the TTK peptide. Thionein inhibited DNA binding by zinc-bound TTK, and Zn-MT restored DNA-binding by zinc deficient apo-TTK. "Free" zinc at low concentrations was as effective as Zn-MT in restoring DNA binding by apopeptide but was inhibitory at concentrations equal to zinc bound to 2 mol eq and higher of Zn-MT. Substitution of cadmium for zinc reduced the affinity of the peptide for its DNA binding site. This effect was reversed by incubation with Zn-MT. The circular dichroic spectra of the TTK peptide indicated that zinc removal resulted in loss of a-helical structures, which are sites of DNA contact points. Reconstitution with cadmium resulted in stoichiometric substitution of 2 mol of Cd/mol of peptide but not recovery of a-helical structures. Incubation of Cd-TTK with Zn MT restored the secondary structure expected for zinc-bound TTK. The ability of Zn-MT and thionein to restore or inhibit DNA-binding by TTK was associated with effects on the metallation status of the peptide and related alterations in its secondary structure.	Univ Maryland, Chesapeake Biol Lab, Ctr Environm Sci, Solomons, MD 20688 USA; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University System of Maryland; University of Maryland Center for Environmental Science; University of Zurich	Roesijadi, G (corresponding author), Univ Maryland, Chesapeake Biol Lab, Ctr Environm Sci, POB 38, Solomons, MD 20688 USA.	groes@cbl.umces.edu			FIC NIH HHS [1 F06 TW02150-1A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002150] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Abshire MK, 1996, J TOXICOL ENV HEALTH, V48, P359, DOI 10.1080/009841096161258; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Badenhorst P, 1996, GENES CELLS, V1, P707, DOI 10.1111/j.1365-2443.1996.tb00011.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1997, ANNU REV BIOPH BIOM, V26, P357, DOI 10.1146/annurev.biophys.26.1.357; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAN HM, 1993, BIOCHEM CELL BIOL, V71, P133, DOI 10.1139/o93-022; CHERIAN MG, 1994, ENVIRON HEALTH PERSP, V102, P131, DOI 10.2307/3431776; CHERIAN MG, 1993, METALLOTHIONEIN, V3, P87; CHURCHICH JE, 1989, BIOCHIM BIOPHYS ACTA, V996, P181, DOI 10.1016/0167-4838(89)90245-8; Da Silva JJR, 1991, BIOL CHEM ELEMENTS, P299; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hanas JS, 1996, NUCLEIC ACIDS RES, V24, P924, DOI 10.1093/nar/24.5.924; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HENEHAN CJ, 1993, PROTEIN SCI, V2, P1756, DOI 10.1002/pro.5560021019; HUANG PC, 1993, METALLOTHIONEIN, V3, P407; HUNZIKER PE, 1995, BIOCHEM J, V306, P265, DOI 10.1042/bj3060265; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; KAGI JHR, 1993, ADV LIF SCI, P29; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRIZEK BA, 1993, INORG CHEM, V32, P937, DOI 10.1021/ic00058a030; KRIZEK BA, 1993, PROTEIN SCI, V2, P1313, DOI 10.1002/pro.5560020814; KUWAHARA J, 1990, BIOCHEMISTRY-US, V29, P8627, DOI 10.1021/bi00489a019; LAZO JS, 1995, ANNU REV PHARMACOL, V35, P635; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; Maret W, 1997, P NATL ACAD SCI USA, V94, P2233, DOI 10.1073/pnas.94.6.2233; NETTESHEIM DG, 1985, BIOCHEMISTRY-US, V24, P6744, DOI 10.1021/bi00345a003; OTVOS JD, 1993, METALLOTHIONEIN, V3, P57; PATTANAIK A, 1994, J INORG BIOCHEM, V54, P91, DOI 10.1016/0162-0134(94)80023-5; POSEWITZ MC, 1995, CHEM RES TOXICOL, V8, P1020, DOI 10.1021/tx00050a005; Roesijadi G, 1996, COMP BIOCHEM PHYS C, V113, P117, DOI 10.1016/0742-8413(95)02077-2; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SIMONS TJB, 1991, J MEMBRANE BIOL, V123, P63, DOI 10.1007/BF01993964; Sunderman FW, 1996, MOL REPROD DEV, V43, P444; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; VASAK M, 1991, METHOD ENZYMOL, V205, P41; VASAK M, 1991, METHOD ENZYMOL, V205, P452; Vasak M, 1997, NATO ASI 2, V26, P195; VASAK M, 1983, MET IONS BIOL SYST, V15, P213; WILLNER H, 1987, BIOCHEMISTRY-US, V26, P6287, DOI 10.1021/bi00393a049; Woo ES, 1996, EXP CELL RES, V224, P365, DOI 10.1006/excr.1996.0146; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; ZENG J, 1991, THESIS U ZURICH ZURI, P55; ZENG J, 1995, HDB EXPT PHARM, P333	56	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17425	17432		10.1074/jbc.273.28.17425	http://dx.doi.org/10.1074/jbc.273.28.17425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651329	hybrid			2022-12-27	WOS:000074816100022
J	Bolivar, J; Guelman, S; Iglesias, C; Ortiz, M; Valdivia, MM				Bolivar, J; Guelman, S; Iglesias, C; Ortiz, M; Valdivia, MM			The fragile-X-related gene FXR1 is a human autoantigen processed during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RNA-BINDING; CGG REPEAT; ANTIBODIES; PROTEIN; FMR1; ANTINUCLEAR; SCLEROSIS; BIOLOGY; SNURPS	We describe a new human autoimmune antigen in a patient suffering from scleroderma with high levels of antibodies to nucleolus and cytoplasmic antigens, Using a Chinese hamster ovary cell expression library, we have shown that this antigen corresponds to the auto somal Fragile-X-related gene FXR1, The deduced amino acid sequence from the hamster cDNA is 97, 98, and 58% homologous to the human, mouse, and Xenopus laevis FXR1 genes, respectively. Expression of the hamster cDNA clone in Escherichia coli and antibody production indicates unequivocally the location of the FXR1 protein in the cytoplasm of hamster cells. Affinity chromatography followed by immunofluorescence microscopy analysis and immunoblots demonstrated the presence of autoimmune IgGs to FXR1 in the scleroderma patient. Immunolabeling studies in Jurkat cells, induced to apoptosis by anti-Fas/APO1 serum, indicated that the FXR1 antigens were clearly displaced from their original cytoplasmic location to several punctuated foci, resembling the bleb-like membranous structures characteristic of cells at certain stages of apoptosis, This phenomenon could be part of a putative mechanism in which the FXR1 protein is presented as a target for the autoimmune response in humans.	Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Puerto Real 11510, Cadiz, Spain; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biol Mol, RA-2000 Rosario, Argentina	Universidad de Cadiz; National University of Rosario	Valdivia, MM (corresponding author), Univ Cadiz, Fac Ciencias, Dept Bioquim & Biol Mol, Puerto Real 11510, Cadiz, Spain.	manuel.valdivia@uca.es	BOLIVAR, JORGE/G-4322-2015; Valdivia, Manuel Jesús Martínez/ABG-8867-2020	BOLIVAR, JORGE/0000-0002-2645-9528; Valdivia, Manuel Jesús Martínez/0000-0002-2888-849X; Ortiz Santesteban, Maria Manuela/0000-0001-9398-6259				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BERNSTEIN RM, 1982, CLIN EXP IMMUNOL, V48, P43; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conrad K, 1997, CLIN EXP RHEUMATOL, V15, P457; COY JF, 1995, HUM MOL GENET, V4, P2209, DOI 10.1093/hmg/4.12.2209; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; LERNER MR, 1981, CELL, V25, P298, DOI 10.1016/0092-8674(81)90047-7; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OOSTRA BA, 1995, BIOESSAYS, V17, P941, DOI 10.1002/bies.950171107; Peng SL, 1997, NAT MED, V3, P276, DOI 10.1038/nm0397-276; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; STEITZ JA, 1988, SCI AM, V258, P56, DOI 10.1038/scientificamerican0688-56; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; VALDIVIA MM, 1985, J CELL BIOL, V101, P1124, DOI 10.1083/jcb.101.3.1124; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; White Barbara, 1995, Current Opinion in Rheumatology, V7, P541, DOI 10.1097/00002281-199511000-00013; WHYTE J, 1994, J AUTOIMMUN, V7, P509, DOI 10.1006/jaut.1994.1037; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x	30	10	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17122	17127		10.1074/jbc.273.27.17122	http://dx.doi.org/10.1074/jbc.273.27.17122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642279	hybrid			2022-12-27	WOS:000074545200069
J	Kantak, SS; Kramer, RH				Kantak, SS; Kramer, RH			E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BETA-CATENIN; TERMINAL DIFFERENTIATION; EXTRACELLULAR-MATRIX; DNA FRAGMENTATION; APOPTOSIS; INVASION; IDENTIFICATION; EXPRESSION; CANCER	Integrin-basement membrane interactions provide essential signals that promote survival and growth of epithelial cells, whereas loss of such adhesions triggers programmed cell death. We found that HSC-3 human squamous carcinoma cells survived and grew readily as monolayers, but when they were suspended as single cells, they ceased proliferating and entered into the apoptotic death pathway, characterized by DNA fragmentation. In contrast, if the suspended carcinoma cells were permitted to form E-cadherin-mediated multicellular aggregates, they not only survived but proliferated. However, aggregated normal keratinocytes were unable to survive in suspension culture and rapidly became apoptotic, Anchorage independence and resistance to apoptosis of HSC-3 cell aggregates required high levels of extracellular Ca2+ and was inhibited with function-perturbing anti-E-cadherin antibody. Resistance to suspension-induced apoptosis in cell aggregates paralleled the up-regulation of Bcl-2 but occurred in the absence of focal adhesion kinase activation. Analysis of suspension-induced death in a set of cloned squamous epithelial cell lines with different levels of E-cadherin expression revealed that receptor-positive cell clones evaded apoptosis and proliferated in three-dimensional aggregate culture, whereas cadherin-negative clones failed to survive, Collectively, these observations indicate that cadherin-mediated intercellular adhesions generate a compensatory mechanism that promotes anchorage-independent growth and suppresses apoptosis.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Dent, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Stomatol, Box 0512, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011436, P50DE011912, R56DE011436] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11912] Funding Source: Medline; NIDCR NIH HHS [DE 11912, DE 11436] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allen E, 1996, J CELL BIOL, V133, P1367, DOI 10.1083/jcb.133.6.1367; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CROIX BS, 1996, NAT MED, V2, P1204; FREYER JP, 1986, CANCER RES, V46, P3504; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HINK L, 1994, TRENDS BIOCHEM SCI, V19, P538; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jensen PJ, 1997, CELL TISSUE RES, V288, P307, DOI 10.1007/s004410050816; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATAYAMA M, 1994, INT J ONCOL, V5, P1049; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kotelnikov VM, 1996, HEAD NECK-J SCI SPEC, V18, P522, DOI 10.1002/(SICI)1097-0347(199611/12)18:6<522::AID-HED6>3.0.CO;2-4; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; LEIGH IM, 1995, BRIT J DERMATOL, V133, P501, DOI 10.1111/j.1365-2133.1995.tb02696.x; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATTIJSSEN V, 1993, INT J CANCER, V55, P580, DOI 10.1002/ijc.2910550411; MonierGavelle F, 1997, J CELL BIOL, V137, P1663, DOI 10.1083/jcb.137.7.1663; MORI C, 1994, ANAT EMBRYOL, V190, P21; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; POLLACK AL, 1997, J CELL BIOL, V137, P651; Ramos DM, 1997, INT J CANCER, V72, P369, DOI 10.1002/(SICI)1097-0215(19970717)72:2<369::AID-IJC28>3.3.CO;2-7; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SAKAKI T, 1994, PATHOL INT, V44, P280; Shibata T, 1996, ONCOGENE, V13, P883; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhang K, 1996, CELL ADHES COMMUN, V4, P159, DOI 10.3109/15419069609014220; Zhu AJ, 1996, J CELL SCI, V109, P3013	53	201	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16953	16961		10.1074/jbc.273.27.16953	http://dx.doi.org/10.1074/jbc.273.27.16953			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642258	hybrid			2022-12-27	WOS:000074545200048
J	Foster, DC; Garbers, DL				Foster, DC; Garbers, DL			Dual role for adenine nucleotides in the regulation of the atrial natriuretic peptide receptor, guanylyl cyclase-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYCLIC-GMP ACCUMULATION; SMOOTH-MUSCLE CELLS; MEDIATED INHIBITION; ACTIVATION; RAT; DEPHOSPHORYLATION; DESENSITIZATION; HYPERTENSION; DECREASES	The ability to both sensitize and desensitize a guanylyl cyclase receptor has not been previously accomplished in a broken cell or membrane preparation. The guanylyl cyclase-A (GC-A) receptor is known to require both atrial natriuretic peptide (ANP) and an adenine nucleotide for maximal cyclase activation. When membranes from NIH 3T3 cells stably overexpressing GC-A were incubated with ATP, AMPPNP, or ATP gamma S, only ATP gamma S dramatically potentiated ANP-dependent cyclase activity. When the membranes were incubated with ATP gamma S and then washed, GC-A now became sensitive to ANP/AMPPNP stimulation, suggestive that thiophosphorylation had sensitized GC-A to ligand and adenine nucleotide binding. Consistent with this hypothesis, the ATP gamma S effects were both time- and concentration-dependent. Protein phosphatase stability of thiophosphorylation (ATP gamma S) relative to phosphorylation (ATP) appeared to explain the differential effects of the two nucleotides since microcystin, beta-glycerol phosphate, or okadaic acid coincident with ATP or ATP gamma S effectively sensitized GC-A to ligand stimulation over prolonged periods of time in either case, GC-A was phosphorylated in the presence of [gamma(32)P]ATP, and the mag nitude of the phosphorylation was increased by the addition of microcystin. Thus, the phosphorylation of GC-A correlates with the acquisition of ligand sensitivity. The establishment of an in vitro system to sensitize GC-A demonstrates that adenine nucleotides have a daul function in the regulation of GC-A through both phosphorylation of and binding to regulatory sites.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garbers, DL (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	garbers@utsw.smmed.edu			NIGMS NIH HHS [5-T32-GM08203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; JAISWAL RK, 1988, FEBS LETT, V227, P47, DOI 10.1016/0014-5793(88)81411-X; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; Melo LG, 1998, AM J PHYSIOL-REG I, V274, pR255, DOI 10.1152/ajpregu.1998.274.1.R255; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; NAMBI P, 1987, BIOCHEM J, V244, P481, DOI 10.1042/bj2440481; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Schulz S, 1998, J BIOL CHEM, V273, P1032, DOI 10.1074/jbc.273.2.1032; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SMITH JB, 1987, AM J PHYSIOL, V253, pC147, DOI 10.1152/ajpcell.1987.253.1.C147; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	33	52	54	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16311	16318		10.1074/jbc.273.26.16311	http://dx.doi.org/10.1074/jbc.273.26.16311			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632692	hybrid			2022-12-27	WOS:000074436600063
J	Sam, JW; Takahashi, S; Lippai, I; Peisach, J; Rousseau, DL				Sam, JW; Takahashi, S; Lippai, I; Peisach, J; Rousseau, DL			Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; IRON-BLEOMYCIN; ACTIVATED BLEOMYCIN; A2 GREEN; STRUCTURAL CHARACTERIZATION; CYTOSINE RELEASE; DEGRADATION; COMPLEXES; CLEAVAGE; NMR	The binding of the iron complex of the antineoplastic glycopeptide bleomycin A(2) (Fe-BLM) to calf thymus DNA and the self-complementary oligonucleotides d(CGCGCG) and d(ATATAT) has been studied using optical, EPR, and resonance Raman spectroscopies. An increase in the intensity of the bands at 365 and 384 nm is observed in the optical spectrum of Fe(III)-BLM when the drug binds to either oligonucleotide. However, in the presence of phosphate, this increase is observed only with d(CGCGCG) and not with d(ATATAT). In addition, the g(max) feature in the EPR spectrum of low spin Fe(III)-BLM is narrowed in a way suggesting a reduction of possible conformers that the drug can achieve when it is bound to d(CGCGCG) or to calf thymus DNA but not when bound to d(ATATAT). When Fe(III)-BLM is bound to d(CGCGCG), changes in the resonance Raman spectrum of the metal drug complex suggest conformational changes in three of the ligands to iron: the beta-hydroxyhistidyl amide, the pyrimidine, and the axial hydroxide. In addition, the Fe-OH band undergoes narrowing, again consistent, with the reduction of conformers of the drug. No such resonance Raman changes are observed upon binding to d(ATATAT). The changes in the pyrimidine modes upon binding d(CGCGCG) to the drug are consistent with a recently proposed model (Wu, W., Vanderwall, D. E., Turner, C. J., Kozarich, J. W., and Stubbe, J. (1996) J. Am. Chem. Soc. 118, 1281-1294) of DNA recognition by activated bleomycin, HOO-Fe(III)-BLM, in which the pyrimidine moiety of the drug is important for the preferential cleavage of 5'-GpPy-3' sequences.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; AT&T Bell Labs, Murray Hill, NJ 07974 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; AT&T; Nokia Corporation; Nokia Bell Labs	Peisach, J (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.				NCRR NIH HHS [RR-02583] Funding Source: Medline; NIGMS NIH HHS [GM40168, GM48714] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040168, R01GM040168, R01GM048714] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTINI JP, 1984, BIOCHEMISTRY-US, V23, P47, DOI 10.1021/bi00296a008; BOGER DL, 1994, J AM CHEM SOC, V116, P5607, DOI 10.1021/ja00092a011; Boger DL, 1998, J AM CHEM SOC, V120, P53, DOI 10.1021/ja971889v; BURGER RM, 1981, J BIOL CHEM, V256, P1636; BURGER RM, 1985, BIOCHEMISTRY-US, V24, P3623, DOI 10.1021/bi00335a034; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; DABROWIAK JC, 1979, BIOCHEM BIOPH RES CO, V91, P721, DOI 10.1016/0006-291X(79)91940-5; DABROWIAK JC, 1982, ADV INORG BIOCHEM, V4, P69; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FREEDMAN TB, 1983, J RAMAN SPECTROSC, V14, P266, DOI 10.1002/jrs.1250140411; GAMCSIK MP, 1990, J BIOMOL STRUCT DYN, V7, P1117, DOI 10.1080/07391102.1990.10508550; GUAJARDO RJ, 1993, J AM CHEM SOC, V115, P7971, DOI 10.1021/ja00071a006; HORI M, 1979, BLEOMYCIN CHEM BIOCH, P195; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; KUWAHARA J, 1988, NUCLEIC ACIDS RES, V19, P131; LOEB KE, 1995, J AM CHEM SOC, V117, P4545, DOI 10.1021/ja00121a013; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; MANDERVILLE RA, 1995, J AM CHEM SOC, V117, P7891, DOI 10.1021/ja00135a007; MANDERVILLE RA, 1994, J AM CHEM SOC, V116, P10851, DOI 10.1021/ja00102a087; OWA T, 1992, TETRAHEDRON, V48, P1193, DOI 10.1016/S0040-4020(01)90783-5; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P665, DOI 10.1021/bi00506a034; RABOW L, 1986, J AM CHEM SOC, V108, P7130, DOI 10.1021/ja00282a063; RABOW LE, 1990, J AM CHEM SOC, V112, P3203, DOI 10.1021/ja00164a050; RAJASEKHARAN RP, 1980, BIOCHEM BIOPH RES CO, V97, P270; SAM JW, 1994, J AM CHEM SOC, V116, P5250, DOI 10.1021/ja00091a032; SAM JW, 1995, J AM CHEM SOC, V117, P1012, DOI 10.1021/ja00108a017; SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2746, DOI 10.1021/bi00607a008; Stubbe J, 1996, ACCOUNTS CHEM RES, V29, P322, DOI 10.1021/ar9501333; SUGIURA Y, 1980, J AM CHEM SOC, V102, P5208, DOI 10.1021/ja00536a015; SUZUKI H, 1969, J ANTIBIOT, V22, P446, DOI 10.7164/antibiotics.22.446; TAKAHASHI S, 1994, J AM CHEM SOC, V116, P4408, DOI 10.1021/ja00089a032; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; TAKITA T, 1978, J ANTIBIOT, V31, P1073, DOI 10.7164/antibiotics.31.1073; THOMAS GA, 1984, BIOCHEMISTRY-US, V23, P3202, DOI 10.1021/bi00309a014; WU JC, 1985, BIOCHEMISTRY-US, V24, P7562, DOI 10.1021/bi00347a009; WU JC, 1983, J BIOL CHEM, V256, P8608; Wu W, 1996, J AM CHEM SOC, V118, P1268, DOI 10.1021/ja9524964; Wu W, 1996, J AM CHEM SOC, V118, P1281, DOI 10.1021/ja952497w; WU W, 1994, J AM CHEM SOC, V116, P10843, DOI 10.1021/ja00102a083	45	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16090	16097		10.1074/jbc.273.26.16090	http://dx.doi.org/10.1074/jbc.273.26.16090			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632661	hybrid			2022-12-27	WOS:000074436600032
J	Santagata, S; Aidinis, V; Spanopoulou, E				Santagata, S; Aidinis, V; Spanopoulou, E			The effect of Me2+ cofactors at the initial stages of V(D)J recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; DIVALENT METAL-IONS; DNA-RECOGNITION; RETROVIRAL INTEGRATION; STRUCTURE REQUIREMENTS; RAG-1-DEFICIENT MICE; RAG2 PROTEINS; 2 STEPS; SEQUENCE; CLEAVAGE	V(D)J site-specific recombination mediates the somatic assembly of the antigen receptor gene segments. This process is initiated by the recombination activating proteins RAG1 and RAG2, which recognize the recombination signal sequences (RSS) and cleave the DNA at the coding/RSS junction, In this study, we show that RAG1 and RAG2 have the ability to directly interact in solution before binding to the DNA. RAG1 forms a homodimer, which leads to the appearance of two distinct RAG1.RAG2 complexes bound to DNA. To investigate the properties of the two RAG1.RAG2 complexes in the presence of different Me2+ cofactors, we established an in vitro Mg2+-based cleavage reaction on a single RSS. Using this system, we found that Mg2+ confers a specific pattern of DNA binding and cleavage. In contrast, Mn2+ allows aberrant binding of RAG1.RAG2 to single-stranded RSS and permits cleavage independent of binding to the nonamer. To determine the contribution of Me2+ ions at the early stages of V(D)J recombination, we analyzed specific DNA recognition and cleavage by RAG1 RAG2 on phosphorothioated substrates. These experiments revealed that Me2+ ions directly coordinate the binding of RAG1.RAG2 to the RSS DNA.	CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Spanopoulou, E (corresponding author), CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.		Santagata, Sandro/A-7714-2009; Aidinis, Vassilis/AAF-5380-2021	Aidinis, Vassilis/0000-0001-9531-7729; Santagata, Sandro/0000-0002-7528-9668	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI40191-01A1] Funding Source: Medline; NIGMS NIH HHS [T32-GM07280-21] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; Junop MS, 1997, EMBO J, V16, P2646, DOI 10.1093/emboj/16.10.2646; Junop MS, 1996, EMBO J, V15, P2547, DOI 10.1002/j.1460-2075.1996.tb00612.x; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Kirch SA, 1996, EUR J IMMUNOL, V26, P886, DOI 10.1002/eji.1830260425; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; QUYANG H, 1997, J EXP MED, V186, P921; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Steen SB, 1997, EMBO J, V16, P2656, DOI 10.1093/emboj/16.10.2656; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	60	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16325	16331		10.1074/jbc.273.26.16325	http://dx.doi.org/10.1074/jbc.273.26.16325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632694	hybrid			2022-12-27	WOS:000074436600065
J	Sun, WL; Godson, GN				Sun, WL; Godson, GN			Synthesis of polyribonucleotide chains from the 3 '-hydroxyl terminus of oligodeoxynucleotides by Escherichia coli primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST DNA PRIMASE; RNA-POLYMERASE; NUCLEOTIDE-SEQUENCES; STRAND SYNTHESIS; DROSOPHILA-MELANOGASTER; MUTATIONAL ANALYSIS; RIBONUCLEIC-ACID; PRIMER SYNTHESIS; PHAGE-G4 ORIGIN; REPLICATION	Escherichia coli primase synthesizes RNA primers on DNA templates for the initiation of DNA replication. The sole known activity of primase is to catalyze synthesis of short RNA chains de novo. We now report a novel activity of primase, namely that it can synthesize RNA from the 3'-hydroxyl terminus of a pre-existing oligodeoxynucleotide. The oligonucleotide-primed synthesis of RNA by primase occurs in both of the G4oric-specific priming system and the dnaB protein associated general priming system. This priming reaction of primase is verified by a number of biochemical methods, including inhibition by modified 3'-phosphate of oligonucleotides and deoxyribonuclease I and ribonuclease H cleavages. We also show that the primed RNA is an effective primer for the synthesis of DNA chain by E. coli DNA polymerase III holoenzyme. The significance of this finding to primases generating multimeric length RNA is discussed.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA	New York University	Godson, GN (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.				NIGMS NIH HHS [GM32898] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; BADARACCO G, 1985, EMBO J, V4, P1313, DOI 10.1002/j.1460-2075.1985.tb03778.x; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BROOKS M, 1989, J BIOL CHEM, V264, P3602; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P4585, DOI 10.1073/pnas.79.15.4585; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; DOWNEY KM, 1971, BIOCHEMISTRY-US, V10, P4970, DOI 10.1021/bi00802a021; FIDDES JC, 1978, P NATL ACAD SCI USA, V75, P1081, DOI 10.1073/pnas.75.3.1081; GODSON GN, 1991, GENE, V100, P59, DOI 10.1016/0378-1119(91)90350-K; GRACHEV MA, 1984, NUCLEIC ACIDS RES, V12, P8509, DOI 10.1093/nar/12.22.8509; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KORNBERG A, 1992, DNA REPLICATION, P279; LAMBERT PF, 1986, J VIROL, V58, P450, DOI 10.1128/JVI.58.2.450-458.1986; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEWIS MK, 1980, J BIOL CHEM, V255, P4928; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Moore DD, 1995, GLOB MOB SURV; MOORE S, 1981, ENZYMES A, V14, P281; NATH K, 1974, J BIOL CHEM, V249, P2605; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; NOMURA N, 1982, P NATL ACAD SCI USA, V79, P2853; ROWEN L, 1978, J BIOL CHEM, V253, P758; ROWEN L, 1978, J BIOL CHEM, V253, P770; RUETSCH N, 1987, J BIOL CHEM, V262, P1674; SAKAI H, 1985, BIOCHIM BIOPHYS ACTA, V826, P30, DOI 10.1016/S0167-4781(85)80005-1; SALUJA D, 1995, J BACTERIOL, V177, P1104, DOI 10.1128/jb.177.4.1104-1111.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SIMS J, 1978, P NATL ACAD SCI USA, V75, P3094, DOI 10.1073/pnas.75.7.3094; SINGH H, 1984, J BIOL CHEM, V259, P7936; SINGH H, 1986, J BIOL CHEM, V261, P8564; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun WL, 1998, J MOL BIOL, V276, P689, DOI 10.1006/jmbi.1997.1471; SUN WL, 1994, P NATL ACAD SCI USA, V91, P11462, DOI 10.1073/pnas.91.24.11462; SUN WL, 1993, J BIOL CHEM, V268, P8026; TSENG BY, 1983, J BIOL CHEM, V258, P9845; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WICKNER S, 1972, BIOCHEM BIOPH RES CO, V48, P619, DOI 10.1016/0006-291X(72)90393-2; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	49	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16358	16365		10.1074/jbc.273.26.16358	http://dx.doi.org/10.1074/jbc.273.26.16358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632699	hybrid			2022-12-27	WOS:000074436600070
J	Zardo, G; Caiafa, P				Zardo, G; Caiafa, P			The unmethylated state of CpG islands in mouse fibroblasts depends on the poly(ADP-ribosyl)ation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; DE-NOVO METHYLATION; CHROMATIN STRUCTURE; DENOVO METHYLATION; STRANDED-DNA; RICH ISLANDS; GENE; PROMOTER; TRANSCRIPTION; SITE	In vivo and in vitro experiments carried out on L929 mouse fibroblasts suggested that the poly(ADP-ribosyl) ation process acts somehow as a protecting agent against full methylation of CpG dinucleotides in genomic DNA. Since CpG islands, which are found almost exclusively at the 5'-end of housekeeping genes, are rich in CpG dinucleotides, which are the target of mammalian DNA methyltransferase, we examined the possibility that the poly(ADP-ribosyl)ation reaction is involved in maintaining the unmethylated state of these DNA sequences. Experiments were conducted by two different strategies, using either methylation-dependent restriction enzymes on purified genomic DNA or a sequence-dependent restriction enzyme on an aliquot of the same DNA, previously modified by a bisulfite reaction. With the methylation-dependent restriction enzymes, it was observed that the "HpaII tiny fragments" greatly decreased when the cells were preincubated with 3-aminobenzamide, a well known inhibitor of poly(ADP-ribose) polymerase, The other experimental approach allowed us to prove that, as a consequence of the inhibition of the poly(ADP-ribosyl)ation process, an anomalous methylation pattern could be evidenced in the CpG island of the promoter fragment of the Htf9 gene, amplified from DNA obtained from fibroblasts preincubated with 3-aminobenzamide. These data confirm the hypothesis that, at least for the Htf9 promoter region, an active poly(ADP-ribosyl)ation protects the unmethylated state of the CpG island.	Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy; CNR, Ctr Biol Mol, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR)	Caiafa, P (corresponding author), Univ Aquila, Dipartimento Sci & Tecnol Biomed, Via Vetoio,Loc Coppito, I-67100 Laquila, Italy.							ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; BELIKOV SV, 1993, NUCLEIC ACIDS RES, V21, P1031, DOI 10.1093/nar/21.4.1031; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRUHAT A, 1995, P NATL ACAD SCI USA, V92, P3678, DOI 10.1073/pnas.92.9.3678; CAROTTI D, 1989, NUCLEIC ACIDS RES, V17, P9219, DOI 10.1093/nar/17.22.9219; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; DAVIS T, 1986, BIOCHIM BIOPHYS ACTA, V866, P233, DOI 10.1016/0167-4781(86)90048-5; DErme M, 1996, BIOCHEM J, V316, P475, DOI 10.1042/bj3160475; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HASSE A, 1994, J BIOL CHEM, V269, P1821; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; Kaludov NK, 1997, J BIOL CHEM, V272, P15120, DOI 10.1074/jbc.272.24.15120; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KHAN R, 1988, J BIOL CHEM, V263, P14374; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; SANTORO R, 1993, BIOCHEM BIOPH RES CO, V190, P86, DOI 10.1006/bbrc.1993.1014; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; VANHOLDE K, 1988, CHROMATIN, P357; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; YISRAELI J, 1984, GENE METHYLATION 16, P353; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zardo G, 1996, BIOCHEM BIOPH RES CO, V220, P102, DOI 10.1006/bbrc.1996.0364; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; ZLATANOVA J, 1992, J CELL SCI, V103, P889; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	55	49	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16517	16520		10.1074/jbc.273.26.16517	http://dx.doi.org/10.1074/jbc.273.26.16517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632720	hybrid			2022-12-27	WOS:000074436600091
J	Adelmant, G; Gilbert, JD; Freytag, SO				Adelmant, G; Gilbert, JD; Freytag, SO			Human translocation liposarcoma CCAAT enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBP beta function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 PREADIPOCYTES; TRANSCRIPTION FACTOR; MYXOID LIPOSARCOMA; GENE-EXPRESSION; NUCLEAR-PROTEIN; PPAR-GAMMA; ADIPOGENESIS; ALPHA; RNA; FUSION	Human translocation liposarcoma (TLS)-CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP) is a fusion oncoprotein found specifically in a malignant tumor of adipose tissue and results from a t(12;16) translocation that fuses the amino-terminal part of TLS to the entire coding region of CHOP. Being that CHOP is a member of the C/EBP transcription factor family, proteins that comprise part of the adipocyte differentiation machinery, we examined whether TLS-CHOP blocked adipocyte differentiation by directly interfering with C/EBP function, Using a single-step retroviral infection protocol, either wild-type or mutant TLS-CHOP were co-expressed along with C/EBP beta in naive NIH3T3 cells, and their ability to inhibit C/EBP beta driven adipogenesis was determined, TLS-CHOP was extremely effective at blocking adipocyte differentiation when expressed at a level comparable to that observed in human myxoid liposarcoma. This effect of TLS-CHOP required a functional leucine zipper domain and correlated with its ability to heterodimerize with C/EBP beta and inhibit C/EBP beta DNA binding and transactivation activity in situ. In contrast, the TLS-CHOP basic region was dispensable, making it unlikely that the inhibitory effect of TLS-CHOP is attributable to unscheduled gene expression resulting from TLS-CHOP's putative transactivation activity. Another adipogenic transcription factor, PPAR gamma 2, was able to rescue TLS-CHOP-inhibited cells, indicating that TLS-CHOP interferes primarily with C/EBP beta-driven adipogenesis and not with other requisite events of the adipocyte differentiation program. Together, the results demonstrate that TLS-CHOP blocks adipocyte differentiation by directly preventing C/EBP beta from binding to and transactivating its target genes. Moreover, they provide strong support for the thesis that a blockade to normal differentiation is an important aspect of the cancer process.	Henry Ford Hlth Syst, Dept Biol Mol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Freytag, SO (corresponding author), Henry Ford Hlth Syst, Dept Biol Mol, 1 Ford Pl,Wing 5D, Detroit, MI 48202 USA.				NCI NIH HHS [CA62295] Funding Source: Medline; NATIONAL CANCER INSTITUTE [S15CA062295] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V14, P1654; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Panagopoulos I, 1996, ONCOGENE, V12, P489; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	32	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15574	15581		10.1074/jbc.273.25.15574	http://dx.doi.org/10.1074/jbc.273.25.15574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624148	hybrid			2022-12-27	WOS:000074284200042
J	Prockop, DJ; Fertala, A				Prockop, DJ; Fertala, A			Inhibition of the self-assembly of collagen I into fibrils with synthetic peptides - Demonstration that assembly is driven by specific binding sites on the monomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; POINTED TIPS; GROWING TIPS; PC-COLLAGEN; INVITRO; FIBRILLOGENESIS; PROCOLLAGEN; CLEAVAGE; PACKING; MODEL	A series of experiments mere carried out to test the hypothesis that the self-assembly of collagen I monomers into fibrils depends on the interactions of specific binding sites in different regions of the monomer. Six synthetic peptides were prepared with sequences found either in the collagen triple helix or in the N- or C-telopeptides of collagen I. The four peptides with sequences found in the telopeptides were found to inhibit self-assembly of collagen I in a purified in vitro system. At concentrations of 2.5 mM, peptides with sequences in the C-telopeptides of the alpha 1(I) and alpha 2(I) chain inhibited assembly at about 95%. The addition of the peptide with the alpha 2-telopeptide sequence was effective in inhibiting assembly if added during the lag phase and early propagation phase but mot later in the assembly process. Experiments with biotinylated peptides indicated that both the N- and C-telopeptides bound to a region between amino acid 776 and 822 of the ol(I) chain. A fragment of nine amino acids with sequences in the alpha 2-telopeptide was effective in inhibiting fibril assembly. Mutating two aspartates in the 9-mer peptide to serine had no effect on inhibition of fibril assembly, but mutating two tyrosine residues and one phenylalanine residue abolished the inhibitory action. Molecular modeling of the binding sites demonstrated favorable hydrophobic and electrostatic interactions between the alpha 2-telopeptide and residues 781-794 of the alpha(I) chain.	Allegheny Univ Hlth Sci, Ctr Gene Therapy, Philadelphia, PA 19102 USA	Drexel University	Fertala, A (corresponding author), Allegheny Univ Hlth Sci, Ctr Gene Therapy, 245 N 15 St,MS 421, Philadelphia, PA 19102 USA.	fertala@auhs.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39740] Funding Source: Medline; PHS HHS [R043366] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bhatnagar RS, 1997, J BIOMOL STRUCT DYN, V14, P547, DOI 10.1080/07391102.1997.10508155; BIRK DE, 1989, P NATL ACAD SCI USA, V86, P4549, DOI 10.1073/pnas.86.12.4549; BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; BROWN RA, 1977, BIOCHEM BIOPH RES CO, V74, P1102, DOI 10.1016/0006-291X(77)91632-1; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; CHEN JM, 1995, J BIOMOL STRUCT DYN, V12, P1129, DOI 10.1080/07391102.1995.10508804; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; Galloway J., 1985, BIOL INVERTEBRATE LO, P73; GELMAN RA, 1980, J BIOL CHEM, V255, P8098; HELSETH DL, 1979, BIOPOLYMERS, V18, P3005, DOI 10.1002/bip.1979.360181208; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; HOLMES DF, 1979, BIOCHEM BIOPH RES CO, V87, P993, DOI 10.1016/S0006-291X(79)80005-4; HOLMES DF, 1992, P NATL ACAD SCI USA, V89, P9855, DOI 10.1073/pnas.89.20.9855; HULMES DJS, 1985, J MOL BIOL, V184, P473, DOI 10.1016/0022-2836(85)90295-5; HULMES DJS, 1981, P NATL ACAD SCI-BIOL, V78, P3567, DOI 10.1073/pnas.78.6.3567; HULMES DJS, 1979, NATURE, V282, P878, DOI 10.1038/282878a0; HULMES DJS, 1995, BIOPHYS J, V68, P1661, DOI 10.1016/S0006-3495(95)80391-7; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; Kadler KE, 1996, BIOCHEM J, V316, P1; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MOULD AP, 1982, J MOL BIOL, V195, P543; NAGAN N, 1994, J BIOL CHEM, V269, P22366; PARKINSON J, 1994, PHYS REV E, V50, P2963, DOI 10.1103/PhysRevE.50.2963; PIEZ KA, 1981, BIOSCIENCE REP, V1, P801, DOI 10.1007/BF01114803; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; POTSCHKA M, 1988, BIOCHEMISTRY-US, V27, P8481, DOI 10.1021/bi00422a028; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SILVER D, 1992, P NATL ACAD SCI USA, V89, P9860, DOI 10.1073/pnas.89.20.9860; SMITH JW, 1968, NATURE, V219, P157, DOI 10.1038/219157a0; VEIS A, 1988, COLLAGEN BIOCH, P113; VITAGLIANO L, 1995, J MOL BIOL, V247, P69, DOI 10.1006/jmbi.1994.0123; WARD NP, 1986, J MOL BIOL, V190, P107, DOI 10.1016/0022-2836(86)90079-3; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WOODHEADGALLOWA.J, 1984, CONNECTIVE TISSUE MA, P133	39	106	108	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15598	15604		10.1074/jbc.273.25.15598	http://dx.doi.org/10.1074/jbc.273.25.15598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624151	hybrid			2022-12-27	WOS:000074284200045
J	Ross, SL; Martin, F; Simonet, L; Jacobsen, F; Deshpande, R; Vassar, R; Bennett, B; Luo, Y; Wooden, S; Hu, S; Citron, M; Burgess, TL				Ross, SL; Martin, F; Simonet, L; Jacobsen, F; Deshpande, R; Vassar, R; Bennett, B; Luo, Y; Wooden, S; Hu, S; Citron, M; Burgess, TL			Amyloid precursor protein processing in sterol regulatory element-binding protein site 2 protease-deficient Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; RECEPTOR; GENE; EXPRESSION; CLEAVAGE; CLONING; LINES	Amyloid peptides of 39-43 amino acids (A beta) are the major constituents of amyloid plaques present in the brains of Alzheimer's (AD) patients. Proteolytic processing of the amyloid precursor protein (APP) by the yet unidentified beta- and gamma-secretases leads to the generation of the amyloidogenic A beta peptides. Recent data suggest that all of the known mutations leading to early onset familial AD alter the processing of APP such that increased amounts of the 42-amino acid form of A beta are generated by a gamma-secretase activity. Identification of the beta- and/or gamma-secretases is a major goal of current AD research, as they are prime targets for therapeutic intervention in AD. It has been suggested that the sterol regulatory element-binding protein site 2 protease (S2P) may be identical to the long sought gamma-secretase. We have directly tested this hypothesis using over-expression of the S2P cDNA in cells expressing APP and by characterizing APP processing in mutant Chinese hamster ovary cells that are deficient in S2P activity and expression. The data demonstrate that S2P does not play an essential role in the generation or secretion of A beta peptides from cells, thus it is unlikely to be a gamma-secretase.	Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Burgess, TL (corresponding author), Amgen Inc, Dept Mammalian Cell Mol Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	tburgess@amgen.com						ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chang TY, 1997, CURR OPIN LIPIDOL, V8, P65, DOI 10.1097/00041433-199704000-00003; CHIN J, 1981, J BIOL CHEM, V256, P6304; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LINENBERGER ML, 1995, EXP HEMATOL, V23, P1104; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332	32	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15309	15312		10.1074/jbc.273.25.15309	http://dx.doi.org/10.1074/jbc.273.25.15309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624107	hybrid			2022-12-27	WOS:000074284200001
J	Zhou, G; Kuo, MT				Zhou, G; Kuo, MT			Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN GENES; MULTIDRUG-RESISTANCE; HEPATOCELLULAR CARCINOMAS; REGULATORY ELEMENTS; MURINE FIBROBLASTS; MAMMALIAN-CELLS; GROWTH ARREST; P53 MUTATIONS; LIVER; PROMOTER	The expression of P-glycoproteins encoded by the mdr gene family is associated with the emergence of the multidrug resistance phenotype in animal cells. mdr expression can be induced by many extracellular stimulants including cytotoxic drugs and chemical carcinogens. However, little is known about the mechanisms involved. Here, we report that the expression of the rat mdr1b can be induced by anticancer drug daunorubicin. Further analysis identified a bona fide p53-binding site spanning from base pairs - 199 to - 180 (5'-GAACATGTAGAGACATGTCT-3') in the rat mdr1b promoter that is essential for basal and daunorubicin-inducible promoter activities. In addition, our results show that wildtype p53 can up-regulate not only the promoter function but also endogenous expression of the rat mdr1b.. To the best of our knowledge, this is the first report showing that a specific p53-binding site is involved in the transcriptional regulation of mdr gene by wild-type p53. Since p53 is a sensor for a wide variety of genotoxic stresses, our finding has broad implications for understanding the mechanisms involved in the inducible expression of mdr gene by anticancer drugs, chemical carcinogens, UV light, and other DNA-damaging agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	t_kuo@path.mdacc.tmc.edu			NCI NIH HHS [CA72404, CA56846, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA056846, R01CA072404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRADLEY G, 1992, CANCER RES, V52, P5154; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; CARR BI, 1987, CANCER RES, V47, P5577; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; Fardel O, 1997, EUR J BIOCHEM, V246, P186, DOI 10.1111/j.1432-1033.1997.t01-1-00186.x; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HO YS, 1995, MOL CARCINOGEN, V13, P182, DOI 10.1002/mc.2940130308; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; NGUYEN KT, 1994, ONCOL RES, V6, P71; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RENZING J, 1995, ONCOGENE, V10, P1865; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; Schrenk D, 1996, BIOCHEM PHARMACOL, V52, P1453, DOI 10.1016/S0006-2952(96)00512-6; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; SONG RD, 1995, J BIOL CHEM, V270, P25468, DOI 10.1074/jbc.270.43.25468; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, MOL CARCINOGEN, V4, P358, DOI 10.1002/mc.2940040506; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOKUSASHI Y, 1994, MOL CARCINOGEN, V10, P45, DOI 10.1002/mc.2940100108; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; vanGijssel HE, 1997, CARCINOGENESIS, V18, P1027, DOI 10.1093/carcin/18.5.1027; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	66	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15387	15394		10.1074/jbc.273.25.15387	http://dx.doi.org/10.1074/jbc.273.25.15387			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624121	hybrid			2022-12-27	WOS:000074284200015
J	Graner, MW; Bunch, TA; Baumgartner, S; Kerschen, A; Brower, DL				Graner, MW; Bunch, TA; Baumgartner, S; Kerschen, A; Brower, DL			Splice variants of the Drosophila PS2 integrins differentially interact with RGD-containing fragments of the extracellular proteins tiggrin, ten-m, and D-laminin alpha 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIR-RULE GENE; FIBRONECTIN-RECEPTOR; SECONDARY STRUCTURE; LIGAND-BINDING; SUBUNIT; SPECIFICITY; MORPHOGENESIS; REQUIREMENTS; MELANOGASTER; ATTACHMENTS	Two new potential ligands of the Drosophila PS2 integrins have been characterized by functional interaction in cell culture. These potential ligands are a new Drosophila laminin alpha 2 chain encoded by the wing blister locus and Ten-m, an extracellular protein known to be involved in embryonic pattern formation. As with previously identified PS2 ligands, both contain RGD sequences, and RGD-containing fragments of these two proteins (DLAM-RGD and TENM-RGD) can support PS2 integrin-mediated cell spreading. In all cases, this spreading is inhibited specifically by short RGD-containing peptides. As previously found for the PS2 ligand tiggrin (and the tiggrin fragment TIG-RGD), TENM-RGD induces maximal spreading of cells expressing integrin containing the alpha(PS2C) splice variant. This is in contrast to DLAM-RGD, which is the first Drosophila polypeptide shown to interact preferentially with cells expressing the alpha(PS2m8) splice variant. The beta(PS) integrin subunit also varies in the presumed ligand binding region as a result of alternative splicing. For TIG-RGD and TENM-RGD, the beta splice variant has little effect, but for DLAM-RGD, maximal cell spreading is supported only by the beta(PS4A) form of the protein. Thus, the diversity in PS2 integrins due to splicing variations, in combination with diversity of matrix ligands, can greatly enhance the functional complexity of PS2-ligand interactions in the developing animal. The data also suggest that the splice variants may alter regions of the subunits that are directly involved in ligand interactions, and this is discussed with respect to models of integrin structure.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Lund Univ, Dept Cell & Mol Biol, S-22100 Lund, Sweden	University of Arizona; University of Arizona; Friedrich Miescher Institute for Biomedical Research; Lund University	Brower, DL (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Life Sci S Bldg, Tucson, AZ 85721 USA.	dbrower@u.arizona.edu	Baumgartner, Stefan/A-5879-2011	Baumgartner, Stefan/0000-0001-5320-8321	NCI NIH HHS [T32 CA09213] Funding Source: Medline; NIGMS NIH HHS [R01 GM42474] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BRABANT MC, 1993, DEV BIOL, V157, P49, DOI 10.1006/dbio.1993.1111; BROWER DL, 1995, DEVELOPMENT, V121, P1311; BROWER DL, 1984, P NATL ACAD SCI-BIOL, V81, P7485, DOI 10.1073/pnas.81.23.7485; BROWER DL, 1989, NATURE, V342, P285, DOI 10.1038/342285a0; BROWN NH, 1993, BIOESSAYS, V15, P383, DOI 10.1002/bies.950150604; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; BUNCH TA, 1992, DEVELOPMENT, V116, P239; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; GOTWALS PJ, 1994, P NATL ACAD SCI USA, V91, P11447, DOI 10.1073/pnas.91.24.11447; GOTWALS PJ, 1994, CURR OPIN CELL BIOL, V6, P734, DOI 10.1016/0955-0674(94)90101-5; HENCHCLIFFE C, 1993, DEVELOPMENT, V118, P325; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEPTIN M, 1987, EMBO J, V6, P1037, DOI 10.1002/j.1460-2075.1987.tb04856.x; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Roote CE, 1996, DEVELOPMENT, V122, P1985; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stark KA, 1997, DEVELOPMENT, V124, P4583; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Takagi Y, 1996, J BIOL CHEM, V271, P18074, DOI 10.1074/jbc.271.30.18074; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WERHLI M, 1993, MECH DEVELOP, V43, P21; WILCOX M, 1981, CELL, V25, P159, DOI 10.1016/0092-8674(81)90240-3; WOODRUFF RC, 1979, GENETICS, V92, P133; WRIGHT TRF, 1960, J EXP ZOOL, V143, P77, DOI 10.1002/jez.1401430107; YEE G, 1993, THESIS MIT; ZAVORTINK M, 1993, CELL ADHES COMMUN, V1, P251, DOI 10.3109/15419069309097258; Ziober BL, 1997, MOL BIOL CELL, V8, P1723, DOI 10.1091/mbc.8.9.1723; ZUSMAN S, 1993, DEVELOPMENT, V118, P737	53	57	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18235	18241		10.1074/jbc.273.29.18235	http://dx.doi.org/10.1074/jbc.273.29.18235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660786	hybrid			2022-12-27	WOS:000074828500041
J	Icatlo, FC; Kuroki, M; Kobayashi, C; Yokoyama, H; Ikemori, Y; Hashi, T; Kodama, Y				Icatlo, FC; Kuroki, M; Kobayashi, C; Yokoyama, H; Ikemori, Y; Hashi, T; Kodama, Y			Affinity purification of Helicobacter pylori urease - Relevance to gastric mucin adherence by urease protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MODEL; CELLS; INFECTION; ADHESION; BINDING; PH; COLONIZATION; IMMUNIZATION; SULFATIDES; ANTIBODIES	A simple, reproducible and high yield method of Helicobacter pylori urease enzyme purification was developed using a heparinoid (Cellufine sulfate) affinity gel. The purification method involved two sequential steps using the same gel that takes advantage of the differential affinity of urease to the heparinoid at two levels of hydrogen ion concentration, SDS-polyacrylamide gel electrophoresis analysis of affinity-purified urease revealed two major protein bands with about 62- and 30-kDa molecular mass. When whole cell lysates of clinical and laboratory strains of H. pylori were probed by Western blot, anti-urease hyperimmune serum produced by affinity-purified urease in rabbit recognized only the two bands corresponding to the urease A and B subunits. To probe the molecular relevance of affinity gel adherence to mucin adherence, the purified urease was derivatized with N-hydroxysuccinimidobiotin and used in adherence assays. Competitive inhibition tests revealed commonality of urease receptors among gastric mucin, heparin, and heparinoid, Composite data on adherence kinetics modulated by pH, salt, incubation time, and concentration of urease or mucin were indicative of conformation-dependent ligand-receptor interaction.	Ghen Corp, Immunol Res Inst, Gifu 50111, Japan		Icatlo, FC (corresponding author), Ghen Corp, Immunol Res Inst, 839-1 Sano, Gifu 50111, Japan.							ASCENCIO F, 1993, J MED MICROBIOL, V38, P240, DOI 10.1099/00222615-38-4-240; CLYNE M, 1995, INFECT IMMUN, V63, P1669, DOI 10.1128/IAI.63.5.1669-1673.1995; Clyne M, 1996, INFECT IMMUN, V64, P2817, DOI 10.1128/IAI.64.7.2817-2820.1996; CorthesyTheulaz I, 1996, INFECT IMMUN, V64, P3827; DAVIES J, 1995, INFECT IMMUN, V63, P2485, DOI 10.1128/IAI.63.7.2485-2492.1995; DUNN BE, 1990, J BIOL CHEM, V265, P9464; Dunn BE, 1997, INFECT IMMUN, V65, P1181, DOI 10.1128/IAI.65.4.1181-1188.1997; EATON KA, 1994, INFECT IMMUN, V62, P3604, DOI 10.1128/IAI.62.9.3604-3607.1994; EATON KA, 1995, SCAND J GASTROENTERO, V30, P434, DOI 10.3109/00365529509093303; EVANS DJ, 1991, MICROB PATHOGENESIS, V10, P15, DOI 10.1016/0882-4010(91)90062-F; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; Haas R, 1997, BIOLOGICALS, V25, P175, DOI 10.1006/biol.1997.0080; Harris PR, 1996, GASTROENTEROLOGY, V111, P419, DOI 10.1053/gast.1996.v111.pm8690207; HEMALATHA SG, 1991, J MED MICROBIOL, V35, P197, DOI 10.1099/00222615-35-4-197; HU LT, 1990, INFECT IMMUN, V58, P992, DOI 10.1128/IAI.58.4.992-998.1990; Huesca M, 1996, INFECT IMMUN, V64, P2643, DOI 10.1128/IAI.64.7.2643-2648.1996; Kabir AMA, 1997, GUT, V41, P49, DOI 10.1136/gut.41.1.49; Kamisago S, 1996, INFECT IMMUN, V64, P624, DOI 10.1128/IAI.64.2.624-628.1996; Kawasaki H, 1996, GLYCOCONJUGATE J, V13, P873, DOI 10.1007/BF00702352; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; Labigne A, 1996, INFECT AGENT DIS, V5, P191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CK, 1995, J INFECT DIS, V172, P161, DOI 10.1093/infdis/172.1.161; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; NAGATA K, 1992, INFECT IMMUN, V60, P4826, DOI 10.1128/IAI.60.11.4826-4831.1992; NATOMI H, 1990, J CLIN GASTROENTEROL, V12, pS52, DOI 10.1097/00004836-199001001-00010; NATOMI H, 1993, LIPIDS, V28, P737, DOI 10.1007/BF02535996; NMAVAR F, 1998, INFECT IMMUN, V66, P444; OFEK I, 1986, J CLIN MICROBIOL, V24, P512, DOI 10.1128/JCM.24.4.512-516.1986; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; PIOTROWSKI J, 1991, BIOCHEM INT, V24, P749; Rostand KS, 1997, INFECT IMMUN, V65, P1; SAITOH T, 1992, EUR J GASTROEN HEPAT, V4, pS49; SCHADE C, 1994, GASTROENTEROLOGY, V107, P180, DOI 10.1016/0016-5085(94)90075-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; TURBETT GR, 1992, INFECT IMMUN, V60, P5259, DOI 10.1128/IAI.60.12.5259-5266.1992; TZOUVELEKIS LS, 1991, INFECT IMMUN, V59, P4252, DOI 10.1128/IAI.59.11.4252-4254.1991; Utt M, 1997, J MED MICROBIOL, V46, P541, DOI 10.1099/00222615-46-7-541; Vanet A, 1998, INFECT IMMUN, V66, P1023, DOI 10.1128/IAI.66.3.1023-1027.1998; Williams CL, 1996, FEMS IMMUNOL MED MIC, V13, P87, DOI 10.1111/j.1574-695X.1996.tb00220.x; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	43	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18130	18138		10.1074/jbc.273.29.18130	http://dx.doi.org/10.1074/jbc.273.29.18130			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660771	hybrid, Green Submitted			2022-12-27	WOS:000074828500026
J	Joneson, T; Bar-Sagi, D				Joneson, T; Bar-Sagi, D			A Rac1 effector site controlling mitogenesis through superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NADPH OXIDASE; ACTIN POLYMERIZATION; CELL PROLIFERATION; JUN KINASE; PATHWAY; GTPASES; CDC42; FIBROBLASTS; DISTINCT	The Rac GTP-binding protein controls signal transduction pathways that are critical for mitogenesis and oncogenesis (1, 2). The biochemical nature of these signaling pathways is presently unknown. Here we report that a region in Rad (residues 124-135), previously defined as the insert region (3), is essential for its mitogenic activity. Deletion of this region does not interfere with the ability of Rad to induce cytoskeletal changes or to activate the Jun kinase mitogen-activated protein kinase cascade but abrogates Rad-induced stimulation of DNA synthesis and Rad-mediated superoxide production in quiescent fibroblasts. Treatment of cells with agents that abolish superoxide generation inhibits specifically the mitogenic effect of Rad. Our results identify an effector site in Rad that is necessary for mitogenic signaling and implicate superoxide generation as a candidate effector pathway of Rac1 dependent cell growth.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA055360, R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; GILI J, 1995, J BIOL CHEM, V270, P29079; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MALY FE, 1989, J IMMUNOL, V142, P1260; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; OLSON M, 1995, SCIENCE, V268, P1270; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	27	157	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					17991	17994		10.1074/jbc.273.29.17991	http://dx.doi.org/10.1074/jbc.273.29.17991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660749	hybrid			2022-12-27	WOS:000074828500004
J	Milanini, J; Vinals, F; Pouyssegur, J; Pages, G				Milanini, J; Vinals, F; Pouyssegur, J; Pages, G			p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; FACTOR EXPRESSION; MAMMALIAN-CELLS; 3T3 CELLS; ACTIVATION; HYPOXIA; MITOGEN; ANGIOGENESIS; FAMILY	Vascular Endothelial Growth Factor (VEGF) is a potent mitogen for vascular endothelial cells that has been implicated in tumor neovascularization. We show that, in hamster fibroblasts (CCL39 cells), VEGF mRNAs are expressed at low levels in serum-deprived or exponentially growing cells, whereas it is rapidly induced after stimulation of quiescent cells with serum. CCL39 derivatives, transformed with Polyoma virus or with active members of the p42/p44 mitogen-activated protein (MAP) kinase pathway, Gly/Val point mutant of Ras at position 12 (Ras-Val(12)), MKK1 in which Ser(218) and Ser(222) were mutated to Asp (MKK1-SS/DD)), express very high levels of VEGF mRNA, To analyze the contribution of the p42/p44MAP kinase in this induction, we used the CCL39 derived cell line (Raf-1:ER) expressing an estradiol-activable Raf-l. We show a time and an estradiol dose-dependent up-regulation of VEGF mRNA clearly detectable after 2 h of stimulation. The induction of VEGF mRNA in response to conditioned activation of Raf-l is reverted by an inhibitor of MKK1, PD 098059, highlighting a specific role for the p42/p44 MAP kinase pathway in VEGF expression. Interestingly, hypoxia has an additive effect on VEGF induction in CCL39 cells stimulated by serum or in Raf-l:ER cells stimulated by estradiol, In contrast to VEGF, the isoforms VEGF-B and VEGF-C are poorly regulated by growth and oncogenic factors. We have identified a GC-rich region of the VEGF promoter between -88 and -66 base pairs which contains all the elements responsible of its up-regulation by constitutive active Ras or MKK1-SS/DD. By mutation of the putative binding sites and electrophoretic mobility supershift experiments, we showed that the GC-rich region constitutively binds Spl and AP-2 transcription factors. Furthermore, following activation of the p42/p44 MAP kinase module, the binding of Spl and AP-2 is increased in the complexes formed in this region of the promoter. Altogether, these data suggest that hypoxia and p42/p44 MAP kinase independently play a key role in the regulation of the VEGF expression.	Univ Nice, Ctr Biochim, CNRS, UMR 6543, F-06108 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Pages, G (corresponding author), Univ Nice, Ctr Biochim, CNRS, UMR 6543, Parc Valrose, F-06108 Nice, France.	gpages@unice.fr	Pages, Gilles/N-7135-2017; Viñals, Francesc/F-5928-2016; Vinals, Francesc/P-6278-2019	Viñals, Francesc/0000-0002-9918-6751; Milanini, Julie/0000-0002-5861-2830				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BRUNET A, 1994, ONCOGENE, V9, P3379; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; COZZOLINO F, 1993, J CLIN INVEST, V91, P2504, DOI 10.1172/JCI116486; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Joukov V, 1996, EMBO J, V15, P290; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOI M, 1991, BIOCHEM BIOPH RES CO, V174, P1287, DOI 10.1016/0006-291X(91)91561-P; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	55	287	302	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18165	18172		10.1074/jbc.273.29.18165	http://dx.doi.org/10.1074/jbc.273.29.18165			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660776	hybrid, Green Published			2022-12-27	WOS:000074828500031
J	Schissel, SL; Keesler, GA; Schuchman, EH; Williams, KJ; Tabas, I				Schissel, SL; Keesler, GA; Schuchman, EH; Williams, KJ; Tabas, I			The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK DISEASE; PROTEIN RECOGNITION DETERMINANTS; PHOSPHOLIPASE-C; PROCATHEPSIN-D; CHOLESTEROL ESTERIFICATION; ATHEROGENIC LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; ENZYME PHOSPHORYLATION; MACROPHAGE UPTAKE	The acid sphingomyelinase (ASM) gene, which has been implicated in ceramide-mediated cell signaling and atherogenesis, gives rise to both lysosomal SMase (L-SMase), which is reportedly cation-independent, and secretory SMase (S-SMase), which is fully or partially dependent on Zn2+ for enzymatic activity. Herein we present evidence for a model to explain how a single mRNA gives rise to two forms of SMase with different cellular trafficking and apparent differences in Zn2+ dependence. First, we show that both S-SMase and SMase, which contain several highly conserved zinc-binding motifs, are directly activated by zinc. In addition, SMase assayed from a lysosome-rich fraction of Chinese hamster ovary cells was found to be partially zinc-dependent, suggesting that intact lysosomes from these cells contain subsaturating levels of Zn2+. Analysis of Asn-linked oligosaccharides and of N-terminal amino acid sequence indicated that S-SMase arises by trafficking through the Golgi secretory pathway, not by cellular release of L-SMase during trafficking to lysosomes or after delivery to lysosomes. Most importantly, when Zn2+-dependent S-SMase was incubated with SMase-negative cells, the enzyme was internalized, trafficked to lysosomes, and became zinc-independent. We conclude that L-SMase is exposed to cellular Zn2+ during trafficking to lysosomes, in lysosomes, and/or during cell homogenization. In contrast, the pathway targeting S-SMase to secretion appears to be relatively sequestered from cellular pools of Zn2+; thus S-SMase requires exogeneous Zn2+ for full activity. This model provides important information for understanding the enzymology and regulation of L- and S-SMase and for exploring possible roles of ASM gene products in cell signaling and atherogenesis.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Amgen, Boulder, CO 80301 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Columbia University; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Jefferson University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Williams, Kevin Jon/0000-0002-0000-2159	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39703, HL 21006] Funding Source: Medline; NICHD NIH HHS [HD28607] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD TY, 1985, J LIPID RES, V26, P1160; ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BAUER J, 1994, J NEUROSCI RES, V38, P365, DOI 10.1002/jnr.490380402; BETTGER WJ, 1981, LIFE SCI, V28, P1425, DOI 10.1016/0024-3205(81)90374-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWSER PA, 1978, J INVEST DERMATOL, V70, P331, DOI 10.1111/1523-1747.ep12543516; Brady R. O., 1983, METABOLIC BASIS INHE, P831; Brand IA, 1996, J BIOL CHEM, V271, P1941, DOI 10.1074/jbc.271.4.1941; CALLAHAN JW, 1978, CAN J BIOCHEM CELL B, V56, P885, DOI 10.1139/o78-137; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CSERMELY P, 1987, CARCINOGENESIS, V8, P1663, DOI 10.1093/carcin/8.11.1663; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTUNG HP, 1992, J NEUROIMMUNOL, V40, P197, DOI 10.1016/0165-5728(92)90134-7; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HORTIN GL, 1989, PREP BIOCHEM, V19, P49, DOI 10.1080/10826068908544896; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; Hung CH, 1997, J BIOL CHEM, V272, P13772, DOI 10.1074/jbc.272.21.13772; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; LITTLE C, 1975, BIOCHIM BIOPHYS ACTA, V391, P326, DOI 10.1016/0005-2744(75)90256-9; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; Neufeld E F, 1980, Birth Defects Orig Artic Ser, V16, P77; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; OKWU AK, 1994, J LIPID RES, V35, P644; OTTERBACH B, 1995, CELL, V77, P759; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; PORN MI, 1995, BIOCHEM J, V308, P269; PRACK MM, 1994, BIOCHEMISTRY-US, V33, P5049, DOI 10.1021/bi00183a007; RAO BG, 1976, J LIPID RES, V17, P506; Reynolds J J, 1996, Oral Dis, V2, P70; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SRIPADA PK, 1987, J LIPID RES, V28, P710; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; SVENSSON M, 1993, BRAIN RES BULL, V30, P499, DOI 10.1016/0361-9230(93)90284-I; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VAN GENDEREN IL, 1994, VIROLOGY, V200, P831, DOI 10.1006/viro.1994.1252; VARKI A, 1983, J BIOL CHEM, V258, P2808; WATANABE K, 1983, J LIPID RES, V24, P596; WATERMAN MR, 1995, SCIENCE, V267, P1780, DOI 10.1126/science.7892600; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YAMAGUCHI S, 1977, J BIOL CHEM, V252, P3805; YAMAMOTO K, 1994, J BIOCHEM, V116, P229, DOI 10.1093/oxfordjournals.jbchem.a124510; Zha XH, 1998, J CELL BIOL, V140, P39, DOI 10.1083/jcb.140.1.39	84	194	199	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18250	18259		10.1074/jbc.273.29.18250	http://dx.doi.org/10.1074/jbc.273.29.18250			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660788	hybrid			2022-12-27	WOS:000074828500043
J	Gotoh, Y; Cooper, JA				Gotoh, Y; Cooper, JA			Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANOUS SUPEROXIDE-DISMUTASE; PROTEIN-KINASE; IONIZING-RADIATION; N-ACETYLCYSTEINE; MAP KINASE; CELLS; STRESS; CYTOTOXICITY; INVOLVEMENT; CERAMIDE	Reactive oxygen species (ROS) have been implicated in the induction of apoptosis by tumor necrosis factor-alpha (TNF alpha) and other cytotoxic insults, although the molecule(s) regulated by ROS in TNF alpha signaling have not been identified. Apoptosis signal regulating kinase 1 (ASK1) is a member of the mitogen activated protein kinase kinase kinase (MAPKKK) superfamily that has been shown to be activated during TNF alpha-induced apoptosis. ASK1 increases apoptosis when overexpressed, but the mechanism of ASK1 activation and the mechanisms of ASK1-induced apoptosis are unclear. We now report that hydrogen peroxide induces the activation of ASK1 in 293 cells. TNF alpha induced activation of ASK1 was inhibited by antioxidants. Hydrogen peroxide-induced apoptosis was markedly enhanced by the expression of ASK1. These results suggest that TNF alpha-induced activation of ASK1 is mediated by ROS. We also examined how ASK1 activity is regulated by ROS. We found that ASK1 formed dimers or higher order oligomers in 293 cells. TNF alpha or hydrogen peroxide treatment increased the dimeric form of ASK1, and pretreatment with N-acetylcysteine decreased it. Furthermore, synthetic dimerization of an ASK1-gyrase B fusion protein by coumermycin resulted in substantial activation of ASK1, suggesting that dimerization of ASK1 is sufficient for its activation. These results taken together suggest that TNF alpha causes ASK1 activation via ROS-mediated dimerization of ASK1.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School	Gotoh, Y (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave,Enders 260, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BASS DA, 1983, J IMMUNOL, V130, P1910; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang XHS, 1996, J BIOL CHEM, V271, P31607; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	56	312	323	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17477	17482		10.1074/jbc.273.28.17477	http://dx.doi.org/10.1074/jbc.273.28.17477			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651337	hybrid			2022-12-27	WOS:000074816100030
J	Hayes, CS; Setlow, P				Hayes, CS; Setlow, P			Identification of protein-protein contacts between alpha/beta-type small, acid-soluble spore proteins of Bacillus species bound to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS SPORES; GENE-EXPRESSION; SIGMA-FACTOR; BINDING; SPORULATION; CLONING	Small, acid-soluble spore proteins (SASP) of the alpha/beta-type from several Bacillus species were cross-linked into homodimers, heterodimers and homooligomers with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in the presence of linear plasmid DNA. Significant protein cross-linking was not detected in the absence of DNA. In all four alpha/beta-type SASP examined, the amino donor in the EDC induced amide cross-links was the cu-amino group of the protein. However, the carboxylate containing amino acid residues involved in cross linking varied. In SASP-A and SASP-C of Bacillus megateriun two conserved glutamate residues, which form part of the germination protease recognition sequence, were involved in cross-link formation. In SscP-A from Bacillus subtilis and Bcel from Bacillus cereus the acidic residues involved in cross-link formation were not in the protease recognition sequence, but at a site closer to the N terminus of the proteins. These data indicate that, although there are likely to be subtle structural differences between different alpha/beta-type SASP, the N-terminal regions of these proteins are involved in protein-protein interactions while in the DNA bound state.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	Setlow, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA.	setlow@sun.uchc.edu	Hayes, Christopher/A-5505-2009		NIGMS NIH HHS [GM19698] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019698, R01GM019698] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRILLOMARTINEZ Y, 1994, J BACTERIOL, V176, P5357, DOI 10.1128/JB.176.17.5357-5363.1994; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; Hayes CS, 1997, J BACTERIOL, V179, P6020, DOI 10.1128/jb.179.19.6020-6027.1997; LOSHON CA, 1986, J BACTERIOL, V167, P168, DOI 10.1128/jb.167.1.168-173.1986; MASON JM, 1986, J BACTERIOL, V167, P174, DOI 10.1128/jb.167.1.174-178.1986; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; NICHOLSON WL, 1990, J BACTERIOL, V172, P6900, DOI 10.1128/jb.172.12.6900-6906.1990; RAO H, 1992, FEBS LETT, V305, P115, DOI 10.1016/0014-5793(92)80876-I; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SETLOW B, 1991, J BACTERIOL, V173, P1642, DOI 10.1128/jb.173.5.1642-1653.1991; SETLOW B, 1995, J BACTERIOL, V177, P4149, DOI 10.1128/jb.177.14.4149-4151.1995; SETLOW B, 1992, J BACTERIOL, V174, P2312, DOI 10.1128/JB.174.7.2312-2322.1992; SETLOW P, 1975, J BIOL CHEM, V250, P8168; SETLOW P, 1969, J BACTERIOL, V100, P1155, DOI 10.1128/JB.100.3.1155-1160.1969; SETLOW P, 1995, ANNU REV MICROBIOL, V49, P29, DOI 10.1146/annurev.mi.49.100195.000333; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	20	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17326	17332		10.1074/jbc.273.28.17326	http://dx.doi.org/10.1074/jbc.273.28.17326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651315	hybrid			2022-12-27	WOS:000074816100008
J	Mate, Z; Sass, L; Szekeres, M; Vass, I; Nagy, F				Mate, Z; Sass, L; Szekeres, M; Vass, I; Nagy, F			UV-B-induced differential transcription of psbA genes encoding the D1 protein of photosystem II in the cyanobacterium Synechocystis 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-7942; ELECTRON-TRANSPORT; NUCLEOTIDE-SEQUENCE; PISUM-SATIVUM; RADIATION; PHOTOSYNTHESIS; LIGHT; EXPRESSION; DEGRADATION; INHIBITION	UV-B irradiation of intact Synechocystis sp, PCC 6803 cells results in the loss of photosystem II activity, which can be repaired via de novo synthesis of the D1 land D2) reaction center subunits, In this study, we investigated the effect of UV-B irradiation on the transcription of the psbA2 and psbA3 genes encoding identical D1 proteins. We show that UV-B irradiation increases the level of psbA2 mRNA 2-3-fold and, more dramatically, it induces a 20-30-fold increase in the accumulation of the psbA3 mRNA even at levels of irradiation too low to produce losses of either photosystem II activity or D1 protein. The induction of psbA3 transcript accumulation is specific for UV-B light (290-330 nm). Low intensity UV-A emission (330-390 nm) and white light induce only a small, at most, 2-3-fold enhancement, whereas no effect of blue light was observed, Expression patterns of chimeric genes containing the promoter regions of the psbA2, psbA3 genes fused to the firefly luciferase (luc) reporter gene indicate that (i) transcription of psbA2/luc and psbA3/luc transgenes was elevated, similarly to that of the endogenous psbA genes, by UV-B irradiation, and that (ii) a short, 80-base pair psbA3 promoter fragment is sufficient to maintain UV-B-induced transcription of the luc reporter gene. Furthermore, our findings indicate that UV-B induced expression of the psbA2 and psbA3 genes is a defense response against UV-B stress, which is regulated, at least, partially at the level of transcription and does not require active electron transport.	Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center	Vass, I (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, POB 521, H-6701 Szeged, Hungary.	imre@everx.szbk.u-szeged.hu	Nagy, Ferenc/D-3532-2015; Vass, Imre/AAS-6171-2021	Nagy, Ferenc/0000-0002-6157-9269; Vass, Imre/0000-0003-4987-7842; Szekeres, Miklos/0000-0002-6354-1790				ALLEN JF, 1995, CURR BIOL, V5, P869, DOI 10.1016/S0960-9822(95)00176-X; Andersson B., 1991, CURRENT TOPICS BIOEN, V16, P1; BASIOUNY FM, 1978, PHYSIOL PLANTARUM, V42, P29, DOI 10.1111/j.1399-3054.1978.tb01533.x; BORNMAN JF, 1989, J PHOTOCH PHOTOBIO B, V4, P145, DOI 10.1016/1011-1344(89)80001-6; BORNMAN JF, 1984, PHOTOBIOCH PHOTOBIOP, V8, P305; BRANDLE JR, 1977, PLANT PHYSIOL, V60, P165, DOI 10.1104/pp.60.1.165; BUSTOS SA, 1992, MOL GEN GENET, V232, P221, DOI 10.1007/BF00280000; Campbell D, 1998, P NATL ACAD SCI USA, V95, P364, DOI 10.1073/pnas.95.1.364; CATENHOLZ RW, 1998, ECOLOGY CYANOBACTERI; FEJES E, 1990, PLANT MOL BIOL, V15, P921, DOI 10.1007/BF00039431; FISCUS EL, 1995, PHOTOSYNTH RES, V43, P81, DOI 10.1007/BF00042965; FRISO G, 1994, BBA-BIOENERGETICS, V1184, P78, DOI 10.1016/0005-2728(94)90156-2; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; JANSSON C, 1987, PLANT PHYSIOL, V85, P1021, DOI 10.1104/pp.85.4.1021; JONES LW, 1966, PLANT PHYSIOL, V41, P1037, DOI 10.1104/pp.41.6.1037; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KREPS S, 1990, MOL GEN GENET, V221, P129, DOI 10.1007/BF00280378; KULANDAIVELU G, 1983, PHYSIOL PLANTARUM, V58, P389, DOI 10.1111/j.1399-3054.1983.tb04199.x; Lao KQ, 1996, P NATL ACAD SCI USA, V93, P5258, DOI 10.1073/pnas.93.11.5258; MELIS A, 1992, BIOCHIM BIOPHYS ACTA, V1100, P312, DOI 10.1016/0167-4838(92)90487-X; METZ J, 1990, NUCLEIC ACIDS RES, V18, P6715, DOI 10.1093/nar/18.22.6715; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; MOHAMED A, 1993, MOL GEN GENET, V238, P161, DOI 10.1007/BF00279543; NAGY F, 1998, PLANT MOL BIOL MANUA, P1; NOGUES S, 1995, PLANT CELL ENVIRON, V18, P781, DOI 10.1111/j.1365-3040.1995.tb00581.x; RAVNIKAR PD, 1989, NUCLEIC ACIDS RES, V17, P3991, DOI 10.1093/nar/17.10.3991; RONTO G, 1989, J PHOTOCH PHOTOBIO B, V3, P497, DOI 10.1016/1011-1344(89)80075-2; Salih GF, 1997, PLANT CELL, V9, P869, DOI 10.1105/tpc.9.6.869; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sass L, 1997, PHOTOSYNTH RES, V54, P55, DOI 10.1023/A:1005895924892; SMITH RC, 1992, SCIENCE, V255, P952, DOI 10.1126/science.1546292; STRID A, 1990, BIOCHIM BIOPHYS ACTA, V1020, P260, DOI 10.1016/0005-2728(90)90156-X; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; TREBST A, 1990, Z NATURFORSCH C, V45, P765; TSINOREMAS NF, 1994, J BIOL CHEM, V269, P16143; Vass I, 1996, BIOCHEMISTRY-US, V35, P8964, DOI 10.1021/bi9530595; VASS I, 1996, HDB PHOTOSYNTHESIS, P931; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; ZHANG JW, 1994, BBA-BIOENERGETICS, V1185, P295, DOI 10.1016/0005-2728(94)90244-5	40	77	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17439	17444		10.1074/jbc.273.28.17439	http://dx.doi.org/10.1074/jbc.273.28.17439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651331	hybrid			2022-12-27	WOS:000074816100024
J	Ramocki, MB; White, MA; Konieczny, SF; Taparowsky, EJ				Ramocki, MB; White, MA; Konieczny, SF; Taparowsky, EJ			A role for RalGDS and a novel Ras effector in the Ras-mediated inhibition of skeletal myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; CELL-TRANSFORMATION; ONCOGENIC RAS; PROTEIN; KINASE; DIFFERENTIATION; SUFFICIENT; BINDING; RHOA; RAC1	Oncogenic Ras inhibits the differentiation of skeletal muscle cells through the activation of multiple downstream signaling pathways, including a Raf-dependent, mitogen-activated or extracellular signal-regulated kinase kinase/mitogen-activated protein kinase (MEK/MAPK)-independent pathway. Here we report that a non-Raf binding Ras effector-loop variant (H-Ras G12V,E37G), which retains interaction with the Ral guanine nucleotide dissociation stimulator (RalGDS), inhibits the conversion of MyoD-expressing C3H10T1/2 mouse fibroblasts to skeletal muscle. We show that H-Ras G12V,E37G, RalGDS, and the membrane-localized RalGDS CAAX protein inhibit the activity of alpha-actin-Luc, a muscle-specific reporter gene containing a necessary E-box and serum response factor (SRF) binding site, while a RalGDS protein defective for Ras interaction has no effect on alpha-actin-Luc transcription. H-Ras G12V,E37G does not activate endogenous MAPK, but does increase SRI-dependent transcription. Interestingly, RalGDS, RalGDS CAAX, and RalA G23V inhibit H-Ras G12V,E37G-induced expression of an SRF-regulated reporter gene, demonstrating that signaling through RalGDS does not duplicate the action of H-Ras G12V,E37G in this system. As additional evidence for this, we show that H-Ras G12V,E37G inhibits the expression of troponin I-Luc, an SRF-independent muscle-specific reporter gene, whereas RalGDS and RalGDS CAAX do not. Although our studies show that signaling through RalGDS can interfere with the expression of reporter genes dependent on SRF activity (including alpha-actin-Luc), our studies also provide strong evidence that an additional signaling molecule(s) activated by H-Ras G12V,E37G is required to achieve the complete inhibition of the myogenic differentiation program.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.				NCI NIH HHS [T32 CA09634, CA71443] Funding Source: Medline; NIAMS NIH HHS [AR41115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009634, R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KONG YF, 1995, MOL CELL BIOL, V15, P5205; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PINSET C, 1997, DEV REP BIOL, V320, P367; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	22	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17696	17701		10.1074/jbc.273.28.17696	http://dx.doi.org/10.1074/jbc.273.28.17696			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651367	hybrid			2022-12-27	WOS:000074816100060
J	Snow, BE; Hall, RA; Krumins, AM; Brothers, GM; Bouchard, D; Brothers, CA; Chung, S; Mangion, J; Gilman, AG; Lefkowitz, RJ; Siderovski, DP				Snow, BE; Hall, RA; Krumins, AM; Brothers, GM; Bouchard, D; Brothers, CA; Chung, S; Mangion, J; Gilman, AG; Lefkowitz, RJ; Siderovski, DP			GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; PHOSPHOLIPASE C-BETA-1; PHOSPHATASE; RECEPTOR; KINASE; FAMILY; SYSTEM	Regulator of G-protein signaling (RGS) proteins increase the intrinsic guanosine triphosphatase (GTPase) activity of G-protein cu subunits in vitro, but how specific G-protein-coupled receptor systems are targeted for down-regulation by RGS proteins remains uncharacterized. Here, we describe the GTPase specificity of RGS12 and identify four alternatively spliced forms of human RGS12 mRNA, Two RGS12 isoforms of 6.3 and 5.7 kilobases (kb), encoding both an N-terminal PDZ ((P) under bar SD-95/ (D) under bar lg/(Z) under bar O-1) domain and the RGS domain, are expressed in most tissues, with highest levels observed in testis, ovary, spleen, cerebellum, and caudate nucleus. The 5,7-kb isoform has an alternative 3' end encoding a putative C-terminal PDZ domain docking site. Two smaller isoforms, of 3.1 and 3.7 kb, which lack the PDZ domain and encode the RGS domain with and without the alternative 3' end, respectively, are most abundantly expressed in brain, kidney, thymus, and prostate. In vitro biochemical assays indicate that RGS12 is a GTPase-activating protein for Gi class a subunits, Biochemical and interaction trap experiments suggest that the RGS12 N terminus acts as a classical PDZ domain, binding selectively to C-terminal (A/S)-T-X-(L/V) motifs as found within both the interleukin-8 receptor B (CXCR2) and the alternative 3' exon form of RGS12. The presence of an alternatively spliced PDZ domain within RGS12 suggests a mechanism by which RGS proteins may target specific G-protein-coupled receptor systems for desensitization.	Amgen Inst, Quantitat Biol lab, Toronto, ON M5G 2C1, Canada; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Siderovski, DP (corresponding author), Amgen Inst, Quantitat Biol lab, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Lefkowitz, Robert/AAW-2649-2021; Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Hall, Randy/0000-0002-8318-8728	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gold SJ, 1997, J NEUROSCI, V17, P8024; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; James P, 1996, GENETICS, V144, P1425; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LEE E, 1994, METHOD ENZYMOL, V237, P146; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805	27	184	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17749	17755		10.1074/jbc.273.28.17749	http://dx.doi.org/10.1074/jbc.273.28.17749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651375	hybrid			2022-12-27	WOS:000074816100068
J	Telo, P; Breviario, F; Huber, P; Panzeri, C; Dejana, E				Telo, P; Breviario, F; Huber, P; Panzeri, C; Dejana, E			Identification of a novel cadherin (vascular endothelial cadherin-2) located at intercellular junctions in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; CYTOPLASMIC REGION; CATENIN COMPLEX; NERVOUS-SYSTEM; VE-CADHERIN; N-CADHERIN; PROTEIN; CLONING; FAMILY; EXPRESSION	Endothelial cells express two major cadherins, VE and N-cadherins, but only the former consistently participates in adherens junction organization. In heart microvascular endothelial cells, we identified a new member of the cadherin superfamily using polymerase chain reaction. The entire putative coding sequence was determined. Similarly to protocadherins, while the extracellular domain presented homology with other members of the cadherin superfamily, the intracellular region was unrelated either to cadherins or to any other known protein. We propose for this new protein the name of vascular endothelial cadherin-2. By Northern blot analysis, the mRNA was present only in cultured endothelial cell lines but not in other cell types such as NIH 3T3, Chinese hamster ovary, or L cells. In addition, mRNA was particularly abundant in highly vascularized organs such as lung or kidney. In endothelial cells and transfectants, this cadherin was unable to bind catenins and presented a weak association with the cytoskeleton. This new molecule shares some functional properties with VE-cadherin and other members of the cadherin family. In Chinese hamster ovary transfectants it promoted homotypic Ca2+ dependent aggregation and adhesion and clustered at intercellular junctions. However, in contrast to VE-cadherin, it did not modify paracellular permeability, cell migration, and density-dependent cell growth. These observations suggest that different cadherins may promote homophilic cell-to cell adhesion but that the functional consequences of this interaction depend on their binding to specific intracellular signaling/cytoskeletal proteins.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Commiss Energie Atom, Lab Transgenese & Differenciat Cellulaire, Dept Biol Mol & Struct, F-38054 Grenoble, France; Univ Milan, Fac Farmacol, I-20129 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; CEA; University of Milan	Telo, P (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	telo@irfmn.mnegri.it	Huber, Philippe/C-7971-2019; Carla, Panzeri Maria/AAN-5327-2020	Huber, Philippe/0000-0002-4153-7694; Carla, Panzeri Maria/0000-0002-3019-0314; DEJANA, ELISABETTA/0000-0002-0007-0426				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; Bardin N, 1996, BIOCHEM BIOPH RES CO, V218, P210, DOI 10.1006/bbrc.1996.0037; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; DEJANA E, 1997, J CLIN INVEST S, V100, P7; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; FUSENIG NE, 1982, CANCER FORUM, V6, P209; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kreft B, 1997, J CELL BIOL, V136, P1109, DOI 10.1083/jcb.136.5.1109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LEACH L, 1993, J CELL SCI, V104, P1073; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955-0674(92)90107-N; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; SALOMON D, 1992, J CELL SCI, V102, P7; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Shibata T, 1997, J BIOL CHEM, V272, P5236, DOI 10.1074/jbc.272.8.5236; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; Suzuki ST, 1996, J CELL SCI, V109, P2609; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	45	60	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17565	17572		10.1074/jbc.273.28.17565	http://dx.doi.org/10.1074/jbc.273.28.17565			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651350	hybrid			2022-12-27	WOS:000074816100043
J	Baden, HA; Sarma, SP; Kapust, RB; Byrd, RA; Waugh, DS				Baden, HA; Sarma, SP; Kapust, RB; Byrd, RA; Waugh, DS			The amino-terminal domain of human STAT4 - Overproduction, purification, and biophysical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; ESCHERICHIA-COLI; BACKBONE DYNAMICS; DNA-BINDING; PROTEINS; CODONS; SPECTROSCOPY; SENSITIVITY; EXPRESSION; DIFFUSION	The multifunctional signal transducer and activator of transcription (STAT) proteins relay signals from the cell membrane to the nucleus in response to cytokines and growth factors. STAT4 becomes activated when cells are treated with interleukin-12, a key cytokine regulator of cell-mediated immunity. Upon activation, dimers of STAT4 bind cooperatively to tandem interferon-gamma activation sequences (GAS elements) near the interferon-gamma gene and stimulate its transcription. The amino-terminal domain of STAT4 (STAT4(1-124)) is required for cooperative binding interactions between STAT4 dimers and activation of interferon-gamma transcription in response to interleukin-12. me have overproduced this domain of human STAT4 (hSTAT4(1-124)) in Escherichia coli and purified it to homogeneity for structural studies. The circular dichroism spectrum of hSTAT4(1-124) indicates that it has a well ordered conformation in solution. The translational diffusion constant of hSTAT4(1-124) was determined by nuclear magnetic resonance methods and found to be consistent with that of a dimer. The rotational correlation time (tau(c)) of hSTAT4(1-124) was estimated from N-15 relaxation to be 16 ns; this value is consistent with a 29-kDa dimeric protein. These results, together with the number of signals observed in the two-dimensional H-1-N-15 heteronuclear single quantum coherence spectrum of uniformly N-15-labeled protein, indicate that hSTAT4(1-124) forms a stable, symmetric homodimer in solution. Cooperativity in native STAT4 probably results from a similar or identical interaction between the amino-terminal domains of adjacent dimers bound to DNA.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Prot Engn Grp, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Macromol NMR Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Waugh, DS (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Prot Engn Grp, Frederick, MD 21702 USA.		Byrd, R. Andrew/F-8042-2015	Byrd, R. Andrew/0000-0003-3625-4232				Altieri AS, 1997, FEBS LETT, V415, P221, DOI 10.1016/S0014-5793(97)01128-9; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Calderone TL, 1996, J MOL BIOL, V262, P407, DOI 10.1006/jmbi.1996.0524; CHEN GFT, 1994, GENE DEV, V8, P2641, DOI 10.1101/gad.8.21.2641; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Hu XY, 1996, PROTEIN EXPRES PURIF, V7, P289, DOI 10.1006/prep.1996.0041; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandel AM, 1996, BIOCHEMISTRY-US, V35, P16009, DOI 10.1021/bi962089k; Miller J. H., 1972, EXPT MOL GENETICS, P431; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Seder RA, 1996, J IMMUNOL, V157, P2745; STUDIER FW, 1991, METHOD ENZYMOL, V186, P60; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; TREMBLEAU S, 1995, IMMUNOL TODAY, V16, P383, DOI 10.1016/0167-5699(95)80006-9; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	29	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17109	17114		10.1074/jbc.273.27.17109	http://dx.doi.org/10.1074/jbc.273.27.17109			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642277	hybrid			2022-12-27	WOS:000074545200067
J	Cardozo, C; Kohanski, RA				Cardozo, C; Kohanski, RA			Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEASOME-RELATED GENE; CLASS-I MOLECULES; NF-KAPPA-B; PROTEOLYTIC ACTIVITY; INTERFERON-GAMMA; ANTIGEN PRESENTATION; 20S PROTEASOME; HUMAN MHC	The multicatalytic proteinase complex (MPC, proteasome) is assembled from 14 nonidentical protein subunits. It expresses five distinct proteolytic activities, including a chymotrypsin-like activity, cleaving after hydrophobic residues, and a branched chain amino acid-preferring component (BrAAP), cleaving preferentially after branched chain residues. Exposure of cells to interferons leads to replacement of the X, Y, and Z subunits by the LMP2, LMP7, and MECL1 subunits. This "immunoproteasome" is critical to processing of certain antigens. The enzymatic basis for enhanced antigen processing has not been determined. To gain insight into this question, we examined sites and relative rates of cleavage of bonds in denatured, reduced, carboxy-amidomethylated lysozyme, a 129-amino acid protein, by MPC from bovine spleen, in which the X, Y, and Z subunits are replaced by LMP2, LMP7, and MECL1. We compared cleavages to those catalyzed by MPC from bovine pituitary, which contains only the X,Y, and Z subunits. We found marked increases in the rates and number of cleavages after branched chain residues in reduced, carboxyamidomethylated lysozyme by the spleen MPC. This was largely due to accelerated cleavages of bonds after a Phi-X-Br motif, where Phi is a hydrophobic residue, Xis a small neutral or polar residue, and Br is a branched chain residue. Inhibitors with these structural properties were selective and potent inhibitors of the BrAAP activity of the spleen MPC. The above findings indicate that alterations in activity and substrate specificity of the BrAAP activity are important factors underlying the altered cleavages after hydrophobic residues associated with incorporation of interferon-inducible subunits. The potential relevance of the findings to antigen processing functions of MPC is discussed.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cardozo, C (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1215,1 Gustave L Levy Pl, New York, NY 10029 USA.		Cardozo, Christopher/R-6021-2019	Cardozo, Christopher/0000-0003-4013-2537	NIDDK NIH HHS [DK25377, DK50074] Funding Source: Medline; NIOSH CDC HHS [KOHL02835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025377, R01DK050074] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIOSH CDC HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMENOFF J, 1983, BIOCHEMISTRY-US, V22, P590, DOI 10.1021/bi00272a011; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mykles DL, 1996, ARCH BIOCHEM BIOPHYS, V325, P77, DOI 10.1006/abbi.1996.0009; Nandi D, 1996, J IMMUNOL, V156, P2361; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Orlowski M, 1997, BIOCHEMISTRY-US, V36, P13946, DOI 10.1021/bi970666e; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFITZNER KE, 1965, J AM CHEM SOC, V87, P5661, DOI 10.1021/ja00952a026; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; Yang Y, 1996, IMMUNOL RES, V15, P208, DOI 10.1007/BF02918250	47	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16764	16770		10.1074/jbc.273.27.16764	http://dx.doi.org/10.1074/jbc.273.27.16764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642232	hybrid			2022-12-27	WOS:000074545200022
J	Matsumoto, R; Matsumoto, H; Seki, M; Hata, M; Asano, Y; Kanegasaki, S; Stevens, RL; Hirashima, M				Matsumoto, R; Matsumoto, H; Seki, M; Hata, M; Asano, Y; Kanegasaki, S; Stevens, RL; Hirashima, M			Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GALACTOSIDE-BINDING LECTIN; REED-STERNBERG CELLS; ALLERGIC INFLAMMATION; FUNCTIONAL-HETEROGENEITY; CHEMOTACTIC LYMPHOKINES; MOLECULAR-CLONING; HODGKINS-DISEASE; MESSENGER-RNA; MAST-CELLS	A 1.6-kilobase pair cDNA was isolated from a human T-cell-derived expression library that encodes a novel eosinophil chemoattractant (designated ecalectin) expressed during allergic and parasitic responses. Based on its deduced amino acid sequence, ecalectin is a 36kDa protein consisting of 323 amino acids. Although ecalectin lacks a hydrophobic signal peptide, it is secreted from mammalian cells. Ecalectin is not related to any known cytokine or chemokine but rather is a variant of human galectin-9, a member of the large family of animal lectins that have affinity for P-galactosides. Recombinant ecalectin, expressed in COS cells and insect cells, exhibited potent eosinophil chemoattractant activity and attracted eosinophils in vitro and in vivo in a dose-dependent manner but not neutrophils, lymphocytes, or monocytes. The finding that the ecalectin transcript is present in abundance in various lymphatic tissues and that its expression increases substantially in antigen-activated peripheral blood mononuclear cells suggests that ecalectin is an important T-cell-derived regulator of eosinophil recruitment in tissues during inflammatory reactions. We believe that this is the first report of the expression of an immunoregulatory galectin expressed by a T-cell line that is selective for eosinophils.	Univ Tokyo, Inst Med Sci, Dept Bacterial Infect, Minato Ku, Tokyo 108, Japan; Hiroshima Univ, Fac Appl Biol Sci, Higashihiroshima 739, Japan; Kagawa Med Sch, Dept Immunol & Immunopathol, Kagawa 76107, Japan; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	University of Tokyo; Hiroshima University; Kagawa University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Matsumoto, R (corresponding author), Univ Tokyo, Inst Med Sci, Dept Bacterial Infect, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	ryoji@hgc.ims.u-tokyo.ac.jp	Kanegasaki, Shiro/AAM-4921-2021					ALMA R, 1997, J ALLERGY CLIN IMMUN, V99, P273; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; COTRAN RS, 1994, ROBBINS PATHOLOGIC B, P771; COTRAN RS, 1994, ROBBINS PATHOLOGIC B, P643; CRAIG SS, 1995, ANAT RECORD, V242, P211, DOI 10.1002/ar.1092420210; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FREW AJ, 1988, J IMMUNOL, V141, P4158; Fukuda T, 1995, J ALLERGY CLIN IMMUN, V96, P1076, DOI 10.1016/S0091-6749(95)70193-1; GAGA M, 1991, J IMMUNOL, V147, P816; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; GRUSS HJ, 1992, CANCER RES, V52, P3353; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRASHIMA M, 1992, LYMPHOKINE CYTOK RES, V11, P331; HIRASHIMA M, 1991, LYMPHOKINE CYTOK RES, V10, P481; HO MK, 1982, J IMMUNOL, V128, P1221; JENG KCG, 1994, IMMUNOL LETT, V42, P113, DOI 10.1016/0165-2478(94)90072-8; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KLEIN S, 1992, HEMATOL ONCOL, V10, P319, DOI 10.1002/hon.2900100605; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; ODA Y, 1993, J BIOL CHEM, V268, P5929; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; RAND TH, 1991, J CLIN INVEST, V88, P825, DOI 10.1172/JCI115383; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; ROTHENBERG ME, 1988, J BIOL CHEM, V263, P13901; SAMOSZUK M, 1990, BLOOD, V75, P13; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SEHMI R, 1991, J IMMUNOL, V147, P2276; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRUONG MJ, 1993, EUR J IMMUNOL, V23, P3230, DOI 10.1002/eji.1830231228; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARRINGA RAJ, 1991, BLOOD, V77, P2694; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	69	221	238	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16976	16984		10.1074/jbc.273.27.16976	http://dx.doi.org/10.1074/jbc.273.27.16976			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642261	hybrid			2022-12-27	WOS:000074545200051
J	Nicolas, E; Beggs, JM; Haltiwanger, BM; Taraschi, TF				Nicolas, E; Beggs, JM; Haltiwanger, BM; Taraschi, TF			A new class of DNA glycosylase apurinic/apyrimidinic lyases that act on specific adenines in single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; T4 ENDONUCLEASE-V; CATALYTIC MECHANISM; DAMAGED DNA; GLYCOSIDASE; EXCISION; REPAIR; RNA; RECOGNITION; RESISTANCE	Although the biological function of DNA glycosylases is to protect the genome by removal of potentially cytotoxic or mutagenic bases, this investigation describes the existence of natural DNA glycosylases with activity on undamaged, nonmispaired bases. Gelonin, pokeweed antiviral protein, and ricin, previously described as ribosome-inactivating proteins, are shown to damage single-stranded DNA by removal of a protein-specific set of adenines and cleavage at the resulting abasic sites. Using an oligonucleotide as the substrate reveals that the reaction proceeds via the enzyme-DNA imino intermediate characteristic of DNA glycosylase/AP lyases. The adenine glycosylase activity on single-stranded DNA reported here challenges the concept that a normal base has to be in a mismatch to be specifically removed. By contrast to other glycosylases, these enzymes are expected to damage DNA rather than participate in repair processes. The significance of this DNase activity to the biological function of these plant proteins and to their toxicity to animal cells remains to be determined.	Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Taraschi, TF (corresponding author), Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Locust St,Rm 229, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI027247, R01AI027247, R01AI041761] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27247, AI-41761] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1994, NATURE, V372, P624, DOI 10.1038/372624a0; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BARBIERI L, 1997, NUCLEIC ACIDS RES, V25, P58; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FRANKEL AE, 1995, SEMIN CANCER BIOL, V6, P307, DOI 10.1006/scbi.1995.0039; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girbes T, 1996, NATURE, V379, P777, DOI 10.1038/379777b0; GO TTM, 1992, LIFE SCI, V51, P1347, DOI 10.1016/0024-3205(92)90634-2; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; IWAI S, 1995, BIOCHEMISTRY-US, V34, P4601, DOI 10.1021/bi00014a013; KAHN JO, 1994, ANTIMICROB AGENTS CH, V38, P260, DOI 10.1128/AAC.38.2.260; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Krokan HE, 1997, BIOCHEM J, V325, P1; LI MX, 1991, NUCLEIC ACIDS RES, V19, P6309, DOI 10.1093/nar/19.22.6309; LING J, 1994, BIOORG CHEM, V22, P395, DOI 10.1006/bioo.1994.1033; LING J, 1995, BIOL CHEM H-S, V376, P637, DOI 10.1515/bchm3.1995.376.11.637; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nicolas E, 1997, FEBS LETT, V406, P162, DOI 10.1016/S0014-5793(97)00267-6; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; Olivieri F, 1996, FEBS LETT, V396, P132, DOI 10.1016/0014-5793(96)01089-7; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P380; RAY T, 1995, ELECTROPHORESIS, V16, P888, DOI 10.1002/elps.11501601149; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; SCHARER OD, 1997, P NATL ACAD SCI USA, V78, P2742; SHAH DM, 1995, TRENDS BIOTECHNOL, V13, P362, DOI 10.1016/S0167-7799(00)88982-9; SHICK VV, 1980, J MOL BIOL, V139, P491, DOI 10.1016/0022-2836(80)90143-6; Stirpe F, 1996, FEBS LETT, V382, P309, DOI 10.1016/0014-5793(96)00188-3; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TELTOW GJ, 1983, ANTIMICROB AGENTS CH, V23, P390, DOI 10.1128/AAC.23.3.390; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	45	56	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17216	17220		10.1074/jbc.273.27.17216	http://dx.doi.org/10.1074/jbc.273.27.17216			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642291	hybrid			2022-12-27	WOS:000074545200081
J	Waugh, MG; Lawson, D; Tan, SK; Hsuan, JJ				Waugh, MG; Lawson, D; Tan, SK; Hsuan, JJ			Phosphatidylinositol 4-phosphate synthesis in immunoisolated caveolae-like vesicles and low buoyant density non-caveolar membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GPI-ANCHORED PROTEINS; KINASE-ACTIVITY; FACTOR RECEPTOR; CELLS; MICRODOMAINS; SECRETION; PIP2; PHOSPHORYLATION; LOCALIZATION	This study examined phosphatidylinositol 4-phosphate (PtdIns4P) synthesis in caveolae that have been suggested to be discrete signaling microdomains of the plasma membrane and are enriched in the marker protein caveolin. Caveolin-rich light membranes (CLMs) were isolated from A431 cells by detergent-free, discontinuous density-gradient centrifugation method. The CLM fraction was separated from the bulk of the cellular protein and was greatly enriched in PtdIns, PtdIns4P, and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) and an adenosine-sensitive type II PtdIns 4-kinase activity. Preparation of CLMs by an OptiPrep-based cell fractionation procedure confirmed the co-localization of PtdIns 4-kinase and caveolin, Electron microscopy confirmed that an anti-caveolin antiserum immunopurified vesicles from CLMs that were within the size range described for caveolae in other systems, Co-immunoprecipitated PtdIns C-kinase activity could utilize endogenous PtdIns, present within the caveolae-like vesicles, to produce PtdIns4P, The addition of recombinant phosphatidylinositol transfer protein increased PtdIns 4-kinase activity both in immunoisolated caveolae and CLMs. However, less than 1% of the total cellular PtdIns and PtdIns 4-kinase activity was present in caveolae-like vesicles, indicating that non-caveolar light membrane rafts are the main site for cellular PtdIns4P production.	UCL, Sch Med, Ludwig Inst Canc Res, London W1P 8BT, England; Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; University of London; University College London	Hsuan, JJ (corresponding author), UCL, Sch Med, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1P 8BT, England.	justin@ludwig.ucl.ac.uk	Waugh, Mark/K-5232-2013; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Waugh, Mark/0000-0002-7241-3168				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Batty IH, 1998, BIOCHEM J, V330, P1069; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BROWN D, 1992, J AM SOC NEPHROL, V3, P895; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNS RR, 1968, J CELL BIOL, V37, P244, DOI 10.1083/jcb.37.2.244; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COCHET C, 1991, J BIOL CHEM, V266, P637; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; IMAI A, 1987, NATURE, V325, P726, DOI 10.1038/325726a0; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; LAWSON D, 1983, J CELL BIOL, V97, P1891, DOI 10.1083/jcb.97.6.1891; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; PIKE MC, 1988, J IMMUNOL, V140, P1967; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353	59	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17115	17121		10.1074/jbc.273.27.17115	http://dx.doi.org/10.1074/jbc.273.27.17115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642278	hybrid			2022-12-27	WOS:000074545200068
J	Arnold, DA; Bianco, PR; Kowalczykowski, SC				Arnold, DA; Bianco, PR; Kowalczykowski, SC			The reduced levels of chi recognition exhibited by the RecBC(1004)D enzyme reflect its recombination defect in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECBCD ENZYME; HOT SPOT ACTIVITY; ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS RECOMBINATION; BACTERIOPHAGE-LAMBDA; RECB(2109)CD ENZYME; HELICASE ACTIVITY; NUCLEASE ACTIVITY; HOTSPOT ACTIVITY	Homologous recombination in Escherichia coli is initiated by the RecBCD enzyme and is stimulated by an 8-nucleotide element known as Chi (chi) We present a detailed biochemical characterization of a mutant RecBCD enzyme, designated RecBC(1004)D, that displays a reduced level of chi site recognition. Initially characterized genetically as unable to respond to the chi sequence, we provide evidence to indicate that the ability of this mutant enzyme to respond to chi is reduced rather than lost; the mutant displays about 20-fold lower chi recognition than wild-type RecBCD enzyme. Although this enzyme exhibits wild-type levels of double-stranded DNA exonuclease, helicase, and ATPase activity, its ability to degrade single-stranded DNA is enhanced 2-3-fold. The data presented here suggest that the reduced recombination proficiency of the recBC(1004)D strain observed in vivo results from a basal level of modification of the RecBC(1004)D enzyme at both chi-specific, as well as nonspecific, DNA sequences.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Genet Grad Grp, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, 1 Shields Ave, Davis, CA 95616 USA.	sckowalczykowski@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1613; CAPALDOK.F, 1971, J BACTERIOL, V106, P204, DOI 10.1128/JB.106.1.204-212.1971; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHENG KC, 1984, J MOL BIOL, V180, P371, DOI 10.1016/S0022-2836(84)80009-1; CHENG KC, 1987, J MOL BIOL, V194, P747, DOI 10.1016/0022-2836(87)90252-X; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; EGGLESTON AK, 1993, J MOL BIOL, V231, P621, DOI 10.1006/jmbi.1993.1314; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EICHLER DC, 1977, J BIOL CHEM, V252, P499; EMMERSON PT, 1968, GENETICS, V60, P19; ENNIS DG, 1987, GENETICS, V115, P11; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Handa N, 1997, GENES CELLS, V2, P525, DOI 10.1046/j.1365-2443.1997.1410339.x; HOWARD-FLANDERS P., 1966, Radiation Research, V6, P156, DOI 10.2307/3583555; KOPPEN A, 1995, P NATL ACAD SCI USA, V92, P6249, DOI 10.1073/pnas.92.14.6249; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MURPHY KC, 1994, J BIOL CHEM, V269, P22507; MYERS RS, 1995, P NATL ACAD SCI USA, V92, P6244, DOI 10.1073/pnas.92.14.6244; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; SCHULTZ DW, 1983, J BACTERIOL, V155, P664, DOI 10.1128/JB.155.2.664-680.1983; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1977, GENETICS, V86, P715; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TELANDERMUSKAVI.KM, 1982, J BIOL CHEM, V257, P2641; VINOGRAD J, 1966, J GEN PHYSIOL, V49, P103, DOI 10.1085/jgp.49.6.103	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16476	16486		10.1074/jbc.273.26.16476	http://dx.doi.org/10.1074/jbc.273.26.16476			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632715	hybrid			2022-12-27	WOS:000074436600086
J	Ciesla, WP; Bobak, DA				Ciesla, WP; Bobak, DA			Clostridium difficile toxins A and B are cation-dependent UDP-glucose hydrolases with differing catalytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE; RHO-PROTEINS; CHOLERAGEN; ACTIVATION; MECHANISM	Toxins A and B of Clostridium difficile are UDP-glucose glucosyltransferases that exert their cellular toxicity primarily through their abilities to monoglucosylate, and thereby inactivate, Rho family small GTPases. Toxin A also hydrolyzes UDP-glucose, although this activity is not well characterized. In this study, we measured the kinetics of UDP-glucose hydrolysis by toxins A and Il and found significant differences in the catalytic activities of these two structurally homologous toxins. The toxins displayed similar Michaelis constants (K-m) for UDP-glucose, but the maximal velocity (V-max) of toxin B was similar to 5-fold greater than that of toxin A. Toxins A and B exert their enzymatic actions intracellularly, and, interestingly, we found that each toxin absolutely required K+ for optimal hydrolase activity; Na+ was inactive. The toxins also required certain divalent cations for activity and exhibited a significantly greater V-max and lower K-m in the presence of Mn2+ as compared with Mg2+. We conclude that C. difficile toxins A and B are cation-dependent UDP-glucose hydrolases that differ significantly in their catalytic activities, a finding that may have important implications in understanding their different cytotoxic effects.	Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Bobak, DA (corresponding author), Univ Virginia, Sch Med, Dept Med, Box 485-HSC, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054572] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32 AI07046] Funding Source: Medline; NIGMS NIH HHS [R01GM54572] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; BONAGAERTS GPA, 1994, MICROB PATHOG, V17, P1; BONGAERTS GPA, 1994, MICROB PATHOGENESIS, V17, P1, DOI 10.1006/mpat.1994.1047; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; CONSLER TG, 1988, J BIOL CHEM, V263, P2794; GLASER L, 1967, J BIOL CHEM, V242, P1944; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hofmann F, 1997, J BIOL CHEM, V272, P11074; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KACHMAR JF, 1953, J BIOL CHEM, V200, P669; LAUGHLIN MR, 1988, J BIOL CHEM, V263, P2285; Lyerly David M., 1995, P867; LYERLY DM, 1985, INFECT IMMUN, V47, P349, DOI 10.1128/IAI.47.2.349-352.1985; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MONCRIEF JS, 1997, CLOSTRIDIA MOL BIOL, P370; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; MOSS J, 1977, J BIOL CHEM, V252, P2455; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; NOWAK T, 1981, MOL CELL BIOCHEM, V35, P65, DOI 10.1007/BF02354821; RIEGLER M, 1995, J CLIN INVEST, V95, P2004, DOI 10.1172/JCI117885; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; Thorne J. E., 1995, Journal of Investigative Medicine, V43, p291A; VILLEMEZ CL, 1979, J BIOL CHEM, V254, P4814; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; VONEICHELSTREIBER C, 1992, MOL GEN GENET, V233, P260, DOI 10.1007/BF00587587; Wedler F C, 1993, Prog Med Chem, V30, P89, DOI 10.1016/S0079-6468(08)70376-X; ZAKIM D, 1973, BIOCHEM BIOPH RES CO, V52, P453, DOI 10.1016/0006-291X(73)90733-X	34	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16021	16026		10.1074/jbc.273.26.16021	http://dx.doi.org/10.1074/jbc.273.26.16021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632652	hybrid			2022-12-27	WOS:000074436600023
J	Severinov, K; Muir, TW				Severinov, K; Muir, TW			Expressed protein ligation, a novel method for studying protein-protein interactions in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; CHEMICAL LIGATION; SIGMA-70 SUBUNIT; PROMOTER; CONSTRUCTION; ACTIVATION; FRAGMENTS; SEQUENCES; PEPTIDES; TARGET	Expressed protein ligation is a novel protein semisynthesis method that permits the in vitro ligation of a chemically synthesized C-terminal segment of a protein to a recombinant N-terminal segment fused through its C terminus to an intein protein splicing element. In principle, the practical convenience of this method, combined with the expanded opportunities in protein engineering that it provides, makes it well suited for probing the molecular basis of complex processes such as transcription. Here we describe the successful application of expressed protein ligation to the similar to 600 amino acid sigma(70) subunit of Escherichia coli RNA polymerase. The resulting semi-synthetic sigma(70) constructs are shown to be fully functional and have been used to map the binding region of the bacteriophage T4 anti-sigma protein, AsiA, to within amino acids 567-600 of sigma(70). The success of these semi-synthesis studies sets the stage for the future generation of semi-synthetic sigma(70) molecules in which unnatural amino acids and biophysical probes are site-specifically incorporated in the RNA polymerase complex.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rockefeller University	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.		Wood, David W/B-2992-2012; Severinov, Konstantin/C-8545-2016; Muir, Tom/AHD-0860-2022	Muir, Tom/0000-0001-9635-0344	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055843, R29GM055843] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55843] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURTON Z, 1981, NUCLEIC ACIDS RES, V9, P2889, DOI 10.1093/nar/9.12.2889; Camarero JA, 1998, J PEPT RES, V51, P303; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; GAERTNER HF, 1992, BIOCONJUGATE CHEM, V3, P262, DOI 10.1021/bc00015a010; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIU CF, 1994, J AM CHEM SOC, V116, P4149, DOI 10.1021/ja00089a001; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MINCHIN S, 1993, BIOCHEM J, V289, P771, DOI 10.1042/bj2890771; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; MUIR TW, 1995, STRUCTURE, V3, P649, DOI 10.1016/S0969-2126(01)00200-3; MUIR TW, 1998, IN PRESS P NATL ACAD; NEFZI A, 1995, TETRAHEDRON LETT, V36, P229, DOI 10.1016/0040-4039(94)02230-9; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; WALLACE CJA, 1995, CURR OPIN BIOTECH, V6, P403, DOI 10.1016/0958-1669(95)80069-7; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	31	160	198	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16205	16209		10.1074/jbc.273.26.16205	http://dx.doi.org/10.1074/jbc.273.26.16205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632677	hybrid			2022-12-27	WOS:000074436600048
J	Smine, A; Xu, XM; Nishiyama, K; Katada, T; Gambetti, P; Yadav, SP; Wu, X; Shi, YC; Yasuhara, S; Homburger, V; Okamoto, T				Smine, A; Xu, XM; Nishiyama, K; Katada, T; Gambetti, P; Yadav, SP; Wu, X; Shi, YC; Yasuhara, S; Homburger, V; Okamoto, T			Regulation of brain G-protein G(o) by Alzheimer's disease gene presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC-G-PROTEINS; IN-VIVO; ENDOPLASMIC-RETICULUM; MISSENSE MUTATIONS; GLIOMA-CELLS; PRECURSOR; RECEPTOR; TRANSPORT; TOXIN; LOCALIZATION	To investigate a possible association between G-proteins and presenilin-1 (PS-1), a series of glutathione S-transferase-fusion proteins containing portions of PS-1 were prepared and used in vitro in binding experiments with tissue and recombinant G-proteins. The results demonstrate that the 39 C-terminal amino acids of PS-1 selectively bind the brain G-protein, G(o). Addition of guanosine 5'-3-O-(thio)triphosphate promoted G(o) dissociation from PS-1, indicating that this domain mimics the function of G-protein-coupling domains found in receptors. The 39-amino acid synthetic polypeptide activated G(o) in a magnesium ion-dependent manner, Physical interaction of full-length PS-1 and G(o) was also demonstrated. Following transfection of G(o alpha) and N-terminally FLAG-tagged PS-1 in COS-7 cells, G(o) was immunoprecipitated by FLAG antibodies. In addition, endogenous PS-1 and G(o alpha) were colocalized immunocytochemically in human glioma cell lines. The results indicate that PS-1 regulates G(o) activities in living cells.	Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mol Biotechnol Core Facil, Cleveland, OH 44195 USA; Univ Tokyo, Fac Pharmaceut Sci, Tokyo 113, Japan; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA; CNRS, UPR 9023, CCIPE, F-34094 Montpellier 5, France	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Tokyo; Case Western Reserve University; Harvard University; Massachusetts General Hospital; Centre National de la Recherche Scientifique (CNRS)	Okamoto, T (corresponding author), Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	OKAMOTT@CESMTP.CCF.ORG		xu, xuemin/0000-0002-7426-272X	NIMH NIH HHS [MH-56036] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DUBOIS DH, 1995, ADV EXP MED BIOL, V376, P105; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAYASHI Y, 1992, BIOCHEM BIOPH RES CO, V187, P1249, DOI 10.1016/0006-291X(92)90437-P; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATADA T, 1994, METHOD ENZYMOL, V237, P131; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; Lagriffoul A, 1996, J BIOL CHEM, V271, P31508, DOI 10.1074/jbc.271.49.31508; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; MULLER L, 1994, MOL CELL NEUROSCI, V5, P556, DOI 10.1006/mcne.1994.1068; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; OKAMOTO T, 1931, CELL, V709, P90; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STOW JL, 1993, J CELL SCI, P33; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	47	48	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16281	16288		10.1074/jbc.273.26.16281	http://dx.doi.org/10.1074/jbc.273.26.16281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632688	hybrid			2022-12-27	WOS:000074436600059
J	Wilson, MC; Jackson, VN; Heddle, C; Price, NT; Pilegaard, H; Juel, C; Bonen, A; Montgomery, I; Hutter, OF; Halestrap, AP				Wilson, MC; Jackson, VN; Heddle, C; Price, NT; Pilegaard, H; Juel, C; Bonen, A; Montgomery, I; Hutter, OF; Halestrap, AP			Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL GIANT VESICLES; INTRACELLULAR PH INDICATOR; LACTATE TRANSPORTER; CDNA CLONING; INHIBITOR SPECIFICITY; FIBER TYPE; RAT; CELLS; IDENTIFICATION; SUBSTRATE	The newly cloned proton-linked monocarboxylate transporter MCT3 was shown by Western blotting and immunofluorescence confocal microscopy to be expressed in all muscle fibers. In contrast, MCT1 is expressed most abundantly in oxidative fibers but is almost totally absent in fast-twitch glycolytic fibers. Thus MCT3 appears to be the major MCT isoform responsible for efflux of glycolytically derived lactic acid from white skeletal muscle. MCT3 is also expressed in several other tissues requiring rapid lactic acid efflux. The expression of both MCT3 and MCT1 was decreased by 40-60% 3 weeks after denervation of rat hind limb muscles, whereas chronic stimulation of the muscles for 7 days increased expression of MCT1 2-3-fold but had no effect on MCT3 expression. The kinetics and substrate and inhibitor specificities of monocarboxylate transport into cell lines expressing only MCT3 or MCT1 have been determined. Differences in the properties of MCT1 and MCT3 are relatively modest, suggesting that the significance of the two isoforms may be related to their regulation rather than their intrinsic properties.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Copenhagen, August Krogh Inst, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Univ Glasgow, Dept Physiol, Glasgow G12 8QQ, Lanark, Scotland	University of Bristol; University of Copenhagen; University of Waterloo; University of Glasgow	Halestrap, AP (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	a.halestrap@Bristol.ac.uk	Halestrap, Andrew P/G-7275-2011; Juel, Carsten/J-5328-2014; Pilegaard, Henriette/M-2315-2014	Juel, Carsten/0000-0002-2373-6358; Pilegaard, Henriette/0000-0002-1071-0327; Wilson, Marieangela/0000-0001-6218-3533; Halestrap, Andrew/0000-0001-5374-2778	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; Carpenter L, 1996, BBA-BIOMEMBRANES, V1279, P157, DOI 10.1016/0005-2736(95)00254-5; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DOYLE FA, 1992, BIOCHEM J, V281, P95, DOI 10.1042/bj2810095; GARCIA CK, 1994, GENOMICS, V23, P500, DOI 10.1006/geno.1994.1532; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Halestrap AP, 1997, AM J CARDIOL, V80, pA17, DOI 10.1016/S0002-9149(97)00454-2; Handberg A, 1996, AM J PHYSIOL-ENDOC M, V271, pE50, DOI 10.1152/ajpendo.1996.271.1.E50; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; JACKSON VN, 1995, BBA-BIOMEMBRANES, V1238, P193, DOI 10.1016/0005-2736(95)00160-5; Johannsson E, 1997, CIRC RES, V80, P400, DOI 10.1161/01.res.0000435856.47954.71; JUEL C, 1991, ACTA PHYSIOL SCAND, V143, P361, DOI 10.1111/j.1748-1716.1991.tb09246.x; Juel C, 1996, BBA-BIOMEMBRANES, V1283, P106, DOI 10.1016/0005-2736(96)00084-3; Juel C, 1997, PHYSIOL REV, V77, P321, DOI 10.1152/physrev.1997.77.2.321; MASON MJ, 1988, J PHYSIOL-LONDON, V400, P459, DOI 10.1113/jphysiol.1988.sp017132; McCullagh KJA, 1997, AM J PHYSIOL-ENDOC M, V273, pE239, DOI 10.1152/ajpendo.1997.273.2.E239; McCullagh KJA, 1996, AM J PHYSIOL-ENDOC M, V271, pE143, DOI 10.1152/ajpendo.1996.271.1.E143; PHILP N, 1995, EXP CELL RES, V219, P64, DOI 10.1006/excr.1995.1205; PILEGAARD H, 1995, AM J PHYSIOL-ENDOC M, V269, pE679, DOI 10.1152/ajpendo.1995.269.4.E679; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Poole RC, 1997, J BIOL CHEM, V272, P14624, DOI 10.1074/jbc.272.23.14624; Price NT, 1998, BIOCHEM J, V329, P321; Spurway NC, 1996, J ANAT, V188, P455; Wang X, 1996, AM J PHYSIOL-HEART C, V270, pH476, DOI 10.1152/ajpheart.1996.270.2.H476; WANG XM, 1994, AM J PHYSIOL-HEART C, V267, pH1759, DOI 10.1152/ajpheart.1994.267.5.H1759; WANG XM, 1993, BIOCHEM J, V290, P249, DOI 10.1042/bj2900249; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588; ZHANG B, 1991, J BIOL CHEM, V266, P990	32	225	228	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15920	15926		10.1074/jbc.273.26.15920	http://dx.doi.org/10.1074/jbc.273.26.15920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632638	hybrid			2022-12-27	WOS:000074436600009
J	Spillmann, D; Witt, D; Lindahl, U				Spillmann, D; Witt, D; Lindahl, U			Defining the interleukin-8-binding domain of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; NEUTROPHIL ELASTASE; BINDING; CHEMOKINES; GLYCOSAMINOGLYCANS; CYTOKINES; PROTEOGLYCANS; ANTITHROMBIN; MECHANISM	Interleukin-8, a member of the CXC chemokine family, has been shown to bind to glycosaminoglycans, It has been suggested that heparan sulfate on cell surfaces could provide specific ligand sites on endothelial cells to retain the highly diffusible inflammatory chemokine for presentation to leukocytes, By using selectively modified heparin and heparan sulfate fragments in a nitrocellulose filter trapping system, we have analyzed sequence requirements for interleukin-8 binding to heparin/heparan sulfate. We demonstrate that the affinity of a monomeric interleukin-8 molecule for heparin/ heparan sulfate is too weak to allow binding at physiological ionic strength, whereas the dimeric form of the protein mediates binding to two sulfated domains of heparan sulfate. These domains, each :In N-sulfated block of similar to 6 monosaccharide units, are contained within an similar to 22-24-mer sequence and are separated by a region of less than or equal to 14 monosaccharide residues that may be fully N-acetylated. Binding to interleukin-8 correlates with the occurrence of the di-O-sulfated disaccharide unit -Id-ceA(2-OSO3)-GlcNSO(3)(6-OSO3)-. We suggest that the heparan sulfate sequence binds in horseshoe fashion over two antiparallel-oriented helical regions on the dimeric protein.	Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Repligen Corp, Needham, MA 02194 USA	Uppsala University	Spillmann, D (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, POB 575, S-75123 Uppsala, Sweden.							Atkins E D, 1975, Adv Exp Med Biol, V52, P19; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CADENE M, 1995, J BIOL CHEM, V270, P13204, DOI 10.1074/jbc.270.22.13204; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DALY TJ, 1995, J BIOL CHEM, V270, P23282, DOI 10.1074/jbc.270.40.23282; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NIEDUSZYNSKI IA, 1977, ACS SYM SER, V48, P73; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Thiery Jean Paul, 1992, Current Opinion in Cell Biology, V4, P782, DOI 10.1016/0955-0674(92)90101-H; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	48	227	237	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15487	15493		10.1074/jbc.273.25.15487	http://dx.doi.org/10.1074/jbc.273.25.15487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624135	hybrid			2022-12-27	WOS:000074284200029
J	Thurmond, DC; Baillie, RA; Goodridge, AG				Thurmond, DC; Baillie, RA; Goodridge, AG			Regulation of the action of steroid/thyroid hormone receptors by medium-chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; PROLIFERATOR-ACTIVATED RECEPTORS; S14 GENE-TRANSCRIPTION; MALIC ENZYME GENE; THYROID-HORMONE; TRANSACTIVATION DOMAIN; FUNCTIONAL-ANALYSIS; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; ORPHAN RECEPTORS	Triiodothyronine (T-3) causes a 30-fold increase in transcription of the malic enzyme gene in chick embryo hepatocytes; medium-chain fatty acids (MCFAs) inhibit this increase. T-3 action is mediated by T-3 receptors (TRs) that bind to T-3 response elements (T3REs) in this gene's 5'-flanking DNA. In transiently transfected hepatocytes, fragments of 5'-flanking DNA of the malic enzyme gene or artificial T3REs that conferred T-3 stimulation also conferred MCFA inhibition to linked reporter genes, Thus, MCFA inhibition may be mediated through cis-acting T3REs and trans-acting TRs, distinguishing MCFA action from that of other fatty acids which act through unique sequence elements. Using binding assays and overexpression of TR, we showed that MCFAs inhibited the transactivating but not the silencing function of TR and did not alter binding of T-3 Ito TR or of TR to T3RE. The C-terminal ligand-binding domain of TR was sufficient to confer stimulation by T-3, but not inhibition by MCFA. Inhibition of transactivation by MCFA was specific: ligand-stimulated transcription from T-3 or estrogen response elements was inhibited, but that from glucocorticoid or cyclic AMP response elements was mot. We propose that MCFAs or metabolites thereof influence the activity of a factor(s) that interacts with the T-3 and estrogen receptors to inhibit ligand-stimulated transcription.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Goodridge, AG (corresponding author), Ohio State Univ, Coll Biol Sci, 484 W 12th Ave, Columbus, OH 43210 USA.		baillie, rebecca/AAQ-3400-2020	baillie, rebecca/0000-0003-3966-6320	NIDDK NIH HHS [DK 21594, DK 25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R01DK021594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BAJAR A, 1991, P NATL ACAD SCI USA, V88, P8208, DOI 10.1073/pnas.88.18.8208; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CHRISTENSEN E, 1991, BIOCHIM BIOPHYS ACTA, V1081, P167, DOI 10.1016/0005-2760(91)90022-A; CONOVER W. J, 1980, PRACTICAL NONPARAMET; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodridge AG, 1996, PROG NUCLEIC ACID RE, V52, P89, DOI 10.1016/S0079-6603(08)60965-4; GOODRIDGE AG, 1968, BIOCHEM J, V108, P655, DOI 10.1042/bj1080655; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1989, J NUTR, V119, P299, DOI 10.1093/jn/119.2.299; GREENE S, 1990, MUTAT RES, V333, P101; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; INOUE A, 1989, EUR J BIOCHEM, V183, P565, DOI 10.1111/j.1432-1033.1989.tb21085.x; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA XJ, 1990, J BIOL CHEM, V265, P18435; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; ONATE SA, 1995, SCIENCE, V270, P1354; ORELLANA M, 1993, FEBS LETT, V322, P61, DOI 10.1016/0014-5793(93)81111-C; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PODILA GK, 1988, SCIENCE, V242, P922, DOI 10.1126/science.242.4880.922; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; RONCERO C, 1992, J BIOL CHEM, V267, P14918; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J., 2002, MOL CLONING LAB MANU; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Thurmond DC, 1998, J BIOL CHEM, V273, P1613, DOI 10.1074/jbc.273.3.1613; TONE Y, 1994, J BIOL CHEM, V269, P31157; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSERNG KY, 1991, BIOCHEMISTRY-US, V30, P2508, DOI 10.1021/bi00223a030; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIERSINGA WM, 1988, METABOLISM, V37, P996, DOI 10.1016/0026-0495(88)90159-X; WOLOSHUK CP, 1986, P NATL ACAD SCI USA, V83, P1704, DOI 10.1073/pnas.83.6.1704; Zhang X, 1996, J BIOL CHEM, V271, P14825, DOI 10.1074/jbc.271.25.14825	50	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15373	15381		10.1074/jbc.273.25.15373	http://dx.doi.org/10.1074/jbc.273.25.15373			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624119	hybrid			2022-12-27	WOS:000074284200013
J	Ruano, MLF; Perez-Gil, J; Casals, C				Ruano, MLF; Perez-Gil, J; Casals, C			Effect of acidic pH on the structure and lipid binding properties of porcine surfactant protein A - Potential role of acidification among its exocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG LAMELLAR BODIES; TRANS-GOLGI NETWORK; PULMONARY SURFACTANT; SP-A; II CELLS; SECRETORY GRANULES; SP-B; BIOPHYSICAL ACTIVITY; INTRACELLULAR PH; CHROMOGRANIN-B	Pulmonary surfactant protein A (SP-A) is synthesized by type II cells and stored intracellularly in secretory granules (lamellar bodies) together with surfactant lipids and hydrophobic surfactant proteins B and C (SP-B and SP-C), We asked whether the progressive decrease in pH along the exocytic pathway could influence the secondary structure and lipid binding and aggregation properties of porcine SP-A. Conformational analysis from CD spectra of SP-A at various pH values indicated that the percentage of alpha-helix progressively decreased and that of beta-sheet increased as the pH was reduced. The protein underwent a marked self-aggregation at mildly acidic pH in the presence of Ca2+, conditions thought to resemble those existing in the trans-Golgi network. Protein aggregation was greater as the pH was reduced. We also found that both neutral and acidic vesicles either with or without SP-B or SP-C bound to SP-A at acidic pH as demonstrated by co-migration during centrifugation. However, the binding of acidic but not neutral vesicles to SP-A led to 1) a striking change in the CD spectra of the protein, which was interpreted as a decrease of the level of SP-A self-aggregation, and 2) a protection of the protein from endoproteinase Glu-C degradation at pH 4.5. SP-A massively aggregated acidic vesicles but poorly aggregated neutral vesicles at acidic pH. Aggregation of dipalmitoylphosphatidylcholine (DPPC) vesicles either with or without SP-B and/or SP-C strongly depended on pH, being progressively decreased as the pH was reduced and markedly increased when pH was shifted back to 7.0. At the pH of lamellar bodies, SP-A-induced aggregation of DPPC vesicles containing SP-B or a mixture of SP-B and SP-C was very low, although SP-A bound to these vesicles. These results indicate that I) DPPC binding and DPPC aggregation are different phenomena that probably have different SP-A structural requirements and 2) aggregation of membranes induced by SP-A at acidic pH is critically dependent on the presence of acidic phospholipids, which affect protein structure, probably preventing the formation of large aggregates of protein.	Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Casals, C (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, E-28040 Madrid, Spain.		Casals, Cristina/H-4658-2015; Perez-Gil, Jesus/H-3102-2019	Casals, Cristina/0000-0003-2696-0918; Perez-Gil, Jesus/0000-0003-3587-7147				Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; CASALS C, 1994, BIOCHEM SOC T, V22, pS370, DOI 10.1042/bst022370s; CASALS C, 1989, BIOCHIM BIOPHYS ACTA, V1003, P201, DOI 10.1016/0005-2760(89)90256-7; CASALS C, 1993, BIOCHEM J, V296, P585, DOI 10.1042/bj2960585; Casals C, 1998, AM J RESP CRIT CARE, V157, P43, DOI 10.1164/ajrccm.157.1.9611106; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANDER A, 1986, J BIOL CHEM, V261, P6126; Chander A, 1996, BIOCHEM J, V318, P271, DOI 10.1042/bj3180271; CHANDER A, 1991, BIOCHIM BIOPHYS ACTA, V1086, P157, DOI 10.1016/0005-2760(91)90003-Z; CHANDER A, 1989, AM J PHYSIOL, V257, pL354, DOI 10.1152/ajplung.1989.257.6.L354; CHANDER A, 1990, AM J PHYSIOL, V258, P241; Clements JA, 1997, ANNU REV PHYSIOL, V59, P1, DOI 10.1146/annurev.physiol.59.1.1; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; ECKENHOFF RG, 1989, J CLIN INVEST, V84, P1295, DOI 10.1172/JCI114297; EFRATI H, 1987, BIOCHEMISTRY-US, V26, P7986, DOI 10.1021/bi00398a066; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hawgood S, 1992, PULMONARY SURFACTANT, P33; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; KING RJ, 1983, J BIOL CHEM, V258, P672; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PEREZGIL J, 1993, BIOCHIM BIOPHYS ACTA, V1168, P261, DOI 10.1016/0005-2760(93)90181-8; PEREZGIL J, 1995, BIOCHEMISTRY-US, V34, P3964, DOI 10.1021/bi00012a014; POULAIN FR, 1992, AM J PHYSIOL, V262, pL730, DOI 10.1152/ajplung.1992.262.6.L730; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSS GF, 1986, J BIOL CHEM, V261, P14283; ROUSER G, 1966, LIPIDS, V12, P505; Ruano MLF, 1996, BIOCHEM J, V313, P683, DOI 10.1042/bj3130683; SCHLAME M, 1988, BIOCHEM J, V253, P209, DOI 10.1042/bj2530209; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VANIWAARDEN JF, 1995, LUNG BIOL HEALTH DIS, V84, P75; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOUNG SL, 1989, J APPL PHYSIOL, V66, P1336, DOI 10.1152/jappl.1989.66.3.1336	49	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15183	15191		10.1074/jbc.273.24.15183	http://dx.doi.org/10.1074/jbc.273.24.15183			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614132	hybrid			2022-12-27	WOS:000074160400074
J	Krause, KH; Fivaz, M; Monod, A; van der Goot, FG				Krause, KH; Fivaz, M; Monod, A; van der Goot, FG			Aerolysin induces G-protein activation and Ca2+ release from intracellular stores in human granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING TOXIN AEROLYSIN; STAPHYLOCOCCAL ALPHA-TOXIN; ESCHERICHIA-COLI HEMOLYSIN; PLANAR LIPID BILAYERS; AEROMONAS-HYDROPHILA; HUMAN-NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; PROTEOLYTIC ACTIVATION; HL-60 CELLS; CHANNEL	Aerolysin is a pore-forming toxin that plays a key role in the pathogenesis of Aeromonas hydrophila infections. In this study, we have analyzed the effect of aerolysin on human granulocytes (HL-60 cells). Proaerolysin could bind to these cells, was processed into active aerolysin, and led to membrane depolarization, indicating that granulocytes are potential targets for this toxin, Fura-a measurements were used to analyze the effect of aerolysin lysin on cytosolic [Ca2+] homeostasis. As expected for a pore-forming toxin, aerolysin addition led to Ca2+ influx across the plasma membrane. In addition, the toxin triggered Ca2+ release from agonist and thapsigargin-sensitive intracellular Ca2+ stores. This Ca2+ release was independent of the aerolysin-induced Ca2+ influx and occurred in two kinetically distinct phases: an initial rapid and transient phase and a second, more sustained, phase. The first, but not the second phase was sensitive to pertussis toxin, Activation of pertussis toxin-sensitive G-proteins appeared to be a consequence of pore formation, rather than receptor activation through aerolysin-binding, as ik (i) was not observed with a binding competent, insertion-incompetent aerolysin mutant, (ii) had a marked lag time, and (iii) was also observed in response to other bacterial pore-forming toxins (staphylococcal alpha-toxin, streptolysin O) which are thought to bind to different receptors, G-protein activation through pore-forming toxins stimulated cellular functions, as evidenced by pertussis toxin-sensitive chemotaxis. Our results demonstrate that granulocytes are potential target cells for aerolysin and that in these cells, Ca2+ signaling in response to a pore-forming toxin involves G-protein-dependent cell activation and Ca2+ release from intracellular stores.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Hosp, Div Infect Dis, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	van der Goot, FG (corresponding author), Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland.		van der Goot, Gisou G/B-2279-2012; Krause, Karl-Heinz/E-8030-2011	van der Goot, Gisou G/0000-0002-8522-274X; Krause, Karl-Heinz/0000-0002-9033-6768; Fivaz, Marc/0000-0003-1003-7934				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; CHAKRABORTY T, 1987, INFECT IMMUN, V55, P2274, DOI 10.1128/IAI.55.9.2274-2280.1987; COWLL S, 1997, MOL MICROBIOL, V25, P343; CYBULSKY AV, 1989, AM J PHYSIOL, V257, pF826, DOI 10.1152/ajprenal.1989.257.5.F826; DAILY OP, 1981, J CLIN MICROBIOL, V13, P769, DOI 10.1128/JCM.13.4.769-777.1981; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; DONTA ST, 1978, INFECT IMMUN, V21, P989, DOI 10.1128/IAI.21.3.989-993.1978; FINK D, 1989, CELL SIGNAL, V1, P387, DOI 10.1016/0898-6568(89)90057-0; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GRIMMINGER F, 1991, J CLIN INVEST, V88, P1531, DOI 10.1172/JCI115463; Grimminger F, 1997, J IMMUNOL, V159, P1909; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JANDA JM, 1984, J CLIN MICROBIOL, V17, P588; JIN GF, 1992, FEMS MICROBIOL LETT, V98, P285; KAPER JB, 1981, J APPL BACTERIOL, V50, P359, DOI 10.1111/j.1365-2672.1981.tb00900.x; KASNER SE, 1992, AM J PHYSIOL, V262, pF462, DOI 10.1152/ajprenal.1992.262.3.F462; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; MORGAN BP, 1985, BIOCHEM J, V231, P205, DOI 10.1042/bj2310205; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; SCHLIZ M, 1995, EUR J DERMATOL, V5, P54; STAALI L, 1998, IN PRESS BACTERIAL P; SUTTORP N, 1988, INFECT IMMUN, V56, P2228, DOI 10.1128/IAI.56.9.2228-2234.1988; TschodrichRotter M, 1996, BIOPHYS J, V70, P723, DOI 10.1016/S0006-3495(96)79612-1; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1994, J BIOL CHEM, V269, P30496; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	39	62	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18122	18129		10.1074/jbc.273.29.18122	http://dx.doi.org/10.1074/jbc.273.29.18122			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660770	hybrid			2022-12-27	WOS:000074828500025
J	Noda, Y; Mamiya, T; Nabeshima, T; Nishi, M; Higashioka, M; Takeshima, H				Noda, Y; Mamiya, T; Nabeshima, T; Nishi, M; Higashioka, M; Takeshima, H			Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTORS; ORPHANIN-FQ; NEUROPEPTIDE; AGONIST; OPIATE	Nociceptin and nociceptin receptor, which show structural similarities to opioid peptides and opioid receptors, respectively, have been recently found to constitute a novel neuromodulatory system. In the brain, however, the physiological role of the modulation via the nociceptin receptor is still unclear. Administered nociceptin produces hyperalgesia and hypolocomotion, whereas the nociceptin receptor-knockout mice show no significant abnormalities in nociceptive thresholds and locomotion. To clarify possible involvement of the nociceptin receptor in the regulation of nociception and locomotion, we made use of the knockout mice and naloxone benzoylhydrazone (NalBzoH) identified originally as a ligand for opioid receptors, Experiments on the cultured cells transfected with the nociceptin receptor cDNA showed that NalBzoH competed with [H-3]nociceptin binding and attenuated the nociceptin-induced inhibition of cAMP accumulation. Furthermore, behavioral studies demonstrated that NalBzoH completely inhibited nociceptin-induced hyperalgesia and hypolocomotion. It is therefore likely that NalBzoH can act as a potent antagonist for the nociceptin receptor in vivo. In wild-type mice, NalBzoH induced antinociception but did not affect locomotor activity. In contrast, in the knockout mice, no significant changes in nociception and locomotion were induced by NalBzoH. These results clearly suggest that the nociceptin system takes part in the physiological regulation of nociceptive thresholds but not in the basal modulation of locomotion.	Nagoya Univ, Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138564, Japan	Nagoya University; University of Tokyo	Nabeshima, T (corresponding author), Nagoya Univ, Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Showa Ku, Nagoya, Aichi 4668560, Japan.			Takeshima, Hiroshi/0000-0003-4525-3725				CLARK JA, 1989, J PHARMACOL EXP THER, V251, P889; Devine DP, 1996, NEUROCHEM RES, V21, P1387, DOI 10.1007/BF02532380; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GISTRAK MA, 1989, J PHARMACOL EXP THER, V251, P469; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Mamiya T, 1998, BRAIN RES, V783, P236, DOI 10.1016/S0006-8993(97)01406-6; Mathis JP, 1997, BIOCHEM BIOPH RES CO, V230, P462, DOI 10.1006/bbrc.1996.5867; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; OkudaAshitaka E, 1996, MOL BRAIN RES, V43, P96, DOI 10.1016/S0169-328X(96)00165-9; Pasternak GW, 1996, TRENDS PHARMACOL SCI, V17, P217, DOI 10.1016/0165-6147(96)81602-6; PRICE M, 1989, MOL PHARMACOL, V35, P67; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Wollemann M, 1996, TRENDS PHARMACOL SCI, V17, P217, DOI 10.1016/0165-6147(96)81601-4; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	16	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18047	18051		10.1074/jbc.273.29.18047	http://dx.doi.org/10.1074/jbc.273.29.18047			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660760	hybrid			2022-12-27	WOS:000074828500015
J	Cormier-Regard, S; Nguyen, SV; Claycomb, WC				Cormier-Regard, S; Nguyen, SV; Claycomb, WC			Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR GENE; TRANSCRIPTIONAL REGULATION; INDUCIBLE FACTOR-1; DIFFERENTIAL DISPLAY; HYPOTENSIVE PEPTIDE; HEART-FAILURE; MESSENGER-RNA; PLASMA; HYPERTENSION; ACTIVATION	Adrenomedullin is a recently discovered hypotensive peptide that is expressed in a variety of cell and tissue types. Using the technique of differential display, the adrenomedullin gene was observed to be differentially expressed in developing rat heart. Reverse transcription polymerase chain reaction analysis revealed that the level of adrenomedullin mRNA was significantly higher in adult ventricular cardiac muscle as compared with embryonic day 17 ventricular cardiac muscle. Adrenomedullin receptor mRNA was constitutively expressed throughout development of the ventricular heart. Two potential hypoxia-inducible factor-1 (HLF-1) consensus binding sites were identified in the mouse adrenomedullin promoter at -1095 and -770 nucleotides from the transcription start site. Exposure of cultured adult rat ventricular cardiac myocytes to hypoxia (1% O-2) resulted in a significant, time-dependent increase in adrenomedullin mRNA levels. Transfection studies revealed that the 5'-flanking sequence of adrenomedullin was capable of mediating a hypoxia-inducible increase in transcription. Mutation of the putative HIF-1 consensus binding sites revealed that the major regulatory sequence that mediates the hypoxia-inducible transcriptional response is located at -1095. These data demonstrate that the adrenomedullin gene is developmentally regulated in ventricular cardiomyocytes, that adrenomedullin transcription can be induced by hypoxia, and that this response is primarily mediated by HIF-1 consensus sites in the adrenomedullin promoter.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System	Claycomb, WC (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	wclayc@lsumc.edu	Cormier, Stephania A/I-7382-2017	Cormier, Stephania A/0000-0002-6050-6172				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CLAYCOMB WC, 1984, IN VITRO CELL DEV B, V20, P647, DOI 10.1007/BF02619615; CLAYCOMB WC, 1980, DEV BIOL, V80, P309; CormierRegard S, 1997, MOL CELL BIOCHEM, V172, P111; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; ISHIMITSU T, 1994, J CLIN INVEST, V94, P2158, DOI 10.1172/JCI117573; ISHIYAMA Y, 1995, CLIN EXP PHARMACOL P, V22, P614, DOI 10.1111/j.1440-1681.1995.tb02075.x; Jougasaki M, 1996, J CLIN INVEST, V97, P2370, DOI 10.1172/JCI118680; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Kato J, 1996, J CLIN ENDOCR METAB, V81, P180, DOI 10.1210/jc.81.1.180; KITAMURA K, 1995, DRUGS, V49, P485, DOI 10.2165/00003495-199549040-00001; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MONTUENGA LM, 1997, ENDOCRINOLOGY, V138, P1; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; Nishikimi T, 1997, HYPERTENSION, V30, P1369, DOI 10.1161/01.HYP.30.6.1369; Richards AM, 1996, CLIN SCI, V91, P3, DOI 10.1042/cs0910003; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; Seko Y, 1996, BIOCHEM BIOPH RES CO, V226, P530, DOI 10.1006/bbrc.1996.1389; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; WANG X, 1996, MOL BIOL CELL, V7, P468; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; WASHIMINE H, 1994, BIOCHEM BIOPH RES CO, V202, P1081, DOI 10.1006/bbrc.1994.2039	34	189	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17787	17792		10.1074/jbc.273.28.17787	http://dx.doi.org/10.1074/jbc.273.28.17787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651380	Green Published, hybrid			2022-12-27	WOS:000074816100073
J	Saraswat, LD; Lowey, S				Saraswat, LD; Lowey, S			Subunit interactions within an expressed regulatory domain of chicken skeletal myosin - Location of the NH2 terminus of the regulatory light chain by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; SINGLE CYSTEINE MUTANTS; SCALLOP MYOSIN; TROPONIN-C; RESOLUTION; MOTOR; SEQUENCE; RESIDUES; BINDING	The regulatory domain (RD), or neck region of the myosin head, consists of two classes of light chains that stabilize an alpha-helical segment of the heavy chain. RD from chicken skeletal muscle myosin was prepared in Escherichia coli by coexpression of a 9-kDa heavy chain fragment with the essential light chain. Recombinant regulatory light chain (RLC), wild type or mutant, was added separately to reconstitute the complex. The affinity of RD for divalent cations was determined by measuring the change in fluorescence of a pair of heavy chain tryptophans upon addition of calcium or magnesium. The complex bound divalent cations with high affinity, similar to the association constants determined for native myosin, The intrinsic fluorescence of the tryptophans could be used as a donor to measure the fluorescence resonance energy transfer distance to a single labeled cysteine engineered at position 2 on RLC, Dansylated Cys(2) could also serve as a donor by preparing RLC with a second cysteine at position 79 which was labeled with an acceptor probe. These fluorescence resonance energy transfer distances (24-30 Angstrom), together with a previous measurement between Cys(2) and Cys(155) (Wolff-Long, V. L., Tao, T., and Lowey, S. (1995) J. Biol. Chem. 270, 31111-31118) suggest a location for the NH2 terminus of RLC that appears to preclude a direct interaction between the phosphorylatable serine and specific residues in the COOH-terminal domain.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA	Brandeis University	Lowey, S (corresponding author), Univ Vermont, Dept Mol Physiol & Phys, Burlington, VT 05405 USA.	lowey@salus.med.uvm.edu			NIAMS NIH HHS [AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350, R01AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ALEXIS MN, 1978, BIOCHEMISTRY-US, V17, P2319, DOI 10.1021/bi00605a010; BOEY W, 1994, EUR J BIOCHEM, V219, P603, DOI 10.1111/j.1432-1033.1994.tb19976.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN R F, 1967, Analytical Letters, V1, P35; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Diffee G. M., 1997, Biophysical Journal, V72, pA331; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKOWITZ JR, 1983, PRINCIPLES FLUORESCE; LOWEY S, 1994, MYOLOGY, P485; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NABESHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6099, DOI 10.1093/nar/10.19.6099; Offer G, 1996, J MOL BIOL, V256, P407, DOI 10.1006/jmbi.1996.0096; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SARASWAT LD, 1992, J BIOL CHEM, V267, P21112; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STORER AC, 1976, BIOCHEM J, V159, P1; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; SZENTGYORGYI AG, 1994, MYOLOGY, P506; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WolffLong VL, 1995, J BIOL CHEM, V270, P31111, DOI 10.1074/jbc.270.52.31111; WOLFFLONG VL, 1993, J BIOL CHEM, V268, P23162; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANG ZH, 1995, J BIOL CHEM, V270, P24646, DOI 10.1074/jbc.270.42.24646	44	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17671	17679		10.1074/jbc.273.28.17671	http://dx.doi.org/10.1074/jbc.273.28.17671			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651364	hybrid			2022-12-27	WOS:000074816100057
J	Saura, CK; Mallol, J; Canela, EI; Lluis, C; Franco, R				Saura, CK; Mallol, J; Canela, EI; Lluis, C; Franco, R			Adenosine deaminase and A(1) adenosine receptors internalize together following agonist-induced receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL-LINE; PROTEIN-KINASE-C; BETA-ARRESTIN; R-PIA; BETA(2)-ADRENERGIC RECEPTOR; HOMOLOGOUS DESENSITIZATION; A(1)-ADENOSINE RECEPTOR; INTRACELLULAR CALCIUM; GUANINE-NUCLEOTIDE; AFFINITY STATES	A(1) adenosine receptors (A(1)Rs) and adenosine deaminase (ADA; EC 3.5.4.4) interact on the cell surface of DDT1MF-2 smooth muscle cells. The interaction facilitates ligand binding and signaling via A(1)R, but it is not known whether it has a role in homologous desensitization of A(1)Rs. Here we show that chronic exposure of DDT1MF-2 cells to the A(1)R agonist, N-6-(R)-(phenylisopropyl)adenosine (R-PIA), caused a rapid aggregation or clustering of A(1) receptor molecules on the cell membrane, which was enhanced by pretreatment with ADA Colocalization between A(1)R and ADA occurred in the R-PLA-induced clusters. Interestingly, colocalization between A(1)R and ADA also occurred in intracellular vesicles after internalization of both protein molecules in response to R-PIA. Agonist-induced aggregation of A(1)Rs was mediated by phosphorylation of A(1)Rs, which was enhanced and accelerated in the presence of ADA Ligand-induced second-messenger desensitization of A(1)Rs was also accelerated in the presence of exogenous ADA, and it correlated well with receptor phosphorylation, However, although phosphorylation of A(1)R returned to its basal state within minutes, desensitization continued for hours. The loss of cell-surface binding sites (sequestration) induced by the agonist was time-dependent (t(1/2) = 10 +/- 1 h) and was accelerated by ADA. All of these results strongly suggest that ADA plays a key role in the regulation of A(1)Rs by accelerating ligand-induced desensitization and internalization and provide evidence that the two cell surface proteins internalize via the same endocytic pathway.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Catalunya, Spain	University of Barcelona	Franco, R (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Catalunya, Spain.		Mallol, Josefa/I-4194-2015; Franco, Rafael/C-3694-2015; Saura, Carlos A/D-2727-2011; Canela, Enric I./M-8726-2013; Saura, Carlos A/AFM-9239-2022	Mallol, Josefa/0000-0002-2479-4162; Franco, Rafael/0000-0003-2549-4919; Saura, Carlos A/0000-0003-3692-5657; Canela, Enric I./0000-0003-4992-7440; 				ARAN JM, 1991, J HISTOCHEM CYTOCHEM, V39, P1001, DOI 10.1177/39.8.1856451; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELARDINELLI L, 1993, DRUG DEVELOP RES, V28, P263, DOI 10.1002/ddr.430280313; CASADO V, 1990, J NEUROSCI RES, V26, P461, DOI 10.1002/jnr.490260409; CASADO V, 1991, FEBS LETT, V286, P221, DOI 10.1016/0014-5793(91)80978-C; Ciruela F, 1997, MOL PHARMACOL, V52, P788, DOI 10.1124/mol.52.5.788; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Ciruela F, 1996, FEBS LETT, V380, P219, DOI 10.1016/0014-5793(96)00023-3; Conlay LA, 1997, NATURE, V389, P136, DOI 10.1038/38160; DENNIS DM, 1995, J PHARMACOL EXP THER, V272, P1024; DICKENSON JM, 1993, BRIT J PHARMACOL, V108, P85, DOI 10.1111/j.1476-5381.1993.tb13444.x; ElHashim A, 1996, BRIT J PHARMACOL, V119, P1262, DOI 10.1111/j.1476-5381.1996.tb16031.x; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FERNANDEZ M, 1996, LIFE SCI, V9, P769; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Franco R, 1997, PROG NEUROBIOL, V52, P283, DOI 10.1016/S0301-0082(97)00013-0; Franco R, 1996, BIOCHEMISTRY-US, V35, P3007, DOI 10.1021/bi952415g; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P228, DOI 10.1111/j.1600-0773.1995.tb00135.x; Garland AM, 1996, MOL PHARMACOL, V49, P438; GERWINS P, 1990, MOL PHARMACOL, V38, P660; GERWINS P, 1992, J BIOL CHEM, V267, P16081; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN A, 1992, J BIOL CHEM, V267, P3223; GREEN A, 1990, J BIOL CHEM, V265, P5206; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Krueger KM, 1997, J BIOL CHEM, V272, P5; LEE HT, 1993, AM J PHYSIOL, V265, pH1916, DOI 10.1152/ajpheart.1993.265.6.H1916; LOHSE MJ, 1984, MOL PHARMACOL, V26, P1; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; Palmer TM, 1996, J BIOL CHEM, V271, P15272, DOI 10.1074/jbc.271.25.15272; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Post SR, 1996, J BIOL CHEM, V271, P895, DOI 10.1074/jbc.271.2.895; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; Ruiz A, 1996, BBA-MOL CELL RES, V1310, P168, DOI 10.1016/0167-4889(95)00152-2; Sanders MA, 1996, J NEUROCHEM, V67, P2362; SAURA C, 1996, J NEUROCHEM, V66, P675; SORENSEN K, 1986, EXPERIENTIA, V42, P161, DOI 10.1007/BF01952446; SPIELMAN WS, 1991, HYPERTENSION, V17, P117, DOI 10.1161/01.HYP.17.2.117; Yang EB, 1996, BIOCHEM BIOPH RES CO, V224, P309, DOI 10.1006/bbrc.1996.1026; YU SS, 1993, J BIOL CHEM, V268, P337	52	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17610	17617		10.1074/jbc.273.28.17610	http://dx.doi.org/10.1074/jbc.273.28.17610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651356	hybrid, Green Published			2022-12-27	WOS:000074816100049
J	Amlal, H; Wang, ZH; Burnham, C; Soleimani, M				Amlal, H; Wang, ZH; Burnham, C; Soleimani, M			Functional characterization of a cloned human kidney Na+: HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; RENAL PROXIMAL TUBULE; HUMAN-ERYTHROCYTE-MEMBRANE; CATION-TRANSPORT; RAT HEPATOCYTES; BICARBONATE; SODIUM; CELLS; PH; EXCHANGE	Functional properties of a cloned human kidney Naf: HCO3- cotransporter (NBC-1) were studied in cultured HEK-293 cells that were transiently transfected with NBC-1 cDNA. The Na+:HCO3-, cotransporter activity was assayed as the Na+ and HCO3- dependent pH(i) recovery from intracellular acidosis with the use of the pH sensitive dye 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein In acid-loaded cells and in the presence of amiloride (to block Na+/H+ exchange), switching to a Na+ containing solution (115 mM) resulted in rapid pH(i), recovery only in the presence of HCO3-. This recovery was completely abolished by 300 mu m 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid. Replacing the Na+ with Li+ (115 mM) caused significant HCO3- dependent, DIDS-sensitive pHi recovery from intracellular acidosis, with Li+ showing lower affinity than Na+, Potassium (K+) had no affinity for the Na+:HCO3-, cotransporter. The Na+-dependent HCO3- cotransport was abolished in the presence of 0.2 mM harmaline. The Na+:HCO3- cotransporter could also function in Na+:OH- cotransport mode, although only at high external pH (7.8), Based on functional similarities with the mammalian kidney experiments, we propose that NBC-1 is the proximal tubule Na+:HCO3- cotransporter.	Univ Cincinnati, Med Ctr, Sch Med, Dept Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Cincinnati, OH 45267 USA	University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Soleimani, M (corresponding author), Univ Cincinnati, Med Ctr, Sch Med, Dept Med, 231 Bethesda Ave,MSB 5502, Cincinnati, OH 45267 USA.	manoocher.soleimani@uc.edu		soleimani, m/0000-0002-3446-8870	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052821, R01DK046789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46789, DK 52821] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; Amlal H, 1997, AM J PHYSIOL-CELL PH, V273, pC1194, DOI 10.1152/ajpcell.1997.273.4.C1194; ARONSON PS, 1991, SEMIN NEPHROL, V11, P28; BECKER BF, 1978, J PHYSIOL-LONDON, V282, P149, DOI 10.1113/jphysiol.1978.sp012454; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Burnham CE, 1997, J BIOL CHEM, V272, P19111, DOI 10.1074/jbc.272.31.19111; BURNHAM CE, 1998, IN PRESS AM J PHYSL; CHRISTOPHER NL, 1971, GASTROENTEROLOGY, V60, P845; deHurtado MCC, 1996, CIRC RES, V79, P698, DOI 10.1161/01.RES.79.4.698; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; FITZ JG, 1989, AM J PHYSIOL, V256, pG491, DOI 10.1152/ajpgi.1989.256.3.G491; FUNDER J, 1980, ACTA PHYSIOL SCAND, V108, P31, DOI 10.1111/j.1748-1716.1980.tb06497.x; GLEESON D, 1989, J CLIN INVEST, V84, P312, DOI 10.1172/JCI114156; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSL SM, 1987, J BIOL CHEM, V262, P2682; HOGAN EM, 1995, J GEN PHYSIOL, V106, P821, DOI 10.1085/jgp.106.5.821; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LEVIEL F, 1992, J CLIN INVEST, V90, P869, DOI 10.1172/JCI115962; LUBMAN RL, 1995, RESP PHYSIOL, V100, P15, DOI 10.1016/0034-5687(94)00114-F; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; PREISIG PA, 1989, AM J PHYSIOL, V256, pF756; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SOLEIMANI M, 1995, J INVEST MED, V43, P419; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1991, J BIOL CHEM, V266, P8706; SOLEIMANI M, 1995, CIRC RES, V76, P530, DOI 10.1161/01.RES.76.4.530; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; SOLEIMANI M, 1989, J CLIN INVEST, V83, P945, DOI 10.1172/JCI113980; WIETH JO, 1970, ACTA PHYSIOL SCAND, V79, P76, DOI 10.1111/j.1748-1716.1970.tb04703.x; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16810	16815		10.1074/jbc.273.27.16810	http://dx.doi.org/10.1074/jbc.273.27.16810			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642239	hybrid			2022-12-27	WOS:000074545200029
J	Borggrefe, T; Wabl, M; Akhmedov, AT; Jessberger, R				Borggrefe, T; Wabl, M; Akhmedov, AT; Jessberger, R			A B-cell-specific DNA recombination complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED FRAGMENTS; CHAIN CLASS SWITCH; ESCHERICHIA-COLI; RECA PROTEIN; BINDING PROTEIN; CIRCULAR DNA; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION	We have purified and biochemically characterized a multiprotein complex designated SWAP. In a DNA transfer assay, SWAP preferentially recombines ("swaps") sequences derived from Ig heavy chain switch regions. We identified four of the proteins in the SWAP complex: B23 (nucleophosmin), C23 (nucleolin), poly(ADP-ribose) polymerase (PARP), and SWAP-70. The first three are proteins known to be present in most cells. B23 promotes single-strand DNA reannealing and the formation of joint molecules in a D-loop assay between homologous, but also between S-mu and S-gamma sequences. SWAP-70 is a novel protein of 70 kDa. Its cDNA was cloned and sequenced, and the protein was overexpressed in Escherichia coli. SWAP-70 protein expression was found only in B lymphocytes that had been induced to switch to various Ig isotypes and in switching B-cell lines. SWAP-70 is a nuclear protein, has a weak affinity for DNA, binds ATP, and forms specific, high affinity complexes with B23, C23, and poly(ADP-ribose) polymerase. These findings are consistent with SWAP being the long elusive "switch recombinase" and with SWAP-70 being the specific recruiting element that assembles the switch recombinase from universal components.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Jessberger, R (corresponding author), Basel Inst Immunol, CH-4005 Basel, Switzerland.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037699] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOCKHEIMSTEEN S, 1996, CURR TOP MICROBIOL I, V217, P61; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BURROWS PD, 1983, NATURE, V306, P243, DOI 10.1038/306243a0; BURROWS PD, 1981, P NATL ACAD SCI-BIOL, V78, P564, DOI 10.1073/pnas.78.1.564; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CROCE CM, 1993, SEMIN ONCOL, V20, P31; Daniels GA, 1996, CURR TOP MICROBIOL, V217, P171; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DEPINHO R, 1984, MOL CELL BIOL, V4, P2905, DOI 10.1128/MCB.4.12.2905; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; GELLERT M, 1992, ANNU REV GENET, V22, P425; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HOLLOMAN WK, 1975, P NATL ACAD SCI USA, V72, P2394, DOI 10.1073/pnas.72.6.2394; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JACK HM, 1988, P NATL ACAD SCI USA, V85, P1581, DOI 10.1073/pnas.85.5.1581; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Jessberger R, 1996, CURR TOP MICROBIOL, V217, P191; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KNIGHT KL, 1985, J BIOL CHEM, V260, P867; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; Lorenz M, 1996, CURR TOP MICROBIOL, V217, P151; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Mussmann R, 1997, EUR J IMMUNOL, V27, P2610, DOI 10.1002/eji.1830271021; RAMSAMOOJ P, 1995, RADIAT RES, V143, P158, DOI 10.2307/3579152; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; SANDERSON RJ, 1976, ANAL BIOCHEM, V71, P615, DOI 10.1016/S0003-2697(76)80036-X; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHULTZ CL, 1991, INT IMMUNOL, V3, P109, DOI 10.1093/intimm/3.2.109; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2606, DOI 10.1073/pnas.77.5.2606; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SHOCKETT P, 1993, J IMMUNOL, V151, P6962; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Stasiak A, 1996, SCIENCE, V272, P828, DOI 10.1126/science.272.5263.828; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; TAKAHASHI N, 1980, GENE, V11, P117; VanGent DC, 1996, CURR TOP MICROBIOL, V217, P1; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0; WABL M, 1985, NATURE, V313, P687, DOI 10.1038/313687a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WUERFFEL RA, 1990, MOL CELL BIOL, V10, P1714, DOI 10.1128/MCB.10.4.1714	61	135	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17025	17035		10.1074/jbc.273.27.17025	http://dx.doi.org/10.1074/jbc.273.27.17025			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642267	hybrid			2022-12-27	WOS:000074545200057
J	Descamps, S; Lebourhis, X; Delehedde, M; Boilly, B; Hondermarck, H				Descamps, S; Lebourhis, X; Delehedde, M; Boilly, B; Hondermarck, H			Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE PROTEIN; HUMAN PROSTATE; NEUROTROPHIN RECEPTORS; EXPRESSION; INHIBITOR; LINES	We show here that nerve growth factor (NGF), the archetypal neurotrophic factor, is able to stimulate the proliferation of breast cancer cells (MCF-7 and MDA-MB-231 cell lines), although it is unable to stimulate growth of normal breast epithelial cells (NBEC), This stimulation induced cells in the G(0) phase to reenter the cell cycle, as well as shortening cell cycle duration. Immunoblotting experiments revealed that both the two cancer cell lines and the NBEC express high affinity (p140(trk)) and low affinity (p75) NGF receptors. Inhibition of the NGF growth-promoting effect by the drugs K-252a and PD98059 indicated that activation of Trk-tyrosine kinase activity and the mitogen-activated protein kinase cascade are necessary to obtain the mitogenic effect. Activation of mitogen-activated protein kinase can be detected in breast cancer cells after 10 min of NGF stimulation, whereas no change was detected in NBEC. These results demonstrate that NGF is a mitogenic factor for human breast cancer cells and that it might constitute a new regulator of breast tumor growth.	Univ Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), Univ Lille, Ctr Biol Cellulaire, Unite Dynam Cellules Embryonnaires & Cancereuses, F-59655 Villeneuve Dascq, France.	Hubert.Hondermarck@univ-lille1.fr	Le+Bourhis, Xuefen/AAL-5141-2021	DELEHEDDE, Maryse/0000-0003-2724-143X				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; DELEHEDDE M, 1995, ONCOL RES, V7, P399; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; DJAKIEW D, 1993, CANCER RES, V53, P1416; DJAKIEW D, 1991, CANCER RES, V51, P3304; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; MURPHY RA, 1977, P NATL ACAD SCI USA, V74, P2330, DOI 10.1073/pnas.74.6.2330; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PFLUG BR, 1992, CANCER RES, V52, P5403; PFLUG BR, 1995, ENDOCRINOLOGY, V136, P262, DOI 10.1210/en.136.1.262; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; SASAKI K, 1987, CYTOMETRY, V8, P526, DOI 10.1002/cyto.990080514; TAPLEY P, 1992, ONCOGENE, V7, P371; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	24	109	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16659	16662		10.1074/jbc.273.27.16659	http://dx.doi.org/10.1074/jbc.273.27.16659			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642218	hybrid			2022-12-27	WOS:000074545200008
J	Hahm, SH; Eiden, LE				Hahm, SH; Eiden, LE			Five discrete cis-active domains direct cell type-specific transcription of the vasoactive intestinal peptide (VIP) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; OCTAMER-BINDING-PROTEINS; NEURON-SPECIFIC ENHANCER; ACHAETE-SCUTE HOMOLOG-1; STAT PROTEINS; DNA-BINDING; EXPRESSION; SEQUENCE; COACTIVATOR; POLYPEPTIDE	Vasoactive intestinal peptide (VIP) is a neuromodulator expressed with great anatomical specificity throughout the nervous system. Cell-specific expression of the VIP gene is mediated by a tissue specifier element (TSE) located within a 2.7-kilobase (kb) region between -5.2 and -2.5 kb upstream from the transcription start site, and requires an intact promoter proximal VIP-CRE (cyclic AMP-responsive element) (Hahm, S, H,, and Eiden, L, E, (1997) J, Neurochem, 67, 1872-1881), We now report that the TSE comprises a 425 base pair domain located between -4.7 and -4.2 kb containing two AT-rich octamer-like sequences. The 425-base pair TSE is sufficient to provide full cell-specific regulation of the VIP gene, when fused to the 5' proximal 1.55 kb of the VIP gene. Mutational analysis and gel shift assays of these octamer-like sequences indicate that the binding of proteins related to the ubiquitously expressed POU-homeodomain proteins Oct-1 and/or Oct-2 to these octamer-like sequences plays a central role for the function of the TSE, The TSE interacts with three additional discrete domains besides the cAMP response element, which are located within the proximal 1.55 kb of the VIP gene, to provide cell-specific expression. An upstream domain from -1.55 to -1.37 kb contains E-boxes and MEF2-like motifs, and deletion of this domain results in complete abrogation of cell-specific transcriptional activity, The region from -1.37 to -1.28 kb contains a STAT motif, and further removal of this domain allows the upstream TSE to act as an enhancer in both SH-EP and HeLa cells. The sequence from -1.28 to -0.9 kb containing a noncanonical AP-1 binding sequence (Symes, A, Gearan, T,, Eby, J,, and Fink, J, S, (1997) J. Biol, Chem. 272, 9648-9654), is absolutely required for TSE-dependent cell-specific expression of the VIP gene. Thus, five discrete domains of the VIP gene provide a combination of enhancer and repressor activities, each completely contingent on VIP gene context, that together result in cell-specific transcription of the VIP gene.	NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Hahm, SH (corresponding author), NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, 36 Convent Dr,MSC 4090,Bldg 36,Rm 2D10, Bethesda, MD 20892 USA.	sungho@codon.nih.gov		Eiden, Lee/0000-0001-7524-944X				AGOSTON DV, 1990, J NEUROSCI RES, V27, P479, DOI 10.1002/jnr.490270407; Ausubel, 1994, CURR PROTOC MOL BIOL, V2, P1; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; EMSON PC, 1979, BRAIN RES, V177, P437, DOI 10.1016/0006-8993(79)90462-1; FAHRENKRUG J, 1979, DIGESTION, V19, P149, DOI 10.1159/000198339; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Hahm SH, 1996, J NEUROCHEM, V67, P1872; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JONES EG, 1986, J NEUROSURG, V65, P135, DOI 10.3171/jns.1986.65.2.0135; KAGEYAMA R, 1995, CRIT REV NEUROBIOL, V9, P177; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUTT V, 1988, ANN NY ACAD SCI, V527, P1; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ROSTENE WH, 1984, PROG NEUROBIOL, V22, P103, DOI 10.1016/0301-0082(84)90022-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SENA M, 1994, DNA SEQUENCE, V5, P25, DOI 10.3109/10425179409039701; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J NEUROCHEM, V65, P1926; WASCHEK JA, 1987, ANN NY ACAD SCI, V493, P308, DOI 10.1111/j.1749-6632.1987.tb27215.x; WASCHEK JA, 1988, P NATL ACAD SCI USA, V85, P9547, DOI 10.1073/pnas.85.24.9547; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467	37	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17086	17094		10.1074/jbc.273.27.17086	http://dx.doi.org/10.1074/jbc.273.27.17086			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642274	hybrid			2022-12-27	WOS:000074545200064
J	Guo, JH; Wang, HY; Malbon, CC				Guo, JH; Wang, HY; Malbon, CC			Conditional, tissue-specific expression of Q205L G alpha(i2) in vivo mimics insulin activation of c-Jun N-terminal kinase and p38 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; GLYCOGEN-SYNTHASE; GROWTH; CELLS; PHOSPHORYLATION; STIMULATION; INDUCTION; PATHWAY	Deficiency of the G-protein subunit G alpha(i2) impairs insulin action (Moxham, C, M,, and MaIbon, C, C, (1996) Nature 379, 840-844), By using the promoter for the phosphoenolpyruvate carboxykinase gene, conditional, tissue-specific expression of the constitutively active mutant form (Q205L) of G alpha(i2) was achieved in mice harboring the transgene, Expression of Q205L Get, was detected in skeletal muscle, liver, and adipose tissue of transgenic mice. Whereas the G alpha(i2)-deficient mice displayed blunted insulin action, the Q205L G alpha(i2)-expressing mice displayed enhanced insulin-like effects. Glycogen synthase in skeletal muscle was found to be activated in Q205L G alpha(i2)-expressing mice, in the absence of the administration of insulin. Analysis of members of mitogen-activated protein kinase family revealed that both c-Jun N-terminal kinase and p38 are constitutively activated in vivo in the mice that express the Q205L G alpha(i2) ERK1,2, in contrast, are unaffected in the Q205L G alpha(i2)-expressing mice, Insulin, like expression of Q205L G alpha(i2), activates both p38 and c-Jun N-terminal kinases as well as glycogen synthase, Activation of c-Jun N-terminal and p38 kinases in vivo with anisomycin, however, was insufficient to activate glycogen synthase, Much like G alpha(i2), deficiency provokes insulin resistance, expression of Q205L constitutively active G alpha(i2) mimics insulin action in vivo, sharing with insulin the activation of two mitogen-activated protein kinase members, p38 and c-Jun N-terminal kinases.	SUNY Stony Brook, Sch Med HSC,Diabet & Metab Dis Res Ctr, Pharmacol HSC, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med HSC,Diabet & Metab Dis Res Ctr, Diabet & Metab Dis Res Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Sch Med HSC,Diabet & Metab Dis Res Ctr, Pharmacol HSC, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; GAWLER D, 1987, NATURE, V327, P229, DOI 10.1038/327229a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; RECORD RD, 1993, EXP CELL RES, V206, P36, DOI 10.1006/excr.1993.1117; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771	24	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16487	16493		10.1074/jbc.273.26.16487	http://dx.doi.org/10.1074/jbc.273.26.16487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632716	hybrid			2022-12-27	WOS:000074436600087
J	Sainz, E; Akeson, M; Mantey, SA; Jensen, RT; Battey, JF				Sainz, E; Akeson, M; Mantey, SA; Jensen, RT; Battey, JF			Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; BOMBESIN-LIKE PEPTIDES; LUNG-CARCINOMA CELLS; SWISS 3T3 CELLS; STIMULATES GROWTH; MOLECULAR-CLONING; SUBSTANCE-P; NONPEPTIDE; DNA; ANTAGONISTS	Three mammalian bombesin receptor subtypes have been characterized: the gastrin-releasing peptide receptor (GRP-R), the neuromedin B receptor (NMB-R), and bombesin receptor subtype 3 (BRS-3). In a previous report we identified four amino acids that are critical for high affinity binding of bombesin and gastrin-releasing peptide (GRP) to the GRP-R. These four amino acids are conserved in all species variants of the GRP-R and NMB-R which bind bombesin with high affinity, but they are diverged in BRS-3, the bombesin receptor subtype that binds bombesin with much lower affinity. Substituting these four divergent amino acids in BRS-3 for the conserved amino acids in either GRP-R or NMB-R increased the affinity of the mutated BRS-3 (4 Delta BRS-3) for bombesin compared with wild-type BRS-3 We hypothesized that the same four amino acids might be critical for high affinity NMB binding to the NMB-R. hr this study we confirm this hypothesis by showing that the affinity of NMB is increased in a mutant BRS-3 receptor (4 Delta BRS-3) that contains these four substitutions resulting in an affinity that is close to the affinity of wild-type NMB-R for NMB. In contrast, these four amino acid substitutions in BRS-3 did not result in the formation of a high affinity binding site for the recently described non-peptide NMB-R antagonist PD168368.	NINCD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Battey, JF (corresponding author), 5 Res Ct,Rm 2B28, Rockville, MD 20850 USA.	jbattey@pop.nidcd.nih.gov						Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BOLOGNA M, 1989, CANCER, V63, P1714; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG DH, 1992, SURGERY, V112, P1059; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS L, 1994, BASIC METHODS MOL BI, P319; Eden JM, 1996, BIOORG MED CHEM LETT, V6, P2617, DOI 10.1016/0960-894X(96)00481-7; ERSPAMER GF, 1988, REGUL PEPTIDES, V21, P1; FATHI Z, 1993, J BIOL CHEM, V268, P5979; FONG TM, 1992, J BIOL CHEM, V267, P25664; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; JI H, 1994, J BIOL CHEM, V269, P16533; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; MCDONALD TJ, 1979, BIOCHEM BIOPH RES CO, V90, P227, DOI 10.1016/0006-291X(79)91614-0; Meng F, 1996, J BIOL CHEM, V271, P32016, DOI 10.1074/jbc.271.50.32016; MINAMINO N, 1983, BIOCHEM BIOPH RES CO, V114, P541, DOI 10.1016/0006-291X(83)90814-8; Pradhan TK, 1998, EUR J PHARMACOL, V343, P275, DOI 10.1016/S0014-2999(97)01527-6; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SPINDEL E, 1986, TRENDS NEUROSCI, V9, P130, DOI 10.1016/0166-2236(86)90042-1; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	32	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15927	15932		10.1074/jbc.273.26.15927	http://dx.doi.org/10.1074/jbc.273.26.15927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632639	hybrid			2022-12-27	WOS:000074436600010
J	Satriano, J; Matsufuji, S; Murakami, Y; Lortie, MJ; Schwartz, D; Kelly, CJ; Hayashi, S; Blantz, RC				Satriano, J; Matsufuji, S; Murakami, Y; Lortie, MJ; Schwartz, D; Kelly, CJ; Hayashi, S; Blantz, RC			Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE-ANTIZYME; CELLS; TRANSPORT; CHEMOTHERAPY; DEPRIVATION; METABOLISM; EXPRESSION; INHIBITOR; PROTEIN; GROWTH	Polyamines are required for entry and progression of the cell cycle. As such, augmentation of polyamine levels is essential for cellular transformation. Polyamines are autoregulated through induction of antizyme, which represses both the rate-limiting polyamine biosynthetic enzyme ornithine decarboxylase and cellular polyamine transport. In the present study we demonstrate that agmatine, a metabolite of arginine via arginine decarboxylase (an arginine pathway distinct from that of the classical polyamines), also serves the dual regulatory functions of suppressing polyamine biosynthesis and cellular polyamine uptake through induction of antizyme, The capacity of agmatine to induce antizyme is demonstrated by: (a) an agmatine-dependent translational frameshift of antizyme mRNA to produce a full-length protein and (b) suppression of agmatine-dependent inhibitory activity by either anti-antizyme IgG or antizyme inhibitor. Furthermore, agmatine administration depletes intracellular polyamine levels to suppress cellular proliferation in a transformed cell lime. This suppression is reversible with polyamine supplementation. We propose a novel regulatory pathway in which agmatine acts as an antiproliferative molecule and potential tumor suppressor by restricting the cellular polyamine supply required to support growth.	Univ Calif San Diego, Vet Affairs Med Ctr, Div Nephrol Hypertens, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Program Mol Pathol, Dept Med, San Diego, CA 92161 USA; Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 105, Japan	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; Jikei University	Satriano, J (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, Div Nephrol Hypertens, Dept Med, Mail Code 9111 H,3350 La Jolla Village Dr, San Diego, CA 92161 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042155, R01DK028602] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48108] Funding Source: Medline; NIDDK NIH HHS [DK42155, DK28602] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Aziz SM, 1996, J PHARMACOL EXP THER, V278, P185; BOGLE RG, 1994, AM J PHYSIOL, V266, pC776, DOI 10.1152/ajpcell.1994.266.3.C776; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; FREDLUND JO, 1995, EXP CELL RES, V216, P86, DOI 10.1006/excr.1995.1011; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HOLLEY JL, 1992, CANCER RES, V52, P4190; JANNE J, 1966, ACTA CHEM SCAND, V20, P1174, DOI 10.3891/acta.chem.scand.20-1174; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; LAULAJAINEN T, 1993, LAB INVEST, V69, P183; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MOULINOUX JP, 1991, CELL MOL BIOL, V37, P773; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; QUEMENER V, 1994, ANTICANCER RES, V14, P443; Regunathan S, 1996, J PHARMACOL EXP THER, V276, P1272; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; WOLF G, 1992, AM J PATHOL, V140, P95	28	120	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15313	15316		10.1074/jbc.273.25.15313	http://dx.doi.org/10.1074/jbc.273.25.15313			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624108	hybrid			2022-12-27	WOS:000074284200002
J	Newbolt, A; Stoop, R; Virginio, C; Surprenant, A; North, RA; Buell, G; Rassendren, F				Newbolt, A; Stoop, R; Virginio, C; Surprenant, A; North, RA; Buell, G; Rassendren, F			Membrane topology of an ATP-gated ion channel (P2X receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-2X RECEPTOR; SEGMENTS; GLUTAMATE; CLONING; FAMILY; SITES	Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X(2) receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor. Functional channels were formed by receptors. lacking any single asparagine, but not by channels mutated in two or three positions. Artificial consensus sequences (N-X-S/T) introduced into the W-terminal region (asparagine at position 9, 16, or 26) were not glycosylated, Asparagines were glycosylated when introduced at the C-terminal end of the first hydrophobic domain (positions 62 and 66) and at the N-terminal end of the second hydrophobic domain (position 324), A protein in which the C terminus of one P2X(2) subunit was joined to the N terminus of a second P2X(2) subunit (from a concatenated cDNA) had twice the molecular mass of the P2X(2) receptor subunit, and formed fully functional channels. The experiments provide direct evidence for the topology originally proposed for the P2X receptor, with intracellular N and C termini, two membrane-spanning domains, and a large extracellular loop.	Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	GlaxoSmithKline	Rassendren, F (corresponding author), Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland.	rassendren@serono.com	North, Richard/GQA-6156-2022; Rassendren, Francois/AAA-6190-2021	Rassendren, Francois/0000-0003-3320-2461				Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Collo G, 1996, J NEUROSCI, V16, P2495; DANI JA, 1995, CURR OPIN NEUROBIOL, V5, P310, DOI 10.1016/0959-4388(95)80043-3; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; KAWASHIMA E, 1998, IN PRESS RECEPTORS C; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; North RA, 1996, CURR OPIN CELL BIOL, V8, P474, DOI 10.1016/S0955-0674(96)80023-8; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Radford KM, 1997, J NEUROSCI, V17, P6529; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; RENARD S, 1994, J BIOL CHEM, V269, P12981; Stoop R., 1997, Society for Neuroscience Abstracts, V23, P376; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Valera S, 1995, RECEPTOR CHANNEL, V3, P283; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485	28	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15177	15182		10.1074/jbc.273.24.15177	http://dx.doi.org/10.1074/jbc.273.24.15177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614131	hybrid			2022-12-27	WOS:000074160400073
J	Webb, NR; Connell, PM; Graf, GA; Smart, EJ; de Villiers, WJS; de Beer, FC; van der Westhuyzen, DR				Webb, NR; Connell, PM; Graf, GA; Smart, EJ; de Villiers, WJS; de Beer, FC; van der Westhuyzen, DR			SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; TRANSGENIC MICE; GENE FAMILY; CHOLESTEROL; IDENTIFICATION; PLASMA; RAT; METABOLISM; EXPRESSION; TRANSPORT	The scavenger receptor class B, type I (SR-BI), binds high density lipoprotein (HDL) and mediates selective uptake of cholesteryl ester from HDL and HDL-dependent cholesterol efflux from cells. We recently identified a new mRNA variant that differs from the previously characterized form in that the encoded C-terminal cytoplasmic domain is almost completely different. In the present study, we demonstrate that the mRNAs for mouse SR-BI and SR-BII (previously termed SR-BI.2) are the alternatively spliced products of a single gene. The translation products predicted from human, bovine, mouse, hamster, and rat cDNAs exhibit a high degree of sequence similarity within the SR-BII C-terminal domain (62-67% identity when compared with the human sequence), suggesting that this variant is biologically important. SR-BII protein represents approximately 12% of the total immunodetectable SR-BI/II protein in mouse liver. Subcellular fractionation of transfected Chinese hamster ovary cells showed that SR-BII, like SR-BI, is enriched in caveolae, indicating that the altered cytoplasmic tail does not affect targeting of the receptor. SR-BII mediated both selective cellular uptake of cholesteryl ether from HDL as well as HDL-dependent cholesterol efflux from cells, although with approximately 4-fold lower efficiency than SR-BI, In vivo studies using adenoviral vectors showed that SR-BII was relatively less efficient than SR-BI in reducing plasma HDL cholesterol, These studies show that SR-BII, an HDL, receptor isoform containing a distinctly different cytoplasmic tail, mediates selective lipid transfer between HDL and cells, but with a lower efficiency than the previously characterized variant.	Univ Kentucky, Med Ctr MN520, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA; Vet Affairs Med Ctr, Lexington, KY 40511 USA	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	van der Westhuyzen, DR (corresponding author), Univ Kentucky, Med Ctr MN520, Dept Internal Med, 800 Rose St, Lexington, KY 40536 USA.	dvwest1@pop.uky.edu	Webb, Nancy/AAL-7030-2021; Eckhardt, Erik/G-1567-2010	Graf, Gregory/0000-0002-0130-9929	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058475, R01HL058475] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58475] Funding Source: Medline; NIA NIH HHS [AG-14668] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GLASS C, 1985, J BIOL CHEM, V260, P744; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Johnson MSC, 1998, ENDOCRINOLOGY, V139, P72, DOI 10.1210/en.139.1.72; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LIU MS, 1994, J BIOL CHEM, V269, P11417; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Rajapaksha WRAKJS, 1997, MOL CELL ENDOCRINOL, V134, P59, DOI 10.1016/S0303-7207(97)00173-1; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1997, J LIPID RES, V38, P1490; WEBB NR, 1997, J LIPID RESHEDR, V38, P45; Welch CL, 1997, MAMM GENOME, V8, P942, DOI 10.1007/s003359900643	37	195	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15241	15248		10.1074/jbc.273.24.15241	http://dx.doi.org/10.1074/jbc.273.24.15241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614139	hybrid			2022-12-27	WOS:000074160400081
J	Bogsch, EG; Sargent, F; Stanley, NR; Berks, BC; Robinson, C; Palmer, T				Bogsch, EG; Sargent, F; Stanley, NR; Berks, BC; Robinson, C; Palmer, T			An essential component of a novel bacterial protein export system with homologues in plastids and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THYLAKOID MEMBRANE; FORMATE DEHYDROGENASE; NITRATE REDUCTASE; SECA-PROTEIN; TRANSPORT; PEPTIDES; PATHWAY; GENE; IDENTIFICATION	Proteins are transported across the bacterial plasma membrane and the chloroplast thylakoid membrane by means of protein translocases that recognize N-terminal targeting signals in their cognate substrates, Transport of many of these proteins involves the well defined Sec apparatus that operates in both membranes. We describe here the identification of a novel component of a bacterial Sec-independent translocase, The system probably functions in a similar manner to a Sec-independent translocase in the thylakoid membrane, and substrates for both systems bear a characteristic twin-arginine motif in the targeting peptide. The translocase component is encoded in Escherichia coli by an unassigned reading frame, yigU, disruption of which blocks the export of at least five twin-Arg-containing precursor proteins that are predicted to bind redox cofactors, and hence fold, prior to translocation. The Sec pathway remains unaffected in the deletion strain, The gene has been designated tatC (for twin-arginine translocation), and we show that homologous genes are present in a range of bacteria, plastids, and mitochondria. These findings suggest a central role for TatC-type proteins in the translocation of tightly folded proteins across a spectrum of biological membranes.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; John Innes Ctr Plant Sci Res, Nitrogen Fixat Lab, Norwich NR4 7UH, Norfolk, England	University of East Anglia; University of Warwick; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Palmer, T (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.			Berks, Ben/0000-0001-9685-4067; Stanley-Wall, Nicola/0000-0002-5936-9721; Sargent, Frank/0000-0002-6841-3624; Palmer, Tracy/0000-0001-9043-2592				ATLUNG T, 1989, J BACTERIOL, V171, P1683, DOI 10.1128/jb.171.3.1683-1691.1989; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; ENOCH HG, 1975, J BIOL CHEM, V250, P6693; GRAHAM A, 1980, FEMS MICROBIOL LETT, V7, P145, DOI 10.1111/j.1574-6941.1980.tb01595.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HENRY R, 1994, J BIOL CHEM, V269, P10189; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Johnson Kit, 1992, Current Opinion in Biotechnology, V3, P481, DOI 10.1016/0958-1669(92)90075-T; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; KALMAN LV, 1989, J BACTERIOL, V171, P3810, DOI 10.1128/jb.171.7.3810-3816.1989; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NAKAI M, 1994, J BIOL CHEM, V269, P31338; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; SARGENT F, 1998, IN PRESS EUR J BIOCH, V225; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; SETTLES MA, 1997, SCIENCE, V278, P1467; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	33	329	340	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18003	18006		10.1074/jbc.273.29.18003	http://dx.doi.org/10.1074/jbc.273.29.18003			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660752	hybrid			2022-12-27	WOS:000074828500007
J	Gray, M; Szabo, G; Otero, AS; Gray, L; Hewlett, E				Gray, M; Szabo, G; Otero, AS; Gray, L; Hewlett, E			Distinct mechanisms for K+ efflux, intoxication, and hemolysis by Bordetella pertussis AC toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; ESCHERICHIA-COLI HEMOLYSIN; GRAM-NEGATIVE BACTERIA; TARGET-CELL MEMBRANES; RED-BLOOD-CELLS; SHEEP ERYTHROCYTES; FATTY-ACYLATION; CALCIUM; PENETRATION; PURIFICATION	Adenylate cyclase (AC) toxin from Bordetella pertussis delivers its catalytic domain to the interior of target cells where it converts host ATP to cAMP in a process referred to as intoxication. This toxin also hemolyzes sheep erythrocytes by a mechanism presumed to include pore formation and osmotic lysis, Intoxication and hemolysis appear at strikingly different toxin concentrations and evolve over different time scales, suggesting that different molecular processes may be involved. The present study was designed to test the hypothesis that intoxication and hemolysis occur by distinct mechanisms. Although the hemolytic activity of AC toxin has a lag of >1 h, intoxication starts immediately. Because of this difference, we sought a surrogate or precursor lesion that leads to hemolysis, and potassium efflux has been observed from erythrocytes treated with Other pore-forming toxins, AC toxin elicits an increase in K+ efflux from sheep erythrocytes and Jurkat cells, a human T-cell leukemia line, that beans within minutes of toxin addition. The toxin concentration dependence along with the analysis of the time course suggest that toxin monomers are sufficient to elicit release of K+ and to deliver the catalytic domain to the cell interior. Hemolysis, on the other hand, is a highly cooperative event that Likely requires a subsequent oligomerization of these individual units. Although induction of Kf efflux shares some structural and environmental requirements with both intoxication and hemolysis, it can occur under conditions in which intoxication is reduced or prevented. The data presented here suggest that the transmembrane pathway by which K+ is released is separate and distinct from the structure required for intoxication but may be related to, or a precursor of, that which is ultimately responsible for hemolysis.	Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Hewlett, E (corresponding author), Univ Virginia, Sch Med, Dept Med, Box 419, Charlottesville, VA 22908 USA.			gray, mary/0000-0003-4441-5905	NHLBI NIH HHS [HL37127] Funding Source: Medline; NIAID NIH HHS [AI18000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037127, R37HL037127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BERKOWITZ SA, 1980, ANN NY ACAD SCI, V1, P356; BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CLINKENBEARD KD, 1991, INFECT IMMUN, V59, P1148, DOI 10.1128/IAI.59.3.1148-1152.1991; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; ENDOH M, 1980, MICROBIOL IMMUNOL, V24, P95, DOI 10.1111/j.1348-0421.1980.tb00567.x; GENTILE F, 1988, EUR J BIOCHEM, V175, P447, DOI 10.1111/j.1432-1033.1988.tb14215.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GUISO N, 1989, MICROB PATHOGENESIS, V7, P373, DOI 10.1016/0882-4010(89)90040-5; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1976, P NATL ACAD SCI USA, V73, P1926, DOI 10.1073/pnas.73.6.1926; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; HEWLETT EL, 1990, BACTERIAL PROTEIN TO, P249; HEWLETT EL, 1992, BACTERIAL PROTEIN TO, P241; JORGENSEN SE, 1983, TOXICON, V21, P717, DOI 10.1016/0041-0101(83)90277-5; KELLERMAYER M, 1994, J CELL PHYSIOL, V159, P197, DOI 10.1002/jcp.1041590202; KIM HR, 1993, LIFE SCI, V53, P571, DOI 10.1016/0024-3205(93)90714-E; MADOFF MA, 1964, J BACTERIOL, V87, P145, DOI 10.1002/path.1700870120; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SHATTUCK RL, 1985, BIOCHEMISTRY-US, V24, P6323, DOI 10.1021/bi00344a001; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; SZABO G, 1994, J BIOL CHEM, V269, P22496; VISSERS MCM, 1994, FREE RADICAL BIO MED, V16, P703, DOI 10.1016/0891-5849(94)90185-6; WALEV I, 1993, INFECT IMMUN, V61, P4972, DOI 10.1128/IAI.61.12.4972-4979.1993; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; Westrop G, 1997, J BACTERIOL, V179, P871, DOI 10.1128/jb.179.3.871-879.1997	48	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18260	18267		10.1074/jbc.273.29.18260	http://dx.doi.org/10.1074/jbc.273.29.18260			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660789	hybrid			2022-12-27	WOS:000074828500044
J	Rieder, C; Strauss, G; Fuchs, G; Arigoni, D; Bacher, A; Eisenreich, W				Rieder, C; Strauss, G; Fuchs, G; Arigoni, D; Bacher, A; Eisenreich, W			Biosynthesis of the diterpene verrucosan-2 beta-ol in the phototrophic Eubacterium Chloroflexus aurantiacus - A retrobiosynthetic NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-MEVALONATE PATHWAY; VERRUCOSANE DITERPENOIDS; ISOPRENOID BIOSYNTHESIS; BACTERIA; CHLOROBIUM; FIXATION; ABSENCE	The biosynthesis of verrucosan-2 beta-ol in the green phototrophic eubacterium Chloroflexus aurantiacus was investigated by in vivo incorporation of singly or doubly C-13-labeled acetate, The C-13 labeling of the isolated diterpene was analyzed by one- and two-dimensional NMR spectroscopy. The C-13-labeling patterns of verrucosan-2 beta-ol were compared with the labeling patterns of intermediary metabolites (acetyl-CoA, pyruvate, and glyceraldehyde 3-phosphate) which were deduced from amino acids and nucleosides by retrobiosynthetic analysis. The results show that verrucosan-2 beta-ol is synthesized via mevalonate and not via the deoxyxylulose pathway, which was discovered recently in some eubacteria, algae, and plants. A scheme for the formation of the unusual tetracyclic ring system is offered. The cyclization process is initiated by the solvolysis of pyrophosphate from geranyllinaloyl pyrophosphate and the mechanism involves a Wagner-Meerwein rearrangement, a 1,5-hydride shift, and a cyclopropylcarbinyl to cyclopropylcarbinyl rearrangement.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Freiburg, Fac Biol, Dept Microbiol, D-79104 Freiburg, Germany; ETH Zurich, Organ Chem Lab, CH-8092 Zurich, Switzerland	Technical University of Munich; University of Freiburg; ETH Zurich	Eisenreich, W (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				ARIGONI D, 1958, EXPERIENTIA, V14, P153, DOI 10.1007/BF02157135; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; ARIGONI D, 1968, Pure and Applied Chemistry, V17, P331, DOI 10.1351/pac196817030331; BIRCH AJ, 1962, J CHEM SOC, P1502, DOI 10.1039/jr9620001502; BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19; Broers STJ, 1994, THESIS EIDGENOSSISCH; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; CANONICA L, 1967, TETRAHEDRON LETT, P4657; Cartayrade A., 1994, 2 S EUR NETW PLANT T; DAUBEN WG, 1967, TETRAHEDRON LETT, P1735; EICHINGER D, 1997, THESIS TU MUNCHEN; EISENREICH W, 1993, EUR J BIOCHEM, V215, P619, DOI 10.1111/j.1432-1033.1993.tb18073.x; Eisenreich W, 1997, TETRAHEDRON LETT, V38, P3889, DOI 10.1016/S0040-4039(97)00761-2; Eisenreich W, 1996, P NATL ACAD SCI USA, V93, P6431, DOI 10.1073/pnas.93.13.6431; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; FUKUYAMA Y, 1988, PHYTOCHEMISTRY, V27, P1797, DOI 10.1016/0031-9422(88)80446-1; GIBSON J, 1985, SYST APPL MICROBIOL, V6, P152, DOI 10.1016/S0723-2020(85)80048-5; GODTFREDSEN S, 1977, CHIMIA, V31, P62; Grammes C, 1997, PHYTOCHEMISTRY, V44, P1495, DOI 10.1016/S0031-9422(96)00781-9; HALFEN LN, 1972, ARCH MIKROBIOL, V82, P240, DOI 10.1007/BF00412195; HAYASHI S, 1978, CHEM LETT, P953, DOI 10.1246/cl.1978.953; HEFTER J, 1993, J GEN MICROBIOL, V139, P2757, DOI 10.1099/00221287-139-11-2757; HOLO H, 1989, ARCH MICROBIOL, V151, P252, DOI 10.1007/BF00413138; JURGENS UJ, 1987, ARCH MICROBIOL, V148, P72, DOI 10.1007/BF00429651; KENYON CN, 1974, J BACTERIOL, V120, P131, DOI 10.1128/JB.120.1.131-138.1974; KNUDSEN E, 1982, ARCH MICROBIOL, V132, P149, DOI 10.1007/BF00508721; KUBO I, 1984, J ORG CHEM, V49, P4644, DOI 10.1021/jo00198a013; Lichtenthaler HK, 1997, FEBS LETT, V400, P271, DOI 10.1016/S0014-5793(96)01404-4; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUO A, 1978, J CHEM SOC CHEM COMM, P198, DOI 10.1039/c39780000198; MATSUO A, 1984, Z NATURFORSCH B, V39, P1281, DOI 10.1515/znb-1984-0923; MEISSNER J, 1988, J BACTERIOL, V170, P3213, DOI 10.1128/jb.170.7.3213-3216.1988; NOZAKI H, 1998, J CHEM SOC P2, P763; OYAIZU H, 1987, SYST APPL MICROBIOL, V9, P47, DOI 10.1016/S0723-2020(87)80055-3; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Schwarz M, 1994, THESIS EIDGENOSSISCH; Schwender J, 1996, BIOCHEM J, V316, P73, DOI 10.1042/bj3160073; STONE KJ, 1969, J CHEM SOC CHEM COMM, P530, DOI 10.1039/c29690000530; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; TAKAOKA D, 1979, J CHEM SOC PERK T 1, P2711, DOI 10.1039/p19790002711; TAKAOKA D, 1983, PHYTOCHEMISTRY, V22, P1653, DOI 10.1016/0031-9422(83)80103-4; Tanaka J, 1997, CHEM LETT, P489, DOI 10.1246/cl.1997.489; WOESE CR, 1987, MICROBIOL REV, V51, P227	44	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18099	18108		10.1074/jbc.273.29.18099	http://dx.doi.org/10.1074/jbc.273.29.18099			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660767	hybrid			2022-12-27	WOS:000074828500022
J	Goodman, PA; Niehoff, LB; Uckun, FM				Goodman, PA; Niehoff, LB; Uckun, FM			Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; MYELOID-LEUKEMIA CELLS; MICE LACKING JAK3; TRANSCRIPTIONAL REGULATION; ACTIVATION DOMAIN; INDUCED APOPTOSIS; PRECURSOR CELLS; RADIATION; PHOSPHORYLATION; SEQUENCE	Exposure of B-lineage lymphoid cells to ionizing radiation induces an elevation of c-jun proto-oncogene mRNA levels. This signal is abrogated by protein-tyrosine kinase (PTK) inhibitors, indicating that activation of an as yet unidentified PTK is mandatory for radiation-induced c-jun expression. Here, we provide experimental evidence that the cytoplasmic tyrosine kinases BTK, SYK, and LYN are not required for this signal. Lymphoma B-cells rendered deficient for LYN, SYK, or both by targeted gene disruption showed increased c-jun expression levels after radiation exposure, but the magnitude of the stimulation was lower than in wild-type cells. Thus, these PTKs may participate in the generation of an optimal signal. Notably, an inhibitor of JAK-3 (Janus family kinase-3) abrogated radiation-induced c-jun activation, prompting the hypothesis that a chicken homologue of JAK-3 may play a key role in initiation of the radiation-induced c-jun signal in B-lineage lymphoid cells.	Wayne Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Wayne Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Wayne Hughes Inst, Dept Mol Oncol, 2665 Long Lake Rd, St Paul, MN 55113 USA.	fatih_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHAE HP, 1993, CANCER RES, V53, P447; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLATA F, 1992, J BIOL CHEM, V267, P18278; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Dosch J, 1996, ONCOGENE, V13, P1927; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hoffman SMG, 1997, GENOMICS, V43, P109, DOI 10.1006/geno.1997.4792; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Jugloff LS, 1997, J IMMUNOL, V159, P1096; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; Kumar A, 1996, ONCOGENE, V13, P2009; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; Levy David E., 1997, Cytokine and Growth Factor Reviews, V8, P81, DOI 10.1016/S1359-6101(96)00054-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P9575, DOI 10.1073/pnas.92.21.9575; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NOMOTO Y, 1990, CHEM PHARM BULL, V38, P1591; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Qin SF, 1997, J BIOL CHEM, V272, P2098; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Riedy MC, 1996, GENOMICS, V37, P57, DOI 10.1006/geno.1996.0520; ROLLING C, 1995, ONCOGENE, V10, P1757; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUBIN E, 1991, MOL PHARMACOL, V39, P697; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Safford MG, 1997, EXP HEMATOL, V25, P374; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sharfe N, 1997, J IMMUNOL, V159, P1107; Sharfe N, 1997, CLIN EXP IMMUNOL, V108, P552, DOI 10.1046/j.1365-2249.1997.4001304.x; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Thomas C.L.M., 1970, CATALYTIC PROCESSES; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TORTOLANI PJ, 1995, J IMMUNOL, V155, P5220; TuelAhlgren L, 1996, LEUKEMIA LYMPHOMA, V20, P417, DOI 10.3109/10428199609052423; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, J CLIN INVEST, V91, P1044, DOI 10.1172/JCI116261; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITTHUHN B, 1998, IN PRESS LEUK LYMPHO; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497	67	55	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17742	17748		10.1074/jbc.273.28.17742	http://dx.doi.org/10.1074/jbc.273.28.17742			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651374	hybrid			2022-12-27	WOS:000074816100067
J	Ilic, MZ; Robinson, HC; Handley, CJ				Ilic, MZ; Robinson, HC; Handley, CJ			Characterization of aggrecan retained and lost from the extracellular matrix of articular cartilage - Involvement of carboxyl-terminal processing in the catabolism of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CORE; PROTEOGLYCAN; CLEAVAGE; CULTURES; SEQUENCE; FRAGMENTS; DOMAIN; IDENTIFICATION; BIOSYNTHESIS; DEGRADATION	The catabolism of aggrecan in bovine articular cartilage explants is characterized by the release into the culture medium of high molecular weight aggrecan fragments, generated by the proteolytic cleavage of the core protein between residues Glu(373) and Ala(374) within the interglobular domain. In this study, the position of the carboxyl-terminus of these aggrecan fragments, as well as a major proteolytically shortened aggrecan core protein present in cartilage matrix, have been deduced by characterizing the peptides generated by the reaction of aggrecan core protein peptides with cyanogen bromide. It was shown that two out of three such peptide fragments having an amino terminus starting at Ala(374) have their carboxyl terminus located within the chondroitin sulfate 1 domain. The third and largest aggrecan core protein peptide, with an amino terminus starting at Ala(374), has a carboxyl terminus in a region of core protein between the chondroitin sulfate 1 domain and the chondroitin sulfate 2 domain. The carboxyl terminus of this peptide appeared to be the same as that of the proteolytically degraded aggrecan core protein, which is retained within the extracellular matrix of the tissue. Another two aggrecan fragments recovered from the medium of explant cultures with amino-terminal sequences in the chondroitin sulfate 2 domain at Ala(1772) and Leu(1872) were shown to have their carboxyl termini within the G3 globular domain. These results suggest that the catabolism of aggrecan between residues Glu(373) and Ala(374) in the interglobular domain by the putative proteinase, aggrecanase, may be dependent on prior proteolytic processing within the carboxyl-terminal region of the core protein.	La Trobe Univ, Sch Human Biosci, Bundoora, Vic 3083, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	La Trobe University; Monash University	Handley, CJ (corresponding author), La Trobe Univ, Sch Human Biosci, Bundoora, Vic 3083, Australia.	C.Handley@latrobe.edu.au						ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BAYLISS MT, 1990, SEMIN ARTHRITIS RHEU, V20, P12; BONNET F, 1983, BIOCHIM BIOPHYS ACTA, V743, P82, DOI 10.1016/0167-4838(83)90420-X; Buttle DJ, 1997, J CLIN PATHOL-MOL PA, V50, P153, DOI 10.1136/mp.50.3.153; BUTTLE DJ, 1993, ARTHRITIS RHEUM, V36, P1709, DOI 10.1002/art.1780361210; CAMPBELL MA, 1989, BIOCHEM J, V259, P21, DOI 10.1042/bj2590021; CATERSON B, 1985, FED PROC, V44, P386; FLANNERY C, 1992, ARCH BIOCHEM BIOPHYS, V297, P52, DOI 10.1016/0003-9861(92)90640-I; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FULOP C, 1993, J BIOL CHEM, V268, P17377; HASCALL VC, 1983, ARCH BIOCHEM BIOPHYS, V224, P206, DOI 10.1016/0003-9861(83)90205-9; Hering TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P259, DOI 10.1006/abbi.1997.0261; HEY NJ, 1990, BIOCHIM BIOPHYS ACTA, V1034, P73, DOI 10.1016/0304-4165(90)90155-P; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; ILIC MZ, 1990, BIOCHEM INT, V21, P977; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MOK MT, 1992, ARCH BIOCHEM BIOPHYS, V292, P442, DOI 10.1016/0003-9861(92)90014-N; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OIKE Y, 1980, BIOCHEM J, V191, P203, DOI 10.1042/bj1910203; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PERIN JP, 1984, FEBS LETT, V176, P37, DOI 10.1016/0014-5793(84)80907-2; PLAAS AHK, 1993, MATRIX, V13, P135, DOI 10.1016/S0934-8832(11)80072-7; SANDY JD, 1991, J BIOL CHEM, V266, P8683	28	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17451	17458		10.1074/jbc.273.28.17451	http://dx.doi.org/10.1074/jbc.273.28.17451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651333	hybrid			2022-12-27	WOS:000074816100026
J	Alzuherri, HM; White, RJ				Alzuherri, HM; White, RJ			Regulation of a TATA-binding protein-associated factor during cellular differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-TFIIIB; PROXIMAL SEQUENCE ELEMENT; HUMAN U6; GENE; SUBUNIT; COMPLEX; TBP; COMPONENT; ENCODES	RNA polymerase III transcription is down-regulated when F9 embryonal carcinoma cells differentiate into parietal endoderm. This reflects a decrease in the activity of TFIIIB, a multisubunit complex that is required for all class III gene expression. Two essential components of TFIIIB are the TATA-binding protein (TBP) and an associated polypeptide called BRF that is specific to this complex. The abundance of both TBP and BRF decreases during F9 cell differentiation. Whereas the amount of TBP assembled into TFIIIB is down-regulated, this is not the case for all TBP-containing complexes. BRF levels show a more dramatic decline that appears sufficient to account for the overall change in transcriptional activity. Developmental regulation of a specific class of genes may therefore be achieved through changes in the availability of a TBP-associated factor.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Larminie CGC, 1998, DNA SEQUENCE, V9, P49, DOI 10.3109/10425179809050025; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MEISSNER W, 1995, MOL CELL BIOL, V15, P5888; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; Mital R, 1996, MOL CELL BIOL, V16, P7031; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; Nothias JY, 1996, EMBO J, V15, P5715, DOI 10.1002/j.1460-2075.1996.tb00955.x; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; VASSEUR M, 1985, EMBO J, V4, P1749, DOI 10.1002/j.1460-2075.1985.tb03846.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; YOON JB, 1995, MOL CELL BIOL, V15, P2019	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17166	17171		10.1074/jbc.273.27.17166	http://dx.doi.org/10.1074/jbc.273.27.17166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642284	hybrid			2022-12-27	WOS:000074545200074
J	Takeda, K; Ichijo, H; Fujii, M; Mochida, Y; Saitoh, M; Nishitoh, H; Sampath, TK; Miyazono, K				Takeda, K; Ichijo, H; Fujii, M; Mochida, Y; Saitoh, M; Nishitoh, H; Sampath, TK; Miyazono, K			Identification of a novel bone morphogenetic protein-responsive gene that may function as a noncoding RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS HOMEOBOX GENE; TGF-BETA SUPERFAMILY; OSTEOGENIC PROTEIN-1; SIGNALING PATHWAYS; MAD PROTEINS; XIST GENE; H19 GENE; DIFFERENTIATION; BMP-4; RECEPTOR	Bone morphogenetic proteins (BMPs)/osteogenic proteins (OPs), members of the transforming growth factor-beta superfamily, have a wide variety of effects on many cell types including osteoblasts and chondroblasts, and play critical roles in embryonic development, BMPs transduce their effects through binding to two different types of serine/threonine kinase receptors, type I and type II. Signaling by these receptors is mediated by the recently identified Smad proteins. Despite the rapid progress in understanding of the signaling mechanism downstream of BMP receptors, the target genes of BMPs are poorly understood in mammals. Here we identified a novel gene, termed BMP/OP-responsive gene (BORG), in C2C12 mouse myoblast cell line which trans-differentiates into osteoblastic cells in response to BMPs. Expression of BORG was dramatically induced in C2C12 cells by the treatment with BMP-2 or OP-l within 2 h and peaked at 12-24 h, whereas transforming growth factor-beta had a minimal effect. BMP-dependent expression of BORG was also detected in other cell types which are known to respond to BMPs, suggesting that BORG is a common target gene of BMPs. Cloning and sequence analysis of BORG; cDNA and the genomic clones revealed that, unexpectedly, the transcript of BORG lacks any extensive open reading frames and contains a cluster of multiple interspersed repetitive sequences in its middle part. The unusual structural features suggested that BORG may function as a noncoding RNA, although it is spliced and polyadenylated as authentic protein-coding mRNAs. Together with the observation that transfection of antisense oligonucleotides of BORG partially inhibited BMP-induced differentiation in C2C12 cells, it is possible that a new class of RNA molecules may have certain roles in the differentiation process induced by BMPs.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Tokyo 1708455, Japan; Creat Biomol Inc, Hopkinton, MA 01748 USA	Japanese Foundation for Cancer Research	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Dept Biomat Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.			Ichijo, Hidenori/0000-0002-5005-6438; Mochida, Yoshiyuki/0000-0002-2115-4303; Takeda, Kohsuke/0000-0002-8359-8399; Nishitoh, Hideki/0000-0002-8652-4109				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; ASKEW DS, 1994, MOL CELL BIOL, V14, P1743, DOI 10.1128/MCB.14.3.1743; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FINI ME, 1989, J CELL BIOL, V108, P2045, DOI 10.1083/jcb.108.6.2045; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kuroda MI, 1997, CELL, V91, P9, DOI 10.1016/S0092-8674(01)80003-9; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Padgett Richard W., 1997, Cytokine and Growth Factor Reviews, V8, P1, DOI 10.1016/S1359-6101(96)00050-0; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; VELLECA MA, 1994, MOL CELL BIOL, V14, P7095, DOI 10.1128/MCB.14.11.7095; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU RH, 1997, MOL CELL BIOL, V17, P486; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090; Zhang HB, 1996, DEVELOPMENT, V122, P2977	61	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17079	17085		10.1074/jbc.273.27.17079	http://dx.doi.org/10.1074/jbc.273.27.17079			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642273	hybrid			2022-12-27	WOS:000074545200063
J	Tang, J; Gary, JD; Clarke, S; Herschman, HR				Tang, J; Gary, JD; Clarke, S; Herschman, HR			PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ZINC-FINGER; S-ADENOSYLMETHIONINE; TRANSCRIPTION FACTOR; BINDING; CLONING; GENE; RNA; METHYLATION; EXPRESSION	Methylation is one of the many post-translational modifications that modulate protein function. Although asymmetric N-G,N-G-dimethylation of arginine residues in glycine-arginine-rich domains of eucaryotic proteins, catalyzed by type I protein arginine N-methyltransferases (PRMT), has been known for some time, members of this enzyme class have only recently been cloned. The first example of this type of enzyme, designated PRMT1, cloned because of its ability to interact with the mammalian TIS21 immediate-early protein, was then shown to have protein arginine methyltransferase activity, We have now isolated rat and human cDNA orthologues that encode proteins with substantial sequence similarity to PRMT1. A recombinant glutathione S-transferase (GST) fusion product of this new rat protein, named PRMT3, asymmetrically dimethylates arginine residues present both in the designed substrate GST-GAR and in substrate proteins present in hypomethylated extracts of a yeast rmt1 mutant that lacks type I arginine methyltransferase activity; PRMT3 is thus a functional type I protein arginine N-methyltransferase, However, rat PRMT1 and PRMT3 glutathione S-transferase fusion proteins have distinct enzyme specificities for substrates present in both hypomethylated rmt1 yeast extract and hypomethylated RAT1 embryo cell extract. TIS21 protein modulates the enzymatic activity of recombinant GST-PRMT1 fusion protein but not the activity of GST-PRMT3, Western blot analysis of gel filtration fractions suggests that PRMT3 is present as a monomer in RAT1 cell extracts. In contrast, PRMT1 is present in an oligomeric complex. Immunofluorescence analysis localized PRMT1 predominantly to the nucleus of RAT1 cells. In contrast, PRMT3 is predominantly cytoplasmic.	Univ Calif Los Angeles, Mol Biol Inst 341, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Mol Biol Inst 341, 611 Circle Dr E, Los Angeles, CA 90095 USA.	hherschman@mednet.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020, R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26020, GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Kim S, 1997, INT J BIOCHEM CELL B, V29, P743, DOI 10.1016/S1357-2725(97)00009-5; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAPEYRE B, 1985, NUCLEIC ACIDS RES, V13, P5805, DOI 10.1093/nar/13.16.5805; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LIM RW, 1987, ONCOGENE, V1, P263; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; RAWAL N, 1995, BBA-PROTEIN STRUCT M, V1248, P11, DOI 10.1016/0167-4838(94)00213-Z; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; WANG C, 1982, J BIOL CHEM, V257, P8356; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; XIE HY, 1993, J BIOL CHEM, V268, P13364	41	268	272	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16935	16945		10.1074/jbc.273.27.16935	http://dx.doi.org/10.1074/jbc.273.27.16935			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642256	hybrid			2022-12-27	WOS:000074545200046
J	Antinozzi, PA; Segall, L; Prentki, M; McGarry, JD; Newgard, CB				Antinozzi, PA; Segall, L; Prentki, M; McGarry, JD; Newgard, CB			Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion - A re-evaluation of the long-chain acyl-CoA hypothesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; MALONYL-COA; PANCREATIC-ISLETS; CARNITINE PALMITOYLTRANSFERASE; FATTY-ACIDS; RAT; LANGERHANS; KETOGENESIS; OBESITY; ESTERS	The mechanism by which glucose stimulates insulin secretion from the pancreatic islets of Langerhans is incompletely understood. It has been suggested that malonyl-CoA plays a regulatory role by inhibiting fatty acid oxidation and promoting accumulation of cytosolic long-chain acyl-CoA (LC-CoA). In the current study, we have re evaluated this "long-chain acyl-CoA hypothesis" by using molecular and pharmacologic methods to perturb lipid metabolism in INS-1 insulinoma cells or rat islets during glucose stimulation. First, we constructed a recombinant adenovirus containing the cDNA encoding malonyl-CoA decarboxylase (AdCMV-MCD), an enzyme that decarboxylates malonyl-CoA to acetyl-CoA. INS-1 cells treated with AdCMV-MCD had dramatically lowered intracellular malonyl CoA levels compared with AdCMV-beta Gal-treated cells at both 3 and 20 mM glucose. Further, at 20 mM glucose, AdCMV-MCD-treated cells were less effective at suppressing [1-C-14]palmitate oxidation and incorporated 43% less labeled palmitate and 50% less labeled glucose into cellular lipids than either AdCMV-beta GAL-treated or untreated INS-1 cells. Despite the large metabolic changes caused by expression of MCD, insulin secretion in response to glucose was unaltered relative to controls. The alternative, pharmacologic approach for perturbing lipid metabolism was to use triacsin C to inhibit long-chain acyl-CoA synthetase. This agent caused potent attenuation of palmitate oxidation and glucose or palmitate incorporation into cellular lipids and also caused a 47% decrease in total LC-CoA. Despite this, the drug had no effect on glucose-stimulated insulin secretion in islets or INS-1 cells. We conclude that significant disruption of the link between glucose and lipid metabolism does not impair glucose-stimulated insulin secretion in pancreatic islets or INS-1 cells.	Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Montreal, Inst Canc Montreal, Ctr Rech LC Simard, Dept Nutr,Mol Nutr Unit, Montreal, PQ H2L 4M1, Canada	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite de Montreal	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Newgard@utsw.swmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R01DK046492, R37DK046492, R37DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18573, DK 46492-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BECKER TC, 1994, METHOD CELL BIOL, V43, P162; BEDOYA FJ, 1984, DIABETES, V33, P858, DOI 10.2337/diabetes.33.9.858; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DOBBINS RL, 1997, IN PRESS J CLIN INVE; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; JANG SH, 1989, J BIOL CHEM, V264, P3500; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; LIANG Y, 1991, DIABETES, V40, P327, DOI 10.2337/diabetes.40.3.327; McCrory W.J., 1988, VIROLOGY, V163, P614; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; SENER A, 1991, BIOCHIMIE, V73, P1287, DOI 10.1016/0300-9084(91)90090-N; Stein DT, 1997, J CLIN INVEST, V100, P398, DOI 10.1172/JCI119546; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; TAMARITRODRIGUEZ J, 1984, BIOCHEM J, V221, P317, DOI 10.1042/bj2210317; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Zhang SY, 1998, CELL SIGNAL, V10, P35, DOI 10.1016/S0898-6568(97)00070-3; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584	33	136	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16146	16154		10.1074/jbc.273.26.16146	http://dx.doi.org/10.1074/jbc.273.26.16146			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632669	hybrid			2022-12-27	WOS:000074436600040
J	Li, N; Seetharam, S; Seetharam, B				Li, N; Seetharam, S; Seetharam, B			Characterization of the human transcobalamin II promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; THYMIDYLATE SYNTHASE PROMOTER; BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; TRANSCRIPTION INITIATION; LESS PROMOTER; SP1; FAMILY; GENE; ELEMENT	Deletion and mutagenesis of the 5'-flanking region of the human transcobalamin II (TC II) transfected in hu man intestinal epithelial Caco-2 cells have revealed that TC II promoter activity is: (a) very weak; (b) restricted to a core region (-29 to -163) that contained multiple transcription initiation sites; (c) not dependent on other potential elements, such as a distally localized CCAAT box, a CF1, a HIP1 binding motif and a MED-1 element; (d) modulated weakly by a positive-acting GC box (-568-GAGGCGGTGC) and strongly by a proximal GC/GT overlapping box (-179 CCCCCGCCCCACCCC). Gel shift and immunosupershift analyses demonstrated that both the positive-acting GC box and the negative-acting GC/GT box were recognized by Sp1 and Sp3. Co-transfection studies using Sp1 and/or Sp3 expression plasmids revealed that while Sp1 stimulated, Sp3 repressed Sp1-mediated transactivation of TC II transcription. The proximal GC/GT box also acted as a negative element in human chronic myelogenous leukemia K-562 and HeLa cells. These results suggest that tissue/cell specific expression of the TC II gene may be controlled by the relative ratios of Sp1 and Sp3 that bind to the GC/GT box and the weak promoter activity of TC II is due to the transcriptional repression caused by the binding of Sp3 to the proximal GC/GT box.	Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, MACC Fund Ctr, Dept Biochem, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Ctr Vet Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Seetharam, B (corresponding author), Med Coll Wisconsin, MACC Fund Ctr, Dept Med, Div Gastroenterol & Hepatol, Rm 6061,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	seethara@post.itsmcw.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026638, R01DK050052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26638, DK-50052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER RS, 1994, J BIOL CHEM, V269, P4381; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; COUNREY A, 1992, KINGSCRIPTIONAL REGU, P743; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANDY DE, 1995, BIOCHEM J, V311, P541, DOI 10.1042/bj3110541; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; JACOB E, 1980, PHYSIOL REV, V60, P918, DOI 10.1152/physrev.1980.60.3.918; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LANS MS, 1994, J BIOL CHEM, V269, P14170; LI N, 1994, BIOCHEM BIOPH RES CO, V204, P1111, DOI 10.1006/bbrc.1994.2577; LI N, 1995, BIOCHEM BIOPH RES CO, V208, P756, DOI 10.1006/bbrc.1995.1402; LI N, 1994, HUM MOL GENET, V3, P1835, DOI 10.1093/hmg/3.10.1835; LI N, 1994, BIOCHEM J, V301, P585, DOI 10.1042/bj3010585; LI N, 1993, BIOCHIM BIOPHYS ACTA, V1219, P515; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; Okumura K, 1996, J BIOL CHEM, V271, P12944, DOI 10.1074/jbc.271.22.12944; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Rolland V, 1996, J BIOL CHEM, V271, P21297, DOI 10.1074/jbc.271.35.21297; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sjottem E, 1996, J VIROL, V70, P188; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	46	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16104	16111		10.1074/jbc.273.26.16104	http://dx.doi.org/10.1074/jbc.273.26.16104			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632663	hybrid			2022-12-27	WOS:000074436600034
J	Wu, P; Brockenbrough, JS; Metcalfe, AC; Chen, SP; Aris, JP				Wu, P; Brockenbrough, JS; Metcalfe, AC; Chen, SP; Aris, JP			Nop5p is a small nucleolar ribonucleoprotein component required for pre-18 S rRNA processing in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							18S RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; PRERIBOSOMAL RNA; U3 SNRNA; PROTEIN; FIBRILLARIN; METHYLATION; IDENTIFICATION; HOMOLOGY; COMMON	We have identified a novel nucleolar protein, Nop5p, that is essential for growth in Saccharomyces cerevisiae. Monoclonal antibodies B47 and 37C12 recognize Nop5p, which has a predicted size of 57 kDa and possesses a KKX repeat motif at its carboxyl terminus. Truncations that removed the KKX motif were functional and localized to the nucleolus, but conferred slow growth at 37 degrees C. Nop5p shows significant sequence homology with yeast Sik1p/Nop56p, and putative homologues in archaebacteria, plants, and human. Depletion of Nop5p in a GAL-NOP5 strain lengthened the doubling time about 5-fold, and selectively reduced steady-state levels of 40 S ribosomal subunits and 18 S rRNA relative to levels of free 60 S subunits and 25 S rRNA. Northern blotting and primer extension analyses showed that Nop5p depletion impairs processing of 35 S pre-rRNA at the A(0) and A(2) cleavage sites. Nop5p is associated with the small nucleolar RNAs U3, snR13, U14, and U18. Depletion of Nop5p caused the nucleolar protein Nop1p (yeast fibrillarin) to be localized to the nucleus and cytosol. Also, 37C12 coimmunoprecipitated Nop1p. These results suggest that Nop5p functions with Nop1p in the execution of early pre-rRNA processing steps that lead to formation of 18 S rRNA.	Univ Florida, Hlth Sci Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Aris, JP (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Anat & Cell Biol, Box 100235, Gainesville, FL 32610 USA.	johnaris@college.med.ufl.edu	Davies, Angela/AAU-9716-2020	Davies, Angela/0000-0002-3365-7231; Aris, John/0000-0002-6475-064X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048586] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48586, R01 GM048586-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BousquetAntonelli C, 1997, EMBO J, V16, P4770, DOI 10.1093/emboj/16.15.4770; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Chen SP, 1997, J BIOL CHEM, V272, P10839; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; Dove JE, 1998, METHOD CELL BIOL, V53, P33; Dujon B, 1997, NATURE, V387, P98, DOI 10.1038/387s098; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; Morrissey JP, 1997, CHROMOSOMA, V105, P515, DOI 10.1007/BF02510488; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Sambrook J., 1989, MOL CLONING, pA1; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354	45	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16453	16463		10.1074/jbc.273.26.16453	http://dx.doi.org/10.1074/jbc.273.26.16453			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632712	hybrid, Green Accepted			2022-12-27	WOS:000074436600083
J	Cao, MY; Huber, M; Beauchemin, N; Famiglietti, J; Albelda, SM; Veillette, A				Cao, MY; Huber, M; Beauchemin, N; Famiglietti, J; Albelda, SM; Veillette, A			Regulation of mouse PECAM-1 tyrosine phosphorylation by the Src and Csk families of protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 PECAM-1; CELL-ADHESION; CYTOPLASMIC DOMAIN; NEGATIVE REGULATION; T-LYMPHOCYTES; SH2 DOMAIN; GENE; LIGAND; CD31; CLONING	PECAM-1 is an adhesion molecule expressed on hemopoietic and endothelial cells. Recently, it was observed that PECAM-1 becomes tyrosine-phosphorylated in response to a variety of physiological stimuli. Furthermore, tyrosine-phosphorylated PECAM-1 was shown to associate with SHP-2, a Src homology 2 (SH2) domain-containing protein-tyrosine phosphatase expressed ubiquitously. In light of the significance of tyrosine protein phosphorylation as a regulatory mechanism, we wished to understand better the nature and impact of the protein-tyrosine kinases (PTKs) mediating PECAM-1 tyrosine phosphorylation. Through reconstitution experiments in COS-l cells, we determined that mouse PECAM-1 could be tyrosine-phosphorylated by Src-related PTKs and Csk-related PTKs, but not by other kinases such as Syk, Itk, and Pyk2. Using site-directed mutagenesis and peptide phosphorylation studies, we found that these PTKs were efficient at phosphorylating Tyr-686, but not Tyr-663, of PECARI-1. Src-related enzymes also phosphorylated mouse PECAM-1 at one or more yet to be identified sites. In other studies, we demonstrated that phosphorylation of PECAM-1 by Src or Csk family kinases was sufficient to trigger its association with SHP-2, Moreover, it was able to promote binding of PECAM-1 to SHP-1, a SHP-8-related protein-tyrosine phosphatase expressed in hemopoietic cells. Taken together, these findings indicated that the Src and Csk families of kinases are strong candidates for mediating tyrosine phosphorylation of PECAM-1 and triggering its association with SH2 domain-containing phosphatases under physiological circumstances.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Dept Oncol, Montreal, PQ H3G 1A4, Canada; Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19014 USA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; University of Pennsylvania	Veillette, A (corresponding author), McGill Univ, Ctr Canc, Rm 715,McIntyre Med Sci Bld,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046311, R01HL046311] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Buckley CD, 1996, J CELL SCI, V109, P437; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deaglio S, 1996, J IMMUNOL, V156, P727; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; Famiglietti J, 1997, J CELL BIOL, V138, P1425, DOI 10.1083/jcb.138.6.1425; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Joukov V, 1997, BIOCHEM J, V322, P927, DOI 10.1042/bj3220927; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PERI KG, 1993, ONCOGENE, V8, P2765; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Prager E, 1996, J EXP MED, V184, P41, DOI 10.1084/jem.184.1.41; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; SHARENBERG AM, 1996, CELL, V87, P961; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; WATT SM, 1993, BLOOD, V82, P2649	52	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15765	15772		10.1074/jbc.273.25.15765	http://dx.doi.org/10.1074/jbc.273.25.15765			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624175	hybrid			2022-12-27	WOS:000074284200069
J	Gonzalez-Barroso, MM; Fleury, C; Bouillaud, F; Nicholls, DG; Rial, E				Gonzalez-Barroso, MM; Fleury, C; Bouillaud, F; Nicholls, DG; Rial, E			The uncoupling protein UCP1 does not increase the proton conductance of the inner mitochondrial membrane by functioning as a fatty acid anion transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; ADP/ATP CARRIER; H+ TRANSPORT; GUINEA-PIG; MECHANISM; ACTIVATION; ENERGETICS	The activity of the brown fat uncoupling protein (UCP1) is regulated by purine nucleotides and fatty acids, Although the inhibition by nucleotides is well established, the activation by fatty acids is still controversial. It has been reported that the ADP/ATP carrier, and possibly other members of the mitochondrial carrier family, mediate fatty acid uncoupling of mitochondria from a variety of sources by facilitating the transibilayer movement of the fatty acid anion. Brown fat mitochondria are known to be more sensitive to fatty acid uncoupling, a property that has been assigned to the presence of UCP1. We have analyzed the transport properties of UCP1 and conclude that fatty acids are not essential for UCP1 function, although they increase its uncoupling activity. Hn order to establish the difference between the proposed carrier-mediated uncoupling and that exerted through UCP1, we have studied the facility with which fatty acids uncouple respiration in mitochondria from control yeast and strains expressing UCP1 or the mutant Cys-304 --> Gly. The concentration of free palmitate required for half-maximal activation of respiration in UCP1-expressing mitochondria is 80 or 40 nM for the mutant protein. These concentrations have virtually no effect on the respiration of mitochondria from control yeast and are nearly 3 orders of magnitude lower than those reported for carrier-mediated uncoupling We propose that there exist two modes of fatty acid-mediated uncoupling; nanomolar concentrations activate proton transport through UCP1, but only if their concentrations rise to the micromolar range do they become substrates for nonspecific carrier-mediated uncoupling.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CNRS, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France; Univ Dundee, Ninewells Med Sch, Inst Neurosci, Dundee DD1 9SY, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Centre National de la Recherche Scientifique (CNRS); University of Dundee	Gonzalez-Barroso, MM (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	rial@fresno.csic.es	Rial, Eduardo/A-4242-2008; NICHOLLS, DAVID G/K-4300-2012; Bouillaud, Frédéric R/L-3238-2017	Rial, Eduardo/0000-0001-8634-8902; Bouillaud, Frédéric R/0000-0002-7518-9237; GONZALEZ BARROSO, MARIA DEL MAR/0000-0002-0278-8298				ANDREYEV AY, 1988, FEBS LETT, V226, P265, DOI 10.1016/0014-5793(88)81436-4; ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GonzalezBarroso MM, 1996, EUR J BIOCHEM, V239, P445, DOI 10.1111/j.1432-1033.1996.0445u.x; HOHORST HJ, 1968, H-S Z PHYSIOL CHEM, V349, P268; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P525, DOI 10.1007/BF01108409; Polcic P, 1997, FEBS LETT, V412, P207, DOI 10.1016/S0014-5793(97)00778-3; PRESSMAN BC, 1956, BIOCHIM BIOPHYS ACTA, V21, P458, DOI 10.1016/0006-3002(56)90182-2; RAFAEL J, 1969, H-S Z PHYSIOL CHEM, V350, P1121, DOI 10.1515/bchm2.1969.350.2.1121; RIAL E, 1984, BIOCHEM J, V222, P685, DOI 10.1042/bj2220685; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Samartsev VN, 1997, BBA-BIOENERGETICS, V1319, P251, DOI 10.1016/S0005-2728(96)00166-1; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; VAARTJES WJ, 1978, BIOCHIM BIOPHYS ACTA, V503, P437, DOI 10.1016/0005-2728(78)90143-3; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Wieckowski MR, 1997, BIOCHEM BIOPH RES CO, V232, P414; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; WOJTCZAK L, 1967, BIOCHEM BIOPH RES CO, V28, P76, DOI 10.1016/0006-291X(67)90409-3	36	83	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15528	15532		10.1074/jbc.273.25.15528	http://dx.doi.org/10.1074/jbc.273.25.15528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624141	Green Published, hybrid			2022-12-27	WOS:000074284200035
J	Gum, RJ; McLaughlin, MM; Kumar, S; Wang, ZL; Bower, MJ; Lee, JC; Adams, JL; Livi, GP; Goldsmith, EJ; Young, PR				Gum, RJ; McLaughlin, MM; Kumar, S; Wang, ZL; Bower, MJ; Lee, JC; Adams, JL; Livi, GP; Goldsmith, EJ; Young, PR			Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; CYTOKINE BIOSYNTHESIS; IDENTIFICATION; DOMAINS; FAMILY; YEAST	Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase compete with ATP for binding, Mutation of 23 residues in the ATP pocket indicated that several residues which affected binding of pyridinyl imidazole photoaffinity cross-linker I-125-SB 206718 did not affect kinase activity, and vice versa, suggesting that pyridinyl imidazoles bind p38 differently than ATP. Two close homologues of p38, SAPK3 and SAPK4, are not inhibited by SE 203580 and differ from p38 by three amino acids near the hinge of the ATP pocket. Substitution of the three amino acids in p38 by those in SAPK3/4 (Thr-106, His-107, and Leu-108 to Met, I?ro, and Phe) resulted in decreased I-125-SB 206718 cross-linking and loss of inhibition by SE 203580. Substitution of just Thr-106 by Met resulted in incomplete loss of inhibition. Conversely, substitution of the three amino acids of p38 into SAPK3, SAPK4, or the more distantly related JNK1 resulted in inhibition by SE 203580, whereas mutation of just Met-106 to Thr resulted in weaker inhibition. These results indicate that these three amino acids can confer specificity and sensitivity to SE 203580 for at least two different classes of MAPKs.	SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Comparat Genet, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Cellular Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA; Univ Texas, SW Med Ctr, Dept Biochem & Biophys, Dallas, TX 75235 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Young, PR (corresponding author), SmithKline Beecham Pharmaceut, Dept Biol Mol, POB 1539, King Of Prussia, PA 19406 USA.	peter_r_young@sbphrd.com						BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Garnes KT, 1996, J LABELLED COMPD RAD, V38, P637, DOI 10.1002/(SICI)1099-1344(199607)38:7<637::AID-JLCR871>3.0.CO;2-T; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	28	210	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15605	15610		10.1074/jbc.273.25.15605	http://dx.doi.org/10.1074/jbc.273.25.15605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624152	hybrid			2022-12-27	WOS:000074284200046
J	Nakamura, H; Oda, T; Hamada, K; Hirano, T; Shimizu, N; Utiyama, H				Nakamura, H; Oda, T; Hamada, K; Hirano, T; Shimizu, N; Utiyama, H			Survival by Mac-1-mediated adherence and anoikis in phorbol ester-treated HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; MYELOID-LEUKEMIA CELLS; CULTURED HUMAN-MONOCYTES; TERMINAL DIFFERENTIATION; PROMYELOCYTIC LEUKEMIA; SPHINGOSINE KINASE; DNA FRAGMENTATION; INDUCED APOPTOSIS; PROTOONCOGENE EXPRESSION	During the exposure of human myelocytic leukemia HL-60 cells to phorbol diester, nonadherent cells die by apoptosis, but adherent cells survive rand growth-arrest at G(1) phase of the cell cycle. Here we have shown that the adherent cells rapidly died by apoptosis after forced detachment (anoikis), indicating that phorbol diester induced apoptosis by default. Dimethylsphingosine induced apoptosis in the adherent cells, and sphingosine-1-phosphate rescued the detached cells from apoptosis, Sphingosine kinase activity in adherent cells was higher than that in nonadherent cells and was decreased by forced detachment. It is likely that the phorbol diester-induced apoptosis and the adhesion-mediated survival are modulated by sphingosine and sphinposine-1-phosphate, respectively. The adherent cells were reverted and reproliferated when allowed to spontaneously detach from plastic surfaces by removal of phorbol tliester, This result suggests that after removal of phorbol diester, the commitment signal of apoptosis by default is lost faster than the survival signal by adherence.	Hiroshima Univ, Fac Integrated Arts & Sci, Life Sci Grp, Higashihiroshima 7398521, Japan; Helix Res Inst, Kisarazu 2920812, Japan	Hiroshima University	Utiyama, H (corresponding author), Hiroshima Univ, Fac Integrated Arts & Sci, Life Sci Grp, Kagamiyama 1-7-1, Higashihiroshima 7398521, Japan.		Oda, Tsukasa/ABI-1855-2020; Hirano, Tetsuo/N-1808-2019	Hirano, Tetsuo/0000-0002-2495-4998; Oda, Tsukasa/0000-0002-8941-161X				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1990, BLOOD, V75, P1037; Baran J, 1996, INFECT IMMUN, V64, P4242, DOI 10.1128/IAI.64.10.4242-4248.1996; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1987, BLOOD, V70, P1233; COOPER RA, 1982, P NATL ACAD SCI-BIOL, V79, P2865, DOI 10.1073/pnas.79.9.2865; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DALTON WT, 1988, BLOOD, V71, P242; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; GALLAGHER R, 1979, BLOOD, V54, P713; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; HICKSTEIN DD, 1987, J IMMUNOL, V138, P513; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIZAKI Y, 1995, MOL BIOL CELL, V6, P1443, DOI 10.1091/mbc.6.11.1443; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; LEE LS, 1978, J ENVIRON PATHOL TOX, V1, P627; Liles WC, 1997, CURR OPIN INFECT DIS, V10, P165, DOI 10.1097/00001432-199706000-00002; Mano N, 1997, ANAL BIOCHEM, V244, P291, DOI 10.1006/abio.1996.9891; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; MEINHARDT G, 1995, LEUKEMIA RES, V19, P699, DOI 10.1016/0145-2126(95)00040-U; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; ODA T, 1993, INT J HEMATOL, V58, P125; OHTA H, 1995, CANCER RES, V55, P691; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PAHL HL, 1992, BLOOD, V79, P865; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROSMARIN AG, 1989, BLOOD, V73, P131; ROSMARIN AG, 1992, BLOOD, V79, P2598; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHIMIZU N, 1994, CANCER RES, V54, P3561; SKOGLUND G, 1988, CANCER RES, V48, P3168; SOKOLOSKI JA, 1993, BLOOD, V82, P625; SOLARY E, 1994, LEUKEMIA, V8, P792; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WRIGHT SD, 1984, J CELL BIOL, V99, P336, DOI 10.1083/jcb.99.1.336; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	61	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15345	15351		10.1074/jbc.273.25.15345	http://dx.doi.org/10.1074/jbc.273.25.15345			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624115	hybrid			2022-12-27	WOS:000074284200009
J	Schirmer, EC; Queitsch, C; Kowall, AS; Parsell, DA; Lindquist, S				Schirmer, EC; Queitsch, C; Kowall, AS; Parsell, DA; Lindquist, S			The ATPase activity of Hsp104, effects of environmental conditions and mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATED ATPASE; DEPENDENT CLP PROTEASE; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; BINDING SITES; SACCHAROMYCES-CEREVISIAE; EXPRESSION; COMPONENT; GENES; IDENTIFICATION	Hspl04 is crucial for stress tolerance in Saccharomyces cerevisiae, and both of its nucleotide-binding domains (NBD1 and NBD2) are required. Here, we characterize the ATPase activity and oligomerization properties of wild-type (WT) Hsp104 and of NBD mutants, In physiological ionic strength buffers (pH 7.5, 37 degrees C) WT Hsp104 exhibits Michaelis-Menten kinetics between 0.5 and 25 mM ATP (K-m similar to 5 mM, V-max similar to 2 nmol min(-1) mu g(-1)). ATPase activity is strongly influenced by factors that vary with cell stress (e.g. temperature, pH, and ADP). Mutations in the P-loop of NBD1 (G217V or K218T) severely reduce ATP hydrolysis but have little effect on oligomerization. Analogous mutations in NBD2 (G619V or K620T) have smaller effects on ATPase activity but impair oligomerization. The opposite relationship was reported for another member of the HSP100 protein family, the Escherichia coli ClpA protein, in studies employing lower ionic strength buffers. Ire such buffers, the K-m of WT Hsp104 for ATP hydrolysis decreased 10-fold and its stability under stress conditions increased, but the effects of the NBD mutations on ATPase activity and oligomerization remained opposite to those of ClpA Either the functions of the two NBDs in ClpA and Hsp104 have been reversed or both contribute to ATP hydrolysis and oligomerization in a complex manner that can be idiosyncratically affected by such mutations.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), 5841 S Maryland Ave,MC1028,Rm AMB N339, Chicago, IL 60637 USA.	s-lindquist@uchicago.edu		Schirmer, Eric/0000-0003-2635-1338	NIGMS NIH HHS [6 T32 GM07183-19] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; PAINTER GR, 1989, P NATL ACAD SCI USA, V86, P2239, DOI 10.1073/pnas.86.7.2239; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; SINGH SK, 1994, J BIOL CHEM, V269, P29537; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Turgay K, 1997, GENE DEV, V11, P119, DOI 10.1101/gad.11.1.119; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEITZEL G, 1987, EXP CELL RES, V170, P64, DOI 10.1016/0014-4827(87)90117-0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WILSON SA, 1995, J BIOL CHEM, V270, P18818, DOI 10.1074/jbc.270.32.18818; WOO KM, 1992, J BIOL CHEM, V267, P20429	34	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15546	15552		10.1074/jbc.273.25.15546	http://dx.doi.org/10.1074/jbc.273.25.15546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624144	hybrid			2022-12-27	WOS:000074284200038
J	Stratikos, E; Gettins, PGW				Stratikos, E; Gettins, PGW			Mapping the serpin-proteinase complex using single cysteine variants of alpha(1)-proteinase inhibitor Pittsburgh	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; PROTEASE COMPLEXES; POTENT INHIBITOR; ANTI-THROMBIN; FACTOR-XII; ALPHA-1-ANTITRYPSIN; KALLIKREIN; TRYPSIN; REACTIVITY; SITE	To probe the covalent serpin-proteinase complex, we used wild-type and 4 new single cysteine variants (T85C, S121C, D159C, and D298C) of alpha(1)-proteinase inhibitor Pittsburgh. Cysteines in each variant could be labeled both in native and proteinase-complexed alpha(1)-proteinase inhibitors. Pre-reaction with 7-nitrobenz-2-oxa-1,3-diazole-chloride or fluorescein prevented complex formation only with the D298C variant. Label at Cys(121) greatly increased the stoichiometry of inhibition for thrombin and gave an emission spectrum that discriminated between native, cleaved, and proteinase-complexed serpin and between complexes with trypsin and thrombin, whereas fluorophore at residue 159 ore helix F was almost insensitive to complex formation. Fluorescence resonance energy transfer measurements for covalent and non-covalent complexes were consistent with a location of the proteinase at the end of the serpin distal from the original location of the reactive center loop, Taken together, these findings are consistent with a serpin-proteinase complex in which the reactive center loop is fully inserted into beta-sheet A, and the proteinase is at the far end of the serpin from its initial site of docking with the reactive center loop close to, but not obscuring, residue 121.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, M-C 536,1819-1853 W Polk St, Chicago, IL 60612 USA.	pgettins@tigger.cc.uic.edu	Stratikos, Efstratios/N-2969-2014	Stratikos, Efstratios/0000-0002-3566-2309	NHLBI NIH HHS [HL49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049234, R01HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKO H, 1972, BIOCHEM BIOPH RES CO, V47, P1402, DOI 10.1016/0006-291X(72)90228-8; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JOHANSEN H, 1987, MOL BIOL MED, V4, P291; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LEWIS JH, 1978, BLOOD, V51, P129; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHAPIRA M, 1986, J CLIN INVEST, V77, P635, DOI 10.1172/JCI112347; SCOTT CF, 1986, J CLIN INVEST, V77, P631, DOI 10.1172/JCI112346; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	22	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15582	15589		10.1074/jbc.273.25.15582	http://dx.doi.org/10.1074/jbc.273.25.15582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624149	hybrid			2022-12-27	WOS:000074284200043
J	Heitmeier, MR; Scarim, AL; Corbett, JA				Heitmeier, MR; Scarim, AL; Corbett, JA			Double-stranded RNA-induced inducible nitric-oxide synthase expression and interleukin-1 release by murine macrophages requires NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BETA-CELLS; INHIBITION; REPLICATION; SYSTEM; SIGNAL	The effects of double-stranded RNA (synthetic polyi nosinic-polycytidylic acid; poly(I-C)) on macrophage expression of inducible nitric-oxide synthase (iNOS), production of nitric oxide, and release of interleukin-1 (IL-1) were investigated. Individually, poly(I-C), interferon-gamma (IFN-gamma), and lipopolysaccharide (LPS) stimulate late nitrite production and iNOS expression by RAW 264.7 cells. In combination, the effects of poly(I-C) + IFN-gamma are additive, while poly(I-C) does not further potentiate LPS-induced nitrite production. These re suits suggest that poly(I-C) and LPS may stimulate iNOS expression by similar signaling pathways, which may be independent of pathways activated by IFN-gamma, LPS-induced iNOS expression is associated with the activation of NF-kappa B. We show that inhibition of NF-kappa B by pyrrolidine dithiocarbamate prevents poly(I-C) + IFN-gamma-, poly(I-C) + LPS-, and LPS-induced iNOS expression, nitrite production and I kappa B degradation by RAW 264.7 cells. The effects of poly(I-C) on iNOS expression appear to be cell-type specific. Poly(I-C), alone or in combination with IFN-gamma, does not stimulate, nor does poly(I-C) potentiate, IL-1-induced nitrite production by rat insulinoma RINm5F cells. In addition, we show that the combination of poly(I-C) + IFN-gamma stimulates iNOS expression, nitrite production I kappa B degradation, and the release of IL-1 by primary mouse macrophages, and these effects are prevented by pyrrolidinedithiocarbamate. These findings indicate that double-stranded RNA, in the presence of IFN-gamma, is a potent activator of macrophages, stimulating iNOS expression, nitrite production, and IL-1 release by a mechanism which requires the activation of NF-kappa B.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	corbettj@wpogate.slu.edu			NIDDK NIH HHS [DK-52194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER P, 1971, NATURE-NEW BIOL, V232, P76, DOI 10.1038/newbio232076a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BEDOYA FJ, 1995, BIOCHEM BIOPH RES CO, V210, P816, DOI 10.1006/bbrc.1995.1731; BROWN T, 1991, CURRENT PROTOCOLS MO, V1; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; BURATOWSKI S, 1991, CURRENT PROTOCOLS MO, V1; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; HIBBS JB, 1990, INT CONGR SER, V897, P189; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KIM HK, 1995, J IMMUNOL, V154, P4741; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Kreil TR, 1996, VIROLOGY, V219, P304, DOI 10.1006/viro.1996.0252; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannick JB, 1995, RES IMMUNOL, V146, P693, DOI 10.1016/0923-2494(96)84920-0; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARCUS PI, 1984, INTERFERON, V3, P113; MCNAIR ANB, 1992, PHARMACOL THERAPEUT, V56, P79, DOI 10.1016/0163-7258(92)90038-2; MELKOVA Z, 1995, J IMMUNOL, V155, P5711; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; TORRES BA, 1985, BIOCHEM BIOPH RES CO, V131, P395, DOI 10.1016/0006-291X(85)91815-7	39	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15301	15307		10.1074/jbc.273.24.15301	http://dx.doi.org/10.1074/jbc.273.24.15301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614147	hybrid			2022-12-27	WOS:000074160400089
J	Furukawa, T; Nukada, T; Mori, Y; Wakamori, M; Fujita, Y; Ishida, H; Fukuda, K; Kato, S; Yoshii, M				Furukawa, T; Nukada, T; Mori, Y; Wakamori, M; Fujita, Y; Ishida, H; Fukuda, K; Kato, S; Yoshii, M			Differential interactions of the C terminus and the cytoplasmic I-II loop of neuronal Ca2+ channels with G-protein alpha and beta gamma subunits - I. Molecular determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; CALCIUM CHANNELS; FUNCTIONAL EXPRESSION; INHIBITION; MODULATION; RECEPTORS; SUBTYPES; CLONING; OOCYTES; BRAIN	Interactions of G-protein a (G alpha) and beta gamma subunits (G beta gamma) with N- (alpha(1B)) and P/Q-type (alpha(1A)) Ca2+ channels were investigated using the Xenopus oocyte expression system. G(i3)alpha was found to inhibit both N- and P/Q-type channels by receptor agonists, whereas G beta(1)gamma(2) was responsible for prepulse facilitation of N-type channels. L-type channels (alpha(1C)) were not regulated by G alpha or G beta gamma. For N-type, prepulse facilitation mediated via G beta gamma was impaired when the cytoplasmic I-II loop (loop 1) was deleted or replaced with the alpha(1C) loop 1. G alpha-mediated inhibitions were also impaired by substitution of the alpha(1C) loop 1, but only when the C terminus was deleted. For P/Q type, by contrast, deletion of the C terminus alone diminished G alpha-mediated inhibition. Moreover, a chimera of L-type with the alpha(1B) loop 1 gained G beta gamma-dependent ent facilitation, whereas an L type chimera with the Nor P/Q-type C terminus gained G alpha-mediated inhibition. These findings provide evidence that loop 1 of N-type channels is a regulatory site for G beta gamma and the C termini of P/Q- and N-types for G alpha.	Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, Tokyo 156, Japan; Tokyo Inst Psychiat, Dept Neurophysiol, Setagaya Ku, Tokyo 156, Japan; Teikyo Univ, Fac Med, Dept Internal Med, Itabashi Ku, Tokyo 173, Japan; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 444, Japan; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 60601, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Kyoto 60601, Japan	Tokyo Institute of Psychiatry; Tokyo Institute of Psychiatry; Teikyo University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University System of Ohio; University of Cincinnati; Kyoto University; Kyoto University	Yoshii, M (corresponding author), Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 156, Japan.			Wakamori, Minoru/0000-0001-8574-3310	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL22619-20] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; Page KM, 1997, J NEUROSCI, V17, P1330; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TSUNOO A, 1986, P NATL ACAD SCI USA, V83, P9832, DOI 10.1073/pnas.83.24.9832; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17585	17594		10.1074/jbc.273.28.17585	http://dx.doi.org/10.1074/jbc.273.28.17585			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651353	hybrid			2022-12-27	WOS:000074816100046
J	Huang, BL; Gudi, R; Wu, PF; Harris, RA; Hamilton, J; Popov, KM				Huang, BL; Gudi, R; Wu, PF; Harris, RA; Hamilton, J; Popov, KM			Isoenzymes of pyruvate dehydrogenase phosphatase - DNA-derived amino acid sequences, expression, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; FUEL SELECTION; LIPOYL DOMAIN; KINASE; MITOCHONDRIA; MECHANISM; COMPLEX; CALCIUM; IONS; RAT	Pyruvate dehydrogenase phosphatase (PDP) is one of the few mammalian phosphatases residing within the mitochondrial matrix space. It is responsible for dephosphorylation and reactivation of the pyruvate dehydrogenase complex (PDC) and, by this means, is intimately involved in the regulation of utilization of carbohydrate fuels in mammals. PDP is a dimeric enzyme consisting of catalytic and regulatory subunits, The catalytic subunit of PDP is a Mg2+-dependent enzyme homologous to the cytosolic phosphatases of the 2C family. In the present study, we isolated two cDNAs encoding for mitochondrial phosphatases, The first cDNA is highly homologous to the previously identified cDNA encoding for the catalytic subunit of PDP (PDP1). The second cDNA. encodes a previously unknown catalytic subunit of PDP (PDP2), The new phosphatase, expressed as the recombinant protein in Escherichia coli, shows strict substrate specificity toward PDC and does not use phosphorylated branched chain alpha-ketoacid dehydrogenase as substrate. Like PDP1, PDP2 is a Mg2+-dependent enzyme, but its sensitivity to Mg2+ ions is almost 10-fold lower than that of PDP1. In contrast to PDP1, PDP2 is not regulated by Ca2+ ions, Instead, it is sensitive to the biological polyamine spermine, which, in turn, has no effect on the enzymatic activity of PDP1, Western blot analysis of PDP extracted from mitochondria isolated from liver and skeletal muscle revealed that PDP1 is predominantly expressed in mitochondria from skeletal muscle, whereas PDP2 is much more abundant in the liver rather than muscle mitochondria. Both isoenzymes are expressed in mitochondria from 3T3-L1 adipocytes, but the level of expression of PDP2 is considerably higher. These observations are consistent with previous findings on the enzymatic parameters of PDP in adipose tissue. Thus, our results provide the first evidence that there are at least two isoenzymes of PDP in mammals that are different with respect to tissue distribution and kinetic parameters and, therefore, are likely to be different functionally.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Popov, KM (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	kpopov@iupui.edu			NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DEBURGOS NMG, 1994, ARCH BIOCHEM BIOPHYS, V308, P520, DOI 10.1006/abbi.1994.1073; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KEDISHVILI NY, 1994, ARCH BIOCHEM BIOPHYS, V315, P317, DOI 10.1006/abbi.1994.1506; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; RANDLE PJ, 1995, P NUTR SOC, V54, P317, DOI 10.1079/PNS19950057; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; RUTTER GA, 1989, ANN NY ACAD SCI, V573, P206, DOI 10.1111/j.1749-6632.1989.tb14998.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEVERSON DL, 1974, BIOCHEM J, V140, P225, DOI 10.1042/bj1400225; SONG H, 1994, J BIOL CHEM, V269, P31573; STEPP LR, 1983, J BIOL CHEM, V258, P9454; SUGDEN MC, 1995, J NUTR, V125, pS1746; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017	38	170	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17680	17688		10.1074/jbc.273.28.17680	http://dx.doi.org/10.1074/jbc.273.28.17680			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651365	hybrid			2022-12-27	WOS:000074816100058
J	Breivogel, CS; Selley, DE; Childers, SR				Breivogel, CS; Selley, DE; Childers, SR			Cannabinoid receptor agonist efficacy for stimulating [S-35]GTP gamma S binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; RECONSTITUTED PHOSPHOLIPID-VESICLES; G-PROTEINS; ADENYLATE-CYCLASE; BRAIN MEMBRANES; GUANOSINE-5'-O-(3-<S-35>THIO)TRIPHOSPHATE BINDING; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); REGULATORY COMPONENT; ADENOSINE RECEPTOR; CARDIAC MEMBRANES	The relationship between GDP and cannabinoid-stimulated [S-35]guanosine-5'-O-(3-thiotriphosphate) ([S-35]GTP gamma S) binding was investigated in rat cerebellar membranes. Kinetic analyses showed that [35S]GTP gamma S binding reached steady-state levels and that the association rate was increased by the agonist WIN 55212-2 proportional to the concentration of GDP. Dissociation of [S-35]GTP gamma S occurred with two rates (t(1/2) = 7 and 170 min), and WIN 55212-2 increased the proportion of sites exhibiting the faster rate. Without GDP, [S-35]GTP gamma S bound to membranes with high and low affinity, and WIN 55212-2 had no effect. With 30 mu M GDP, [S-35]GTP gamma S bound to low and intermediate affinity sites, and WIN 55212-2 induced high affinity [S-35]GTP gamma S binding without affecting low affinity sites, GDP competed for high affinity [S-35]GTP gamma S binding with high and intermediate affinity in the absence of WIN 55212-2 and with high and low affinity in the presence of WIN 55212-2. Cannabinoid ligands displayed differential abilities to maximally stimulate [S-35]GTP gamma S binding in the presence of GDP. Efficacy differences among ligands increased with increasing GDP concentrations. GDP competition curves revealed that agonists induced low affinity GDP Ki values that were proportional to agonist E-max values, indicating that agonist efficacy is determined by displacement of GDP from G-proteins.	Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Ctr Neurobiol Invest Drug Abuse, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Investigat Neurosci, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Childers, SR (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Ctr Neurobiol Invest Drug Abuse, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Breivogel, Chris/0000-0001-5657-2735	NIDA NIH HHS [DA-06784, DA-07246] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007246, R01DA006784] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ASANO T, 1984, BIOCHEMISTRY-US, V23, P5467, DOI 10.1021/bi00318a014; BIDAUTRUSSELL M, 1990, J NEUROCHEM, V55, P21, DOI 10.1111/j.1471-4159.1990.tb08815.x; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breivogel CS, 1997, J NEUROCHEM, V68, P1462; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Burkey TH, 1997, EUR J PHARMACOL, V323, pR3, DOI 10.1016/S0014-2999(97)00146-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; Gifford AN, 1996, J PHARMACOL EXP THER, V277, P1431; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Glass M, 1997, J NEUROSCI, V17, P5327, DOI 10.1523/jneurosci.17-14-05327.1997; HAMPSON RE, 1995, LIFE SCI, V56, P2081, DOI 10.1016/0024-3205(95)00192-9; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HILF G, 1992, EUR J BIOCHEM, V204, P725, DOI 10.1111/j.1432-1033.1992.tb16687.x; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; KEEN M, 1991, TRENDS PHARMACOL SCI, V12, P371, DOI 10.1016/0165-6147(91)90606-S; Kenalin T, 1993, PHARM ANAL DRUG RECE, P249; Lorenzen A, 1996, MOL PHARMACOL, V49, P915; LORENZEN A, 1993, MOL PHARMACOL, V44, P115; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MACKIE K, 1995, J NEUROSCI, V15, P6552; Maneuf YP, 1997, BRIT J PHARMACOL, V120, P1397, DOI 10.1038/sj.bjp.0701101; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; SanudoPena MC, 1997, NEUROSCI LETT, V223, P125, DOI 10.1016/S0304-3940(97)13424-3; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Selley DE, 1996, LIFE SCI, V59, P659, DOI 10.1016/0024-3205(96)00347-5; Shen MX, 1996, J NEUROSCI, V16, P4322; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Sim Laura J., 1997, V31, P1; SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242, DOI 10.1073/pnas.92.16.7242; Sim LJ, 1996, J NEUROSCI, V16, P8057; SIM LJ, 1996, EUR J PHARMACOL, V307, P95; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WATKINS DC, 1987, J BIOL CHEM, V262, P10651	55	157	159	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16865	16873		10.1074/jbc.273.27.16865	http://dx.doi.org/10.1074/jbc.273.27.16865			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642247	hybrid			2022-12-27	WOS:000074545200037
J	El Nemer, W; Gane, P; Colin, Y; Bony, V; Rahuel, C; Galacteros, F; Cartron, JP; Le Van Kim, C				El Nemer, W; Gane, P; Colin, Y; Bony, V; Rahuel, C; Galacteros, F; Cartron, JP; Le Van Kim, C			The Lutheran blood group glycoproteins, the erythroid receptors for laminin, are adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; IMMUNOGLOBULIN SUPERFAMILY; MEMBRANE; ATTACHMENT; PROTEINS; CLONING; BINDING; LIGAND	The Lutheran antigens are recently characterized glycoproteins in which the extracellular region contains five immunoglobulin like domains, suggesting some recognition function. A recent abstract suggests that the Lutheran glycoproteins (Lu gps) act as erythrocyte receptors for soluble laminin (Udani, M., Jefferson, S., Daymont, C., Zen, Q., and Telen, M. J. (1996) Blood 88, Suppl. 1, 6 (abstr.)). In the present report, we provided the definitive proof of the laminin receptor function of the Lu gps by demonstrating that stably transfected cells (murine L929 and human K562 cell lines) expressing the Lu gps bound laminin in solution and acquired adhesive properties to laminin-coated plastic dishes but not to fibronectin, vitronectin, transferrin, fibrinogen, or fibrin. Furthermore, expression of either the long-tail (85 kDa) or the short-tail (78 kDa) Lu gps, which differ by the presence or the absence of the last 40 amino acids of the cytoplasmic domain, respectively, conferred to transfected cells the same laminin binding capacity. We also confirmed by flow cytometry analysis that the level of laminin binding to red cells is correlated with the level of Lu antigen expression. Indeed, Lu-null cells did not bind to laminin, whereas sickle cells from most patients homozygous for hemoglobin S overexpressed Lu antigens and exhibited an increased binding to laminin, as compared with normal red cells. Laminin binding to normal and sickle red cells as well as to Lu transfected cells was totally inhibited by a soluble Lu-Fc chimeric fragment containing the extracellular domain of the Lu gps. During in vitro erythropoiesis performed by two-phase liquid cultures of human peripheral blood, the appearance of Lu antigens in late erythroid differentiation was concomitant with the laminin binding capacity of the cultured erythroblasts. Altogether, our results demonstrated that long-tail and short-tail Lu gps are adhesion molecules that bind equally well laminin and strongly suggested that these glycoproteins are the unique receptors for laminin in normal and sickle mature red cells as well as in erythroid progenitors.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Hop Henri Mondor, INSERM, U91, F-94100 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Le Van Kim, C (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	clvkim@infobiogen.fr	Nemer, Wassim El/N-4247-2017; le van kim, caroline/O-7030-2017; colin, yves/O-1910-2017	Nemer, Wassim El/0000-0001-8184-427X; le van kim, caroline/0000-0002-3251-1310; colin, yves/0000-0001-5196-4254				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; BUNN HF, 1992, NEW ENGL J MED, V337, P762; CAMPBELL IG, 1994, CANCER RES, V54, P5761; CARLOS TM, 1994, BLOOD, V84, P2068; CHESAGARIN P, 1994, INT J ONCOL, V5, P1261; CUTBUSH M, 1956, NATURE, V178, P855, DOI 10.1038/178855b0; DANIELS G, 1989, VOX SANG, V57, P137, DOI 10.1111/j.1423-0410.1989.tb01151.x; DANIELS G, 1995, HUMAN BLOOD GROUPS, P356; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; FIBACH E, 1990, AM J HEMATOL, V35, P151, DOI 10.1002/ajh.2830350303; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GREENWALT TJ, 1967, TRANSFUSION, V7, P189, DOI 10.1111/j.1537-2995.1967.tb05509.x; Hanspal M, 1997, Curr Opin Hematol, V4, P142; HEBBEL RP, 1991, BLOOD, V77, P214; Hillery CA, 1996, BLOOD, V87, P4879, DOI 10.1182/blood.V87.11.4879.bloodjournal87114879; INGLIS G, 1993, TRANSFUS MED S, V3, P94; JOHANSSON S, 1981, J CELL BIOL, V90, P260, DOI 10.1083/jcb.90.1.260; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; Parsons SF, 1997, BLOOD, V89, P4219, DOI 10.1182/blood.V89.11.4219; PARSONS SF, 1987, TRANSFUSION, V27, P61, DOI 10.1046/j.1537-2995.1987.27187121477.x; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; RACE RR, 1975, BLOOD GROUPS MAN, P261; Rahuel C, 1996, BLOOD, V88, P1865; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; RIWOM S, 1994, VOX SANG, V66, P61, DOI 10.1111/j.1423-0410.1994.tb00279.x; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; SOUTHCOTT MJG, 1997, BLOOD S, V90, P175; TELEN MJ, 1995, BLOOD CELL BIOCH, V6, P281; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; UDANI M, 1996, BLOOD S, V88, P6; Wick T M, 1996, Curr Opin Hematol, V3, P118; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YURCHENKO PD, 1993, MOL CELLULAR ASPECTS, P121	40	99	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16686	16693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642222				2022-12-27	WOS:000074545200012
J	Motojima, K; Passilly, P; Peters, JM; Gonzalez, FJ; Latruffe, N				Motojima, K; Passilly, P; Peters, JM; Gonzalez, FJ; Latruffe, N			Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; LIPOPROTEIN-LIPASE; BINDING-PROTEIN; PPAR-GAMMA; RAT-LIVER; DIFFERENTIATION; CLONING; HEPATOCARCINOGENICITY; LIGAND; MOUSE	Regulation of gene expression of three putative long-chain fatty acid transport proteins, fatty acid translocase (FAT), mitochondrial aspartate aminotransferase (mAspAT), and fatty acid transport protein (FATP), by drugs that activate peroxisome proliferator-activated receptor (PPAR) alpha and gamma were studied using normal and obese mice and rat hepatoma cells. FAT mRNA was induced in liver and intestine of normal mice and in hepatoma cells to various extents only by PPAR alpha-activating drugs. FATP mRNA was similarly induced in liver, but to a lesser extent in intestine. The induction time course in the liver was slower for FAT and FATP mRNA than that of an mRNA encoding a peroxisomal enzyme. An obligatory role of PPAR alpha in hepatic FAT and FATP induction was demonstrated, since an increase in these mRNAs was not observed in PPAR alpha-null mice. Levels of mAspAT mRNA were higher in liver and intestine of mice treated with peroxisome proliferators, while levels in hepatoma cells were similar regardless of treatment. In white adipose tissue of KKAy obese mice, thiazolidinedione PPAR gamma activators (pioglitazone and troglitazone) induced FAT and FATP more efficiently than the PPAR alpha activator, clofibrate. This effect was absent in brown adipose tissue. Under the same conditions, levels of mAspAT mRNA did not change significantly in these tissues. In conclusion, tissue-specific expression of FAT and FATP genes involves both PPAR alpha and -gamma. Our data suggest that among the three putative long-chain fatty acid transporters, FAT and FATP appear to have physiological roles. Thus, peroxisome proliferators not only influence the metabolism of intracellular fatty acids but also cellular uptake, which is likely to be an important regulatory step in lipid homeostasis.	Toho Univ, Sch Pharmaceut Sci, Dept Biochem, Funabashi, Chiba 274, Japan; Univ Bourgogne, Lab Biol Mol & Cellulaire, F-21004 Dijon, France; NIH, Lab Metab, Bethesda, MD 20892 USA	Toho University; Universite de Bourgogne; National Institutes of Health (NIH) - USA	Motojima, K (corresponding author), Toho Univ, Sch Pharmaceut Sci, Dept Biochem, Funabashi, Chiba 274, Japan.	motojima@phar.toho-u.ac.jp	Peters, Jeffrey/D-8847-2011; Passilly-Degrace, Patricia/AAF-5903-2021	Peters, Jeffrey/0000-0003-2782-2998				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVCHAND PR, 1996, NATURE, V384, P34; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Goldberg IJ, 1996, J LIPID RES, V37, P693; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; ISOLA LM, 1995, P NATL ACAD SCI USA, V92, P9866, DOI 10.1073/pnas.92.21.9866; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KIRSCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MARSMAN DS, 1988, CANCER RES, V48, P6739; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1996, ANN NY ACAD SCI, V804, P413, DOI 10.1111/j.1749-6632.1996.tb18632.x; Motojima K, 1997, BIOCHEM BIOPH RES CO, V230, P155, DOI 10.1006/bbrc.1996.5906; Motojima K, 1997, BIOCHIMIE, V79, P101, DOI 10.1016/S0300-9084(97)81498-8; MOTOJIMA K, 1992, BIOCHEM BIOPH RES CO, V188, P799, DOI 10.1016/0006-291X(92)91127-C; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; REDDY JK, 1986, ENVIRON HEALTH PERSP, V65, P317, DOI 10.2307/3430199; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; SAHA AK, 1994, AM J PHYSIOL, V267, pE95, DOI 10.1152/ajpendo.1994.267.1.E95; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; TIGRATTI BL, 1996, BIOCHEM J, V313, P487; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	32	433	451	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16710	16714		10.1074/jbc.273.27.16710	http://dx.doi.org/10.1074/jbc.273.27.16710			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642225	hybrid			2022-12-27	WOS:000074545200015
J	Previs, SF; Hallowell, PT; Neimanis, KD; David, F; Brunengraber, H				Previs, SF; Hallowell, PT; Neimanis, KD; David, F; Brunengraber, H			Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis - Heterogeneity of glucose labeling in incubated hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE; RAT-LIVER; GLYCEROL; TURNOVER; ZONATION; PATTERN	We previously reported (Previs, S, F,, Fernandez, C, A, Yang, D,, Soloviev, M, V., David, F,, and Brunengraber, H. (1995) J, Biol. Chem. 270, 19806-19815) that glucose made in isolated livers from starved rats perfused with physiological concentrations of lactate, pyruvate, and either [2-C-13]- or [U-C-13(3)]glycerol had a mass isotopomer distribution incompatible with glucose being made from a homogeneously labeled pool of triose phosphates, Similar data were obtained in live rats infused with [U-C-13(3)]glycerol, We ascribed the labeling heterogeneity to major decreases in glycerol concentration and enrichment across the liver, We concluded that [C-13]glycerol is unsuitable for tracing the contribution of gluconeogenesis to total glucose production. We now report isotopic heterogeneity of gluconeogenesis in hepatocytes, even when all cells are in contact with identical concentrations and enrichments of gluconeogenic substrates, Total rat hepatocytes were incubated with concentrations of glycerol, lactate, and pyruvate that were kept constant by substrate infusions. To modulate competition between substrates, the (glycerol)/(lactate + pyruvate) infusion ratio ranged from 0.23 to 3.60, Metabolic and isotopic steady states were achieved in all cases. The apparent contribution of gluconeogenesis to glucose production (f) was calculated from the mass isotopomer distribution of glucose. When all substrates were C-13-labeled, f was 97%, as expected in glycogen-deprived hepatocytes, As the infusion ratio ([C-13]glycerol)/(lactate C pyruvate) increased, f increased from 73% to 94%, In contrast, as the infusion ratio (glycerol)/([C-13]lactate + [C-13]pyruvate) increased, f decreased from 93% to 76%, In all cases, f increased with the rate of supply of the substrate that was labeled. Variations in f show that the C-13 labeling of triose phosphates was not equal in all hepatocytes, even when exposed to the same substrate concentrations and enrichments, We also showed that zonation of glycerol kinase activity is minor in rat liver. We conclude that zonation of other processes than glycerol phosphorylation contributes to the heterogeneity of triose phosphate labeling from glycerol in rat liver.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Surg, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brunengraber, H (corresponding author), Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.				NIDDK NIH HHS [DK35543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1984, HISTOCHEMISTRY, V80, P97, DOI 10.1007/BF00492778; BARTELS H, 1993, HISTOCHEMISTRY, V99, P303, DOI 10.1007/BF00269103; BERGMEYER HU, 1984, METHOD ENZYMAT AN, P574; BEYLOT M, 1993, ANAL BIOCHEM, V212, P526, DOI 10.1006/abio.1993.1363; Brunengraber H, 1997, ANNU REV NUTR, V17, P559, DOI 10.1146/annurev.nutr.17.1.559; Dekker E, 1997, J CLIN ENDOCR METAB, V82, P2514, DOI 10.1210/jc.82.8.2514; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; GUDER WG, 1976, H-S Z PHYSIOL CHEM, V357, P1793, DOI 10.1515/bchm2.1976.357.2.1793; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; Landau BR, 1996, AM J PHYSIOL-ENDOC M, V271, pE1110, DOI 10.1152/ajpendo.1996.271.6.E1110; LANDAU BR, 1993, ADV EXP MED BIOL, V334, P209; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LEE WNP, 1994, J CLIN RES, V42, pA28; MCMENAMY RH, 1981, ANAL BIOCHEM, V112, P117, DOI 10.1016/0003-2697(81)90268-2; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; NEESE RA, 1995, J BIOL CHEM, V270, P14464; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; OSYPIW JC, 1994, BIOCHEM J, V304, P617, DOI 10.1042/bj3040617; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Peroni O, 1997, METABOLISM, V46, P1358, DOI 10.1016/S0026-0495(97)90244-4; Peroni O, 1996, METABOLISM, V45, P897, DOI 10.1016/S0026-0495(96)90166-3; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; Previs SF, 1996, AM J PHYSIOL-ENDOC M, V271, pE1118, DOI 10.1152/ajpendo.1996.271.6.E1118; ROGNSTAD R, 1979, J BIOL CHEM, V254, P1875; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SESTOFT L, 1975, BIOCHIM BIOPHYS ACTA, V375, P462, DOI 10.1016/0005-2736(75)90360-0; SHIOTA M, 1993, AM J PHYSIOL, V265, pE559, DOI 10.1152/ajpendo.1993.265.4.E559; TENG CT, 1953, J BIOL CHEM, V202, P705; WEIDEMANN MJ, 1969, BIOCHEM J, V112, P149, DOI 10.1042/bj1120149; Wieland O.H., 1984, METHOD ENZYMAT AN, VVI, P504	36	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16853	16859		10.1074/jbc.273.27.16853	http://dx.doi.org/10.1074/jbc.273.27.16853			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642245	hybrid			2022-12-27	WOS:000074545200035
J	Hisabori, T; Motohashi, K; Kroth, P; Strotmann, H; Amano, T				Hisabori, T; Motohashi, K; Kroth, P; Strotmann, H; Amano, T			The formation or the reduction of a disulfide bridge on the gamma subunit of chloroplast ATP synthase affects the inhibitory effect of the epsilon subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; THERMOPHILIC BACTERIUM; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNITS; BETA-SUBUNITS; F1-ATPASE; SPINACH	We have studied the change of the catalytic activity of chimeric complexes that were formed by chloroplast coupling factor 1 (CF1) -gamma, alpha and beta subunits of thermophilic bacterial F-1 after formation or reduction of the disulfide bridge of different gamma subunits modified by oligonucleotide-directed mutagenesis techniques. For this purpose, three mutant gamma subunits were produced: gamma(Delta 194-230), here 37 amino acids from Pro-194 to Ile-230 are deleted, gamma(C199A), Cys-199 is changed to Ala, and gamma(Delta 200-204), amino acids from Asp-200 to Lys-204 are deleted. All of the chimeric subunit complexes produced from each of these mutant CF1-gamma subunits and alpha and beta subunits from thermophilic bacterial F-1 lost the sensitivity against thiol reagents when compared with the complex containing wild-type CF1-gamma. The pH optimum (pH 8.5-9.0) and the concentration of methanol to stimulate ATPase activities were not affected by these mutations, These indicate that the introduction of the mutations did not change the main features of ATPase activity of the chimeric complex, However, the interaction between gamma subunit and epsilon subunit was strongly influenced by the type of gamma subunit itself. Although the ATPase activity of the chimeric complex that contained gamma(Delta 200-204) or gamma(C199A) was inhibited by the addition of recombinant epsilon subunit from CF1 similarly to complexes containing the reduced wild-type gamma subunit, the recombinant epsilon subunit did not inhibit the ATPase of the complex, which contained the oxidized form of gamma subunit, Therefore the affinity of the epsilon subunit to the gamma subunit may be dependent on the state of the gamma subunit or the epsilon subunit may bind to the oxidized form of gamma subunit in a mode that does not inhibit the activity. The ATPase activity of the complex that contains gamma Delta 194-230 was not efficiently inhibited by epsilon subunit, These results show that the formation or reduction of the disulfide bond on the gamma subunit may induce a conformational change in the region that directly affects the interaction of this subunit with the adjacent epsilon subunit.	Tokyo Inst Technol, Resources Utilizat Res Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany	Tokyo Institute of Technology; Heinrich Heine University Dusseldorf	Hisabori, T (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, Midori Ku, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Kroth, Peter G/A-9728-2008; Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Kroth, Peter G/0000-0003-4734-8955; Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDRALOJC PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P55, DOI 10.1016/0005-2728(90)90006-P; ANTHON GE, 1984, BIOCHIM BIOPHYS ACTA, V723, P358; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cruz JA, 1997, PLANT PHYSIOL, V113, P1185, DOI 10.1104/pp.113.4.1185; CRUZ JA, 1995, PLANT PHYSIOL, V109, P1379, DOI 10.1104/pp.109.4.1379; DUHE RJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P70, DOI 10.1016/0005-2728(90)90180-C; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; GABRYS H, 1994, PLANT PHYSIOL, V104, P769, DOI 10.1104/pp.104.2.769; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P87, DOI 10.1016/0003-9861(92)90054-Z; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MUNN AL, 1991, BIOCHIM BIOPHYS ACTA, V1060, P82, DOI 10.1016/S0005-2728(05)80122-7; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; Ross SA, 1996, J BIOENERG BIOMEMBR, V28, P49; ROSS SA, 1995, J BIOL CHEM, V270, P9813, DOI 10.1074/jbc.270.17.9813; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SARASTE M, 1981, NUCLEIC ACIDS RES, V9, P5287, DOI 10.1093/nar/9.20.5287; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; SELMANREIMER S, 1981, BIOCHEMISTRY-US, V20, P5476, DOI 10.1021/bi00522a020; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; STROTMANN H, 1984, ANNU REV PLANT PHYS, V35, P97; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; YOSHIDA M, 1977, J BIOL CHEM, V252, P3348; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	41	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15901	15905		10.1074/jbc.273.26.15901	http://dx.doi.org/10.1074/jbc.273.26.15901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632635	hybrid			2022-12-27	WOS:000074436600006
J	Jean, D; Gershenwald, JE; Huang, SY; Luca, M; Hudson, MJ; Tainsky, MA; Bar-Eli, M				Jean, D; Gershenwald, JE; Huang, SY; Luca, M; Hudson, MJ; Tainsky, MA; Bar-Eli, M			Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN-MALIGNANT MELANOMA; PRIMARY CUTANEOUS MELANOMA; INDUCIBLE ENHANCER; ADHESION MOLECULE; BCL-2 EXPRESSION; GENE-EXPRESSION; SUPPRESSOR GENE; PHORBOL ESTER; MESSENGER-RNA	MCAM/MUC18 is a cell-surface glycoprotein of 113 kDa, originally identified as a melanoma antigen, whose expression is associated with tumor progression and the development of metastatic potential. We have previously shown that enforced expression of MCAM/MUC18 in primary cutaneous melanoma led to increased tumor growth and metastatic potential in nude mice. The mechanism for up-regulation of MCAM/MUC18 during melanoma progression is unknown. Here we show that up-regulation of MCAM/MUC18 expression in highly metastatic cells correlates with loss of expression of the transcription factor AP-2. The MCAM/MUC18 promoter contains four binding sites for AP-2, and electrophoretic mobility shift assay gels demonstrated that the AP-2 protein bound directly to the MCAM/MUC18 promoter. Transfection of AP-2 into highly metastatic A375SM melanoma cells (AP-a-negative and MCAM/MUC18-poposive) inhibited MCAM/MUC18 promoter-driven chloramphenicol acetyltransferase reporter gene in a dose-dependent manner. MCAM/MUC18 mRNA and protein expression were down-regulated in AP-2-transfected but not in control cells. In addition, re-expression of AP-2 in A375SM cells inhibited their tumorigenicity and metastatic potential in nude mice. These results indicate that the expression of MCAM/MUC18 is regulated by AP-2 and that enforced AP-2 expression suppresses tumorigenicity and metastatic potential of human melanoma cells, possibly by dawn-regulating MCAM/MUC18 gene expression. Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as c-KIT, E-cadherin, MMP-2, and p21(WAF-1), We propose that loss of AP-2 is a crucial event in the development of malignant melanoma.	Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA.	mbareli@notes.mdacc.tmc.edu	Jean, Didier/A-1615-2009; Gershenwald, Jeff/AAX-4367-2020	Jean, Didier/0000-0001-5823-7404; Gershenwald, Jeff/0000-0003-4519-5369; Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R21CA064137] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64137] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; Bani MR, 1996, CANCER RES, V56, P3075; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COPEMAN MC, 1992, PATHOLOGY, V24, P307, DOI 10.3109/00313029209068886; Cowley GP, 1996, J PATHOL, V179, P183, DOI 10.1002/(SICI)1096-9896(199606)179:2<183::AID-PATH554>3.0.CO;2-W; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DIGNAM J, 1983, MOL CELL BIOL, V13, P3415; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FIDLER IJ, 1992, CUTANEOUS MELANOMA, V2, P112; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HOLMAN CDJ, 1980, INT J CANCER, V25, P317, DOI 10.1002/ijc.2910250303; HOLZMANN B, 1987, INT J CANCER, V39, P466, DOI 10.1002/ijc.2910390410; HUANG S, 1996, ONCOGENE, V123, P2339; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JIANG HP, 1995, ONCOGENE, V10, P1855; Johnson JP, 1997, INT J CANCER, V73, P769; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN JM, 1987, CANCER RES, V47, P841; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NATALI PG, 1994, INT J CANCER, V56, P341, DOI 10.1002/ijc.2910560308; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; RADINSKY R, 1994, ONCOGENE, V9, P1977; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; Rummel MM, 1996, CANCER RES, V56, P2218; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, AM J PATHOL, V145, P837; SHIH IM, 1994, CANCER RES, V54, P2514; SINGH RK, 1995, CANCER RES, V55, P3669; SOBER AJ, 1984, CUTANEOUS MELANOMA P, P126; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TRENT JM, 1989, CANCER RES, V49, P420; VANDENOORD JJ, 1994, AM J PATHOL, V145, P294; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WALKER GJ, 1994, INT J CANCER, V59, P771, DOI 10.1002/ijc.2910590611; WELCH DR, 1994, ONCOGENE, V9, P255; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XIE S, 1902, ONCOGENE, V15, P2069; Xie SH, 1997, CANCER RES, V57, P2295; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG J, 1995, CANCER RES, V55, P4640; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	67	129	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16501	16508		10.1074/jbc.273.26.16501	http://dx.doi.org/10.1074/jbc.273.26.16501			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632718	hybrid			2022-12-27	WOS:000074436600089
J	Vik, SB; Patterson, AR; Antonio, BJ				Vik, SB; Patterson, AR; Antonio, BJ			Insertion scanning mutagenesis of subunit a of the F1F0 ATP synthase near His(245) and implications on gating of the proton channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F0F1-ATPASE; AMINO-ACID INSERTIONS; ALPHA-SUBUNIT; A-SUBUNIT; B-SUBUNIT; TRANSLOCATING ATPASE; NUCLEOTIDE-SEQUENCE; F-0 COMPLEX; UNC OPERON; MUTATIONS	Subunit a of the E. coli F1F0 ATP synthase was probed by insertion scanning mutagenesis in a region between residues Glu(219) and His(245). A series of single amino acid insertions, of both alanine and aspartic acid, were constructed after the following residues: 225, 229, 233, 238, 243, and 245. The mutants were tested for growth yield, binding of F-1 to membranes, dicyclohexylcarbodiimide sensitivity of ATPase activity, ATP-driven proton translocation, and passive proton permeability of membranes stripped of F-1. Significant loss of function was seen only with insertions after positions 238 and 243. In contrast, both insertions after residue 225 and the alanine insertion after residue 245 were nearly identical in function to the wild type. The other insertions showed an intermediate loss of function. Missense mutations of His(245) to serine and cysteine were nonfunctional, while the W241C mutant showed nearly normal ATPase function. Replacement of Leu(162) by histidine failed to suppress the 245 mutants, but chemical rescue of H245S was partially successful using acetate, An interaction between Trp(241) and His(245) may be involved in gating a "half-channel" from the periplasmic surface of F-0 to Asp(61) of subunit a.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.			Vik, Steven/0000-0002-5285-015X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040508, GM40508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; FernandezRecio J, 1997, J MOL BIOL, V267, P184, DOI 10.1006/jmbi.1996.0831; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; JANS DA, 1984, BIOCHEM J, V221, P43, DOI 10.1042/bj2210043; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KUMAMOTO CA, 1987, J BIOL CHEM, V262, P3060; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; MARTI T, 1992, P NATL ACAD SCI USA, V89, P1219, DOI 10.1073/pnas.89.4.1219; Miller J. H., 1972, EXPT MOL GENETICS, P431; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; TU CK, 1990, BIOCHEMISTRY-US, V29, P6400, DOI 10.1021/bi00479a009; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1994, J BIOL CHEM, V269, P30364; VIK SB, 1987, J BIOL CHEM, V262, P8340; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WANG S, 1994, J BIOL CHEM, V269, P3095	43	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16229	16234		10.1074/jbc.273.26.16229	http://dx.doi.org/10.1074/jbc.273.26.16229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632681	hybrid			2022-12-27	WOS:000074436600052
J	Fleming, KG; Hohl, TM; Yu, RC; Muller, SA; Wolpensinger, B; Engel, A; Engelhardt, H; Brunger, AT; Sollner, TH; Hanson, PI				Fleming, KG; Hohl, TM; Yu, RC; Muller, SA; Wolpensinger, B; Engel, A; Engelhardt, H; Brunger, AT; Sollner, TH; Hanson, PI			A revised model for the oligomeric state of the N-ethylmaleimide-sensitive fusion protein, NSF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; ELECTRON-MICROSCOPY; BOUNDARY ANALYSIS; LIGHT-SCATTERING; MEMBRANE-FUSION; ALPHA-SNAP; COMPLEX; ATP; DOCKING; MACROMOLECULES	The N-ethylmaleimide-sensitive fusion protein (NSF) is an ATPase that plays an essential role in intracellular membrane trafficking, Previous reports have concluded that NSF forms either a tetramer or a trimer in solution, and that assembly of the oligomer is essential for efficient activity in membrane transport reactions. However, in recent electron microscopic analyses NSF appears as a hexagonal cylinder similar in size to related ATPases known to be hexamers. We have therefore reevaluated NSF's oligomeric state using a variety of quantitative biophysical techniques. Sedimentation equilibrium and sedimentation velocity analytical ultracentrifugation, transmission electron microscopy with rotational image analysis, scanning transmission electron microscopy, and multiangle light scattering all demonstrate that, in the presence of nucleotide, NSF is predominantly a hexamer. Sedimentation equilibrium results further suggest that the NSF hexamer is held together by oligomerization of its D2 domains. The sedimentation coefficient, s(20,w)(0), of 13.4 (+/-0.1) S indicates that NSF has unusual hydrodynamic characteristics that cannot be solely explained by its shape. The demonstration that NSF is a hexameric oligomer highlights structural similarities between it and several related ATPases which act by switching the conformational states of their protein substrates in order to activate them for subsequent reactions.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Basel, Maurice E Muller Inst, Bioctr, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Yale University; Memorial Sloan Kettering Cancer Center; University of Basel; Max Planck Society; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid,Campus Box 8228, St Louis, MO 63110 USA.		Hanson, Phyllis/E-9420-2012; Fleming, Karen/E-7892-2011	Hohl, Tobias/0000-0002-9097-5412; Brunger, Axel/0000-0001-5121-2036	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016769] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK2704420] Funding Source: Medline; NIGMS NIH HHS [GM54160, GM16769] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Beyer A, 1997, PROTEIN SCI, V6, P2043; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Boudier JA, 1996, EUR J NEUROSCI, V8, P545, DOI 10.1111/j.1460-9568.1996.tb01239.x; DELATORRE JG, 1994, BIOPHYS J, V67, P530, DOI 10.1016/S0006-3495(94)80512-0; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; FRANK J, 1982, J MOL BIOL, V161, P134, DOI 10.1016/0022-2836(82)90282-0; FROHLICH KU, 1995, BBA-PROTEIN STRUCT M, V1253, P25, DOI 10.1016/0167-4838(95)00136-I; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P314; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Pamnani V, 1997, FEBS LETT, V404, P263, DOI 10.1016/S0014-5793(97)00138-5; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STAFFORD WF, 1996, BIOPHYS J, V70; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	39	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15675	15681		10.1074/jbc.273.25.15675	http://dx.doi.org/10.1074/jbc.273.25.15675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624162	hybrid			2022-12-27	WOS:000074284200056
J	Ferreira, MCD; Helies-Toussaint, C; Imbert-Teboul, M; Bailly, C; Verbavatz, JM; Bellanger, AC; Chabardes, D				Ferreira, MCD; Helies-Toussaint, C; Imbert-Teboul, M; Bailly, C; Verbavatz, JM; Bellanger, AC; Chabardes, D			Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in the cortical thick ascending limb cell of the rat kidney - Inhibition of hormone-dependent camp accumulation by extracellular Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; PERTUSSIS TOXIN; MOLECULAR-CLONING; BINDING PROTEIN; GLIOMA-CELLS; CA-2+; LOCALIZATION; VASOPRESSIN; IDENTIFICATION; CALCIUM	The Ca2+-sensing receptor protein and the Ca2+-inhibitable type 6 adenylyl cyclase mRNA are present in a defined segment of the sat renal tubule leading to the hypothesis of their possible functional co-expression in a same cell and thus to a possible inhibition of cAMP content by extracellular Ca2+. By using microdissected segments, we compared the properties of regulation of extracellular Ca2+-mediated activation of Ca2+ receptor to those elicited by prostaglandin E-2 and angiotensin II. The three agents inhibited a common pool of hormone-stimulated cAMP content by different mechanisms as follows. (i) Extracellular Ca2+, coupled to phospholipase C activation via a pertussis toxin-insensitive G protein, induced a dose-dependent inhibition of cAMP content (1.25 mM Ca2+ eliciting 50% inhibition) resulting from both stimulation of cAMP hydrolysis and inhibition of cAMP synthesis; this latter effect was mediated by capacitive Ca2+ influx as well as release of intracellular Ca2+. (ii) Angiotensin II, coupled to the same transduction pathway, also decreased cAMP content; however, its inhibitory effect on cAMP was mainly accounted for by an increase of cAMP hydrolysis, although angiotensin II and extracellular Ca2+ can induce comparable release of intracellular Ca2+. (iii) Prostaglandin E-2, coupled to pertussis toxin-sensitive G protein, inhibited the same pool of adenylyl cyclase units as extracellular Ca2+ but by a different mechanism, The functional properties of the adenylyl cyclase were similar to those described for type 6. The results establish that the co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in a same cell allows an inhibition of cAMP accumulation by physiological concentrations of extracellular Ca2+.	CEA Saclay, Dept Biol Cellulaire & Mol, Serv Biol Cellulaire, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Chabardes, D (corresponding author), CEA Saclay, Dept Biol Cellulaire & Mol, Serv Biol Cellulaire, Bat 520, F-91191 Gif Sur Yvette, France.	chabardes@dsvidf.cea.fr		Verbavatz, Jean-Marc/0000-0002-4654-1174				AARAB L, 1993, PFLUG ARCH EUR J PHY, V423, P397, DOI 10.1007/BF00374933; ABE T, 1995, J CLIN INVEST, V96, P657, DOI 10.1172/JCI118108; ANTONI FA, 1995, J BIOL CHEM, V270, P28055; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bouby N, 1997, J AM SOC NEPHROL, V8, P1658; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1997, BONE, V20, P303, DOI 10.1016/S8756-3282(97)00002-1; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BUSH KT, 1994, J BIOL CHEM, V269, P23694; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; Champigneulle A, 1997, J MEMBRANE BIOL, V156, P117, DOI 10.1007/s002329900194; CHEN CJ, 1989, ENDOCRINOLOGY, V124, P233, DOI 10.1210/endo-124-1-233; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; FIRSOV D, 1995, PFLUG ARCH EUR J PHY, V429, P636, DOI 10.1007/BF00373984; HAWKINS D, 1989, ENDOCRINOLOGY, V124, P838, DOI 10.1210/endo-124-2-838; HOEY M, 1990, BIOCHEM PHARMACOL, V40, P193, DOI 10.1016/0006-2952(90)90678-E; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; KOCH B, 1993, MOL CELL ENDOCRINOL, V92, P175, DOI 10.1016/0303-7207(93)90005-5; KOCH B, 1994, CELL SIGNAL, V6, P467, DOI 10.1016/0898-6568(94)90094-9; Kriz W, 1992, KIDNEY PHYSL PATHOPH, P707; Meneton P, 1996, AM J PHYSIOL-RENAL, V271, pF382, DOI 10.1152/ajprenal.1996.271.2.F382; MOREL F, 1987, KIDNEY INT, V31, P512, DOI 10.1038/ki.1987.30; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; MOREL F, 1982, KIDNEY INT S11, V21, pS55; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Paulais M, 1996, AM J PHYSIOL-RENAL, V271, pF1052, DOI 10.1152/ajprenal.1996.271.5.F1052; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Riccardi D, 1996, AM J PHYSIOL-RENAL, V271, pF951, DOI 10.1152/ajprenal.1996.271.4.F951; SHANMUGAM S, 1995, AM J PHYSIOL-RENAL, V268, pF922, DOI 10.1152/ajprenal.1995.268.5.F922; Shen TS, 1997, AM J PHYSIOL-CELL PH, V273, pC323, DOI 10.1152/ajpcell.1997.273.1.C323; SMITH JA, 1993, FEBS LETT, V327, P137, DOI 10.1016/0014-5793(93)80157-P; STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; TAKAICHI K, 1986, AM J PHYSIOL, V250, pF770, DOI 10.1152/ajprenal.1986.250.5.F770; TAKAICHI K, 1988, J CLIN INVEST, V82, P1437, DOI 10.1172/JCI113749; TAKAICHI K, 1986, MINER ELECTROL METAB, V12, P342; TAKEUCHI K, 1993, BIOCHEM BIOPH RES CO, V194, P885, DOI 10.1006/bbrc.1993.1904; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORIKAI S, 1983, AM J PHYSIOL, V245, pF58, DOI 10.1152/ajprenal.1983.245.1.F58; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wang WH, 1996, AM J PHYSIOL-CELL PH, V271, pC103, DOI 10.1152/ajpcell.1996.271.1.C103; Yang TX, 1997, AM J PHYSIOL-RENAL, V272, pF751, DOI 10.1152/ajprenal.1997.272.6.F751; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396	53	80	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15192	15202		10.1074/jbc.273.24.15192	http://dx.doi.org/10.1074/jbc.273.24.15192			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614133	hybrid			2022-12-27	WOS:000074160400075
J	Fu, DX; Maloney, PC				Fu, DX; Maloney, PC			Structure-function relationships in OxlT, the oxalate/formate transporter of Oxalobacter formigenes - Topological features of transmembrane helix 11 as visualized by site-directed fluorescent labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; TRANSLOCATION PATHWAY; FORMATE EXCHANGE; MEMBRANE CARRIER; LACTOSE CARRIER; PROTEIN; PERMEASE; OXALATE; IDENTIFICATION	Analysis of hydropathy suggests that in OxlT, the oxalate/formate antiporter of Oxalobacter formigenes, lysine 355 is within transmembrane helix no. 11. To test this idea, we used single-cysteine, histidine-tagged OxlT variants to study the organization of a 30-residue segment (residues 344-373) containing this region. Topology was examined by probing the A345C and A370C proteins with Oregon Green maleimide carboxylic acid, an impermeant and fluorescent thiol-reactive agent. Examination of purified protein showed that only A370C was fluorescent after treating intact cells with the probe, while both proteins were modified in tests with isolated membrane ghosts, In addition, labeling of A370C,but not A345C, was blocked when external cysteines were protected with the impermeant and nonfluorescent agent, methanethiosulfonate ethyltrimethylammonium. These findings confirm that A345 faces the cytoplasm, while 4370C faces the periplasm, A similar study focused on 13 single-cysteine variants positioned throughout the target segment. That work revealed a striking discontinuity in reactivity toward Oregon Green maleimide; cysteines within a 10-residue central core (residues 351-360) were not labeled when membranes were probed, but were readily modified after protein denaturation. We suggest this core resides within the lipid bilayer, unavailable to an impermeant reporter. Since this region includes position 355, we also suggest that lysine 355 lies within the OxlT hydrophobic sector, where it may facilitate the binding and translocation of the anionic substrates, oxalate and formate.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.			Fu, Dax/0000-0002-2663-1316				Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; Fu DX, 1997, J BIOL CHEM, V272, P2129; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HAMA H, 1994, J BIOL CHEM, V269, P1063; Harold F. M., 1996, ESCHERICHIA COLI SAL, P283; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JI, 1993, J BIOL CHEM, V268, P20007; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; POURCHER T, 1993, J BIOL CHEM, V268, P3209; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Tamai E, 1997, PROTEIN EXPRES PURIF, V10, P275, DOI 10.1006/prep.1997.0754; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0	34	34	35	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17962	17967		10.1074/jbc.273.28.17962	http://dx.doi.org/10.1074/jbc.273.28.17962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651403	hybrid			2022-12-27	WOS:000074816100096
J	Johnson, AO; Subtil, A; Petrush, R; Kobylarz, K; Keller, SR; McGraw, TE				Johnson, AO; Subtil, A; Petrush, R; Kobylarz, K; Keller, SR; McGraw, TE			Identification of an insulin-responsive, slow endocytic recycling mechanism in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; SUBCELLULAR TRAFFICKING KINETICS; RECEPTOR CYTOPLASMIC DOMAIN; RAT ADIPOSE-CELLS; TRANSFERRIN RECEPTOR; INTERNALIZATION MOTIF; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; CHO CELLS; SIGNAL	In adipocytes, the insulin-regulated aminopeptidase (IRAP) is trafficked through the same insulin-regulated recycling pathway as the GLUT4 glucose transporter. We find that a chimera, containing the cytoplasmic domain of IRAP fused to transmembrane and extracellular domains of the transferrin receptor, is slowly recycled and rapidly internalized in Chinese hamster ovary cells. Morphological studies indicate that the chimera is slowly trafficked through the general endosomal recycling compartment rather than being sorted to a specialized recycling pathway. A chimera in which a di-leucine sequence within the cytoplasmic domain of IRAP has been mutated to alanines is rapidly internalized and rapidly recycled, indicating that this di-leucine is required for the slow recycling but not for the rapid internalization. Insulin stimulates a 2-3-fold increase in the recycling of the chimera and only a 1.2-fold increase in the recycling of the transferrin receptor. The effect of insulin on the recycling of the chimera is blocked by wortmannin, a phosphatidylinositol S'-kinase inhibitor. GTP gamma S (guanosine 5'-3-O-(thio)triphosphate) increases the recycling of the chimera by 50% but has no effect on the recycling of the transferrin receptor. In these studies, we have identified in Chinese hamster ovary cells a novel, slow endocytic recycling mechanism that is regulated by insulin.	Cornell Univ Med Coll, Dept Biochem, New York, NY 10021 USA; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Cornell University; Dartmouth College	McGraw, TE (corresponding author), Cornell Univ Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	temcgraw@mail.med.cornell.med	Subtil, Agathe/C-7464-2017	Subtil, Agathe/0000-0002-7481-4846	NIDDK NIH HHS [R01-DK52852] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052852] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1996, BIOCHEM J, V315, P153, DOI 10.1042/bj3150153; ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDINI G, 1991, J BIOL CHEM, V266, P4037; Chavez RA, 1996, J CELL BIOL, V133, P1177, DOI 10.1083/jcb.133.6.1177; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KANAI F, 1993, J BIOL CHEM, V268, P14523; KANDROR KV, 1994, J BIOL CHEM, V269, P3077; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KELLER SR, 1998, INPRESS HDB PROTEOLY; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; ODORIZZI JF, 1994, J CELL BIOL, V126, P707; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROBINSON L, 1992, J CELL BIOL, V117, P1118; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SPIRO DJ, 1996, MOL BIOL CELL, V7, P335; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; YANG J, 1993, J BIOL CHEM, V268, P4600; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	59	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17968	17977		10.1074/jbc.273.28.17968	http://dx.doi.org/10.1074/jbc.273.28.17968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651404	hybrid			2022-12-27	WOS:000074816100097
J	Noel, J; Turcotte, B				Noel, J; Turcotte, B			Zinc cluster proteins Leu3p and Uga3p recognize highly related but distinct DNA targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; BINDING DOMAIN; DAL81 GENE; IN-VIVO; SEQUENCE; GAL4; ACTIVATION; ELEMENTS	Members of the family of fungal zinc cluster DNA-binding proteins possess 6 highly conserved cysteines that bind to two zinc atoms forming a structure (Zn,Cys,) that is required for recognition of specific DNA sequences. Many zinc cluster proteins have been shown to bind as homodimers to a pair of CGG triplets oriented either as direct (CGG NX CGG), inverted (CGG NX CCG), or everted repeats (CCG NX CGG), where N indicates nucleotides. Variation in the spacing between the CGG triplets also contributes to the diversity of sites recognized. For example, Leu3p binds to the everted sequence CCG N4 CGG with a strict requirement for a 4-base pair spacing. Here, we show that another member of the family, Uga3p, recognizes the same DNA motif as Leu3p. However, these transcription factors have distinct DNA targets. We demonstrate that additional specificity of binding is provided by nucleotides located between the two everted CGG triplets. Altering the 4 nucleotides between to the two everted CGG triplets switches the specificity from a Uga3p site to a Leu3p site in both in vitro and in vivo assays. Thus, our results identify a new mechanism that expands the repertoire of DNA targets of the family of zinc cluster proteins. These experiments provide a model for discrimination between targets of zinc cluster proteins.	McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							ANDRE B, 1990, MOL GEN GENET, V220, P269; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BRICMONT PA, 1991, MOL CELL BIOL, V11, P1161, DOI 10.1128/MCB.11.2.1161; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; Davis MA, 1996, J BACTERIOL, V178, P3406, DOI 10.1128/jb.178.11.3406-3409.1996; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; Gray WM, 1996, MOL CELL BIOL, V16, P347; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Holmberg S, 1996, GENETICS, V144, P467; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; KALTZMANN DJ, 1994, MOL CELL BIOL, V14, P4653; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KIRKPATRICK CR, 1995, MOL CELL BIOL, V15, P4021; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; SIKORSKI RS, 1989, GENETICS, V122, P19; Strauss J, 1998, MOL CELL BIOL, V18, P1339, DOI 10.1128/MCB.18.3.1339; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TALIBI D, 1995, NUCLEIC ACIDS RES, V23, P550, DOI 10.1093/nar/23.4.550; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; TU H, 1990, NUCLEIC ACIDS RES, V18, P3923, DOI 10.1093/nar/18.13.3923; VASHEE S, 1993, J BIOL CHEM, V268, P24699; VISSERS S, 1990, EUR J BIOCHEM, V187, P611, DOI 10.1111/j.1432-1033.1990.tb15344.x; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; [No title captured]	48	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17463	17468		10.1074/jbc.273.28.17463	http://dx.doi.org/10.1074/jbc.273.28.17463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651335	hybrid, Green Submitted			2022-12-27	WOS:000074816100028
J	Duan, CM; Clemmons, DR				Duan, CM; Clemmons, DR			Differential expression and biological effects of insulin-like growth factor-binding protein-4 and -5 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE-EXPRESSION; IGF-I; MYOBLAST DIFFERENTIATION; BALLOON DENUDATION; HUMAN-FIBROBLASTS; MESSENGER-RNA; RAT AORTA; RECEPTOR; IDENTIFICATION; PROLIFERATION	Insulin-like growth factor-I (IGF-I) plays an important role in regulating vascular smooth muscle cell (VSMC) proliferation, migration, and apoptosis, The bioactivity of IGF-I is modulated by a group of high affinity, specific binding proteins (IGF-binding proteins; IGFBPs) that are present in the interstitial fluid, Previously, we have reported that porcine VSMCs synthesize and secrete IGF-I and several forms of IGFBPs, including IGFBP-2, IGFBP-4, and IGFBP-5, In this study, we examined the role of autocrine/paracrine secreted IGF-I in controlling the expression of IGFBP-4 and IGFBP-5 as well as the effects of these IGFBPs in modulating the cellular replication response to IGF-I. The concentrations of IGFBP-4 in the conditioned medium increased significantly from <50 ng/ml to 742 +/- 105 ng/ml, This increase was associated with a decrease in the activity of an IGF-I-regulated IGFBP-4 protease, In contrast, the synthesis of IGFBP-5 was inversely correlated with culture density, and its concentration decreased from 792 +/- 91 to 44 +/- 14 ng/ml, IGFBP-5 mRNA in sparse cultures was 3-fold higher compared with those in confluent cultures. This culture density-dependent change in IGFBP-5 mRNA correlated closely with endogenous IGF-I levels. Since treatment of VSMC with exogenous IGF-I increased IGFBP-5 mRNA levels, we neutralized the effect of endogenously secreted IGF-I with an anti-IGF-I antibody to determine if it would alter IGFBP-5 mRNA abundance. This resulted in a 4.4-fold decrease in IGFBP-5 mRNA levels. When added together with IGF-I, exogenous IGFBP-4 inhibited IGF-I-induced DNA synthesis in a concentration-dependent manner. IGFBP-5, on the other hand, potentiated the effect of IGF-I, Therefore, IGFBP-4 and IGFBP-5 appear to be differentially regulated by autocrine/paracrine IGF-I through distinct mechanisms. These two proteins, in turn, play opposing roles in modulating IGF-I action in stimulating VSMC proliferation.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Duan, CM (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056850] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56850] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Boes M, 1996, ENDOCRINOLOGY, V137, P5357, DOI 10.1210/en.137.12.5357; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BORNFELDT KE, 1990, J ENDOCRINOL, V125, P381, DOI 10.1677/joe.0.1250381; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; DAVENPORT ML, 1988, J CLIN ENDOCR METAB, V67, P1231, DOI 10.1210/jcem-67-6-1231; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; Duan CM, 1996, J BIOL CHEM, V271, P4280; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; KHORSANDI MJ, 1992, J CLIN INVEST, V90, P1926, DOI 10.1172/JCI116070; LIAU G, 1989, J BIOL CHEM, V264, P10315; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Singh P, 1996, ENDOCRINOLOGY, V137, P1764, DOI 10.1210/en.137.5.1764; STRAUCH AR, 1989, J BIOL CHEM, V264, P8345; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; VEVERIS J, 1994, AM J MED SCI, V307, P77	37	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16836	16842		10.1074/jbc.273.27.16836	http://dx.doi.org/10.1074/jbc.273.27.16836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642243	Green Published, hybrid			2022-12-27	WOS:000074545200033
J	Gasman, S; Chasserot-Golaz, S; Hubert, P; Aunis, D; Bader, MF				Gasman, S; Chasserot-Golaz, S; Hubert, P; Aunis, D; Bader, MF			Identification of a potential effector pathway for the trimeric G(o) protein associated with secretory granules - G(o) stimulates a granule-bound phosphatidylinositol 4 kinase by activating RhoA in chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ANTERIOR-PITUITARY-CELLS; SERINE-THREONINE KINASE; REGULATED EXOCYTOSIS; MAST-CELLS; CA2+-ACTIVATED SECRETION; ESCHERICHIA-COLI; PLASMA-MEMBRANE; PUTATIVE TARGET; ALPHA-SUBUNIT	Besides having a role in signal transduction, heterotrimeric G proteins may be involved in membrane trafficking events. In chromaffin cells, G, is associated with secretory organelles, and its activation inhibits the ATP-dependent priming of exocytosis, By using permeabilized cells, we previously described that the control exerted by the granule-bound G, on exocytosis may be related to effects on the cortical actin network through a sequence possibly involving Rho, To provide further insight into the function of Rho in exocytosis, we focus here on its intracellular localization in chromaffin cells. By immunoreplica analysis, immunoprecipitation, and confocal immunofluorescence, we found that RhoA is specifically associated with the membrane of secretory chromaffin granules, Parallel subcellular fractionation experiments revealed the occurrence of a mastoparan-stimulated phosphatidylinositol 4-kinase activity in purified chromaffin granule membranes. This stimulatory effect of mastoparan was mimicked by GAP-43, an activator of the granule-associated G,, and specifically inhibited by antibodies against G alpha(0). In addition, Clostridium botulinum C3 exoenzyme completely blocked the activation of phosphatidylinositol 4-kinase by mastoparan. We propose that the control exerted by G, on peripheral actin and exocytosis is related to the activation of a downstream RhoA-dependent phosphatidylinositol 4-kinase associated with the membrane of secretory granules.	INSERM, U338, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bader, MF (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	bader@neurochem.u-strasbg.fr	stéphane, gasman/Q-1145-2019; Gasman, Stephane/D-5113-2017; Bader, Marie-France/O-2098-2016; Hubert, Pierre/C-6678-2013; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017	stéphane, gasman/0000-0001-8415-1276; Gasman, Stephane/0000-0001-8415-1276; Hubert, Pierre/0000-0002-7549-8910; 				AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; AUNIS D, 1973, BIOCHEM PHARMACOL, V22, P2581, DOI 10.1016/0006-2952(73)90066-X; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Cussac D, 1996, MOL CELL ENDOCRINOL, V119, P195, DOI 10.1016/0303-7207(96)03814-2; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; EHRHART M, 1986, J HISTOCHEM CYTOCHEM, V34, P1673, DOI 10.1177/34.12.2878021; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NISHIOKA H, 1989, J ANTIBIOT, V42, P823, DOI 10.7164/antibiotics.42.823; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; RUPNIK M, 1995, NEUROREPORT, V6, P853, DOI 10.1097/00001756-199504190-00007; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; Vitale N, 1997, CELL MOL NEUROBIOL, V17, P71, DOI 10.1023/A:1026329121099; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	63	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16913	16920		10.1074/jbc.273.27.16913	http://dx.doi.org/10.1074/jbc.273.27.16913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642253	hybrid			2022-12-27	WOS:000074545200043
J	Schandar, M; Laugwitz, KL; Boekhoff, I; Kroner, C; Gudermann, T; Schultz, G; Breer, H				Schandar, M; Laugwitz, KL; Boekhoff, I; Kroner, C; Gudermann, T; Schultz, G; Breer, H			Odorants selectively activate distinct G protein subtypes in olfactory cilia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; NEMATODE CAENORHABDITIS-ELEGANS; ADIPOCYTE PLASMA-MEMBRANES; 2ND MESSENGER PATHWAYS; ALPHA-SUBUNITS; SIGNAL TRANSDUCTION; ADENYLYL-CYCLASE; PHOSPHOINOSITIDE TURNOVER; MOLECULAR-CLONING; XENOPUS-OOCYTES	Chemoelectrical signal transduction in olfactory neurons appears to involve intracellular reaction cascades mediated by heterotrimeric GTP-binding proteins. In this study attempts were made to identify the G protein subtype(s) in olfactory cilia that are activated by the primary (odorant) signal. Antibodies directed against the alpha subunits of distinct G protein subtypes interfered specifically with second messenger reponses elicited by defined subsets of odorants; odor-induced cAMP-formation was attenuated by G alpha(s) antibodies, whereas G alpha(o) antibodies blocked odor-induced inositol 1,4,5-trisphosphate (IP3) formation. Activation-dependent photolabeling of G alpha subunits with [alpha-(32)p]GTP azidoanilide followed by immunoprecipitation using subtype-specific antibodies enabled identification of particular individual G protein subtypes that were activated upon stimulation of isolated olfactory cilia by chemically distinct odorants, For example odorants that elicited a cAMP response resulted in labeling of a G alpha(s)-like protein, whereas odorants that elicited an IP3 response led to the labeling of a G alpha(o)-like protein. Since odorant-induced IP3 formation was also blocked by G(beta) antibodies, activation of olfactory phospholipase C might be mediated by beta gamma subunits of a G(o)-like G protein. These results indicate that different subsets of odorants selectively trigger distinct reaction cascades and provide evidence for dual transduction pathways in olfactory signaling.	Univ Stuttgart Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	University Hohenheim; Free University of Berlin	Breer, H (corresponding author), Univ Stuttgart Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany.	physiol1@uni-hohenheim.de						Ache Barry W., 1994, Seminars in Cell Biology, V5, P55, DOI 10.1006/scel.1994.1008; ANHOLT RRH, 1987, BIOCHEMISTRY-US, V26, P788, DOI 10.1021/bi00377a020; ANHOLT RRH, 1986, J NEUROSCI, V6, P1962; Berghard A, 1996, J NEUROSCI, V16, P909; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1991, CHEM SENSES, V16, P19, DOI 10.1093/chemse/16.1.19; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHEN Z, 1986, J BIOL CHEM, V261, P1299; Dellacorte C, 1996, NEUROSCIENCE, V74, P261, DOI 10.1016/0306-4522(96)00115-7; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1988, COLD SPRING HARB SYM, V53, P349, DOI 10.1101/SQB.1988.053.01.042; JONES DT, 1987, J BIOL CHEM, V262, P14241; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MANIAFARNELL B, 1990, DEV BRAIN RES, V51, P103, DOI 10.1016/0165-3806(90)90262-W; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MENCO B, 1992, MICROSC RES TECHNIQ, V22, P215; MENCO BPM, 1994, J NEUROCYTOL, V23, P708, DOI 10.1007/BF01181645; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P268; PACE U, 1986, P NATL ACAD SCI USA, V83, P4947, DOI 10.1073/pnas.83.13.4947; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Restrepo D, 1996, J NEUROBIOL, V30, P37; RONNETT GV, 1993, J NEUROSCI, V13, P1751; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SILVA IF, 1990, J MOL BIOL, V215, P483, DOI 10.1016/S0022-2836(05)80160-3; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEINER AL, 1972, J BIOL CHEM, V247, P1114; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Zwaal RR, 1997, GENETICS, V145, P715	57	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16669	16677		10.1074/jbc.273.27.16669	http://dx.doi.org/10.1074/jbc.273.27.16669			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642220	hybrid			2022-12-27	WOS:000074545200010
J	Antolovic, R; Kost, H; Mohadjerani, M; Linder, D; Linder, M; Schoner, W				Antolovic, R; Kost, H; Mohadjerani, M; Linder, D; Linder, M; Schoner, W			A specific binding protein for cardiac glycosides exists in bovine serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIGITALIS-LIKE COMPOUNDS; ADRENOCORTICAL-CELLS; ENDOGENOUS OUABAIN; NA+/K+-ATPASE; HUMAN PLASMA; NA,K-ATPASE; GLOBULIN; IDENTIFICATION; HYPOTHALAMUS; INHIBITION	Searching for a binding protein in blood, which may be involved in the specific transport of cardiac glycosides to their receptor sites on the sodium pump, we isolated a cardiac glycoside-binding protein (CGBG) of 26 kDa from the globulin fraction of bovine serum by affinity chromatography and on a ouabain-Sepharose 4B column by a purification factor of 5000. The cardiac glycoside-binding globulin was labeled specifically and covalently by the protein-reactive digoxigenin derivative HDMA (N-hydroxysuccimidyldigoxigenin-3-O-methylcarbonyl-epsilon-aminocaproate). Even very high concentrations of other steroids, such as estrogen, testosterone, progesterone, and cortisone, did not prevent HDMA-labeling (at 5 and 100 nM) of CGBG, but the cardenolides ouabain and digoxin or the bufadienolide proscillaridin A did so. CGBG is a homodimer of two 26-kDa subunits forming disulfide bonds, since HDMA labeling of a protein of 53 kDa was observed in SDS-polyacrylamide gel electrophoresis when beta-mercaptoethanol was absent during SDS denaturation, The N-terminal amino acid sequence K-D-V-Y-R-A-P-D-G-T-Q-S-A showed no sequence similarity with proteins recorded in gene and protein sequence data banks. A 90-kDa cytosolic CGBG exists in bovine kidneys and reacts with antibodies against CGBG. Binding of ouabain to the cardiac glycoside-binding globulin was monitored by quenching of intrinsic tryptophan fluorescence. Such studies reveal two negatively cooperative ouabain binding sites with K-d' of 1.52 nM and K-d" = 75 nM and with an interaction factor of 50 using a Koshland-Nemethy-Filmer model. The demonstration of a cardiac glycoside-binding globulin in plasma is consistent with the recent finding of endogenous cardiac glycosides in mammals.	Univ Giessen, Fachbereich Vet Med, Inst Biochem & Endokrinol, Fac Med Vet, D-35392 Giessen, Germany; Univ Giessen, Fac Human Med, Inst Biochem, D-35392 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Antolovic, R (corresponding author), Univ Giessen, Fachbereich Vet Med, Inst Biochem & Endokrinol, Fac Med Vet, Frankfurter Str 100, D-35392 Giessen, Germany.	roberto.antolovic@vetmed.uni-giessen.de	Mohadjerani, Maryam/AAV-7308-2020	Mohadjerani, Maryam/0000-0002-8217-9918				Antolovic R, 1997, ANN NY ACAD SCI, V834, P618, DOI 10.1111/j.1749-6632.1997.tb52331.x; ANTOLOVIC R, 1995, EUR J BIOCHEM, V227, P61, DOI 10.1111/j.1432-1033.1995.tb20359.x; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; Bagrov AY, 1996, AM J HYPERTENS, V9, P982, DOI 10.1016/0895-7061(96)00148-3; BAGROV AY, 1995, HYPERTENSION, V26, P781, DOI 10.1161/01.HYP.26.5.781; BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; Beck K, 1997, EUR J BIOCHEM, V247, P339, DOI 10.1111/j.1432-1033.1997.00339.x; BLANCO G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P1, DOI 10.1016/0005-2736(90)90039-Q; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; COOLE NE, 1985, J CLIN INVEST, V76, P2420; FLINK IL, 1986, P NATL ACAD SCI USA, V84, P5153; GOTO A, 1992, PHARMACOL REV, V44, P377; GOTO A, 1990, BIOCHEM BIOPH RES CO, V173, P1093, DOI 10.1016/S0006-291X(05)80898-8; GOTTLIEB SS, 1992, CIRCULATION, V86, P420, DOI 10.1161/01.CIR.86.2.420; GYORGYI AS, 1953, CHEM PHYSL CONTRACTI; HAMLYN JM, 1994, SODIUM PUMP, P722; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65; Huang LY, 1997, J MOL CELL CARDIOL, V29, P429, DOI 10.1006/jmcc.1996.0320; KOCHSIEK K, 1986, CARDIAC GLYCOSIDES 1, P407; KRIEGLSTEIN J, 1981, HDB EXP PHARM, V56, P95; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LAREDO J, 1995, BIOCHEM BIOPH RES CO, V212, P487, DOI 10.1006/bbrc.1995.1996; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LICHTSTEIN D, 1993, J CARDIOVASC PHARM, V22, pS102, DOI 10.1097/00005344-199322002-00033; LICHTSTEIN D, 1993, EUR J BIOCHEM, V216, P261, DOI 10.1111/j.1432-1033.1993.tb18141.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIXENT JM, 1987, J BIOL CHEM, V262, P6842; MANUNTA P, 1994, J HYPERTENS, V12, P549; NG YC, 1987, AM J PHYSIOL, V252, pH1016; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; PETRA PH, 1986, C INSERM, V149, P15; Repke KRH, 1997, DRUG DISCOV TODAY, V2, P110, DOI 10.1016/S1359-6446(97)01001-5; RETETOFF S, 1989, ENDOCR REV, V10, P275; ROSNER W, 1990, ENDOCR REV, V11, P80, DOI 10.1210/edrv-11-1-80; Schneider R, 1998, J BIOL CHEM, V273, P784, DOI 10.1074/jbc.273.2.784; Schoner W, 1993, Prog Drug Res, V41, P249; Segel I. H., 1975, ENZYME KINETICS, P355; Sich B, 1996, HYPERTENSION, V27, P1073, DOI 10.1161/01.HYP.27.5.1073; SWEADNER KJ, 1993, TRENDS CARDIOVAS MED, V3, P2, DOI 10.1016/1050-1738(93)90020-7; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; Valle, 1995, METABOLIC BASIS INHE, P4159; Warburg O., 1942, BIOCHEM Z, V310, P384; WESTPHAL U, 1978, H-S Z PHYSIOL CHEM, V359, P431; ZHAO N, 1995, BIOCHEMISTRY-US, V34, P9893, DOI 10.1021/bi00031a010	46	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16259	16264		10.1074/jbc.273.26.16259	http://dx.doi.org/10.1074/jbc.273.26.16259			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632685	hybrid			2022-12-27	WOS:000074436600056
J	Baudino, TA; Kraichely, DM; Jefcoat, SC; Winchester, SK; Partridge, NC; MacDonald, PN				Baudino, TA; Kraichely, DM; Jefcoat, SC; Winchester, SK; Partridge, NC; MacDonald, PN			Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; NUCLEAR RECEPTORS; POLYTENE CHROMOSOMES; HORMONE-RECEPTOR; RETINOIC ACID; EXPRESSION; SEQUENCE; CBP; INTERACTS; PUFFS	The vitamin D receptor (VDR) forms a heterodimeric complex with retinoid X receptor (RXR) and binds to vitamin D-responsive promoter elements to regulate the transcription of specific genes or gene networks. The precise mechanism of transcriptional regulation by the VDR RXR heterodimer is not well understood, but it may involve interactions of VDR RXR with transcriptional coactivator or corepressor proteins. Here, a yeast two-hybrid strategy was used to isolate proteins that selectively interacted with VDR and other nuclear receptors, One cDNA clone designated NCoA-62, encoded a 62,000-Da protein that is highly related to BX42, a Drosophila melanogaster nuclear protein involved in ecdysone-stimulated gene expression. Yeast two-hybrid studies and in vitro protein-protein interaction assays using glutathione S-transferase fusion proteins demonstrated that NCoA-62 formed a direct protein-protein contact with the ligand binding domain of VDR, Coexpression of NCoA-62 in a vitamin D-responsive transient gene expression system augmented 1,25-dihydroxyvitamin D-3-activated transcription, but it had little or no effect on basal transcription or gal4-VP16-activated transcription. NCoA-62 also interacted with retinoid receptors, and its expression enhanced retinoic acid-, estrogen-, and glucocorticoid-mediated gene expression. These data indicate that NCoA-62 may be classified into an emerging set of transcriptional coactivator proteins that function to facilitate vitamin D- and other nuclear receptor-mediated transcriptional pathways.	St Louis Univ, Hlth Sci Ctr, Dept Pharmacol & Physiol Sci, Cell & Mol Biol Program, St Louis, MO 63104 USA	Saint Louis University	MacDonald, PN (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand, St Louis, MO 63104 USA.			Partridge, Nicola/0000-0002-5406-4814	NIDDK NIH HHS [R01DK50348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRASCH M, 1989, CHROMOSOMA, V97, P272, DOI 10.1007/BF00371966; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Summers MD, 1987, MANUAL METHODS BACUL; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VONBAUR E, 1996, EMBO J, V15, P110; WIELAND C, 1992, CHROMOSOMA, V101, P517, DOI 10.1007/BF00352475	35	117	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16434	16441		10.1074/jbc.273.26.16434	http://dx.doi.org/10.1074/jbc.273.26.16434			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632709	hybrid			2022-12-27	WOS:000074436600080
J	Ho, DH; Badellino, K; Baglia, FA; Walsh, PN				Ho, DH; Badellino, K; Baglia, FA; Walsh, PN			A binding site for heparin in the Apple 3 domain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; MOLECULAR-WEIGHT KININOGEN; FACTOR-IX; HUMAN-PLATELETS; HUMAN-PLASMA; DISULFIDE BONDS; HEAVY-CHAIN; ACTIVATION; IDENTIFICATION; MECHANISM	Since heparin potentiates activated factor XI (FXIa) inhibition by protease nexin-2 by providing a template to which both proteins bind (Zhang, Y., Scandura, J. M., Van Nostrand, W. E., and Walsh, P. N. (1997) J. Biol. Chem. 272, 26139-26144), we examined binding of factor XI (FXI) and FXIa to heparin. FXIa binds to heparin (K-d -0.7 x 10(-9) M) > 150-fold more tightly than FXI (K-d similar to 1.1 x 10(-7) M). To localize the heparin-binding site on FXI, rationally designed conformationally constrained synthetic peptides were used to compete with I-125-FXI binding to heparin. A peptide derived from the Apple 3 (A3) domain of FXI (Asn(235)-Arg(266)) inhibited FXI binding to heparin (K-d similar to 3.4 x 10(-6) M), whereas peptides from the A1 domain (Phe(56)-Ser(86)), A2 domain (Ala(134)-Ala(176)), and A4 domain (Ala(317)-Gly(350)) had no such effect. The recombinant A3 domain (rA3, Ala(181)-Val(271)) inhibited FXI binding to heparin (K-i similar to 1.4 x 10(-7) M) indicating that all the information necessary for FXI binding to heparin is contained entirely within the A3 domain. The A3 domain also contains a platelet-binding site (Asn(235)-Arg(266)), consisting of three surface-exposed loop structures, Pro(229)-Gln(233), Thr(741)-Leu(246), and Thr(249)-Phe(260) (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1995) J. Biol. Chem. 270, 6734-6740). Only peptide Thr(249-)Phe(260) (which contains a heparin binding consensus sequence, RIKKSKA) inhibits FXI binding to heparin (K-i = 2.1 x 10(-7) M), whereas peptides Pro(229)-Gln(233) and Thr(241)-Leu(246) had no effect. Fine mapping of the heparin-binding site using prekallikrein analogue amino acid substitutions of the synthetic peptide Thr(249)-Phe(260) and alanine scanning of the recombinant A3 indicated that the amino acids Lys(252) and Lys(253) are important for heparin binding. Thus, the sequence Thr(249)-Phe(260) which contains most of the binding energy for FXI interaction with platelets also mediates the binding of FXI to heparin.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL56153, HL46213, HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486, R01HL046213, R01HL056153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P3244; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, BLOOD, V85, P2078, DOI 10.1182/blood.V85.8.2078.bloodjournal8582078; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BAILEY JL, 1959, J BIOL CHEM, V234, P1733; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Ho D. H., 1996, Blood, V88, p283A; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KLOMPMAKERS AA, 1986, ANAL BIOCHEM, V153, P80, DOI 10.1016/0003-2697(86)90064-3; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NAITO K, 1991, J BIOL CHEM, V266, P7353; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; WALSH PN, 1993, METHOD ENZYMOL, V222, P65; WALSH PN, 1981, BLOOD, V57, P106; ZAMMIT A, 1993, THROMB HAEMOSTASIS, V70, P951; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139	41	65	68	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16382	16390		10.1074/jbc.273.26.16382	http://dx.doi.org/10.1074/jbc.273.26.16382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632702	hybrid			2022-12-27	WOS:000074436600073
J	Huang, S; Shao, G; Liu, LM				Huang, S; Shao, G; Liu, LM			The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; TRANSCRIPTION FACTOR; ACUTE LEUKEMIAS; DROSOPHILA-TRITHORAX; MYELOID-LEUKEMIA; ALL-1 GENE; TRANSLOCATIONS; HETEROZYGOSITY; CHROMOSOME-1; REPRESSOR	The PR domain, first noted as the PRDI-BF1-RIZ1 homologous region, defines a sub-class of zinc finger genes that appear to function as negative regulators of tumorigenesis. This family includes the MDS1-EVI1 gene inactivated in myeloid leukemia, the PRDI-BF1/BLIMP1 transcription repressor of c-myc involved in driving B-cell differentiation, and the RIZ gene, which encodes proteins capable of binding to the retinoblastoma tumor suppressor protein (Rb). The PR domain of MDS1-EVI1 is disrupted by translocations linked to myeloid leukemia, resulting in the activation of the PR-minus oncogenic product EVI1. Remarkably similar to MDS1-EVI1, RIZ gene also normally produces two protein products of different length, and the smaller protein RIZ2 lacks the PR domain of RIZ1 but is otherwise identical to RIZ1. These observations raise considerable interest to determine the function of PR. We show here that RIZ1 PR domain mediates protein-protein interaction. Recombinant fusion proteins of PR can bind to in vitro translated RIZ1 and RIZ2 proteins. The binding can be disrupted by amino acid substitutions at conserved residues of PR, suggesting that binding is specific. Of the three conserved exons of PR, the first two appear dispensable for binding, whereas the third exon is required. A region in the carboxyl terminus of RIZ proteins was mapped to be necessary and sufficient for PR binding. We also found that the PR domain shares significant sequence identity to the SET domain present in chromosomal proteins that function in modulating gene expression from yeast to mammals. Our data suggest that the PR domain is a derivative of SET domain and may function as protein binding interface in the regulation of chromatin-mediated gene expression.	Burnham Inst, Program Oncogenes & Tumor Suppressor Genes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Huang, S (corresponding author), Burnham Inst, Program Oncogenes & Tumor Suppressor Genes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA76146, R01CA57496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076146, R01CA057496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; BARDI G, 1993, CANCER RES, V53, P1895; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Buyse IM, 1996, GENOMICS, V34, P119, DOI 10.1006/geno.1996.0249; DeRubertis F, 1996, NATURE, V384, P589; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Ekwall K, 1996, J CELL SCI, V109, P2637; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FONG CT, 1992, CANCER RES, V52, P1780; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; NAGAI H, 1995, CANCER RES, V55, P1752; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Seum C, 1996, DEVELOPMENT, V122, P1949; SIMON D, 1991, ONCOGENE, V6, P765; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	47	131	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					15933	15939		10.1074/jbc.273.26.15933	http://dx.doi.org/10.1074/jbc.273.26.15933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632640	hybrid			2022-12-27	WOS:000074436600011
J	Motta, MC; Landsberger, N; Merli, C; Badaracco, G				Motta, MC; Landsberger, N; Merli, C; Badaracco, G			In vitro reconstitution of Artemia satellite chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION EFFECT VARIEGATION; CELL-FREE SYSTEM; NUCLEOSOME REMODELING FACTOR; LINKER HISTONES; SACCHAROMYCES-CEREVISIAE; SPACED CHROMATIN; W-CHROMOSOME; RAT-LIVER; DNA; SEQUENCE	We report the characterization of an in vitro chromatin assembly system derived from Artemia embryos and its application to the study of AluI-113 satellite DNA organization in nucleosomes. The system efficiently reconstitutes chromatin templates by associating DNA, core histones, and H1. The polynucleosomal complexes show physiological spacing of repeat length 190 +/- 5 base pairs, and the internucleosomal distances are modulated by energy-using activities that contribute to the dynamics of chromatin conformation. The assembly extract was used to reconstitute tandemly repeated AluI-113 sequences. The establishment of preferred histone octamer/satellite DNA interactions was observed, In vitro, AluI-113 elements dictated the same nucleosome translational localizations as found in rico. Specific rotational constraints seem to be the central structural requirement for nucleosome association. Satellite dinucleosomes showed decreased translational mobility compared with mononucleosomes. This could be the consequence of interactions between rotationally positioned nucleosomes separated by Linker DNA of uniform length. AluI-113 DNA led to weak cooperativity of nucleosome association in the proximal flanking regions, which decreased with distance. Moreover, the structural properties of satellite chromatin can spread, thus leading to a specific organization of adjacent nucleosomes.	Univ Milan, Fac Sci 3, Dipartimento Biol Stutterale & Funz, I-21100 Varese, Italy	University of Milan	Badaracco, G (corresponding author), Univ Milan, Fac Sci 3, Dipartimento Biol Stutterale & Funz, Via Ravasi 2, I-21100 Varese, Italy.	hetero@imiucca.csi.unimi.it	Motta, Maria Cristina M/I-3140-2014	Landsberger, Nicoletta/0000-0003-0820-3155				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BADARACCO G, 1992, BIOCHEM J, V282, P249, DOI 10.1042/bj2820249; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BANERJEE S, 1991, NUCLEIC ACIDS RES, V19, P5999, DOI 10.1093/nar/19.21.5999; BARSACCHIPILONE G, 1986, CHROMOSOMA, V93, P435, DOI 10.1007/BF00285826; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BENFANTE R, 1989, NUCLEIC ACIDS RES, V17, P8273, DOI 10.1093/nar/17.20.8273; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BOCK H, 1984, J MOL BIOL, V176, P131, DOI 10.1016/0022-2836(84)90385-1; BUTTINELLI M, 1993, P NATL ACAD SCI USA, V90, P9315, DOI 10.1073/pnas.90.20.9315; CARRERA P, 1991, NUCLEIC ACIDS RES, V19, P5639, DOI 10.1093/nar/19.20.5639; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; DIMITROV S, 1995, BBA-GENE STRUCT EXPR, V1260, P1, DOI 10.1016/0167-4781(94)00182-3; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; DREW HR, 1991, J MOL BIOL, V219, P391, DOI 10.1016/0022-2836(91)90179-A; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Heitz E., 1928, JB WEISS BOT, V69, P726; HENIKOFF S, 1994, GENETICS, V138, P1; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HORZ W, 1996, NUCLEIC ACIDS RES, V3, P3213; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KARPOV VL, 1982, NUCLEIC ACIDS RES, V10, P4321, DOI 10.1093/nar/10.14.4321; KIYOE U, 1995, EMBO J, V14, P3752; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LEWIS EB, 1950, ADV GENET, V3, P73, DOI 10.1016/S0065-2660(08)60083-8; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; LINXWEILER W, 1985, CELL, V42, P281; Liu K, 1997, J MOL BIOL, V270, P559, DOI 10.1006/jmbi.1997.1136; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; LOHR D, 1986, J BIOL CHEM, V261, P9904; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MARTINEZBALBAS A, 1990, BIOCHEMISTRY-US, V29, P2342, DOI 10.1021/bi00461a019; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PAGES M, 1988, EUR J BIOCHEM, V174, P391, DOI 10.1111/j.1432-1033.1988.tb14110.x; PARDUE ML, 1994, CURR OPIN GENET DEV, V4, P845, DOI 10.1016/0959-437X(94)90069-8; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PENNINGS S, 1989, J MOL BIOL, V207, P183, DOI 10.1016/0022-2836(89)90449-X; PFEIFFER W, 1975, NATURE, V258, P450, DOI 10.1038/258450a0; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SAITOH Y, 1991, CHROMOSOMA, V101, P32, DOI 10.1007/BF00360684; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SATCHWELL SC, 1989, EMBO J, V8, P229, DOI 10.1002/j.1460-2075.1989.tb03368.x; SESSA G, 1990, NUCLEIC ACIDS RES, V18, P5449, DOI 10.1093/nar/18.18.5449; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STRAUSS F, 1983, EMBO J, V2, P51, DOI 10.1002/j.1460-2075.1983.tb01379.x; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WIDOM J, 1992, P NATL ACAD SCI USA, V89, P1095, DOI 10.1073/pnas.89.3.1095; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; YAO J, 1993, P NATL ACAD SCI USA, V90, P9364, DOI 10.1073/pnas.90.20.9364; ZHANG XY, 1983, NUCLEIC ACIDS RES, V11, P4287, DOI 10.1093/nar/11.13.4287; ZHANG XY, 1984, J MOL BIOL, V176, P105, DOI 10.1016/0022-2836(84)90384-X	81	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18028	18039		10.1074/jbc.273.29.18028	http://dx.doi.org/10.1074/jbc.273.29.18028			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660758	hybrid			2022-12-27	WOS:000074828500013
J	Pan, ZQ; Camara, B; Gardner, HW; Backhaus, RA				Pan, ZQ; Camara, B; Gardner, HW; Backhaus, RA			Aspirin inhibition and acetylation of the plant cytochrome P450, allene oxide synthase, resembles that of animal prostaglandin endoperoxide H synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALICYLIC-ACID SIGNAL; NF-KAPPA-B; JASMONIC ACID; HYDROPEROXIDE LYASE; SODIUM-SALICYLATE; GENE DISRUPTION; TOMATO LEAVES; GLYCINE-MAX; BIOSYNTHESIS; PATHWAY	The enzymatic reactions leading to octadecanoid lipid signaling intermediates in plants are similar to those of animals and are inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs) such as salicylic acid and aspirin. In animals, NSAIDs inhibit the cyclooxygenase (COX) activity of prostaglandin endoperoxide H synthase, which ultimately blocks the formation of prostaglandins. In plants, NSAIDs block the formation of 12-oxophytodienoic acid and jasmonates, which are the equivalent signaling compounds. In this study we show that NSAIDs act as competitive inhibitors of allene oxide synthase (AOS), the cytochrome P450 that initiates plant oxylipin synthesis. We also show that aspirin causes the time-dependent inhibition and acetylation of AOS, which leads the irreversible inactivation of this enzyme. This inhibition and acetylation superficially resembles that observed for the inactivation of COX in animals. In AOS, aspirin acetylates three serine residues near the C-terminal region that appear to be highly conserved among AOS sequences from other plants but are not conserved among "classical" type P450s. The role of these serine residues is unclear. Unlike animal COX, where acetylation of a single serine residue within the substrate channel leads to inactivation of prostaglandin endoperoxide H synthase, the three serine residues in AOS are not thought to line the putative substrate channel. Thus, inhibition by aspirin may be by a different mechanism. It is possible that aspirin and related NSAIDs could inhibit other P450s that have motifs similar to AOS and consequently serve as potential biochemical targets for this class of drugs.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; ARS, USDA, Peoria, IL 61064 USA	Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; United States Department of Agriculture (USDA)	Backhaus, RA (corresponding author), Arizona State Univ, Dept Plant Biol, Box 871601, Tempe, AZ 85287 USA.							AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; Capdevila Jorge H., 1995, P443; CHEN ZX, 1995, P NATL ACAD SCI USA, V92, P4134, DOI 10.1073/pnas.92.10.4134; COREY EJ, 1973, J AM CHEM SOC, V95, P2054, DOI 10.1021/ja00787a079; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P302; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1983, AM J MED, V95, P405; DOARES SH, 1995, PLANT PHYSIOL, V108, P1741, DOI 10.1104/pp.108.4.1741; DOHERTY HM, 1988, PHYSIOL MOL PLANT P, V33, P377, DOI 10.1016/0885-5765(88)90004-5; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Gardner Harold W., 1996, P162; GARDNER HW, 1995, HORTSCIENCE, V30, P197; GARDNER HW, 1991, PLANT PHYSIOL, V97, P1059, DOI 10.1104/pp.97.3.1059; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; HAMBERG M, 1993, J LIPID MEDIATOR, V6, P375; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAMBERG M, 1989, J AM OIL CHEM SOC, V66, P1439; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; KALB VF, 1988, P NATL ACAD SCI USA, V85, P7221, DOI 10.1073/pnas.85.19.7221; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1439, DOI 10.1007/BF00016484; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Laudert D, 1996, PLANT MOL BIOL, V31, P323, DOI 10.1007/BF00021793; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; Mansuy Daniel, 1995, P537; Marnett Lawrence J., 1995, P49; Matsui K, 1996, FEBS LETT, V394, P21, DOI 10.1016/0014-5793(96)00924-6; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Pan ZQ, 1996, ARCH BIOCHEM BIOPHYS, V332, P196, DOI 10.1006/abbi.1996.0333; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROME LH, 1976, PROSTAGLANDINS, V11, P23, DOI 10.1016/0090-6980(76)90169-6; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; SIMPSON TD, 1995, PLANT PHYSIOL, V108, P199, DOI 10.1104/pp.108.1.199; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SMITH WL, 1990, STROKE, V21, P24; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; VICK BA, 1979, PLANT PHYSIOL, V63, P490, DOI 10.1104/pp.63.3.490; Vick Brady A., 1993, P167; Von Wachenfeldt Claes, 1995, P183; WEILER EW, 1993, PHYTOCHEMISTRY, V32, P591, DOI 10.1016/S0031-9422(00)95142-2	53	46	52	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18139	18145		10.1074/jbc.273.29.18139	http://dx.doi.org/10.1074/jbc.273.29.18139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660772	hybrid			2022-12-27	WOS:000074828500027
J	Dong, LQ; Porter, S; Hu, DR; Liu, F				Dong, LQ; Porter, S; Hu, DR; Liu, F			Inhibition of hGrb10 binding to the insulin receptor by functional domain-mediated oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GRB-IR; KINASE; PROTEIN; ASSOCIATION	hGrb10 is a newly identified Src homology 2 (SH2) and pleckstrin homology (PH) domain-containing protein that binds to autophosphorylated receptor tyrosine kinases, including the insulin and insulin-like growth factor receptors. To identify potential downstream proteins that interact with hGrb10, we screened a yeast two-hybrid cDNA library using the full-length hGrb10 gamma as bait. A fragment of hGrb10, which included the IPS (insert between the PH and SH2 domain) and the SH2 domains, was found to bind with high affinity to the full-length protein. The interaction between the IPSI SH2 domain and the full-length hGrb10 was further confirmed by in, vitro glutathione S-transferase fusion protein binding studies. Gel filtration assays showed that hGrb10 underwent tetramerization in mammalian cells. The interaction involved at least two functional domains, the IPS/SH2 region and the PH domain, both of which interacted with the NH2-terminal amino acid sequence of hGrb10 gamma (hGrb10 gamma Delta C, residues 4-414), Competition studies showed that hGrb10 gamma Delta C inhibited the binding of hGrb10 to the tyrosine-phosphorylated insulin receptor, suggesting that this region may play a regulatory role in hGrb10/insulin receptor interaction. We present a model for hGrb10 tetramerization and its potential role in receptor tyrosine kinase signal transduction.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cattanach BM, 1996, GENET RES, V68, P35, DOI 10.1017/S0016672300033863; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Jerome CA, 1997, GENOMICS, V40, P215, DOI 10.1006/geno.1996.4535; KOTZOT D, 1995, HUM MOL GENET, V4, P583, DOI 10.1093/hmg/4.4.583; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PARSON T, 1997, SCIENCE, V278, P2075; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	25	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17720	17725		10.1074/jbc.273.28.17720	http://dx.doi.org/10.1074/jbc.273.28.17720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651371	hybrid			2022-12-27	WOS:000074816100064
J	Haussmann, C; Rohdich, F; Schmidt, E; Bacher, A; Richter, F				Haussmann, C; Rohdich, F; Schmidt, E; Bacher, A; Richter, F			Biosynthesis of pteridines in Escherichia coli - Structural and mechanistic similarity of dihydroneopterin-triphosphate epimerase and dihydroneopterin aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE-I; PNEUMOCYSTIS-CARINII; FOLIC-ACID; DIHYDROPTEROATE SYNTHASE; GENE; SULFONAMIDES; SEQUENCE; PLASMID; STRAIN	An open reading frame located at 69.0 kilobases on the Escherichia coli chromosome was shown to code for dihydroneopterin aldolase, catalyzing the conversion of 7,8 dihydroneopterin to 6-hydroxymethyl-7,8-dihydropterin in the biosynthetic pathway of tetrahydrofolate, The gene was subsequently designated folB. The FolB protein shows 30% identity to the paralogous dihydroneopterin-triphosphate epimerase, which is specified by the folX gene located at 2427 kilobases on the E. coli chromosome, The folX and folB gene products were both expressed to high yield in recombinant E. coli strains, and the recombinant proteins were purified to homogeneity. Both enzymes form homo octamers. Aldolase can use L-threo-dihydroneopterin and D-erythro-dihydroneopterin as substrates for the formation of 6-hydroxymethyldihydropterin, but it can also catalyze the epimerization of carbon 2' of dihydroneopterin and dihydromonapterin at appreciable velocity. Epimerase catalyzes the epimerization of carbon 2' in the triphosphates of dihydroneopterin and dihydromonapterin, However, the enzyme can also catalyze the cleavage of the position 6 side chain of several pteridine derivatives at a slow rate. Steady-state kinetic parameters are reported for the various enzyme catalyzed reactions. We propose that the polarization of the 3'-hydroxy group of the substrate could serve as the initial reaction step for the aldolase as web as for the epimerase activity. A deletion mutant obtained by targeting the folX gene of E, coli has normal growth properties on complete medium as well as on minimal medium. Thus, the physiological role of the E. coli epimerase remains unknown. The open reading frame ygiG of Hemophilus influenzae specifies a protein with the catalytic properties of an aldolase. However, the genome of H. influenzae does not specify a dihydroneopterin-triphosphate epimerase.	Tech Univ Munich, Dept Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Bacher, A (corresponding author), Tech Univ Munich, Dept Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	Bacher@oc3gra.org.chemie.tu-muenchen.de	Richter, Gerald/F-3642-2011					Achari A, 1997, NAT STRUCT BIOL, V4, P490, DOI 10.1038/nsb0697-490; BROEDEL SE, 1990, J BACTERIOL, V172, P4023, DOI 10.1128/jb.172.7.4023-4031.1990; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Chio LC, 1996, ANTIMICROB AGENTS CH, V40, P727, DOI 10.1128/AAC.40.3.727; Chistoserdova L, 1997, MICROBIOL-UK, V143, P1729, DOI 10.1099/00221287-143-5-1729; DESAIZIEU A, 1995, BIOCHEM J, V306, P371, DOI 10.1042/bj3060371; Fermer C, 1997, J BACTERIOL, V179, P831, DOI 10.1128/jb.179.3.831-837.1997; FIHN SD, 1988, ANN INTERN MED, V108, P350, DOI 10.7326/0003-4819-108-3-350; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARG SK, 1986, INT J CLIN PHARM TH, V24, P23; GERDING H, 1989, BIOL CHEM H-S, V370, P383; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; GUROFF G, 1969, J BIOL CHEM, V244, P142; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Haussmann C, 1997, J BACTERIOL, V179, P949, DOI 10.1128/jb.179.3.949-951.1997; HEINE MC, 1975, BIOCHIM BIOPHYS ACTA, V411, P236, DOI 10.1016/0304-4165(75)90304-9; Hughes WT, 1996, ANTIMICROB AGENTS CH, V40, P962, DOI 10.1128/AAC.40.4.962; Kaneko T, 1996, DNA Res, V3, P109; LACKS SA, 1995, J BACTERIOL, V177, P66, DOI 10.1128/jb.177.1.66-74.1995; LANE TM, 1992, ANAL ULTRACENTRIFUGA, P90; Mathis J B, 1980, Methods Enzymol, V66, P556; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NORRBY SR, 1990, REV INFECT DIS, V12, P458; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SPITZY KH, 1991, INFECTION, V19, pS52, DOI 10.1007/BF01644736; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUZUKI Y, 1974, J BIOL CHEM, V249, P2405; VOLPE F, 1995, GENE, V160, P41, DOI 10.1016/0378-1119(95)00203-I; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972	32	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17418	17424		10.1074/jbc.273.28.17418	http://dx.doi.org/10.1074/jbc.273.28.17418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651328	hybrid			2022-12-27	WOS:000074816100021
J	Miyoshi, H; Iwata, J; Sakamoto, K; Furukawa, H; Takada, M; Iwamura, H; Watanabe, T; Kodama, Y				Miyoshi, H; Iwata, J; Sakamoto, K; Furukawa, H; Takada, M; Iwamura, H; Watanabe, T; Kodama, Y			Specificity of pyridinium inhibitors of the ubiquinone reduction sites in mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE DINUCLEOTIDE DEHYDROGENASE; BINDING SITE; ELECTRON-TRANSPORT; ESCHERICHIA-COLI; Q OXIDOREDUCTASE; PIERICIDIN-A; NADH; ANALOGS; 1-METHYL-4-PHENYLPYRIDINIUM; ROTENONE	Dual binding sites for pyridinium-type inhibitors in bovine heart mitochondrial complex I have been proposed (Gluck, Ri. R., Krueger, M. J., Ramsay, R. R., Sablin, S. O., Singer, T. P., and Nickles, W. J. (1994) J. Biol. Chem. 269, 3167-3174). The marked biphasic nature of the dose-response curve for inhibition of the enzyme by MP-6(N-methyl-4-[2-(p-tert-butylbenzyl)propyl]-pyridinium) makes this compound the first selective inhibitor of the two sites (Miyoshi, H., Inoue, M., Okamoto, S., Ohshima, M., Sakamoto, K., and Iwamura, H. (1997) J. Biol. Chem. 272, 16176-16183). Modifications of the structure of MP-6 show that a tert-butyl group on the benzene ring, a methyl group attached to the pyridine nitrogen atom, para-substitution pattern in the pyridine ring, and the presence of a branched structure in the spacer moiety are important for the selective inhibition. On the basis of the structural specificity, we synthesized a selective inhibitor, MP-24 (N-methyl-4-[2-methyl-2-(p-tert-butylbenzyl)propyl]pyridinium), which elicits greater selectivity. Characterization of the inhibitory behavior of MP-24 provided further strong evidence for the dual binding sites model.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2228567, Japan	Kyoto University; Meiji Holdings Co., Ltd.	Miyoshi, H (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	miyoshi@kais.kyoto-u.ac.jp	Sakamoto, Kimitoshi/G-4539-2014					ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; GLUCK MR, 1994, J BIOL CHEM, V269, P3167; GUTMAN M, 1970, J BIOL CHEM, V245, P1992; GUTMAN M, 1970, BIOCHEMISTRY-US, V9, P2678, DOI 10.1021/bi00815a016; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; KEAN EA, 1971, J BIOL CHEM, V246, P2346; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; Miyoshi H, 1997, J BIOL CHEM, V272, P16176, DOI 10.1074/jbc.272.26.16176; MURPHY MP, 1995, BIOCHEM J, V306, P359, DOI 10.1042/bj3060359; Ohshima M, 1998, BIOCHEMISTRY-US, V37, P6436, DOI 10.1021/bi9800202; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; RAMSAY RR, 1987, ARCH BIOCHEM BIOPHYS, V259, P645, DOI 10.1016/0003-9861(87)90531-5; RAMSAY RR, 1991, BIOCHEM J, V273, P481, DOI 10.1042/bj2730481; RYDON HN, 1988, ORG SYNTH, V50-9, P830; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; Sakamoto K, 1996, J BIOL CHEM, V271, P29897, DOI 10.1074/jbc.271.47.29897; SAYRE LM, 1990, ARCH BIOCHEM BIOPHYS, V280, P274, DOI 10.1016/0003-9861(90)90330-2; UENO H, 1994, EUR J BIOCHEM, V225, P411, DOI 10.1111/j.1432-1033.1994.00411.x; vanBelzen R, 1997, BIOCHEMISTRY-US, V36, P886, DOI 10.1021/bi9612982; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8	25	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17368	17374		10.1074/jbc.273.28.17368	http://dx.doi.org/10.1074/jbc.273.28.17368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651320	hybrid			2022-12-27	WOS:000074816100013
J	Perry, SW; Hamilton, JA; Tjoelker, LW; Dbaibo, G; Dzenko, KA; Epstein, LG; Hannun, Y; Whittaker, JS; Dewhurst, S; Gelbard, HA				Perry, SW; Hamilton, JA; Tjoelker, LW; Dbaibo, G; Dzenko, KA; Epstein, LG; Hannun, Y; Whittaker, JS; Dewhurst, S; Gelbard, HA			Platelet-activating factor receptor activation - An initiator step in HIV-1 neuropathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; GLUTAMATE UPTAKE; INDUCED APOPTOSIS; ARACHIDONIC-ACID; 2 DISTINCT; RAT-BRAIN; EXPRESSION; DEMENTIA; CELLS	Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system results in neuronal apoptosis. Activated HIV-1-infected monocytes secrete high levels of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and the phospholipid mediator platelet-activating factor (PAF). TNF-alpha and PAF are elevated in the central nervous system of patients with HIV-1-associated dementia. We now demonstrate that conditioned media from activated HIV-1-infected monocytes induces neuronal apoptosis, which can be prevented by co-incubation with PAF acetylhydrolase, the enzyme that catabolizes PAF in the central nervous system. Preceding apoptosis is a TNF-alpha-induced increase in neuronal ceramide levels. TNF-alpha-mediated neuronal apoptosis can also be blocked by co-incubation with PAF acetylhydrolase, or a PAF receptor antagonist. Blocking pathologic activation of PAF receptors may therefore be a pivotal step in the treatment of HIV-1-associated dementia.	Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; ICOS Corp, Bothell, WA 98021 USA; Amer Univ Beirut, Dept Pediat, Beirut, Lebanon; Univ Connecticut, Dept Pharmacol, Farmington, CT 06030 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Icos Corporation; American University of Beirut; University of Connecticut; Duke University	Gelbard, HA (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Child Neurol Div, Box 631601 Elmwood Ave, Rochester, NY 14642 USA.	hgelbard@mail.neurology.rochester.edu	Gelbard, Harris/M-9260-2019; Dbaibo, Ghassan S./X-2978-2019	Perry, Seth W/0000-0002-1503-6634; Dewhurst, Stephen/0000-0001-7729-7920; Epstein, Leon/0000-0003-4264-3867; Gelbard, Harris/0000-0001-5095-7976	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH057556, R01MH056838] Funding Source: NIH RePORTER; NIMH NIH HHS [P01 MH57556, R01 MH56838] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; Dzenko Kirk A., 1995, Society for Neuroscience Abstracts, V21, P561; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GELBARD HA, 1995, NEUROPATH APPL NEURO, V21, P208, DOI 10.1111/j.1365-2990.1995.tb01052.x; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORTH R, 1989, BRIT J PHARMACOL, V98, P653, DOI 10.1111/j.1476-5381.1989.tb12640.x; LOCARDI C, 1990, J VIROL, V64, P5874, DOI 10.1128/JVI.64.12.5874-5882.1990; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Mori M, 1996, J NEUROSCI, V16, P3590; NOTTET HS, 1995, J IMMUNOL, V24, P3567; Perry SW, 1997, BIOTECHNIQUES, V22, P1102, DOI 10.2144/97226st01; PETITO CK, 1995, AM J PATHOL, V146, P1121; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WEISSMAN D, 1993, P NATL ACAD SCI USA, V90, P2537, DOI 10.1073/pnas.90.6.2537; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Westmoreland SV, 1996, J NEUROVIROL, V2, P118, DOI 10.3109/13550289609146545; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O	33	113	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17660	17664		10.1074/jbc.273.28.17660	http://dx.doi.org/10.1074/jbc.273.28.17660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651362	hybrid			2022-12-27	WOS:000074816100055
J	Waxham, MN; Tsai, AL; Putkey, JA				Waxham, MN; Tsai, AL; Putkey, JA			A mechanism for calmodulin (CaM) trapping by CaM-kinase II defined by a family of CaM-binding peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LIGHT-CHAIN KINASE; CALCIUM-BINDING; INHIBITION; DOMAIN; AUTOPHOSPHORYLATION; COMPLEXES; FRAGMENT; SITES	Autophosphorylation of Ca2+/calmodulin (CaM)-dependent protein kinase II (CaM-kinase II) induces a striking >1,000-fold increase in its affinity for CaM, which has been called CaM trapping. Two peptides modeled after the CaM binding domain of CaM-kinase II were previously shown to kinetically resemble CaM: binding to phosphorylated and dephosphorylated forms of the enzyme, thus providing a model system with which to define the molecular basis of CaM trapping, In this report, the specific contribution of each amino acid to the rates of association and dissociation, and the overall K-d of CaM binding to CaM-kinase II was determined using an overlapping peptide family, and a fluorescently labeled CaM. The association rate constants were similar for the entire family of peptides and ranged from 8 x 10(7) to 32 x 10(7) M-1 s(-1). In contrast, the dissociation rate constants for the peptides varied by >3500-fold and ranged from 0.26 to 7 x 10(-5) s(-1). These rate constants yield overall K-d values for binding CaM to the peptides that range from 2 x 10(-9) M to 2 x 10(-13) M. Extending the low affinity CaM-binding peptide, CKII(296-312), to include (293)Phe-Asn-Ala(295) provided the single largest contribution to the decreased dissociation rate constant, 1,300-fold. It was further shown using Ala-substituted peptides that the basic residues (296)Arg-Arg-Lys(299) were also essential for slow CaM dissociation; however, their contribution was realized only when (293)Phe-Asn-Ala(295) were present, These results suggest a plausible model in which autophosphorylation of CaM-kinase II leads to a conformational change in the region of (293)Phe-Asn-Ala(295) which makes these residues accessible for binding to CaM, As a consequence of these changes, further CaM contacts with (296)Arg-Arg-Lys(299) are established leading to high affinity CaM binding or "CaM trapping.".	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System	Putkey, JA (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA.			Waxham, M. Neal/0000-0003-4801-1190	NHLBI NIH HHS [HL45724] Funding Source: Medline; NIGMS NIH HHS [GM44911] Funding Source: Medline; NINDS NIH HHS [NS26086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026086, R56NS026086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Smith J., 1992, J MENTAL HLTH, V1, P61; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	20	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17579	17584		10.1074/jbc.273.28.17579	http://dx.doi.org/10.1074/jbc.273.28.17579			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651352	hybrid			2022-12-27	WOS:000074816100045
J	Liu, JQ; Dairi, T; Itoh, N; Kataoka, M; Shimizu, S; Yamada, H				Liu, JQ; Dairi, T; Itoh, N; Kataoka, M; Shimizu, S; Yamada, H			A novel metal-activated pyridoxal enzyme with a unique primary structure, low specificity D-threonine aldolase from Arthrobacter sp. strain DK-38 - Molecular cloning and cofactor characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMINO ACIDS; DEPSIPEPTIDE; ALIGNMENT	The gene encoding low specificity D-threonine aldolase, catalyzing the interconversion of D-threonine/D-allo-threonine and glycine plus acetaldehyde, was cloned from the chromosomal DNA of Arthrobacter sp, strain DK-38, The gene contains an open reading frame consisting of 1,140 nucleotides corresponding to 379 amino acid residues. The enzyme was overproduced in recombinant Escherichia coli cells and purified to homogeneity by ammonium sulfate fractionation and three-column chromatography steps. The recombinant aldolase was identified as a pyridoxal enzyme with the capacity of binding 1 mol of pyridoxal 5'-phosphate per mol of subunit, and Lys(59) Of the enzyme was determined to be the cofactor binding site by chemical modification with NaBH4. In addition, Mn2+ ion was demonstrated to be an activator of the enzyme, although the purified enzyme contained no detectable metal ions. Equilibrium dialysis and atomic absorption studies revealed that the recombinant enzyme could bind 1 mol of Mn2+ ion per mol of subunit, Remarkably, the predicted amino acid sequence of the enzyme showed no significant similarity to those of the currently known pyridoxal 5'-phosphate-dependent enzymes, indicating that low specificity D-threonine aldolase is a new pyridoxal enzyme with a unique primary structure. Taken together, low specificity D-threonine aldolase from Arthrobacter sp. strain DK-38, with a unique primary structure, is a novel metal-activated pyridoxal enzyme.	Toyama Univ, Biotechnol Res Ctr, Lab Biocatalyt Chem, Toyama 9390398, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6068502, Japan	University of Toyama; Kyoto University	Yamada, H (corresponding author), Toyama Univ, Biotechnol Res Ctr, Lab Biocatalyt Chem, Kurokawa 5180,Kosugi Machi, Toyama 9390398, Japan.	ryu@pu-toyama.ac.jp	Kataoka, Michihiko/E-5847-2011; Dairi, Tohru/A-5448-2012	Dairi, Tohru/0000-0002-3406-7970				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BURKE TR, 1989, TETRAHEDRON LETT, V30, P519, DOI 10.1016/S0040-4039(00)95242-0; DAINTY RH, 1970, BIOCHEM J, V117, P585, DOI 10.1042/bj1170585; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FUKUSHIMA T, 1995, BIOL PHARM BULL, V18, P1130; HERBERT RB, 1994, CAN J CHEM, V72, P114, DOI 10.1139/v94-018; HERBERT RB, 1993, J CHEM SOC CHEM COMM, P205, DOI 10.1039/c39930000205; Kajimura Y, 1996, J ANTIBIOT, V49, P129, DOI 10.7164/antibiotics.49.129; Kataoka M, 1997, EUR J BIOCHEM, V248, P385, DOI 10.1111/j.1432-1033.1997.00385.x; Kataoka M, 1997, FEMS MICROBIOL LETT, V151, P245, DOI 10.1016/S0378-1097(97)00168-7; KUMAGAI H, 1972, BIOCHIM BIOPHYS ACTA, V258, P779, DOI 10.1016/0005-2744(72)90179-9; Liu JQ, 1997, EUR J BIOCHEM, V245, P289, DOI 10.1111/j.1432-1033.1997.00289.x; Liu JQ, 1998, APPL ENVIRON MICROB, V64, P549; Liu JQ, 1997, J BACTERIOL, V179, P3555, DOI 10.1128/jb.179.11.3555-3560.1997; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MATSUO Y, 1959, J BIOL CHEM, V234, P507; Mildvan A.S., 1970, ENZYMES, P445; OHASHI N, 1984, Patent No. 0128684; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAZ MA, 1965, ARCH BIOCHEM BIOPHYS, V109, P548, DOI 10.1016/0003-9861(65)90400-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIRCH L, 1962, J BIOL CHEM, V237, P2578; Shibata K, 1996, TETRAHEDRON LETT, V37, P2791, DOI 10.1016/0040-4039(96)00430-3; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; Takeyama H, 1997, MICROBIOL-UK, V143, P2725, DOI 10.1099/00221287-143-8-2725; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VASSILEV VP, 1995, TETRAHEDRON LETT, V36, P4081, DOI 10.1016/0040-4039(95)00720-W; VASSILEV VP, 1995, TETRAHEDRON LETT, V36, P5063, DOI 10.1016/0040-4039(95)00924-2; WADA H, 1961, J BIOL CHEM, V236, P2089; WOEHL EU, 1995, COORDIN CHEM REV, V144, P147, DOI 10.1016/0010-8545(94)08001-8; YAMADA H, 1970, BIOCHEM BIOPH RES CO, V39, P53, DOI 10.1016/0006-291X(70)90756-4	33	45	49	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16678	16685		10.1074/jbc.273.27.16678	http://dx.doi.org/10.1074/jbc.273.27.16678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642221	hybrid			2022-12-27	WOS:000074545200011
J	Smith, MD; Ensor, EA; Coffin, RS; Boxer, LM; Latchman, DS				Smith, MD; Ensor, EA; Coffin, RS; Boxer, LM; Latchman, DS			Bcl-2 transcription from the proximal P2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; EXPRESSION; GENE; SURVIVAL; PROTEIN; APOPTOSIS; DIFFERENTIATION; REGION; DEATH; DISTINCT	The BCL-2 protein is able to protect neuronal and other cell types from apoptotic programmed cell death and plays a key role in regulating the rate of apoptosis during development of the nervous system. We have previously demonstrated that the Brn-3a POU domain transcription factor protects sensory neurons from apoptotic programmed cell death induced by nerve growth factor withdrawal. We report here that Bcl-2 transcription is predominantly initiated from the Bcl-2 Pa promoter in both the ND7 neuronal cell line and primary dorsal root ganglion neurons, in contrast to the predominant use of the Bcl-2 P1 promoter in other cell types. Moreover, Bcl-2 transcription initiated from the P2 region increases in ND7 cells stably overexpressing Brn-3a, resulting in enhanced BCL-2 protein levels. Similarly, the Bcl-2 P2 promoter is directly activated by Brn-3a in co-transfection assays in both ND7 cells and dorsal, root ganglion neurons. Analysis of the Bcl-2 regulatory sequence revealed a binding site for Brn-3a that is required for maximal activation by Brn-3a both in transfected cells and during differentiation of ND7 cells. Together these data identify Brn-3a as the first transcription factor regulating Bcl-2 activity specifically in neuronal cells and indicate that the anti-apoptotic effect of Brn-3a is likely to be mediated, at least in part, via the up-regulation of Bcl-2 expression.	UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA	University of London; University College London; Stanford University	Latchman, DS (corresponding author), UCL, Windeyer Inst Med Sci, Dept Mol Pathol, Cleveland St, London W1P 6DB, England.	d.latchman@ucl.ac.uk			NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP TE, 1995, EUR J NEUROSCI, V7, P1266, DOI 10.1111/j.1460-9568.1995.tb01116.x; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; BUDHRAMMAHADEO V, 1995, NEUROSCI LETT, V185, P48, DOI 10.1016/0304-3940(94)11222-5; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Coffin RS, 1996, GENE THER, V3, P886; Davies A. M., 1995, NEURAL CELL CULTURE, P153; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HEWITT SM, 1995, CANCER RES, V55, P5386; HIGUSHI R, 1990, PCR PROTOCOLS GUIDE, P173; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MERRY DE, 1994, DEVELOPMENT, V120, P301; Middleton G, 1996, DEVELOPMENT, V122, P695; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	46	108	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16715	16722		10.1074/jbc.273.27.16715	http://dx.doi.org/10.1074/jbc.273.27.16715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642226	hybrid			2022-12-27	WOS:000074545200016
J	Sommarin, Y; Wendel, M; Shen, ZX; Hellman, U; Heinegard, D				Sommarin, Y; Wendel, M; Shen, ZX; Hellman, U; Heinegard, D			Osteoadherin, a cell-binding keratan sulfate proteoglycan in bone, belongs to the family of leucine-rich repeat proteins of the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; IN-GEL DIGESTION; CORE PROTEIN; COLLAGEN FIBRILLOGENESIS; OSTEOINDUCTIVE FACTOR; CONNECTIVE TISSUES; MOLECULAR-CLONING; DECORIN; CARTILAGE; EXPRESSION	Osteoadherin is a recently described bone proteoglycan containing keratan sulfate. It promotes integrin (alpha(v)beta(3))-mediated cell binding (Wendel, M., Sommarin, Y., and Heinegard, D. (1998) J. Cell Biol. 141, 839-847). The primary structure of bovine osteoadherin has now been determined by nucleotide sequencing of a cDNA clone from a primary bovine osteoblast expression library. The entire translated primary sequence corresponds to a 49,116-Da protein with a calculated isoelectric point for the mature protein of 5.2. The dominating feature is a central region.consisting of 11 B-type, leucine-rich repeats ranging in length from 20 to 30 residues. The full, primary sequence contains four putative sites for tyrosine sulfation, three of which are at the N-terminal end of the molecule. There are six potential sites for N-linked glycosylation present, Osteoadherin shows highest sequence identity, 42%, to bovine keratocan and 31-38% identity to bovine fibromodulin, lumican, and human PRELP. Unique to osteoadherin is the presence of a large and very acidic C-terminal domain. The distribution of cysteine residues resembles that of other leucine-rich repeat proteins except for two centrally located cysteines. Northern blot analysis of RNA samples from various bovine tissues showed a 4.5-kilobase pair message for osteoadherin to be expressed in bone only. Osteoadherin mRNA was detected by in situ hybridization in mature osteoblasts located superficially on trabecular bone.	Univ Lund, Dept Cellular & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Ludwig Institute for Cancer Research	Sommarin, Y (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, S-22100 Lund, Sweden.							ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHRISTOFFERSEN J, 1991, ANAT RECORD, V230, P435, DOI 10.1002/ar.1092300402; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Janel N, 1995, GENE, V167, P291, DOI 10.1016/0378-1119(95)00696-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Landgren C, 1998, GENOMICS, V47, P84, DOI 10.1006/geno.1997.5085; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NIEHRS C, 1994, CHEM-BIOL INTERACT, V92, P257, DOI 10.1016/0009-2797(94)90068-X; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROBEY PG, 1995, OSTEOPOROSIS, P95; ROSAPIMENTEL E, 1992, ARTICULAR CARTILAGE, P95; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	50	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					16723	16729		10.1074/jbc.273.27.16723	http://dx.doi.org/10.1074/jbc.273.27.16723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642227	hybrid			2022-12-27	WOS:000074545200017
J	D'Silva, PR; Lala, AK				D'Silva, PR; Lala, AK			Unfolding of diphtheria toxin - Identification of hydrophobic sites exposed on lowering of pH by photolabeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; IMMUNOCHEMICAL ANALYSIS; MEMBRANE TRANSLOCATION; TRANSMEMBRANE DOMAIN; DEPENDENT INSERTION; ALPHA-LACTALBUMIN; REFINED STRUCTURE; PLASMA-MEMBRANE; B-FRAGMENT; 3 DOMAINS	We report here the use of a hydrophobic photoactivable reagent, 2-[H-3]diazofluorene (DAF), to map the hydrophobic sites exposed when the pH is lowered in diphtheria toxin (DT), The reagent binds to DT, and on photolysis with light of wavelength >350 nm, it covalently attaches itself to DT. The labeling was observed to increase considerably when the pH was lowered from 7.4 to 5.2. Although both A- and B-chains were labeled to a similar degree at pH 7,4, at lower pH (5.2), B-chain was labeled to a much higher extent. Subsequent chemical and enzymatic fragmentation of DT followed by separation indicated that the putative transmembrane domain was labeled to its maximum extent at pH 5,2, with the bulk of labeling associated with residues 340-459. Protein sequencing analysis indicated that the two buried hydrophobic helices, identified in the crystal structure and suggested to insert and span the membrane bilayer, corresponding to residues 326-347 and 358-376, are strongly labeled. The Pro-345 residue was observed to be labeled maximally at lower pH values. Finally, the DAF labeling pattern indicated that the parent structural motifs are retained at low pH, suggesting that the low pH conformation of DT corresponds to an equilibrium molten globule state.	Indian Inst Technol, Dept Chem, Biomembrane Lab, Bombay 400076, Maharashtra, India; Indian Inst Technol, Ctr Biotechnol, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Lala, AK (corresponding author), Indian Inst Technol, Dept Chem, Biomembrane Lab, Bombay 400076, Maharashtra, India.	anillala@chem.iitb.ernet.in	D'Silva, Patrick/L-6653-2019					BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BRASSEUR R, 1986, BIOCHEM BIOPH RES CO, V136, P160, DOI 10.1016/0006-291X(86)90890-9; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DELEERS M, 1983, FEBS LETT, V160, P82, DOI 10.1016/0014-5793(83)80941-7; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; HARTER C, 1989, J BIOL CHEM, V264, P6459; HONJO T, 1968, J BIOL CHEM, V243, P3553; JOHNSON VG, 1993, J BIOL CHEM, V268, P3514; Kaul P, 1996, PROTEIN SCI, V5, P687; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLOURESCE; LALA AK, 1995, J PROTEIN CHEM, V14, P601, DOI 10.1007/BF01886886; LALA AK, 1995, J BIOL CHEM, V270, P11348, DOI 10.1074/jbc.270.19.11348; LALA AK, 1992, J BIOL CHEM, V267, P19914; LOH SN, 1995, P NATL ACAD SCI USA, V92, P5446, DOI 10.1073/pnas.92.12.5446; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOZDZANOWSKI J, 1992, ANAL BIOCHEM, V207, P11, DOI 10.1016/0003-2697(92)90492-P; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; Paliwal R, 1996, BIOCHEMISTRY-US, V35, P2374, DOI 10.1021/bi952469q; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PRADHAN D, 1987, J BIOL CHEM, V262, P8242; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHEN WH, 1994, J BIOL CHEM, V269, P29077; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; STEINBERG IZ, 1960, J AM CHEM SOC, V82, P5263, DOI 10.1021/ja01505a001; TORTORELLA D, 1995, J BIOL CHEM, V270, P27439, DOI 10.1074/jbc.270.46.27439; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; WEISS MS, 1995, BIOCHEMISTRY-US, V34, P773, DOI 10.1021/bi00003a010; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	49	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16216	16222		10.1074/jbc.273.26.16216	http://dx.doi.org/10.1074/jbc.273.26.16216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632679	hybrid			2022-12-27	WOS:000074436600050
J	Rossi, A; Elia, G; Santoro, MG				Rossi, A; Elia, G; Santoro, MG			Activation of the heat shock factor 1 by serine protease inhibitors - An effect associated with nuclear factor-kappa B inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; FACTOR NF-KAPPA; TRANSCRIPTION FACTOR; HUMAN-CELLS; GENE-TRANSCRIPTION; STRESS; HSP70; EXPRESSION; PROTEINS	Heat shock proteins (HSPs) have a cytoprotective role in several human diseases, including ischemia and viral infection. Nuclear factor-kappa B (NF-kappa B) is a critical regulator of inflammation and virus replication. Here we report that a class of serine protease inhibitors with NF-kappa B-inhibitory activity are potent HSP inducers via activation of heat shock transcription factor 1 (HSF1) in human cells. 3,4-Dichloroisocoumarin, the most effective compound, rapidly induces HSF1 DNA binding activity and phosphorylation, leading to transcription and translation of heat shock genes for a period of several hours. HSF1 activation is independent of de novo protein synthesis and is correlated in a concentration- and time-dependent manner with NF-kappa B inhibition. Cysteine protease inhibitors E64 and calpain inhibitor II, which do not block NF-kappa B activation, do not induce HSF DNA binding activity. HSP induction by 3,4-dichloroisocoumarin is associated with antiviral activity during rhabdovirus infection. These results identify a new class of HSP inducers and indicate a link between the regulatory pathways of HSF and NF-kappa B, suggesting novel strategies to simultaneously switch on cytoprotective genes and down-regulate inflammatory and viral genes.	CNR, Inst Expt Med, I-00185 Rome, Italy; Univ Rome Tor Vergata, Dept Biol, I-00133 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	Santoro, MG (corresponding author), CNR, Inst Expt Med, Via Fosso Cavaliere, I-00185 Rome, Italy.	santoro@biocell.irmkant.rm.cnr.it	Elia, Giuliano/H-3438-2011; Elia, Giuliano/P-4725-2019	Elia, Giuliano/0000-0001-8216-9560; Elia, Giuliano/0000-0002-7941-223X; ROSSI, ANTONIO/0000-0003-0383-3828; Santoro, Maria Gabriella/0000-0003-1432-4949				AMICI C, 1994, J VIROL, V68, P6890, DOI 10.1128/JVI.68.11.6890-6899.1994; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; AMICI C, 1993, EXP CELL RES, V207, P230, DOI 10.1006/excr.1993.1188; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; Bush KT, 1997, J BIOL CHEM, V272, P9086; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Elia G, 1996, J BIOL CHEM, V271, P16111, DOI 10.1074/jbc.271.27.16111; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; IAATTELA M, 1992, EMBO J, V11, P3507; KIM HK, 1995, J IMMUNOL, V154, P4741; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; RUSBRIDGE NM, 1990, FEBS LETT, V268, P133, DOI 10.1016/0014-5793(90)80991-Q; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SANTORO MG, 1996, STRESS INDUCIBLE CEL, P337; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VIJAYALAKSHMI J, 1991, BIOCHEMISTRY-US, V30, P2175, DOI 10.1021/bi00222a022; VILLAR J, 1993, AM REV RESPIR DIS, V147, P177, DOI 10.1164/ajrccm/147.1.177; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZABEL U, 1991, J BIOL CHEM, V266, P252	40	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16446	16452		10.1074/jbc.273.26.16446	http://dx.doi.org/10.1074/jbc.273.26.16446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632711	hybrid			2022-12-27	WOS:000074436600082
J	Yoshida, T; Imai, T; Kakizaki, M; Nishimura, M; Takagi, S; Yoshie, O				Yoshida, T; Imai, T; Kakizaki, M; Nishimura, M; Takagi, S; Yoshie, O			Identification of single C motif-1 lymphotactin receptor XCR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CHEMOKINE; EXPRESSION; SCM-1	Single C motif-1 (SCM-1)/lymphotactin is a member of the chemokine superfamily, but retains only the and and 4th of the four cysteine residues conserved in other chemokines. In humans, there are two highly homologous SCM-1 genes encoding SCM-1 alpha and SCM-1 beta with two amino acid substitutions. To identify a specific receptor for SCM-1 proteins, we produced recombinant SCM-1 alpha and SCM-1 beta by the baculovirus expression system and tested them on murine L1.2 cells stably expressing eight known chemokine receptors and three orphan receptors. Both proteins specifically induced migration in cells expressing an orphan receptor, GPR5. The migration was chemotactic and suppressed by pertussis toxin, indicating coupling to a G alpha type of G protein. Both proteins also induced intracellular calcium mobilization in GPR5-expressing L1.2 cells with efficient mutual cross desensitization. SCM-1 alpha bound specifically to GPR5-expressing L1.2 cells with a K-d of 10 nM. By Northern blot analysis, GPR5 mRNA of about 5 kilobases was detected strongly in placenta and weakly in spleen and thymus among various human tissues. Identification of a specific receptor for SCM-1 would facilitate our investigation on its biological function. Following the set rule for the chemokine receptor nomenclature, we propose to designate GPR5 as XCR1 from XC chemokine receptor-1.	Shionogi Inst Med Sci, Settsu, Osaka 5660022, Japan	Shionogi & Company Limited	Yoshie, O (corresponding author), Kinki Univ, Sch Med, Dept Bacteriol, 377-2 Ohno Higashi, Osaka 5898511, Japan.			Yoshie, Osamu/0000-0003-4353-5809				Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BIANCHI G, 1996, EUR J IMMUNOL, V26, P3238; Boismenu R, 1996, J IMMUNOL, V157, P985; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; Mueller Sabine, 1995, European Journal of Immunology, V25, P1744; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rumsaeng V, 1997, J IMMUNOL, V158, P1353; Yoshida T, 1996, FEBS LETT, V395, P82, DOI 10.1016/0014-5793(96)01004-6; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634	24	122	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16551	16554		10.1074/jbc.273.26.16551	http://dx.doi.org/10.1074/jbc.273.26.16551			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632725	hybrid			2022-12-27	WOS:000074436600096
J	Yamashita, T; Kaneko, S; Shirota, Y; Qin, WP; Nomura, T; Kobayashi, K; Murakami, S				Yamashita, T; Kaneko, S; Shirota, Y; Qin, WP; Nomura, T; Kobayashi, K; Murakami, S			RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE NONSTRUCTURAL PROTEINS; NON-B-HEPATITIS; POLIOVIRUS RNA; REPLICATION COMPLEXES; IN-VITRO; NON-A; HEPATOCELLULAR-CARCINOMA; JAPANESE PATIENTS; HELICASE ACTIVITY; ESCHERICHIA-COLI	The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRP), which is the central catalytic enzyme of HCV replicase, We established a new method to purify soluble HCV NS5B in the glutathione S-transferase-fused form NS5Bt from Escherichia coli which lacks the C-terminal 21 amino acid residues encompassing a putative anchoring domain (anino acids 2990-3010). The recombinant soluble protein exhibited RdRP activity in vitro which was dependent upon the template and primer, but it did not exhibit the terminal transferase activity that has been reported to be associated with the recombinant NS5B protein from insect cells. The RdRP activity of purified glutathione S-transferase-NS5Bt and thrombin-cleavaged non-fused NS5Bt shares most of the properties. Substitution mutations of NS5Bt at the GDD motif, which is highly conserved among viral RdRPs, and at the clustered basic residues (amino acids 2919-2924 and 2693-2699) abolished the RdRP activity. The C-terminal region of NS5B, which is dispensable for the RdRP activity, dramatically affected the subcellular localization of NS5B retaining it in perinuclear sites in transiently overexpressed mammalian cells. These results may provide some clues to dissecting the molecular mechanism of the HCV replication and also act as a basis for developing new anti-viral drugs.	Kanazawa Univ, Inst Canc Res, Dept Mol Oncol, Kanazawa, Ishikawa, Japan; Kanazawa Univ, Dept Internal Med 1, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University	Murakami, S (corresponding author), Kanazawa Univ, Inst Canc Res, Dept Mol Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa, Japan.	semuraka@kenroku.ipc.kanazawa-u.ac.jp		Shirota, Yukihiro/0000-0001-6561-4626				ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTON DJ, 1995, J VIROL, V69, P5516, DOI 10.1128/JVI.69.9.5516-5527.1995; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; Francki RIB, 1991, ARCH VIROL         S, V2, P223; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HONDA M, 1993, ARCH VIROL, V128, P163, DOI 10.1007/BF01309797; Hwang SB, 1997, VIROLOGY, V227, P439, DOI 10.1006/viro.1996.8357; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAMA J, 1995, J BIOL CHEM, V270, P14430, DOI 10.1074/jbc.270.24.14430; LEMM JA, 1993, J VIROL, V67, P1905, DOI 10.1128/JVI.67.4.1905-1915.1993; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996; MANABE S, 1994, VIROLOGY, V198, P636, DOI 10.1006/viro.1994.1075; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MORROW CD, 1987, P NATL ACAD SCI USA, V84, P6050, DOI 10.1073/pnas.84.17.6050; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Nakajima N, 1996, J VIROL, V70, P3325, DOI 10.1128/JVI.70.5.3325-3329.1996; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; Osman TAM, 1996, J VIROL, V70, P6227, DOI 10.1128/JVI.70.9.6227-6234.1996; Owen KE, 1996, J VIROL, V70, P2757, DOI 10.1128/JVI.70.5.2757-2763.1996; Pilipenko EV, 1996, EMBO J, V15, P5428, DOI 10.1002/j.1460-2075.1996.tb00926.x; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; QUADT R, 1995, P NATL ACAD SCI USA, V92, P4892, DOI 10.1073/pnas.92.11.4892; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCINCLAIR DA, 1997, SCIENCE, V277, P1313; SHIMIZU YK, 1994, J VIROL, V68, P8406, DOI 10.1128/JVI.68.12.8406-8408.1994; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; SONG CZ, 1995, J VIROL, V69, P4020, DOI 10.1128/JVI.69.7.4020-4028.1995; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Yi MK, 1997, VIROLOGY, V231, P119, DOI 10.1006/viro.1997.8516; Yi MY, 1997, J VIROL, V71, P5997, DOI 10.1128/JVI.71.8.5997-6002.1997; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249	62	202	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15479	15486		10.1074/jbc.273.25.15479	http://dx.doi.org/10.1074/jbc.273.25.15479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624134	hybrid			2022-12-27	WOS:000074284200028
J	Lakich, MM; Diagana, TT; North, DL; Whalen, RG				Lakich, MM; Diagana, TT; North, DL; Whalen, RG			MEF-2 and Oct-1 bind to two homologous promoter sequence elements and participate in the expression of a skeletal muscle-specific gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; CREATINE-KINASE ENHANCER; POU-DOMAIN PROTEINS; TRANSCRIPTION FACTORS; DNA-BINDING; HOMEODOMAIN PROTEINS; REGULATORY ELEMENTS; MOUSE MUSCLE; ACTIVATION; CELLS	The murine adult IIB myosin heavy chain (IIB MyHC) gene is expressed only in certain skeletal muscle fibers. Within the proximal promoter are two A + T-rich motifs, mAT1 and mAT2, which greatly enhance muscle-specific transcription; myogenic cells contain proteins that bind to these sequences. MEF-2 binds to both mAT1 and mAT2; a mutation abolishing its binding to mAT1 greatly diminishes the activity of the promoter. Both mAT motifs also form complexes with a protein requiring a target sequence typical of POU domain proteins, which migrate in electrophoretic mobility shift assays to the same position as a complex containing purified Oct-1 and which are supershifted by an antibody specific to Oct-1; this protein is therefore probably Oct-1. Footprinting experiments demonstrate that mAT1 is preferentially occupied by MEF-2 and mAT2 by Oct-1 and that these two proteins appear to bind cooperatively to their respective sites. Although the two mAT motifs have sequences that are very similar, they nonetheless exhibit distinct behaviors and perform differ entry in the activation of the promoter. The contribution. of the IIB MyHC gene to specification of the myogenic phenotype is thus at least in part regulated by MEF-2 and Oct-1.	Inst Pasteur, Dept Biol Mol, Unite Biochim, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lakich, MM (corresponding author), Rhone Poulenc Rorer Gencell, Mol Biol & Vectorol Dept, 5301 Patrick Henry Dr, Santa Clara, CA 95054 USA.							AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUTLERBROWNE GS, 1982, NATURE, V299, P830, DOI 10.1038/299830a0; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAS G, 1993, J BIOL CHEM, V268, P25026; DIAGANA T, 1995, THESIS U PARIS PARIS; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JAFFE J, 1995, BBA-GENE STRUCT EXPR, V1261, P201, DOI 10.1016/0167-4781(94)00246-Y; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Mead J, 1996, MOL CELL BIOL, V16, P2135; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1311; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SOUSSIYANICOSTAS N, 1993, HUM MOL GENET, V2, P563, DOI 10.1093/hmg/2.5.563; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TAKEDA S, 1995, J BIOL CHEM, V270, P15664, DOI 10.1074/jbc.270.26.15664; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TAKEDA S, 1992, CR ACAD SCI III-VIE, V315, P467; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YOON SJ, 1992, P NATL ACAD SCI USA, V89, P12078, DOI 10.1073/pnas.89.24.12078; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	59	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15217	15226		10.1074/jbc.273.24.15217	http://dx.doi.org/10.1074/jbc.273.24.15217			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614136	hybrid			2022-12-27	WOS:000074160400078
J	Marheineke, K; Krude, T				Marheineke, K; Krude, T			Nucleosome assembly activity and intracellular localization of human CAF-1 changes during the cell division cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; DNA-REPLICATION INVITRO; FACTOR-I; NEGATIVE REGULATOR; BINDING PROTEIN; S-PHASE; CHROMATIN; YEAST; DROSOPHILA; HOMOLOG	We characterized changes of nucleosome assembly activity, intracellular localization, and reversible phosphorylation of the human chromatin assembly factor CAF-1 during the somatic cell division cycle. HeLa cells were synchronized in the G(1), S, G(2), and M phases of the cell cycle. All three subunits of human CAF-1 (p150, p60, and p48) are present during the entire cell cycle. In interphase, p150 and p60 are bound to the nucleus, but they predominantly dissociate from chromatin during mitosis, During S phase, p150 and p60 are concentrated at sites of intranuclear DNA replication. Only a fraction of total p48 is associated with p150 and p60, and the majority is present in other high molecular weight complexes. The other nucleosome assembly protein, NAP-1, is predominantly cytosolic throughout the cell cycle, Human CAF-1 efficiently mediates nucleosome assembly during complementary DNA strand synthesis in G(1), S, and G(2) phase cytosolic extracts. Active CAF-1 can be isolated as a 6.5 S complex from G(1), S, and G(2) phase nuclei. In contrast, CAF-1 isolated from mitotic cytosol does not support nucleosome assembly during DNA synthesis. In mitosis, the p60 subunit of inactive CAF-1 is hyperphosphorylated, whereas active CAF-1 in interphase contains hypophosphorylated and/or phosphorylated forms of p60.	Univ Cambridge, Wellcome Canc Res Campaign Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1TN, England	University of Cambridge; University of Cambridge	Krude, T (corresponding author), Univ Cambridge, Wellcome Canc Res Campaign Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk1@mole.bio.cam.ac.uk	Marheineke, Kathrin/C-1797-2008	Krude, Torsten/0000-0002-1842-1933; Marheineke, Kathrin/0000-0002-1514-0167				Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; FRIEDBERG EC, 1996, DNA REPLICATION EUKA, P249; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harlow E., 1988, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KRUDE T, 1993, J BIOL CHEM, V268, P14432; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Krude T, 1996, J CELL SCI, V109, P309; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RUSSEV G, 1982, P NATL ACAD SCI-BIOL, V79, P3143, DOI 10.1073/pnas.79.10.3143; SCHULTE D, 1995, J CELL SCI, V108, P1381; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; van Holde KE., 1989, SPRINGER SERIES MOL; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WOLFFE A, 1992, CHROMATIN STRUCTURE; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	52	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 12	1998	273	24					15279	15286		10.1074/jbc.273.24.15279	http://dx.doi.org/10.1074/jbc.273.24.15279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZU088	9614144	hybrid			2022-12-27	WOS:000074160400086
J	Cheneval, D; Ramage, P; Kastelic, T; Szelestenyi, T; Niggli, H; Hemmig, R; Bachmann, M; MacKenzie, A				Cheneval, D; Ramage, P; Kastelic, T; Szelestenyi, T; Niggli, H; Hemmig, R; Bachmann, M; MacKenzie, A			Increased mature interleukin-1 beta (IL-1 beta) secretion from THP-1 cells induced by nigericin is a result of activation of p45 IL-1 beta-converting enzyme processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTES; MATURATION; PRECURSOR; RELEASE	Perregaux and Gabel (Perregaux, D., and Gabel, C. A. (1994) J. Biol. Chem. 269, 15195-15203) reported that potassium depletion of lipopolysaccharide-stimulated mouse macrophages induced by the potassium ionophore, nigericin, leads to the rapid release of mature interleukin-1 beta (IL-1 beta). me have now shown a similar phenomenon in lipopolysaccharide-stimulated human monocytic leukemia THP-1 cells. Rapid secretion of mature, 17-kDa IL-1 beta occurred, in the presence of nigericin (4-16 mu M). No effects on the release of tumor necrosis factor-alpha, IL-6, or proIL-1 beta were seen. Addition of the irreversible interleukin-1 beta-converting enzyme (ICE) inhibitor, Z-Val-Ala-Asp-dichlorobenzoate, or a radicicol analog, inhibited nigericin-induced mature IL-1 beta release and activation of p45 ICE precursor. The radicicol analog itself did not inhibit ICE, but markedly, and very rapidly depleted intracellular levels of 31-kDa proIL-1 beta, By contrast, dexamethasone, cycloheximide, and the Na+/H+ antiporter inhibitor, 5-(N-ethyl-N-isopropyl)amiloride, had no effect on nigericin-induced release of IL-I beta. We have therefore shown conclusively, for the first time, that nigericin-induced release of IL-1 beta is dependent upon activation of p45 ICE processing. So far, the mechanism by which reduced intracellular potassium ion concentration triggers p45 ICE processing is not known, but further investigation in this area could lead to the discovery of novel molecular targets whereby control of IL-1 beta production might be effected.	Novartis Pharma, CH-4002 Basel, Switzerland	Novartis	Cheneval, D (corresponding author), Novartis Pharma, CH-4002 Basel, Switzerland.							AYALA JM, 1994, J IMMUNOL, V153, P2592; ELFORD PR, 1996, PHARM COMMUN, V7, P301; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kastelic T, 1996, CYTOKINE, V8, P751, DOI 10.1006/cyto.1996.0100; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; ORLINSKA U, 1992, AM J PHYSIOL, V263, pC1073, DOI 10.1152/ajpcell.1992.263.5.C1073; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; SCHNYDER J, 1990, AGENTS ACTIONS, V30, P350, DOI 10.1007/BF01966299; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x	13	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17846	17851		10.1074/jbc.273.28.17846	http://dx.doi.org/10.1074/jbc.273.28.17846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651388	hybrid			2022-12-27	WOS:000074816100081
J	Kristensen, C; Wiberg, FC; Schaffer, L; Andersen, AS				Kristensen, C; Wiberg, FC; Schaffer, L; Andersen, AS			Expression and characterization of a 70-kDa fragment of the insulin receptor that binds insulin - Minimizing ligand binding domain of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; ALANINE-SCANNING MUTAGENESIS; EPIDERMAL GROWTH-FACTOR; ALPHA-SUBUNIT; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CROSS-LINKING; SITE; HORMONE; REGION	In order to characterize regions of the insulin receptor that are essential for ligand binding and possibly identify a smaller insulin-binding fragment of the receptor, we have used site-directed mutagenesis to construct a series of insulin receptor deletion mutants. From 112 to 246 amino acids were deleted from the alpha-subunit region comprising amino acids 469-729. The receptor constructs were expressed as soluble insulin receptor IgG fusion proteins in baby hamster kidney cells and were characterized in binding assays by immunoblotting and chemical cross-linking with radiolabeled insulin. The shortest receptor fragment identified was a free monomeric a-subunit deleted of amino acids 469-703 and 718-729 (exon 11); the mass of this receptor fragment was found by mass spectrometry to be 70 kDa. This small insulin receptor fragment bound insulin with an affinity (K-d) of 4.4 nM, which is similar to what was found for the full-length ectodomain of the insulin receptor (5.0 nM). Cross-linking experiments confirmed that the 70-kDa receptor fragment specifically bound insulin. In summary we have minimized the insulin binding domain of the insulin receptor by identifying a 70-kDa fragment of the ectodomain that retains insulin binding affinity making this an interesting candidate for detailed structural analysis.	Novo Nordisk AS, Hlth Care Discovery, Dept Insulin Res, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Hlth Care Discovery, Dept Cell Technol, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Kristensen, C (corresponding author), Novo Nordisk AS, Hlth Care Discovery, Dept Insulin Res, Novo Alle 6B1-90, DK-2880 Bagsvaerd, Denmark.	clak@novo.dk	Kristensen, Claus/O-8047-2015	Kristensen, Claus/0000-0002-2594-7722				ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; DAmbrosio C, 1996, CANCER RES, V56, P4013; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; FUH G, 1990, J BIOL CHEM, V265, P3111; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; McKern NM, 1997, PROTEIN SCI, V6, P2663; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SUNG CK, 1994, MOL ENDOCRINOL, V8, P315, DOI 10.1210/me.8.3.315; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAYLOR S, 1994, ENDOCR REV, V2, P58; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; XU QY, 1990, J BIOL CHEM, V265, P18673; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	40	52	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 10	1998	273	28					17780	17786		10.1074/jbc.273.28.17780	http://dx.doi.org/10.1074/jbc.273.28.17780			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100KW	9651379	hybrid			2022-12-27	WOS:000074816100072
J	Ono, Y; Shimada, H; Sorimachi, H; Richard, I; Saido, TC; Beckmann, JS; Ishiura, S; Suzuki, K				Ono, Y; Shimada, H; Sorimachi, H; Richard, I; Saido, TC; Beckmann, JS; Ishiura, S; Suzuki, K			Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SARCOGLYCAN; ALPHA-FODRIN; GENE; EXPRESSION; SITE; EFFICIENT; DISTINCT; ADHALIN; FAMILY; DNA	p94 (calpain3), a muscle-specific member of the calpain family, has been shown to be responsible for limb-girdle muscular dystrophy type 2A (LGMD2A), a form of autosomal recessive and progressive neuromuscular disorder. To elucidate the molecular mechanism of LGMD2A, we constructed nine p94 missense point mutants found in LGMD2A and analyzed their p94 unique properties, All mutants completely or almost completely lose the proteolytic activity against a potential substrate, fodrin. However, some of the mutants still possess autolytic activity and/or connectin/titin binding ability, indicating these properties are not necessary for the LGMD2A phenotypes, These results provide strong evidence that LGMD2A results from the loss of proteolysis of substrates by p94, suggesting a novel molecular mechanism leading to muscular dystrophies.	Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol Biol, Lab Mol Struct & Funct,Bunkyo Ku, Tokyo 1130032, Japan; Genethon, F-91000 Evry, France; Tokyo Metropolitan Inst Med Sci, Dept Mol Biol, Bunkyo Ku, Tokyo 1130021, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Sorimachi, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol Biol, Lab Mol Struct & Funct,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	sorimach@iam.u-tokyo.ac.jp	Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015; Richard, isabelle/J-8298-2013; Sorimachi, Hiroyuki/C-6448-2009; Beckmann, Jacques S/A-9772-2008	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903; Sorimachi, Hiroyuki/0000-0001-9509-6727; Beckmann, Jacques S/0000-0002-9741-1900				Arthur JSC, 1996, BIOCHEM J, V319, P535, DOI 10.1042/bj3190535; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Braman J, 1996, Methods Mol Biol, V57, P31; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Fardeau M, 1996, NEUROMUSCULAR DISORD, V6, P447, DOI 10.1016/S0960-8966(96)00387-2; HARPER JW, 1993, CELL, V75, P805; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kolmerer B, 1996, J MOL BIOL, V256, P556, DOI 10.1006/jmbi.1996.0108; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Maruyama K, 1997, FASEB J, V11, P341, DOI 10.1096/fasebj.11.5.9141500; MCMAHON AP, 1987, BIOCHEM SOC T, V15, P804, DOI 10.1042/bst0150804; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PassosBueno MR, 1996, J MED GENET, V33, P97, DOI 10.1136/jmg.33.2.97; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Poussard S, 1996, CELL GROWTH DIFFER, V7, P1461; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1996, ADV BIOPHYS, V33, P101; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANOMMEN GJ, 1995, NAT MED, V1, P412; WALTON JN, 1988, MUSCULAR DYSTROPHIES	38	123	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17073	17078		10.1074/jbc.273.27.17073	http://dx.doi.org/10.1074/jbc.273.27.17073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642272	hybrid			2022-12-27	WOS:000074545200062
J	Warren, RA; Green, FA; Stenberg, PE; Enns, CA				Warren, RA; Green, FA; Stenberg, PE; Enns, CA			Distinct saturable pathways for the endocytosis of different tyrosine motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY-LIPOPROTEIN; FACTOR-II RECEPTOR; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; COATED PIT ADAPTINS; TRANSFERRIN RECEPTOR; INTERNALIZATION SIGNAL; MANNOSE 6-PHOSPHATE; CYTOPLASMIC DOMAIN	Endocytosis of surface proteins through clathrin-coated pits requires an internalization signal in the cytoplasmic domain. Two types of internalization signal have been described: one requiring a tyrosine as the critical residue (tyrosine-based motif), and the other consisting of either two consecutive leucines or an isoleucine and leucine (dileucine motif), Although it seems that these signals are necessary and sufficient for endocytic targeting, the mechanism of recognition is not well understood. To examine this question, tetracycline-repressible cell lines were used to overexpress one of several receptors bearing a tyrosine-based internalization signal. By measuring the rates of endocytosis for either the over expressed receptor,or that of other en receptors, we were able to show that the endocytosis of identical receptors could be saturated, but a complete lack of competition exists between the transferrin receptor (TfR), the low-density lipoprotein receptor, and the epidermal growth factor receptor. Overexpression of any one of these receptors resulted in its redistribution toward the cell surface, implying that entry into coated pits is limited. During high levels of TfR expression, however, a significant increase in the amount of surface Lamp1, but not low-density lipoprotein receptor, epidermal growth factor receptor, or Lamp2, is detected. This suggests that Lamp1 and TfR compete for the same endocytic sites. Together, these results support the idea that there are at least three distinct saturable components involved in clathrin-mediated endocytosis.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CHANG M P, 1991, Journal of Cell Biology, V115, p186A; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P3667; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MAXFIELD FR, 1978, CELL, V14, P805, DOI 10.1016/0092-8674(78)90336-7; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; NEUTRA MR, 1985, J HISTOCHEM CYTOCHEM, V33, P1134, DOI 10.1177/33.11.2997327; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VIA DP, 1982, EXP CELL RES, V141, P15, DOI 10.1016/0014-4827(82)90062-3; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLINGHAM MC, 1983, EXP CELL RES, V146, P163, DOI 10.1016/0014-4827(83)90334-8; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	59	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 3	1998	273	27					17056	17063		10.1074/jbc.273.27.17056	http://dx.doi.org/10.1074/jbc.273.27.17056			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZX700	9642270	hybrid			2022-12-27	WOS:000074545200060
J	Bianchetti, M; Zheleva, D; Deak, Z; Zharmuhamedov, S; Klimov, V; Nugent, J; Vass, I; Barber, J				Bianchetti, M; Zheleva, D; Deak, Z; Zharmuhamedov, S; Klimov, V; Nugent, J; Vass, I; Barber, J			Comparison of the functional properties of the monomeric and dimeric forms of the isolated CP47-reaction center complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION-CENTER; SPECIAL TRIPLE-RESONANCE; IRON-QUINONE COMPLEX; PHOTOSYSTEM-II; ELECTRON-TRANSFER; ACCEPTOR; PROTEIN; DONOR; SPINACH; ENDOR	Chlorophyll fluorescence, thermoluminescence, and EPR spectroscopy have been used to investigate the functional properties of the monomeric and dimeric forms of the photosystem II CP47-reaction center (CP47-RC) subcore complex that was isolated (Zheleva, D., Sharma, J., Panico, M., Morris, H. R., and Barber, J. (1998) J. Biol. Chem. 273, 16122-16127). Chlorophyll fluorescence yield changes induced either by the initiation of continuous actinic light or by repetitive light flashes indicated that the dimeric, but not the monomeric, form of the CP47-RC complex showed secondary electron transport properties indicative of Q(A) reduction. Thermoluminescence measurements also clearly distinguished the monomer from the dimer in that the latter showed a Z(V) band, which appeared at -55 degrees C, following illumination at -80 degrees C. This band has been determined to be an indicator of the photoaccumulation of Q(A)(radical anion). The ability of the dimeric CP47-RC to show secondary electron transport properties was clearly demonstrated by EPR studies. The dimer was characterized by organic radical signals at about g = 2 induced either by illumination or by the addition of dithionite. The dithionite-induced signal was attributed to Q(A)(radical anion), but there was no indication of any interaction with non-heme iron. The signal induced by light was more complex, being composed not only of the Q(A)(radical anion) radical but also of radicals generated on the donor side. Difference analyses indicated that one of these radicals is likely to be due to a D1 tyrosine 161 or D2 tyrosine 161. In contrast, the monomeric CP47-RC complex did not show similar EPR-detectable radicals and instead was dominated by a high yield of the spin-polarized triplet signal generated by recombination reactions between the oxidized primary reductant, pheophytin, and the primary donor, P680. It is also concluded from EPR analyses that both the monomeric and dimeric forms of the CP47-RC subcore complex contain one cytochrome b(559) per reaction center. Overall the results suggest that photosystem II normally functions as a dimer complex and that monomerization at the level of the CP47-RC subcore complex leads to destabilization of the bound plastoquinone, which functions as Q(A).	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England; Inst Plant Biol, Biol Res Ctr, H-6701 Szeged, Hungary; UCL, Dept Biol, London WC1E 6BT, England	Imperial College London; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of London; University College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England.	j.barber@ic.ac.uk	Vass, Imre/AAS-6171-2021	Vass, Imre/0000-0003-4987-7842				ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; ANDREASSON LE, 1995, BBA-BIOENERGETICS, V1230, P155, DOI 10.1016/0005-2728(95)00047-M; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; CHAPMAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1057, P391, DOI 10.1016/S0005-2728(05)80153-7; CHAPMAN DJ, 1991, METHODS PLANT BIOCH, V5, P171; DELASRIVAS J, 1993, BIOCHIM BIOPHYS ACTA, V1142, P155, DOI 10.1016/0005-2728(93)90097-Y; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Gantt E, 1996, PHOTOSYNTH RES, V48, P47, DOI 10.1007/BF00040995; GHANOTAKIS DF, 1989, BIOCHIM BIOPHYS ACTA, V974, P44, DOI 10.1016/S0005-2728(89)80164-1; HALLAHAN BJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P181, DOI 10.1016/S0005-2728(05)80203-8; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Hoshida H, 1997, BIOCHEMISTRY-US, V36, P12053, DOI 10.1021/bi9710885; KITAMURA K, 1994, FEBS LETT, V354, P113, DOI 10.1016/0014-5793(94)01089-7; KLIMOV VV, 1977, FEBS LETT, V82, P183, DOI 10.1016/0014-5793(77)80580-2; KLIMOV VV, 1995, PHOTOSYNTH RES, V44, P67, DOI 10.1007/BF00018297; Kurreck J, 1997, FEBS LETT, V403, P283, DOI 10.1016/S0014-5793(97)00071-9; MIYAZAKI A, 1989, BIOCHIM BIOPHYS ACTA, V923, P423; Morris EP, 1997, STRUCTURE, V5, P837, DOI 10.1016/S0969-2126(97)00237-2; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NUGENT JHA, 1981, FEBS LETT, V124, P241, DOI 10.1016/0014-5793(81)80146-9; Nugent JHA, 1996, EUR J BIOCHEM, V237, P519, DOI 10.1111/j.1432-1033.1996.00519.x; NUGENT JHA, 1989, FEBS LETT, V255, P53, DOI 10.1016/0014-5793(89)81059-2; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P10043, DOI 10.1021/bi00199a031; RIGBY SEJ, 1995, BIOCHEMISTRY-US, V34, P12075, DOI 10.1021/bi00037a051; SANAKIS Y, 1994, BIOCHEMISTRY-US, V33, P9922, DOI 10.1021/bi00199a014; TELFER A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P143, DOI 10.1016/0005-2728(90)90145-T; TYYSTJARVI E, 1990, PHOTOSYNTH RES, V26, P126; VASS I, 1989, PHOTOSYNTH RES, V22, P295, DOI 10.1007/BF00048307; VASS I, 1985, PHOTOCHEM PHOTOBIOL, V40, P407; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; Zheleva D, 1996, BIOCHEMISTRY-US, V35, P15074, DOI 10.1021/bi961382h	35	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16128	16133		10.1074/jbc.273.26.16128	http://dx.doi.org/10.1074/jbc.273.26.16128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632666	hybrid			2022-12-27	WOS:000074436600037
J	Govers, P; van Kerkhof, P; Schwartz, AL; Strous, GJ				Govers, P; van Kerkhof, P; Schwartz, AL; Strous, GJ			Di-leucine-mediated internalization of ligand by a truncated growth hormone receptor is independent of the ubiquitin conjugation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; CYTOPLASMIC DOMAIN; PROTEASOME PATHWAY; PLASMA-MEMBRANE; INDUCED ENDOCYTOSIS; TYROSINE KINASE; BINDING-PROTEIN; DOWN-REGULATION; DEGRADATION; MOTIF	The growth hormone receptor (GHR) is a member of the cytokine receptor family. Its function is to mediate cellular responses upon binding of growth hormone. Ligand binding induces dimerization and activation of the GHR. One mechanism by which the GHR is rapidly inactivated involves the ubiquitin conjugation system, a system implicated in the degradation of cytosolic and nuclear proteins. We have shown previously that the ubiquitin-conjugating system mediates internalization of the GHR. Here, we present evidence that in addition to the ubiquitin-dependent endocytosis signal, the cytosolic tail of the GHR contains a di-leucine motif. Upon truncation of the GHR at amino acid residue 349, this di-leucine motif is activated and mediates ubiquitin-independent internalization of the receptor. wDi-leucine-mediated GHR internalization requires functional clathrin-coated pits and results in GHR transport to the lysosome. Although the full-length GHR internalizes independent of the di-leucine motif, this motif may function in internalization of GHR isoforms.	Univ Utrecht, Fac Med, Dept Cell Biol, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Utrecht University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Strous, GJ (corresponding author), Univ Utrecht, Fac Med, Dept Cell Biol, Biomembrane Inst, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	strous@med.uu.nl	Govers, Roland/O-5782-2016	Govers, Roland/0000-0003-1359-5333; van Kerkhof, Peter/0000-0002-8954-2230				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Baxter GT, 1997, J NEUROSCI, V17, P2683; BAXTER RC, 1985, ENDOCRINOLOGY, V117, P650, DOI 10.1210/endo-117-2-650; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chuang PI, 1997, J BIOL CHEM, V272, P24813, DOI 10.1074/jbc.272.40.24813; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DELEHAYEZERVAS MC, 1994, J CLIN ENDOCR METAB, V78, P1473; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Heidmann DEA, 1997, J NEUROCHEM, V68, P1372; HERSHKO A, 1998, IN PRESS ANN REV BIO, V67; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; HOCQUETTE JF, 1989, ENDOCRINOLOGY, V125, P2167, DOI 10.1210/endo-125-4-2167; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; ILONDO MM, 1992, ENDOCRINOLOGY, V130, P2037, DOI 10.1210/en.130.4.2037; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; LAI ZN, 1993, BRAIN RES, V621, P260, DOI 10.1016/0006-8993(93)90114-3; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; Maki CG, 1996, CANCER RES, V56, P2649; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MURPHY LJ, 1984, ENDOCRINOLOGY, V115, P1625, DOI 10.1210/endo-115-4-1625; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; ROUPAS P, 1986, MOL CELL ENDOCRINOL, V47, P81, DOI 10.1016/0303-7207(86)90018-3; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; SU CC, 1996, ANNU REV PHYSIOL, V58, P187; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; URBANEK M, 1992, MOL ENDOCRINOL, V6, P279, DOI 10.1210/me.6.2.279; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013	65	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16426	16433		10.1074/jbc.273.26.16426	http://dx.doi.org/10.1074/jbc.273.26.16426			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632708				2022-12-27	WOS:000074436600079
J	Leonard, DA; Lin, R; Cerione, RA; Manor, D				Leonard, DA; Lin, R; Cerione, RA; Manor, D			Biochemical studies of the mechanism of action of the Cdc42-GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; BINDING-PROTEIN; PHOSPHOINOSITIDE 3-KINASE; NUCLEOTIDE EXCHANGE; CRYSTAL-STRUCTURE; TYROSINE KINASE; N-CHIMAERIN; DOMAIN; RAS; CDC42HS	The small GTP-binding proteins Rac, Rho, and Cdc42 were shown to mediate a variety of signaling pathways including cytoskeletal rearrangements, cell-cycle progression, and transformation. Key to the proper function of these GTP-binding proteins is an efficient shutoff mechanism that ensures the decay of the signal. Regulatory proteins termed GAPs (GTPase-activating proteins) enhance the intrinsic GTP hydrolysis of the GTP-binding proteins, thereby ensuring signal termination. We have used site specific mutagenesis to elucidate the limit domain for GAP activity in Cdc42-GAP, and show that in addition to the known GAP-homology domain (three conserved boxes), a C-terminal region outside that domain is also essential for GAP activity. In addition, we have replaced the conserved arginine (Arg(305)), which was suggested by structural studies to be a key catalytic residue, with an alanine and found that the R305A Cdc42-GAP mutant has a greatly diminished catalytic capacity but is still able to bind Cdc42 with high affinity. Thus, a key catalytic role for this residue is confirmed. However, we also present evidence for the involvement of an additional residue(s), since the R305A Cdc42-GAP mutant still exhibits measurable activity. Some of this residual activity might result from a neighboring arginine, since a double mutant R305A/R306A shows a further decrease in catalytic activity.	Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	Cornell University	Manor, D (corresponding author), Cornell Univ, Ctr Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA.	dm43@cornell.edu			NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; AHMED S, 1994, J BIOL CHEM, V269, P17642; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CERIONE RA, 1996, CURR OPIN CELL BIOL, V8, P205; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hoffman GR, 1998, J BIOL CHEM, V273, P4392, DOI 10.1074/jbc.273.8.4392; JOHN J, 1993, J BIOL CHEM, V268, P923; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lackowicz J.R., 2006, PRINCIPLES FLUORESCE, DOI 10.1007/978-0-387-46312-4; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; LI A, 1993, NATURE, V363, P85; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; Pal E.F., 1989, NATURE, V341, P209; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	42	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16210	16215		10.1074/jbc.273.26.16210	http://dx.doi.org/10.1074/jbc.273.26.16210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632678	hybrid			2022-12-27	WOS:000074436600049
J	Nemoto, S; Xiang, JL; Huang, S; Lin, AN				Nemoto, S; Xiang, JL; Huang, S; Lin, AN			Induction of apoptosis by SB202190 through inhibition of p38 beta mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; SIGNAL-TRANSDUCTION; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; STRESS; PHOSPHORYLATION; CASCADE; PATHWAY; MEMBER; FAMILY	p38, a subfamily of the mitogen-activated protein kinase, regulates gene expression in response to various extracellular stimuli. The pyridinyl imidazoles like SB202190 are specific inhibitors of p38 alpha and p38 beta and have been widely used in investigation of the biological functions of p38. Here we show that SB202190 by itself was sufficient to induce cell death, with typical apoptotic features such as nucleus condensation and intranucleosomal DNA fragmentation. SB202190 stimulated the activity of CPP32-like caspases, and its apoptotic effect was completely blocked by the protease inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone and expression of bcl-2. In addition, SB202190 was able to potentiate apoptosis induced by Fas(APO-1) ligation or UV irradiation. Expression of p38 beta attenuated the apoptotic effect of SB202190 and the cell death induced by Fas ligation and UV irradiation. In contrast, expression of p38 alpha induced cell death mildly. These results indicate that SB202190 induces apoptosis through activation of CPP32-like caspases and suggest that distinct members of the p38 subfamily of mitogen-activated protein kinase have different functions in apoptosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Gene Therapy Program, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute	Lin, AN (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.	lin@vh.path.uab.edu			NCI NIH HHS [CA73740] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073740] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GOEDERT M, 1997, EMBO J, V16, P3663; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JACOBSON MJ, 1997, CELL, V91, P347; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PETER J, 1997, MOL CELL BIOL, V17, P24; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TOMPSON CB, 1995, SCIENCE, V267, P1456, DOI DOI 10.1126/SCIENCE.7878464; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	58	247	255	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 26	1998	273	26					16415	16420		10.1074/jbc.273.26.16415	http://dx.doi.org/10.1074/jbc.273.26.16415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZW685	9632706	hybrid			2022-12-27	WOS:000074436600077
J	Beger, RD; Bolton, PH				Beger, RD; Bolton, PH			Structures of apurinic and apyrimidinic sites in duplex DNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ABASIC SITES; CELL-CYCLE; CYTOSINE DEAMINATION; REPAIR ENZYMES; GLYCOSYLASE; PROTEIN; NMR; HETERODUPLEXES; CONFORMATION	Natural and exogenous processes can give rise to abasic sites with either a purine or pyrimidine as the base on the opposing strand. The solution state structures of the apyrimidinic DNA duplex, with D(6) indicating an abasic site, d(C(1) G(2) C(3) G(4) A(5) D(6) R(7) C(8) G(9) C(10)C(11)) d( G(22)C(21)G(20)C(19)T(18)A(17)T(16)G(15)C(14)G(13)G(12)) referred to as AD, and the apurinic DNA duplex with a dC(17), referred to as CD, have been determined, A particularly striking difference is that the abasic site in CD is predominantly a beta hemiacetal, whereas in AD the alpha and beta forms are equally present. Hydrogen bonding with water by the abasic site and the base on the opposite strand appears to play a large role in determining the structure near the damaged site. Comparison of these structures with that of a duplex DNA containing a thymine glycol at the same position as the abasic site and with that of a duplex DNA containing an abasic site in the middle of a curved DNA sequence offers some insight into the common and distinct structural features of damaged DNA sites.	Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA	Wesleyan University	Bolton, PH (corresponding author), Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA.	pbolton@wesleyan.edu						[Anonymous], 1985, DNA REPAIR; BALASUBRAMANIAN S, 1994, J BIOL CHEM, V270, P296; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEGER RD, 1995, J BIOL CHEM, V270, P16840, DOI 10.1074/jbc.270.28.16840; BEGER RD, 1998, IN PRESS J MAGN RESO; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; Cleaver JE, 1997, BIOCHEM J, V328, P1, DOI 10.1042/bj3280001; CLEAVER JE, 1995, CELL, V80, P825, DOI 10.1016/0092-8674(95)90283-X; Coleman C N, 1996, Oncology (Williston Park), V10, P399; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; Efrati E, 1997, J BIOL CHEM, V272, P2559; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; GANNETT PM, 1993, CHEM RES TOXICOL, V6, P690, DOI 10.1021/tx00035a015; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; GOODMAN MF, 1994, ANN NY ACAD SCI, V726, P132, DOI 10.1111/j.1749-6632.1994.tb52804.x; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; HANAWALT PC, 1993, MUTAT RES, V289, P7, DOI 10.1016/0027-5107(93)90125-Y; Ide H, 1992, Nucleic Acids Symp Ser, P167; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Krishnamurthy VV, 1996, J MAGN RESON SER B, V113, P46, DOI 10.1006/jmrb.1996.0153; Krokan HE, 1997, BIOCHEM J, V325, P1; Kung HC, 1997, J BIOL CHEM, V272, P9227; Kung HC, 1996, MAGN RESON CHEM, V34, pS47, DOI 10.1002/(SICI)1097-458X(199612)34:13<S47::AID-OMR44>3.0.CO;2-O; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Lundquist AJ, 1997, J BIOL CHEM, V272, P21408, DOI 10.1074/jbc.272.34.21408; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8209; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1191; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOSBAUGH DW, 1994, PROG NUCL ACID RES, V48, P316; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Plum GE, 1995, BIOCHEMISTRY-US, V34, P16148, DOI 10.1021/bi00049a030; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCHEZ G, 1994, MUTAT RES LETT, V325, P39, DOI 10.1016/0165-7992(94)90025-6; SANCHEZ G, 1994, ENVIRON MOL MUTAGEN, V23, P32, DOI 10.1002/em.2850230106; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; TESSMAN I, 1994, GENETICS, V136, P439; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Wang KY, 1997, BIOCHEMISTRY-US, V36, P11629, DOI 10.1021/bi971464l; WARD JF, 1991, PHYSICAL CHEM MECHAN, V58, P403; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WITHKA JM, 1992, J MAGN RESON, V98, P611, DOI 10.1016/0022-2364(92)90014-X; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; Young MA, 1995, METHOD ENZYMOL, V261, P121	68	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15565	15573		10.1074/jbc.273.25.15565	http://dx.doi.org/10.1074/jbc.273.25.15565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624147	hybrid			2022-12-27	WOS:000074284200041
J	Gurevich, VV				Gurevich, VV			The selectivity of visual arrestin for light-activated phosphorhodopsin is controlled by multiple nonredundant mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; RHODOPSIN INTERACTION; 48-KDA PROTEIN; OGUCHI DISEASE; BINDING; EXPRESSION; DROSOPHILA; GENE; PHOSPHORYLATION; LOCALIZATION	Arrestin plays an important role in quenching photo transduction via its ability to bind to the phosphorylated light-activated form of the visual receptor rhodopsin (P-Rh*). Remarkable selectivity of visual arrestin toward this functional form is determined by an elegant sequential multisite binding mechanism. Previous structure-function studies have suggested that the COOP-terminal region of arrestin (residues 356-404) is not directly involved in rhodopsin interaction, but instead plays a regulatory role. This region supports basal arrestin conformation and ensures arrestin's transition into a high affinity rhodopsin-binding state upon an encounter with P-Rh*. Overall, our results corroborate this hypothesis and identify three functional subregions (residues 361-368, 369-378, and 379-404) and individual amino acids involved in the control of arrestin stability and binding selectivity. Two of the most potent mutants, arrestin(1-378) and arrestin(F375A,V376A,F377A) belong to a novel class of constitutively active arrestins with high affinity for P-Rh*, dark P-Rh. and Rh* (but not dark Ph), in contrast to earlier constructed mutants arrestin(R175E) and arrestin(Delta 2-16) with high affinity for light-activated forms only. The implications of these findings for the mechanism of arrestin-rhodopsin interaction are discussed in light of the recently determined crystal structure of arrestin.	Sun Hlth Res Inst, Sun City, AZ 85372 USA	Banner Research; Banner Health; Banner Sun Health Research Institute	Gurevich, VV (corresponding author), Sun Hlth Res Inst, 10515 W Santa Fe Dr, Sun City, AZ 85372 USA.	vgurevich@sunhealth.org	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MAW MA, 1995, J MED GENET, V32, P396, DOI 10.1136/jmg.32.5.396; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P319; RAMING K, 1993, CELL SIGNAL, V5, P69, DOI 10.1016/0898-6568(93)90009-B; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1170; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH WC, 1994, J BIOL CHEM, V269, P15407; SMITH WC, 1993, INVEST OPHTH VIS SCI, V34, P807; SMITH WC, 1995, J NEUROCHEM, V64, P1; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175	35	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15501	15506		10.1074/jbc.273.25.15501	http://dx.doi.org/10.1074/jbc.273.25.15501			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624137	hybrid			2022-12-27	WOS:000074284200031
J	Hortensteiner, S; Wuthrich, KL; Matile, P; Ongania, KH; Krautler, B				Hortensteiner, S; Wuthrich, KL; Matile, P; Ongania, KH; Krautler, B			The key step in chlorophyll breakdown in higher plants - Cleavage of pheophorbide alpha macrocycle by a monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORELLA-PROTOTHECOIDES; STRUCTURE ELUCIDATION; SENESCENT LEAVES; REDUCED FERREDOXIN; A CATABOLITE; IN-VITRO; RAPE; PHAEOPHORBIDE; CONSTITUTION; REQUIREMENT	Chlorophyll breakdown in green plants is a longstanding biological enigma. Recent work has shown that pheophorbide a (Pheide a) derived from chlorophyll (Chl) is converted oxygenolytically into a primary fluorescent catabolite (pFCC-1) via a red Chl catabolite (RCC) intermediate. RCC, the product of the ring cleavage reaction catalyzed by Pheide a oxygenase, which is suggested to be the key enzyme in Chi breakdown in green plants, is converted into pFCC-1 by a reductase. In the present study, an in vitro assay comprising O-18(2) Pheide a oxygenase and RCC reductase yielded labeled pFCC-1. Fast atom bombardment-mass spectrometric analysis of the purified pFCC-1 product revealed that only one of the two oxygen atoms newly introduced into Pheide a in the course of the cleavage reaction is derived from molecular oxygen. Analysis of the fragment ions located the oxygen atom derived from molecular oxygen on the formyl group of pyrrole B, This finding demonstrates that the cleavage of Pheide a in vascular plants is catalyzed by a monooxygenase. Chlorophyll breakdown is therefore indicated to be mechanistically related in higher plants and in the green alga Chlorella protothecoides.	Univ Innsbruck, Inst Organ Chem, A-6020 Innsbruck, Austria; Univ Zurich, Dept Plant Biol, CH-8008 Zurich, Switzerland	University of Innsbruck; University of Zurich	Hortensteiner, S (corresponding author), Univ Innsbruck, Inst Organ Chem, Innrain 52A, A-6020 Innsbruck, Austria.	horten@bbsrc.ac.uk; Bernhard.Kraeutler@uibk.ac.at						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown SB., 1991, CHLOROPHYLLS, P465; CURTY C, 1995, FEBS LETT, V364, P41, DOI 10.1016/0014-5793(95)00348-D; Curty C, 1996, PHYTOCHEMISTRY, V42, P1531, DOI 10.1016/0031-9422(96)00155-0; Engel N, 1996, PLANT PHYSIOL BIOCH, V34, P77; ENGEL N, 1991, FEBS LETT, V293, P131, DOI 10.1016/0014-5793(91)81168-8; GINSBURG S, 1994, PLANT PHYSIOL, V105, P545, DOI 10.1104/pp.105.2.545; Hinder B, 1996, J BIOL CHEM, V271, P27233, DOI 10.1074/jbc.271.44.27233; HORTENSTEINER S, 1995, NEW PHYTOL, V129, P237, DOI 10.1111/j.1469-8137.1995.tb04293.x; ITURRASPE J, 1994, PHYTOCHEMISTRY, V35, P1387, DOI 10.1016/S0031-9422(00)86861-2; ITURRASPE J, 1995, J ORG CHEM, V60, P6664, DOI 10.1021/jo00126a007; Krautler B, 1997, HELV CHIM ACTA, V80, P1355, DOI 10.1002/hlca.19970800504; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; Matile P, 1996, PLANT PHYSIOL BIOCH, V34, P55; MATILE P, 1988, P NATL ACAD SCI USA, V85, P9529, DOI 10.1073/pnas.85.24.9529; Mendel JG., 1865, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.1093/OXFORDJOURNALS.JHERED.A106151; Muhlecker W, 1996, PLANT PHYSIOL BIOCH, V34, P61; Muhlecker W, 1997, ANGEW CHEM INT EDIT, V36, P401, DOI 10.1002/anie.199704011; MUHLECKER W, 1993, HELV CHIM ACTA, V76, P2976, DOI 10.1002/hlca.19930760822; OSHIO Y, 1969, PLANT CELL PHYSIOL, V10, P41; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rodoni S, 1997, PLANT PHYSIOL, V115, P677, DOI 10.1104/pp.115.2.669; Rodoni S, 1997, PLANT PHYSIOL, V115, P669, DOI 10.1104/pp.115.2.669; SCHELLENBERG M, 1993, PLANTA, V191, P417, DOI 10.1007/BF00195702; Thomas H, 1996, BOT ACTA, V109, P3, DOI 10.1111/j.1438-8677.1996.tb00862.x; VICENTINI F, 1995, NEW PHYTOL, V129, P247, DOI 10.1111/j.1469-8137.1995.tb04294.x	26	129	139	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15335	15339		10.1074/jbc.273.25.15335	http://dx.doi.org/10.1074/jbc.273.25.15335			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624113	hybrid			2022-12-27	WOS:000074284200007
J	Iordanov, MS; Pribnow, D; Magun, JL; Dinh, TH; Pearson, JA; Magun, BE				Iordanov, MS; Pribnow, D; Magun, JL; Dinh, TH; Pearson, JA; Magun, BE			Ultraviolet radiation triggers the ribotoxic stress response in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCED GENE-EXPRESSION; RIBOSOMAL-RNA; GROWTH-FACTOR; UV RESPONSE; DNA-DAMAGE; C-FOS; MECHANISM; PATHWAYS; SIGNAL	The ribotoxic stress response, which is conserved between prokaryotes and eukaryotes, is a cellular reaction to cytotoxic interference with the function of the 3'-end of the large (23 S/28 S) ribosomal RNA. The S'-end of the large rRNA is directly involved in the three sequential steps of translational elongation: the aminoacyl-tRNA binding, the peptidyl transfer, and the ribosomal translocation. In mammalian cells, the ribotoxic stress response involves activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase and the p38 mitogen-activated protein kinase and transcriptional induction of immediate early genes such as c-fos and c-jun. Active ribosomes are essential mediators of the ribotoxic stress response. We demonstrate here that the transcriptional response of mammalian cells to ultraviolet radiation (W response) displays the characteristics of a ribotoxic stress response, inasmuch as (i) the activation of stress kinases and gene expression in response to W requires the presence of active ribosomes at the moment of irradiation; (ii) UV irradiation inhibits protein synthesis; and (iii) irradiation of cells with W causes specific damage to the 3'-end of the 28 S rRNA. Ire contrast, the activation of the stress kinases by hyperosmolarity, by the DNA-cross-linking agent diepoxybutane, or by growth factors and cytokines does not depend on the presence of active ribosomes. Our results identify W as a potential ribotoxic stressor and support the notion that some of the cellular signaling cascades in response to UV might be generated in the ribosome, possibly triggered by damage to rRNA.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Magun, BE (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.				NCI NIH HHS [CA-39360] Funding Source: Medline; NIEHS NIH HHS [ES-08456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BUSCHER M, 1988, ONCOGENE, V3, P301; CUNDLIFFE E, 1990, RIBOSOME, P479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GU ZP, 1994, P NATL ACAD SCI USA, V91, P5612, DOI 10.1073/pnas.91.12.5612; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; HUMMEL H, 1987, NUCLEIC ACIDS RES, V15, P2431, DOI 10.1093/nar/15.6.2431; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Iordanov MS, 1998, J BIOL CHEM, V273, P3528, DOI 10.1074/jbc.273.6.3528; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIEV IG, 1994, EMBO J, V13, P1682, DOI 10.1002/j.1460-2075.1994.tb06432.x; LIN A, 1995, SCIENCE, V268, P3286; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAGUN BE, 1995, CELL GROWTH DIFFER, V6, P891; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1004; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Spahn CMT, 1996, J BIOL CHEM, V271, P32849, DOI 10.1074/jbc.271.51.32849; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SWEENEY R, 1991, GENETICS, V127, P327; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; YAN MH, 1994, NATURE, V372, P798; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	44	137	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15794	15803		10.1074/jbc.273.25.15794	http://dx.doi.org/10.1074/jbc.273.25.15794			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624179	hybrid			2022-12-27	WOS:000074284200073
J	Schultz, CP; Wolf, V; Lange, R; Mertens, E; Wecke, J; Naumann, D; Zahringer, U				Schultz, CP; Wolf, V; Lange, R; Mertens, E; Wecke, J; Naumann, D; Zahringer, U			Evidence for a new type of outer membrane lipid in oral spirochete Treponema denticola - Functioning permeation barrier without lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; FATTY-ACID PROFILES; BORRELIA-BURGDORFERI; SPHINGOMONAS-PAUCIMOBILIS; INFRARED-SPECTROSCOPY; STAPHYLOCOCCUS-AUREUS; STRUCTURAL-ANALYSIS; CHEMICAL-STRUCTURE; SURFACE-ANTIGEN; FT-IR	A new class of outer membrane lipid (OML) was isolated from the oral spirochete Treponema denticola strain ATCC 33521 using a phenol/chloroform/light petroleum procedure normally applied far lipopolysaccharide extraction. In addition to chemical analysis, Fourier transform infrared (FTIR) spectroscopy was applied to compare the biophysical properties of OML with lipopolysaccharides (LPS) and lipoteichoic acids (LTA), Isolated OML fractions represent 1.4% of the total dry cell weight, are about 4 kDa in size, and contain 6% amino sugars, 8% neutral sugars, 14% phosphate, 35% carbazol-positive compounds, and 11% fatty acids (containing iso-and anteiso-fatty acyl chains), Rare for outer membrane lipids, OML contains no significant amount of 3-deoxy-D-manno-octulosonic acids, heptoses, and beta-hydroxy fatty acids. The fatty acyl chain composition, being similar to that of the cytoplasmic membrane, is quite heterogeneous with anteiso-pentadecanoic acid (12%), palmitic acid (51%), and iso-palmitic acid (19%) as the predominant fatty acids present. Findings of a glycerol-hexose unit and two glycerol-hexadecanoic acid fragments indicate a glycolipid membrane anchor typically found in LTA. There was also no evidence for the presence of a sphingosine-based lipid structure. The results of FTIR measurements strongly suggest that the reconstituted lipid forms normal bilayer structures (vesicles) expressing a high membrane state of order with a distinct phase transition as typical for isolated LPS, However, in contrast to LPS, OML of T. denticola has a lower T-m near 22 degrees C and a lower cooperativity of the phase transition. The results suggest a different kind of permeation barrier that is built lip by this particular OML of T. denticola, which is quite different from LPS normally essential for Gram-negative bacteria.	Robert Koch Inst, D-13353 Berlin, Germany; Immanuel Krankenhaus, D-14109 Berlin, Germany; Zentrum Med & Biowissensch, Forschungszentrum Borstel, D-23845 Borstel, Germany	Robert Koch Institute; Forschungszentrum Borstel	Schultz, CP (corresponding author), Natl Res Council Canada, Inst Biodiagnost, 435 Ellice Ave, Winnipeg, MB R3B 1Y6, Canada.							BECK G, 1985, J INFECT DIS, V152, P108, DOI 10.1093/infdis/152.1.108; BRADE H, 1982, EUR J BIOCHEM, V122, P233, DOI 10.1111/j.1432-1033.1982.tb05871.x; BRONDZ I, 1991, APMIS, V99, P567, DOI 10.1111/j.1699-0463.1991.tb05192.x; CINCO M, 1991, FEMS MICROBIOL IMMUN, V76, P33, DOI 10.1111/j.1574-6968.1991.tb04160.x; COCKAYNE A, 1989, J GEN MICROBIOL, V135, P3209; Dahle UR, 1996, ENDOD DENT TRAUMATOL, V12, P202; DMITRIEV BA, 1980, EUR J BIOCHEM, V106, P643, DOI 10.1111/j.1432-1033.1980.tb04612.x; EGLI C, 1993, INFECT IMMUN, V61, P1694, DOI 10.1128/IAI.61.5.1694-1699.1993; FABIAN H, 1993, J MOL BIOL, V232, P967, DOI 10.1006/jmbi.1993.1442; FISCHER W, 1981, J BACTERIOL, V146, P467, DOI 10.1128/JB.146.2.467-475.1981; Fischer W, 1997, EUR J BIOCHEM, V244, P913, DOI 10.1111/j.1432-1033.1997.00913.x; GREER JM, 1989, INFECT IMMUN, V57, P717, DOI 10.1128/IAI.57.3.717-723.1989; HAAPASALO M, 1992, INFECT IMMUN, V60, P2058, DOI 10.1128/IAI.60.5.2058-2065.1992; HELM D, 1995, FEMS MICROBIOL LETT, V126, P75, DOI 10.1111/j.1574-6968.1995.tb07393.x; HINDERSSON P, 1992, RES MICROBIOL, V143, P629, DOI 10.1016/0923-2508(92)90121-4; HOLST O, 1993, CARBOHYD RES, V245, P159, DOI 10.1016/0008-6215(93)80069-Q; KAWAHARA K, 1991, FEBS LETT, V292, P107, DOI 10.1016/0014-5793(91)80845-T; KAWAHARA K, 1987, EUR J BIOCHEM, V163, P489, DOI 10.1111/j.1432-1033.1987.tb10895.x; KAWASAKI S, 1994, J BACTERIOL, V176, P284, DOI 10.1128/JB.176.2.284-290.1994; LABISCHINSKI H, 1991, EUR J BIOCHEM, V202, P1269, DOI 10.1111/j.1432-1033.1991.tb16499.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISTGARTEN MA, 1981, J CLIN PERIODONTOL, V8, P122, DOI 10.1111/j.1600-051X.1981.tb02352.x; LIVESLEY MA, 1993, J GEN MICROBIOL, V139, P2197, DOI 10.1099/00221287-139-9-2197; LOESCHE WJ, 1982, P HOST PARASITE INTE, P62; LOWRY OH, 1954, J BIOL CHEM, V207, P1; MANTSCH HH, 1991, CHEM PHYS LIPIDS, V57, P213, DOI 10.1016/0009-3084(91)90077-O; NAUMANN D, 1989, J MOL STRUCT, V214, P313; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SCHULTZ C, 1991, FEBS LETT, V294, P43, DOI 10.1016/0014-5793(91)81339-A; SCHULTZ CP, 1993, THESIS FREE U BERLIN; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; WANNEMUEHLER MJ, 1988, INFECT IMMUN, V56, P3032, DOI 10.1128/IAI.56.12.3032-3039.1988; WECKE J, 1995, ORAL MICROBIOL IMMUN, V10, P278, DOI 10.1111/j.1399-302X.1995.tb00154.x; WECKE J, 1990, APMIS, V98, P71, DOI 10.1111/j.1699-0463.1990.tb01004.x; WESTERGAARD J, 1987, ACTA PATH MICRO IM B, V95, P49; Wilkinson S., 1988, MICROBIAL LIPIDS; WOLF V, 1993, ARCH MICROBIOL, V160, P206; WOLF V, 1993, THESIS FREE U BERLIN; YOTIS W, 1993, J PERIODONTAL RES, V28, P387, DOI 10.1111/jre.1993.28.6.387; YOTIS WW, 1991, J CLIN MICROBIOL, V29, P1397, DOI 10.1128/JCM.29.7.1397-1406.1991; YOTIS WW, 1995, J BASIC MICROB, V35, P255, DOI 10.1002/jobm.3620350411	44	67	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 19	1998	273	25					15661	15666		10.1074/jbc.273.25.15661	http://dx.doi.org/10.1074/jbc.273.25.15661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZV238	9624160	hybrid			2022-12-27	WOS:000074284200054
